0001114483-22-000002.txt : 20220222 0001114483-22-000002.hdr.sgml : 20220222 20220222073351 ACCESSION NUMBER: 0001114483-22-000002 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 144 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220222 DATE AS OF CHANGE: 20220222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Integer Holdings Corp CENTRAL INDEX KEY: 0001114483 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 161531026 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16137 FILM NUMBER: 22655000 BUSINESS ADDRESS: STREET 1: 5830 GRANITE PARKWAY., SUITE 1150 CITY: PLANO STATE: TX ZIP: 75024 BUSINESS PHONE: (214) 618-5243 MAIL ADDRESS: STREET 1: 5830 GRANITE PARKWAY., SUITE 1150 CITY: PLANO STATE: TX ZIP: 75024 FORMER COMPANY: FORMER CONFORMED NAME: GREATBATCH, INC. DATE OF NAME CHANGE: 20050531 FORMER COMPANY: FORMER CONFORMED NAME: WILSON GREATBATCH TECHNOLOGIES INC DATE OF NAME CHANGE: 20000511 10-K 1 gb-20211231.htm 10-K gb-20211231
0001114483false2021FYhttp://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602MemberP3Yhttp://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent00011144832021-01-012021-12-3100011144832021-07-02iso4217:USD00011144832022-02-16xbrli:shares00011144832021-12-3100011144832020-12-31iso4217:USDxbrli:shares00011144832020-01-012020-12-3100011144832018-12-292019-12-310001114483us-gaap:RetainedEarningsMember2021-01-012021-12-310001114483us-gaap:RetainedEarningsMember2020-01-012020-12-310001114483us-gaap:RetainedEarningsMember2018-12-292019-12-3100011144832019-12-3100011144832018-12-280001114483us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-12-310001114483us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2019-12-310001114483us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2018-12-280001114483us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-01-012021-12-310001114483us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-01-012020-12-310001114483us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2018-12-292019-12-310001114483us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-12-310001114483us-gaap:TreasuryStockMember2019-12-310001114483us-gaap:TreasuryStockMember2018-12-280001114483us-gaap:TreasuryStockMember2018-12-292019-12-310001114483us-gaap:TreasuryStockMember2020-01-012020-12-310001114483us-gaap:TreasuryStockMember2021-12-310001114483us-gaap:TreasuryStockMember2020-12-310001114483us-gaap:RetainedEarningsMember2020-12-310001114483us-gaap:RetainedEarningsMember2019-12-310001114483us-gaap:RetainedEarningsMember2018-12-2800011144832017-12-302018-12-280001114483srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2018-12-280001114483us-gaap:RetainedEarningsMember2021-12-310001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-280001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-292019-12-310001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31gb:segmentgb:customer00011144832019-09-282019-12-310001114483srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2021-01-012021-12-310001114483us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2021-01-012021-12-310001114483us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2021-01-012021-12-310001114483us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2021-01-012021-12-310001114483srt:MinimumMemberus-gaap:OfficeEquipmentMember2021-01-012021-12-310001114483srt:MaximumMemberus-gaap:OfficeEquipmentMember2021-01-012021-12-310001114483srt:MinimumMemberus-gaap:PatentsMember2021-01-012021-12-310001114483srt:MaximumMemberus-gaap:PatentsMember2021-01-012021-12-310001114483srt:MinimumMemberus-gaap:CustomerListsMember2021-01-012021-12-310001114483srt:MaximumMemberus-gaap:CustomerListsMember2021-01-012021-12-310001114483srt:MinimumMemberus-gaap:OtherIntangibleAssetsMember2021-01-012021-12-310001114483srt:MaximumMemberus-gaap:OtherIntangibleAssetsMember2021-01-012021-12-310001114483us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001114483srt:MinimumMembergb:RestrictedStockAndUnitAwardsMember2021-01-012021-12-310001114483srt:MaximumMembergb:RestrictedStockAndUnitAwardsMember2021-01-012021-12-310001114483gb:RestrictedStockAndUnitAwardsMembersrt:DirectorMember2021-01-012021-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMembersrt:MaximumMember2021-01-012021-12-310001114483gb:OscorIncMember2021-12-01xbrli:pure0001114483gb:OscorIncMember2021-12-012021-12-010001114483gb:OscorIncMember2021-12-010001114483gb:OscorIncMember2021-12-012021-12-310001114483gb:OfficeAndManufacturingFacilitiesMembergb:OscorIncMember2021-12-310001114483us-gaap:CustomerListsMember2021-01-012021-12-310001114483us-gaap:TechnologyBasedIntangibleAssetsMember2021-01-012021-12-310001114483us-gaap:TradeNamesMember2021-01-012021-12-310001114483us-gaap:CustomerListsMemberus-gaap:IncomeApproachValuationTechniqueMembergb:MeasurementInputAnnualAttritionRateMember2021-12-31iso4217:USDiso4217:EUR0001114483us-gaap:TechnologyBasedIntangibleAssetsMembersrt:MaximumMembergb:MeasurementInputRoyaltyRateMemberus-gaap:IncomeApproachValuationTechniqueMember2021-12-310001114483us-gaap:TechnologyBasedIntangibleAssetsMembersrt:MinimumMembergb:MeasurementInputRoyaltyRateMemberus-gaap:IncomeApproachValuationTechniqueMember2021-12-310001114483gb:MeasurementInputRoyaltyRateMemberus-gaap:TradeNamesMemberus-gaap:IncomeApproachValuationTechniqueMember2021-12-310001114483gb:InoMecLtdMember2020-02-192020-02-190001114483gb:InoMecLtdMember2020-02-190001114483gb:USBioDesignLLCMember2019-10-072019-10-070001114483gb:USBioDesignLLCMember2019-10-070001114483gb:USBioDesignLLCMembergb:TechnologyMember2019-10-070001114483gb:USBioDesignLLCMember2020-01-012020-12-310001114483gb:USBioDesignLLCMembergb:TechnologyMember2019-10-072019-10-070001114483gb:OscorIncMember2021-01-012021-12-310001114483gb:InoMecLtdMember2021-01-012021-12-310001114483gb:USBioDesignLLCMember2021-01-012021-12-310001114483gb:InoMecLtdMember2020-01-012020-12-310001114483gb:USBioDesignLLCMember2018-12-292019-12-310001114483gb:OscorIncMember2020-01-012020-12-310001114483us-gaap:MachineryAndEquipmentMember2021-12-310001114483us-gaap:MachineryAndEquipmentMember2020-12-310001114483us-gaap:BuildingAndBuildingImprovementsMember2021-12-310001114483us-gaap:BuildingAndBuildingImprovementsMember2020-12-310001114483us-gaap:ComputerEquipmentMember2021-12-310001114483us-gaap:ComputerEquipmentMember2020-12-310001114483us-gaap:LeaseholdImprovementsMember2021-12-310001114483us-gaap:LeaseholdImprovementsMember2020-12-310001114483us-gaap:FurnitureAndFixturesMember2021-12-310001114483us-gaap:FurnitureAndFixturesMember2020-12-310001114483us-gaap:LandAndLandImprovementsMember2021-12-310001114483us-gaap:LandAndLandImprovementsMember2020-12-310001114483us-gaap:ConstructionInProgressMember2021-12-310001114483us-gaap:ConstructionInProgressMember2020-12-310001114483us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2021-12-310001114483us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2020-12-310001114483gb:MedicalSegmentMember2019-12-310001114483gb:NonMedicalSegmentMember2019-12-310001114483gb:MedicalSegmentMember2020-01-012020-12-310001114483gb:NonMedicalSegmentMember2020-01-012020-12-310001114483gb:MedicalSegmentMember2020-12-310001114483gb:NonMedicalSegmentMember2020-12-310001114483gb:MedicalSegmentMember2021-01-012021-12-310001114483gb:NonMedicalSegmentMember2021-01-012021-12-310001114483gb:MedicalSegmentMember2021-12-310001114483gb:NonMedicalSegmentMember2021-12-310001114483gb:PurchasedTechnologyTradenamesAndPatentsMember2021-12-310001114483us-gaap:CustomerListsMember2021-12-310001114483us-gaap:OtherIntangibleAssetsMember2021-12-310001114483us-gaap:TrademarksAndTradeNamesMember2021-12-310001114483gb:PurchasedTechnologyTradenamesAndPatentsMember2020-12-310001114483us-gaap:CustomerListsMember2020-12-310001114483us-gaap:OtherIntangibleAssetsMember2020-12-310001114483us-gaap:TrademarksAndTradeNamesMember2020-12-310001114483us-gaap:TrademarksAndTradeNamesMembergb:LakeRegionMedicalMember2021-12-310001114483us-gaap:TrademarksAndTradeNamesMembergb:LakeRegionMedicalMember2020-12-310001114483gb:NonMedicalSegmentMemberus-gaap:LicenseMembergb:SimilarIdentifiableAssetsRelatingToALicenseToUseTechnologyMember2020-01-012020-12-310001114483us-gaap:CostOfSalesMember2021-01-012021-12-310001114483us-gaap:CostOfSalesMember2020-01-012020-12-310001114483us-gaap:CostOfSalesMember2018-12-292019-12-310001114483us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310001114483us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310001114483us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-12-292019-12-310001114483gb:TermLoanATLAFacilityMemberus-gaap:SecuredDebtMemberus-gaap:LoansPayableMember2021-12-310001114483gb:TermLoanATLAFacilityMemberus-gaap:SecuredDebtMemberus-gaap:LoansPayableMember2020-12-310001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMemberus-gaap:LoansPayableMember2021-12-310001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMemberus-gaap:LoansPayableMember2020-12-310001114483us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-12-310001114483us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2020-12-3100011144832021-09-020001114483us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-09-022021-09-020001114483us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-09-020001114483us-gaap:SecuredDebtMembergb:TermLoanATLAFacilityMember2021-09-022021-09-020001114483us-gaap:SecuredDebtMembergb:TermLoanATLAFacilityMember2021-09-020001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMember2021-09-022021-09-020001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMember2021-09-020001114483gb:TermLoanATLAFacilityMemberus-gaap:SecuredDebtMemberus-gaap:LoansPayableMember2021-01-012021-12-310001114483us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-09-010001114483gb:NewRevolvingCreditFacility2015Memberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-09-020001114483gb:TermLoanATLAFacilityMemberus-gaap:SecuredDebtMemberus-gaap:LoansPayableMember2021-09-020001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMemberus-gaap:LoansPayableMember2021-09-020001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMemberus-gaap:LoansPayableMember2021-09-022021-09-020001114483gb:NewRevolvingCreditFacility2015Membergb:SwinglineLoansMemberus-gaap:SecuredDebtMember2020-07-130001114483us-gaap:StandbyLettersOfCreditMember2021-12-310001114483srt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembergb:LondonInterbankOfferedRateOneMonthLIBORMember2021-01-012021-12-310001114483srt:MaximumMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembergb:LondonInterbankOfferedRateOneMonthLIBORMember2021-01-012021-12-310001114483srt:MinimumMembergb:TermLoanATLAFacilityMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-01-012021-12-310001114483gb:TermLoanATLAFacilityMembersrt:MaximumMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-01-012021-12-310001114483gb:TermLoanATLAFacilityMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:FederalFundsEffectiveSwapRateMember2021-01-012021-12-310001114483gb:TermLoanATLAFacilityMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembergb:LondonInterbankOfferedRateOneMonthLIBORMember2021-01-012021-12-310001114483us-gaap:RevolvingCreditFacilityMember2021-12-310001114483srt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-01-012021-12-310001114483srt:MaximumMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-01-012021-12-310001114483us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-01-012021-12-310001114483us-gaap:SecuredDebtMemberus-gaap:LondonInterbankOfferedRateLIBORMembergb:TermLoanBTLBFacilityMember2021-01-012021-12-310001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMemberus-gaap:BaseRateMember2021-01-012021-12-310001114483us-gaap:SecuredDebtMembergb:TermLoanATLAFacilityMember2021-12-310001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMember2021-12-310001114483us-gaap:SecuredDebtMembergb:TermLoanATLAFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-01-012021-12-310001114483us-gaap:SecuredDebtMembergb:ITGRTermLoanATLAFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-01-012021-12-310001114483us-gaap:RevolvingCreditFacilityMember2020-12-310001114483us-gaap:RevolvingCreditFacilityMember2021-01-012021-12-310001114483us-gaap:RevolvingCreditFacilityMember2021-12-310001114483gb:TermLoanAndSeniorNotesMember2020-12-310001114483gb:TermLoanBTLBFacilityMember2020-12-310001114483gb:TermLoanAndSeniorNotesMember2021-01-012021-12-310001114483gb:TermLoanBTLBFacilityMember2021-01-012021-12-310001114483gb:TermLoanAndSeniorNotesMember2021-12-310001114483gb:TermLoanBTLBFacilityMember2021-12-310001114483us-gaap:LoansPayableMember2021-12-310001114483us-gaap:LongTermDebtMemberus-gaap:LoansPayableMember2021-12-310001114483us-gaap:OtherAssetsMemberus-gaap:RevolvingCreditFacilityMember2021-12-310001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMember2021-01-012021-12-310001114483srt:MaximumMember2021-01-012021-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsMember2021-01-012021-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsMember2020-01-012020-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsMember2018-12-292019-12-310001114483us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001114483us-gaap:EmployeeStockOptionMember2018-12-292019-12-310001114483gb:RSUsAndPRSUsMember2021-01-012021-12-310001114483gb:RSUsAndPRSUsMember2020-01-012020-12-310001114483gb:RSUsAndPRSUsMember2018-12-292019-12-310001114483us-gaap:CostOfSalesMember2021-01-012021-12-310001114483us-gaap:CostOfSalesMember2020-01-012020-12-310001114483us-gaap:CostOfSalesMember2018-12-292019-12-310001114483us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310001114483us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310001114483us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-12-292019-12-310001114483us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001114483us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001114483us-gaap:ResearchAndDevelopmentExpenseMember2018-12-292019-12-310001114483gb:OtherOperatingExpensesNetMember2021-01-012021-12-310001114483gb:OtherOperatingExpensesNetMember2020-01-012020-12-310001114483gb:OtherOperatingExpensesNetMember2018-12-292019-12-310001114483us-gaap:EmployeeStockOptionMember2021-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsTimeBasedMember2020-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsTimeBasedMember2021-01-012021-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsTimeBasedMember2021-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsMember2021-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember2020-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember2021-01-012021-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember2021-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember2021-01-012021-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember2021-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember2020-01-012020-12-310001114483gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember2018-12-292019-12-310001114483gb:OperationalExcellenceInitiativesMember2021-10-022021-12-310001114483gb:OperationalExcellenceInitiativesMember2020-01-012020-12-310001114483gb:OperationalExcellenceInitiativesMember2018-12-292019-12-310001114483gb:StrategicReorganizationAndAlignmentMember2021-10-022021-12-310001114483gb:StrategicReorganizationAndAlignmentMember2020-01-012020-12-310001114483gb:StrategicReorganizationAndAlignmentMember2018-12-292019-12-310001114483gb:ManufacturingAlignmentToSupportGrowthMember2021-10-022021-12-310001114483gb:ManufacturingAlignmentToSupportGrowthMember2020-01-012020-12-310001114483gb:ManufacturingAlignmentToSupportGrowthMember2018-12-292019-12-3100011144832021-10-022021-12-310001114483gb:OperationalExcellenceInitiativesTwoThousandTwentyOneInitiativesMembersrt:MinimumMemberus-gaap:EmployeeSeveranceMember2021-12-310001114483gb:OperationalExcellenceInitiativesTwoThousandTwentyOneInitiativesMemberus-gaap:EmployeeSeveranceMembersrt:MaximumMember2021-12-310001114483gb:OperationalExcellenceInitiativesTwoThousandTwentyOneInitiativesMemberus-gaap:EmployeeSeveranceMember2021-12-310001114483gb:TwoThousandTwentyTwoRestructuringPlanMember2021-01-012021-12-310001114483srt:MinimumMembergb:StrategicReorganizationAndAlignmentInitiativesTwoThousandTwentyOneInitiativesMember2021-12-310001114483srt:MaximumMembergb:StrategicReorganizationAndAlignmentInitiativesTwoThousandTwentyOneInitiativesMember2021-12-310001114483gb:StrategicReorganizationAndAlignmentInitiativesTwoThousandTwentyOneInitiativesMember2021-12-310001114483gb:StrategicReorganizationAndAlignmentMembergb:MedicalSegmentMember2020-07-030001114483gb:ManufacturingAlignmentToSupportGrowthMember2021-12-310001114483gb:TwoThousandTwentyTwoRestructuringPlanMember2020-12-310001114483gb:StrategicReorganizationAndAlignmentMember2020-12-310001114483gb:TwoThousandTwentyTwoRestructuringPlanMember2021-01-012021-12-310001114483gb:StrategicReorganizationAndAlignmentMember2021-01-012021-12-310001114483gb:TwoThousandTwentyTwoRestructuringPlanMember2021-12-310001114483gb:StrategicReorganizationAndAlignmentMember2021-12-310001114483country:US2021-01-012021-12-310001114483country:US2020-01-012020-12-310001114483country:US2018-12-292019-12-310001114483gb:InternationalMember2021-01-012021-12-310001114483gb:InternationalMember2020-01-012020-12-310001114483gb:InternationalMember2018-12-292019-12-310001114483us-gaap:StateAndLocalJurisdictionMember2021-12-310001114483gb:InternationalJurisdictionMember2021-12-310001114483us-gaap:DomesticCountryMembergb:ForeignTaxCreditCarryforwardMember2021-12-310001114483us-gaap:StateAndLocalJurisdictionMemberus-gaap:ResearchMember2021-12-310001114483us-gaap:StateAndLocalJurisdictionMembergb:StateTaxCreditCarryforwardMember2021-12-3100011144832020-10-012020-10-310001114483us-gaap:RoyaltyMember2021-01-012021-12-310001114483us-gaap:RoyaltyMember2020-01-012020-12-310001114483us-gaap:RoyaltyMember2018-12-292019-12-310001114483us-gaap:InterestExpenseMember2021-01-012021-12-310001114483us-gaap:InterestExpenseMember2020-01-012020-12-31gb:facility0001114483gb:TimeVestedStockOptionsRestrictedStockAndRestrictedStockUnitsMember2021-01-012021-12-310001114483gb:TimeVestedStockOptionsRestrictedStockAndRestrictedStockUnitsMember2020-01-012020-12-310001114483gb:TimeVestedStockOptionsRestrictedStockAndRestrictedStockUnitsMember2018-12-292019-12-310001114483gb:PerformanceVestedRestrictedStockUnitsMember2021-01-012021-12-310001114483gb:PerformanceVestedRestrictedStockUnitsMember2020-01-012020-12-310001114483gb:PerformanceVestedRestrictedStockUnitsMember2018-12-292019-12-310001114483us-gaap:CommonStockMember2019-12-310001114483us-gaap:TreasuryStockCommonMember2019-12-310001114483us-gaap:CommonStockMember2020-01-012020-12-310001114483us-gaap:TreasuryStockCommonMember2020-01-012020-12-310001114483us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMember2020-01-012020-12-310001114483us-gaap:RestrictedStockUnitsRSUMemberus-gaap:TreasuryStockCommonMember2020-01-012020-12-310001114483us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001114483us-gaap:CommonStockMember2020-12-310001114483us-gaap:TreasuryStockCommonMember2020-12-310001114483us-gaap:CommonStockMember2021-01-012021-12-310001114483us-gaap:TreasuryStockCommonMember2021-01-012021-12-310001114483us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMember2021-01-012021-12-310001114483us-gaap:RestrictedStockUnitsRSUMemberus-gaap:TreasuryStockCommonMember2021-01-012021-12-310001114483us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001114483us-gaap:CommonStockMember2021-12-310001114483us-gaap:TreasuryStockCommonMember2021-12-310001114483us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310001114483us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310001114483us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001114483gb:AccumulatedAdjustmentAttributableToParentMember2019-12-310001114483gb:AccumulatedOtherComprehensiveIncomeTaxMember2019-12-310001114483us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-12-310001114483us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-12-310001114483us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-12-310001114483us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-12-310001114483us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-12-310001114483us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310001114483us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310001114483us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001114483gb:AccumulatedAdjustmentAttributableToParentMember2020-12-310001114483gb:AccumulatedOtherComprehensiveIncomeTaxMember2020-12-310001114483us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-12-310001114483us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-12-310001114483us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-12-310001114483us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-12-310001114483us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-12-310001114483us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310001114483us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310001114483us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001114483gb:AccumulatedAdjustmentAttributableToParentMember2021-12-310001114483gb:AccumulatedOtherComprehensiveIncomeTaxMember2021-12-310001114483us-gaap:FairValueMeasurementsRecurringMember2021-12-310001114483us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001114483us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001114483us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001114483us-gaap:FairValueMeasurementsRecurringMember2020-12-310001114483us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001114483us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001114483us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001114483us-gaap:OtherNoncurrentLiabilitiesMembergb:InterestRateSwapMaturingJuneTwoThousandTwentyThreeMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310001114483us-gaap:OtherNoncurrentLiabilitiesMembergb:InterestRateSwapMaturingJuneTwoThousandTwentyThreeMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001114483us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMembergb:ForeignExchangeContractMaturingDecemberTwoThousandTwentyTwoContractOneMember2021-12-31iso4217:USDiso4217:MXN0001114483us-gaap:PrepaidExpensesAndOtherCurrentAssetsMembergb:ForeignExchangeContractMaturingDecemberTwoThousandTwentyTwoContractTwoMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-31iso4217:USDiso4217:UYU0001114483gb:ForeignExchangeContractMaturingDecemberTwoThousandTwentyTwoContractThreeMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310001114483gb:ForeignExchangeContractMaturingSeptemberTwoThousandTwentyOneContractOneMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001114483us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMembergb:ForeignExchangeContractMaturingSeptemberTwoThousandTwentyOneContractTwoMember2020-12-310001114483gb:ForeignExchangeContractMaturingMarchTwoThousandTwentyOneMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001114483us-gaap:PrepaidExpensesAndOtherCurrentAssetsMembergb:ForeignExchangeContractMaturingDecemberTwoThousandTwentyOneMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001114483us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMembergb:ForeignExchangeContractMaturingAugustTwoThousandTwentyOneMember2020-12-310001114483us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMembergb:ForeignExchangeContractMaturingNovemberTwoThousandTwentyOneMember2020-12-310001114483us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2021-01-012021-12-310001114483us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2020-01-012020-12-310001114483us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2018-12-292019-12-310001114483us-gaap:InterestExpenseMember2018-12-292019-12-310001114483us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMember2021-01-012021-12-310001114483us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMember2020-01-012020-12-310001114483us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMember2018-12-292019-12-310001114483us-gaap:SalesMember2021-01-012021-12-310001114483us-gaap:SalesMember2020-01-012020-12-310001114483us-gaap:SalesMember2018-12-292019-12-310001114483us-gaap:ForeignExchangeForwardMemberus-gaap:CostOfSalesMember2021-01-012021-12-310001114483us-gaap:ForeignExchangeForwardMemberus-gaap:CostOfSalesMember2020-01-012020-12-310001114483us-gaap:ForeignExchangeForwardMemberus-gaap:CostOfSalesMember2018-12-292019-12-310001114483us-gaap:ForeignExchangeForwardMemberus-gaap:OperatingExpenseMember2021-01-012021-12-310001114483us-gaap:ForeignExchangeForwardMemberus-gaap:OperatingExpenseMember2020-01-012020-12-310001114483us-gaap:ForeignExchangeForwardMemberus-gaap:OperatingExpenseMember2018-12-292019-12-310001114483us-gaap:OperatingExpenseMember2021-01-012021-12-310001114483us-gaap:OperatingExpenseMember2020-01-012020-12-310001114483us-gaap:OperatingExpenseMember2018-12-292019-12-310001114483us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-12-310001114483us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2021-01-012021-12-310001114483gb:InoMecLtdMember2021-12-310001114483srt:WeightedAverageMembergb:MeasurementInputRevenueVolatilityMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001114483srt:WeightedAverageMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001114483gb:InoMecLtdMember2020-12-310001114483srt:WeightedAverageMembergb:MeasurementInputRevenueVolatilityMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001114483srt:WeightedAverageMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-3100011144832020-10-032020-12-310001114483gb:ChineseVentureCapitalFundMember2021-12-310001114483gb:CardioAndVascularMembergb:MedicalSegmentMember2021-01-012021-12-310001114483gb:CardioAndVascularMembergb:MedicalSegmentMember2020-01-012020-12-310001114483gb:CardioAndVascularMembergb:MedicalSegmentMember2018-12-292019-12-310001114483gb:CardiacNeuromodulationMembergb:MedicalSegmentMember2021-01-012021-12-310001114483gb:CardiacNeuromodulationMembergb:MedicalSegmentMember2020-01-012020-12-310001114483gb:CardiacNeuromodulationMembergb:MedicalSegmentMember2018-12-292019-12-310001114483gb:AdvancedSurgicalOrthopedicsandPortableMedicalMembergb:MedicalSegmentMember2021-01-012021-12-310001114483gb:AdvancedSurgicalOrthopedicsandPortableMedicalMembergb:MedicalSegmentMember2020-01-012020-12-310001114483gb:AdvancedSurgicalOrthopedicsandPortableMedicalMembergb:MedicalSegmentMember2018-12-292019-12-310001114483gb:MedicalSegmentMember2018-12-292019-12-310001114483gb:NonMedicalSegmentMember2018-12-292019-12-310001114483country:US2021-01-012021-12-310001114483country:US2020-01-012020-12-310001114483country:US2018-12-292019-12-310001114483country:PR2021-01-012021-12-310001114483country:PR2020-01-012020-12-310001114483country:PR2018-12-292019-12-310001114483country:CR2021-01-012021-12-310001114483country:CR2020-01-012020-12-310001114483country:CR2018-12-292019-12-310001114483gb:RestOfWorldMember2021-01-012021-12-310001114483gb:RestOfWorldMember2020-01-012020-12-310001114483gb:RestOfWorldMember2018-12-292019-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerAMembergb:MedicalSegmentMember2021-01-012021-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerAMembergb:MedicalSegmentMember2020-01-012020-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerBMembergb:MedicalSegmentMember2021-01-012021-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerBMembergb:MedicalSegmentMember2020-01-012020-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerCMembergb:MedicalSegmentMember2021-01-012021-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerCMembergb:MedicalSegmentMember2020-01-012020-12-310001114483gb:NonMedicalSegmentMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerDMember2021-01-012021-12-310001114483gb:NonMedicalSegmentMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerDMember2020-01-012020-12-310001114483gb:NonMedicalSegmentMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerEMember2020-01-012020-12-310001114483gb:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2021-01-012021-12-310001114483gb:NonMedicalSegmentMembergb:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001114483gb:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2020-01-012020-12-310001114483gb:NonMedicalSegmentMembergb:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001114483us-gaap:RevenueFromContractWithCustomerMembercountry:USus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2021-01-012021-12-310001114483gb:NonMedicalSegmentMemberus-gaap:RevenueFromContractWithCustomerMembercountry:USus-gaap:GeographicConcentrationRiskMember2021-01-012021-12-310001114483us-gaap:RevenueFromContractWithCustomerMembercountry:USus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2020-01-012020-12-310001114483gb:NonMedicalSegmentMemberus-gaap:RevenueFromContractWithCustomerMembercountry:USus-gaap:GeographicConcentrationRiskMember2020-01-012020-12-310001114483us-gaap:RevenueFromContractWithCustomerMembergb:AllOtherCountriesMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2021-01-012021-12-310001114483gb:NonMedicalSegmentMemberus-gaap:RevenueFromContractWithCustomerMembergb:AllOtherCountriesMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-12-310001114483us-gaap:RevenueFromContractWithCustomerMembergb:AllOtherCountriesMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2020-01-012020-12-310001114483gb:NonMedicalSegmentMemberus-gaap:RevenueFromContractWithCustomerMembergb:AllOtherCountriesMemberus-gaap:GeographicConcentrationRiskMember2020-01-012020-12-310001114483us-gaap:OperatingSegmentsMembergb:MedicalSegmentMember2021-01-012021-12-310001114483us-gaap:OperatingSegmentsMembergb:MedicalSegmentMember2020-01-012020-12-310001114483us-gaap:OperatingSegmentsMembergb:MedicalSegmentMember2018-12-292019-12-310001114483us-gaap:OperatingSegmentsMembergb:NonMedicalSegmentMember2021-01-012021-12-310001114483us-gaap:OperatingSegmentsMembergb:NonMedicalSegmentMember2020-01-012020-12-310001114483us-gaap:OperatingSegmentsMembergb:NonMedicalSegmentMember2018-12-292019-12-310001114483us-gaap:OperatingSegmentsMember2021-01-012021-12-310001114483us-gaap:OperatingSegmentsMember2020-01-012020-12-310001114483us-gaap:OperatingSegmentsMember2018-12-292019-12-310001114483us-gaap:MaterialReconcilingItemsMember2021-01-012021-12-310001114483us-gaap:MaterialReconcilingItemsMember2020-01-012020-12-310001114483us-gaap:MaterialReconcilingItemsMember2018-12-292019-12-310001114483us-gaap:OperatingSegmentsMembergb:MedicalSegmentMember2021-12-310001114483us-gaap:OperatingSegmentsMembergb:MedicalSegmentMember2020-12-310001114483us-gaap:OperatingSegmentsMembergb:NonMedicalSegmentMember2021-12-310001114483us-gaap:OperatingSegmentsMembergb:NonMedicalSegmentMember2020-12-310001114483us-gaap:OperatingSegmentsMember2021-12-310001114483us-gaap:OperatingSegmentsMember2020-12-310001114483us-gaap:MaterialReconcilingItemsMember2021-12-310001114483us-gaap:MaterialReconcilingItemsMember2020-12-310001114483country:US2021-12-310001114483country:US2020-12-310001114483country:MX2021-12-310001114483country:MX2020-12-310001114483country:IE2021-12-310001114483country:IE2020-12-310001114483gb:RestOfWorldMember2021-12-310001114483gb:RestOfWorldMember2020-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerAMember2021-01-012021-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerAMember2020-01-012020-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerAMember2018-12-292019-12-310001114483us-gaap:CustomerConcentrationRiskMembergb:CustomerAMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001114483us-gaap:CustomerConcentrationRiskMembergb:CustomerAMemberus-gaap:AccountsReceivableMember2020-01-012020-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerBMember2021-01-012021-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerBMember2020-01-012020-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerBMember2018-12-292019-12-310001114483us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMembergb:CustomerBMember2021-01-012021-12-310001114483us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMembergb:CustomerBMember2020-01-012020-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerCMember2021-01-012021-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerCMember2020-01-012020-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:CustomerCMember2018-12-292019-12-310001114483us-gaap:CustomerConcentrationRiskMembergb:CustomerCMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001114483us-gaap:CustomerConcentrationRiskMembergb:CustomerCMemberus-gaap:AccountsReceivableMember2020-01-012020-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:TopCustomersMember2021-01-012021-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:TopCustomersMember2020-01-012020-12-310001114483us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:TopCustomersMember2018-12-292019-12-310001114483us-gaap:CustomerConcentrationRiskMembergb:TopCustomersMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001114483us-gaap:CustomerConcentrationRiskMembergb:TopCustomersMemberus-gaap:AccountsReceivableMember2020-01-012020-12-310001114483us-gaap:DiscontinuedOperationsHeldforsaleMembergb:ASOBusinessMember2021-10-022021-12-310001114483us-gaap:DiscontinuedOperationsHeldforsaleMembergb:ASOBusinessMember2021-01-012021-12-310001114483us-gaap:DiscontinuedOperationsHeldforsaleMembergb:ASOBusinessMember2020-01-012020-12-310001114483us-gaap:DiscontinuedOperationsHeldforsaleMembergb:ASOBusinessMember2018-12-292019-12-310001114483us-gaap:AllowanceForCreditLossMember2020-12-310001114483us-gaap:AllowanceForCreditLossMember2021-01-012021-12-310001114483us-gaap:AllowanceForCreditLossMember2021-12-310001114483us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-12-310001114483us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-01-012021-12-310001114483us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-12-310001114483us-gaap:AllowanceForCreditLossMember2019-12-310001114483us-gaap:AllowanceForCreditLossMember2020-01-012020-12-310001114483us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-12-310001114483us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-01-012020-12-310001114483us-gaap:AllowanceForCreditLossMember2018-12-280001114483us-gaap:AllowanceForCreditLossMember2018-12-292019-12-310001114483us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-12-280001114483us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-12-292019-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________ 
FORM 10-K
_____________________________________ 
ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For The Fiscal Year Ended December 31, 2021
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____ to ____
Commission File Number 1-16137
 _____________________________________ 
gb-20211231_g1.jpg
INTEGER HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)
  _____________________________________ 

Delaware 16-1531026
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

5830 Granite Parkway,Suite 1150Plano,Texas 75024
(Address of principal executive offices) (Zip Code)
(214) 618-5243
(Registrant’s telephone number, including area code)
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.001 Per ShareITGR New York Stock Exchange
Securities Registered Pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
 Yes  ☒    No  ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes  ☐    No  ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes  ☒    No  ☐
Indicate by checkmark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
 Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
 Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  ☒
The aggregate market value of common stock held by non-affiliates as of July 2, 2021 (the last business day of the registrant’s most recently completed second fiscal quarter), based on the last sale price of $95.34, as reported on the New York Stock Exchange on that date: $3.1 billion. Solely for the purpose of this calculation, shares held by directors and officers and 10 percent stockholders of the registrant have been excluded. This exclusion should not be deemed a determination or an admission that these individuals are, in fact, affiliates of the registrant.
Shares of common stock outstanding as of February 16, 2022: 33,097,540
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the following document are specifically incorporated by reference into the indicated parts of this report:
 
DocumentPart
Proxy Statement for the 2022 Annual Meeting of Stockholders
Part III, Item 10
“Directors, Executive Officers and Corporate Governance”
Part III, Item 11
“Executive Compensation”
Part III, Item 12
“Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters”
Part III, Item 13
“Certain Relationships and Related Transactions, and Director Independence”
Part III, Item 14
“Principal Accounting Fees and Services”



INTEGER HOLDINGS CORPORATION
ANNUAL REPORT ON FORM 10-K
For the Year Ended December 31, 2021
TABLE OF CONTENTS
PAGE

- 2 -
PART I

ITEM 1.    BUSINESS

OVERVIEW
Integer Holdings Corporation, headquartered in Plano, Texas, is among the world’s largest medical device outsource (“MDO”) manufacturing companies, serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. We provide innovative, high quality medical technologies that enhance the lives of patients worldwide. In addition to medical technologies, we develop batteries for high-end niche applications in energy, military, and environmental markets. Our brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Our primary customers include large, multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries. When used in this report, the terms “Integer,” “we,” “us,” “our” and the “Company” mean Integer Holdings Corporation and its subsidiaries.
We organize our business into two reportable segments, Medical and Non-Medical, and derive our revenues from four principal product lines. The Medical segment includes the Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation (“Cardiac & Neuromodulation”) and Advanced Surgical, Orthopedics & Portable Medical product lines and the Non-Medical segment comprises the Electrochem product line.
Our Acquisitions and Divestitures
On December 1, 2021, we acquired 100% of the outstanding equity interests of Oscor Inc., Oscor Caribe, LLC and Oscor Europe GmbH (collectively “Oscor”), privately-held companies with operations in Florida, the Dominican Republic and Germany that design, develop, manufacture and market a comprehensive portfolio of highly specialized medical devices, venous access systems and diagnostic catheters and implantable devices. Refer to Note 2 “Business Acquisitions” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information about the acquisition.
On February 19, 2020, we acquired certain assets and liabilities of InoMec Ltd. (“InoMec”), a privately-held company based in Israel that specializes in the research, development and manufacturing of medical devices, including minimally invasive tools, delivery systems, tubing and catheters, surgery tools, drug-device combination, laser combined devices, and tooling and production. The acquisition enabled us to create a research and development center in Israel, closer to the customer base in the region. Refer to Note 2 “Business Acquisitions” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information about the acquisition.
On October 7, 2019, we acquired certain assets and liabilities of US BioDesign, LLC (“USB”), a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The acquisition added a differentiated capability related to the complex development and manufacture of braided and formed biomedical structures to our broad portfolio, that we believe further positioned us as a partner of choice for innovative medical technologies. Refer to Note 2 “Business Acquisitions” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information about the acquisition.
On July 2, 2018, we completed the sale of the Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) to Viant. As a result, we classified the results of operations of the AS&O Product Line as discontinued operations in the Consolidated Statements of Operations for all periods presented. All results and information presented exclude the AS&O Product Line unless otherwise noted. Refer to Note 20 “Discontinued Operations” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information about the divestiture.
- 3 -
MEDICAL SEGMENT
Cardio & Vascular
The Cardio & Vascular product line leverages a global footprint to produce a full range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures.
The following are the principal products and services offered by our Cardio & Vascular product line:
Interventional Cardiology. Our interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Key products and capabilities span a full suite of devices including coronary stents, balloon catheters, atherectomy devices, imaging and sensing devices, chronic total occlusion solutions, percutaneous transluminal coronary angioplasty and access guidewires, introducer sheaths, and vascular closure devices. Core areas of technical expertise include laser-cut hypotubes, catheter shafts (extrusion, filmcast, and reflow), integrated hub assemblies, pad printing, tip shaping, polytetrafluoroethylene (PTFE) coating, complex machining, and sensor integration.
Structural Heart and Heart Failure. Structural heart and heart failure products include those used by cardiologists, echocardiographers, cardiac surgeons, and heart failure specialists to treat diseases or defects of the heart, such as valvular diseases and congenital defects. Integer provides components, subassemblies, and finished devices to these markets leveraging a wide range of technologies and capabilities. These include laser-cut and machined components, complex braided meshes, guidewires, introducer sheaths, steerable sheaths and delivery catheters, and implants used in transcatheter aortic valve replacement, balloon aortic valvuloplasty, transcatheter mitral valve repair and replacement, atrial and defect closure, left ventricular assist, and shunt procedures.
Peripheral Vascular, Neurovascular, and Interventional Oncology. Our peripheral vascular, neurovascular, urology and oncology portfolio is primarily focused on the design, development and manufacture of devices used during the treatment of peripheral artery disease, transcatheter embolization and occlusion, aortic aneurysm repair, and neurovascular stroke prevention. Our broad portfolio of devices, capabilities and technology platforms provides our customers with cost effective, high quality solutions ranging from device components to complex assemblies to finished devices such as regulatory approved guidewires and introducers.
Integer’s broad technology and capability portfolio within the peripheral vascular markets enables us to address the full spectrum of devices needed in the diagnoses and treatment of peripheral vascular disease. In the peripheral artery disease markets, our technologies are focused on the manufacture and development of interventional guidewires, support catheters, introducers and guiding sheaths, balloon catheters, self-expanding stents and stent grafts as well as embolic protection devices. Our neurovascular technology portfolio encompasses micro guidewires, micro and access catheters, aspiration catheters, stent retrievers, embolization coils, as well as flow diverters. In the interventional oncology market, we offer customers guidewires and microcatheters designed to enable the effective delivery of embolic agents.
Electrophysiology. Electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation. Integer primarily produces devices used for treatment of atrial fibrillation, the most prevalent cardiac arrythmia. These devices include sheaths and needles for transseptal access, diagnostic and mapping catheters to record and map the arrythmia sources, and ablation catheters to create lesions for blocking the arrythmia signals. Integer has the technical capabilities and expertise to provide the full spectrum of products from components to finished devices. Typical components include polyimide tubing, electrode rings, platinum tips and fine wires. Sub-assemblies include electrode ring and wire assemblies, steerable handle assemblies, and spline and basket assemblies. Finished devices include steerable transseptal sheaths, diagnostic catheters and ablation catheters.
Vascular Access, Infusion Therapy and Hemodialysis. Our solutions in these markets are focused on vessel access, treatment and device placement for medication and fluid delivery in patients with severe conditions requiring repeated vessel access. We design and manufacture a wide range of vascular access guidewires, stylets, catheters, valved / non-valved peelable and micro introducers. Our portfolio of market-ready vascular access guidewires and introducers kits enables a range of venous and arterial access applications, including transradial access. Additionally, we support customers with custom introducer sheaths and kit solutions leveraging our deep expertise in thin-wall sheath design, hydrophilic coatings and guidewire manufacturing (including poly-jacketed, mandrel, and nitinol core guidewire constructions).
- 4 -
Non-vascular Markets: Within the Cardio & Vascular group, we also manage non-vascular markets for which we have expertise and offer a broad range of products, technologies and capabilities. Those markets include:
Urology. Our main focus is in endourology for which we develop and manufacture finished devices and components for access and interventional devices such as guidewires, ureteral access sheaths, dilation devices, retrieval devices, ureteral stents, biopsy forceps, holmium laser fibers, and endoscopes.
Gastroenterology. Our comprehensive range of technologies and capabilities enable us to support our customers’ needs with a broad variety of products such as guidewires, dilatation devices, retrieval devices, snares, wire-formed and polymer stents, stent delivery systems, RF ablation devices, and endoscopes.
Cardiac & Neuromodulation
The Cardiac & Neuromodulation product line offers design, development and manufacturing capabilities for components, sub-assemblies, assemblies, and finished medical device systems. We support a variety of clinical markets, with an emphasis on the following markets:
Cardiac Rhythm Management. The Cardiac Rhythm Management (“CRM”) market comprises implanted medical devices (“IMDs”), implanted leads, procedure accessories, as well as external devices that monitor and treat heart rhythm disorders and heart disease. Examples of CRM products include implantable pacemakers, implantable cardioverter defibrillators (“ICDs”), insertable cardiac monitors (“ICMs”), implantable cardiac pacing and defibrillation leads, and heart failure therapies such as ventricular assist devices and cardiac resynchronization devices (“CRT-P” and “CRT-D”). An IMD system generally includes an implantable pulse generator (“IPG”) and one or more stimulation leads. An IPG is a small battery powered device implanted under the skin in the chest that can sense and produce electrical pulses through specialized wires called leads. These leads sense electrical heart signals and carry them back to the IPG which in turn delivers electrical pulses back through the lead to the heart to deliver therapy.
Our portfolio of technologies and products include components, sub-assemblies, and assemblies for active IPGs, implanted sensing and stimulation leads, accessories, or external instruments. Our investments in research and development have created leadership positions in battery, capacitor, and feedthrough technology, including filtered feedthroughs. We are also a supplier of medical stamped components, and shallow and deep draw casings and assemblies.
Beyond the IPG, Integer’s CRM product line provides lead development and manufacturing solutions including expertise in low-polarization specialty-coated electrodes and components, and lead and device accessories such as stylets, guidewires, introducers, and lead adapters. Integer also offers fully designed and manufactured epicardial pacing leads.
Neuromodulation. Similar to the CRM market, the Neuromodulation (“Neuro”) market comprises IPGs, implanted leads, procedure accessories, and external devices, such as battery chargers, trial stimulators and patient controllers. Examples of Neuro products include implantable spinal cord stimulators for chronic pain, sacral nerve stimulators for incontinence, deep brain stimulators for movement disorders and other IMDs to treat psychiatric disorders, sleep disorders and hearing loss. The Neuro market also includes several new emerging applications, such as implanted bioelectronic devices aimed at treating chronic diseases.
Within the Neuro market we offer IMD component technologies that have been developed to meet the needs of our customers including our Xcellion® line of lithium-ion rechargeable batteries, QMR® and CFx non-rechargeable batteries, feedthroughs, device enclosures, machined components and lead components and sub-assemblies. Additionally, Integer helps OEMs and other emerging companies with the development and manufacture of complete neuromodulation IMD solutions, including custom IPGs, programmer systems, battery chargers, patient controllers, fully finished lead systems and accessories from initial development through commercial quantities.
Advanced Surgical, Orthopedics & Portable Medical
The Advanced Surgical, Orthopedics & Portable Medical (“AS&O”) product line offers a broad range of products and services across the many businesses it serves. This product line includes sales to the acquirer of our AS&O Product Line, Viant.
The following are the principal products and services offered by our AS&O product line:
Portable Medical. We are a leading provider of advanced batteries and power solutions for global OEMs. We specialize in the design and manufacture of Li-ion battery packs and chargers. Through the combination of our innovative research and development expertise, manufacturing excellence and leading customer partnerships we advance the way healthcare is powered. Our offerings include customized rechargeable batteries and chargers to power medical devices across multiple clinical markets including patient monitoring, ventilators, portable defibrillators, portable ultrasound, X-Ray machines, hearing devices, and LVAD devices. We collaborate with our customers on product development opportunities incorporating our power solutions into Class I, II or III medical devices.
- 5 -
Minimally Invasive & General Surgery. Our minimally invasive and general surgery products are primarily arthroscopic, laparoscopic, and general surgery devices and components used for minimally invasive procedures in the joint, abdominal, gastroesophageal reflux disease (“GERD”), ophthalmology, oncology, and general surgery spaces. Our products include, harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles.
Orthopedic. Our orthopedic products include instruments used in hip, knee, and spine surgeries. Our products primarily consist of reamers and chisels.
NON-MEDICAL SEGMENT
Our power solutions enable the success and advancement of our customers’ critical non-medical applications. We provide custom battery packs to the energy, military and environmental markets for use in extreme environments where failure is not an option.
The following are the principal products and services offered by our Non-Medical product line:
Electrochem. Electrochem provides customized battery power and power management systems to markets where safety, reliability, quality and durability are critical. We design customized primary (non-rechargeable) battery solutions, which are used in the energy, military and environmental markets.
Electrochem’s primary lithium power solutions, which include high, moderate and low rate non-rechargeable cell solutions, are utilized in extreme conditions and are built to withstand exceptionally high and low temperatures, and high shock and vibration. Electrochem’s product design capability includes protective circuitry, glass-to-metal hermetic seals, fuses and diodes to help ensure safe, durable and reliable power as devices using our battery solutions are subjected to harsh conditions. Electrochem also manufactures complementary technologies in the form of real time battery monitoring, and an alternate power technology in the form of high temperature super capacitors. Our primary batteries are used in remote and demanding environments, including down hole drilling tools, pipeline inspection, military devices, and oceanographic buoys.
OTHER FACTORS IMPACTING OUR OPERATIONS
Customers
Our products are designed to provide reliable, long-lasting solutions that meet the evolving requirements and needs of our customers. The nature and extent of our commercial relationships with each of our customers are different in terms of breadth of products purchased, product volumes, length of contractual commitment, ordering patterns, inventory management, and selling prices. Contracts with customers can include rebates and tiered pricing arrangements based on pre-determined volume levels, in which higher volume levels typically have lower pricing, or fixed annual price downs that are offered to customers in exchange for increased volume levels and/or longer contract terms.  Typically, our contracts specify minimum order quantities and lead times.
We have limited visibility into our customers’ future purchases, covering only a relatively short period of time. Our customers may have inventory management programs, vertical integration plans and/or alternate supply arrangements that may not be communicated to or shared with us. Additionally, the relative market share among the OEM manufacturers changes periodically, which may cause customer inventory levels to rebalance to match new demand. Consequently, these and other factors can significantly impact our sales in any given period. Our customers may initiate field actions with respect to market-released products. These actions may include product recalls or communications with a significant number of physicians about a product or labeling issue. The scope of such actions can range from very minor issues affecting a small number of units to more significant actions.
Our Medical customers include large multi-national medical device OEMs and their subsidiaries. During 2021, three of our Medical segment customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 47% of our total sales. We believe that the diversification of our sales among the various subsidiaries and market segments with those three customers reduces our exposure to negative developments with any one customer. Our Non-Medical customers include large multi-national OEMs and their subsidiaries serving the energy, military and environmental services markets. During 2021, sales to one of our Non-Medical segment customers was in excess of 10% of our Non-Medical segment sales, but did not exceed 10% of our total sales. The loss of a significant amount of business from any large customer or a further consolidation of such customers could have a material adverse effect on our financial condition and results of operations, as further explained in Item 1A “Risk Factors” of this report.
- 6 -
Sales and Marketing
We sell our products directly to our customers. In 2021, approximately 55% of our products sold were shipped to locations in the U.S. Sales within and outside the U.S. are primarily to customers whose corporate offices are located and headquartered in the U.S. Information regarding our sales by geographic area is set forth in Note 18 “Segment and Geographic Information” of the Notes to Consolidated Financial Statements contained in Item 8 of this report.
Although the majority of our customers contract with us to develop custom components and assemblies to fit their product specifications, we also provide system and device solutions ready for market distribution by OEMs. We have established close working relationships between our internal program managers and our customers. We market our products and technologies at industry meetings and trade shows domestically and internationally. We have placed additional emphasis on reaching long-term agreements with our OEM customers to secure our revenue base and incentivize growth.
Internal account executives support all sales activity and involve engineers and technology professionals in the sales process to address customer requests across all product lines. For system and device solutions, we partner with our customers’ research, marketing, and clinical groups to jointly develop technology platforms in alignment with their product roadmaps and therapy needs.
We leverage our account executives with support from our engineers to design and sell product solutions into our targeted markets. Our account executives are trained to assist our customers in selecting appropriate materials and configurations. We market our products and services through well-defined selling strategies and marketing campaigns that are customized for each of the industries we target.
Firm backlog orders at December 31, 2021 were approximately $461 million. The majority of the orders outstanding at December 31, 2021 are expected to be shipped within one year.
Competition
The MDO manufacturing industry has traditionally been highly fragmented with several thousand companies, many of which we believe have limited manufacturing capabilities and limited sales and marketing expertise. We believe that very few companies offer the scope of manufacturing capabilities and services that we provide to medical device companies, however, we may compete in the future against other companies that provide broad manufacturing capabilities and related services. We compete against different companies depending on the type of product or service offered or the geographic area served. We also face competition from existing and prospective customers that employ in-house capabilities to produce some of the products we provide.
Our existing or potential competitors include suppliers with different subsets of our manufacturing capabilities, suppliers that concentrate in niche markets, and suppliers that have, are developing, or may in the future develop, broad manufacturing capabilities and related services. We compete for new business at all phases of the product life cycle, which includes development of new products, the redesign of existing products and transfer of mature product lines to outsourced manufacturers. Competitive advantage is generally based on reputation, quality, delivery, responsiveness, breadth of capabilities, including design and engineering support, price, customer relationships and increasingly the ability to provide complete supply chain solutions rather than only producing and providing individual components.
Acquisitions and Investments
One facet of our growth strategy is to acquire additional technology or manufacturing capability to expand our product offering in our key existing growth markets. We expect to continue to engage in business development activities and technology licensing arrangements to support our growth in these markets.
As our customers grow and consolidate, they seek suppliers who can offer broad product capabilities, manufacturing scale and facilitate speed to market. Our strategy aligns with enhancing our portfolio from both organic and inorganic means to partner more broadly with our customers to support their growth. Our inorganic strategy will be primarily focused on strategic “bolt-on” acquisitions that will supplement our existing product portfolio.
- 7 -
Strategic Overview
We continue to take steps to better align our resources in order to invest to grow and protect, and preserve our portfolio of products. In addition to our portfolio strategy, we continue to execute our six key operational strategic imperatives designed to drive excellence in everything we do:
•Sales Force Excellence: We have changed the organizational structure to match product line growth strategies and customer needs. This change is about getting more out of the capabilities we already have, and has increased individual accountability and clarity of ownership, while serving customers more effectively.
•Market Focused Innovation: We are ensuring we get the most return on our research and development investments. We are focused on having a clear picture of how we spend our money so we can increase investments to drive future growth.
•Manufacturing Excellence: The goal is to deliver world-class operational performance in the areas of safety, quality, delivery and overall efficiency. We want to transition our manufacturing into a competitive advantage through a single, enterprise-wide manufacturing structure known as the Integer Production System. This system will provide standardized systems and processes by leveraging best practices and applying them across all of our global sites.
•Business Process Excellence: We are taking a systematic approach to driving excellence in everything we do by standardizing, optimizing and ultimately sustaining all of our processes.
•Leadership Capability: We have a robust plan to make leadership a competitive advantage for us, and as the success rate is higher with internal hires, we are focusing on finding and developing leaders from within the Company to build critical capabilities for future success.
•Performance Excellence: We are raising the bar on associate performance to maximize our impact. This includes aligning key roles with critical capabilities, positioning the best talent against the biggest work, and putting tools and processes in place to provide higher financial rewards for top performers, so our top performers can see increased results in pay for increased results in their performance.
We believe we are well-positioned within the medical technology and MDO manufacturing market and that there is a robust pipeline of opportunities to pursue. We have expanded our medical device capabilities and are excited about opportunities to partner with customers to drive innovation. We believe we have the scale and global presence, supported by world-class manufacturing and quality capabilities, to capture these opportunities. We are confident in our capabilities as one of the largest MDO manufacturers, with a long history of successfully integrating companies, driving down costs and growing revenues over the long-term. Ultimately, our strategic vision is to drive shareholder value by enhancing the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.
Research and Product Development
Our position as a leading developer and manufacturer of medical devices and components is largely the result of our long history of technological innovation. Our scientists, engineers and technicians focus on developing new products, improving and enhancing existing products, and expanding the use of our products in new or tangential applications. In addition to our internal technology and capability development efforts aimed at providing our customers with differentiated solutions, we also engage outside research institutions for unique technology projects.
Medical. We believe our core business is well positioned because our OEM customers leverage our portfolio of intellectual property. We continue to build a healthy pipeline of diverse medical technology opportunities and provide a new level of industry leading capabilities and services to our OEM customers across the full range of medical device products and services. We are at the forefront of innovating technologies and products that help change the face of healthcare, enabling us to provide our customers with a distinct advantage as they bring complete medical systems and solutions to market. In turn, our customers are able to accelerate patient access to life enhancing therapies. We offer our customers a comprehensive portfolio comprising the best technologies, providing a single point of support, and driving optimal outcomes.
- 8 -
Some of the more significant product development opportunities our Medical segment is pursuing are as follows:
Product LineProduct Development Projects
Cardio & VascularActive projects in structural heart delivery systems subassemblies, structural heart delivery accessories, structural heart implants, electrophysiology catheters, accessories and subassemblies, peripheral vascular catheters and guidewires, neurovascular therapies to prevent hemorrhagic and ischemic stroke, enhanced access introducers, gastrointestinal scope components, fractional flow reserve guidewire subassemblies, sensor-enabled guidewires, and oncology catheters. Technology investments to enable our customer’s catheter, delivery system, introducer, guidewire, and implant development programs in our core Cardio & Vascular markets.
Cardiac & NeuromodulationActive projects to develop custom batteries, filtered feedthroughs, high voltage capacitors and finished device solutions including both leads and IPG systems that reduce the size and cost, while improving performance, for cardiac and neuromodulation devices.
Non-Medical. Some of the more significant product development opportunities in our Non-Medical segment are next generation medium-rate and high-rate batteries that offer extended performance such as higher power pulsing capabilities and increased operating temperature range, real time battery monitoring, and high temperature super capacitors.
Patents and Proprietary Technology
Our policy is to protect our intellectual property rights related to our technologies and products, and we rely on a combination of patents, licenses, trade secrets and know-how to establish and protect our rights. Where appropriate, we apply for U.S. and foreign patents. We also are a party to license agreements with third parties under which we have obtained, on varying terms, exclusive or non-exclusive rights to patents held by them. In the aggregate, these intellectual property assets and licenses are of material importance to our business; however, we believe that no single patent, technology, trademark, intellectual property asset or license is material in relation to any segment of our business or to our business as a whole. As of December 31, 2021, we owned 505 U.S. and foreign patents, and have license right to another 221 patents.
Design, development and regulatory aspects of our business also provide competitive advantages, and we require our employees, consultants and other parties having access to our confidential information to execute confidentiality agreements. These agreements prohibit disclosure of confidential information to third parties, except in specified circumstances. In the case of employees and consultants, the agreements generally provide that all confidential information relating to our business is the exclusive property of Integer.
Manufacturing, Regulatory and Quality Assurance
We leverage our strength as an innovative designer and manufacturer of finished devices and components to the medical device industry. Our manufacturing and engineering services include: design, testing, component manufacture, and device manufacture. We also provide regulatory services including product registration and post-market surveillance in accordance with the regulatory requirements of the U.S. and EU as well as other geographies. We have integrated our proprietary technologies in our own products and those of our customers. Our flexible, high productivity manufacturing capabilities span sites across the United States, Mexico, Uruguay, Ireland, Malaysia, the Dominican Republic, and Israel.
Due to the highly regulated nature of the products we produce, we have implemented strong quality systems across all sites. The quality systems at our sites are compliant with and certified to various recognized international standards, requirements, and directives. Each site’s quality system is certified under an applicable International Organization for Standardization (“ISO”) quality system standard, such as ISO 13485 (Medical device and component sites) or ISO 9001 (Electrochem). This certification requires, among other things, an implemented quality system that applies (where applicable) to the design and manufacture of components, assemblies and finished medical devices, including component quality and supplier control. Maintenance of these certifications for each facility requires periodic re-examination from an independent notified body.
Along with ISO 13485, the facilities producing finished medical devices are subject to oversight by Notified Bodies and extensive and rigorous regulation by numerous government bodies, including the U.S. Food and Drug Administration (“FDA”) and other international regulatory agencies, to assure the conformance of devices and components on a worldwide basis. For these facilities, we maintain FDA registration and compliance with all applicable domestic and international regulations. Compliance with applicable regulatory requirements is subject to continual review and is monitored through periodic inspections by the FDA and international regulatory bodies.
- 9 -
Suppliers and Raw Materials
We purchase some critical raw materials from a limited number of suppliers due to the technically challenging requirements of the supplied product and/or the lengthy process required to qualify these materials both internally and with our customers. We cannot quickly establish additional or replacement suppliers for these materials because of these rigid requirements. For these critical raw materials, we maintain safety stocks and partner with suppliers through contract to help ensure the continuity of supply.
Many of the raw materials that are used in our products are subject to fluctuations in market price. In particular, the prices of precious metals, such as platinum, have historically fluctuated, and the prices that we pay for these materials, and, in some cases, their availability, are dependent upon general market conditions. In most cases, we have pass-through pricing arrangements with our customers that purchase components containing precious metals or have established firm-pricing agreements with our suppliers that are designed to minimize our exposure to market fluctuations.
We utilize competitive pricing methods such as bulk purchases, precious metal pool buys, blanket orders, and long-term contracts to secure supply.
As discussed more fully in Item 1A “Risk Factors” of this report, our business depends on a continuous supply of raw materials from a limited number of suppliers. If an unforeseen interruption of supply were to occur, we may be unable to obtain substitute sources for these raw materials on a timely basis, on terms acceptable to us or at all, which could harm our ability to manufacture our products profitably or on time. Additionally, we may be unable to quickly establish additional or replacement suppliers for these materials as there are a limited number of worldwide suppliers.
Working Capital Practices
Our goal is to carry sufficient levels of inventory to ensure that we have adequate supply of raw materials from suppliers and meet the product delivery needs of our customers. We also provide and receive payment terms to customers and from suppliers in the normal course of business. It will continue to be a priority for us to maintain appropriate working capital levels while improving our operating cash flow and managing our leverage ratio.
Government Regulation
Medical Device Regulation
Integer develops, manufactures, markets and sells products in multiple countries throughout the world and is therefore subject to regulation by numerous agencies and legislative bodies, including the FDA, European Commission, Health Product Regulatory Agency, Health Canada, Therapeutics Goods Administration and other comparable foreign counterparts. These regulatory requirements subject our products and our business to numerous risks that are specifically discussed within “Risks Related to Our Industries” under Item 1A “Risk Factors” of this report. A summary of critical aspects of our regulatory environment is included below.  
In the U.S., these regulations are enacted by the Federal Food, Drug and Cosmetic Act and its subsequent amendments, and the regulations issued or proposed thereunder.
The FDA’s Quality System Regulation sets forth basic quality requirements for our sites that includes product design and manufacturing processes, requires the maintenance of certain records, and provides for on-site inspection of our facilities and continuing review by the FDA. Authorization to commercially market our non-exempt products in the U.S. is granted by the FDA under procedures referred to as 510(k) pre-market notification or pre-market approval (“PMA”).  These processes require us to notify the FDA of the new product and obtain FDA clearance or approval before marketing the device.
The FDA classifies medical devices based on the risks associated with use of the device. Devices are classified into one of three categories - Class I, Class II, or Class III. Class I devices are deemed to be low risk and are therefore subject to the least regulatory controls, referred to as General Controls. Class II devices are higher risk devices than Class I and require greater regulatory controls, generally General Controls, and Special Controls which includes a PMA, which provides reasonable assurance of the device’s safety and effectiveness as well as substantial equivalence to a previously cleared device, as demonstrated by data. Class III devices are generally the highest risk devices and are therefore subject to the highest level of regulatory control, requiring a PMA by the FDA before they are marketed and continued controls in the form of amendments or supplements required when product or process changes are made.
- 10 -
The member countries of the European Union (“EU”) have adopted the European Medical Device Directives ("MDD”) and Active Implantable Medical Device Directive (“AIMDD”), which create a single set of requirements for all member countries that apply to our products. The MDD and AIMDD are in the process of being replaced by the European Medical Device Regulation (“EU-MDR”) which became effective in May 2021 after being delayed one (1) year due to the COVID-19 pandemic. These directives require, and the EU-MDR requires, companies that wish to manufacture and distribute medical devices in the EU to obtain a CE Mark for those products. The CE Mark indicates the product has met minimum standards of performance, essential requirements, safety conformity assessment and quality. Companies must work with an EU recognized Notified Body to gain approval for the product and manufacturing site before obtaining free movement of products throughout the member countries. In Europe, our devices are considered either Class I, Class IIa, Class III, or AIMD, under MDD or AIMDD and will be with Class I, Class IIa or Class III under the EU-MDR.
In addition to the U.S. and EU, we have approval to manufacture or market our products in numerous foreign countries and therefore are subject to other regulations affecting, among other things, product standards, sterilization, packaging requirements, labeling requirements, and import laws. We are also subject to onsite inspection by independent bodies with the authority to issue or not issue certifications we may require to be able to sell products in certain countries.  Many of the regulations applicable to our devices and products in these countries are similar to those of the FDA or EU; however, others vary widely, ranging from simple product registrations to detailed submissions such as those required by the FDA.
We believe that the procedures we use for quality controls, development, testing, manufacturing, labeling, marketing and distribution of our medical devices conform to the requirements of all pertinent regulations.
Environmental Health and Safety Laws
We are subject to direct governmental regulation, including the laws and regulations generally applicable to all businesses in the jurisdictions in which we operate. We are subject to federal, state and local environmental laws and regulations governing the emission, discharge, use, storage and disposal of hazardous materials and the remediation of contamination associated with the release of these materials at our facilities and at off-site disposal locations. Our manufacturing and RD&E activities may involve the controlled use of small amounts of hazardous materials. Liabilities associated with hazardous material releases arise principally under the Federal Comprehensive Environmental Response, Compensation and Liability Act and analogous state laws that impose strict, joint and several liability on owners and operators of contaminated facilities and parties that arrange for the offsite disposal of hazardous materials. We are not aware of any material noncompliance with the environmental laws currently applicable to our business and we are not subject to any material claim for liability with respect to contamination at any of our facilities or any offsite location. We may have environmental liability associated with historic operations as disclosed in Note 13 “Commitments and Contingencies” of the Notes to Consolidated Financial Statements contained in Item 8 of this report. We may also become subject to environmental liabilities in the future as a result of other historic or current operations.
Conflict Minerals and Supply Chain
We are subject to Securities and Exchange Commission (“SEC”) rules adopted pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act concerning “conflict minerals” (generally tin, tantalum, tungsten and gold) and similar rules are being implemented by the EU. Certain of these conflict minerals are used in the manufacture of our products. These rules require us to investigate the source of any conflict minerals necessary to the production or functionality of our products. If any such conflict minerals originated in the Democratic Republic of the Congo or adjoining countries (the “DRC region”), we must undertake due diligence efforts to determine whether such minerals financed or benefited armed groups in the DRC region. Since our supply chain is complex, our ongoing compliance with these rules could affect the pricing, sourcing and availability of conflict minerals used in the manufacture of our products.
We are also subject to disclosure requirements regarding abusive labor practices in portions of our supply chain under the California Transparency in Supply Chains Act and the UK Modern Slavery Act.
Other Laws and Regulations
Our sales and marketing practices are subject to regulation by the U.S. Department of Health and Human Services pursuant to federal anti-kickback laws, and are also subject to similar state laws.
- 11 -
Human Capital
As of December 31, 2021, Integer employed approximately 9,000 associates worldwide, of whom approximately 4,000 are located in the U.S., 2,400 in Mexico, 1,300 in Ireland, 600 in the Dominican Republic, 300 in Uruguay, 300 in Malaysia, as well as a small number of associates in Germany, Israel, and Switzerland. We also employ approximately 50 temporary associates worldwide to assist with various projects and service functions and address peaks in staff requirements. We believe that we have a good relationship with our associates. Our Board of Directors and the executive team put significant focus on our human capital resources, as we strive to build leadership capability and create a diverse, inclusive work environment that inspires excellence. This cultural framework recognizes the value of individuals as critical to Integer’s operational strategy.
Associate Management and Development
Leaders at Integer are responsible for managing and developing the talent of their associates. To facilitate leaders’ efforts, we rely on a “Talent Cycle” framework, which provides an integrated method for meeting the human capital needs of the company. The Talent Cycle (i) defines the major categories of leadership responsibilities in alignment with the employment lifecycle and (ii) prioritizes programs and resources to ensure these responsibilities are executed consistently. Stages of the Talent Cycle include:
•Planning for current and future capabilities
•Acquiring the critical talent needed to run our business
•Engaging our associates to motivate and retain them
•Differentiating our talent at all levels to foster a performance culture
•Developing our talent to achieve performance excellence
•Building leadership capability and promoting associates who have demonstrated strong leadership capability
Developing our talent is one of the most critical stages in the Talent Cycle and an ongoing focus at Integer. To support the advancement of our associates, we have defined a model of core skills and competencies to guide associates in their development planning, and we encourage associates to actively focus on their own development though individual development plans, designed to help each associate be more effective in their current role and to prepare for their next role. Additionally, we regularly conduct talent reviews and succession planning to identify and develop our top leadership talent. Finally, all of our associates participate in our performance management process, which involves both ongoing feedback and a formal performance evaluation at year-end.
Leadership Development
Our success as a company is tied to the effectiveness of our leaders in setting direction, aligning resources and engaging our workforce in accomplishing our strategic goals. To that end we have built a foundation of leadership development resources and programs to enhance our leaders’ capabilities. This includes leadership competencies, 360-degree feedback for senior leadership, and various online and virtual programs aligned to our leadership competencies.
Competitive Pay/Benefits and Gender Equity
Our total rewards program is designed to attract, retain and motivate associates to contribute to Integer’s success, and includes market-competitive elements reflective of the geographies in which we operate. We incorporate many factors into associate pay decisions, including market comparisons of compensation and benefits for similar roles, individual associate skills and experience in their role, individual performance annually and over multiple years, and relative contributions to the Company’s short- and long-term success. Reflective of our commitment to diverse representation at Integer, 46% of our workforce are women, and we have analyzed the compensation of our senior leadership team and concluded there is no pay gap between genders.
Focus on Diversity, Inclusion and Non-Discrimination
At Integer, through our values, Code of Conduct, and commitment to Diversity and Inclusion (“D&I”), we strive to create a culture that unifies and embraces the uniqueness each associate brings to Integer, positioning the Company for long-term success. We are committed to creating a better, more inclusive company in which all of us accept, respect and value one another’s individual differences, encouraging different perspectives and ideas that improve team synergy and communication.
Our management approach continues to accelerate our D&I strategy, creating a robust engagement platform designed to increase innovation and enhance business. We have infused D&I into our business processes and created local and global engagement opportunities for associates.
- 12 -
Key successes in our diversity and inclusion strategy include:
•In the United States, 39% of our employee population are people of color
•100% executive leadership actively serve as executive sponsors of D&I initiatives
•Three cross functional governing diversity and inclusion councils, which advance the global D&I strategy at all levels of the organization
•Expanding employee resource groups, which are voluntary, employee-led groups comprised of associates who join together based on common interests, backgrounds or demographic factors
•Diversity and inclusion site champions, whose responsibility it is to promote the company’s diversity and inclusion initiatives at each Integer location
•In 2021, we hosted our first annual Day of Understanding, designed to connect all Integer associates around our core value of inclusion
As part of our management approach and culture of promoting, protecting and respecting all associates, we continue to encourage a workplace free from discrimination or unlawful harassment. We continue to achieve our goal for 100% of associates globally to complete annual Code of Conduct and Anti-Harassment, Non-Discrimination and Anti-Retaliation training. Training is conducted in multiple languages, including English, Spanish and Malay, covering all legal and ethical requirements, and is provided when onboarding all associates hired at Integer and conducted annually thereafter. In addition, all Board members and professional and management associates are required to annually review and certify their understanding of, and agreement to comply with, the Code of Conduct.
Impact of COVID-19
Throughout the COVID-19 global pandemic, the health and safety of our associates has remained a priority for us. We have continually improved our robust and comprehensive pandemic plan in an effort to create a safe work environment to minimize the transmission of COVID-19. Our plan aligns and complies with guidance from government and health authorities worldwide and includes policies, procedures, protocols and guidance related to, among other things, COVID-19 symptom awareness and reporting, education and tools for effective hygiene practices, travel and visitor requirements, social distancing and face covering expectations, temperature and health screening, work-from-home programs and enhanced workplace cleaning. In addition, we have facilitated vaccinations by providing transportation or hosting onsite mobile clinics at many of our sites.
We have consistently monitored benefits available or required for our associates under various governmental programs, including assistance for associates unable to work for COVID-19 reasons. We have sought, and will continue to seek, to understand whether these benefits apply to our associates and how the available benefits support the best interests of our associates; to execute programs to comply with required benefits; and to analyze whether the available benefits may impact our business now or in the future.
Seasonality
Our business is generally not seasonal in nature. However, since most of our customers are large OEM businesses, our sales are influenced by the inventory levels they carry, which can cause shifts in our sales volume as their inventories fluctuate.
Available Information
Our Internet address is www.integer.net. We also make available free of charge through our website our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file those reports with, or furnish them to, the SEC. The information contained on our website is not incorporated by reference in this annual report on Form 10-K and should not be considered a part of this report. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers, including the Company, that file electronically with the SEC. The public can obtain any documents that we file with the SEC at www.sec.gov.
- 13 -
INFORMATION ABOUT OUR EXECUTIVE OFFICERS
Information concerning our executive officers is presented below as of February 22, 2022. The officers’ terms of office run from year to year until the first meeting of the Board of Directors occurring immediately following our Annual Meeting of Stockholders, and until their successors are elected and qualified, except in the case of earlier death, retirement, resignation or removal.
Joseph W. Dziedzic, age 53, is President and Chief Executive Officer of the Company and a member of our Board of Directors. He assumed that role on July 16, 2017 following his appointment as interim President & Chief Executive Officer on March 27, 2017. Mr. Dziedzic was the Executive Vice President and Chief Financial Officer of The Brink’s Company from 2009 to 2016, and prior to joining The Brink’s Company in 2009, he had a 20-year career with General Electric.
Jason K. Garland, age 48, is the Company’s Executive Vice President and Chief Financial Officer. Mr. Garland had served as Divisional Vice President & Chief Financial Officer, Global Sales, for Tiffany & Co. from October 2017 until joining the Company in October 2018, and had served as Divisional Vice President & Chief Financial Officer, Diamond & Jewelry Supply, for Tiffany & Co. from July 2015 to October 2017. From 1995 to 2015, Mr. Garland served in various financial and operational roles at General Electric, including as Chief Financial Officer, GE Industrial Solutions, from March 2010 to June 2015.
Joel Becker, age 54, is President, CRM & Neuromodulation, and joined the Company in April 2019. Mr. Becker is also the leader for the Sales Force Excellence strategic imperative. Prior to joining the Company, he was the President of Viking North Ventures from October 2016 to April 2019 and served as the Chief Executive Officer of XchangeLabs LLC from August 2017 to August 2018. Prior to those positions, Mr. Becker had a nearly 20-year career with St. Jude Medical where he held a variety of different roles including President, Americas Division from July 2013 to February 2016, and President, United States Division from October 2011 to July 2013.
Jennifer M. Bolt, age 53, is Senior Vice President, Global Operations and ESG, and has served in that position since April 2019. From October 2015 to April 2019, Ms. Bolt served as President, Electrochem. In November 2017, Ms. Bolt assumed leadership of the Portable Medical product line, and in February 2018, she assumed leadership for the Integer Manufacturing Excellence strategic imperative. From June 2013 to October 2015, she was Vice President, Supply Chain and Operational Excellence for Greatbatch.  Ms. Bolt held the position of Vice President, Operations for Electrochem from May 2012 to June 2013, and prior to that served as Director of Operations of our Raynham, MA facility from September 2007 to May 2012.  Ms. Bolt joined our Company in May 2005 as the Manufacturing Engineering Manager for our Alden, New York facility.  Prior to joining our Company, she served in a variety of engineering and operational roles at General Motors/Delphi and Eastman Kodak.
Margaret Carthy, age 58, is Senior Vice President, Quality and Regulatory Affairs. She joined the Company in 2004 and was promoted to her current position in January 2022. Before assuming this role, Ms. Carthy served as Vice President of Quality and Regulatory for our Cardio & Vascular product category. Prior to joining our Company, Ms. Carthy was a Quality & Regulatory Leader for the European Region at Sola International, now Carl Zeiss.
Carter Houghton, age 53, is President, Electrochem and Power Solutions. From December 2016 until joining the Company in May 2019, Mr. Houghton was President of the Hospital Business Unit at Haemonetics Corporation. Prior to joining Haemonetics, Mr. Houghton had over an 11-year career with Hologic where he served in various leadership roles including Senior Vice President & General Manager, GYN Surgical Solutions Division from February 2013 to August 2015, and Vice President & General Manager, Interventional Breast Solutions Division from February 2010 to September 2013.
Payman Khales, age 52, is President, Cardio & Vascular, and joined the Company on February 20, 2018. Mr. Khales is also the leader for the Integer Market Focused Innovation strategic imperative. Prior to joining Integer, Mr. Khales was the President of the Environmental Technologies Segment at CECO Environmental Company from May 2014 through July 2017. Previously, he was employed by Ingersoll Rand Company where he held a variety of different roles in the United States and Canada, including Vice President Product Management for the global Power Tools division from January 2012 through April 2014, and Vice President Strategic Accounts & Channels from February 2010 through December 2011.
McAlister C. Marshall, II, age 52, is Senior Vice President, General Counsel, Chief Ethics and Compliance Officer and Corporate Secretary. He joined the Company in September 2021 on an interim basis and assumed his current role on a permanent basis in January 2022. Mr. Marshall was previously the Senior Vice President, General Counsel and Chief Administrative Officer at The Brink’s Company from July 2016 until December 2018, after serving as Vice President and General Counsel beginning in September 2008. Mr. Marshall continued to serve as a consultant for The Brink’s Company until December 2019.
Kirk Thor, age 58, is Executive Vice President and Chief Human Resources Officer. From 2013 until joining the Company in January 2018, Mr. Thor was Vice President for Global Talent Management & Organization Effectiveness at Flowserve Corporation. From 2007 to 2012, he served as Vice President for Talent Management & Organization Development at JC Penney. In February 2018, he assumed leadership for the Integer Culture strategic imperative.
- 14 -
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:
•the impact of the COVID-19 global pandemic on the Company and our business;
•future development and expected growth of our business and industry;
•our ability to execute our business model and our business strategy;
•having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and
•projected contractual debt service obligations.
You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report.
Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following:
•operational risks, such as the duration, scope and impact of the COVID-19 pandemic, including the evolving health, economic, social and governmental environments and the effect of the pandemic on our associates, suppliers and customers as well as the global economy; our dependence upon a limited number of customers; pricing pressures that we face from customers; our reliance on third party suppliers for raw materials, key products and subcomponents; the potential for harm to our reputation caused by quality problems related to our products; the dependence of our energy market-related revenues on the conditions in the oil and natural gas industry; interruptions in our manufacturing operations; our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures; our dependence upon our senior management team and technical personnel; and global climate change and the emphasis on ESG matters by various stakeholders;
•strategic risks, such as the intense competition we face and our ability to successfully market our products; our ability to respond to changes in technology; our ability to develop new products and expand into new geographic and product markets; and our ability to successfully identify, make and integrate acquisitions to expand and develop our business in accordance with expectations;
•financial risks, such as our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under our senior secured credit facilities; economic and credit market uncertainties that could interrupt our access to capital markets, borrowings or financial transactions; financial and market risks related to our international operations and sales; our complex international tax profile; and our ability to realize the full value of our intangible assets; and
•legal and compliance risks, such as regulatory issues resulting from product complaints, recalls or regulatory audits; the potential of becoming subject to product liability or intellectual property claims; our ability to protect our intellectual property and proprietary rights; our ability and the cost to comply with environmental regulations; our ability to comply with customer-driven policies and third party standards or certification requirements; our ability to obtain necessary licenses for new technologies; legal and regulatory risks from our international operations; and the fact that the healthcare industry is highly regulated and subject to various regulatory changes; and
•other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of this report.
- 15 -

ITEM 1A.    RISK FACTORS
Our business faces many risks, and you should carefully consider the following risk factors, together with all of the other information included in this report, including the financial statements and related notes contained in Item 8 of this report, when deciding to invest in us. Any of the risks discussed below, or elsewhere in this report or in our other SEC filings, could have a material impact on our business, financial condition or results of operations. Additional risks not currently known to us or that we currently consider immaterial also may materially adversely affect our business, financial condition or results of operations in the future.
Operational Risks
Our operations have been and may continue to be adversely impacted by the ongoing global impact of the COVID-19 pandemic.
The global spread of the novel coronavirus, or COVID-19, has created significant uncertainty and worldwide economic disruption. COVID-19 has negatively impacted our operating results and may continue to do so in the future. The duration and scope of the impact is uncertain given the evolving health, economic, social and governmental environments.
Specific impacts to our business have included delayed and reduced customer orders, increased absenteeism, disruptions in our supply chain, delays in shipments to and from certain countries, and restrictions on our associates’ ability to travel or work. We expect delayed and reduced customer demand will continue to impact our operations, and the timing of that impact will continue to lag that of our customers, based on varying demand for products and approaches to inventory management. The pandemic has affected and continues to affect our manufacturing facilities and our associates’ health. If the operations of any of our manufacturing sites are materially impacted as a result of the pandemic, it may not be possible for us to continue to timely manufacture relevant products at required levels, or at all. We have modified, and may continue to further modify, our business practices in response to the COVID-19 pandemic and related third-party responses, including from government authorities. Any continued or renewed business closures, operating disruptions, or travel or work restrictions that impact our associates, customers, suppliers or manufacturing facilities will likely continue to adversely affect our operations locally and worldwide and could have a material adverse effect on our operating results and financial condition.
The ultimate impact of the COVID-19 pandemic on our operations and financial performance depends on many factors that are not within our control, including, but not limited, to: governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic (including restrictions on travel, transport and workforce pressures); the impact of the pandemic and actions taken in response on global and regional economies, travel, and economic activity; the availability of federal, state, local or non-U.S. funding programs; general economic uncertainty in key global markets and financial market volatility; global economic conditions and levels of economic growth; and the pace of recovery when the COVID-19 pandemic subsides, which could be impacted by a number of factors, including limited provider capacity to perform procedures using our products that were deferred as a result of the pandemic.
We depend heavily on a limited number of customers, and if we lose any of them or they reduce their business with us, we would lose a substantial portion of our revenues.
In 2021, our top three customers collectively accounted for approximately 47% of our revenues. Reductions in demand from these customers, largely because of reduction in demand for medical procedures during the COVID-19 pandemic, has negatively impacted our results of operations during prior fiscal years and may impact our future results of operations if material reductions in demand recur. These customers may not agree to renew or extend our supply agreements with them. Furthermore, many of our supply agreements do not contain minimum purchase level requirements and therefore there is no guaranteed source of revenue that we can depend upon under these agreements. In addition, we are dependent on the continued growth, viability and financial stability of these customers. The markets in which these customers operate are subject to rapid technological change, vigorous competition and short product life cycles. As a result, when these customers are adversely affected by these factors, we may be similarly adversely affected. The loss of any large customer, a material reduction of business with that customer, or a delay or failure by that customer to make payments due to us, would harm our business, financial condition and results of operations.
We are subject to pricing pressures from customers, which could harm our operating results and financial condition.
Given the highly competitive industry in which we operate, we have reduced prices to some of our customers in recent years and we expect customer pressure for continued price reductions in future periods. These additional price reductions, if they were to occur, may cause our operating results and financial condition to suffer.
- 16 -
We rely on third party suppliers for raw materials, key products and subcomponents. Unavailability of, or increased prices for, these materials, products or subcomponents could adversely affect our results of operations.
Our business depends on a continuous supply of raw materials. The principal raw materials used in our business include platinum, stainless steel, gold, titanium, nitinol, lithium, palladium, iridium, tantalum, nickel cobalt, ruthenium, gallium trichloride, vanadium oxide, CFx and plastics. The supply and price of raw materials may be susceptible to fluctuations due to transportation issues, government regulations, price controls, foreign civil unrest, tariffs, worldwide economic conditions or other unforeseen circumstances, including the continuing impact of the global pandemic. Increasing global demand for raw materials has caused prices of certain materials to increase. Significant increases in the cost of raw materials that cannot be recovered through increases in the prices of our products could adversely affect our results of operations. There can be no assurance that the marketplace will support higher prices or that price increases and productivity gains, procurement deflation projects or savings will fully offset any raw material cost increases in the future. In addition, there are a limited number of worldwide suppliers of several raw materials needed to manufacture our products. For reasons of quality, cost effectiveness or availability, we obtain some raw materials from a single supplier. Although we work closely with our suppliers to seek to ensure continuity of supply, we may not be able to continue to procure raw materials critical to our business at all or to procure them at acceptable price levels. A disruption in deliveries from our suppliers, price increases or decreased availability of raw materials could have an adverse effect on our ability to meet our commitments to our customers and increase our operating costs.
In addition, we rely on third party manufacturers to supply many of the products and subcomponents that are incorporated into our products and components. These third party manufacturers have their own complex supply chains. Manufacturing problems may occur with these and other outside sources, as a supplier may fail to develop or manufacture products and subcomponents for us on a timely basis, or may supply us with products and subcomponents that do not meet our quality, quantity and cost requirements. If any of these problems occur, we may be unable to obtain substitute sources for these products and subcomponents on a timely basis or on terms acceptable to us, which could harm our ability to manufacture our own products and components profitably or on time. In addition, to the extent the processes our suppliers use to manufacture products and subcomponents are proprietary, we may be unable to obtain comparable products and subcomponents from alternative suppliers.
Our business is also subject to risks associated with U.S. and foreign legislation, regulations and trade agreements relating to the materials we import, including the tariffs on steel that the U.S. has imposed and other quotas, duties, tariffs or taxes or restrictions on imports, which could adversely affect our operations and our ability to import materials used in our products at current or increased levels. We cannot predict whether additional U.S. and foreign customs quotas, duties (including antidumping or countervailing duties), tariffs, taxes or other charges or restrictions, requirements as to where raw materials must be purchased or other restrictions on our imports will be imposed in the future or adversely modified, or what effect such actions would have on our costs of operations. Future quotas, duties or tariffs may adversely affect our business, financial condition, results of operations or cash flows. Future trade agreements could also provide our competitors with an advantage over us, or increase our costs, either of which could adversely affect our business, financial condition, results of operations or cash flows.
Quality problems with our products could result in warranty claims and additional costs, could harm our reputation and could erode our competitive advantage.
Quality is important to us and our customers, and our products are held to high quality and performance standards. In the event our products fail to meet these standards, we generally allow customers to return defective or damaged products under warranty. We carry a safety stock of inventory for our customers that may be impacted by warranty claims. We reserve for our exposure to warranty claims based upon recent historical experience and other specific information as it becomes available. However, these reserves may not be adequate to cover future warranty claims. If our reserves for warranty claims are inadequate, additional warranty costs or inventory write-offs may need to be incurred in the future, which could harm our operating results. We also could be subject to negative publicity and our reputation could be harmed if we fail to meet quality standards. This could erode our competitive advantage over competitors, causing us to lose or see a material reduction in business from customers and resulting in lower revenues. In addition, we might be required to devote significant resources to address any quality issues associated with our products, which could reduce the resources available for product development and other matters.
Our energy market revenues are dependent on conditions in the oil and natural gas industry, which historically have been volatile.
Sales of our products into the energy market depend upon the condition of the oil and gas industry. We believe it is likely that oil and natural gas prices will continue to fluctuate in the future. The current and anticipated prices of oil and natural gas influence the oil and gas exploration and production industry and are affected by a variety of political and economic factors, including worldwide demand for oil and natural gas, worldwide and domestic supplies of oil and natural gas, the ability of the Organization of Petroleum Exporting Countries (“OPEC”) to set and maintain production levels and pricing, the level of production of non-OPEC countries, the price and availability of alternative fuels, political stability in oil producing regions and the policies of the various governments regarding exploration and development of their oil and natural gas reserves.
- 17 -
Interruptions of our manufacturing operations could delay production and adversely affect our operations.
Our products are designed and manufactured in facilities located around the world. In most cases, the manufacturing of specific product lines is concentrated in one or a few locations. If an event (including any weather or natural disaster-related event) occurred that resulted in material damage or loss of one or more of these manufacturing facilities or we lacked sufficient labor to fully operate the facility, we might be unable to transfer the manufacture of the relevant products to another facility or location in a cost-effective or timely manner, if at all. This potential inability to transfer production could occur for a number of reasons, including but not limited to a lack of necessary relevant manufacturing capability at another facility, or the regulatory requirements of the FDA or other governmental regulatory bodies. Other disruptions in our manufacturing operations for any reason, including equipment malfunction, failure to follow specific protocols and procedures, or environmental factors could lead to an inability to supply our customers with our products, unanticipated costs, lost revenues and damage to our reputation. The ongoing COVID-19 pandemic has caused, and may continue to cause, delays in production, unanticipated costs and lost revenues. In addition, our business involves complex manufacturing processes and the use of various hazardous materials, chemicals and other regulated substances, such as trichloroethylene, that can be dangerous to our associates. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations. Although we employ safety procedures in the design and operation of our facilities, there is a risk that an accident or death could occur. Any accident, such as a chemical spill or fire, could result in significant manufacturing delays or claims for damages resulting from injuries, which would harm our operations and financial condition. The potential liability resulting from any such accident or death, to the extent not covered by insurance, could harm our financial condition or operating results. Any disruption of operations at any of our facilities, and in particular our larger facilities, could result in production delays, which could adversely affect our operations and harm our business.
Our operations are subject to cyber-attacks and other information technology disruptions that could have a material adverse effect on our business, consolidated results of operations and consolidated financial condition.
In the ordinary course of business, our operations are, and in the future are expected to continue to be, dependent on digital technologies and information technology (“IT”) systems. The COVID-19 pandemic has caused us to modify our business practices, including the requirement that many of our office-based employees work from home, at least part-time. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data. We use these technologies and systems for internal purposes, including data storage, processing and transmissions, as well as in our interactions with customers and suppliers. The security of this information and these systems are important to our operations and business strategy. Our IT systems and infrastructure have been, and in the future are expected to continue to be, subject to the risk of cyber-attacks by hackers or malware, or breach due to associate error, malfeasance or other disruptions, including natural disasters, failures in hardware or software, and power fluctuations. As the techniques used to obtain unauthorized access, disable or degrade service, or sabotage infrastructure and systems change frequently and may be difficult to detect for long periods of time, we may be unable to anticipate these techniques or implement adequate preventive measures. If our systems for protecting against cybersecurity risks or other IT disruptions prove insufficient, our business could be disrupted, resulting in numerous consequences, including temporary or permanent loss of, damage to, third party access to, or misappropriation or public disclosure of intellectual property, proprietary or confidential information, or customer, supplier, or employee data; interruption of our business operations; and increased costs required to prevent, respond to, or mitigate such cybersecurity attacks or IT disruptions. In addition, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed or stolen. These risks could harm our reputation and brand, and our relationships with customers, suppliers, employees and other third parties, and may result in claims or proceedings against us. In certain circumstances, we may rely on third party vendors to process, store and transmit data for our business whose operations are subject to similar risks. These risks could have a material adverse effect on our business, financial condition and results of operations. While we maintain insurance for cyber events, our insurance may not be sufficient to cover us against all losses that could potentially result from a breach of our systems or loss of sensitive data.
We may not be able to attract, train and retain a sufficient number of qualified associates to maintain and grow our business.
We monitor the markets in which we compete and assess opportunities to better align expenses with revenues, while preserving our ability to make needed investments in RD&E projects, capital and our associates that we believe are critical to our long-term success. Our success will depend in large part upon our ability to attract, train, retain and motivate highly skilled associates. There is currently aggressive competition for employees who have experience in technology and engineering. We compete intensely with other companies to recruit and hire from this limited pool, which competition has become more acute during the term of the COVID-19 pandemic. The industries in which we compete for employees are characterized by high levels of employee attrition. Although we believe we offer competitive salaries and benefits, we may have to increase spending to attract, train and retain qualified personnel.
- 18 -
We are dependent upon our senior management team and key technical personnel and the loss of any of them could significantly harm us.
Our future performance depends to a significant degree upon the continued contributions of our senior management team and key technical personnel. In general, only highly qualified and trained scientists have the necessary skills to develop our products, which are often highly technical in nature. The loss or unavailability to us of any member of our senior management team or a key technical employee could significantly harm us. We face intense competition for these professionals from our competitors, customers and companies operating in our industry, which competition has become more acute during the term of the COVID-19 pandemic. To the extent that the services of members of our senior management team and key technical personnel would be unavailable to us for any reason, we would be required to hire other personnel to manage and operate our Company and to develop our products and technology, which could adversely impact our business. We may not be able to locate or employ these qualified personnel on acceptable terms or may need to increase spending to attract these qualified personnel.
Global climate change and related emphasis on environmental, social and governance ("ESG") matters by various stakeholders could negatively affect our business.
Customer, investor and employee expectations relating to ESG have been rapidly evolving and increasing. In addition, government organizations are enhancing or advancing legal and regulatory requirements specific to ESG matters. The heightened stakeholder focus on ESG issues related to our business requires the continuous monitoring of various and evolving laws, regulations, standards and expectations and the associated reporting requirements. A failure to adequately meet stakeholder expectations may result in noncompliance, the loss of business, reputational impacts, diluted market valuation, and an inability to attract customers. In addition, our adoption of certain standards or mandated compliance to certain requirements could necessitate additional investments that could impact our profitability.
Climate changes could disrupt our operations by impacting the availability and cost of materials within our supply chain and could also increase our other operating costs. Further, increased public awareness and concern regarding global climate change may result in new or enhanced legal requirements to reduce or mitigate the effects of greenhouse gas emissions. There continues to be a lack of consistent climate legislation, which creates economic and regulatory uncertainty. Such uncertainty may have an impact on our business, including increased costs of compliance, which may impact our results of operations.
Consolidation in the healthcare industry could result in greater competition and reduce our revenues and harm our business.
Many healthcare industry companies are consolidating to create new companies with greater market power. As the healthcare industry consolidates, competition to provide products and services to industry participants will become more intense. These industry participants may try to use their market power to negotiate price reductions for our products or may undertake additional vertical integration or supplier diversification initiatives. If we are forced to reduce our prices, our revenues would decrease and our operating results would suffer.
Strategic Risks
If we are unable to successfully market our current or future products, our business will be harmed and our revenues and operating results will be adversely affected.
If the markets for our products do not grow as we or industry experts forecast, our revenues could be less than expected. Furthermore, it is difficult to predict the rate at which the markets for our products will grow or if new and increased competition will result in market saturation. Slower growth in the cardiac rhythm, neuromodulation, cardio and vascular, environmental, military or energy markets in particular would adversely impact our revenues. In addition, we face the risk that our products will lose widespread market acceptance. Our customers may not continue to utilize the products we offer and a market may not develop for our future products.
We may at times determine that it is not technically or economically feasible for us to continue to manufacture certain products and we may not be successful in developing or marketing replacement products. Additionally, new technologies that we develop may not be rapidly accepted because of industry-specific factors, including the need for regulatory clearance, entrenched patterns of clinical practice and uncertainty over third party reimbursement. If any of these events occurs, our business will be harmed and our revenues and operating results will be adversely affected.
- 19 -
We may face intense competition that could harm our business, including competitors, in-sourcing and the possibility of dual sourcing; and we may be unable to compete successfully against new entrants and established companies with greater resources.
Competition in connection with the manufacturing of our medical products across all of our product lines, which is fragmented and subject to rapid technological change, has intensified in recent years and may continue to intensify in the future. We encounter significant competition across our product lines and in each market in which our medical products are sold from various medical device companies, some of which may have greater financial, operational, personnel, sales, technical and marketing resources than we do and are more well-established. In addition, our medical customers have in the past elected, and may in the future elect, to insource production or implement supplier diversification initiatives. Such actions have in the past resulted in, and may in the future result in, the customer manufacturing or dual-sourcing some or all of the components or products that we currently supply to them, which could cause our operating results to suffer.
If we do not respond to changes in technology, our products may become obsolete or less competitive and we may experience a loss of customers and lower revenues.
We sell our products to customers in several industries that are characterized by extensive research and development, rapid technological changes, new product introductions and evolving industry standards. Without the timely introduction of new products, technologies and enhancements, our products and services will likely become technologically obsolete or less competitive over time and we may lose or see a reduction in business from a significant number of our customers. We dedicate a significant amount of effort and resources to the development of our products, technologies and enhancements. Our product development efforts may be affected by a number of factors, including our ability to anticipate customer needs, develop or acquire new technologies and enhancements, secure intellectual property protection for our products, and manufacture products in a cost effective manner. We would be harmed if we did not meet customer requirements and expectations. Our inability, for technological or other reasons, to successfully develop and introduce new and innovative products, technologies and enhancements could result in a loss of customers and lower revenues.
We intend to develop new products and expand into new geographic and product markets, which may not be successful and could harm our operating results.
We intend to develop new and modified products using our existing technologies and engineering capabilities and to continue to expand into new geographic and product markets. These efforts have required and will continue to require us to make substantial investments, including significant RD&E expenditures and capital expenditures for new, expanded or improved manufacturing facilities. Additionally, many of the new products we are developing take longer and more resources to develop and commercialize than those products we are currently marketing, including more time and resources required to obtain regulatory approvals.
Specific risks in connection with expanding into new products and product markets include: longer product development cycles, the inability to transfer our quality standards and technology into new products, the failure to receive or the delay in receipt of regulatory approval for new products or modifications to existing products, and the failure of our existing customers or the market generally to accept the new or modified products. Our inability to develop new products or expand into new geographic and product markets, as currently intended, could hurt our business, financial condition and results of operations.
If we are not successful in making acquisitions to expand and develop our business, our operating results may suffer.
One facet of our growth strategy is to make acquisitions that complement our core competencies in technology and manufacturing to enable us to manufacture and sell additional or enhanced products to our existing customers and to expand our business into related markets. Our continued growth may depend on our ability to successfully identify and acquire companies that complement or enhance our existing business on acceptable terms. We may not be able to identify or complete future acquisitions. In addition, we will need to comply with the terms of our Senior Secured Credit Facility and any future financing that we may incur, to pursue and complete future acquisitions. In connection with pursuing this growth strategy, some of the risks that we may encounter include expenses associated with and difficulties in identifying potential targets, the costs associated with unsuccessful acquisitions, and higher prices for acquired companies because of significant competition for attractive acquisition targets.
- 20 -
Successful integration and anticipated benefits of acquisitions cannot be assured and integration matters could divert attention of management away from operations.
Part of our business strategy includes acquiring additional businesses and assets. If we do not successfully integrate acquisitions, including the acquisition of Oscor, we may not realize anticipated operating advantages and cost savings. Our ability to realize the anticipated benefits from acquisitions will depend, to a large extent, on our ability to integrate these acquired businesses with our legacy businesses. Integrating and coordinating aspects of the operations and personnel of the acquired business with legacy businesses involves complex operational, technological and personnel-related challenges. This process is time-consuming and expensive, disrupts the businesses of both companies and may not result in the achievement of the full benefits expected by us, including cost synergies expected to arise from supply chain efficiencies and overlapping general and administrative functions.
The potential difficulties, and resulting costs and delays, include:
•managing a larger combined company;
•consolidating corporate and administrative infrastructures;
•issues in integrating manufacturing, warehouse and distribution facilities, RD&E and sales forces;
•difficulties attracting and retaining key personnel;
•loss of customers and suppliers and inability to attract new customers and suppliers;
•unanticipated issues in integrating information technology, communications and other systems;
•incompatibility of purchasing, logistics, marketing, administration and other systems and processes; and
•unforeseen and unexpected liabilities related to the acquired business.
Additionally, the integration of our legacy businesses with an acquired company’s operations, products and personnel may place a significant burden on management and other internal resources. The attention of our management may be directed towards integration considerations and may be diverted from our day-to-day business operations, and matters related to the integration may require commitments of time and resources that could otherwise have been devoted to other opportunities that might have been beneficial to us and our business. The diversion of management’s attention, and any difficulties encountered in the transition and integration process, could harm our business, financial condition and operating results.
We may not be able to maintain the levels of operating efficiency that acquired companies have achieved or might achieve separately. Successful integration of each acquisition will depend upon our ability to manage those operations and to eliminate redundant and excess costs. Difficulties in integration may be magnified if we make multiple acquisitions over a relatively short period of time. Because of difficulties in combining and expanding operations, we may not be able to achieve the cost savings and other size-related benefits that we hoped to achieve after these acquisitions.
Financial Risks
Our operating results may fluctuate, which may make it difficult to forecast our future performance and may result in volatility in our stock price.
Our operating results have fluctuated in the past and are likely to continue to fluctuate from quarter to quarter, making forecasting future performance difficult and resulting in volatility in our stock price. These fluctuations are due to a variety of factors, including the following:
•the impact of the ongoing pandemic and the pace of recovery;
•timing of orders placed by our customers;
•our customers’ approach to inventory management;
•changes in the mix of our revenue represented by our various products and customers could result in reductions in our profits if the mix of our revenue represented by lower margin products increases;
•a portion of our costs are fixed in nature, which results in our operations being particularly sensitive to fluctuations in production volumes;
•increased costs and decreased availability of raw materials or supplies; and
•our ability to effectively execute on operational initiatives to drive manufacturing efficiencies.
- 21 -
We have significant indebtedness that could affect our operations, financial condition, and cash flows if we fail to meet certain financial covenants required by our debt agreements or if our access to capital markets is interrupted.
At December 31, 2021,we had $835 million in principal amount of debt outstanding. As of December 31, 2021, our debt service obligations, comprising principal and interest, are estimated to be approximately $33 million for 2022. The outstanding indebtedness and the terms and covenants of the agreements under which this debt was incurred, could, among other things:
•require us to dedicate a large portion of our cash flow from operations to the servicing and repayment of our outstanding indebtedness, thereby reducing funds available for working capital, capital expenditures, acquisitions, RD&E expenditures and other general corporate requirements;
•limit our ability to obtain additional financing to fund future working capital, capital expenditures, RD&E expenditures and other general corporate requirements in the future;
•limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;
•restrict our ability to make strategic acquisitions or dispositions or to exploit business opportunities;
•place us at a competitive disadvantage compared to our competitors that have less outstanding indebtedness; and
•adversely affect the market price of our common stock.
Additionally, our failure to comply with the covenants contained in our debt agreements, if not waived, could cause a default under the applicable debt agreement that requires repayment in full, or acceleration, of debt payments. If that were to occur, there can be no assurance that we would be able to refinance or obtain a replacement financing on favorable terms or at all.
The transition away from LIBOR may adversely affect our borrowing costs.
In 2017, the U.K.’s Financial Conduct Authority, which regulates the London Interbank Offered Rate, or LIBOR, announced its intention to phase out LIBOR by the end of 2021. The deadline has been mostly extended and most U.S. dollar-denominated LIBOR maturity tenors will continue to be published until June 30, 2023. Our Senior Secured Credit Facility uses LIBOR as a benchmark for determining borrowing rates but also provides for the use of the Secured Overnight Finance Rate, or SOFR, in the event LIBOR is no longer available. The change to SOFR as the benchmark borrowing rate may result in an effective increase in the applicable interest rate, and thus increased borrowing costs, under our Senior Secured Credit Agreement, which could impact our financial condition and results of operations.
Economic and credit market uncertainty could interrupt our access to capital markets, borrowings, or financial transactions to hedge certain risks, which could adversely affect our business prospects and financial condition.
To date, we have been able to access debt and equity financing that has allowed us to complete acquisitions, make investments in growth opportunities and fund working capital requirements. In addition, we enter into financial transactions to hedge certain risks, including foreign exchange and interest rate risk. Our continued access to capital markets, the stability of our lenders under our Senior Secured Credit Facility and their willingness to support our needs, and the stability of the parties to our financial transactions that hedge risks are essential for us to meet our current and long-term obligations, fund operations, and fund our strategic initiatives. An interruption in our access to external financing or financial transactions to hedge risk could adversely affect our business prospects and financial condition.
Our international sales and operations are subject to a variety of market and financial risks and costs that could affect our profitability and operating results.
Our sales outside the U.S., which accounted for approximately 45% of sales for 2021, and our operations in Europe, Asia, Israel, Mexico, South America and the Caribbean are and will continue to be subject to a number of risks and potential costs, including:
•changes in foreign economic conditions or regulatory requirements;
•changes in foreign currency exchange rates;
•local product preferences and product requirements;
•outstanding accounts receivables that take longer to collect than is typical in the U.S.;
•difficulties in enforcing agreements through foreign legal systems;
•less protection of intellectual property in some countries outside of the U.S.;
•trade protection measures and import and export licensing requirements;
•work force instability;
•political and economic instability;
•transportation delays or interruptions; and
•complex tax and cash management issues.
These risks are also present in connection with our entry into new geographic markets.
- 22 -
Additionally, as a result of our international operations, we are subject to exposure from currency exchange rate fluctuations. We purchase forward currency contracts in certain currencies to reduce our exposure; however, these transactions may not be adequate or effective to protect us from the exposure for which they are purchased. Historically, foreign currency exchange rate fluctuations have not had a material effect on our net financial results. However, fluctuations in foreign currency exchange rates could have a significant impact on our financial results in the future.
We have a complex tax profile due to the global nature of our operations and may experience significant variability in our quarterly and annual effective tax rate due to several factors, including changes in the mix of pre-tax income and the jurisdictions to which it relates, business acquisitions, settlements with taxing authorities, and changes in tax rates.
Our global operations encompass multiple taxing jurisdictions. Variability in the mix and profitability of domestic and international activities, identification and resolution of various tax uncertainties, changes in tax laws and rates, and the extent to which we are able to realize net operating loss and other carryforwards included in deferred tax assets and avoid potential adverse outcomes included in deferred tax liabilities, among other matters, may significantly affect our effective income tax rate in the future.
Changes in international tax laws or additional changes in U.S. tax laws could materially affect our financial position and results of operations. In addition, many countries in the EU, as well as a number of other countries and organizations such as the Organization for Economic Cooperation and Development, are also actively considering changes to existing tax laws. If tax laws and related regulations change, our financial results could be materially impacted. Given the unpredictability of these possible changes and their potential interdependency, it is possible such changes could adversely impact our financial results.
Our effective income tax rate is the result of the income tax rates in the various countries in which we do business. Our mix of income and losses in these jurisdictions affects our effective tax rate. For example, relatively more income in higher tax rate jurisdictions would increase our effective tax rate and thus lower our net income. Similarly, if we generate losses in tax jurisdictions for which no benefits are available, our effective income tax rate will increase. Our effective income tax rate may also be impacted by the recognition of discrete income tax items, such as required adjustments to our liabilities for uncertain tax positions or our deferred tax asset valuation allowance. A significant increase in our effective income tax rate could have a material adverse impact on our earnings.
We have recorded deferred tax assets based on our assessment that we will be able to realize the benefits of our net operating losses and other favorable tax attributes. Realization of deferred tax assets involve significant judgments and estimates which are subject to change and ultimately depends on generating sufficient taxable income of the appropriate character during the appropriate periods. Changes in circumstances may affect the likelihood of such realization, which in turn may trigger a write-down of our deferred tax assets, the amount of which would depend on a number of factors. A write-down would reduce our reported net income, which may adversely impact our financial condition or results of operations or cash flows.  In addition, we are potentially subject to ongoing and periodic tax examinations and audits in various jurisdictions, including with respect to the amount of our net operating losses and any limitation thereon. An adjustment to such net operating loss carryforwards, including an adjustment from a taxing authority, could result in higher tax costs, penalties and interest, thereby adversely impacting our financial condition, results of operations or cash flows.
We may never realize the full value of our intangible assets, which represent a significant portion of our total assets.
At December 31, 2021, we had $1.7 billion of goodwill and other intangible assets, representing 67% of our total assets. These intangible assets consist primarily of goodwill, trademarks, tradenames, customer lists and patented technology arising from our acquisitions. Goodwill and other intangible assets with indefinite lives are not amortized, but are tested annually or upon the occurrence of certain events that indicate that the assets may be impaired. Definite lived intangible assets are amortized over their estimated useful lives and are tested for impairment upon the occurrence of certain events that indicate that the assets may not be recoverable. We may not receive the recorded value for our intangible assets if we sell or liquidate our business or assets. In addition, our significant amount of intangible assets increases the risk of a large charge to earnings in the event that the recoverability of these intangible assets is impaired. In the event of a significant charge to earnings, the market price of our common stock could be adversely affected. In addition, intangible assets with definite lives, which represent $717.5 million of our net intangible assets at December 31, 2021, will continue to be amortized. These expenses will continue to reduce our future earnings or increase our future losses. The accounting for intangible assets requires reliance on forward looking estimates of sales and/or earnings. Due to the uncertainty surrounding the global pandemic, estimating the future performance of our business is extremely challenging and the range of deviation from internal estimates could be more significant in this environment. As of December 31, 2021, the pandemic has not had an impact on the carrying value of our goodwill and other intangible assets. A prolonged pandemic could have adverse changes on the underlying estimates, assumptions or judgments and could have a material adverse impact on the fair value of our goodwill and other indefinite-lived intangible assets.
- 23 -
Legal and Compliance Risks
Regulatory issues resulting from product complaints, or recalls, or regulatory audits could harm our ability to produce and supply products or bring new products to market.
The products that we design, manufacture and distribute, including our customers’ finished medical devices, product components that are incorporated into our customers’ finished medical devices, and our own finished medical devices, are designed, manufactured and distributed globally in compliance with applicable regulations and standards. However, a product complaint, recall or negative regulatory audit may cause our products, including product components and finished medical devices, to be removed from the market and harm our operating results or financial condition. In addition, during the period in which corrective action is being taken by us to remedy a complaint, recall or negative regulatory audit, regulators may not allow our new products or components to be cleared for marketing and sale.
If we become subject to product liability claims, our operating results and financial condition could suffer.
Our business exposes us to potential product liability claims, which may take the form of a one-off claim from a single claimant or a class action lawsuit covering multiple claimants. Product failures, including those that arise from the failure to meet product specifications, misuse or malfunction, or design flaws, or the use of our products with other components, systems or medical devices not manufactured or sold by us could result in product liability claims or a recall. Many of our products are components that interact with our customers’ medical devices. For example, our batteries are produced to meet electrical performance, longevity and other specifications, but the actual performance of those products is dependent on how they are utilized as part of our customers’ devices over the lifetime of their products. Product performance and device interaction from time to time have been, and may in the future be, different than expected for a number of reasons. Consequently, it is possible that customers may experience problems with their medical devices that could require device recall or other corrective action, where our batteries met the specification at delivery, and for reasons that are not related primarily or at all to any failure by our product to perform in accordance with specifications. It is possible that our customers (or end-users) may in the future assert that our products caused or contributed to device failure. Even if these assertions do not lead to product liability or contract claims, they could harm our reputation and our customer relationships. Furthermore, the design and manufacturing of finished medical devices of the types that we also produce entail an inherent risk of product liability claims. Some of the medical devices that we manufacture and sell are designed to be implanted into the human body. A number of factors could result in an unsafe condition or injury to, or death of, a patient with respect to these medical devices. These factors could also result in product liability claims, a recall of one or more of our medical devices or a safety alert relating to one or more of our medical devices.
Provisions contained in our agreements with key customers attempting to limit our damages, including provisions to limit damages to liability for negligence, may not be enforceable in all instances or may otherwise fail to adequately protect us from liability for damages. Product liability claims or product recalls, regardless of their ultimate outcome and whether related to a product component or a finished medical device, could require us to spend significant time and money in litigation and require us to pay significant damages and could divert the attention of our management from our business operations. The occurrence of product liability claims or product recalls could affect our operating results and financial condition.
We carry product liability insurance with coverage that is limited in scope and amount. We may not be able to maintain this insurance at a reasonable cost or on reasonable terms, or at all. This insurance may not be adequate to protect us against product liability claims made against us.
If we are unable to protect our intellectual property and proprietary rights, our business could be harmed.
We rely on a combination of patents, licenses, trade secrets and know-how to establish and protect our rights to our technologies and products. However, these measures afford only limited protection, and our patent rights, whether issued, subject to license or in process, and our other intellectual property protections may be misappropriated, circumvented or invalidated. The laws of some foreign countries do not offer the same level of protection for our intellectual property as the laws of the U.S. Further, no assurances can be given that any patent application we have filed or will file will result in a patent being issued, or that any existing or future patents will afford adequate or meaningful protection against competitors or against similar technologies. In addition, competitors may design around our technology or develop competing technologies that do not infringe our proprietary rights. As patents and other intellectual property protection expire, we may lose our competitive advantage. If third parties infringe or misappropriate our patents or other proprietary rights, our businesses could be seriously harmed.
- 24 -
In addition, we cannot be assured that our existing or planned products do not or will not infringe on the intellectual property rights of others or that others will not claim such infringement. Our industry has experienced extensive ongoing patent litigation which can result in the incurrence of significant legal costs for indeterminate periods of time, injunctions against the manufacture or sale of infringing products and significant royalty payments. At any given time, we may be a plaintiff or defendant in these types of actions. We cannot assure you that we will be able to prevent competitors from challenging our patents or other intellectual property rights or entering markets we currently serve.
In addition to seeking formal patent protection whenever possible, we attempt to protect our proprietary rights and trade secrets by entering into confidentiality agreements with employees, consultants and third parties with which we do business. However, these agreements may be breached and, if a breach occurs, there may be no adequate remedies available to us and we may be unable to prevent the unauthorized disclosure or use of our technical knowledge, practices or procedures. If our trade secrets become known, we may lose our competitive advantages.
We may be subject to intellectual property claims, which could be costly and time consuming and could divert our management’s attention from our business operations.
In producing our products, third parties may claim that we are infringing on their intellectual property rights, and we may be found to have infringed on those intellectual property rights. We may be unaware of the intellectual property rights of others that may be used in our technology and products. In addition, third parties may claim that our patents have been improperly granted and may seek to invalidate our existing or future patents. If any claim for invalidation prevailed, third parties may manufacture and sell products that compete with our products and our revenues from any related license agreements would decrease accordingly. Former employers of our associates may assert claims that these associates have improperly disclosed to us the confidential or proprietary information of those former employers. We also typically do not receive significant indemnification from parties that license technology to us against third party claims of intellectual property infringement.
Any litigation or other challenges regarding our patents or other intellectual property, with or without merit, could be costly and time consuming and could divert the attention of our management and key personnel from our business operations. The complexity of the technology involved in producing our products and the uncertainty of intellectual property litigation increases these risks. If we are not successful in defending these claims, we could be required to stop selling, delay shipments of, or redesign our products, discontinue the use of related technologies or designs, pay monetary amounts as damages, and satisfy indemnification obligations that we have with some of our customers. Claims of intellectual property infringement may also require us to enter into costly royalty or license agreements. However, we may not be able to obtain royalty or license agreements on terms acceptable to us, or at all. We also may be made subject to significant damages or injunctions against development and sale of our products.
A failure to comply with customer-driven policies and standards and third-party certification requirements or standards could adversely affect our business and reputation.
Our customers have in the past, and may in the future, require us to comply with their own or third-party quality standards, business policies, commercial terms, or other policies or standards, which have been, and may continue to be, even more restrictive than current laws and regulations as well as our pre-existing policies or terms with our suppliers, before they commence, or continue, doing business with us. These policies or standards may be customer-driven, established by the market sectors in which we operate or imposed by third party organizations.
Our compliance with these heightened or additional policies, standards and third-party certification requirements, and managing a supply chain in accordance with those policies, standards and requirements, could be costly and time consuming, and our failure to comply could adversely affect our operations, customer relationships, reputation and profitability. In addition, our adoption of these standards could adversely affect our cost competitiveness and ability to provide customers with required service levels. In certain circumstances, to meet the requirements or standards of our customers, we may be obligated to select certain suppliers or make other sourcing choices, and we may bear responsibility for adverse outcomes even if these matters are the result of third-party actions or outside of our control.
Our failure to obtain licenses from third parties for new technologies or the loss of these licenses could impair our ability to design and manufacture new products and reduce our revenues.
We occasionally license technologies from third parties rather than depending exclusively on our own proprietary technology and developments. Our ability to license new technologies from third parties is and will continue to be critical to our ability to offer new and improved products. We may not be able to continue to identify new technologies developed by others and even if we are able to identify new technologies, we may not be able to negotiate licenses on favorable terms, or at all. Additionally, we may lose rights granted under licenses for reasons beyond our control or if the license has a finite term and cannot be renewed on favorable terms or at all.
- 25 -
Our business is subject to environmental regulations that could be costly to comply with.
Federal, state and local regulations impose various environmental controls on the manufacturing, transportation, storage, use and disposal of batteries and hazardous chemicals and other materials used in, and hazardous waste produced by the manufacturing of our products. Conditions relating to our historical operations, including a former manufacturing facility located in South Plainfield, New Jersey previously operated by a subsidiary of Lake Region Medical, may require expenditures for clean-up in the future that could materially adversely affect our financial results. In addition, changes in environmental laws and regulations may impose costly compliance requirements on us or otherwise subject us to future liabilities. Additional or modified regulations relating to the manufacture, transportation, storage, use and disposal of materials used to manufacture our products or restricting disposal or transportation of batteries may be imposed that may result in higher costs or lower operating results. In addition, we cannot predict the effect that additional or modified environmental regulations may have on us or our customers.
Our international operations expose us to legal and regulatory risks, which could adversely affect our business.
Our profitability and international operations are, and will continue to be, subject to risks relating to changes in foreign legal and regulatory requirements. In addition, our international operations are governed by various U.S. laws and regulations, including the U.S. Foreign Corrupt Practices Act (“FCPA”) and other similar anti-corruption laws in other countries that prohibit us and our business partners and other intermediaries from making improper payments or offers of payment to foreign governments and their officials and political parties for the purpose of obtaining or retaining business. Any alleged or actual violations of these regulations may subject us to government scrutiny, severe criminal or civil sanctions and other liabilities and could adversely affect our business, reputation, operating results, and financial condition.
The healthcare industry is highly regulated and subject to various political, economic and regulatory changes that could increase our compliance costs and force us to modify how we develop and price our products.
The healthcare industry is highly regulated and is influenced by changing political, economic and regulatory factors. Several of our product lines are subject to international, federal, state and local health and safety, packaging and product content regulations, including the new European Medical Device Regulation that went into effect in May 2021, which was adopted by the European Union as a common legal framework for all European Union member states. In addition, medical devices are subject to regulation by the FDA and similar governmental agencies. These regulations cover a wide variety of product activities from design and development to labeling, manufacturing, promotion, sales and distribution. Compliance with these regulations is time consuming, burdensome and expensive and could adversely affect our ability to sell products. This may result in higher than anticipated costs or lower than anticipated revenues.
Furthermore, healthcare industry regulations are complex, change frequently and have tended to become more stringent over time. Federal and state legislatures have periodically considered and implemented programs to reform or amend the U.S. healthcare system at both the federal and state levels. In addition, these regulations may contain proposals to increase governmental involvement in healthcare, lower reimbursement rates or otherwise change the environment in which healthcare industry participants operate. We may be required to incur significant expenses to comply with these regulations or remedy past violations of these regulations. Our failure to comply with applicable government regulations could also result in cessation of portions or all of our operations, impositions of fines and restrictions on our ability to carry on or expand our operations. In addition, because many of our products are sold into regulated industries, we must comply with additional regulations in marketing our products.
In response to perceived increases in healthcare costs in recent years, there have been and continue to be proposals by the Presidential administrations, members of Congress, state governments, regulators and third-party payors to control these costs and, more generally, to reform the U.S. healthcare system, including by amending, repealing or replacing the Patient Protection and Affordable Care Act. It is unclear how such reforms will progress under the new presidential administration. Elements of health care reform such as comparative effectiveness research, an independent payment advisory board, payment system reforms including shared savings pilots and other provisions could meaningfully change the way healthcare is developed and delivered, and may materially adversely impact numerous aspects of our business, results of operations and financial condition.
Our business is indirectly subject to healthcare industry cost containment measures that could result in reduced sales of our products.
Several of our customers rely on third party payors, such as government programs and private health insurance plans, to reimburse some or all of the cost of the procedures in which our products are used. The continuing efforts of governments, insurance companies and other payors of healthcare costs to contain or reduce those costs could lead to patients being unable to obtain approval for payment from these third party payors for procedures in which our products are used. If this occurs, sales of medical devices may decline significantly and our customers may reduce or eliminate purchases of our products, or demand further price reductions. The cost containment measures that healthcare payors are instituting, both in the U.S. and internationally, could reduce our revenues and harm our operating results.
- 26 -

ITEM 1B.    UNRESOLVED STAFF COMMENTS
None.

ITEM 2.    PROPERTIES
Our principal executive office and headquarters is located in Plano, Texas, in a leased facility. As of December 31, 2021, we operated 18 facilities in the U.S., five in Europe, three in Mexico, two in Asia, one in the Dominican Republic, one in South America, and one in Israel. Of these facilities, 24 were leased and 7 were owned. We occupy approximately two million square feet of manufacturing and RD&E space worldwide. We believe the facilities we operate and their equipment are effectively utilized, well maintained, generally are in good condition, and will be able to accommodate our capacity needs to meet current levels of demand. We continuously review our anticipated requirements for facilities and, on the basis of that review, may from time to time acquire additional facilities, expand or dispose of existing facilities.

ITEM 3.    LEGAL PROCEEDINGS
For information regarding certain legal proceedings pending against us, see Note 13 “Commitments and Contingencies” of the Notes to Consolidated Financial Statements contained in Item 8 of this report.

ITEM 4.    MINE SAFETY DISCLOSURES
Not applicable.
PART II

ITEM 5.    MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES
Common Stock and Dividends. The Company’s common stock trades on the New York Stock Exchange (“NYSE”) under the symbol “ITGR.” We have not paid cash dividends and do not anticipate paying any cash dividends in the foreseeable future.
Stockholders. According to the records of our transfer agent, there were approximately 100 holders of record of our common stock on February 16, 2022. Because many of these shares are held by brokers and other institutions on behalf of the ultimate beneficial holders of these shares, we are unable to estimate the total number of stockholders represented by these record holders.
- 27 -
PERFORMANCE GRAPH
The following graph compares, for the five year period ended December 31, 2021, the cumulative total stockholder return for Integer Holdings Corporation, the Russell 2000 Index, IHI (iShares US Medical Devices ETF), the S&P SmallCap 600 Index, and the Hemscott Peer Group Index. The Hemscott Peer Group Index includes approximately 100 comparable companies included in the Hemscott Industry Group 520 Medical Instruments & Supplies and 521 Medical Appliances & Equipment (“Hemscott Peer Group Index”). The graph assumes that $100 was invested on December 30, 2016 and assumes reinvestment of dividends. No adjustments have been made for the value provided to shareholders for spin-offs. The stock price performance shown on the following graph is not necessarily indicative of future price performance.gb-20211231_g2.jpg
Company/Index12/30/1612/29/1712/28/1812/31/1912/31/2012/31/21
Integer Holdings Corporation$100.00 $153.82 $258.17 $273.11 $275.69 $290.63 
Russell 2000 Index100.00 113.23 103.63 127.24 141.60 179.58 
iShares US Medical Devices ETF100.00 114.65 102.02 128.06 153.62 176.39 
S&P SmallCap 600 Index100.00 130.96 146.70 190.81 221.97 254.41 
Hemscott Peer Group Index100.00 131.17 150.92 199.70 242.69 286.59 
The Russell 2000 Index and IHI (iShares US Medical Devices ETF) have been added to the stock performance chart during fiscal 2021 and will be included in future filings. The Russell 2000 Index contains companies with historical performances similar to our own and we believe is a more appropriate index for comparison of our stock price at this time. We believe the iShares US Medical Devices ETF more appropriately represents medical device companies of comparable size, performance, and complexity to that of Integer. As a result, we will not include the S&P SmallCap 600 Index and the Hemscott Peer Group Index in future filings.

ITEM 6.    [RESERVED]

- 28 -

ITEM 7.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes appearing in Item 8 of this report. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those under the heading “Risk Factors” in Item 1A of this report.
Our Business
•Our business
•Impact of COVID-19
•Recent business acquisitions
•Discontinued operations
•Patent litigation
•Financial overview
Our Financial Results
•Fiscal 2021 compared with fiscal 2020
•Liquidity and capital resources
•Cash and other commitments
•Impact of recently issued accounting standards
Critical Accounting Estimates
•Acquisition method of accounting
•Inventories
•Valuation of goodwill and intangible assets
Our Business
Integer Holdings Corporation is one of the largest MDO manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular and advanced surgical markets. We also develop batteries for high-end niche applications in the non-medical energy, military, and environmental markets. Our vision is to enhance the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.
We organize our business into two reportable segments, Medical and Non-Medical, and derive our revenues from four principle product lines. The Medical segment includes the Cardio & Vascular, Cardiac & Neuromodulation and Advanced Surgical, Orthopedics & Portable Medical product lines and the Non-Medical segment comprises the Electrochem product line. For more information on our segments, please refer to Note 18 “Segment and Geographic Information” of the Notes to Consolidated Financial Statements contained in Item 8 of this report.
Impact of COVID-19
Beginning in early March 2020, the global spread of the novel coronavirus (“COVID-19”) created significant uncertainty and worldwide economic disruption. Specific impacts to our business include labor shortages, disruptions in the supply chain, delayed or reduced customer orders and sales, restrictions on associates’ ability to travel or work, and delays in shipments to and from certain countries. The extent to which COVID-19 will continue to impact our operations will depend on future developments, which remain highly uncertain and difficult to predict, including, among others, the duration of the outbreak, the effectiveness and utilization of vaccines for COVID-19 and its variants, new information that may emerge concerning the severity of COVID-19 and the actions, especially those taken by governmental authorities to contain the pandemic or treat its impact. As pandemic-related events continue to evolve, additional impacts may arise or worsen that we are not aware of currently. Any prolonged material disruption of our labor force, suppliers, manufacturing, or customers could materially impact our consolidated financial position, results of operations or cash flows.
- 29 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
Recent Business Acquisitions
On December 1, 2021, we acquired 100% of the outstanding equity interests of Oscor, privately-held companies with operations in Florida, the Dominican Republic and Germany that design, develop, manufacture and market a comprehensive portfolio of highly specialized medical devices, venous access systems and diagnostic catheters and implantable devices. Refer to Note 2 “Business Acquisitions” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information about the acquisition.
On February 19, 2020, we acquired certain assets and liabilities of InoMec, a privately-held company based in Israel that specializes in the research, development and manufacturing of medical devices, including minimally invasive tools, delivery systems, tubing and catheters, surgery tools, drug-device combination, laser combined devices, and tooling and production. The acquisition enabled us to create a research and development center in Israel, closer to the customer base in the region.
Refer to Note 2 “Business Acquisitions” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information about the acquisition of Oscor and InoMec.
Discontinued Operations
In July 2018, we completed the sale of the AS&O Product Line within our Medical segment to Viant (formerly MedPlast, LLC). For all periods presented, financial results reported as discontinued operations relate to the divested AS&O Product Line. All results and information presented exclude the AS&O Product Line unless otherwise noted.
During 2021, we recognized income from discontinued operations of $3.8 million or $0.11 per diluted share. There was no income from discontinued operations during 2020.
Refer to Note 20 “Discontinued Operations” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information.
Patent Litigation
In April 2013, we commenced an action against a competitor alleging they had infringed on the our patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate our patented technology.
Following four trials and an appeal, the United States Court of Appeals for the Federal Circuit affirmed, in all respects, a judgment in our favor. We received proceeds related to the judgment of $28.9 million in October 2020, and after recognizing certain related expenses, recognized a net gain of $28.2 million, which is recorded in Selling, general and administrative expenses. The proceeds were used to pay down a portion of our Revolving Credit Facility.
Refer to Note 13 “Commitments and Contingencies” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information on this matter.
Financial Overview
Fiscal 2021 Compared with Fiscal 2020
Income from continuing operations for 2021 was $93.0 million or $2.80 per diluted share compared to $77.3 million or $2.33 per diluted share for 2020. These variances are primarily the result of the following:
•Sales for 2021 increased 14% to $1.221 billion as we began to see our sales return to pre-pandemic levels as the demand for many of our products continues to recover from the impacts of the COVID-19 pandemic.
•Gross profit for 2021 increased $51.3 million or 18%, primarily from higher sales volume and production efficiencies.
•Operating expenses for 2021 increased by $36.2 million compared to 2020, primarily due to increases of $32.4 million in SG&A expenses and $3.5 million in RD&E expenses. Included in SG&A expenses for 2020 is a net gain of $28.2 million recognized in connection with a previously mentioned patent litigation judgment.
•Interest expense for 2021 decreased by $6.6 million primarily due to lower interest rates and lower average outstanding debt balances.
•We recognized a net loss on equity investments of $3.1 million in 2021, compared to a net gain on equity investments of $5.3 million during 2020. Gains and losses on equity investments are generally unpredictable in nature.
•Other (income) loss, net for 2021 was income of $0.1 million compared to a loss of $1.5 million during 2020, primarily due to fluctuations in foreign currency gains and losses in the respective periods.
•We recorded provisions for income taxes of $8.0 million and $8.9 million for 2021 and 2020, respectively. The changes in income tax were primarily due to relative changes in pre-tax income and the impact of discrete tax items.
- 30 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
Fiscal 2020 Compared with Fiscal 2019
Income from continuing operations for 2020 was $77.3 million or $2.33 per diluted share compared to $91.2 million or $2.76 per diluted share for 2019. These variances are primarily the result of the following:
•Sales from continuing operations for 2020 decreased 15% primarily due to the impact of the COVID-19 pandemic.
•Gross profit for 2020 decreased $69.3 million or 20%, primarily from a decrease in sales volume, price reductions to our customers, and a loss in volume leverage, which resulted from our sales decrease, partially offset by 2019 charges associated with a customer bankruptcy. Cost of sales for fiscal years 2020 and 2019 included pre-tax charges of $1.1 million and $21.4 million, respectively, in connection with the customer bankruptcy.
•Operating expenses for 2020 decreased by $32.3 million compared to 2019, due to decreases of $29.7 million in SG&A expenses and $4.5 million in Other operating expenses, partially offset by a $1.9 million increase in RD&E expenses. Included in SG&A expenses for 2020 is a net gain of $28.2 million recognized in connection with a previously mentioned patent litigation judgment.
•Interest expense for 2020 decreased by $14.3 million primarily due to lower interest rates and lower outstanding debt balances.
•We recognized a net gain on equity investments of $5.3 million in 2020, compared to a net loss on equity investments of $0.5 million during 2019. Gains and losses on equity investments are generally unpredictable in nature.
•Other loss, net for 2020 was $1.5 million compared to other income, net of $0.6 million during 2019, primarily due to fluctuations in foreign currency gains and losses in the respective periods.
•We recorded provisions for income taxes of $8.9 million and $14.0 million for 2020 and 2019, respectively. The decrease in provision for income taxes is primarily due to our decrease in pre-tax income and the beneficial impact of the final Treasury Regulations issued in 2020.
- 31 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
Our Financial Results
The following table presents selected financial information derived from our Consolidated Financial Statements, contained in Item 8 of this report, for the periods presented (dollars in thousands, except per share amounts):
 ChangeChange
2021 vs. 20202020 vs. 2019
202120202019$%$%
Medical Sales:
Cardio & Vascular$626,013 $569,948 $610,056 $56,065 10 %$(40,108)(7)%
Cardiac & Neuromodulation446,569 346,242 457,194 100,327 29 %(110,952)(24)%
Advanced Surgical, Orthopedics &
  Portable Medical		110,044 121,788 132,429 (11,744)(10)%(10,641)(8)%
Total Medical Sales1,182,626 1,037,978 1,199,679 144,648 14 %(161,701)(13)%
Non-Medical 38,453 35,464 58,415 2,989 8 %(22,951)(39)%
Total sales1,221,079 1,073,442 1,258,094 147,637 14 %(184,652)(15)%
Cost of sales884,109 787,735 903,084 96,374 12 %(115,349)(13)%
Gross profit336,970 285,707 355,010 51,263 18 %(69,303)(20)%
Gross profit as a % of sales27.6 %26.6 %28.2 %
Operating expenses:
Selling, general and administrative (“SG&A”)141,418 109,006 138,695 32,412 30 %(29,689)(21)%
SG&A as a % of sales11.6 %10.2 %11.0 %
Research, development and engineering (“RD&E”)51,985 48,468 46,529 3,517 7 %1,939 4 %
RD&E as a % of sales4.3 %4.5 %3.7 %
Other operating expenses7,856 7,621 12,151 235 3 %(4,530)(37)%
Total operating expenses201,259 165,095 197,375 36,164 22 %(32,280)(16)%
Operating income135,711 120,612 157,635 15,099 13 %(37,023)(23)%
Operating income as a % of sales11.1 %11.2 %12.5 %
Interest expense31,628 38,220 52,545 (6,592)(17)%(14,325)(27)%
(Gain) loss on equity investments, net3,143 (5,337)475 8,480 (159)%(5,812)
NM
Other (income) loss, net(123)1,522 (578)(1,645)(108)%2,100 
NM
Income from continuing operations
   before taxes		101,063 86,207 105,193 14,856 17 %(18,986)(18)%
Provision for income taxes8,043 8,949 13,975 (906)(10)%(5,026)(36)%
Effective tax rate8.0 %10.4 %13.3 %
Income from continuing operations$93,020 $77,258 $91,218 $15,762 20 %$(13,960)(15)%
Income from continuing
operations as a % of sales		7.6 %7.2 %7.3 %
Diluted earnings per share from
   continuing operations		$2.80 $2.33 $2.76 $0.47 20 %$(0.43)(16)%
NM - Calculated change not meaningful.
- 32 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
The following discussion is a comparison between fiscal year 2021 and fiscal year 2020 results. For a discussion of our results of operations for fiscal year 2020 compared to fiscal year 2019, please refer to Item 7 of Part II, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which was filed with the SEC on February 18, 2021.
Fiscal 2021 Compared with Fiscal 2020
Sales
Sales by product line for 2021 and 2020 were as follows (dollars in thousands):
 Change
20212020$%
Medical Sales:
Cardio & Vascular$626,013 $569,948 $56,065 9.8 %
Cardiac & Neuromodulation446,569 346,242 100,327 29.0 %
Advanced Surgical, Orthopedics & Portable Medical110,044 121,788 (11,744)(9.6)%
Total Medical Sales1,182,626 1,037,978 144,648 13.9 %
Non-Medical 38,453 35,464 2,989 8.4 %
Total sales$1,221,079 $1,073,442 $147,637 13.8 %
Total 2021 sales increased 14% to $1.221 billion in comparison to 2020. The most significant drivers of this decrease were as follows:
Cardio & Vascular sales for 2021 increased $56.1 million or 10% in comparison to 2020. Cardio & Vascular sales for 2021 reflect the continued recovery from the negative impact of the COVID-19 pandemic, with strong increases across all Cardio & Vascular markets, particularly in the neurovascular market, despite end market demand fluctuations and supply chain constraints. During 2021, price changes reduced Cardio & Vascular sales by $0.4 million in comparison to 2020. Foreign currency exchange rate fluctuations increased Cardio & Vascular sales for 2021 by $1.5 million. Cardio & Vascular sales for 2021 include Oscor sales since the date of acquisition of $2.9 million.
Cardiac & Neuromodulation sales for 2021 increased $100.3 million or 29% in comparison to 2020. Cardiac & Neuromodulation sales for 2021 reflect the continued recovery from the negative impact of the COVID-19 pandemic and strong sales across all markets, despite end market demand fluctuations and supply chain constraints. Sales in the cardiac rhythm management market and neuromodulation market saw double-digit increases when comparing fiscal year 2021 to fiscal year 2020. During 2021, price changes reduced Cardiac & Neuromodulation sales by approximately $10.8 million in comparison to 2020. Foreign currency exchange rate fluctuations did not have a material impact on Cardiac & Neuromodulation sales during 2021 in comparison to 2020. Cardiac & Neuromodulation sales for 2021 include Oscor sales since the date of acquisition of $1.8 million.
In addition to Portable Medical sales, Advanced Surgical, Orthopedic & Portable Medical includes sales to the acquirer of our former AS&O Product Line, under supply agreements entered into as part of the divestiture in 2018. Advanced Surgical, Orthopedics & Portable Medical sales for 2021 decreased by $11.7 million in comparison to 2020. The decreases in 2021 sales reflects a double-digit decline in Advanced Surgical and Orthopedics, the divested product line currently under supply agreement, and a low single-digit decline in Portable Medical driven by lower demand for COVID-related ventilators and patient monitoring components. Price changes reduced Advanced Surgical, Orthopedic & Portable Medical sales by $0.4 million in comparison to 2020. Foreign currency exchange rate fluctuations did not have a material impact on Advanced Surgical, Orthopedic & Portable Medical sales during 2021 in comparison to 2020.
Non-Medical sales for 2021 increased $3.0 million or 8% in comparison to 2020. The sales increase reflects moving from a period of energy market contraction to recovery beginning in the second quarter of 2021. Price and foreign currency exchange rate fluctuations did not have a material impact on Non-Medical sales during 2021 in comparison to 2020.
- 33 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
Gross Profit
Changes to gross profit as a percentage of sales (“Gross Margin”) from the prior year were due to the following:
% Change
 2021 vs. 2020
Price(a)
(0.7)%
Mix(b)
0.8 
Production efficiencies and volume(c)
0.7 
Customer Bankruptcy(d)
0.2 
Total percentage point change to gross profit as a percentage of sales1.0 %
__________
(a)Our Gross Margin for 2021 was negatively impacted by price reductions given to our larger OEM customers in return for long-term volume commitments.
(b)Amount represents the impact to our Gross Margin attributable to changes in the mix of product sales during the period.
(c)Our Gross Margin for 2021 was positively impacted by higher sales volume and production efficiencies, mainly due to our Manufacturing Excellence imperative.
(d)In November 2019, one of our customers, Nuvectra Corporation, filed a voluntary Chapter 11 bankruptcy petition (the “Customer Bankruptcy”). During fiscal year 2021, we recognized benefits from favorable settlements on supplier purchase order termination clauses and utilization of previously reserved inventory. During fiscal year 2020, we incurred costs and recorded charges associated with the Customer Bankruptcy, primarily consisting of charges related to inventory recorded in cost of sales.
SG&A Expenses
Changes to SG&A expenses were primarily due to the following (in thousands): 
 $ Change
2021 vs. 2020
Compensation and benefits(a)
$5,069 
Patent litigation gain, net(b)
28,167 
All other SG&A, net(c)
(824)
Net increase in SG&A Expenses$32,412 
__________
(a)Compensation and benefits increased during 2021 compared to 2020, primarily due to higher stock-based compensation expense.
(b)We recognized a net gain of $28.2 million during 2020 related to a patent litigation judgment. See “Patent Litigation” in the Financial Overview section for additional information.
(c)The net decrease in all other SG&A expenses for 2021 compared to 2020 is primarily attributable to lower travel related expenses and depreciation expense.
RD&E Expenses
RD&E expenses for 2021 and 2020 were $52.0 million and $48.5 million, respectively. The increase in RD&E expenses for 2021 compared to 2020 is primarily attributable to increased compensation and benefits costs, consistent with our strategy to invest in capabilities for growth. RD&E expenses are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. Our research and development initiatives continue to emphasize new product development, product improvements, and the development of new technological platform innovations.
- 34 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
Other Operating Expenses
OOE comprises the following for 2021 and 2020 (in thousands):
20212020Change
Operational excellence(a)
$3,893 $2,791 $1,102 
Strategic reorganization and alignment(b)
911 686 225 
Manufacturing alignment to support growth(c)
— 241 (241)
Acquisition and integration costs(d)
2,544 (776)3,320 
Other general expenses(e)
508 4,679 (4,171)
Other operating expenses$7,856 $7,621 $235 
__________
(a)These projects focus on changing our organizational structure to match product line growth strategies and customer needs, transitioning our manufacturing process into a competitive advantage and standardizing and optimizing our business processes. Costs related for 2021 and 2020 primarily consist of termination benefits.
(b)The Company’s strategic reorganization and alignment initiatives primarily include those that align resources with market conditions and the Company’s strategic direction in order to enhance the profitability of its portfolio of products. Costs related for 2021 primarily consist of termination benefits. Costs related for 2021 primarily consist of termination benefits and fees for professional services.
(c)In 2017, we commenced several initiatives designed to reduce costs, increase manufacturing capacity to accommodate growth and improve operating efficiencies.  The plan involved the relocation of certain manufacturing operations and expansion of certain of our facilities. These actions were substantially complete at the end of 2020.
(d)Amounts include expenses related to the acquisitions of Oscor in 2021 and InoMec in 2020. The 2020 amount also includes a $2.0 million adjustment to reduce the fair value of acquisition-related contingent consideration liabilities. See Note 17 “Financial Instruments and Fair Value Measurements” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information related to the fair value measurement of the contingent consideration.
(e)Amounts include expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce future costs and improve efficiencies. The 2020 amounts primarily include severance, information technology systems conversion expenses, expenses incurred in connection with the Customer Bankruptcy, and expenses related to the restructuring of certain legal entities of the Company.
Refer to Note 11 “Other Operating Expenses” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information regarding these initiatives.
- 35 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
Interest Expense
Interest expense consists primarily of cash interest and debt related charges, such as amortization of deferred debt issuance costs and original issue discount. Interest expense decreased $6.6 million to $31.6 million in 2021 from $38.2 million in 2020, primarily due to lower interest rates and lower average outstanding debt balances. The weighted average interest rates on outstanding borrowings during 2021 and 2020 was 3.50% and 3.79%, respectively.
Debt related charges included in interest expense were $7.0 million for 2021 compared to $4.8 million for 2020. The increase in debt related charges during 2021 compared to 2020 is primarily attributable to write-offs of deferred debt issuance costs and unamortized discount (losses from extinguishment of debt) related to prepayments of portions of our Term Loan B facility and a write off of $3.3 million of deferred issuance costs and unamortized discount in connection with the refinancing of our credit facilities in September 2021. We recognized losses from extinguishment of debt during 2021 and 2020 of $3.8 million and $0.5 million, respectively.
As of December 31, 2021, approximately 18% of our principal amount of debt outstanding has been effectively converted to fixed-rate borrowings through the use of interest rate swaps, in comparison to approximately 27% as of December 31, 2020.  We enter into interest rate swap agreements to reduce our exposure to fluctuations in the LIBOR rate. See Note 17 “Financial Instruments and Fair Value Measurements” of the Notes to the Consolidated Financial Statements contained in Item 8 of this report for additional information pertaining to our interest rate swap agreements.
(Gain) Loss on Equity Investments, Net
During 2021, we recognized a net loss of $3.1 million on our equity investments compared to net gains of $5.3 million for 2020. Gains and losses on equity investments are generally unpredictable in nature. During 2021 and 2020, we recognized impairment charges of $0.1 million and $0.4 million, respectively, related to investments in our non-marketable equity securities. The residual amounts for 2021 and 2020 relate to our share of equity method investee gains/losses, including unrealized appreciation and depreciation of the underlying interests of the investee. As of December 31, 2021 and December 31, 2020, the carrying value of our equity investments was $21.8 million and $27.2 million, respectively. See Note 17 “Financial Instruments and Fair Value Measurements” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for further details regarding these investments.
Other (Income) Loss, Net
Other (income) loss, net was income of $0.1 million during 2021 compared to a loss of $1.5 million during 2020. Other (income) loss, net primarily includes gains/losses from the impact of exchange rates on transactions denominated in foreign currencies. Our foreign currency transaction gains/losses are based primarily on fluctuations of the U.S. dollar relative to the Euro, Mexican peso, Uruguayan peso, Malaysian ringgits, Dominican peso, or Israeli shekel.
The impact of foreign currency exchange rates on transactions denominated in foreign currencies included in Other (income) loss, net for 2021 and 2020 were net gains of $0.1 million and net losses of $1.6 million, respectively. We continually monitor our foreign currency exposures and seek to take steps to mitigate these risks. However, fluctuations in foreign currency exchange rates could have a significant impact, positive or negative, on our financial results in the future.
- 36 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
Provision for Income Taxes
During 2021 and 2020, our provision for income taxes was $8.0 million on worldwide pre-tax income of $101.1 million
(effective tax rate of 8.0%) and $8.9 million on worldwide pre-tax income of $86.2 million (effective tax rate of 10.4%), respectively. The stand-alone U.S. component of the effective tax rate for 2021 reflected a $2.0 million provision on $48.3 million of pre-tax book income (effective tax rate of 4.2%) versus a $3.1 million provision on $35.3 million of pre-tax book income (effective tax rate of 8.9%) for 2020. The stand-alone International component of the effective tax rate for 2021 reflected a $6.0 million provision on $52.8 million of pre-tax book income (effective tax rate of 11.4%) versus a $5.8 million provision on $50.9 million of pre-tax book income (effective tax rate of 11.4%) for 2020.
The provision for income taxes for 2021 differs from the U.S. statutory rate due to the following (dollars in thousands):
 U.S.InternationalCombined
 $%$%$%
Income before provision for income taxes$48,293 $52,770 $101,063 
Provision at statutory rate$10,141 21.0 %$11,082 21.0 %$21,223 21.0 %
Federal tax credits (including R&D)(11,929)(24.8)— — (11,929)(11.8)
Foreign rate differential1,366 2.8 (6,531)(12.4)(5,165)(5.1)
Stock-based compensation(1,084)(2.2)— — (1,084)(1.1)
Uncertain tax positions18 — — — 18 — 
State taxes, net of federal benefit1,183 2.4 — — 1,183 1.2 
U.S. tax on foreign earnings, net of §250 deduction1,913 4.0 — — 1,913 1.9 
Valuation allowance— — 524 1.0 524 0.5 
Other398 0.8 962 1.8 1,360 1.4 
Provision for income taxes$2,006 4.0 %$6,037 11.4 %$8,043 8.0 %
The provision for income taxes for 2020 differs from the U.S. statutory rate due to the following (dollars in thousands):
 U.S.InternationalCombined
 $%$%$%
Income before provision for income taxes$35,337 $50,870 $86,207 
Provision at statutory rate$7,420 21.0 %$10,683 21.0 %$18,103 21.0 %
Federal tax credits (including R&D)(7,009)(19.9)— — (7,009)(8.1)
Foreign rate differential339 1.0 (5,672)(11.2)(5,333)(6.2)
Stock-based compensation(1,459)(4.1)— — (1,459)(1.7)
Uncertain tax positions1,208 3.4 — — 1,208 1.4 
State taxes, net of federal benefit553 1.6 — — 553 0.6 
U.S. tax on foreign earnings, net of §250 deduction3,216 9.1 — — 3,216 3.7 
Valuation allowance(470)(1.3)125 0.2 (345)(0.4)
Other(674)(1.9)689 1.4 15 0.1 
Provision for income taxes$3,124 8.9 %$5,825 11.4 %$8,949 10.4 %
Our effective tax rate of 8.0% for 2021 is lower than our effective tax rate of 10.4% for 2020, primarily due to the beneficial impact of a year over year increase in R&D tax credits, an increase in Foreign tax credits and Foreign Derived Intangible Income (“FDII”) resulting from an increase in foreign source income in 2021, and the release of Uncertain Tax Positions relating to the tax years 2017 and 2018 as the Internal Revenue Service (“IRS”) effectively concluded its examination of those years during 2021.
- 37 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
The Company’s effective tax rate for 2021 differs from the U.S. federal statutory tax rate of 21% due principally to the estimated impact of Federal Tax Credits (including R&D credits and Foreign tax credits), stock based compensation windfalls, and the impact of the Company’s earnings realized in foreign jurisdictions with statutory rates that are different than the U.S. federal statutory rate. These benefits are partially offset by the impact of U.S taxes on foreign earnings, including the GILTI provision which requires the Company to include foreign subsidiary earnings in excess of a deemed return on a foreign subsidiary’s tangible assets in its U.S. income tax return. The U.S. tax on foreign earnings is reflected net of a statutory deduction of 50% of the GILTI inclusion (subject to limitations based on U.S. taxable income, if any) and net of FDII that provides a 37.5% deduction to domestic companies for certain foreign sales and services income. The primary foreign jurisdictions in which we operate and the statutory tax rate for each respective jurisdiction include Switzerland (22%), Mexico (30%), Uruguay (25%), Ireland (12.5%) and Malaysia (24%). We currently have a tax holiday in Malaysia through April 2023 provided certain conditions continue to be met. In addition, we acquired manufacturing operations in the Dominican Republic as part of the acquisition of Oscor, and are operating under a free trade zone agreement in the Dominican Republic through March 2034.
There is a potential for volatility of our effective tax rate due to several factors, including changes in the mix of pre-tax income and the jurisdictions to which it relates, business acquisitions, settlements with taxing authorities, changes in tax rates, and foreign currency exchange rate fluctuations. In addition, we continue to explore tax planning opportunities that may have a material impact on our effective tax rate.
The balance of unrecognized tax benefits is not expected to materially change over the course of the next twelve months as a result of the lapse of the statute of limitations and/or audit settlements. As of December 31, 2021, approximately $5.5 million of unrecognized tax benefits would favorably impact the effective tax rate (net of federal impact on state issues), if recognized.
Liquidity and Capital Resources 
(dollars in thousands)December 31,
2021		December 31,
2020
Cash and cash equivalents$17,885 $49,206 
Working capital$293,353 $256,746 
Current ratio2.84 2.64 
Cash and cash equivalents at December 31, 2021 decreased by $31.3 million from December 31, 2020. In 2021, we generated $156.7 million of cash from operating activities and borrowed a net amount of $95.8 million under our Senior Secured Credit Facility, which was more than offset by $218.0 million of net cash paid for the Oscor acquisition and net purchases of property, plant and equipment of $53.0 million.
Working capital increased by $36.6 million from December 31, 2020, primarily from positive working capital fluctuations associated with accounts receivable, contract assets, prepaid expenses and other current assets, and the current portion of long-term debt aggregating to $84.6 million, which were partially offset by fluctuations in cash and cash equivalents and accounts payable aggregating to $56.6 million. During 2021, accounts receivable increased mainly from higher sequential sales, and contract assets increased mainly due to a contract modification to add existing products and extend the contractual term, while the current portion of long-term debt decreased due to the refinancing of our term loan facilities during the third quarter of 2021. Cash and cash equivalents decreased primarily from net cash outflow in connection with the Oscor acquisition, while accounts payable increased mainly from the timing of supplier payments and higher sequential inventory purchases.
At December 31, 2021, $13.1 million of our cash and cash equivalents were held by foreign subsidiaries. We intend to limit our distributions from foreign subsidiaries to previously taxed income or current period earnings. If distributions are made utilizing current period earnings, we will record foreign withholding taxes in the period of the distribution.
Summary of Cash Flow
The following cash flow summary information includes cash flows related to discontinued operations (in thousands):
20212020
Cash provided by (used in):
Operating activities$156,666 $181,341 
Investing activities(270,998)(56,576)
Financing activities81,986 (88,578)
Effect of foreign currency exchange rates on cash and cash equivalents1,025 (516)
Net change in cash and cash equivalents$(31,321)$35,671 
- 38 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
Operating Activities - Cash provided by operating activities decreased $24.7 million in 2021 compared to 2020. Net income as adjusted for non-cash items such as depreciation and amortization increased $39.2 million but was more than offset by a decrease from fluctuations in operating assets and liabilities, which totaled $63.9 million.
The increase in net income adjusted for non-cash items such as depreciation and amortization is primarily from higher sales volume, margin expansion and lower interest expense partially offset by higher SG&A from the aforementioned patent litigation judgement in the prior year. The decrease associated with changes in operating assets and liabilities is primarily related to the impact of declining sales volume in the prior year, which caused a significant prior year benefit to operating cash flow from the collection of accounts receivable in a period of declining sales and a lower investment in inventory. In addition, we deferred payment of the employer portion of Social Security taxes during 2020 under the provisions of the CARES Act, which further contributed to the prior year benefit. These unfavorable impacts were partially offset with accounts payable fluctuations based on timing of supplier payments.
Investing Activities – The $214.4 million increase in net cash used in investing activities was primarily attributable to an increase in net cash paid for business acquisitions of $212.8 million and increased purchases of property, plant, and equipment of $6.6 million, partially offset by a decrease from the purchase of an intangible asset of $4.6 million in 2020.
Financing Activities – Net cash provided by financing activities during 2021 was $82.0 million compared to net cash used of $88.6 million in 2020. Financing activities during 2021 included net borrowings of $95.8 million compared to net payments of $87.5 million in 2020. The net cash inflow for 2021 included $220.0 million in borrowings to fund the Oscor acquisition. The payments made during 2020 include the utilization of proceeds received in conjunction with the patent litigation judgment during the fourth quarter of 2020.
Capital Structure - As of December 31, 2021, our capital structure consists of $828.1 million of debt, net of deferred debt issuance costs and unamortized discounts, outstanding under our Senior Secured Credit Facilities and 33 million shares of common stock outstanding. We have access to $375.0 million of borrowing capacity under our Revolving Credit Facility, available for normal course of business and letters of credit. We are also authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. As of December 31, 2021, our contractual debt service obligations for 2022, consisting of principal and interest on our outstanding debt, are estimated to be approximately $33 million. Actual principal and interest payments may be higher if, for instance, the applicable interest rates on our Senior Secured Credit Facilities increase, we borrow additional amounts on our Revolving Credit Facility, or we pay principal amounts in excess of the required minimums reflected in the contractual debt service obligations above.
Credit Facilities - On September 2, 2021, we entered into a new credit agreement (the “2021 Credit Agreement”) which permits borrowings and other extensions of credit in an initial aggregate principal amount of up to $1 billion (as may be increased from time to time in accordance with the terms). The 2021 Credit Agreement governs the Company’s senior secured credit facilities (the “Senior Secured Credit Facilities”), which consist of a five-year $400 million revolving credit facility (the “Revolving Credit Facility”), which had available borrowing capacity of $375.0 million as of December 31, 2021, a five-year “term A” loan (the “TLA Facility”) with outstanding principal balance of $467 million, and a seven-year “term B” loan (the “TLB Facility”) with outstanding principal balance of $349 million. The Revolving Credit and TLA Facilities mature on September 2, 2026. The TLB Facility matures on September 2, 2028.
Our off-balance sheet commitments related to our outstanding letters of credit as of December 31, 2021 were $5.7 million.
The 2021 Credit Agreement contains customary terms and conditions, including representations and warranties and affirmative and negative covenants, as well as financial covenants for the benefit of the lenders under the Revolving Credit Facility and the TLA Facility, which require that we maintain (i) a total net leverage ratio not to exceed 5.50:1.00 (stepping down to 5.00:1.00 for the third fiscal quarter of 2023 through maturity and subject to increase in certain circumstances following qualified acquisitions, but not to exceed 5.50:1.00) and (ii) an interest coverage ratio of at least 2.50:1.00. As of December 31, 2021, we were in compliance with these financial covenants. The TLB Facility does not contain any financial maintenance covenants. As of December 31, 2021, our total net leverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 2.7 to 1.0. For the twelve month period ended December 31, 2021, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 12.5 to 1.0.
Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us.
Refer to Note 8 “Debt” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for further description of our outstanding debt.
- 39 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
Cash and Other Commitments
We have material cash requirements to pay third parties under various contractual obligations discussed below.
Presented below is a summary of contractual obligations and other minimum commitments as of December 31, 2021. Refer to Note 13 “Commitments and Contingencies” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information regarding self-insurance liabilities, which are not reflected in the table below.
 Payments due by period
TotalLess than 1 year1-3 years3-5 yearsMore than 5 years
Principal amount of debt outstanding(a)
$835,487 $15,250 $48,126 $440,489 $331,622 
Interest on debt(a)
99,758 17,532 34,173 30,780 17,273 
Operating lease obligations(b)
80,691 12,423 22,126 20,490 25,652 
Finance lease obligations(b)
9,894 876 1,784 1,427 5,807 
(a)Interest payments in the table above reflect the contractual interest payments on our outstanding debt based upon the balance outstanding and applicable interest rates at December 31, 2021, and exclude the impact of the debt issuance cost and discount amortization and the impact of interest rate swap agreements. Refer to Note 8 “Debt” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information regarding long-term debt.
(b)Refer to Note 14 “Leases” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information about our operating and finance lease obligations.
Capital expenditures for 2021 totaled $53.5 million, compared to $46.8 million and $48.2 million in 2020 and 2019, respectively. Capital expenditures in 2021 related primarily to upgrades of manufacturing facilities and information technology. We expect 2022 capital expenditures to approximate $65 million to $75 million, with a significant portion related to additional upgrades of manufacturing facilities and information technology, as well as for manufacturing equipment to support productivity initiatives.
In addition to debt obligations, lease obligations, and capital expenditures, we enter into a variety of contractual obligations in connection with the execution of our business. As of December 31, 2021, we had purchase obligations for raw materials and other parts of approximately $91 million which we will incur during 2022.
We have recorded liabilities for unrecognized tax benefits that, because of their nature, have a high degree of uncertainty regarding the timing of future cash payment and other events that extinguish these liabilities. Refer to Note 12 “Income Taxes” of the Notes to Consolidated Financial Statements in Item 8 of this report for additional information about these unrecognized tax benefits.
Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and availability under our Revolving Credit Facility are sufficient to meet our working capital, debt service and capital expenditure requirements for at least the next twelve months. However, such cash flows are dependent upon our future operating performance which, in turn, is subject to prevailing economic conditions, the effects of the COVID-19 pandemic, and to financial, business and other factors, including the conditions of our markets, some of which are beyond our control. If our future financing needs increase, we may need to arrange additional debt or equity financing. We continually evaluate and consider various financing alternatives to enhance or supplement our existing financial resources, including our Senior Secured Credit Facilities. However, we cannot be assured that we will be able to enter into any such arrangements on acceptable terms or at all.
Impact of Recently Issued Accounting Standards
In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), SEC, or other authoritative accounting bodies to determine the potential impact they may have on our Consolidated Financial Statements. Refer to Note 1 “Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements contained in Item 8 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.
- 40 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
CRITICAL ACCOUNTING ESTIMATES
Management’s discussion and analysis of financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with GAAP. We make estimates and assumptions in the preparation of our consolidated financial statements that affect the reported amounts of assets and liabilities, revenue and expenses and related disclosures of contingent assets and liabilities. We base our estimates and judgments upon historical experience and other factors that are believed to be reasonable under the circumstances. Changes in estimates or assumptions could result in a material adjustment to the consolidated financial statements.
We have identified several critical accounting estimates. An accounting estimate is considered critical if both: (a) the nature of the estimates or assumptions is material due to the levels of subjectivity and judgment involved, and (b) the impact of changes in the estimates and assumptions have had or are reasonably likely to have a material effect on the consolidated financial statements. This listing is not a comprehensive list of all of our accounting policies. For further information regarding the application of these and other accounting policies, see Note 1 “Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements contained in Item 8 of this report.
Inventories
Inventories are measured on a first-in, first-out basis at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The valuation of inventory requires us to estimate obsolete or excess inventory, as well as inventory that is not of saleable quality.
Historically, our inventory adjustment has been adequate to cover our losses. However, variations in methods or assumptions could have a material impact on our results. If our demand forecast for specific products is greater than actual demand and we fail to reduce manufacturing output accordingly, we could be required to record additional inventory write-down or expense a greater amount of overhead costs, which would negatively impact our net income.
Acquisition Method of Accounting
The Company accounts for business combinations using the acquisition method of accounting. We recognize the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquiree at their estimated fair values on the date of acquisition. Any excess purchase price over the fair value of net assets acquired is recorded to goodwill. Determining the fair value of these items requires management’s judgment and more often than not the utilization of independent valuation specialists. The judgments made in the determination of the estimated fair values assigned to the assets acquired, the liabilities assumed and any noncontrolling interest in the investee, as well as the estimated useful life of each asset and the duration of each liability, can materially impact the financial statements in periods after acquisition, such as through depreciation and amortization expense. For more information on our acquisitions and application of the acquisition method, see Note 2 “Business Acquisitions”of the Notes to Consolidated Financial Statements contained in Item 8 of this report.
Valuation of Goodwill and Intangible Assets
We make assumptions in establishing the carrying value, fair value and, if applicable, the estimated lives of our intangible and other long-lived assets. Goodwill and intangible assets determined to have an indefinite useful life are not amortized. Instead, these assets are evaluated for impairment on an annual basis on the last day of our fiscal year and whenever events or business conditions change that could indicate that the asset is impaired. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (asset group) may not be recoverable.
Evaluation of goodwill for impairment
We test each reporting unit’s goodwill for impairment on the last day of our fiscal year and between annual tests if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of a reporting unit below its carrying value. In conducting this annual impairment testing, we may first perform a qualitative assessment of whether it is more-likely-than-not that a reporting unit’s fair value is less than its carrying value. If not, no further goodwill impairment testing is required. If it is more-likely-than-not that a reporting unit’s fair value is less than its carrying value, or if we elect not to perform a qualitative assessment of a reporting unit, a quantitative analysis is performed, in which the fair value of the reporting unit is compared to its carrying value. If the carrying value of a reporting unit exceeds its fair value, an impairment loss is recognized equal to the excess, limited to the amount of goodwill allocated to that reporting unit.
- 41 -
MANAGEMENT’S DISCUSSION AND ANALYSIS
We performed a qualitative assessment of our Medical reporting unit as of December 31, 2021. As part of this analysis, we evaluated factors including, but not limited to, our market capitalization and stock price performance, macro-economic conditions, market and industry conditions, cost factors, the competitive environment, and the operational stability and overall financial performance of the reporting unit. The assessment indicated that it was more likely than not that the fair value of the Medical reporting unit exceeded its carrying value. 
We elected to bypass the qualitative assessment and performed a quantitative analysis for our Non-Medical reporting unit. Resulting from the quantitative analysis, the fair value exceeded the carrying value of the Non-Medical reporting unit by approximately 184%. We do not believe that any of our reporting units are at risk for impairment. However, changes to the factors considered above could affect the estimated fair value of one or more of our reporting units and could result in a goodwill impairment charge in a future period. We may be unaware of one or more significant factors that, if we had been aware of, would cause our conclusion to change, which could result in a goodwill impairment charge in a future period.
Evaluation of indefinite-lived intangible assets for impairment
Our indefinite-lived intangible assets include the Greatbatch Medical and Lake Region Medical tradenames. Similar to goodwill, we perform an annual impairment review of our indefinite-lived intangible assets on the last day of our fiscal year, unless events occur that trigger the need for an interim impairment review. We have the option to first assess qualitative factors in determining whether it is more-likely-than-not that an indefinite-lived intangible asset is impaired. If we elect not to use this option, or we determine that it is more-likely-than-not that the asset is impaired, we perform a quantitative assessment that requires us to estimate the fair value of each indefinite-lived intangible asset and compare that amount to its carrying value. Fair value is estimated using the relief-from-royalty method. Significant assumptions inherent in this methodology include estimates of royalty rates and discount rates. The discount rate applied is based on the risk inherent in the respective intangible assets and royalty rates are based on the rates at which comparable tradenames are being licensed in the marketplace. Impairment, if any, is based on the excess of the carrying value over the fair value of these assets.
We performed a quantitative assessment to test our indefinite-lived intangible assets for impairment as of December 31, 2021. For the Greatbatch Medical tradename, the excess of the estimated fair value over carrying value (expressed as a percentage of carrying value) was in excess of its carrying value of $20 million by approximately 386% as of December 31, 2021. The Lake Region Medical tradename had an excess of the estimated fair value over carrying value of approximately 78% and a carrying value of $70 million at December 31, 2021. We do not believe that our indefinite-lived intangible assets are at risk for impairment. However, a significant increase in the discount rate, decrease in the terminal growth rate, increase in tax rates, decrease in the royalty rate or substantial reductions in our end-markets and volume assumptions could have a negative impact on the estimated fair values of either of our tradenames and require us to recognize impairments of these indefinite-lived intangible assets in a future period.
Evaluation of long-lived assets for impairment
When impairment indicators exist, we determine if the carrying value of the long-lived asset(s) or definite-lived intangible asset(s) including, but not limited to, PP&E and right-of-use lease assets, exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted future cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. When it is determined that the useful life of an asset (asset group) is shorter than the originally estimated life, and there are sufficient cash flows to support the carrying value of the asset (asset group), we accelerate the rate of depreciation/amortization in order to fully depreciate/amortize the asset over its shorter useful life.
Estimation of the cash flows and useful lives of long-lived assets and definite-lived intangible assets requires significant management judgment. Events could occur that would materially affect our estimates and assumptions. Unforeseen changes, such as the loss of one or more significant customers, technology obsolescence, or significant manufacturing disruption, among other factors, could substantially alter the assumptions regarding the ability to realize the return of our investment in long-lived assets, definite-lived intangible assets or their estimated useful lives.
- 42 -

ITEM 7A.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
MARKET RISK
In the normal course of business, we are exposed to market risk primarily due to changes in foreign currency exchange rates and interest rates. Changes in these rates could result in fluctuations in our earnings and cash flows. We regularly assess these risks and have established policies and business practices to help protect against the adverse effects of these and other potential exposures. However, fluctuations in foreign currency exchange rates and interest rates could have a significant impact, positive or negative, on our financial results in the future.
Foreign Currency Exchange Rate Risk
We have foreign operations in the Dominican Republic, Germany, Ireland, Israel, Malaysia, Mexico, Switzerland, and Uruguay which expose us to foreign currency exchange rate fluctuations due to transactions denominated in Dominican pesos, Euros, Israeli shekels, Malaysian ringgits, Mexican pesos, Swiss francs, and Uruguayan pesos. We continuously evaluate our foreign currency risk, and we use operational hedges and forward currency exchange rate contracts, to manage the impact of currency exchange rate fluctuations on earnings and cash flows. We do not enter into currency exchange rate derivative instruments for speculative purposes. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency exposures would have had an impact of approximately $5 million on our 2021 annual sales. This amount is not indicative of the hypothetical net earnings impact due to the partially offsetting impacts on cost of sales and operating expenses in those currencies. We estimate that foreign currency exchange rate fluctuations during 2021 increased sales in comparison to 2020 by $1.5 million.
We had currency derivative instruments with notional amounts totaling $48.2 million outstanding as of December 31, 2021. As of December 31, 2021, we recorded assets totaling $0.7 million to recognize the fair value of these derivative instruments on our Consolidated Balance Sheets. The amounts recorded during 2021 related to our forward contracts were decreases in Sales, Cost of sales and Operating expenses of $0.7 million, $1.4 million and $0.1 million, respectively. Refer to Note 17 “Financial Instruments and Fair Value Measurements” to the Consolidated Financial Statements contained in Item 8 of this report for additional information regarding our outstanding forward contracts.
To the extent that our monetary assets and liabilities, including short-term and long-term intercompany loans, are recorded in a currency other than the functional currency of the subsidiary, these amounts are remeasured each period at the period-end exchange rate, with the resulting gain or loss being recorded in Other (income) loss, Net, in the Consolidated Statements of Operations. We recorded net foreign currency transaction gains of $0.1 million for 2021.
We translate all assets and liabilities of our foreign operations where the U.S. dollar is not the functional currency at the period-end exchange rate and translate sales and expenses at the average exchange rates in effect during the period. The net effect of these translation adjustments is recorded in the Consolidated Financial Statements as Comprehensive income (loss). The translation adjustment for 2021 was a loss of $27.8 million and primarily related to the strengthening U.S. dollar relative to the Euro. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in our foreign subsidiaries. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency net assets would have had an impact of approximately $37 million on our foreign net assets as of December 31, 2021.
Interest Rate Risk
We regularly monitor interest rate risk attributable to our outstanding debt obligations. From time to time, we may enter into interest rate swap agreements in order to reduce the cash flow risk caused by interest rate changes on our outstanding floating rate borrowings. As of December 31, 2021, we had $835 million in principal amount of debt outstanding. Interest rates on our Revolving Credit Facility, TLA Facility and TLB Facility, reset, at our option, based upon the prime rate or LIBOR rate, thus subjecting us to interest rate risk. Our TLB Facility has a 0.50% LIBOR floor, thus is only variable when LIBOR interest rates are above 0.50%. A hypothetical one percentage point (100 basis points) change in the LIBOR rate on the $685 million of unhedged variable rate debt outstanding at December 31, 2021 would increase our interest expense by approximately $5 million.
As of December 31, 2021, approximately 18% of our principal amount of debt outstanding has been effectively converted to fixed-rate borrowings through the use of interest rate swaps, in comparison to approximately 27% as of December 31, 2020.  We had an interest swap agreement with a notional amount of $150 million outstanding as of December 31, 2021. We entered into this agreement in order to reduce our exposure to fluctuations in the LIBOR rate. The amount recorded during 2021 related to this interest rate swap was an increase of $3.4 million to Interest expense. As of December 31, 2021, these swaps had an unfavorable fair value of $3.0 million.
- 43 -
Refer to Note 8 “Debt” and Note 17 “Financial Instruments and Fair Value Measurements” of the Notes to Consolidated Financial Statements in Item 8 of this report for additional information about our outstanding debt and interest rate swap agreement, respectively.
- 44 -

ITEM 8.    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
INTEGER HOLDINGS CORPORATION
Index to Consolidated Financial Statements
Page


- 45 -
MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
The Company’s certifying officers are responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is designed and maintained under the supervision of its certifying officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s consolidated financial statements for external reporting purposes in accordance with accounting principles generally accepted in the United States of America.
As of December 31, 2021, management conducted an assessment of the effectiveness of the Company’s internal control over financial reporting based on the framework established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has determined that the Company’s internal control over financial reporting as of December 31, 2021 is effective. As permitted by guidance issued by the Securities and Exchange Commission, management excluded from its assessment of its system of internal control over financial reporting the operations associated with Oscor Inc., Oscor Caribe, LLC and Oscor Europe GmbH, which were acquired on December 1, 2021, and whose financial statements constitute, 9% of total assets, 16% of net assets, and less than 1% of both sales and net income of the consolidated financial statement amounts as of and for the year ended December 31, 2021. The Company is in the process of evaluating the existing controls and procedures of the acquired business and integrating the acquired business into its system of internal control over financial reporting. As a result, management was unable, without incurring unreasonable effort or expense, to conduct an assessment of internal control over financial reporting for the acquired business.
The effectiveness of internal control over financial reporting as of December 31, 2021 has been audited by Deloitte & Touche LLP, the Company’s independent registered public accounting firm.
Dated: February 22, 2022
 
/s/ Joseph W. Dziedzic  /s/ Jason K. Garland
Joseph W. Dziedzic  Jason K. Garland
President & Chief Executive Officer  Executive Vice President & Chief Financial Officer

- 46 -
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the stockholders and the Board of Directors of Integer Holdings Corporation
Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of Integer Holdings Corporation and subsidiaries (the “Company”) as of December 31, 2021, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements and financial statement schedule as of and for the year ended December 31, 2021 of the Company and our report dated February 22, 2022 expressed an unqualified opinion on those consolidated financial statements and financial statement schedule.
As described in Management’s Report on Internal Control Over Financial Reporting, management excluded from its assessment the internal control over financial reporting the operations associated with Oscor Inc., Oscor Caribe, LLC and Oscor Europe GmbH, which were acquired on December 1, 2021, and whose financial statements constitute, 9% of total assets, 16% of net assets, and less than 1% of both sales and net income of the consolidated financial statement amounts as of and for the year ended December 31, 2021. Accordingly, our audit did not include the internal control over financial reporting at Oscor Inc., Oscor Caribe, LLC and Oscor Europe GmbH.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Deloitte & Touche LLP
Williamsville, New York
February 22, 2022
- 47 -
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the stockholders and the Board of Directors of Integer Holdings Corporation
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Integer Holdings Corporation and subsidiaries (the “Company”) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income, cash flows, and stockholders’ equity for each of the three years in the period ended December 31, 2021, and the related notes and the schedule listed in the Index at Item 15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021and 2020, and the results of its operations and its cash flows each of the three years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 22, 2022 expressed an unqualified opinion on the Company’s internal control over financial reporting.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Inventories - Refer to Notes 1 and 4 to the financial statements
Critical Audit Matter Description
Inventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. The valuation of inventory requires the Company to estimate obsolete or excess inventory, as well as inventory that is not of saleable quality. Variations in assumptions used could have a material impact to the amount of write-downs for excess, obsolete or expired inventory. A significant change in the timing or level of demand for specific products may result in recording material adjustments for excess, obsolete or expired inventory in the future.
Given the amount of judgment required by management in estimating the timing or level of demand forecast for a specific product, performing audit procedures to evaluate the reasonableness of the estimated excess or obsolete inventory, or inventory that is not of saleable quality required a high degree of auditor judgment and an increased extent of effort.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to the valuation of excess or obsolete inventory or inventory that is not of saleable quality, included the following, among others:
•We tested the effectiveness of controls over management’s review of the periodic calculation of the valuation for excess or obsolete inventory or inventory that is not of saleable quality.
- 48 -
•We tested management’s process for determining the valuation of inventory, including:
◦We tested the accuracy and completeness of the source information underlying the determination of the valuation for excess or obsolete inventory, or inventory that is not of saleable quality.
◦We tested the demand forecast by obtaining documentation to support customer orders, contracts with customers, as well as historical and future sales that corroborate the amount stated for the demand forecast.
◦We evaluated whether the methodology and assumptions applied by management are reasonable and consistent with the nature of the inventory.
◦We performed a retrospective review of the prior-year estimates for excess or obsolete inventory, or inventory that is not of saleable quality, to determine whether management’s judgments and assumptions relating to those estimates indicate a possible bias.
Other Intangible Assets, Net - Lake Region Medical Tradename - Refer to Notes 1 and 6 to the financial statements
Critical Audit Matter Description
The carrying value of the Lake Region Medical tradename intangible asset was $70 million as of December 31, 2021. The Company assesses its indefinite-lived intangible assets for impairment at least annually by comparing the fair value of the indefinite-lived asset to the carrying value. The fair value of the tradename is estimated using the relief-from-royalty method. The determination of the fair value requires management to make estimates and use assumptions, including those assumption related to the royalty rate for similar transactions to estimate the present value of cash flows that would be derived from the royalties. Changes in the assumption could have a significant impact on the fair value of the Lake Region Medical tradename asset and a significant change in fair value could cause a material impairment of the asset.
Given the determination of fair value of the Lake Region Medical tradename asset requires management to make a significant estimate and assumption relating to the selection of the royalty rate, performing audit procedures to evaluate the reasonableness of such estimate and assumption requires a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to the assumption used for the selection of the royalty rate, included the following, among others:
•We tested the effectiveness of controls over management’s intangible asset impairment evaluation, including those over the determination of the fair value of the Lake Region Medical tradename asset, such as controls related to management’s selection of the royalty rate.
•We performed sensitivity analysis of the royalty rate assumption to evaluate changes in the fair value of the Lake Region Medical tradename asset that would result from changes in the underlying assumption.
•With the assistance of our fair value specialists, we evaluated the reasonableness of the royalty rate by:
–Testing the source information underlying the determination of the royalty rate and the mathematical accuracy of the calculation.
–Developing a range of independent estimates and comparing those to both market and industry data as well as to the royalty rate selected by management.
Business Acquisitions — Oscor Inc., Oscor Caribe, LLC, and Oscor Europe GmbH — Customer Lists Intangible Asset — Refer to Note 1 and 2 to the financial statements
Critical Audit Matter Description
The Company completed the acquisition of Oscor Inc., Oscor Caribe, LLC, and Oscor Europe GmbH for $220.4 million on December 1, 2021. The Company accounted for the acquisition under the acquisition method of accounting for business combinations. Accordingly, the purchase price was allocated to the assets acquired and liabilities assumed based on their respective fair values, including recording a customer lists intangible asset of $73.8 million. Management estimated the fair value of the customer lists intangible asset using the multi-period excess earnings method, which is a specific discounted cash flow method under the income approach. The fair value determination of the customer lists intangible asset required management to make significant estimates and assumptions related to the customer attrition rate and the selection of the discount rate used in the valuation of the intangible asset.
- 49 -
Given the fair value determination of a customer lists intangible asset requires management to make significant estimates and assumptions related to the customer attrition rate and the selection of the discount rate, performing audit procedures to evaluate the reasonableness of these estimates and assumptions required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to the customer attrition rate and the selection of the discount rate for the customer lists intangible asset included the following, among others:
•We tested the effectiveness of controls over the valuation of the customer lists intangible asset, including management’s controls over the determination of the customer attrition rate and the selection of the discount rate.
•We performed sensitivity analyses of the significant assumptions used in the valuation model to evaluate the change in fair value resulting from changes in the significant assumptions.
•We tested the completeness, accuracy and relevance of underlying historical customer data used to determine the customer attrition rate.
•With the assistance of our fair value specialists, we evaluated the reasonableness of the (1) valuation methodology, (2) customer attrition rate and (3) discount rate by:
–Testing the mathematical accuracy of the customer attrition rate used and comparing it to historical customer data.
–Testing the source information underlying the determination of the discount rate and testing the mathematical accuracy of the calculation.
–Developing a range of independent estimates and comparing those to the discount rate selected by management.
/s/ Deloitte & Touche LLP
Williamsville, New York
February 22, 2022
We have served as the Company’s auditor since 1985.
- 50 -
INTEGER HOLDINGS CORPORATION
CONSOLIDATED BALANCE SHEETS

(in thousands except share and per share data)December 31,
2021		December 31,
2020
ASSETS
Current assets:
Cash and cash equivalents$17,885 $49,206 
Accounts receivable, net of provision for credit losses of $0.1 million and $0.2 million as
  of December 31, 2021 and 2020, respectively
182,310 156,207 
Inventories155,699 149,323 
Refundable income taxes4,735 2,087 
Contract assets64,743 40,218 
Prepaid expenses and other current assets27,610 15,896 
Total current assets452,982 412,937 
Property, plant and equipment, net277,099 253,964 
Goodwill924,704 859,442 
Other intangible assets, net807,810 757,224 
Deferred income taxes5,711 4,398 
Operating lease assets70,053 45,153 
Other long-term assets43,856 38,739 
Total assets$2,582,215 $2,371,857 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt$15,250 $37,500 
Accounts payable76,859 51,570 
Income taxes payable725 1,847 
Operating lease liabilities9,862 8,431 
Accrued expenses and other current liabilities56,933 56,843 
Total current liabilities159,629 156,191 
Long-term debt812,876 693,758 
Deferred income taxes171,505 182,304 
Operating lease liabilities59,767 37,861 
Other long-term liabilities23,741 30,688 
Total liabilities1,227,518 1,100,802 
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding as of December 31, 2021 and 2020
— — 
Common stock, $0.001 par value; 100,000,000 shares authorized; 33,063,336 and 32,908,178 shares issued and outstanding as of December 31, 2021 and 2020, respectively
33 33 
Additional paid-in capital713,150 700,814 
Retained earnings614,324 517,516 
Accumulated other comprehensive income27,190 52,692 
Total stockholders’ equity1,354,697 1,271,055 
Total liabilities and stockholders’ equity$2,582,215 $2,371,857 

The accompanying notes are an integral part of these consolidated financial statements.
- 51 -
INTEGER HOLDINGS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS

 Fiscal Year Ended December 31,
(in thousands except per share data)202120202019
Sales$1,221,079 $1,073,442 $1,258,094 
Cost of sales884,109 787,735 903,084 
Gross profit336,970 285,707 355,010 
Operating expenses:
Selling, general and administrative141,418 109,006 138,695 
Research, development and engineering51,985 48,468 46,529 
Other operating expenses7,856 7,621 12,151 
Total operating expenses201,259 165,095 197,375 
Operating income135,711 120,612 157,635 
Interest expense31,628 38,220 52,545 
(Gain) loss on equity investments, net3,143 (5,337)475 
Other (income) loss, net(123)1,522 (578)
Income from continuing operations before taxes 101,063 86,207 105,193 
Provision for income taxes8,043 8,949 13,975 
Income from continuing operations$93,020 $77,258 $91,218 
Discontinued operations:
Income from discontinued operations before taxes4,931 — 5,296 
Provision for income taxes1,143 — 178 
Income from discontinued operations$3,788 $— $5,118 
Net income$96,808 $77,258 $96,336 
Basic earnings per share:
Income from continuing operations$2.82 $2.35 $2.80 
Income from discontinued operations0.11 — 0.16 
Basic earnings per share2.93 2.35 2.95 
Diluted earnings per share:
Income from continuing operations$2.80 $2.33 $2.76 
Income from discontinued operations0.11 — 0.15 
Diluted earnings per share2.91 2.33 2.92 
Weighted average shares outstanding:
Basic32,993 32,845 32,627 
Diluted33,258 33,113 33,037 

The accompanying notes are an integral part of these consolidated financial statements.
- 52 -
INTEGER HOLDINGS CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

 Fiscal Year Ended December 31,
(in thousands)202120202019
Comprehensive Income
Net income$96,808 $77,258 $96,336 
Other comprehensive income (loss):
Foreign currency translation gain (loss)(27,826)34,907 (7,900)
Net change in cash flow hedges, net of tax2,105 (2,052)(4,580)
Defined benefit plan liability adjustment, net of tax219 (151)(536)
Other comprehensive income (loss), net(25,502)32,704 (13,016)
Comprehensive income$71,306 $109,962 $83,320 

The accompanying notes are an integral part of these consolidated financial statements.
- 53 -
INTEGER HOLDINGS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS

 Fiscal Year Ended December 31,
(in thousands)202120202019
Cash flows from operating activities:
Net income$96,808 $77,258 $96,336 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization81,369 79,324 77,895 
Debt related charges included in interest expense6,954 4,774 7,772 
Stock-based compensation16,185 9,163 9,294 
Non-cash (gains) charges related to customer bankruptcy(348)554 21,695 
Non-cash lease expense8,235 7,810 7,443 
Non-cash (gain) loss on equity investments3,143 (5,337)475 
Contingent consideration fair value adjustment133 (2,000)— 
Other non-cash (gains) losses2,202 600 (162)
Deferred income taxes(10,270)(6,966)(10,285)
Gain on sale of discontinued operations— — (4,974)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable(17,539)38,153 (6,976)
Inventories4,700 18,441 3,724 
Prepaid expenses and other assets(2,409)(864)(6,293)
Contract assets(24,923)(15,451)(24,767)
Accounts payable19,525 (9,055)1,887 
Accrued expenses and other liabilities(22,984)(10,721)(2,744)
Income taxes payable(4,115)(4,342)(4,962)
Net cash provided by operating activities156,666 181,341 165,358 
Cash flows from investing activities:
Acquisition of property, plant and equipment(53,463)(46,832)(48,198)
Purchase of intangible asset— (4,607)— 
Proceeds from sale of property, plant and equipment443 82 28 
Purchase of equity investments— — (417)
Proceeds from sale of discontinued operations— — 4,734 
Acquisitions, net(217,978)(5,219)(15,009)
Net cash used in investing activities(270,998)(56,576)(58,862)
Cash flows from financing activities:
Principal payments of term loans(741,786)(87,500)(111,500)
Proceeds from issuance of term loans818,250 — — 
Proceeds from revolving credit facility82,300 185,000 34,000 
Payments of revolving credit facility(63,000)(185,000)(39,000)
Proceeds from the exercise of stock options743 3,263 3,242 
Payment of debt issuance costs(8,139)(515)(1,385)
Tax withholdings related to net share settlements of restricted stock awards(4,592)(3,820)(3,283)
Contingent consideration payments(1,621)— — 
Principal payments on finance leases(169)(6)— 
Net cash provided by (used in) financing activities81,986 (88,578)(117,926)
Effect of foreign currency exchange rates on cash and cash equivalents1,025 (516)(604)
Net increase (decrease) in cash and cash equivalents(31,321)35,671 (12,034)
Cash and cash equivalents, beginning of year49,206 13,535 25,569 
Cash and cash equivalents, end of year$17,885 $49,206 $13,535 

The accompanying notes are an integral part of these consolidated financial statements.
- 54 -
INTEGER HOLDINGS CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 Fiscal Year Ended December 31,
(in thousands)202120202019
Total stockholders’ equity, beginning balance$1,271,055 $1,152,488 $1,060,493 
Common stock and additional paid-in capital
Balance, beginning of period700,847 701,051 691,116 
Stock awards exercised or vested(3,849)(9,367)641 
Stock-based compensation16,185 9,163 9,294 
Balance, end of period713,183 700,847 701,051 
Treasury stock
Balance, beginning of period— (8,809)(8,125)
Treasury shares purchased— — (2,961)
Treasury shares reissued— 8,809 2,277 
Balance, end of period— — (8,809)
Retained earnings
Balance, beginning of period517,516 440,258 344,498 
Cumulative effect of adopting a new accounting standard (ASC 842)— — (576)
Net income96,808 77,258 96,336 
Balance, end of period614,324 517,516 440,258 
Accumulated other comprehensive income
Balance, beginning of period52,692 19,988 33,004 
Other comprehensive income (loss)(25,502)32,704 (13,016)
Balance, end of period27,190 52,692 19,988 
Total stockholders’ equity, ending balance$1,354,697 $1,271,055 $1,152,488 

The accompanying notes are an integral part of these consolidated financial statements.
- 55 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition to medical technologies, the Company develops batteries for high-end niche applications in the energy, military, and environmental markets. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries.
Basis of Presentation and Principles of Consolidation
The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of Integer Holdings Corporation and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
In July 2018, the Company completed the sale of its Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC). For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&O Product Line. The Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s (parent) centralized treasury and cash management processes. See Note 20 “Discontinued Operations” for the financial results and cash flow amounts for discontinued operations. All results and information in the consolidated financial statements are presented as continuing operations and exclude the AS&O Product Line unless otherwise noted specifically as discontinued operations.
The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. The discontinued operations of the AS&O Product Line were reported in the Medical segment. Refer to Note 18 “Segment and Geographic Information,” for additional information on the Company’s reportable segments.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting periods. Actual results could differ materially from those estimates.
Risks and Uncertainties
Beginning in early March 2020, the global spread of the novel coronavirus (“COVID-19”) created significant uncertainty and worldwide economic disruption. Specific impacts to the Company’s business included and continue to include labor shortages, disruptions in the supply chain, delayed or reduced customer orders and sales, restrictions on associates’ ability to travel or work, and delays in shipments to and from certain countries. The extent to which COVID-19 will continue to impact the Company’s operations depends on future developments, which remain highly uncertain and difficult to predict, including, among others, the duration of the outbreak, the effectiveness and utilization of vaccines for COVID-19 and its variants, new information that may emerge concerning the severity of COVID-19 and the actions, especially those taken by governmental authorities to contain the pandemic or treat its impact. As pandemic-related events continue to evolve, additional impacts may arise that the Company is not aware of currently. Any prolonged material disruption of the Company’s labor force, suppliers, manufacturing, or customers could materially impact its consolidated financial position, results of operations or cash flows.
Cash and Cash Equivalents
Cash and cash equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three months or less.
- 56 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and accounts receivable are to three customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 19 “Revenue from Contracts with Customers” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks.
Trade Accounts Receivable and Provision for Current Expected Credit Losses
The Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains a provision for those customer receivables that it does not expect to collect. In accordance with Accounting Standards Codification (“ASC”) Topic 326, the Company accrues its estimated losses from uncollectable accounts receivable to the provision based upon recent historical experience, the length of time the receivable has been outstanding, other specific information as it becomes available, and reasonable and supportable forecasts not already reflected in the historical loss information. Provisions for current expected credit losses are charged to current operating expenses. Actual losses are charged against the provision when incurred. In 2020, the Company wrote-off $2.3 million of outstanding receivables that were previously reserved for as of December 31, 2019, in connection with a customer bankruptcy in the fourth quarter of 2019.
Supplier Financing Arrangements
The Company utilizes supplier financing arrangements with financial institutions to sell certain accounts receivable on a non-recourse basis. These transactions are treated as a sale of, and are accounted for as a reduction to, accounts receivable. The agreements transfer control and risk related to the receivables to the financial institutions. The Company has no continuing involvement in the transferred receivables subsequent to the sale. During the years ended December 31, 2021 and December 31, 2020, the Company sold and de-recognized accounts receivable and collected cash of $116.1 million and $73.3 million, respectively. The costs associated with the supplier financing arrangements were not material for the years ended December 31, 2021 and December 31, 2020.
Inventories
Inventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held, historical sales volume, and estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4 “Inventories” contains additional information on the Company’s inventory. In connection with a customer bankruptcy in the fourth quarter of 2019, the Company wrote-down inventory by $19.0 million.
Leases
The Company determines if an arrangement is, or contains, a lease at inception and classifies it at as finance or operating.  The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Finance lease assets and corresponding liabilities are included in Other long-term assets, Accrued expenses and other current liabilities, and Other long-term liabilities, respectively, on the Consolidated Balance Sheets.
Lease right-of-use (“ROU”) assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term at commencement date. When discount rates implicit in leases cannot be readily determined, the Company uses its incremental borrowing rate based on information available at commencement date in determining the present value of future payments.  The incremental borrowing rate is determined based on the Company’s recent debt issuances, the Company’s specific credit rating, lease term and the currency in which lease payments are made.
- 57 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such option. Costs associated with operating leases are recognized within operating expenses on a straight-line basis over the lease term. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. The interest component of a finance lease is included in Interest expense and recognized using the effective interest method over the lease term. The Company combines lease and non-lease components for all asset classes. For certain leases where rent escalates based upon a change in a financial index, such as the Consumer Price Index, the difference between the rate at lease inception and the subsequent fluctuations in that rate are included in variable lease costs.  Additionally, because the Company does not separate lease and non-lease components, variable costs also include payments to the landlord for common area maintenance, real estate taxes, insurance and other operating expenses.  The Company does not apply the recognition requirements to leases with lease terms of 12 months or less. Note 14 “Leases” contains additional information on the Company’s leases.
Property, Plant and Equipment (“PP&E”)
PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 12-30 years; machinery and equipment 3-10 years; office equipment 3-10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, whichever is shorter. The costs of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. The Company also reviews its PP&E for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its fixed assets exceeds the related undiscounted future cash flows. In cases where the carrying value of the Company's long-lived assets or asset groups (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. Note 5 “Property, Plant and Equipment, Net” contains additional information on the Company’s PP&E.
Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. the “exit price”) in an orderly transaction between market participants at the measurement date. ASC 820, Fair Value Measurements, establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows:
Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment.
Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market.
Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations.
Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements.
Acquisitions
The Company accounts for acquisitions under the acquisition method of accounting for business combinations. Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill.
- 58 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
All direct acquisition-related costs are expensed as incurred and are recognized as a component of Other operating expenses. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.
Contingent Consideration
In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable performance target. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect.
The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The Company determines the initial fair value of contingent consideration liabilities using a Monte Carlo (“Monte Carlo”) valuation model, which involves a simulation of future revenues during the earn out-period using management’s best estimates, or a probability-weighted discounted cash flow analysis.
In periods subsequent to the initial measurement, contingent consideration liabilities are remeasured to fair value each reporting period until the contingent consideration is settled using various assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, revenue volatility and projected payment dates. The current portion of contingent consideration liabilities is included in Accrued expenses and other current liabilities and the non-current portion is included in Other long-term liabilities on the Consolidated Balance Sheets. Adjustments to the fair value of contingent consideration liabilities are included in Other operating expenses in the Consolidated Statements of Operations, and cash flows from operating activities in the Consolidated Statements of Cash Flows. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on contingent consideration recorded at fair value in the consolidated financial statements.
Goodwill
Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired and is assigned to one or more reporting units. The Company’s reporting units are the same as its reportable segments, Medical and Non-Medical. The Company tests each reporting unit’s goodwill for impairment at least annually as of the last day of the fiscal year and between annual tests if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of a reporting unit below its carrying amount. In conducting its goodwill test, the Company either performs a qualitative assessment or a quantitative assessment. A qualitative assessment requires that the Company consider events or circumstances including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, changes in strategy, changes in customers, changes in the Company’s stock price, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair values of its reporting units are greater than the carrying amounts, then the quantitative goodwill impairment test is not performed. The Company may elect to bypass the qualitative analysis and perform a quantitative analysis.
If the qualitative assessment indicates that the quantitative analysis should be performed or if management elects to bypass a qualitative analysis to perform a quantitative analysis, the Company then evaluates goodwill for impairment by comparing the fair value of each of its reporting units to its carrying value, including the associated goodwill. To determine the fair values, the Company uses a weighted combination of the market approach based on comparable publicly traded companies and the income approach based on estimated discounted future cash flows. The cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors.
- 59 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
The Company completed its annual goodwill impairment test as of December 31, 2021 and determined, after performing a qualitative review of its Medical reporting unit, that it is more likely than not that the fair value of the Medical reporting unit exceeds its carrying amount. Accordingly, there was no indication of impairment and the quantitative goodwill impairment test was not performed for the Medical reporting unit. The Company bypassed the qualitative analysis for its Non-Medical reporting unit and performed a quantitative analysis. The fair value of the Non-Medical reporting unit exceeded its carrying amount as of December 31, 2021.
Other Intangible Assets
Other intangible assets consist of purchased technology and patents, customer lists and trademarks. Definite-lived intangible assets are amortized on an accelerated or straight-line basis, which approximates the projected cash flows used to determine the fair value of those definite-lived intangible assets at the time of acquisition, as follows: purchased technology and patents 5-20 years; customer lists 7-20 years and other intangible assets 1-20 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized. The Company expenses the costs incurred to renew or extend the term of intangible assets.
The Company reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets or asset groups exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted future cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis.
The Company assesses its indefinite-lived intangible assets for impairment periodically to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment at least annually by comparing the fair value of the indefinite-lived intangible asset to its carrying value. The fair value is determined using the relief from royalty method.
Refer to Note 6 “Goodwill and Other Intangible Assets, Net” for further details of the Company’s goodwill and other intangible assets.
Equity Investments
The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other long-term assets on the Consolidated Balance Sheets. Equity investments are measured and recorded as follows:
•Non-marketable equity securities are equity securities without readily determinable fair value that are measured and recorded at fair value with changes in fair value recognized within net income. The Company measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. If an impairment is recognized on the Company’s non-marketable equity securities during the period, these assets are classified as Level 3 within the fair value hierarchy based on the nature of the fair value inputs.
•Equity method investments are equity securities in investees the Company does not control but over which it has the ability to exercise influence. Equity method investments are recorded at cost and are adjusted to recognize (1) the Company’s share, based on percentage ownership or other contractual basis, of the investee’s income or loss, (2) additional contributions made and dividends or other distributions received, and (3) impairments resulting from other-than-temporary declines in fair value.
Realized and unrealized gains and losses resulting from changes in fair value or the sale of these equity investments are recorded through (Gain) loss on equity investments, net. For some investments, the Company records its share of the investee’s income or loss one quarter in arrears due to the timing of our receipt of such information. The carrying value of the Company’s non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities by the same issuer. Determining whether an observed transaction is similar to a security within the Company’s portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of the Company’s equity securities as a result of observable price changes requires quantitative assessments of the fair value of these securities using various valuation methodologies and involves the use of estimates.
- 60 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. The Company’s quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee’s fair value. Qualitative factors considered include the investee’s financial condition and business outlook, market for technology, operational and financing cash flow activities, technology and regulatory approval progress, and other relevant events and factors affecting the investee. When indicators of impairment exist, quantitative assessments of the fair value of the Company’s non-marketable equity investments are prepared.
To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security’s fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and the Company’s ability and intent to hold the investment for a sufficient period of time to allow for recovery.
The Company has determined that its investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant. Refer to Note 17 “Financial Instruments and Fair Value Measurements” for additional information on the Company’s equity investments.
Debt Issuance Costs and Discounts
Debt issuance costs and discounts associated with the issuance of debt by the Company are deferred and amortized over the lives of the related debt. Debt issuance costs incurred in connection with the Company’s issuance of its revolving credit facility are classified within Other long-term assets and amortized to Interest expense on a straight-line basis over the contractual term of the revolving credit facility. Debt issuance costs and discounts related to the Company’s term-debt are recorded as a reduction of the carrying value of the related debt and are amortized to Interest expense using the effective interest method over the period from the date of issuance to the maturity date. Upon prepayment of the related debt, the Company also recognizes a proportionate amount of the costs as extinguishment of debt. Costs treated as extinguishment of debt are expensed and included in Interest expense in the accompanying Consolidated Statements of Operations. The amortization of debt issuance costs and discounts, and debt extinguishment charges are included in Debt related charges included in interest expense in the Consolidated Statements of Cash Flows. Note 8 “Debt” contains additional information on the Company’s debt issuance costs and discounts.
Income Taxes
The consolidated financial statements of the Company have been prepared using the asset and liability approach to account for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined, within each taxing jurisdiction, that it is more likely than not that the asset will not be realized.
The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision for income taxes. Penalties, if incurred, are recognized as a component of Selling, general and administrative (“SG&A”) expenses.
The Company and its subsidiaries file a consolidated United States (“U.S.”) federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where the tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates.
- 61 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Derivative Financial Instruments
The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. The Company’s use of derivative instruments is generally limited to cash flow hedges of certain interest rate risks and minimizing foreign currency exposure on foreign currency transactions, which are typically designated in hedging relationships, and intercompany balances, which are not designated as hedging instruments. Under master agreements with the respective counterparties to our derivative contracts, subject to applicable requirements, we have the right of set-off and are allowed to net settle transactions of the same type with a single net amount payable by one party to the other. Gains and losses on cash flow hedges are recorded in Accumulated Other Comprehensive Income in the Consolidated Balance Sheets until the underlying transaction is recorded in earnings. When the hedged item is realized, gains or losses are reclassified from Accumulated Other Comprehensive Income (“AOCI”) to the Consolidated Statement of Operations on the same line item as the underlying transaction. In the event the forecasted transactions do not occur, or it becomes probable that they will not occur, the Company reclassifies any gain or loss on the related cash flow hedge to earnings in the respective period. Cash flows related to these derivative financial instruments are included in cash flows from operating activities. Foreign currency contracts not designated as hedging relationships are recorded at fair value in Accrued expenses and other current liabilities in the Consolidated Balance Sheets and resulting gains or losses are recorded in the Consolidated Statement of Operations.
Revenue Recognition
The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The majority of contracts have an original expected duration of one year or less. Consideration payable to customers is included in the transaction price. In accordance with ASC 340-40-25-4, the Company expenses incremental costs of obtaining a contract when incurred because the amortization period is less than one year.
The Company evaluates revenue recognition in contracts with customers as performance obligations are satisfied and as the customer obtains control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits of the products. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Most of the Company’s revenues are recognized at the point in time when the products are shipped to customers. When contracts with customers for products, which do not have an alternative use to the Company, contain provisions that provide the Company with an enforceable right to payment for performance completed to date for costs incurred plus a reasonable profit throughout the duration of the contract, revenue is recognized over time as control is transferred to the customer. In contracts with customers where revenue is recognized over time, the Company uses an input measure to determine progress towards completion and total estimated costs at completion. Under this method, sales and gross profit are recognized as work is performed generally based on actual costs incurred. Revenue is recognized net of sales tax, value-added taxes and other taxes.
Performance Obligations
The Company considers each shipment of an individual product included on a purchase order to be a separate performance obligation, as each shipment is separately identifiable and the customer can benefit from each individual product separately from the other products included on the purchase order. Accordingly, a contract can have one or more performance obligations to manufacture products. Standard payment terms range from 30 to 90 days and may include a discount for early payment.
The Company does not offer its customers a right of return. Rather, the Company warrants that each unit received by the customer will meet the agreed upon technical and quality specifications and requirements. Only when the delivered units do not meet these requirements can the customer return the non-compliant units as a corrective action under the warranty. The remedy offered to the customer is repair of the returned units or replacement if repair is not viable. Accordingly, the Company records a warranty reserve and any warranty activities are not considered to be a separate performance obligation.
- 62 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Contract Balances
The timing of revenue recognition, billings and cash collections results in billed accounts receivable and less frequently, unearned revenue. Accounts receivable are recorded when the right to consideration becomes unconditional. Unearned revenue is recorded when customers pay or are billed in advance of the Company’s satisfaction of performance obligations. Contract liabilities are classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. For contracts with customers where revenue is recognized over time, the Company records a contract asset for unbilled revenue associated with non-cancellable customer orders, which is recorded within Contract assets on the Consolidated Balance Sheets.
Transaction Price
Generally, the transaction price of the Company’s contracts consists of a unit price for each individual product included in the contract, which can be fixed or variable based on the number of units ordered. In some instances, the transaction price also includes a rebate for meeting certain volume-based targets over a specified period of time. The transaction price of a contract is determined based on the unit price and the number of units ordered, reduced by the rebate expected to be earned on those units. Rebates are estimated based on the expected achievement of the volume-based target using the most likely amount method and are updated quarterly. Adjustments to these estimates are recognized under the cumulative catch-up method and in the period in which they are identified. When contracts with customers include consideration payable at the beginning of the contract, the transaction price is reduced at the later of when the Company recognizes revenue for the transfer of the related goods to the customer or when the Company pays or promises to pay the consideration. Volume discounts and rebates and other pricing reductions earned by customers are offset against their receivable balances.
The transaction price is allocated to each performance obligation on a relative standalone selling price basis. As the majority of products sold to customers are manufactured to meet the specific requirements and technical specifications of that customer, the products are considered unique to that customer and the unit price stated in the contract is considered the standalone selling price.
Contract Modifications
Contract modifications, which can include a change in scope, price, or both, most often occur related to contracts that are governed by a long-term arrangement. Contract modifications typically relate to the same products already governed by the long-term arrangement, and therefore, are accounted for as part of the existing contract. If a contract modification is for additional products, it is accounted for as a separate contract.
Environmental Costs
Environmental expenditures that relate to an existing condition caused by past operations and that do not provide future benefits are expensed as incurred. Liabilities are recorded when environmental assessments are made, the requirement for remedial efforts is probable and the amount of the liability can be reasonably estimated. Liabilities are recorded generally no later than the completion of feasibility studies. The Company has a process in place to monitor, identify, and assess how the current activities for known exposures are progressing against the recorded liabilities. The process is also designed to identify other potential remediation sites that are not presently known.
Restructuring Expenses
The Company continually evaluates alternatives to align its resources with the changing needs of its customers and markets, and to lower its operating costs. This includes realignment of existing manufacturing capacity, facility closures, process optimization, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in voluntary or involuntary employee termination benefits. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. All other exit costs are expensed as incurred. Refer to Note 11 “Other Operating Expenses” for additional information.
Research, Development and Engineering (“RD&E”)
RD&E costs are expensed as incurred. The primary costs are salary and benefits for personnel, material costs used in development projects and subcontracting costs.
- 63 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Product Warranties
The Company allows customers to return defective or damaged products for credit, replacement, or repair. The Company warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The Company accrues its estimated exposure to warranty claims, through Cost of Sales, based upon experience and other specific information as it becomes available. The product warranty liability is classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. Adjustments to pre-existing estimated exposure for warranties are made as changes to the obligations become reasonably estimable. Note 13 “Commitments and Contingencies” contains additional information on the Company’s product warranties.
Stock-Based Compensation
The Company recognizes stock-based compensation expense for its compensation plans. These plans include stock options, restricted stock units (“RSUs”) and performance-based restricted stock units (“PRSUs”). For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares to be earned depends on the achievement of targets based on market conditions, such as total shareholder return, or performance conditions based on the Company’s operating results. The Company records forfeitures of equity awards in the period in which they occur.
The fair value of the stock-based compensation is determined at the grant date. The Company uses the Black-Scholes standard option pricing model (“Black-Scholes model”) to determine the fair value of stock options. The fair value of each RSU is determined based on the Company’s closing stock price on the date of grant. The fair value of each PRSU is determined based on either the Company’s closing stock price on the date of grant or through a Monte Carlo valuation model for those awards that include a market-based condition. In addition to the closing stock price on the date of grant, the determination of the fair value of awards using both the Black-Scholes and Monte Carlo valuation models is affected by other assumptions, including the following:
Expected Term - The Company analyzes historical employee exercise and termination data to estimate the expected term assumption for stock options. For market-based awards, the term is commensurate with the performance period remaining as of the grant date.
Risk-free Interest Rate - A risk-free rate is based on the U.S. Treasury rates in effect on the grant date for a maturity equal to or approximating the expected term of the award.
Expected Volatility - For stock options, expected volatility is calculated using historical volatility based on the daily closing prices of the Company’s common stock over a period equal to the expected term. For market-based awards, a combination of historical and implied volatility for the Company and members of its peer group are used in developing the expected volatility assumption.
Dividend Yield - The dividend yield assumption is based on the Company’s expected annual dividend yield on the grant date.
The Company recognizes compensation expense over the required service or vesting period based on the fair value of the award on the date of grant. Certain executive stock-based awards contain market, performance and service conditions. Compensation expense for awards with market conditions is recognized over the service period and is not reversed if the market condition is not met. Compensation expense for awards with performance conditions is reassessed each reporting period and recognized based upon the probability that the performance targets will be achieved.
All stock option awards granted under the Company’s compensation plans have an exercise price equal to the closing stock price on the date of grant, a ten-year contractual life and generally, vest annually over a three-year vesting term. RSUs typically vest in equal annual installments over a three or four year period. RSUs issued to members of the Company’s Board of Directors as a portion of their annual retainer vest quarterly over a one-year vesting term. Earned PRSUs typically vest three years from the date of grant.
The Company records deferred tax assets for awards that result in deductions on the Company’s income tax returns, based on the amount of stock-based compensation expense recognized and the statutory tax rate in the jurisdiction in which it will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported on the income tax return are recorded as a component of Provision for income taxes in the Consolidated Statements of Operations. Note 10 “Stock-Based Compensation” contains additional information on the Company’s stock-based compensation.
- 64 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Defined Benefit Plans
The Company recognizes in its balance sheet as an asset or liability the overfunded or underfunded status of its defined benefit plans provided to its employees located in Mexico and Switzerland. This asset or liability is measured as the difference between the fair value of plan assets, if any, and the benefit obligation of those plans. For these plans, the benefit obligation is the projected benefit obligation, which is calculated based on actuarial computations of current and future benefits for employees. Actuarial gains or losses and prior service costs or credits that arise during the period, but are not included as components of net periodic benefit expense, are recognized as a component of AOCI on the Consolidated Balance Sheets. The Company records the service cost component of net benefit costs in Cost of sales and SG&A expenses. The interest cost component of net benefit costs is recorded in Interest expense and the remaining components of net benefit costs, amortization of net losses and expected return on plan assets, are recorded in Other (income) loss, net.
Foreign Currency Translation and Remeasurement
The Company translates all assets and liabilities of its foreign subsidiaries, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translates income and expenses at the average exchange rates in effect during the period. The net effect of this translation is recorded in the consolidated financial statements as a component of AOCI. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in the Company’s foreign subsidiaries.
The Company has foreign operations in the Dominican Republic, Germany, Ireland, Israel, Malaysia, Mexico, Switzerland, and Uruguay, which expose the Company to foreign currency exchange rate fluctuations due to transactions denominated in Dominican pesos, Euros, Israeli shekels, Malaysian ringgits, Mexican pesos, Swiss francs, and Uruguayan pesos. To the extent that monetary assets and liabilities, including short-term and long-term intercompany loans, are recorded in a currency other than the functional currency of the subsidiary, these amounts are remeasured each period at the period-end exchange rate, with the resulting gain or loss being recorded in Other (income) loss, net in the Consolidated Statements of Operations. Net foreign currency transaction (gains) losses included in Other (income) loss, net amounted to ($0.1 million), $1.6 million and $0.1 million for fiscal years 2021, 2020 and 2019, respectively, and primarily related to the fluctuation of the U.S. dollar relative to the Euro and the remeasurement of certain intercompany loans.
Earnings Per Share (“EPS”)
Basic EPS is calculated by dividing Net Income by the weighted average number of shares outstanding during the period. Diluted EPS is calculated by adjusting the weighted average number of shares outstanding for potential common shares if dilutive to the EPS calculation. Note 15 “Earnings Per Share” contains additional information on the computation of the Company’s EPS.
Comprehensive Income
The Company’s comprehensive income as reported in the Consolidated Statements of Comprehensive Income includes net income, foreign currency translation adjustments, the net change in cash flow hedges, net of tax, and defined benefit plan liability adjustments, net of tax. The Consolidated Statements of Comprehensive Income and Note 16 “Stockholders’ Equity” contain additional information on the computation of the Company’s comprehensive income.
Recent Accounting Pronouncements
In the normal course of business, management evaluates all new Accounting Standards Updates (“ASU”) and other accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements.
Accounting Guidance Not Yet Elected or Adopted
In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company will early adopt ASU 2021-08 as of January 1, 2022 on a prospective basis. The impact of the adoption of ASU 2021-08 cannot currently be determined, as it is dependent on future business combinations that the Company may enter into.
- 65 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(2.)    BUSINESS ACQUISITIONS
2021 Acquisition
On December 1, 2021, the Company acquired 100% of the equity interests of Oscor Inc., Oscor Caribe, LLC and Oscor Europe GmbH (collectively “Oscor”), privately-held companies with operations in Florida, the Dominican Republic and Germany that design, develop, manufacture and market a comprehensive portfolio of highly specialized medical devices, venous access systems and diagnostic catheters and implantable devices for a cash purchase price of $220.4 million, of which $2.6 million is net cash acquired subject to payment in connection with working capital and other closing adjustments. Serving the Company’s current markets, Oscor broadens the Company’s product portfolio, expands its research and development capabilities, and adds low-cost manufacturing capacity. The Company used proceeds from its Senior Secured Credit Facilities to fund the acquisition. See Note 8 “Debt” for additional information. Oscor is included in the Company’s Medical segment.
The Oscor acquisition was structured as a stock purchase, however the parties agreed to coordinate the election of Section 338(h)(10) of the Internal Revenue Code relative to this transaction for tax purposes. Therefore, the excess purchase price over the fair value of net assets acquired was recorded as goodwill, which will be amortized over 15 years for income tax filing purposes.
The Company has provisionally estimated fair values for the assets purchased, liabilities assumed and purchase consideration as of the date of the acquisition. The determination of estimated fair value required management to make significant estimates and assumptions based on information that was available at the time the consolidated financial statements were prepared. The amounts reported are considered provisional as the Company is completing the valuations that are required to allocate the purchase price in areas such as property and equipment, intangible assets, lease-related assets and liabilities, deferred taxes and goodwill. As a result, the allocation of the provisional purchase price may change in the future, which could be material.
The preliminary purchase price allocation was as follows (in thousands):
Fair value of net assets acquired
Current assets (excluding inventory)$12,148 
Inventory12,212 
Property, plant and equipment17,977 
Goodwill77,887 
Intangible assets105,300 
Operating lease assets15,142 
Other noncurrent assets695 
Current liabilities(8,875)
Operating lease liabilities(12,044)
Fair value of net assets acquired$220,442 
The preliminary fair values of the assets acquired were determined using one of three valuation approaches: market, income or cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations.
The market approach estimates the value for a subject asset based on available market pricing for comparable assets. The income approach estimates the value for a subject asset based on the present value of cash flows projected to be generated by the asset. The projected cash flows were discounted at a required rate of return that reflects the relative risk of the asset and the time value of money. The projected cash flows for each asset considered multiple factors from the perspective of a marketplace participant including revenue projections from existing customers, attrition trends, technology life-cycle assumptions, marginal tax rates and expected profit margins giving consideration to historical and expected margins. The cost approach estimates the value for a subject asset based on the cost to replace the asset and reflects the estimated reproduction or replacement cost for the asset, less an allowance for loss in value due to depreciation or obsolescence, with specific consideration given to economic obsolescence if indicated. These fair value measurement approaches are based on significant unobservable inputs, including management estimates and assumptions.
- 66 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(2.)    BUSINESS ACQUISITIONS (Continued)
Current Assets and Liabilities
The fair value of current assets and liabilities, excluding inventory, was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities.
The fair value of in-process and finished goods inventory acquired was estimated by applying a version of the income approach called the comparable sales method. This approach estimates the fair value of the assets by calculating the potential revenue generated from selling the inventory and subtracting from it the costs related to the completion and sale of that inventory and a reasonable profit allowance for these remaining efforts. Based upon this methodology, the Company recorded the inventory acquired at fair value resulting in an increase in inventory of $1.0 million.
Property, Plant and Equipment
The fair value of PP&E acquired was estimated by applying the cost approach for personal property and leasehold improvements. The cost approach was applied by developing a replacement cost and adjusting for economic depreciation and obsolescence.
Leases
The Company recognized operating lease liabilities and operating lease right-of-use assets for office and manufacturing facilities in the U.S., Dominican Republic, and Germany in accordance with ASC 842, Leases. Additionally, the Company recorded favorable lease terms associated with the operating leases in the U.S. of $3.1 million. The favorable lease terms were recorded as an increase to the ROU lease asset.
Goodwill
The excess of the purchase price over the fair value of net tangible and intangible assets acquired and liabilities assumed was allocated to goodwill. Various factors contributed to the establishment of goodwill, including the value of Oscors’s highly trained assembled work force and management team, the incremental value resulting from Oscor’s industry leading capabilities and services to OEMs, enhanced synergies, and the expected revenue growth over time that is attributable to increased market penetration from future products and customers. The goodwill acquired in connection with the acquisition was allocated to the Medical segment and is deductible for tax purposes.
Intangible Assets
The purchase price was allocated to intangible assets as follows (dollars in thousands):
Definite-lived Intangible AssetsFair Value AssignedWeighted Average Amortization Period
(Years)		Weighted Average Discount Rate
Customer lists$73,800 20.09.5%
Technology15,200 15.09.5%
Tradenames16,300 20.09.5%

Customer Lists - Customer lists represent the estimated fair value of contractual and non-contractual customer relationships Oscor had as of the acquisition date. The primary customers of Oscor include large original equipment manufacturers in various geographic locations around the world. These relationships were valued separately from goodwill at the amount that an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The estimated useful life of the existing customer base was based upon the historical customer annual attrition rate of 5%, as well as management’s understanding of the industry and product life cycles.
Technology - Technology consists of technical processes, patented and unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by Oscor and that will be leveraged in current and future products. The fair value of technology acquired was determined utilizing the relief from royalty method, a form of the income approach, with a royalty rate that ranged from 4.0% to 4.5%. The estimated useful life of the technology is based upon management’s estimate of the product life cycle associated with the technology before they will be replaced by new technologies.

- 67 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(2.)    BUSINESS ACQUISITIONS (Continued)
Tradenames - Tradenames represents the estimated fair value of Oscor’s corporate and product names. The acquired tradenames were valued separately from goodwill at the amount that an independent third party would be willing to pay for use of these names. The fair value of the tradenames was determined by utilizing the relief from royalty method, a form of the income approach, with a royalty rate of 2.0%. Tradenames were assumed to have a definite useful life based upon long-term management expectations and future operating plans.
2020 Acquisition
On February 19, 2020, the Company acquired certain assets and liabilities of InoMec Ltd. (“InoMec”), a privately-held company based in Israel that specializes in the research, development and manufacturing of medical devices, including minimally invasive tools, delivery systems, tubing and catheters, surgery tools, drug-device combination, laser combined devices, and tooling and production. The acquisition enabled the Company to create a research and development center in Israel, closer to the customer base in the region. The fair value of the consideration transferred was $7.0 million, which included an initial cash payment of $5.3 million and $1.7 million in estimated fair value of contingent consideration. The contingent consideration represented the estimated fair value of the Company’s obligation, under the asset purchase agreement, to make additional payments of up to $3.5 million if specified conditions are met through February 2024. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration.
Based on the final purchase price allocation, the assets acquired principally comprise $2.0 million of intangible assets, $4.8 million of goodwill, $0.3 million of acquired property, plant and equipment, and a net liability for other working capital items of $0.1 million. Intangible assets included developed technology, customer relationships and non-compete provisions, which are being amortized over a weighted average period of 5.9 years. Goodwill for the InoMec acquisition is deductible for income tax purposes.
2019 Acquisition
On October 7, 2019, the Company acquired certain assets and liabilities of US BioDesign, LLC (“USB”), a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The acquisition added a differentiated capability related to the complex development and manufacture of braided and formed biomedical structures to the Company’s broad portfolio. The fair value of the consideration transferred was $19.1 million, which included a cash payment of $14.9 million and $4.2 million in estimated fair value of contingent consideration. The contingent consideration represents the estimated fair value of the Company’s obligation, under the asset purchase agreement, to make additional payments of up to $5.5 million if certain revenue goals are met through 2023. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration.
Based on the final purchase price allocation, the assets acquired principally consist of $7.4 million of developed technology, $10.4 million of goodwill, $0.7 million of acquired property, plant and equipment, and $0.6 million of other working capital items. The $10.4 million of goodwill reflects a $0.1 million decrease resulting from a favorable working capital adjustment recorded in 2020. The technology intangible asset is being amortized over a useful life of 8 years. Goodwill for the USB acquisition is deductible for income tax purposes.
Actual and Pro Forma (unaudited) disclosures
For segment reporting purposes, the results of operations and assets from the Oscor, InoMec and USB acquisitions have been included in the Company’s Medical segment since the respective acquisition dates. For the year ended December 31, 2021, sales related to Oscor, InoMec and USB were $4.7 million, $3.5 million and $4.8 million, respectively. For the year ended December 31, 2020, sales related to InoMec and USB were $3.4 million and $4.5 million, respectively. For the year ended December 31, 2019, sales related to USB were $0.8 million. Earnings related to the operations of Oscor, InoMec and USB for the fiscal years 2021, 2020 and 2019 were not material. Pro forma financial information has not been presented for the InoMec and USB acquisitions as the net effects were not significant or material to the Company’s results of operations or financial position.
- 68 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(2.)    BUSINESS ACQUISITIONS (Continued)
The following unaudited pro forma information presents the consolidated results of operations of the Company and Oscor as if the acquisition occurred as of the beginning of fiscal year 2020 (in thousands):
 20212020
Sales$1,274,148 $1,128,137 
Income from continuing operations$91,844 $67,529 
The unaudited pro forma results are presented for illustrative purposes only and do not reflect the realization of potential cost savings, and any related integration costs. Certain costs savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These unaudited pro forma results do not purport to be indicative of the results that would have been obtained, or to be a projection of results that may be obtained in the future. These unaudited pro forma results include certain adjustments, primarily due to increases in amortization expense due to the fair value adjustments of intangible assets, the increases to interest expense reflecting the amount borrowed in connection with the acquisition, acquisition related costs and the impact of income taxes on the pro forma adjustments.
Acquisition costs
During the fiscal years 2021, 2020 and 2019, direct costs of these acquisitions of $2.0 million, $0.9 million and $0.4 million, respectively, were expensed as incurred and included in Other Operating Expenses in the Consolidated Statements of Operations.
(3.)    SUPPLEMENTAL CASH FLOW INFORMATION
The following represents supplemental cash flow information for fiscal years 2021, 2020 and 2019 (in thousands):
 202120202019
Non-cash investing and financing activities:
Property, plant and equipment purchases included in accounts payable$5,556 $3,597 $8,646 
Cash paid during the year for:
Interest24,740 33,933 44,784 
Income taxes19,649 18,477 30,034 

(4.)     INVENTORIES
Inventories comprise the following (in thousands):
December 31,
2021		December 31,
2020
Raw materials$70,956 $72,477 
Work-in-process74,152 58,806 
Finished goods10,591 18,040 
Total$155,699 $149,323 

- 69 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(5.)     PROPERTY, PLANT AND EQUIPMENT, NET
PP&E comprises the following (in thousands):
December 31, 2021December 31,
2020
Manufacturing machinery and equipment$352,391 $320,807 
Buildings and building improvements98,007 102,037 
Information technology hardware and software72,752 69,969 
Leasehold improvements85,931 77,382 
Furniture and fixtures17,099 16,250 
Land and land improvements13,980 11,598 
Construction work in process41,813 26,389 
Other1,431 1,238 
683,404 625,670 
Accumulated depreciation(406,305)(371,706)
Total$277,099 $253,964 
Depreciation expense for PP&E was as follows for fiscal years 2021, 2020 and 2019 (in thousands):
202120202019
Depreciation expense$39,772 $38,193 $37,819 

(6.)     GOODWILL AND OTHER INTANGIBLE ASSETS, NET
Goodwill
The change in the carrying amount of goodwill by reportable segment during fiscal years 2021 and 2020 was as follows (in thousands):
MedicalNon-MedicalTotal
December 31, 2019$822,617 $17,000 $839,617 
Acquisition4,800 — 4,800 
Acquisition-related adjustments (Note 2)(85)— (85)
Foreign currency translation15,110 — 15,110 
December 31, 2020842,442 17,000 859,442 
Acquisition (Note 2)77,887 — 77,887 
Foreign currency translation(12,625)— (12,625)
December 31, 2021$907,704 $17,000 $924,704 
As of December 31, 2021, no accumulated impairment loss has been recognized for the goodwill allocated to the Company’s Medical or Non-Medical segments.
- 70 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(6.)     GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Continued)
Intangible Assets
Intangible assets comprise the following (in thousands):
Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
December 31, 2021
Definite-lived:
Purchased technology, tradenames and patents$285,659 $(164,371)$121,288 
Customer lists783,618 (187,412)596,206 
Other4,162 (4,134)28 
Total amortizing intangible assets$1,073,439 $(355,917)$717,522 
Indefinite-lived:
Trademarks and tradenames$90,288 
December 31, 2020
Definite-lived:
Purchased technology and patents$257,453 $(152,798)$104,655 
Customer lists723,791 (161,856)561,935 
Other4,142 (3,796)346 
Total amortizing intangible assets$985,386 $(318,450)$666,936 
Indefinite-lived:
Trademarks and tradenames$90,288 
See Note 2 “Business Acquisitions” for additional details regarding intangible assets acquired during 2021 and 2020. Included in the Company’s indefinite-lived intangible assets are the Lake Region Medical and Greatbatch Medical tradenames with carrying values of $70.0 million and $20.3 million, respectively.
When acquiring certain assets, the Company assesses whether the acquired assets are a result of a business combination or a purchase of an asset. During 2020, the Company acquired a set of similar identifiable intangible assets relating to a license to use technology within its Non-Medical segment. The Company purchased the technology for $4.5 million, which includes $1.0 million of contingent consideration paid during 2020 upon completion of certain milestones, and capitalized $0.1 million of costs associated with acquiring the license as an intangible asset. The intangible asset of $4.6 million is being amortized over 11 years, the remaining useful life of the patented technology.
Aggregate intangible asset amortization expense comprises the following for fiscal years 2021, 2020 and 2019 (in thousands):
202120202019
Cost of sales$13,090 $12,860 $13,111 
SG&A28,507 28,271 26,965 
Total intangible asset amortization expense$41,597 $41,131 $40,076 
Estimated future intangible asset amortization expense based upon the carrying value as of December 31, 2021 is as follows (in thousands):
20222023202420252026After 2026
Amortization expense$46,594 $48,490 $47,576 $45,946 $43,612 $485,304 

- 71 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(7.)    ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities comprise the following (in thousands):
December 31, 2021December 31,
2020
Salaries and benefits$27,733 $24,512 
Profit sharing and bonuses18,325 19,204 
Contract liabilities3,776 2,498 
Product warranties509 163 
Accrued interest76 1,644 
Other6,514 8,822 
Total$56,933 $56,843 

(8.)     DEBT
Long-term debt comprises the following (in thousands):
 December 31, 2021December 31,
2020
Senior secured term loan A $467,062 $229,687 
Senior secured term loan B 349,125 508,286 
Senior secured revolving credit facility19,300 — 
Unamortized discount on term loan B and deferred debt issuance costs(7,361)(6,715)
Total debt828,126 731,258 
Current portion of long-term debt(15,250)(37,500)
Total long-term debt$812,876 $693,758 
Senior Secured Credit Facilities
On September 2, 2021, the Company entered into a new credit agreement (the “2021 Credit Agreement”), which permits borrowings and other extensions of credit in an initial aggregate principal amount of up to $1 billion (as may be increased from time to time in accordance with the terms). The 2021 Credit Agreement governs the Company’s senior secured credit facilities (the “Senior Secured Credit Facilities”), which consist of a five-year $400 million revolving credit facility (the “Revolving Credit Facility”), a five-year $250 million “term A” loan (the “TLA Facility”) and a seven-year $350 million “term B” loan (the “TLB Facility” and, together with the TLA Facility, the “Term Loan Facilities”). The TLB Facility was issued at a 0.50% discount. The 2021 Credit Agreement also includes an alternative benchmark rate as a replacement to the London Interbank Offered Rate (“LIBOR”) in the event LIBOR is no longer available. In connection with closing of the Oscor acquisition, on December 1, 2021, the Company amended the 2021 Credit Agreement to provide for, among other things, the incurrence of an additional $220 million aggregate principal amount of term A loans. As of December 31, 2021, the weighted average interest rate on all outstanding borrowings is 2.04%.
The obligations under the 2021 Credit Agreement are guaranteed by certain specified subsidiaries of the Company. Among other things, the 2021 Credit Agreement contains covenants that restrict the Company’s and certain of its subsidiaries’ ability to incur liens on certain assets, incur indebtedness, make material changes in corporate structure or materially alter the nature of its business, dispose of material assets, engage in mergers, consolidations and certain other fundamental changes, or engage in certain transactions with affiliates. The 2021 Credit Agreement contains customary default provisions, including, but not limited to, failure to pay interest or principal when due and failure to comply with covenants.





- 72 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(8.)     DEBT (Continued)
Prior to September 2, 2021, the Company was party to an amended and restated credit agreement (the “2015 Credit Agreement”), dated as of October 27, 2015. The 2015 Credit Agreement provided for certain credit facilities to the Company in an aggregate principal amount not to initially exceed $1.6 billion. At the time of the refinancing on September 2, 2021, the 2015 Credit Agreement provided for a $200 million revolving credit facility with no outstanding borrowings, a term loan A facility and a term loan B facility with outstanding principal balances of $210.9 million and $462.3 million, respectively. The term loan B facility under the 2015 Credit Agreement was issued at a 1% discount. The 2015 Credit Agreement was terminated concurrently with entering into the 2021 Credit Agreement. Details of our Long-term debt as of December 31, 2020 can be found within our 2020 Form 10-K.
Revolving Credit Facility
The Revolving Credit Facility matures on September 2, 2026 and includes a $40 million sublimit for swingline loans and standby letters of credit. As of December 31, 2021, the Company had available borrowing capacity on the Revolving Credit Facility of $375.0 million after giving effect to $19.3 million of outstanding borrowings and $5.7 million of outstanding standby letters of credit.
Interest rates on the Revolving Credit Facility are at the Company’s option, either at: (i) the applicable LIBOR (or an applicable benchmark replacement) plus the applicable margin, which will range between 1.25% and 2.25%, based on the Company’s Total Net Leverage Ratio (as defined in the 2021 Credit Agreement), or (ii) the Base Rate (as defined below) plus the applicable margin, which will range between 0.25% and 1.25%, based on the Company’s Total Net Leverage Ratio. The Base Rate is defined, for any day, as the per annum rate equal to the highest of (i) the prime rate (as defined in the 2021 Credit Agreement), (ii) the Federal Funds Rate, as published by the Federal Reserve Bank of New York, plus 0.50%, and (iii) one-month LIBOR plus 1.00%. As of December 31, 2021, the weighted average interest rate on outstanding borrowings under the Revolving Credit Facility was 1.35%.
The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.15% and 0.25%, depending on the Company’s Total Net Leverage Ratio. As of December 31, 2021, the commitment fee on the unused portion of the Revolving Credit Facility was 0.15%.
Term Loan Facilities
The TLA Facility and TLB Facility mature on September 2, 2026 and September 2, 2028, respectively, and require quarterly principal installments. The quarterly principal installments under the TLA Facility increase over the term of the loan. The interest rate terms for the TLA Facility are the same as those outlined above for the Revolving Credit Facility. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the applicable LIBOR rate plus 2.50%, with LIBOR subject to a 0.50% floor, or (ii) the Base Rate plus 1.50%. As of December 31, 2021, the interest rates on the TLA Facility and TLB Facility were 1.35% and 3.00%, respectively.
Covenants
The 2021 Credit Agreement contains customary terms and conditions, including representations and warranties and affirmative and negative covenants, as well as financial covenants for the benefit of the lenders under the Revolving Credit Facility and the TLA Facility, which require that (i) the Company maintain a Total Net Leverage Ratio not to exceed 5.50:1.00 (stepping down to 5.00:1.00 for the third fiscal quarter of 2023 through maturity and subject to increase in certain circumstances following qualified acquisitions, but shall not exceed 5.50:1.00) and (ii) the Company maintain an interest coverage ratio of at least 2.50:1.00. The TLB Facility does not contain any financial maintenance covenants. As of December 31, 2021, the Company was in compliance with these financial covenants.
Contractual maturities under the Senior Secured Credit Facilities for the next five years and thereafter, as of December 31, 2021, are as follows (in thousands):
20222023202420252026After 2026
Future minimum principal payments$15,250 $18,188 $29,938 $38,750 $401,739 $331,622 
- 73 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(8.)     DEBT (Continued)
Deferred Debt Issuance Costs and Discounts
The change in deferred debt issuance costs related to the Company’s Revolving Credit Facility is as follows (in thousands):
December 31, 2020891 
Financing costs incurred2,762 
Write-off of deferred debt issuance costs(72)
Amortization during the period(542)
December 31, 2021$3,039 
The change in unamortized discount and deferred debt issuance costs related to the Term Loan Facilities is as follows (in thousands):
Deferred Debt Issuance CostsUnamortized Discount on TLB FacilityTotal
December 31, 20205,258 1,457 6,715 
Financing costs incurred5,236 1,750 6,986 
Write-off of deferred debt issuance costs and unamortized discount(2,677)(954)(3,631)
Amortization during the period(2,143)(566)(2,709)
December 31, 2021$5,674 $1,687 $7,361 

In connection with the 2021 Credit Agreement, the Company incurred and capitalized $8.8 million of issuance costs, including an original issue discount on the TLB Facility of $1.8 million. In connection with December 1, 2021 amendment to the TLA Facility, the Company incurred and capitalized $1.0 million of issuance costs. An aggregate of $7.0 million of original issue discount and debt issuance costs have been recorded as a reduction of the carrying value of the related debt and $2.8 million of debt issuance costs attributable to the Revolving Credit Facility have been recorded as a component of Other long-term assets on the Consolidated Balance Sheets as of December 31, 2021.
In connection with terminating the 2015 Credit Agreement and entering into the 2021 Credit Agreement, for each separate debt instrument on a lender by lender basis, in accordance with ASC 470-50, Debt Modifications and Extinguishment, the Company performed an assessment of whether the transaction was deemed to be new debt, a modification of existing debt, or an extinguishment of existing debt. Debt issuance costs are either deferred and amortized over the term of the associated debt or expensed as incurred.
Based on this assessment, $1.2 million of unamortized deferred debt issuance costs and unamortized discount related to the 2015 Credit Agreement were deemed to be related to the issuance of new debt, or the modification of existing debt, and therefore will continue to be deferred and amortized over the term of the associated debt. The remaining $3.3 million of unamortized deferred debt issuance costs and unamortized discount related to the 2015 Credit Agreement were deemed to be related to the extinguishment of debt and were expensed. Additionally, in connection with prepayments on the TLB Facility made during 2021 under the 2015 Credit Agreement, $0.3 million of unamortized deferred debt issuance costs and unamortized discount were treated as extinguishment of debt and were expensed.
- 74 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(9.)     BENEFIT PLANS
Savings Plan
The Company sponsors a defined contribution 401(k) plan (the “Plan”) for its U.S. based employees. The Plan provides for the deferral of employee compensation under Internal Revenue Code §401(k) and a Company match. The Company matches $0.50 per dollar of each participant’s deferral made to the Plan up to 6% of their compensation, subject to Internal Revenue Service guidelines. The Company temporarily suspended the Company match beginning in August 2020 through the end of 2020 as part of its cost reduction actions to reduce discretionary spending in response to the effect of the COVID-19 pandemic on its operations. Contributions from employees, as well as those matched by the Company, vest immediately. Net costs related to defined contribution plans were $7.9 million in 2021, $5.0 million in 2020 and $7.2 million in 2019.
Defined Benefit Plans
The Company is required to provide its employees located in Switzerland and Mexico certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age and compensation. The defined benefit pension plan provided to the Company’s employees located in Switzerland is a funded contributory plan, while the plans that provide benefits to the Company’s employees located in Mexico are unfunded and noncontributory. The assets of the Switzerland plan are held at an AA- rated insurance carrier who bears the pension risk and longevity risk, and will be used to cover the pension liability for the remaining retirees of the Swiss plan, as well as the remaining employees at that location. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees. The aggregated projected benefit obligation for these plans was $3.9 million and $3.7 million as of December 31, 2021 and December 31, 2020, respectively. Net periodic pension cost for fiscal years 2021, 2020 and 2019 was $0.5 million, $0.4 million and $0.3 million, respectively. Over the next ten years, we expect gross benefit payments to be $1.0 million in total for the years 2022 through 2026, and $1.8 million in total for the years 2027 through 2031.
(10.)     STOCK-BASED COMPENSATION
Stock-based Compensation Plans
The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors (the “Board”) or the Compensation and Organization Committee of the Board. The stock-based compensation plans provide for the granting of stock options, RSAs, RSUs, stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers.
On March 25, 2021, the Company’s Board adopted, subject to stockholder approval, the Integer Holdings Corporation 2021 Omnibus Incentive Plan (the “2021 Plan”). The Company’s stockholders approved the 2021 Plan at the Company’s 2021 annual meeting of stockholders on May 19, 2021, at which time the 2021 Plan replaced the Company’s 2016 Stock Incentive Plan (the “2016 Plan”) and the Company ceased granting any new awards under the 2016 Plan. The number of shares initially reserved for issuance under the 2021 Plan is (i) 1,450,000 plus (ii) the total number of shares of common stock available for issuance under the 2016 Plan, plus (iii) any shares of common stock that are subject to awards forfeited, cancelled, expired, terminated or otherwise lapsed or settled in cash, in whole or in part, without the delivery of shares under the 2016 Plan. Each of the Company’s 2011 Stock Incentive Plan, the 2009 Stock Incentive Plan and the 2005 Stock Incentive Plan have expired, and no awards are available for issuance under these expired plans. As of December 31, 2021, there were 1,636,980 shares available for future grants under the 2021 Plan.
The Company recognized an excess net tax benefit from the exercise of stock options and vesting of RSUs of $1.1 million, $1.5 million and $2.8 million for fiscal years 2021, 2020 and 2019, respectively. These amounts are recorded as a component of Provision for income taxes.
- 75 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(10.)     STOCK-BASED COMPENSATION (Continued)
Stock-based Compensation Expense
The components and classification of stock-based compensation expense for fiscal years 2021, 2020 and 2019 were as follows (in thousands):
202120202019
Stock options$— $43 $410 
RSUs and PRSUs16,185 9,120 8,884 
Total stock-based compensation expense$16,185 $9,163 $9,294 
Cost of sales$3,365 $1,658 $1,011 
SG&A11,579 6,942 7,827 
RD&E969 563 269 
OOE272 — 187 
Total stock-based compensation expense$16,185 $9,163 $9,294 
Stock Options
There were no stock options granted in fiscal years 2021, 2020 or 2019. The following table summarizes stock option activity during the fiscal year ended December 31, 2021:
Number of
Stock
Options		Weighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Term
(in years)		Aggregate
Intrinsic
Value
(in millions)
Outstanding at December 31, 2020281,873 $36.05 
Exercised(34,233)21.72 
Outstanding at December 31, 2021247,640 $38.03 4.2$11.8 
Vested and exercisable at December 31, 2021247,640 $38.03 4.2$11.8 
Intrinsic value is calculated for in-the-money options (exercise price less than market price) as the difference between the market price of the Company’s common stock as of December 31, 2021 ($85.59) and the weighted average exercise price of the underlying stock options, multiplied by the number of options outstanding and/or exercisable. Shares are distributed from the Company’s authorized but unissued reserve upon the exercise of stock options.
The following table provides certain information relating to the exercise of stock options during fiscal years 2021, 2020 and 2019 (in thousands):
202120202019
Intrinsic value$2,370 $4,773 $7,998 
Cash received743 3,263 3,242 
Restricted Stock Units
The following table summarizes RSU activity during the fiscal year ended December 31, 2021:
Time-Vested
Activity		Weighted
Average Grant Date
Fair Value
Nonvested at December 31, 2020207,923 $75.38 
Granted208,624 81.98 
Vested(149,464)74.47 
Forfeited(18,952)79.84 
Nonvested at December 31, 2021248,131 $81.14 
- 76 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(10.)     STOCK-BASED COMPENSATION (Continued)
As of December 31, 2021, there was $13.9 million of total unrecognized compensation cost related to RSUs, which is expected to be recognized over a weighted-average period of approximately 1.6 years. The fair value of RSU shares vested in fiscal years 2021, 2020 and 2019 was $12.9 million, $9.9 million and $2.4 million, respectively. The weighted average grant date fair value of RSUs granted during fiscal years 2021, 2020 and 2019 was $81.98, $83.94 and $82.31, respectively.
Performance Restricted Stock Units
The following table summarizes PRSU activity during the fiscal year ended December 31, 2021:
Performance-
Vested
Activity		Weighted
Average Grant Date
Fair Value
Nonvested at December 31, 2020219,391 $72.33 
Granted92,384 85.16 
Vested(38,882)37.75 
Forfeited(74,024)53.45 
Nonvested at December 31, 2021198,869 $92.07 
For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares earned depends on the achievement of financial or market-based performance conditions. The financial performance condition is based on the Company’s sales targets. The market conditions are based on the Company’s achievement of a relative total shareholder return (“TSR”) performance requirement, on a percentile basis, compared to a defined group of peer companies over three year performance periods. All PRSUs awarded during the 2021 fiscal year were subject to market-based performance conditions.
At December 31, 2021, there was $6.0 million of total unrecognized compensation cost related to unvested PRSUs, which is expected to be recognized over a weighted-average period of approximately 1.9 years. The fair value of PRSU shares vested in fiscal years 2021, 2020 and 2019 was $3.1 million, $2.9 million and $6.7 million, respectively. The weighted average grant date fair value of PRSUs granted during fiscal years 2021, 2020 and 2019 was $85.16, $95.06 and $101.17, respectively.
The grant-date fair value of the market-based portion of the PRSUs granted during fiscal years 2021, 2020 and 2019 was determined using the Monte Carlo valuation model on the date of grant. The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows:
 202120202019
Weighted average fair value$85.16 $107.27 $117.03 
Risk-free interest rate0.19 %1.29 %2.46 %
Expected volatility41 %30 %40 %
Expected life (in years)3.02.92.8
Expected dividend yield— %— %— %

The valuation of the TSR portion of the PRSUs granted during fiscal years 2021 and 2020 also reflects a weighted average illiquidity discount of 8.19% and 8.00%, respectively, related to the six-month period that recipients are restricted from selling, transferring, pledging or assigning the underlying shares, in the event of vesting.
- 77 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(11.)     OTHER OPERATING EXPENSES
The Company continuously evaluates the business and identifies opportunities to realign its resources to better serve its customers and markets, improve operational efficiency and capabilities, and lower its operating costs. To realize the benefits associated with these opportunities, the Company undertakes restructuring-type activities to transform its business. In addition, from time to time, the Company incurs cost associated with acquiring and integrating businesses and certain other general expenses, including asset impairments. The Company classifies costs associated with these items as OOE.
The following tables summarize OOE by program in each of the preceding three years (in thousands):
202120202019
Operational excellence initiatives$3,893 $2,791 $— 
Strategic reorganization and alignment911 686 5,812 
Manufacturing alignment to support growth— 241 2,145 
Acquisition and integration costs (adjustments)2,544 (776)377 
Other general expenses508 4,679 3,817 
Total other operating expenses$7,856 $7,621 $12,151 
Operational excellence initiatives
The Company’s operational excellence (“OE”) initiatives mainly consist of costs associated with executing on its sales force, manufacturing, business process, and performance excellence operational strategic imperatives. These projects focus on changing the Company’s organizational structure to match product line growth strategies and customer needs, transitioning its manufacturing process into a competitive advantage and standardizing and optimizing its business processes.
2021 OE Initiatives - Costs related to the Company’s 2021 OE initiatives are primarily recorded within the Medical segment or unallocated operating expenses and mainly include termination benefits. The Company estimates that it will incur aggregate pre-tax charges in connection with the 2021 OE initiatives of between approximately $4 million to $5 million, the majority of which are expected to be cash expenditures. As of December 31, 2021, total restructuring and related charges incurred since inception were $3.6 million. These actions are expected to be substantially complete by the end of 2022.
2020 Initiatives - Costs related to the Company’s 2020 initiatives are primarily recorded within the Medical segment and mainly include termination benefits. As of December 31, 2021, total restructuring and related charges incurred since inception were $3.1 million. These actions were substantially complete at the end of 2020.
Strategic reorganization and alignment
The Company’s strategic reorganization and alignment (“SRA”) initiatives primarily include those that align resources with market conditions and the Company’s strategic direction in order to enhance the profitability of its portfolio of products.
2021 SRA Initiatives - During the fourth quarter of 2021, the Company initiated plans to exit certain markets served in our Medical segment to enhance profitability and reallocate manufacturing capacity needed to support our overall growth plans. The Company estimates that it will incur a range of pre-tax charges in connection with the 2021 SRA initiatives of approximately $5 million and $8 million, the majority of which are expected to be cash expenditures. Costs related to the Company’s 2021 SRA Initiatives are primarily recorded within the Medical segment and mainly include termination benefits. As of December 31, 2021, total charges incurred since inception were $0.9 million. These actions are expected to be completed by the end of 2025.
2017 SRA Initiatives - In 2017, to better align its resources to enhance the profitability of its portfolio of products, the Company began aligning resources with its strategic direction, improving profitability to invest in accelerated growth and the expansion of a facility. These actions began in 2017 and were completed during the second quarter of 2020. The Company recorded, primarily within the Medical segment, $23.0 million of restructuring and related charges since inception.
- 78 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(11.)     OTHER OPERATING EXPENSES (Continued)
Manufacturing alignment to support growth
In 2017, the Company commenced several initiatives designed to reduce costs, increase manufacturing capacity to accommodate growth and improve operating efficiencies.  The plan involved the relocation of certain manufacturing operations and expansion of certain of the Company’s facilities. Costs related to the Company’s manufacturing alignment to support growth initiative were primarily recorded within the Medical segment. As of December 31, 2021, total restructuring and related charges incurred for this initiative since inception were $5.8 million. These actions were completed during 2020.
The following table summarizes the change in accrued liabilities, presented within Accrued expenses and other current liabilities on the Consolidated Balance Sheets, related to the initiatives described above (in thousands):
Operational excellence initiatives
Strategic reorganization and alignment
Total
December 31, 2020$291 $— $291 
Charges incurred, net of reversals3,893 911 4,804 
Cash payments(3,886)(777)(4,663)
December 31, 2021$298 $134 $432 
Acquisition and integration costs
During 2021, acquisition and integration costs included $2.4 million of expenses primarily related to the acquisition of Oscor, and a net $0.1 million adjustment to increase the fair value of acquisition-related contingent consideration liability associated with the Company’s other acquisitions. During 2020, acquisition and integration costs included $1.2 million of expenses primarily related to the acquisition of certain assets and liabilities of InoMec, and a $2.0 million adjustment to reduce the fair value of acquisition-related contingent consideration liability associated with the Company’s acquisition of USB. During 2019, acquisition and integration costs primarily related to direct acquisition costs incurred in connection with the acquisition of USB. Acquisition and integration costs primarily consist of professional fees and other costs. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration.
Other general expenses
During 2021, 2020 and 2019, the Company recorded expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce future costs and improve efficiencies. The 2021, 2020 and 2019 amounts primarily include severance, information technology systems conversion expenses, expenses incurred in connection with a customer filing Chapter 11 bankruptcy, and expenses related to the restructuring of certain legal entities of the Company.

- 79 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(12.)     INCOME TAXES
Income from continuing operations before taxes for fiscal years 2021, 2020 and 2019 consisted of the following (in thousands):
202120202019
U.S.$48,293 $35,337 $40,203 
International52,770 50,870 64,990 
Total income from continuing operations before taxes$101,063 $86,207 $105,193 
The provision for income taxes from continuing operations for fiscal years 2021, 2020 and 2019 comprises the following (in thousands):
202120202019
Current:
Federal$9,511 $7,784 $14,090 
State1,553 1,233 87 
International8,459 6,898 10,083 
19,523 15,915 24,260 
Deferred:
Federal(8,665)(4,648)(8,813)
State(393)(1,245)332 
International(2,422)(1,073)(1,804)
(11,480)(6,966)(10,285)
Total provision for income taxes$8,043 $8,949 $13,975 
The provision for income taxes from continuing operations differs from the U.S. statutory rate for fiscal years 2021, 2020 and 2019 due to the following:
202120202019
Statutory rate$21,223 21.0 %$18,103 21.0 %$22,091 21.0 %
Federal tax credits (including R&D)(11,929)(11.8)(7,009)(8.1)(4,797)(4.6)
Foreign rate differential(5,165)(5.1)(5,333)(6.2)(5,479)(5.2)
Stock-based compensation(1,084)(1.1)(1,459)(1.7)(2,422)(2.3)
Uncertain tax positions18 — 1,208 1.4 (920)(0.9)
State taxes, net of federal benefit1,183 1.2 553 0.6 1,106 1.1 
U.S. tax on foreign earnings, net of §250 deduction1,913 1.9 3,216 3.7 5,201 4.9 
Valuation allowance524 0.5 (345)(0.4)(1,606)(1.5)
Other1,360 1.4 15 0.1 801 0.8 
Effective tax rate$8,043 8.0 %$8,949 10.4 %$13,975 13.3 %
The difference between the Company’s effective tax rate and the U.S. federal statutory income tax rate in the current year is primarily attributable to the availability of Foreign Tax Credits, R&D Credits, the impact of the Company’s earnings realized in foreign jurisdictions with statutory rates that are different than the U.S. federal statutory rate, and the provision for Global Intangible Low Taxed income (“GILTI”), net of the statutory deduction of 50% of the GILTI inclusion and the Foreign Derived Intangible Income (“FDII”) deduction (collectively “Section 250 deduction”). The Company’s foreign earnings are primarily derived from Switzerland, Mexico, Uruguay, Ireland and Malaysia. The Company currently has a tax holiday in Malaysia through April 2023 provided certain conditions continue to be met. In addition, the Company acquired manufacturing operations in the Dominican Republic as part of the acquisition of Oscor and is operating under a free trade zone agreement in the Dominican Republic through March 2034.
- 80 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(12.)     INCOME TAXES (Continued)
Difference Attributable to Foreign Investment: Certain foreign subsidiary earnings are subject to U.S. taxation under the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”) . The Company intends to permanently reinvest substantially all of our foreign subsidiary earnings, as well as our capital in our foreign subsidiaries, with the exception of planned distributions made out of current year earnings and profits (“E&P”) and E&P previously taxed as of and for the year ended December 29, 2017, including E&P subject to the toll charge under the Tax Reform Act. The Company accrues for withholding taxes on distributions in the year associated with earnings that are intended to be distributed.
The net deferred tax liability consists of the following (in thousands):
December 31,
2021		December 31,
2020
Tax credit carryforwards$11,394 $13,449 
Inventories14,147 14,099 
Net operating loss carryforwards11,721 10,436 
Operating lease liabilities17,950 11,969 
Stock-based compensation3,724 3,276 
Accrued expenses9,348 8,058 
Gross deferred tax assets68,284 61,287 
Less valuation allowance(19,456)(20,739)
Net deferred tax assets48,828 40,548 
Property, plant and equipment(7,354)(5,824)
Intangible assets(186,150)(197,048)
Operating lease assets(17,974)(11,290)
Other(3,144)(4,292)
Gross deferred tax liabilities(214,622)(218,454)
Net deferred tax liability$(165,794)$(177,906)
Presented as follows:
Noncurrent deferred tax asset$5,711 $4,398 
Noncurrent deferred tax liability(171,505)(182,304)
Net deferred tax liability$(165,794)$(177,906)
As of December 31, 2021, the Company has the following carryforwards available:
JurisdictionTax
Attribute		Amount
(in millions)		Begin to Expire
U.S. State
Net operating losses(1)
$120.7 2022
International
Net operating losses(1)
12.2 2022
U.S. FederalForeign tax credits6.7 2022
U.S. StateR&D tax credits1.4 2022
U.S. StateState tax credits4.9 2022
__________
(1)     Net operating losses (“NOLs”) are presented as pre-tax amounts.
- 81 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(12.)     INCOME TAXES (Continued)
In assessing the realizability of deferred tax assets, management considers, within each taxing jurisdiction, whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the consideration of the weight of both positive and negative evidence, management has determined it is more likely than not that a portion of the deferred tax assets as of December 31, 2021 and December 31, 2020 related to certain foreign tax credits, state investment tax credits, and foreign and state net operating losses will not be realized.
The Company files annual income tax returns in the U.S., various state and local jurisdictions, and in various foreign jurisdictions. A number of years may elapse before an uncertain tax position, for which the Company has unrecognized tax benefits, is examined and finally settled. While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that its unrecognized tax benefits reflect the most probable outcome. The Company adjusts these unrecognized tax benefits, as well as the related interest, in light of changing facts and circumstances. The resolution of an uncertain tax position, if recognized, would be recorded as an adjustment to the provision for income taxes and the effective tax rate in the period of resolution.
Below is a summary of changes to the unrecognized tax benefit for fiscal years 2021, 2020 and 2019 (in thousands):
202120202019
Balance, beginning of year$5,484 $4,446 $5,369 
Additions based upon tax positions related to the current year3,324 300 300 
Additions (reductions) related to prior period tax returns(3,271)738 (1,223)
Balance, end of year$5,537 $5,484 $4,446 
The tax years that remain open and subject to tax audits vary depending on the tax jurisdiction. During 2021, the Internal Revenue Service (“IRS”) effectively concluded its examination of the U.S. subsidiaries of the Company for the taxable years 2017 and 2018. Taxable years 2019 and forward remain subject to examination by the IRS.
The balance of unrecognized tax benefits is not expected to materially change over the course of the next twelve months as a result of the lapse of the statute of limitations and/or audit settlements. As of December 31, 2021, approximately $5.5 million of unrecognized tax benefits would favorably impact the effective tax rate (net of federal impact on state issues), if recognized.
The Company recognizes interest related to unrecognized tax benefits as a component of Provision for income taxes on the Consolidated Statements of Operations. During 2021, 2020 and 2019, the recorded amounts for interest and penalties, respectively, were not significant.
In response to the COVID-19 pandemic, many governments have enacted or are contemplating measures to provide aid and economic stimulus. These measures may include deferring the due dates of tax payments or other changes to their income and non-income-based tax laws. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020 in the U.S., includes measures to assist companies, including temporary changes to income and non-income-based tax laws. The CARES Act provided for deferred payment of the employer portion of social security taxes through the end of 2020. As of December 31, 2020, the Company had deferred a total of $9.7 million of payroll taxes, of which it paid $4.9 million in December 2021. As of December 31, 2021, the Company had a remaining deferred amount of $4.8 million, which the Company expects to pay withing the next twelve months. The deferred payroll taxes are included within Accrued expenses and other current liabilities on the Consolidated Balance Sheets.
See Note 20 “Discontinued Operations” for additional information pertaining to income taxes from discontinued operations.
- 82 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(13.)     COMMITMENTS AND CONTINGENCIES
Contingent Consideration Arrangements
The Company records contingent consideration liabilities related to the earn-out provisions for certain acquisitions. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information.
Litigation
The Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action will not become material in the future.
The Company records a contingent gain for litigation when all of the following conditions have been met: (a) the amount to be paid to the Company is known, (b) there is no potential for appeal or reversal, and (c) collectability is reasonably assured.
In April 2013, the Company commenced an action against AVX Corporation and AVX Filters Corporation (collectively “AVX”) alleging that AVX had infringed on the Company’s patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate the Company’s patented technology. Following four trials and an appeal, the United States Court of Appeals for the Federal Circuit affirmed, in all respects, a judgment in favor of the Company. The Company received the payment of $28.9 million in October 2020, and after recognizing certain related expenses, recognized a net gain of $28.2 million.
Selling, general and administrative expenses
The net gain on patent litigation of $28.2 million is recorded in Selling, general and administrative expenses in the Company’s Consolidated Statements of Operations for the year ended December 31, 2020.
Environmental Matters
The Company acquired Lake Region Medical Holdings, Inc. (“LRM”) in 2015. At the direction of the New Jersey Department of Environmental Protection (“NJDEP”), LRM has been performing, and has agreed to fund approximately $0.3 million for, environmental investigations of a manufacturing facility LRM owned in South Plainfield, New Jersey from 1971 to 2004, and where it conducted operations from 1971 to 2007. NJDEP required LRM to perform and fund these environmental investigations due to concerns that prior investigations by LRM at the property were inadequate and because NJDEP concluded that the property was a source of local ground water contamination during LRM’s operations, including the Franklin Street Regional Groundwater Contamination Area, which has been designated as an immediate environmental concern by NJDEP. LRM funded the environmental investigation undertaken by NJDEP’s contractor by placing approximately $0.3 million in escrow for the environmental investigation. As of December 31, 2021, approximately $0.2 million had been drawn down from the escrow account by NJDEP to pay for the environmental investigation, and approximately $0.1 million remains in escrow for anticipated future costs associated with the environmental investigation. These environmental investigations may conclude that remediation of the property by LRM, and the reimbursement of costs and damages, including natural resource damages, associated with the groundwater immediate environmental concern, are necessary. Further, the current owner of the property claims to have been financially impacted by LRM’s inadequate environmental investigations. While the Company does not expect this environmental matter will have a material effect on its consolidated results of operations, financial position or cash flows, there can be no assurance that this environmental matter will not become material in the future. As of December 31, 2021, there was $0.1 million recorded in Accrued expenses and other current liabilities in the Consolidated Balance Sheets in connection with this environmental matter.
License Agreements
The Company is a party to various license agreements for technology that is utilized in certain of its products. The most significant of these agreements are the licenses for basic technology used in the production of wet tantalum capacitors, filtered feedthroughs and MRI compatible lead systems. Expenses related to license agreements were $1.3 million, $1.2 million, and $1.4 million, for 2021, 2020 and 2019, respectively, and are primarily included in Cost of Sales.
- 83 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(13.)     COMMITMENTS AND CONTINGENCIES (Continued)
Product Warranties
The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The change in product warranty liability for fiscal years 2021 and 2020 comprises the following (in thousands):
20212020
Beginning balance$163 $1,933 
Additions to warranty reserve, net of reversals(15)(156)
Adjustments to pre-existing warranties (71)(119)
Warranty claims settled— (1,495)
Acquisitions$432 — 
Ending balance$509 $163 
Self-Insurance Liabilities
As of December 31, 2021, and at various times in the past, the Company self-funded certain of its workers’ compensation and employee medical and dental expenses. The Company has established reserves to cover these self-insured liabilities and also maintains stop-loss insurance to limit its exposures under these programs. Claims reserves represent accruals for the estimated uninsured portion of reported claims, including adverse development of reported claims, as well as estimates of incurred but not reported claims. Claims incurred but not reported are estimated based on the Company’s historical experience, which is continually monitored, and accruals are adjusted when warranted by changes in facts and circumstances. The Company’s actual experience may be different than its estimates, sometimes significantly. Changes in assumptions, as well as changes in actual experience could cause these estimates to change. Insurance and claims expense will vary from period to period based on the severity and frequency of claims incurred in a given period.  The Company’s self-insurance reserves totaled $5.6 million and $5.4 million as of December 31, 2021 and December 31, 2020, respectively. These accruals are recorded in Accrued expenses and other current liabilities and Other long-term liabilities on the Consolidated Balance Sheets.
(14.)     LEASES
The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Gross assets acquired under finance leases are recorded in Other long-term assets and were $8.3 million as of December 31, 2021. Accumulated amortization associated with finance leases was $0.2 million as of December 31, 2021. Finance leases were not material as of December 31, 2020.
The components and classification of lease cost are as follows (in thousands):
December 31,
2021		December 31,
2020
Finance lease cost:
Amortization of lease assets$223 $7 
Interest on lease liabilities59 1 
Finance lease cost282 8 
Operating lease cost10,729 10,425 
Short-term lease cost (leases with initial term of 12 months or less)137 86 
Variable lease cost2,619 2,615 
Sublease income(1,392)(1,495)
Total lease cost$12,375 $11,639 
Cost of sales$9,642 $9,141 
SG&A1,817 1,803 
RD&E857 694 
Interest expense$59 $1 
Total lease cost$12,375 $11,639 
- 84 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(14.)     LEASES (Continued)
The Company’s sublease income is derived primarily from certain real estate leases to several non-affiliated tenants under operating sublease arrangements.
At December 31, 2021, the maturities of operating and finance lease liabilities were as follows (in thousands):
Operating Leases Finance Leases
2022$12,423 $876 
202311,317 888 
202410,809 896 
202510,634 787 
20269,856 640 
Thereafter25,652 5,807 
Gross lease liabilities80,691 9,894 
Less: imputed interest(11,062)(1,836)
Present value of lease liabilities69,629 8,058 
Less: current portion of lease liabilities(9,862)(608)
Total long-term lease liabilities$59,767 $7,450 
As of December 31, 2021, the Company did not have any leases that have not yet commenced.
The following table presents the weighted average remaining lease term and discount rate.
December 31,
2021		December 31,
2020
Weighted-average remaining lease term - operating leases (in years)7.07.0
Weighted-average remaining lease term - finance leases (in years)12.23.8
Weighted-average discount rate - operating leases3.9 %5.3 %
Weighted-average discount rate - finance leases3.5 %2.2 %

Supplemental cash flow information related to leases for fiscal years 2021 and 2020 is as follows (in thousands):
20212020
Cash paid for operating leases$10,808 $10,385 
Cash paid for interest on finance leases59 1 
Assets acquired under operating leases32,466 9,059 
Assets acquired under finance leases8,154 127 
During the fiscal year ended December 31, 2021, the Company extended the lease terms for three of its manufacturing facilities. As a result of these lease modifications, the Company re-measured the lease liability and adjusted the ROU asset on the modification dates.
- 85 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(15.)     EARNINGS PER SHARE
The following table sets forth a reconciliation of the information used in computing basic and diluted EPS for fiscal years 2021, 2020 and 2019 (in thousands, except per share amounts):
202120202019
Numerator for basic and diluted EPS:
Income from continuing operations$93,020 $77,258 $91,218 
Income from discontinued operations3,788 — 5,118 
Net income$96,808 $77,258 $96,336 
Denominator for basic EPS:
Weighted average shares outstanding32,993 32,845 32,627 
Effect of dilutive securities:
Stock options, restricted stock and restricted stock units265 268 410 
Denominator for diluted EPS33,258 33,113 33,037 
Basic earnings per share:
Income from continuing operations$2.82 $2.35 $2.80 
Income from discontinued operations0.11 — 0.16 
Basic earnings per share2.93 2.35 2.95 
Diluted earnings per share:
Income from continuing operations$2.80 $2.33 $2.76 
Income from discontinued operations0.11 — 0.15 
Diluted earnings per share2.91 2.33 2.92 
The diluted weighted average share calculations do not include the following securities for fiscal years 2021, 2020 and 2019, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):
202120202019
Time-vested stock options, restricted stock and restricted stock units4 98 30 
Performance-vested restricted stock units92 89 47 

- 86 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(16.)     STOCKHOLDERS’ EQUITY
Common Stock
The following table sets forth the changes in the number of shares of common stock for fiscal years 2021 and 2020:
IssuedTreasury StockOutstanding
Shares outstanding at December 31, 201932,847,017 (146,546)32,700,471 
Stock options exercised27,544 74,596 102,140 
Vesting of RSUs, net of shares withheld to cover taxes33,617 71,950 105,567 
Shares outstanding at December 31, 202032,908,178 — 32,908,178 
Stock options exercised34,233 — 34,233 
Vesting of RSUs, net of shares withheld to cover taxes120,925 — 120,925 
Shares outstanding at December 31, 202133,063,336 — 33,063,336 
Accumulated Other Comprehensive Income
Accumulated other comprehensive income comprises the following (in thousands): 
Defined
Benefit
Plan
Liability		Cash
Flow
Hedges		Foreign
Currency
Translation
Adjustment		Total
Pre-Tax
Amount		TaxNet-of-Tax
Amount
December 31, 2019$(912)$(2,358)$22,639 $19,369 $619 $19,988 
Unrealized loss on cash flow hedges— (6,683)— (6,683)1,404 (5,279)
Realized loss on foreign currency hedges— 638 — 638 (134)504 
Realized loss on interest rate swap hedges— 3,447 — 3,447 (724)2,723 
Net defined benefit plan adjustments(183)— — (183)32 (151)
Foreign currency translation gain— — 34,907 34,907 — 34,907 
December 31, 2020$(1,095)$(4,956)$57,546 $51,495 $1,197 $52,692 
Unrealized gain on cash flow hedges— 91 — 91 (19)72 
Realized gain on foreign currency hedges— (832)— (832)175 (657)
Realized loss on interest rate swap hedges— 3,406 — 3,406 (716)2,690 
Net defined benefit plan adjustments205 — — 205 14 219 
Foreign currency translation loss— — (27,826)(27,826)— (27,826)
December 31, 2021$(890)$(2,291)$29,720 $26,539 $651 $27,190 

- 87 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(17.)     FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Assets and Liabilities Measured at Fair Value on a Recurring Basis
Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments and contingent consideration. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis.
The Company is exposed to global market risks, including the effect of changes in interest rates and foreign currency exchange rates, and uses derivatives to manage these exposures that occur in the normal course of business. The Company does not hold or issue derivatives for trading or speculative purposes. All derivatives are recorded at fair value on the balance sheet.
The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):
Fair ValueQuoted
Prices in
Active
Markets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
December 31, 2021
Assets: Foreign currency hedging contracts$687 $— $687 $— 
Liabilities: Interest rate swap2,978 — 2,978 — 
Liabilities: Contingent consideration2,415 — — 2,415 
December 31, 2020
Assets: Foreign currency hedging contracts$2,070 $— $2,070 $— 
Liabilities: Interest rate swaps7,026 — 7,026 — 
Liabilities: Contingent consideration3,900 — — 3,900 
Derivatives Designated as Hedging Instruments
Interest Rate Swaps
The Company periodically enters into interest rate swap agreements to reduce the cash flow risk caused by interest rate changes on its outstanding floating rate borrowings. Under these swap agreements, the Company pays a fixed rate of interest and receives a floating rate equal to one-month LIBOR. The variable rate received from the swap agreements and the variable rate paid on the outstanding debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The Company has designated these swap agreements as cash flow hedges based on concluding the hedged forecasted transaction is probable of occurring within the period the cash flow hedge is anticipated to affect earnings.
The Company receives fair value estimates from the swap agreement counterparties. The fair value of the Company’s swap agreements are determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. The Company’s interest rate swap agreements are categorized in Level 2 of the fair value hierarchy. The estimated fair value of the swap agreements represents the amount the Company would receive (pay) to terminate the contracts.
Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of December 31, 2021 is as follows (dollars in thousands):
Notional AmountStart DateEnd
Date		Pay Fixed RateReceive Current Floating RateFair ValueBalance Sheet Location
$150,000 Jun 2020Jun 20232.1785 %0.1013 %$(2,978)Other long-term liabilities

- 88 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(17.)     FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands):
Notional AmountMaturity
Date		Pay Fixed RateReceive Current Floating RateFair ValueBalance Sheet Location
$200,000 Jun 20232.1785 %0.1480 %$(7,026)Other long-term liabilities
Foreign Currency Contracts
The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations. The Company has designated these foreign currency forward contracts as cash flow hedges.
The Company receives fair value estimates from the foreign currency contract counterparties. The fair value of foreign currency contracts are determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rate and credit spread curves. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as Sales or Cost of Sales as the inventory, which the contracts are hedging, is sold.
Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2021 is as follows (dollars in thousands):
Notional AmountMaturity
Date		$/Foreign CurrencyFair ValueBalance Sheet Location
$22,201 Dec 20220.0463MXN Peso$408 Prepaid expenses and other current assets
17,017 Dec 20221.1344Euro130 Prepaid expenses and other current assets
9,020 Dec 20220.0220UYU Peso149 Prepaid expenses and other current assets
Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands):
Notional AmountMaturity
Date		$/Foreign CurrencyFair ValueBalance Sheet Location
$16,132 Sep 20211.1949Euro$399 Prepaid expenses and other current assets
10,224 Sep 20210.0454MXN Peso922 Prepaid expenses and other current assets
2,656 Mar 20210.0443MXN Peso341 Prepaid expenses and other current assets
7,269 Dec 20210.0485MXN Peso77 Prepaid expenses and other current assets
3,252 Aug 20210.0232UYU Peso165 Prepaid expenses and other current assets
3,966 Nov 20210.0227UYU Peso166 Prepaid expenses and other current assets
The following table presents the impact of cash flow hedge derivative instruments on other comprehensive income (“OCI”), AOCI and the Company’s Consolidated Statement of Operations for fiscal years 2021, 2020 and 2019 (in thousands):
Gain (Loss) Recognized in OCIGain (Loss) Reclassified from AOCI
Derivative202120202019Location in Statement of Operations 202120202019
Interest rate swaps$642 $(7,405)$(5,618)Interest expense$(3,406)$(3,447)$1,621 
Foreign exchange contracts(943)1,017 (1,044)Sales(674)618 (1,334)
Foreign exchange contracts399 (355)2,634 Cost of sales1,437 (1,177)1,482 
Foreign exchange contracts(7)60 — Operating expenses69 (79)— 
The Company expects to reclassify net losses totaling $1.8 million related to its cash flow hedges from AOCI into earnings during the next twelve months.
- 89 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(17.)     FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
Derivatives Not Designated as Hedging Instruments
The Company also has foreign currency exposure on balances, primarily intercompany, that are denominated in a foreign currency and are adjusted to current values using period-end exchange rates. To minimize foreign currency exposure, the Company enters into foreign currency contracts with a one month maturity. At December 31, 2021, the Company had one contract outstanding, with a notional amount of $15.0 million and a fair value of $0.1 million. The Company recorded a net gain on foreign currency contracts not designated as hedging instruments of $0.4 million for fiscal year 2021, which are included in Other (income) loss, net and generally offset the gains or losses from the foreign currency adjustments on the intercompany balances that are also included in Other (income) loss, net.
Contingent Consideration
The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for fiscal years 2021 and 2020 (in thousands):
December 31, 2019$4,200 
Amount recorded for current year acquisitions
2,700 
Fair value measurement adjustment(2,000)
Payments
(1,000)
December 31, 20203,900 
Fair value measurement adjustment133 
Payments
(1,621)
Foreign currency translation3 
December 31, 2021$2,415 
On February 19, 2020, the Company acquired certain assets and liabilities of InoMec. On October 7, 2019, the Company acquired certain assets and liabilities of USB, a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The contingent consideration at December 31, 2021 is the estimated fair value of the Company’s obligations, under the asset purchase agreements for InoMec and USB, to make additional payments if certain revenue goals are met. See Note 2 “Business Acquisitions” for additional information about the InoMec and USB acquisitions.
During 2021, the Company made payments associated with the InoMec and USB acquisitions, resulting from achievement of revenue-based goals for the period from March 1, 2020 to February 28, 2021 for InoMec and January 1, 2020 to December 31, 2020 for USB. During 2020, the Company made payments to settle a portion of a contingent consideration arrangement relating to a license to use technology.
As of December 31, 2021 and December 31, 2020, the current portion of contingent consideration liabilities included in Accrued expenses and other current liabilities was $0.9 million and $1.7 million, respectively, and the non-current portion included in Other long-term liabilities on the Consolidated Balance Sheets was $1.5 million and $2.2 million, respectively.
The following table provides quantitative information associated with the fair value measurement of the Company’s liabilities for contingent consideration:
December 31, 2021
Contingency TypeRemaining Maximum Payout (undiscounted)Fair ValueValuation TechniqueUnobservable InputsWeighted Average or Range
Revenue-based payments$6,750 $2,415 Monte CarloRevenue volatility29.0 %
Discount rate1.8 %
Projected year(s) of payment2022-2024
- 90 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(17.)     FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
December 31, 2020
Contingency TypeRemaining Maximum Payout (undiscounted)Fair ValueValuation TechniqueUnobservable InputsWeighted Average or Range
Revenue-based payments$9,000 $3,900 Monte CarloRevenue volatility35.0 %
Discount rate4.0 %
Projected year(s) of payment2021-2024

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, contract assets, accounts payable and accrued expenses approximate fair value due to the short-term nature of these items.
Borrowings under the Company’s Revolving Credit Facility, TLA Facility and TLB Facility accrue interest at a floating rate tied to a standard short-term borrowing index, selected at the Company’s option, plus an applicable margin. The carrying amount of this floating rate debt approximates fair value based upon the respective interest rates adjusting with market rate adjustments.
Equity Investments
Equity investments comprise the following (in thousands):
December 31,
2021		December 31,
2020
Equity method investment$16,192 $21,470 
Non-marketable equity securities5,637 5,723 
Total equity investments
$21,829 $27,193 
The components of (Gain) loss on equity investments, net for each period were as follows (in thousands):
202120202019
Equity method investment (income) loss$3,057 $(5,706)$(1,100)
Impairment charges86 369 1,575 
Total (gain) loss on equity investments, net
$3,143 $(5,337)$475 
During 2021, 2020 and 2019, the Company determined that certain non-marketable equity securities were impaired. In both 2021 and 2020, new equity financings by two of the Company’s non-marketable equity securities indicated new values for the investments. During the fourth quarters of 2021 and 2020, the Company recorded impairment charges of $0.1 million and $0.4 million, respectively, to reduce the carrying value of these non-marketable equity securities to their estimated fair value of zero and $2.2 million, respectively. The fair values of these investments were derived from observable price changes of similar securities of the investees. In 2019, the Company determined the fair value for one of its non-marketable equity securities to be zero based upon available market information. This assessment was based on qualitative indications of impairment. Factors that significantly influenced the determination of the impairment loss included the equity security’s investee’s financial condition, priority claims to the equity security, distributions rights and preferences, and status of the regulatory approval required to bring its product to market. During 2021, 2020 and 2019, the Company received cash distributions representing a return on equity method investments of $2.2 million, $0.4 million and $0.1 million, respectively.
The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. As of December 31, 2021, the Company owned 6.7% of this fund.
- 91 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(18.)     SEGMENT AND GEOGRAPHIC INFORMATION
The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker, to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting.
The Company defines segment income from operations as sales less cost of sales including amortization and expenses attributable to segment-specific selling, general, administrative, research, development, engineering and other operating activities. The remaining unallocated operating and other expenses are primarily administrative corporate headquarter expenses and capital costs that are not allocated to reportable segments. Transactions between the two segments are not significant.
The following table presents sales by product line for fiscal years 2021, 2020 and 2019 (in thousands).
202120202019
Segment sales by product line:
Medical
Cardio & Vascular $626,013 $569,948 $610,056 
Cardiac & Neuromodulation446,569 346,242 457,194 
Advanced Surgical, Orthopedics & Portable Medical110,044 121,788 132,429 
Total Medical1,182,626 1,037,978 1,199,679 
Non-Medical38,453 35,464 58,415 
Total sales$1,221,079 $1,073,442 $1,258,094 
Geographic Area Information
The following table presents sales by significant country for fiscal years 2021, 2020 and 2019. In these tables, sales are allocated based on where the products are shipped (in thousands).
202120202019
Sales by geographic area:
United States$671,502 $596,804 $698,474 
Non-Domestic locations:
Puerto Rico110,162 96,048 154,644 
Costa Rica66,975 58,853 63,634 
Rest of world372,440 321,737 341,342 
Total sales$1,221,079 $1,073,442 $1,258,094 
The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues for fiscal years 2021 and 2020.
20212020
CustomerMedicalNon-MedicalMedicalNon-Medical
Customer A19%*19%*
Customer B17%*17%*
Customer C14%*15%*
Customer D*36%*22%
Customer E***10%
All other customers50%64%49%68%
__________
* Less than 10% of segment’s total revenues for the period.
- 92 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(18.)     SEGMENT AND GEOGRAPHIC INFORMATION (Continued)
The following table presents revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped for fiscal years 2021 and 2020.
20212020
Ship to LocationMedicalNon-MedicalMedicalNon-Medical
United States54%71%55%60%
Rest of world46%29%45%40%
The following table presents income from continuing operations for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).
202120202019
Segment income from continuing operations:
Medical$213,600 $169,396 $223,873 
Non-Medical8,022 4,848 16,289 
Total segment income from continuing operations221,622 174,244 240,162 
Unallocated operating expenses(85,911)(53,632)(82,527)
Operating income135,711 120,612 157,635 
Unallocated expenses, net(34,648)(34,405)(52,442)
Income from continuing operations before taxes$101,063 $86,207 $105,193 
The following table presents depreciation and amortization expense for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).
 202120202019
Segment depreciation and amortization:
Medical$75,366 $72,338 $68,867 
Non-Medical1,167 996 1,039 
Total depreciation and amortization included in segment
   income from continuing operations
76,533 73,334 69,906 
Unallocated depreciation and amortization4,836 5,990 7,989 
Total depreciation and amortization$81,369 $79,324 $77,895 
The following table presents total assets for the Company’s reportable segments as of December 31, 2021 and December 31, 2020 (in thousands).
December 31,
2021		December 31,
2020
Identifiable assets:
Medical$2,448,123 $2,212,489 
Non-Medical 56,158 52,682 
Total reportable segments2,504,281 2,265,171 
Unallocated assets77,934 106,686 
Total assets$2,582,215 $2,371,857 
- 93 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(18.)     SEGMENT AND GEOGRAPHIC INFORMATION (Continued)
The following table presents capital expenditures for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).
 202120202019
Expenditures for tangible long-lived assets:
Medical$48,364 $42,435 $44,026 
Non-Medical628 1,038 397 
Total reportable segments48,992 43,473 44,423 
Unallocated long-lived tangible assets4,471 3,359 3,775 
Total expenditures$53,463 $46,832 $48,198 
The following table presents PP&E by geographic area as of December 31, 2021 and December 31, 2020. In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands).
December 31,
2021		December 31,
2020
Long-lived tangible assets by geographic area:
United States$184,474 $170,871 
Mexico33,877 32,723 
Ireland41,501 38,526 
Rest of world17,247 11,844 
Total$277,099 $253,964 

(19.)     REVENUE FROM CONTRACTS WITH CUSTOMERS
Disaggregated Revenue
In general, the Company’s business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. For a summary by disaggregated product line sales for each segment, refer to Note 18, “Segment and Geographic Information.”
A significant portion of the Company’s sales for fiscal years 2021, 2020 and 2019 and accounts receivable at December 31, 2021 and December 31, 2020 were to three customers as follows:
 SalesAccounts Receivable
202120202019December 31,
2021		December 31,
2020
Customer A18%18%21%15%15%
Customer B16%16%17%19%19%
Customer C13%14%12%10%13%
47%48%50%44%47%
Revenue recognized from products and services transferred to customers over time during fiscal years 2021 and 2020 represented 33% and 29%, respectively, of total revenue. Substantially all of the revenue recognized from products and services transferred to customers over time during fiscal years 2021 and 2020 was within the Medical segment.
- 94 -
INTEGER HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(19.)     REVENUE FROM CONTRACTS WITH CUSTOMERS (Continued)
Contract Balances
The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands):
December 31,
2021		December 31,
2020
Contract assets$64,743 $40,218 
Contract liabilities3,776 2,498 
Contract assets at December 31, 2021, increased $24.5 million from December 31, 2020, primarily due to a contract modification to add existing products and extend the contractual term. During the fiscal year ended December 31, 2021, the Company recognized $1.9 million of revenue that was included in the contract liability balance as of December 31, 2020. During the fiscal year ended December 31, 2020, the Company recognized $1.3 million of revenue that was included in the contract liability balance as of December 31, 2019.
(20.)    DISCONTINUED OPERATIONS
Divestiture of AS&O Product Line
In July 2018, the Company completed the sale of its AS&O Product Line within its Medical segment to Viant (formerly MedPlast, LLC). For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&O Product Line.
During the fourth quarter of 2021, the Company recognized other income from discontinued operations of $4.9 million for the release of pre-divestiture indemnified tax liabilities resulting from the lapse of the statute of limitations and the effective settlement of tax audits. During 2019, the Company received, and recognized as gain on sale from discontinued operations, $4.8 million due to the final net working capital adjustment agreed to with Viant.
Income from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands):
202120202019
Gain on sale of discontinued operations$— $— $(4,974)
Other income, net(4,931)— (322)
Income from discontinued operations before taxes4,931 — 5,296 
Provision for income taxes1,143 — 178 
Income from discontinued operations$3,788 $— $5,118 
Cash flow information from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands):
202120202019
Cash used in operating activities$— $— $(78)
Cash provided by investing activities— — 4,734 

- 95 -

ITEM 9.    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.

ITEM 9A.    CONTROLS AND PROCEDURES
Management’s Report on Internal Control Over Financial Reporting appears in Part II, Item 8, “Financial Statements and Supplementary Data” of this report and is incorporated into this Item 9A by reference.
a.Evaluation of Disclosure Controls and Procedures
Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the SEC as of December 31, 2021. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the SEC’s rules and forms. Based on their evaluation, as of December 31, 2021, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.
b. Changes in Internal Control Over Financial Reporting
In accordance with guidance issued by the SEC, companies are permitted to exclude acquisitions from their final assessment of internal control over financial reporting for a period not to exceed one year from the acquisition date. Our management’s evaluation of internal control over financial reporting excluded the internal control activities of Oscor Inc., Oscor Caribe, LLC and Oscor Europe GmbH (collectively “Oscor”), which we acquired on December 1, 2021, as discussed in Note 2 “Acquisitions” of the Notes to Consolidated Financial Statements. Prior to its acquisition, Oscor was a privately-held company not subject to the Sarbanes-Oxley Act of 2002, the rules and regulations of the SEC, or other corporate governance requirements to which public companies may be subject. We have included the financial results of Oscor in our consolidated financial statements from the date of acquisition. The financial results of Oscor constituted, 9% of total assets, 16% of net assets, and less than 1% of both sales and net income of the consolidated financial statement amounts as of and for the year ended December 31, 2021. The Company is in the process of evaluating the existing controls and procedures of the acquired business and integrating the acquired business into its system of internal control over financial reporting. As a result, management was unable, without incurring unreasonable effort or expense, to conduct an assessment of internal control over financial reporting for the acquired business.
Other than as described above, there were no changes in the Company's internal control over financial reporting during the Company's fourth fiscal quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

ITEM 9B.    OTHER INFORMATION
None.

ITEM 9C.    DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.
- 96 -
PART III

ITEM 10.    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Information regarding the Company’s directors appearing under the caption “Election of Directors” in the Company’s Proxy Statement for its 2022 Annual Meeting of Stockholders is incorporated herein by reference.
Information regarding the Company’s executive officers is presented under the caption “Information About our Executive Officers” in Part I of this Annual Report on Form 10-K.
The other information required by Item 10 is incorporated herein by reference from the Company’s Proxy Statement for its 2022 Annual Meeting of Stockholders.

ITEM 11.    EXECUTIVE COMPENSATION
Information regarding executive compensation appearing under the captions “Compensation Discussion and Analysis”, “Executive Compensation” and “Compensation Committee Interlocks and Insider Participation” in the Company’s Proxy Statement for the 2022 Annual Meeting of Stockholders is incorporated herein by reference.

ITEM 12.    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
Information regarding security ownership of certain beneficial owners and management and related stockholder matters, including the table titled “Equity Compensation Plan Information” and under the caption “Security Ownership of Certain Beneficial Owners and Management” in the Company’s Proxy Statement for the 2022 Annual Meeting of Stockholders is incorporated herein by reference.

ITEM 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
Information regarding certain relationships and related transactions, and director independence under the captions “Related-Person Transactions” and “Board Independence” in the Company’s Proxy Statement for the 2022 Annual Meeting of Stockholders is incorporated herein by reference.

ITEM 14.    PRINCIPAL ACCOUNTING FEES AND SERVICES
The Company’s independent registered public accounting firm is Deloitte & Touche LLP, Williamsville, New York, PCAOB Auditor Firm ID: 34.
Information regarding the fees paid to and services provided by Deloitte & Touche LLP is provided under the caption “Ratification of the Appointment of Independent Registered Public Accounting Firm” in the Company’s Proxy Statement for the 2022 Annual Meeting of Stockholders is incorporated herein by reference.
- 97 -
PART IV

ITEM 15.    EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a) LIST OF DOCUMENTS FILED AS PART OF THIS REPORT
(1)Financial statements and financial statement schedules filed as part of this Annual Report on Form 10-K. Refer to Part II, Item 8. “Financial Statements and Supplementary Data.”
(2)The following financial statement schedule is included in this Annual Report on Form 10-K (in thousands):
Schedule II—Valuation and Qualifying Accounts
 Col. C—Additions    
Column A
Description		Col. B Balance at Beginning
of Period		Charged to Costs &
Expenses		Charged to Other Accounts- Describe Col. D Deductions
- Describe		 Col. E Balance at End of
Period
December 31, 2021
Provision for credit losses
$155 $20 
(1)
$— $(43)
(4)
$132 
Valuation allowance for deferred tax assets$20,739 $(941)
(2)
$26 
(3)
$(368)
(2)
$19,456 
December 31, 2020
Provision for credit losses
$2,443 $28 
(1)
$— $(2,316)
(4)
$155 
Valuation allowance for deferred tax assets$22,229 $(275)
(2)
$— $(1,215)
(2)(4)(5)
$20,739 
December 31, 2019
Allowance for doubtful accounts$592 $1,884 
(1)
$2 
(3)
$(35)
(4)
$2,443 
Valuation allowance for deferred tax assets$34,339 $736 
(2)
$— $(12,846)
(2)(4)(5)
$22,229 
(1)Valuation allowance recorded in the provision for credit losses (allowance for doubtful accounts in years prior to 2020). The 2019 amount includes a $2.3 million reserve recorded in connection with a customer bankruptcy, net of adjustments to the Company’s general and specific reserves.
(2)Valuation allowance recorded in the provision for income taxes for certain net operating losses and tax credits. The 2021, 2020 and 2019 deductions include the expiration of certain net operating losses and tax credits.
(3)Includes foreign currency translation effect.
(4)Accounts written off and reductions to allowances existing at the beginning of the year. The 2020 amount includes $2.3 million of accounts receivable recorded during 2019 in connection with a customer bankruptcy.
(5)The 2020 and 2019 deductions include releases of the allowance for net operating losses utilized during that year and return to provision adjustments for prior years.
Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.
(3)See exhibits listed under Part (b) below.
- 98 -
(b) EXHIBITS:
EXHIBIT
NUMBER		DESCRIPTION
2.1
3.1
3.2
4.1
10.1
10.2
10.3#
10.4#
10.5#
10.6#
10.7#
10.8#
10.9#
10.10#
10.11#
10.12#
10.13#
10.14#
10.15#
- 99 -
EXHIBIT
NUMBER		DESCRIPTION
10.16#
10.17#
10.18#
10.19#
10.20#
10.21#
10.22#
10.23#
10.24#
10.25#
10.26#
10.27#
10.28#
10.29#
10.30#
10.31#
10.32#
10.33#
- 100 -
EXHIBIT
NUMBER		DESCRIPTION
10.34#
10.35#
10.36#
10.37#
10.38#
10.39#
10.40#
10.41#
10.42#
10.43#
10.44#
10.45#
10.46#
10.47#
21.1*
23.1*
31.1*
31.2*
32.1**
101.INS*XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*XRBL Taxonomy Extension Schema Document
- 101 -
EXHIBIT
NUMBER		DESCRIPTION
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document
104
Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101)

* -Filed herewith.
** -Furnished herewith.
# -Indicates exhibits that are management contracts or compensation plans or arrangements required to be filed pursuant to Item 15(b) of Form 10-K.


ITEM 16.    FORM 10-K SUMMARY
None.

- 102 -
SIGNATURES
Pursuant to the requirements of Sections 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
INTEGER HOLDINGS CORPORATION
Dated:February 22, 2022By/s/ Joseph W. Dziedzic
Joseph W. Dziedzic (Principal Executive Officer)
President and Chief Executive Officer

- 103 -
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated. 
SignatureTitleDate
/s/ Joseph W. Dziedzic President, Chief Executive Officer and DirectorFebruary 22, 2022
Joseph W. Dziedzic(Principal Executive Officer)
/s/ Jason K. GarlandExecutive Vice President and Chief Financial OfficerFebruary 22, 2022
Jason K. Garland(Principal Financial Officer)
/s/ Tom P. ThomasVice President, Corporate ControllerFebruary 22, 2022
Tom P. Thomas(Principal Accounting Officer)
/s/ Bill R. SanfordChairmanFebruary 22, 2022
Bill R. Sanford
/s/ Sheila AntrumDirectorFebruary 22, 2022
Sheila Antrum
/s/ Pamela G. BaileyDirectorFebruary 22, 2022
Pamela G. Bailey
/s/ Cheryl C. CappsDirectorFebruary 22, 2022
Cheryl C. Capps
/s/ James F. HinrichsDirectorFebruary 22, 2022
James F. Hinrichs
/s/ Jean M. HobbyDirectorFebruary 22, 2022
Jean M. Hobby
/s/ Tyrone JeffersDirectorFebruary 22, 2022
Tyrone Jeffers
/s/ M. Craig MaxwellDirectorFebruary 22, 2022
M. Craig Maxwell
/s/ Filippo PasseriniDirectorFebruary 22, 2022
Filippo Passerini
/s/ Donald J. SpenceDirectorFebruary 22, 2022
Donald J. Spence
/s/ William B. Summers, Jr.DirectorFebruary 22, 2022
William B. Summers, Jr.

- 104 -
 EX-21.1 2 itgr-20211231ex211.htm EX-21.1 Document

EXHIBIT 21.1
SUBSIDIARIES OF INTEGER HOLDINGS CORPORATION
 
Subsidiary  Jurisdiction of
Accellent LLCColorado
Brivant Limited, d/b/a Lake Region Medical Ireland
Centro de Construcción de Cardioestimuladores del Uruguay SAUruguay
Electrochem Solutions, Inc.  Massachusetts
Greatbatch LLCDelaware
Greatbatch Ltd., d/b/a Greatbatch Medical  New York
Greatbatch Medical, S. de R.L. de C.V.  Mexico
Greatbatch Medical SA  Switzerland
Greatbatch MCSO, S. de R.L. de C.VMexico
Greatbatch Netherlands B.V.Netherlands
Integer EBDO SASwitzerland
Integer SMI Ltd.Israel
Integer Ireland Medical LimitedIreland
Lake Region Manufacturing, Inc., d/b/a Lake Region Medical Minnesota
Lake Region Medical LimitedIreland
Lake Region Medical, Inc., d/b/a Lake Region MedicalMaryland
Lake Region Medical Holdings LimitedIreland
Lake Region Medical Sdn. Bhd.Malaysia
Lake (Shanghai) Medical Device Trading Co., Ltd.China
Oscor IncFlorida
Oscor Caribe LLCFlorida
Oscor Europe GmbHGermany
Venusa de Mexico, S. de R.L. de C.V.Mexico
Venusa, LtdNew York


 EX-23.1 3 itgr-20211231ex231.htm EX-23.1 Document

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-61476, 333-97209, 333-129002, 333-143519, 333-161159, 333-174559, 333-184604, 333-196320, 333-211609 and 333-256404 on Form S-8 and Registration Statement No. 333-210967 on Form S-3 of our reports dated February 22, 2022, relating to the financial statements of Integer Holdings Corporation (the “Company”), and the effectiveness of the Company’s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2021.
/s/ Deloitte & Touche LLP
Williamsville, New York
February 22, 2022

 EX-31.1 4 itgr-20211231ex311.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION
I, Joseph W. Dziedzic, certify that:
1.I have reviewed this annual report on Form 10-K for the fiscal year ended December 31, 2021 of Integer Holdings Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5.     The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditor and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated:
February 22, 2022
/s/ Joseph W. Dziedzic
Joseph W. Dziedzic
President and Chief Executive Officer
(Principal Executive Officer)




 EX-31.2 5 itgr-20211231ex312.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION
I, Jason K. Garland, certify that:
1.I have reviewed this annual report on Form 10-K for the fiscal year ended December 31, 2021 of Integer Holdings Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditor and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated:
February 22, 2022/s/ Jason K. Garland
Jason K. Garland
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)


 EX-32.1 6 itgr-20211231ex321.htm EX-32.1 Document

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Integer Holdings Corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Form 10-K”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:
February 22, 2022
/s/ Joseph W. Dziedzic
Joseph W. Dziedzic
President and Chief Executive Officer
(Principal Executive Officer)
Dated:
February 22, 2022/s/ Jason K. Garland
Jason K. Garland
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)



 EX-101.SCH 7 gb-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000010001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000020002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 100010003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030005 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100040006 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 100050007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100060008 - Statement - Consolidated Statement of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 210011001 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 220022001 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 240034001 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 210041002 - Disclosure - Business Acquisition link:presentationLink link:calculationLink link:definitionLink 230053001 - Disclosure - Business Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 240064002 - Disclosure - Business Acquisition (Acquisition of Assets from Oscor Inc Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240074003 - Disclosure - Business Acquisition (Allocation Of The Provisional Purchase Price ) (Details) link:presentationLink link:calculationLink link:definitionLink 240084004 - Disclosure - Business Acquisition (Acquisition of Assets from InoMec Ltd Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240094005 - Disclosure - Business Acquisition (Acquisition of Assets from US BioDesign LLC Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240104006 - Disclosure - Business Acquisition (Indefinite-Lived Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 240114007 - Disclosure - Business Acquisition ( Pro Forma Information) (Details) link:presentationLink link:calculationLink link:definitionLink 210121003 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 230133002 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 240144008 - Disclosure - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 210151004 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 230163003 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 240174009 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 210181005 - Disclosure - Property, Plant and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 230193004 - Disclosure - Property, Plant and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 240204010 - Disclosure - Property, Plant and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 240214011 - Disclosure - Property, Plant and Equipment, Net (Depreciation Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 210221006 - Disclosure - Goodwill and Other Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 230233005 - Disclosure - Goodwill and Other Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 240244012 - Disclosure - Goodwill and Other Intangible Assets, Nets (Schedule of Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 240254013 - Disclosure - Goodwill and Other Intangible Assets, Net (Schedule of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 240264014 - Disclosure - Goodwill and Other Intangible Assets, Net (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240274015 - Disclosure - Goodwill and Other Intangible Assets, Net (Amortization Expense by categories) (Details) link:presentationLink link:calculationLink link:definitionLink 240284016 - Disclosure - Goodwill and Other Intangible Assets, Net (Future Amortization Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 210291007 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 230303006 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 240314017 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 210321008 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 230333007 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 240344018 - Disclosure - Debt (Schedule of Long-Term Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 240344018 - Disclosure - Debt (Schedule of Long-Term Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 240354019 - Disclosure - Debt (Senior Secured Credit Facilities) (Details) link:presentationLink link:calculationLink link:definitionLink 240364020 - Disclosure - Debt (Revolving Credit Facility) (Details) link:presentationLink link:calculationLink link:definitionLink 240374021 - Disclosure - Debt (Term Loan Facilities) (Details) link:presentationLink link:calculationLink link:definitionLink 240384022 - Disclosure - Debt (Covenants) (Details) link:presentationLink link:calculationLink link:definitionLink 240394023 - Disclosure - Debt (Long-term Debt Maturity Schedule) (Details) link:presentationLink link:calculationLink link:definitionLink 240404024 - Disclosure - Debt (Deferred Financing Fees) (Details) link:presentationLink link:calculationLink link:definitionLink 240414025 - Disclosure - Debt (Deferred Debt Issuance Costs and Discounts) (Details) link:presentationLink link:calculationLink link:definitionLink 210421009 - Disclosure - Benefit Plans link:presentationLink link:calculationLink link:definitionLink 240434026 - Disclosure - Benefit Plans (Savings Plan Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240444027 - Disclosure - Benefit Plans (Defined Benefit Plans Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 210451010 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 230463008 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 240474028 - Disclosure - Stock-Based Compensation (Narratives) (Details) link:presentationLink link:calculationLink link:definitionLink 240484029 - Disclosure - Stock-Based Compensation (Components of Stock-Based Compensation Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 240494030 - Disclosure - Stock-Based Compensation (Weighted-Average Fair Value and Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 240504031 - Disclosure - Stock-Based Compensation (Stock Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 240514032 - Disclosure - Stock-Based Compensation (Exercise of Stock Option) (Details) link:presentationLink link:calculationLink link:definitionLink 240524033 - Disclosure - Stock-Based Compensation (Restricted Stock and Restricted Stock Units) (Details) link:presentationLink link:calculationLink link:definitionLink 210531011 - Disclosure - Other Operating Expenses link:presentationLink link:calculationLink link:definitionLink 230543009 - Disclosure - Other Operating Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 240554034 - Disclosure - Other Operating Expenses (Schedule of Other Operating Expenses) (Details) link:presentationLink link:calculationLink link:definitionLink 240564035 - Disclosure - Other Operating Expenses (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240574036 - Disclosure - Other Operating Expenses (Changes in Accrued Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 210581012 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 230593010 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 240604037 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240614038 - Disclosure - Income Taxes (Income Before Income Tax Domestic And Foreign) (Details) link:presentationLink link:calculationLink link:definitionLink 240624039 - Disclosure - Income Taxes (Provision Benefit of Income Taxes) (Details) link:presentationLink link:calculationLink link:definitionLink 240634040 - Disclosure - Income Taxes (Effect Tax Rate Reconciliation) (Details) link:presentationLink link:calculationLink link:definitionLink 240644041 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 240644041 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 240654042 - Disclosure - Income Taxes (Income Tax Carry Forward) (Details) link:presentationLink link:calculationLink link:definitionLink 240664043 - Disclosure - Income Taxes (Unrecognized Tax Benefits) (Details) link:presentationLink link:calculationLink link:definitionLink 210671013 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 230683011 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 240694044 - Disclosure - Commitments and Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240704045 - Disclosure - Commitments and Contingencies (Change in Product Warranty Liability) (Details) link:presentationLink link:calculationLink link:definitionLink 210711014 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 230723012 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 240734046 - Disclosure - Leases (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240744047 - Disclosure - Leases (Schedule of Lease Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 240754048 - Disclosure - Leases (Schedule of Operating Lease Liability Maturities) (Details) link:presentationLink link:calculationLink link:definitionLink 240754048 - Disclosure - Leases (Schedule of Operating Lease Liability Maturities) (Details) link:presentationLink link:calculationLink link:definitionLink 240764049 - Disclosure - Leases (Lease Term and Discount Rate) (Details) link:presentationLink link:calculationLink link:definitionLink 240774050 - Disclosure - Leases (Schedule of Operating Lease Supplemental Cash Flow Information) (Details) link:presentationLink link:calculationLink link:definitionLink 210781015 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 230793013 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 240804051 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 240814052 - Disclosure - Earnings Per Share (Antidilutive Securities) (Details) link:presentationLink link:calculationLink link:definitionLink 210821016 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 230833014 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 240844053 - Disclosure - Stockholders' Equity (Schedule of Changes in Number of Shares of Common Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 240854054 - Disclosure - Stockholders' Equity (Schedule of Accumulated Other Comprehensive Income) (Details) link:presentationLink link:calculationLink link:definitionLink 210861017 - Disclosure - Financial Instruments and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 230873015 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 240884055 - Disclosure - Financial Instruments and Fair Value Measurements (Assets and Liabilities Recorded at Fair Value on a Recurring Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 240894056 - Disclosure - Financial Instruments and Fair Value Measurements (Schedule of Interest Rate Swaps) (Details) link:presentationLink link:calculationLink link:definitionLink 240904057 - Disclosure - Financial Instruments and Fair Value Measurements (Schedule of Foreign Currency Contracts) (Details) link:presentationLink link:calculationLink link:definitionLink 240914058 - Disclosure - Financial Instruments and Fair Value Measurements (Schedule of Derivative Instruments with Hedge Accounting Designation) (Details) link:presentationLink link:calculationLink link:definitionLink 240924059 - Disclosure - Financial Instruments and Fair Value Measurements (Narratives) (Details) link:presentationLink link:calculationLink link:definitionLink 240934060 - Disclosure - Financial Instruments and Fair Value Measurements (Estimated Fair Values for Contingent Consideration) (Details) link:presentationLink link:calculationLink link:definitionLink 240944061 - Disclosure - Financial Instruments and Fair Value Measurements (Contingent Consideration Measurement Inputs) (Details) link:presentationLink link:calculationLink link:definitionLink 240954062 - Disclosure - Financial Instruments and Fair Value Measurements (Equity Method Investments) (Details) link:presentationLink link:calculationLink link:definitionLink 210961018 - Disclosure - Segment and Geographic Information link:presentationLink link:calculationLink link:definitionLink 230973016 - Disclosure - Segment and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 240984063 - Disclosure - Segment and Geographic Information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240994064 - Disclosure - Segment and Geographic Information (Sales by Product Lines) (Details) link:presentationLink link:calculationLink link:definitionLink 241004065 - Disclosure - Segment and Geographic Information (Sales by Geographic Information) (Details) link:presentationLink link:calculationLink link:definitionLink 241014066 - Disclosure - Segment and Geographic Information (Significant Customers) (Details) link:presentationLink link:calculationLink link:definitionLink 241024067 - Disclosure - Segment and Geographic Information (Schedule of Revenue by Ship To Location) (Details) link:presentationLink link:calculationLink link:definitionLink 241034068 - Disclosure - Segment and Geographic Information (Reconciliation of Segment Information) (Details 1) link:presentationLink link:calculationLink link:definitionLink 241044069 - Disclosure - Segment and Geographic Information (Long lived Tangible Assets by Region) (Details) link:presentationLink link:calculationLink link:definitionLink 211051019 - Disclosure - Revenue From Contracts With Customers link:presentationLink link:calculationLink link:definitionLink 231063017 - Disclosure - Revenue From Contracts With Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 241074070 - Disclosure - Revenue From Contracts With Customers (Disaggregated Revenue) (Details) link:presentationLink link:calculationLink link:definitionLink 241084071 - Disclosure - Revenue From Contracts With Customers (Contract Balances) (Details) link:presentationLink link:calculationLink link:definitionLink 211091020 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 231103018 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 241114072 - Disclosure - Discontinued Operations (AS&O Business Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 241124073 - Disclosure - Discontinued Operations (Income from Discontinued Operations) (Details) link:presentationLink link:calculationLink link:definitionLink 241134074 - Disclosure - Discontinued Operations (Cash Flow Information from Discontinued Operations) (Details) link:presentationLink link:calculationLink link:definitionLink 211141021 - Disclosure - Schedule II - Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 241154075 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 gb-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 gb-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 gb-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cash paid during the year for: Supplemental Cash Flow Information [Abstract] Customer [Domain] Name of Major Customer [Domain] Customer [Domain] State Current State and Local Tax Expense (Benefit) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Leasehold improvements Leasehold Improvements [Member] Effective Income Tax Rate Reconciliation, Amount [Abstract] Effective Income Tax Rate Reconciliation, Amount [Abstract] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Acquisition related costs Business Combination, Acquisition Related Costs Measurement input Acquired Intangible Assets, Measurement Input Acquired Intangible Assets, Measurement Input Other Other Intangible Assets [Member] Contract assets Increase (Decrease) in Contract with Customer, Asset Security Exchange Name Security Exchange Name Equity method investment Equity Method Investments, Fair Value Disclosure Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Schedule of Contract Assets and Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Contingent consideration payments Payment for Contingent Consideration Liability, Financing Activities Weighted-average remaining lease term - operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Foreign Currency Translation and Remeasurement Foreign Currency Transactions and Translations Policy [Policy Text Block] Non-marketable securities impairment Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Derivative Financial Instruments Derivatives, Policy [Policy Text Block] Other Operating Expenses Net [Table] Other Operating Expenses Net [Table] Table showing components of Other Operating Expenses, net Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Valuation, Income Approach Valuation, Income Approach [Member] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] 2023 Long-Term Debt, Maturity, Year Two Income taxes payable Increase (Decrease) in Income Taxes Payable Fair value measurement adjustment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Acquisition-related adjustments (Note 2) Acquisition-related adjustments (Note 2) Goodwill, Purchase Accounting Adjustments Additions to warranty reserve, net of reversals Standard Product Warranty Accrual, Increase For Warranties Issued, (Decrease) For Reversals Standard Product Warranty Accrual, Increase For Warranties Issued, (Decrease) For Reversals Charged to Costs & Expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Profit sharing and bonuses Accrued Bonuses, Current Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract One Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract One [Member] Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract One Number of customers Concentration Risk, Number of Customers Concentration Risk, Number of Customers Contingent consideration Business Combination, Liabilities Arising from Contingencies, Amount Recognized Total intangible asset amortization expense Amortization of Intangible Assets Schedule of Restructuring Reserve by Type of Cost Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Weighted Average Amortization Period (Years) Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Securities excluded (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Contract with customer, liability, revenue recognized Contract with Customer, Liability, Revenue Recognized RD&E Research and Development Expense [Member] Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Business Combination and Asset Acquisition [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] Schedule of Contingent Consideration Measurement Inputs Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Operating lease assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-of-use Asset Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-of-use Asset Award Type [Domain] Award Type [Domain] Movement in Standard Product Warranty Accrual [Roll Forward] Movement in Standard Product Warranty Accrual [Roll Forward] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Local Phone Number Local Phone Number Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding as of December 31, 2021 and 2020 Preferred Stock, Value, Issued Fair Value Assigned Finite-lived Intangible Assets Acquired Cardiac & Neuromodulation Cardiac Neuromodulation [Member] Cardiac Neuromodulation [Member] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Retained earnings Retained Earnings [Member] Unallocated other income (expense), net Unallocated Other Expense Total expenses other than operating not allocated to business segments Warranty claims settled Standard Product Warranty Accrual, Decrease for Payments FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivatives and Fair Value [Text Block] Costa Rica COSTA RICA Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Equity method investment, return of capital Proceeds from Equity Method Investment, Distribution Accounts receivable Increase (Decrease) in Accounts Receivable Property, plant and equipment purchases included in accounts payable Capital Expenditures Incurred but Not yet Paid Payment for employment taxes Payment For Employment Taxes Payment For Employment Taxes Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Financing costs incurred Financing Costs Deferred Financing costs deferred during the period. Weighted average interest rate Debt, Weighted Average Interest Rate Principal payments on finance leases Finance Lease, Principal Payments Pay Fixed Rate Derivative, Fixed Interest Rate Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Basic earnings per share (in dollars per share) Earnings Per Share, Basic Operating lease cost Operating Lease, Expense REVENUE FROM CONTRACTS WITH CUSTOMERS Revenue from Contract with Customer [Text Block] Sublease income Sublease Income Cash acquired from acquisition Cash Acquired from Acquisition Balance at beginning of period Balance at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 2022 Long-Term Debt, Maturity, Year One Raw materials Inventory, Raw Materials, Gross Geographic Concentration Risk Geographic Concentration Risk [Member] Inventory adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Gain Contingencies [Line Items] Gain Contingencies [Line Items] Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Schedule II - Valuation and Qualifying Accounts SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Cash provided by investing activities Cash Provided by (Used in) Investing Activities, Discontinued Operations Costs incurred from sale of accounts receivable Accounts Receivable Sale, Cost Of Sale Accounts Receivable Sale, Cost Of Sale Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Manufacturing machinery and equipment Machinery and Equipment [Member] Gross assets acquired Finance Leased Asset, Gross Assets Acquired Finance Leased Asset, Gross Assets Acquired Net deferred tax liability Deferred Tax Liabilities, Net Other non-cash (gains) losses Other Noncash Income (Expense) Fair Value Fair value Derivative Asset, Fair Value, Gross Asset Property, plant and equipment Deferred Tax Liabilities, Property, Plant and Equipment Gain (Loss) Recognized in OCI Gain (loss) recognized in OCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Customer C Customer C Customer C [Member] Customer C [Member] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Entity Voluntary Filers Entity Voluntary Filers Rest of world All Other Countries [Member] All Other Countries [Member] Total debt Long-term Debt Long-term Debt Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Total Pre-Tax Amount Accumulated Adjustment Attributable To Parent [Member] Accumulated Adjustment Attributable To Parent State taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Entity Small Business Entity Small Business Operating Leases Lessee, Operating Lease, Liability, Payment, Due [Abstract] U.S. tax on foreign earnings, net of §250 deduction Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Base Rate Base Rate [Member] Additions based upon tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Basis of Presentation and Principles of Consolidation Basis Of Accounting And Consolidation, Policy [Policy Text Block] Basis Of Accounting And Consolidation, Policy [Policy Text Block] Customer B Customer B Customer B [Member] Customer B [Member] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Unrecognized tax benefit Unrecognized Tax Benefits that Would Impact Effective Tax Rate Accounts payable Increase (Decrease) in Accounts Payable Amount recorded for current year acquisitions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Interest rate swaps Interest Rate Swap [Member] Restricted Stock And Units Type Of Vesting [Domain] Restricted Stock And Units Type Of Vesting [Domain] Schedule of Time based vesting versus Performance based vesting SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current After 2026 Long-Term Debt, Maturity, after Year Five 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four Manufacturing alignment to support growth Manufacturing Alignment To Support Growth [Member] Manufacturing Alignment To Support Growth [Member] Refundable income taxes Income Taxes Receivable, Current Schedule of Long-Lived Tangible Assets and Identifiable Assets by Geographic Area Reconciliation of Assets from Segment to Consolidated [Table Text Block] Fair value reduction adjustment for acquisition-related contingent consideration liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Balance Sheet Location [Domain] Balance Sheet Location [Domain] Schedule of Share-based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions Schedule of Share-based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block] Balance, beginning of year Balance, end of year Unrecognized Tax Benefits Foreign Exchange Contract Maturing September 2021, Contract Two Foreign Exchange Contract Maturing September Two Thousand Twenty One, Contract Two [Member] Foreign Exchange Contract Maturing September Two Thousand Twenty One, Contract Two Income Tax Authority [Domain] Income Tax Authority [Domain] Gross deferred tax assets Deferred Tax Assets, Gross Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Entity Address, State or Province Entity Address, State or Province Other income, net Disposal Group, Including Discontinued Operation, Operating Income (Loss) Restructuring reserve, beginning balance Restructuring reserve, ending balance Restructuring Reserve Loss contingency damages sought Loss Contingency, Damages Sought, Value Reclassification from AOCI, current period, net of tax, attributable to parent Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Non-marketable equity securities Non-marketable Equity Securities Non-marketable Equity Securities Deferred income taxes Noncurrent deferred tax asset Deferred Income Tax Assets, Net Current liabilities: Liabilities, Current [Abstract] Restructuring Plan [Domain] Restructuring Plan [Domain] Tax Accumulated Other Comprehensive Income, Tax [Member] Accumulated Other Comprehensive Income, Tax INVENTORIES Inventory Disclosure [Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Outstanding, weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Other noncurrent assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Present value of lease liabilities Operating Lease, Liability Federal Current Federal Tax Expense (Benefit) Document Transition Report Document Transition Report Income from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Common stock, $0.001 par value; 100,000,000 shares authorized; 33,063,336 and 32,908,178 shares issued and outstanding as of December 31, 2021 and 2020, respectively Common Stock, Value, Issued Weighted-average discount rate - finance leases Finance Lease, Weighted Average Discount Rate, Percent Other Operating Income Expense Detail [Line Items] Other Operating Income Expense Detail [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Customer Concentration Risk Customer Concentration Risk [Member] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Increase in contract assets Increase (Decrease) In Contract With Customer, Asset, Net Of Foreign Currency Increase (Decrease) In Contract With Customer, Asset, Net Of Foreign Currency Leases Lessee, Operating Leases [Text Block] Amortization of lease assets Finance Lease, Right-of-Use Asset, Amortization Supplier Financing Arrangements Supplier Financing Arrangements, Policy [Policy Text Block] Supplier Financing Arrangements, Policy Total, Financing costs incurred Financing And Unamortized Discount, Costs Incurred Financing And Unamortized Discount, Costs Incurred BUSINESS ACQUISITIONS Business Combination Disclosure [Text Block] Senior secured term loan A Term Loan A (TLA) Facility [Member] Term Loan A (TLA) Facility [Member] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] International Deferred Foreign Income Tax Expense (Benefit) Effect of dilutive securities stock options, restricted stock and restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Strategic Reorganization And Alignment Initiatives Two Thousand Twenty One Initiatives Strategic Reorganization And Alignment Initiatives Two Thousand Twenty One Initiatives [Member] Strategic Reorganization And Alignment Initiatives Two Thousand Twenty One Initiatives Goodwill [Line Items] Goodwill [Line Items] Income from continuing operations Business Acquisition, Pro Forma Net Income (Loss) Schedule of Income Tax Contingencies Summary of Income Tax Contingencies [Table Text Block] Income Tax Authority [Axis] Income Tax Authority [Axis] Schedule of Other Operating Cost and Expense, by Component Schedule of Other Operating Cost and Expense, by Component [Table Text Block] Thereafter Finance Lease, Liability, to be Paid, after Year Five Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current SG&A Selling, General and Administrative Expenses [Member] Accrued expenses and other current liabilities Total Accrued Liabilities, Current Sales Total sales Revenue from Contract with Customer, Excluding Assessed Tax Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Foreign Exchange Contract Maturing November 2021 Foreign Exchange Contract Maturing November Two Thousand Twenty One [Member] Foreign Exchange Contract Maturing November Two Thousand Twenty One Percent of revenue from contract with customer compared to total revenue Percent Of Revenue From Contract With Customer Compared To Total Revenue Percent Of Revenue From Contract With Customer Compared To Total Revenue Stock options Share-based Payment Arrangement, Option [Member] Consolidation Items [Domain] Consolidation Items [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Equity [Abstract] Equity [Abstract] Comprehensive Income Comprehensive Income, Policy [Policy Text Block] Federal tax credits (including R&D) Effective Income Tax Rate Reconciliation, Tax Credit, Percent Product Warranties Standard Product Warranty, Policy [Policy Text Block] Measurement Input Type [Domain] Measurement Input Type [Domain] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Variable Rate [Axis] Variable Rate [Axis] SEGMENT AND GEOGRAPHIC INFORMATION Segment Reporting Disclosure [Text Block] Weighted-average remaining lease term - finance leases (in years) Finance Lease, Weighted Average Remaining Lease Term Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Variable Rate [Domain] Variable Rate [Domain] Expected future benefit payments next five years Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Equity Investments Equity Method Investments [Policy Text Block] Acquisitions Standard Product Warranty Accrual, Additions from Business Acquisition Other Assets Other Assets [Member] Other (income) loss, net Other Nonoperating Income (Expense) Term Loan And Senior Notes Term Loan And Senior Notes [Member] Term Loan And Senior Notes [Member] Maximum Maximum [Member] Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Schedule of Accrued Liabilities and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Award Type [Axis] Award Type [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Treasury shares reissued Treasury Stock Reissued at Lower than Repurchase Price Schedule of Operating Lease Liability Maturities (Topic 842) Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of Revenue by Major Customers by Reporting Segments Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Total stockholders’ equity Total stockholders’ equity, beginning balance Total stockholders’ equity, ending balance Stockholders' Equity Attributable to Parent City Area Code City Area Code Description of payment terms Revenue, Performance Obligation, Description of Payment Terms Schedule of Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Ireland IRELAND Property, plant and equipment, useful life Property, Plant and Equipment, Useful Life Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Gain on sale of discontinued operations Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Operating lease liabilities Operating Lease, Liability, Noncurrent Gross lease liabilities Finance Lease, Liability, Payment, Due Total Current Income Tax Expense (Benefit) Net periodic pension cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Acquisition and integration costs (adjustments) Business Combination, Acquisition And Integration Related Costs Business Combination, Acquisition And Integration Related Costs Compensation expense tax benefit Share-based Payment Arrangement, Expense, Tax Benefit Operating Segments Operating Segments [Member] Puerto Rico PUERTO RICO Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] RSUs Restricted Stock Units (RSUs) [Member] Unused capacity commitment fee Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Schedule of Summary of Final Allocation of Purchase Consideration Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Charged to Other Accounts- Describe SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account Present value of lease liabilities Finance Lease, Liability Gross deferred tax liabilities Deferred Tax Liabilities, Gross Total equity investments Equity Method Investments Income Statement [Abstract] Income Statement [Abstract] Restricted Stock And Units Type Of Vesting [Table] Restricted Stock And Units Type Of Vesting [Table] Schedule of Time based vesting versus Performance based vesting Entity Registrant Name Entity Registrant Name Components of Deferred Tax Assets and Liabilities [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Current assets (excluding inventory) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables 2024 Finance Lease, Liability, to be Paid, Year Three 2025 Finance Lease, Liability, to be Paid, Year Four Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Discontinued Operations, Held-for-sale Discontinued Operations, Held-for-sale [Member] Rest of world Rest Of World [Member] Rest Of World [Member] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount London Interbank Offered Rate One - Month (LIBOR) London Interbank Offered Rate One - Month (LIBOR) [Member] London Interbank Offered Rate One - Month (LIBOR) Provision for income taxes Total provision for income taxes Income Tax Expense (Benefit) Accounts receivable, net of provision for credit losses of $0.1 million and $0.2 million as of December 31, 2021 and 2020, respectively Accounts Receivable, after Allowance for Credit Loss, Current Inventories Deferred Tax Assets, Inventory Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Income Before Tax Components by Geographic Region [Domain] Income Before Tax Components by Geographic Region [Domain] Identification of income before income taxes by geographic region. Entity Tax Identification Number Entity Tax Identification Number Investment Type [Axis] Investment Type [Axis] Performance Based Restricted Stock And Restricted Stock Units Restricted Stock And Restricted Stock Units Performance Based [Member] Disclosure relating to restricted stock and restricted stock units that are performance-based vesting Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Accounts Receivable Accounts Receivable [Member] Gross lease liabilities Lessee, Operating Lease, Liability, to be Paid Mexico MEXICO Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Stock-Based Compensation Share-based Payment Arrangement [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Schedule of Assets Useful Life [Table] Schedule of Assets Useful Life [Table] -- None. No documentation exists for this element. -- SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Accrued environmental loss contingencies, current Accrued Environmental Loss Contingencies, Current Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Current portion of long-term debt Current portion of long-term debt Long-term Debt, Current Maturities Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Restructuring Plan [Axis] Restructuring Plan [Axis] Segment Reporting, Asset Reconciling Item [Line Items] Segment Reporting, Asset Reconciling Item [Line Items] Weighted average fair value(in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Disposal Group Name [Domain] Disposal Group Name [Domain] Debt issuance costs Debt Issuance Costs, Gross Unamortized discount on TLB Facility, Amortization during the period Amortization of Debt Discount (Premium) Finite Lived Intangible Assets Amortization Expense [Table] Finite Lived Intangible Assets Amortization Expense [Table] Amortization expense by expense category Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Weighted Average Weighted Average [Member] Schedule of Depreciation Expense Depreciation Expense Disclosure [Table Text Block] Tabular disclosure of depreciation expense. Less: current portion of lease liabilities Finance Lease, Liability, Current Income from continuing operations before taxes Income (loss) from continuing operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Other Other Capitalized Property Plant and Equipment [Member] Receive Current Floating Rate Derivative, Variable Interest Rate Auditor Location Auditor Location Customer D Customer D [Member] Customer D [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Type of Restructuring [Domain] Type of Restructuring [Domain] Intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Finance lease cost Finance Lease, Interest Expense Use of Estimates Use of Estimates, Policy [Policy Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Finance Leases Finance Lease, Liability, Payment, Due [Abstract] Customer A Customer A Customer A [Member] Customer A [Member] Title of 12(b) Security Title of 12(b) Security Interest expense ratio Debt Instrument Covenant Adjusted EBITDA To Interest Expense Ratio Debt Instrument Covenant Adjusted EBITDA To Interest Expense Ratio Deferred income taxes Deferred Income Taxes and Tax Credits Common stock, shares authorized (in shares) Common Stock, Shares Authorized Vested and exercisable , weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Title of Individual [Axis] Title of Individual [Axis] Document Type Document Type Product and Service [Domain] Product and Service [Domain] Liabilities: Contingent consideration Fair Value Business Combination, Contingent Consideration, Liability Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving Credit Facility Revolving Credit Facility [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Valuation allowance for deferred tax assets SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] Notional Amount Derivative Liability, Notional Amount Schedule of Lease Term, Discount Rate, Lease Costs and Supplemental Cash Flow Information Lease, Cost [Table Text Block] Geographical [Axis] Geographical [Axis] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] U.S. State State and Local Jurisdiction [Member] Interest expense Interest Expense [Member] Other Other Accrued Liabilities Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] -- None. No documentation exists for this element. -- Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Other Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Equity method investment (income) loss Income (Loss) from Equity Method Investments Additions (reductions) related to prior period tax returns Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Charges incurred, net of reversals Restructuring Charges Concentration Risk Type [Axis] Concentration Risk Type [Axis] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Liabilities: Interest rate swaps Interest Rate Derivative Liabilities, at Fair Value 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Three Income from discontinued operations (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Acquisitions and Contingent Consideration Business Combinations Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Document Period End Date Document Period End Date Purchase of intangible asset Payments to acquire intangible asset Payments to Acquire Intangible Assets Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sale of accounts receivable Accounts Receivable, Sale Number of Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Time-vested stock options, restricted stock and restricted stock units Time-Vested Stock Options, Restricted Stock And Restricted Stock Units [Member] Time-Vested Stock Options, Restricted Stock And Restricted Stock Units State taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State Deferred State and Local Income Tax Expense (Benefit) Income Before Tax Components by Geographic Region [Table] Income Before Tax Components by Geographic Region [Table] Table presenting income before taxes by geographic region Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Debt instrument term Debt Instrument, Term Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Property, plant and equipment, net Total Long-lived tangible assets Property, Plant and Equipment, Net Total operating expenses Operating Expenses Land and land improvements Land and Land Improvements [Member] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Purchase of equity investments Sale Purchase Of Cost Equity Method Investments Net (proceeds from sale) purchase of cost and equity method investments, net Principal payments of term loans Repayments of Other Long-term Debt Income from discontinued operations (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Property, plant and equipment, gross Property, Plant and Equipment, Gross Foreign currency translation gain (loss) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Sales Revenue from Contract with Customer Benchmark [Member] Lake Region Medical Lake Region Medical [Member] Lake Region Medical [Member] Foreign Exchange Contract Foreign Exchange Contract [Member] Finished goods Inventory, Finished Goods, Gross Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease liabilities Deferred Tax Assets, Operating Lease Liabilities Deferred Tax Assets, Operating Lease Liabilities Patents Patents [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] Finance lease accumulated amortization Finance Lease, Right-of-Use Asset, Accumulated Amortization Entity Current Reporting Status Entity Current Reporting Status Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Amortization during the period Amortization of Debt Issuance Costs Vested and exercisable , aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Income Before Tax Components by Geographic Region [Axis] Income Before Tax Components by Geographic Region [Axis] Information by geographic region of income before income taxes. Business Combination, Separately Recognized Transactions [Line Items] Business Combination, Separately Recognized Transactions [Line Items] Contract assets Contract with Customer, Asset, after Allowance for Credit Loss, Current Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] U.S. United States UNITED STATES Discount rate Measurement Input, Discount Rate [Member] Schedules of Concentration of Risk by Reveune and Accounts Receivable Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Leases [Abstract] Leases [Abstract] Income Taxes Income Tax, Policy [Policy Text Block] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Other Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Capital investments expended Restructuring And Related Activities, Capital Expenditures Incurred To Date Total capital expenditures incurred to date in connection with restructuring and related activities Disposal Group Classification [Domain] Disposal Group Classification [Domain] Reclassification from AOCI, current period, before tax, attributable to parent Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Anticipated future costs remaining Anticipated Future Costs Remaining Anticipated Future Costs Remaining Entity Address, Postal Zip Code Entity Address, Postal Zip Code Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Three Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Three [Member] Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Three Diluted (in shares) Denominator for diluted EPS (in shares) Weighted Average Number of Shares Outstanding, Diluted INCOME TAXES Income Tax Disclosure [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Schedule of Share-based Compensation, Stock Options, Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Senior secured term loan B Term Loan B (TLB) Facility [Member] Term Loan B (TLB) Facility [Member] Spread on variable rate Debt Instrument, Basis Spread on Variable Rate Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Stock awards exercised or vested Stock Issued During Period, Value, Stock Options Exercised Or Vested Stock Issued During Period, Value, Stock Options Exercised Or Vested Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Operating lease liabilities Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Schedule of Operating Loss and Tax Credit Carryforwards Summary of Operating Loss and Tax Credit Carryforwards [Table Text Block] Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards and tax credit carryforwards, including an assessment of the likelihood of utilization. Vested and exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Class of Stock [Line Items] Class of Stock [Line Items] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Credit Facility [Axis] Credit Facility [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Measurement Input, Annual Attrition Rate Measurement Input, Annual Attrition Rate [Member] Measurement Input, Annual Attrition Rate Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Entity Shell Company Entity Shell Company Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Expected life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Tax withholdings related to net share settlements of restricted stock awards Payment, Tax Withholding, Share-based Payment Arrangement Contingent consideration fair value adjustment Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset Similar Identifiable Assets Relating To A License To Use Technology Similar Identifiable Assets Relating To A License To Use Technology [Member] Similar Identifiable Assets Relating To A License To Use Technology Restricted Stock And Restricted Stock Units Time Based Restricted Stock And Restricted Stock Units Time Based [Member] Disclosure relating to restricted stock and restricted stock units that are time-based vesting Fair value of net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Foreign exchange contracts Foreign Exchange Forward [Member] Net leverage ratio incremental increase option Debt Instrument Covenant Maximum Leverage Ratio Debt Instrument Covenant Maximum Leverage Ratio Employer matching contribution, percentage of employees' gross pay Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Current Fiscal Year End Date Current Fiscal Year End Date Unamortized discount on term loan B and deferred debt issuance costs Total, Beginning Balance Total, Ending Balance Unamortized debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Interest rate floor Debt Instrument, Interest Rate, Floor Debt Instrument, Interest Rate, Floor State tax credits State Tax Credit Carryforward [Member] State Tax Credit Carryforward Restricted Stock And Units Type Of Vesting [Axis] Restricted Stock And Units Type Of Vesting [Axis] Schedule of Time based vesting versus Performance based vesting Statement [Table] Statement [Table] Recently Accounting Pronouncements Adopted, Accounting Guidance Not Yet Elected or Adopted New Accounting Pronouncements, Policy [Policy Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Total unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Statistical Measurement [Axis] Statistical Measurement [Axis] Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) Derivative, Forward Exchange Rate Total long-term lease liabilities Finance Lease, Liability, Noncurrent Income from discontinued operations before taxes Income from discontinued operations before taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Vesting of RSUs, net of shares withheld to cover taxes (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures And RSU Vesting Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures And RSU Vesting Net Carrying Amount Finite-Lived Intangible Assets, Net Goodwill Goodwill acquired Beginning balance Ending balance Goodwill Product warranties Beginning balance Ending balance Standard Product Warranty Accrual Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Total, Write-off during the period Financing And Unamortized Discount Costs, Write-Off Financing And Unamortized Discount Costs, Write-Off Federal tax credits (including R&D) Effective Income Tax Rate Reconciliation, Tax Credit, Amount Proceeds from legal settlements Proceeds from Legal Settlements Schedule of Goodwill Schedule of Goodwill [Table Text Block] Information technology hardware and software Computer Equipment [Member] Defined Benefit Plan Liability Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Total Deferred Income Tax Expense (Benefit) Common stock and additional paid-in capital Common Stock Including Additional Paid in Capital [Member] Hedging Designation [Domain] Hedging Designation [Domain] Asset Acquisition [Axis] Asset Acquisition [Axis] Foreign Exchange Contract Maturing December 2021 Foreign Exchange Contract Maturing December Two Thousand Twenty One [Member] Foreign Exchange Contract Maturing December Two Thousand Twenty One Net foreign currency transaction gains (losses) Foreign Currency Transaction Gain (Loss), Realized Statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Work-in-process Inventory, Work in Process, Gross Earnings Per Share (EPS) Earnings Per Share, Policy [Policy Text Block] Trademarks and tradenames Trademarks and Trade Names [Member] US BioDesign LLC US BioDesign LLC [Member] US BioDesign LLC [Member] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Net income Net income Net income Net Income (Loss) Attributable to Parent Operating lease assets Operating Lease, Right-of-Use Asset Defined Benefit Plans Pension and Other Postretirement Plans, Policy [Policy Text Block] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Accounts Payable and Accrued Liabilities [Abstract] Accounts Payable and Accrued Liabilities [Abstract] Restructuring Expenses Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Non-cash (gain) loss on equity investments Non-Cash Cost And Equity Method Investments Realized Gain Loss Non-cash portion of cost and equity method investments realized gain loss Schedule of Sales by Geographic Area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Restricted Stock and Restricted Stock Units Restricted Stock and Restricted Stock Units [Member] -- None. No documentation exists for this element. -- Restricted Stock And Unit Awards Restricted Stock And Unit Awards [Member] The allocation of expense to restricted stock and restricted stock units. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Restructuring Type [Axis] Restructuring Type [Axis] Other long-term assets Other Assets, Noncurrent Segments [Axis] Business Segments [Axis] Segments [Axis] Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Discount percent Debt Instrument, Discount, Percentage Debt Instrument, Discount, Percentage Retirement Benefits [Abstract] Entity File Number Entity File Number Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Asset acquisition transaction costs capitalized Asset Acquisition, Transaction Costs Capitalized Asset Acquisition, Transaction Costs Capitalized DISCONTINUED OPERATIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Variable lease cost Variable Lease, Cost Non-Medical Non-Medical Segment [Member] Non-Medical Segment [Member] Impairment charges Equity Method Investment, Other than Temporary Impairment International International [Member] -- None. No documentation exists for this element. -- (Gain) loss on equity investments, net Cost And Equity Method Investments Realized Gain Loss This item represents the gain (loss) realized during the period from the sale of investments accounted for under the cost or equity method of accounting and any losses recognized thereon for impairments of other than a temporary nature. Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Fair value of shares vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Deferred payroll taxes Accrued Payroll Taxes Title of Individual [Domain] Title of Individual [Domain] Disposal Group Name [Axis] Disposal Group Name [Axis] Customer E Customer E [Member] Customer E Credit Facility [Domain] Credit Facility [Domain] ASSETS Assets [Abstract] 2024 Long-Term Debt, Maturity, Year Three Accumulated impairment loss Goodwill, Impaired, Accumulated Impairment Loss Assets acquired under finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Unallocated Amount to Segment Segment Reconciling Items [Member] Restructuring Costs Restructuring Costs Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Research, development and engineering Research and Development Expense (Excluding Acquired in Process Cost) Concentration risk percentage Concentration Risk, Percentage GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill and Intangible Assets Disclosure [Text Block] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Tradenames Trade Names [Member] Debt Instrument [Axis] Debt Instrument [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Unobservable Inputs Business Combination, Contingent Consideration, Liability, Measurement Input Secured Debt Secured Debt [Member] Schedule of Finite-Lived Intangible Assets, Amortization Expense Schedule of Finite-Lived Intangible Assets, Amortization Expense [Table Text Block] Schedule of amortization expense for finite-lived intangible assets Provision for income taxes Provision for income taxes Discontinued Operation, Tax Effect of Discontinued Operation Assets acquired under operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Operational Excellence Initiatives Operational Excellence Initiatives [Member] Operational Excellence Initiatives Schedule of Business Acquisition, Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Assets Useful Life [Line Items] Schedule of Assets Useful Life [Line Items] -- None. No documentation exists for this element. -- Operating expenses Operating Expense [Member] Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Contingent consideration liability, current Business Combination, Contingent Consideration, Liability, Current Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Defined benefit plan liability adjustment, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Employer matching contribution, per dollar Defined Contribution Plan, Employer Matching Contribution, Amount Matched Per Dollar Defined Contribution Plan, Employer Matching Contribution, Amount Matched Per Dollar After 2026 Finite-Lived Intangible Asset, Expected Amortization, after Year Five Provision for credit losses SEC Schedule, 12-09, Allowance, Credit Loss [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] 2026 Long-Term Debt, Maturity, Year Five Net costs recognized Defined Contribution Plan, Cost Time-Vested and Performance-Vested Restricted Stock Units and Awards Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Operational excellence initiatives Two Thousand Twenty Two Restructuring Plan [Member] Two Thousand Twenty Two Restructuring Plan Acquired finite lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Measurement Input, Royalty Rate Measurement Input, Royalty Rate [Member] Measurement Input, Royalty Rate Gain (loss) reclassification from accumulated OCI to income, estimated net amount to be transferred Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Cash paid for operating leases Operating Lease, Payments Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Asset acquisition contingent consideration liability paid Asset Acquisition, Contingent Consideration, Liability Paid Asset Acquisition, Contingent Consideration, Liability Paid Research, Development and Engineering (RD&E) Research and Development Expense, Policy [Policy Text Block] Total depreciation and amortization Depreciation And Amortization Including Inventory Step-Up Depreciation And Amortization Including Inventory Step-Up Consideration transferred Business Combination, Consideration Transferred Long-term debt, gross Long-term Debt, Gross Goodwill [Roll Forward] Goodwill [Roll Forward] Income from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Finance lease right-of-use asset Finance Lease, Right-of-Use Asset, after Accumulated Amortization Foreign Exchange Contract Maturing September 2021, Contract One Foreign Exchange Contract Maturing September Two Thousand Twenty One, Contract One [Member] Foreign Exchange Contract Maturing September Two Thousand Twenty One, Contract One Schedule of Deferred Financing Costs Schedule of Deferred Financing Costs [Table Text Block] Tabular disclosure of deferred financing costs Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Operational Excellence Initiatives Two Thousand Twenty One Initiatives Operational Excellence Initiatives Two Thousand Twenty One Initiatives [Member] Operational Excellence Initiatives Two Thousand Twenty One Initiatives Total liabilities and stockholders’ equity Liabilities and Equity Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Schedule Of Defined Contribution And Benefit Plan Disclosures [Table] Schedule Of Defined Contribution And Benefit Plan Disclosures [Table] -- None. No documentation exists for this element. -- Illiquidity discount percent Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Weighted Average Illiquidity Discount Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Weighted Average Illiquidity Discount Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Contract liabilities Contract with Customer, Liability, Current 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Finite Lived Intangible Assets Amortization Expense [Domain] Finite Lived Intangible Assets Amortization Expense [Domain] Amortization Expense by expense type Cash and cash equivalents Cash Equivalents, at Carrying Value Assets: Foreign currency hedging contracts Foreign Currency Contract, Asset, Fair Value Disclosure Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Reclassification from AOCI, current period, tax Reclassification from AOCI, Current Period, Tax EARNINGS PER SHARE Earnings Per Share [Text Block] Treasury shares purchased Treasury Stock, Value, Acquired, Cost Method Operating expenses: Operating Expenses [Abstract] Percentage of ownership interest Equity Method Investment, Ownership Percentage Performance-vested restricted stock units Performance-Vested Restricted Stock Units [Member] Performance-Vested Restricted Stock Units Standby Letters of Credit Standby Letters of Credit [Member] Minimum Minimum [Member] Non-cash (gains) charges related to customer bankruptcy Non-Cash Charges Related To Customer Bankruptcy Non-Cash Charges Related To Customer Bankruptcy Gross profit Gross Profit Chinese Venture Capital Fund Chinese Venture Capital Fund [Member] Chinese Venture Capital Fund [Member] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Outstanding amount Long-term Line of Credit Effect of foreign currency exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents RSUs and PRSUs RSUs and PRSUs [Member] RSUs and PRSUs Selling, general and administrative Selling, General and Administrative Expense Debt issuance costs, Beginning Balance Debt issuance costs, Ending Balance Debt Issuance Costs, Net Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Schedule Of Stock Option Exercise Information Schedule Of Stock Option Exercise Information [Table Text Block] Schedule reflecting information relating to the exercise of stock options during the period. Asset Acquisition, Contingent Consideration [Line Items] Asset Acquisition, Contingent Consideration [Line Items] Closing stock price (in dollars per share) Closing Stock Price Closing stock price of entity Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Medical Medical Segment [Member] Medical Segment [Member] Percentage of business acquired Business Acquisition, Percentage of Voting Interests Acquired 2025 Long-Term Debt, Maturity, Year Four SUPPLEMENTAL CASH FLOW INFORMATION Cash Flow, Supplemental Disclosures [Text Block] Acquisitions, net Payments to Acquire Businesses, Net of Cash Acquired Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] DEBT Debt Disclosure [Text Block] Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Line of Credit Line of Credit [Member] STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Number of reportable segments Number of Reportable Segments Outstanding standby letters of credit Letters of Credit Outstanding, Amount Schedule of Segment Sales by Product Line Revenue from External Customers by Products and Services [Table Text Block] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] New Revolving Credit Facility 2015 New Revolving Credit Facility 2015 [Member] New Revolving Credit Facility 2015 [Member] Treasury Stock, Common Treasury Stock, Common [Member] Cardio & Vascular Cardio And Vascular [Member] Cardio And Vascular [Member] OOE Other Operating Expenses, net [Member] The allocation (or location) of expense to (in) other operating expenses, net. Acquisition Goodwill, Acquired During Period Commitments and contingencies (Note 13) Commitments and Contingencies Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Increase in inventory valuation reserves Inventory Write-down Payment of debt issuance costs Payments of Debt Issuance Costs Disposal Group Classification [Axis] Disposal Group Classification [Axis] Auditor Name Auditor Name Cover page. Cover [Abstract] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Strategic reorganization and alignment Strategic Reorganization And Alignment [Member] Strategic Reorganization And Alignment [Member] Numerator for basic and diluted EPS: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Cash used in operating activities Cash Provided by (Used in) Operating Activities, Discontinued Operations Foreign currency translation Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Currency Translation Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Currency Translation Environmental Costs Environmental Cost, Expense Policy [Policy Text Block] Office And Manufacturing Facilities Office And Manufacturing Facilities [Member] Office And Manufacturing Facilities Less: imputed interest Finance Lease, Liability, Undiscounted Excess Amount Office Equipment Office Equipment [Member] Proceeds from revolving credit facility Proceeds from Secured Lines of Credit Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Cash payments Payments for Restructuring 2026 Finance Lease, Liability, to be Paid, Year Five Common Stock Common Stock [Member] Operating income Operating income as reported Operating Income (Loss) Stock-based compensation Effective Income Tax Rate Reconciliation, Deductible Expense In Excess Of Nondeductible Expense, Share-Based Compensation Cost, Percent Effective Income Tax Rate Reconciliation, Deductible Expense In Excess Of Nondeductible Expense, Share-Based Compensation Cost, Percent Operating lease liabilities Less: current portion of lease liabilities Operating Lease, Liability, Current 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two Hedging Designation [Axis] Hedging Designation [Axis] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Long-term Debt Long-term Debt [Member] Accumulated Other Comprehensive Income [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Depreciation expense Depreciation Technology Technology-Based Intangible Assets [Member] Finance lease cost Finance Lease, Cost Finance Lease, Cost Treasury stock Treasury Stock [Member] Schedule of Product Warranty Liability Schedule of Product Warranty Liability [Table Text Block] Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities InoMec Ltd InoMec Ltd [Member] InoMec Ltd [Member] Foreign Exchange Contract Maturing March 2021 Foreign Exchange Contract Maturing March Two Thousand Twenty One [Member] Foreign Exchange Contract Maturing March Two Thousand Twenty One Acquisition of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] International International Jurisdiction [Member] -- None. No documentation exists for this element. -- Finite Lived Intangible Assets Amortization Expense [Axis] Finite Lived Intangible Assets Amortization Expense [Axis] Amortization expense by expense category Total liabilities Liabilities Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] 2022 Finite-Lived Intangible Asset, Expected Amortization, Year One Outstanding, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested and exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Weighted Average Discount Rate Acquired Finite-lived Intangible Assets, Weighted Average Discount Rate Acquired Finite-lived Intangible Assets, Weighted Average Discount Rate Consolidation Items [Axis] Consolidation Items [Axis] Measurement Input Type [Axis] Measurement Input Type [Axis] Net operating loss Operating Loss Carryforwards Common stock, shares issued (in shares) Shares outstanding at beginning of year (in shares) Shares outstanding at end of year (in shares) Common Stock, Shares, Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair value of purchase consideration Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract] Entity Address, City or Town Entity Address, City or Town Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Net change in cash flow hedges, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Balance Sheet Location [Axis] Balance Sheet Location [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Oscor Inc Oscor Inc [Member] Oscor Inc Interest expense Interest Expense 2022 Finance Lease, Liability, to be Paid, Year One Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Discontinued operations: Discontinued Operations and Disposal Groups [Abstract] Fair value of net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Retained earnings Retained Earnings (Accumulated Deficit) Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Contractual life Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Equity Method Investments Equity Method Investments [Table Text Block] Unamortized discount on TLB Facility, Financing costs incurred Debt Instrument, Unamortized Discount, Financing Costs Incurred Debt Instrument, Unamortized Discount, Financing Costs Incurred Entity Filer Category Entity Filer Category Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Schedule of Rollforward of Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Indefinite-lived intangible assets (excluding goodwill) Indefinite-lived Intangible Assets (Excluding Goodwill) Proceeds from the exercise of stock options Cash received Proceeds from Stock Options Exercised 2023 Finance Lease, Liability, to be Paid, Year Two Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Amendment Flag Amendment Flag Proceeds from issuance of term loans Proceeds from Issuance of Long-term Debt Adjustments to pre-existing warranties Standard Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties Equity Components [Axis] Equity Components [Axis] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Denominator for basic EPS: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Foreign Exchange Contract Maturing August 2021 Foreign Exchange Contract Maturing August Two Thousand Twenty One [Member] Foreign Exchange Contract Maturing August Two Thousand Twenty One Other Operating Expense Net [Domain] Other Operating Expense Net [Domain] Other Operating expense net domain Inventories Total Inventory, Net Stock options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Federal Deferred Federal Income Tax Expense (Benefit) Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Contingent consideration liability, noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Product and Service [Axis] Product and Service [Axis] Non-marketable securities fair value Equity Securities without Readily Determinable Fair Value, Amount OTHER OPERATING EXPENSES Other Income and Other Expense Disclosure [Text Block] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Entity Public Float Entity Public Float Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Advanced Surgical, Orthopedics & Portable Medical Advanced Surgical, Orthopedics, and Portable Medical [Member] Advanced Surgical, Orthopedics, and Portable Medical [Member] Short-term lease cost (leases with initial term of 12 months or less) Short-term Lease, Cost Lease ROU asset, adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Operating Lease Assets, Right Of Use Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Operating Lease Assets, Right Of Use Assets Statement [Line Items] Statement [Line Items] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Unamortized discount on TLB Facility, Write-off during the period Debt Instrument, Unamortized Discount, Write-Off During The Period Debt Instrument, Unamortized Discount, Write-Off During The Period Stock-based compensation Effective Income Tax Rate Reconciliation, Deductible Expense In Excess Of Nondeductible Expense, Share-Based Compensation Cost, Amount Effective Income Tax Rate Reconciliation, Deductible Expense In Excess Of Nondeductible Expense, Share-Based Compensation Cost, Amount Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] U.S. Federal Domestic Tax Authority [Member] Revenue-based payments Remaining Maximum Payout (undiscounted) Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Debt Disclosure [Abstract] Debt Disclosure [Abstract] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Trade Accounts Receivable and Provision for Current Expected Credit Losses Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Less valuation allowance Deferred Tax Assets, Valuation Allowance Swingline Loans Swingline Loans [Member] Swingline Loans [Member] Aggregated projected benefit obligation Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Customer [Axis] Major Customers [Axis] Customer [Axis] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] BENEFIT PLANS Retirement Benefits [Text Block] Grants in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Document Annual Report Document Annual Report Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Statement, Operating Expenses [Axis] Statement, Operating Expenses [Axis] Expenses reported in a statement Current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Total assets Total assets Assets Gain on litigation settlement Gain (Loss) Related to Litigation Settlement Director Director [Member] Salaries and benefits Accrued Bonuses Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical [Domain] Geographical [Domain] Expected costs Restructuring and Related Cost, Expected Cost Comprehensive Income Net Income (Loss) Attributable to Parent [Abstract] SEC Schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense, customer bankruptcy SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Cost And Expense, Customer Bankruptcy SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Cost And Expense, Customer Bankruptcy Discontinued operation, gain (loss) on disposal of discontinued operation, net of tax Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Derivative Contract [Domain] Derivative Contract [Domain] Proceeds from sale of discontinued operations, gross Proceeds From Divestiture Of Businesses, Gross Proceeds From Divestiture Of Businesses, Gross SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Tax Credit Tax Credit Carryforward, Amount Schedule of Debt Schedule of Debt [Table Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Furniture and fixtures Furniture and Fixtures [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Expenditures for Tangible Long-Lived Assets, Excluding Acquisitions Schedule Of Expenditures For Tangible Longlived Assets By Segment [Table Text Block] -- None. No documentation exists for this element. -- Basic earnings per share: Earnings Per Share, Basic [Abstract] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Basic (in shares) Weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted earnings per share (in dollars per share) Earnings Per Share, Diluted U.S. tax on foreign earnings, net of §250 deduction Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Segments [Domain] Segments [Domain] Payments of revolving credit facility Repayments of Long-term Lines of Credit Debt related charges included in interest expense Total, Amortization during the period Amortization of Debt Issuance Costs and Discounts Sales Sales [Member] Income taxes Income Taxes Paid, Net Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible Enumeration] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Employee Severance Employee Severance [Member] Contract liabilities Contract with Customer, Liability Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Debt Issuance Costs and Discounts Debt, Policy [Policy Text Block] Deferred income taxes Noncurrent deferred tax liability Deferred Income Tax Liabilities, Net Operating lease assets Deferred Tax Liabilities, Operating Lease Right-Of-Use Assets Deferred Tax Liabilities, Operating Lease Right-Of-Use Assets Loans Payable Loans Payable [Member] Other long-term liabilities Other Noncurrent Liabilities [Member] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Income from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Auditor Information [Abstract] Auditor Information [Abstract] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Accounts payable Accounts Payable, Current Depreciation and amortization Depreciation, Depletion and Amortization Revenue, Major Customer [Line Items] Revenue, Major Customer [Line Items] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule Of Long Lived Assets [Table] Schedule Of Long Lived Assets [Table] Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas. Accumulated other comprehensive income Net-of-Tax Amount AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Defined Contribution And Benefit Plan Disclosure [Line Items] Defined Contribution And Benefit Plan Disclosure [Line Items] -- None. No documentation exists for this element. -- Common stock, shares outstanding (in shares) Shares outstanding at beginning of year (in shares) Shares outstanding at beginning of year (in shares) Common Stock, Shares, Outstanding Other operating expenses Total other operating expenses Other Operating Income (Expense), Net Cost of sales Expenses related to license agreements Cost of Goods and Services Sold Proceeds from sale of discontinued operations Proceeds from Divestiture of Businesses Entity Central Index Key Entity Central Index Key Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total lease cost Lease, Cost Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Number of facilities in which lease terms were extended Number Of Facilities, Lease Terms Extended Number Of Facilities, Lease Terms Extended Accrued expenses Deferred Tax Assets, Tax Deferred Expense PROPERTY, PLANT AND EQUIPMENT, NET Property, Plant and Equipment Disclosure [Text Block] Foreign tax credits Foreign Tax Credit Carryforward [Member] Foreign Tax Credit Carryforward [Member] Other long-term liabilities Other Liabilities, Noncurrent Drawn down from the escrow Escrow Drawn Down Escrow Drawn Down Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Debt Instrument [Line Items] Debt Instrument [Line Items] Trading Symbol Trading Symbol Sales Business Acquisition, Pro Forma Revenue ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Other Deferred Tax Liabilities, Other Gain on sale of discontinued operations Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Uncertain tax positions Effective Income Tax Rate Reconciliation, Tax Contingency, Percent Purchased technology, tradenames and patents Purchased Technology, Tradenames And Patents [Member] Acquired in a business combination or other transaction, Purchased technology, tradenames and patents. Long-term debt Long-term Debt, Excluding Current Maturities Schedule of Goodwill [Table] Schedule of Goodwill [Table] Total stock-based compensation expense Share-based Payment Arrangement, Expense Fair value of contingent consideration Business Combination, Consideration Transferred, Liabilities Incurred R&D tax credits Research Tax Credit Carryforward [Member] Top Customers Top Customers [Member] Top Customers Investments [Domain] Investments [Domain] Schedule of Income before Income Tax, Domestic and Foreign Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Construction work in process Construction in Progress [Member] Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents All other customers All Other Customers [Member] All Other Customers [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Current assets: Assets, Current [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Expected future benefit payments first five years Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months Through Year Five Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months Through Year Five Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Income from discontinued operations Income from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Other comprehensive income (loss), net Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Fair Value, Recurring Fair Value, Recurring [Member] Performance period (over) Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Accrued interest Interest Payable, Current Total (gain) loss on equity investments, net Debt and Equity Securities, Realized Gain (Loss) STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Outstanding receivables previously reserved, written off Accounts Receivable, Allowance for Credit Loss, Writeoff Schedule of Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Cash Flow Hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Two Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Two [Member] Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Two Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Five Auditor Firm ID Auditor Firm ID Royalty Royalty [Member] Revenue volatility Measurement Input, Revenue Volatility [Member] Measurement Input, Revenue Volatility Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Segment Income (Loss) from Operations Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Buildings and building improvements Building and Building Improvements [Member] Changes in operating assets and liabilities, net of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Notional Amount Notional amount Derivative Asset, Notional Amount Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Debt instrument increase Debt Instrument, Increase (Decrease), Net Cash paid Payments to Acquire Businesses, Gross Intangible assets Deferred Tax Liabilities, Goodwill and Intangible Assets Interest on lease liabilities Finance Lease, Interest Payment on Liability Credit facility maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Schedule of Segment Depreciation and Amortization Reconciliation Of Depreciation And Amortization By Reportable Segment To Consolidated [Table Text Block] -- None. No documentation exists for this element. -- Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Business Combination, Separately Recognized Transactions [Table] Business Combination, Separately Recognized Transactions [Table] AS&O Product Line AS&O Business [Member] AS&O Business [Member] Technology Technology [Member] Technology [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Fed Funds Effective Rate Overnight Index Swap Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Customer lists Customer lists Customer Lists [Member] Asset Acquisition, Contingent Consideration [Table] Asset Acquisition, Contingent Consideration [Table] Prepaid Expenses and Other Current Assets Prepaid Expenses and Other Current Assets [Member] Costs incurred since inception Restructuring and Related Cost, Cost Incurred to Date Fair Value Derivative Liability, Fair Value, Gross Liability Original issue discount Debt Instrument, Unamortized Discount (Premium), Net Statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Deferred Finance Costs [Roll Forward] Deferred Finance Costs [Roll Forward] A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Gain (Loss) Reclassified from AOCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Interest Rate Swap Maturing June 2023 Interest Rate Swap Maturing June Two Thousand Twenty Three [Member] Interest Rate Swap Maturing June Two Thousand Twenty Three Balance at beginning of period Balance at end of period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Cost of sales Cost of Sales [Member] License License [Member] Income from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income taxes payable Accrued Income Taxes, Current Write-off of debt issuance costs and unamortized discount Write off of debt issuance cost Write off of Deferred Debt Issuance Cost Inventories Inventory, Policy [Policy Text Block] International Current Foreign Tax Expense (Benefit) Non-cash lease expense Operating Lease, Right-Of-Use Asset, Amortization Operating Lease, Right-Of-Use Asset, Amortization Self insurance reserve Self Insurance Reserve Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Gain Contingencies [Table] Gain Contingencies [Table] Schedule of Changes in Number of Shares of Common Stock Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Unamortized discount on TLB Facility, Beginning Balance Unamortized discount on TLB Facility, Ending Balance Debt Instrument, Unamortized Discount Uncertain tax positions Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Other general expenses Other Expenses ITGRTerm Loan A T L A Facility ITGRTerm Loan A T L A Facility [Member] ITGRTerm Loan A T L A Facility Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Expenditures for tangible long-lived assets, excluding acquisitions Expenditures For Additions To Long-Lived Assets, Excluding Those Acquired Through Acquisition Expenditures For Additions To Long-Lived Assets, Excluding Those Acquired Through Acquisition Accounting Standards Update 2016-02 [Member] EX-101.PRE 11 gb-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 gb-20211231_g1.jpg begin 644 gb-20211231_g1.jpg M_]C_X 02D9)1@ ! 0$ > !X #_X1#V17AI9@ 34T *@ @ !P,! 4 M ! (;@,# $ ! %$0 $ ! 0 %$1 0 ! N(U$2 M 0 ! N(X=I 0 ! (=NH< < @, 8@ G)E4WI.5&-Z:V,Y9"<_/@T*/'@Z M>&UP;65T82!X;6QN&UL M;G,Z&UP;65T83X-"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $, @$! @$! @(" M @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P' M"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_ !$( D\': ,! M(@ "$0$#$0'_Q ? !!0$! 0$! 0 0(#! 4&!P@)"@O_Q "U M$ " 0,# @0#!04$! 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'! M%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.T MM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_ MQ ? 0 # 0$! 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$ M!P4$! ! G< 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K" MP\3%QL?(RKR\_3U]O?X^?K_V@ , P$ A$# M$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1W$:EF(55&23VH 6LWQ; MXQTGP%H%QJNM:C9Z5IMJNZ6YNI1%&@^I[GL.IKYL_:?_ ."I?@_X.BXTOPGY M/C'Q"F5W0R?\2^U;_;E'^L(_NQY'4%E-?GU\Y-?IG"_ACF.9VKXK]S2[M>\_2/ZNW=)GX-Q_X^9'D M/-A:^_/V8?\ @K%X:^)!M])\>0P^%=:?"+?(2=-N6]23EH23V8E1W<=* MUXH\+^O5=?6/S2.;@#Z062YWRX3-K87$/35_NY/RD_A;[2M MV4I,^O**CL[R'4+2.XMY8YX)E#QR1L&1U/(((X(/J*DK\NVT9_0*DFKH**** M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%\<>*&0\+4_^%"KS5;75..LWVNMHKSDTNUWH?9'[2G[ M;?@7]F.TDAU?4/[0UW;F+2+(B2Z;(R"_.(U/JY&1T#=*_.W]IS_@H%XZ_:4> MXL9+K_A'_#,A(72K!RJRKZ32<-+[@X3OM!KP^[O)M0NI)[B62::9B\DDC%F= MCR22>23ZFHZ_H?A?P[RS*+5I+VM5?:DMG_=CLO75^9_$W'_C=GW$O-AJ2_ORTH4445]^?C04444 >P?LV?MN^.OV9+N.'2=0_M M'0MV9-(OB9+4YZE.H;I7Z)?LQ_M_^!?VE8X+*&Z_X1_Q+)@'2;^0 M!Y6_Z8R<+*.O P_&2H%?D;2H[1L&4E64Y!':OA>)O#_+,XO5:]G5_GBM_P#$ MMI?@_,_7. ?&?/\ AAQH1E[;#K_EW-O1?W):N'IK'^ZV?O'17Y@_LP_\%3?& M'P>^SZ7XL$WC'P_'A \LF-0M5_V93_K .?EDY/ #J*_07X'_ +1_@[]HG0/M M_A76+>^,:@SVK?N[JUSVDC/S#GC/*GL37\[\2<$YGDLN;$0YJ?2<=8_/K%^3 M^39_;7 OBMD'%,%#!5.2M;6E.RGYVZ27G%O3=+8[FBBBOD3]*"BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^;OVGO^"F/@GX#"XTS1Y( M_%WB:/*&VLY1]EM7Z?O9AD9!SE$W-D8.WK7I97D^,S*LL/@J;G+RZ>;>R7FV MCP^(.)LKR/"O&YK6C2@NK>K?:*6LGY)-GT+KWB"Q\+:/<:AJ=Y:Z?86B;Y[F MYE6**%?5F8@ ?6OB_P#:>_X*Z:?H/VC2?AG:IJEV,H^LWD96VC/K%&<-(?\ M:;"\=&%?'_[0/[5WC?\ :6U?S_$VK2/9QOOM]-MLQ65MUQMCSRW)^9BS8.,X MXKS>OWKA?PEPV&M7S=^TG_(O@7KUE^"\F?QWQ_\ 20Q^.YL'PW%T*>WM';VC M_P *U4%]\NJ<7H;GQ!^).O?%?Q--K'B35K[6-2GX:>YD+$#J%4=%49X50 .P M%8=%%?L%.G"G!4Z:22T26B2\D?S+B,15KU)5JTG*4G=MMMM]VWJV%%%%:&(4 M444 %%%% !1110 5I>$?&6K> ?$%OJNB:E>:3J5JVZ*YM96BD3\1V/<=".#6 M;14SA&<7":NGNGLS2E5G2FJE-N,D[IIV::ZI]&?>7[,'_!7G M]'^*%KG^!= M=L8?UG@4?7YHQZ#9U-?;_@_QGI/Q \/6^K:'J5GJVFW:[HKFUE$D;_B.XZ$' MD'@U^%U=Q\$/VB_&'[._B#^T/"NLW&G^8P,]JQ\RUNP.TD1^5O3/##)P17Y' MQ1X3X/%WKY4U2G_+]A^G6/RNO)'])\ ?2-S/+>7!\0IXBEMSK^+%>=[*?SM+ MJY/8_:RBOE?]F'_@J=X1^,!M]*\6K#X/\028022R?\2^Y;_9D/\ JR?[LG'8 M,37U-'(LT:LK*RL,@@Y!%?@6;Y)CLLK>PQU-PETOL_-/9KT/['X;XLRG/\+] M+[2B]8OR:7EH.HHHKRCZ(**** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN M?^)?Q6\._!WPS+K'B;6++1]/B_Y:3O@R'^ZB_>=O]E03[5I1HU*LU3I12C"*NVVDDN[;T2]3H*\Q_:)_:]\#_LR:69/$6J*^I2 M)OM]*M,2WMQZ'9D;%//S.57@X)/%?'?[3_\ P5PUCQ8+G1_AO;2:%I[91M7N M5#7LPZ9C3E8@?4[FP01L-?&NKZQ=Z_J=Q?7]U<7UY=.9)KBXD,DLSGJS,Q)) M/J:_8^%_"3$8BV(S=^SC_(OB?J]H_B_1G\P\?_22P6#YL'PU%5JFWM)7]FO\ M*TRZ^;>[?F[L_C[/N(\SSO%/&YK6E5J/J MWLNR6T5Y))>04445Z!X@4444 %%%% !114EM;27MS'##')--,P1$12S.Q. M!R23VH!)MV1'15C5-*NM#U&:SO;:XL[NWAJO2C)-71 M4HN+<9*S04444R0HHHH **** "O'45PYAEN%Q]%X?&4U.#Z-?BNJ?FM3ULES[,)?AM]GTGQY%/XKT5<(MZI U*V7U).!, .S$-_M]J_">*/".M2OB,F?/'^1 MOWE_A>S]'9^;9_7G 'TE,-B.7!\41]G/;VL4^1_XXZN/K&Z\HH_2JBN3^#_Q MS\*_'GPRNK>%=9M=6M1@2JAVS6S'^&2,X9#]1SU&1S765^,U\/5H5'2K1<9+ M1IJS7JF?U+@\90Q=&.)PLU.$E=2BTTUW36C"BBBL3I"BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J'4M3M]& MT^:[O+B&UM;9#)--,XCCB0#)9F/ '7E8_]WE_]G'-?G=^T=^V9XY_:RI/[4EJU_=CN_5V7FS\6X_\<?6;UD_GT7DK(_BCC;Q,S[BFK?,:MJ=[JG&Z@ MOE?WGYR;?9I:!1117U!^?A1110 4444 %%%% !17;?!+]G?QA^T-XA_L[PIH MUQJ#1D">X(\NUM >\DI^5>Y SN.#@&OT$_9?_P""5_A+X1?9=6\8-#XP\01X M<1.G_$NM6_V8SS*1_>DX/!V*:^1XDXURS)8VQ$^:ITA'67S[+S?RN?I/ OA5 MG_%,U+!4^2C?6K.Z@N]NLGY13UW:W/C/]F7]@;QU^TO+#>6MK_8?AQSEM6OX MRLL>7?M%?L?>!_VF]- M9?$&F+'JBIL@U6TQ%>0>GS8PZC^ZX(],'FOSP_:?_P""63'.67MHI(_!NBOU0_:@_X)E^"?CL+ MC4]#2/PAXEDRYGM(A]DNVZ_O81@ D_QI@\DG=TK\]?V@/V5?&W[-6M?9O$VD MR1VDCE;?4;?,MG=?[LF.#WVL%;VK^B.&N.LLSE*%&7)5_DEH_ETDO37ND?Q+ MQYX1Y_PM)U<33]I0Z587%%%% !1110 4444 M ;7P_P#B/KWPK\30:QX=U:]T?4[<_)/;2%&([JPZ,I[JP(/<&ONO]F#_ (*Z MV.L+;:/\3;5=.NL"-=;LXB;>4],S1#F,^K)E\+UO:976]QN\J'_$6G M^+-&M]1TN]M=1L+I=\-Q;2K+%*OJK*2#5ROQA_9__:J\;?LU:U]I\,ZM)':2 M.&N-.N,RV=U_O1YX/;OT*_9?_X*:>"?CL+?3-<>/PAXEDP@@NY1]DNV MZ?NIC@ D_P #X/( W=:_GOBCPTS+*[UL/^^I=TO>2_O1_5775V/[5X \>,BX MAY<+C']6Q#TY9/W)/^Y/1:](RL^BYMSZ4HHHK\W/W(**** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BL?QU\0-$^&7AN?6/$&J66CZ M9;CY[BZE$:YY(49^\QP<*,D]@:^&?VG_ /@KM\,)X7V:3)Y^ZIYKZ+A_A7,LYJ,]=N=4U>^N]2U&\?S)[FYE,LLK>I8\FJ-?T+POX9Y;E=JV)_ M?5>[7NI_W8_J[OJK'\5^('CUGG$'-A<"WAL.].6+]^2_O3T>O\L;+H^;<"=Q MR:***_23\*"BBB@ HHHH **** "BE16D8*H+,QP !UKZC_9?_P""6_C#XR_9 M]4\5>=X/\.R$.%FB_P")A=+U^2(_ZL'^])C'!"L*\O-LZP664?K&.J*$?/=^ M26[?HCZ#AOA7-<_Q2P>4T)5)];;17>4GI%>;:/FWPGX0U3QYX@M])T73[S5- M2O&V0VUK$9))#[ =AW/0#FOMS]E__@D.TIM]8^*%UL7AUT.QFY/M/,O3W6,Y M_P!L=*^O/@7^S9X-_9R\/_8/"NCPV;2(%N+Q_P!Y=WA'>24\GGG:,*,\ 5W5 M?@?%'BQB\7>AE2=*'\S^-^G2/RN_-']C^'_T<SG M\[1Z.+W,OP9X(T?X=^';?2-"TVSTG3;5=L5M:Q".-?4X'4GJ2>2>22:U***_ M(:E24Y.N(93DQ]\*^5R?O**^$_B!\.=> M^%7B:?1_$6DWNCZG;GYX+F,HQ'9E/1E/9E)![$U^Y5L;K^[U/Q'HKZZ_:@_X)/^)?AM]HU; MP'+/XKT5, MEHUZ.ZZI,CHHHKV#YD**** "BBB@ HHHH ^A/V8/^"CGCC]G<6VFW4Q\4>&( M<(-/O93YEL@[030>ORYPZC^\A(]<'BOQLJQI6K76A:E#>6-U<6=Y:N)(9X)#')$PZ,K#!!' MJ*_/.*/#?+.>>\. M+PLPZ<_*_4DN>*^]/AC\6O#?QF\+Q:SX7UBSUC3Y./,@?YHV_NNAPR-_LL ? M:OYXXBX1S/)IVQ<6 MUYWT.BHHHKYD^^"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO%/VFOV\O O M[,L,UI>7G]M>(U'R:18.&F0XX\UONQ#I][YL'(4UW9?EN*QU98?"0B/*SK/,ORG"RQN95HTJ<=W)V^2ZMOHE=OHCVBXN([2"265TCBC4N[N=J MH!R23V KY._:@_X*L^%OA;]ITGP1'#XMUZ/*&ZW'^S;5O]\8,Q'HA"_[>1BO MC;]IC]NOQU^TU<2V^H7O]D>'V;,>D6#%(".WFM]Z5O\ >^7/(5:\8K]TX7\( MZ5.V(SF7,_Y(O1?XGN_167FT?R)Q_P#24Q%?FP?"\?9QV]K)>\_\$7I'UE=^ M46=A\9OCYXM^/_B0ZIXKUJZU292?)B8[;>U!_ABC'RH.!G R<9))YKCZ**_: M,/AZ5"FJ-"*C%:))62]$C^6<9CL1C*\L3BYN=23NY2;;;[MO5A1116QRA111 M0 4444 %%%=5\(_@EXJ^.WB9=)\*Z+>:M=\&0QKB*W4_Q22'"HONQ&>@R>*Q MKXBG1INK6DHQ6K;=DO5LZ,)@Z^*K1P^&@YSD[*,4VV^R2U9RM>O?LV?L2^.O MVG+R.71]/-AH6_;+K%Z#':K@\A.\K#IA <'J5ZU]C_LO_P#!)OPW\/!;ZM\0 M)8?%.L+AUT],C3;=NOS X:8_[P"WA4)'%&@5(U M' X 'H*_&>*/%RC1OA\F7/+^=_"O\ "MWZNR\FC^I/#_Z-F*Q/+C.)Y>SA MNJ46N=_XI:J*[I7EYQ9X=^S%_P $_/ O[-:P7T=M_P )!XFC )U6^C#-"WK# M'RL7U&7_ -K'%>ZT45^$YCFF+Q]9XC&5'.;ZM_@NB7DM#^O,E=>J[-=&K-=&?D9^TY^P%XZ_ M9H>:^N+7^WO#49)75K!"R1KGCSH^6B/3DY3)P&)KPZOWBDC6:-E9596&"",@ MBOEG]I__ ()9>$?C ;C5/")A\'^(),L8XH_^)?=-_M1#_5D_WH^.Y4FOW/A? MQ=A.V'SJ/*_YXK3_ +>BMO577DC^1^/_ *-=6ES8SA:?-'?V4W[R_P $WH_) M2L_[S9^8=%=Q\N.&&1D M"N'K]JPV*HXBDJU"2E%[-.Z?S1_*N.P&)P5>6%QE.5.I%V<9)II^:>H4445N M<@4444 %%%% !72?"_XN^)?@OXFCUCPOK%[HVH)P7@?Y95_NNARKK_LL"/:N M;HK.M1IU8.G5BI1>C35T_5,WPN*K8:K&OAYN$XNZE%M-/NFM4_0_1K]F#_@K M7H?C4V^D?$2WA\.ZDV$75( 383GUD'+0DGO\R]R5%?8>F:I:ZWIT-Y9W$%Y: M7*"2&:&021RJ>C*PX(/J*_"*O5/V<_VQ_'/[,>H+_P (_J7G:2[[I])O,RV< MV>I"Y!1C_>0J3@9R.*_&^*/".A7OB,G?LY?R/X7Z/>/IJO1']0< ?22QF$Y< M'Q-%UJ>WM8IRD*Y_ND[?J?QMQ-Q;FW$&*^N9M7=272_P ,5VC%:17HM=W=A111 M7K'S@4444 %%%% !1110 5;T+0;[Q/J]OI^FV=UJ%]=N(X+:VB:669O154$D M^PKZ%_9A_P"":/C;X]_9]2U9'\(^&Y,.+F\A/VFZ7_IE"<'!_O,57G(W=*_0 MS]GS]E#P3^S/H_V?PSI*+>R)LN-3N<2WMR..&DP,+P/E4*O&<9YK\YXH\2LM MRJ]&@_;5>T7HG_>EM\E=]['[AP!X$Y[Q#RXK%KZMAGKS27O27]R&CUZ2E9=5 MS;'Q[^R__P $C-2\0?9]8^)=T^E6; .NC6D@-U*.N)9!E8Q_LKEN>J$5]W?# MSX9^'_A-X:AT?PWI-EH^FP_=AMH]H8]V8]68]V8DGUK>(.+,RSFIS8R M?N](K2*^75^;N_,_M;@OPYR+A>CR991]]JTJDM9R]9=%_=BE'RN%%%%?-GW0 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F>,/!FD_$#P] M<:3KFFV>K:;=KMEMKJ(21O\ @>XZ@CD'D5\0?M/_ /!(; N-8^%]UG^-M"OI MOT@G8_3Y9#Z_/T%?>5%?09#Q1F.3U?:8*I9=8O6+]5^JL^S/B^,/#_(^)Z'L MFWFDZE:MMEMKJ%HI$_ ] MCV/0CD5FU^UGQP_9R\'_ +1/A_\ L_Q5H\%]Y:D6]TO[NZM">\<@Y7UQRIQR M#7Y]?M/_ /!+/QA\'C<:IX2\[QAX?C^;%9=?%8=:WBO?BO[T%> MZ7\T;KJU$^6**5U:-BK JRG!!'2DK],/P4**** "BBB@ HHHH =IR*^F/V8 M/^"G/C3X&_9]+UYI/&'AN/Y!#=2XO+5?^FBO,S7)\%F M5'ZOCJ:G'SW7FGNGYIGO<.\49ID6*6,RFM*E/RV:[23TDO)IH_:+X!_M2>"O MVE-%-UX7U:.>XB4-<6$X\J\M,_WX\].VY25)Z$UZ%7X4>'?$FH>$-:M]2TF^ MO--U"T??!/5N.Q^@5%8_@3XA:'\3_ Y#J_A[5+'6--N!\D]K*'7/ MH>ZL.ZG!'<5L5^05*RC_ '=G:=?]7$. <'&XY8CJ37QI M_P %I/'.L?#W_@KY\8M0T74+K3;R/4;4>9"^-P^P6W##HP]B"*J_ [_@H/8Z MVT.G^-($TVZ8A5U&W4FW<]/G3DI]1E?]T5_2'A_A\EP5"G4=.U:23YY:[J]D M_LK^FV?Q;XUT>+LUQ%6-&LZF%A)KV4%RVL[7DKMU'I?=V>T4?3%%5]+U2VUO M3X;NSN(;JUN%#Q30N'CD7U!'!%6*_8$TU='\IRBXMQDK-!11102%%%% !111 M0 45T'PU^%GB+XP>)X=&\,Z1>ZQJ,W2*W3(0=-SM]U%'=F( ]:^\?V8/^"1^ MD^%Q;ZO\2;B/7+\8==(M7*V<)_Z:/PTI'H-J\8.\5\SQ#Q=EN30YL9/WND5K M)_+HO-V7F?><%>&V>\4UN7+*7[M.TJDM(1^?5^44WY6/CS]GG]D3QQ^TSJ>S MPWI3+IL;[)]4N\PV5N>X+X.YAQ\J!FY'&.:_0[]F'_@FWX'_ &??L^I7\2^* M_$T6&^VWL0\FV;_IC#RJXQPS;F!Z$=*]_P!'T:S\/:7!8Z?:VUC96J".&WMX MEBBA4=%55 'L!5FOYYXH\2,RS6]&B_94OY8O5K^]+=^BLN]S^UN / O(N'> M7%8E?6<2M>>:]V+_ +D-4O)N\NJ:V"BBBOSL_;@HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \-_:<_8 \"_M M*QSWLUK_ ,(_XEDR1JUA& \K?]-H^%E'3DX?C 8"OSM_:3_8A\=?LR74DVK6 M']HZ%NQ%J]B#);'/0/QNC;V< $]"W6OV$J.\LX=0M)+>XBCG@F4I)'(H9'4\ M$$'@@^AK[_A?Q$S/*+49/VM+^63V7]U[KTU7D?C?'_@CD/$O-B81^KXE_P#+ MR"5I/^_'12]5:7]ZVA^#]%?I1^U!_P $GO#?Q)-QJW@.:'PKK3Y=K%@3IMRW MH ,M"2>Z@K_L#K7P'\7O@?XJ^!'B5M)\5Z+>:3=# M2]M]/^"ZO_*6+XR?]A&U_P#2"VKY*KZU M_P""ZO\ REB^,G_81M?_ $@MJ^2J_7_@/\)]UP:^O_ ('?MH^&/BV(;*]D70=; M?"_9[EQY4[8_Y9R=#ST5L'TS7P517TN6YUB<&[0=X]GM\NQ^>\3<"Y7G22KTG'1_/I)>NO9H_5BBO@OX'_MI^*/A,8;.^D;7]%3"_9[ESYT*_P#3.3DC M'96R.PQ7U]\(/V@?#/QLT[S-&OE^U* 9K*?$=Q"<9Y7^(>ZDCWK] RW/,-C/ M=B^679_IW_/R/YTXGX!S3)6ZE2//2_GCM_V\MX_/3LV=M117OG[,7_!/#QU^ MT#D?#^99SBE@LKHRJU'TBMO-O:*[MM)=SPG3M.N-7OX;6TMYKJZN' M$<4,*%Y)6/ 55'))]!7V!^S!_P $EM>\=BWU;XA7$WAG2FPZZ;#@ZA./]LG* MPCZAFZ@JIYK['_9P_8R\#?LQV"MH>FBZUAEVS:M>@2WGO(YGX5?!SPS\$?#":/X5T:ST>Q7!985^>9@,;I'.6D;_:8DUT MU%%?C-:M4K3=6K)RD]6V[M^K9_4&%PM'#4HX?#04(15E&*2279):)>@4445F M= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 5B?$'X;Z#\5O#$^C>(])L]8TRX^_!BOAL?Q,:^+=?\/WWA76;C M3M3L[K3]0LW\N>VN8C%+$WHRL 0?K7[L5YS^T!^RIX)_:5T;[/XFTF.2\C0I M;ZE;XBO;7_=DQR!UVL&7/:OV#A?Q:Q6&MA\W3J0_F7QKUZ2_!^;/YE\0/HWX M#'&8 M\N;BTB/VJU3K^]A&3@<_.FX8&3MZ5\VU^]97G&#S*BL1@JBG'RW7DUNGY-(_ MCSB#AG-,CQ3P6:T94IKHUHUWBUI)>:;045F>)?&&G^$K7S;ZX2'C*H.9'^B] M37D_C;XXZAX@WP:?NT^U;@D']ZX]SV_#\ZZJV*A3T>_8SRS(\5C7>"M'^9[? M+O\ UJCT7QK\5M,\&JT;2?:KS'$$1Y!_VC_#_/VKR'QE\2]4\:2,L\ODVN?E MMXCA/;/]X_7]*P&8NQ9B2Q.23WI*\BMBIU-'MV/T3+,@PN#]Z*YI]W^G;\_, M*]1_8>_Y/4^$'_8[:-_Z7PUY=7J/[#W_ ">I\(/^QVT;_P!+X:\K,O\ =*O^ M&7Y,^KRC_?J/^./_ *4C^C>BBBOY#/[X"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** /Y>/^"ZO_*6+XR?]A&U_](+:ODJO MK7_@NK_REB^,G_81M?\ T@MJ^2J_.X?Q4<92C44(2E'F2= MI*+::OLUW7IL?AGJ&I7&K7;3W4TD\TARSNV2:AHHK^HS^+$DE9!1110 5ZC^ MP]_R>I\(/^QVT;_TOAKRZO4?V'O^3U/A!_V.VC?^E\-<>9?[I5_PR_)GH91_ MOU'_ !Q_]*1_1O1117\AG]\!1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% '\O'_ 75_P"4L7QD_P"PC:_^D%M7R57UK_P7 M5_Y2Q?&3_L(VO_I!;5\E5^Y97_N=+_#'\D?@6:_[[6_QR_-A1117<< 4444 M?T#?\&I7_*/'QE_V46]_]-FEU^FU?F3_ ,&I7_*/'QE_V46]_P#39I=?IM7X MOQ!_R,:OJ?N7#O\ R+:/^$****\<]H**** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "ODG_ (+?_P#*.KQ9_P!?VG?^ED5?6U?)/_!;_P#Y1U>+/^O[ M3O\ TLBKW.&?^1OAO^OD/_2D?,\9_P#(AQG_ %ZG_P"DL_"VBBBOZL/X="BB MB@ KU']A[_D]3X0?]CMHW_I?#7EU>H_L/?\ )ZGP@_[';1O_ $OAKCS+_=*O M^&7Y,]#*/]^H_P"./_I2/Z-Z***_D,_O@**** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ K^93_@Y2_P""FG[0G[-G_!7'QYX1^'_QF^(O@_PO8:;I M$EMI>DZW/:VL#2:? [E45@ 69BQ]237]-=?R0_\ !U__ ,IM?B/_ -@K1/\ MTV6] '@'_#ZS]KC_ *.-^,'_ (4US_\ %4?\/K/VN/\ HXWXP?\ A37/_P 5 M7S!10!]/_P##ZS]KC_HXWXP?^%-<_P#Q5'_#ZS]KC_HXWXP?^%-<_P#Q5?,% M% 'T_P#\/K/VN/\ HXWXP?\ A37/_P 57[R?\&B'[7?Q0_:Z_9S^+^I?%#Q] MXJ\?7^C^)+2VLKC7-0DO)+6)K4LR(7)*J6YP.]?R^5_1]_P9#?\ )K/QP_[& MJQ_])#0!^WU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 <3^TMK=YX:_9R^(&I:?Q%?QL?\/K/VN/^CC?C!_X4US_\57]CO[67_)K' MQ,_[%35/_226OX0Z /I__A]9^UQ_T<;\8/\ PIKG_P"*H_X?6?M#?'?QJ^)'B[PKK']M?;M)U M77)[FTN_*T34)H]\;,0VV2-'&>C(#VK^H:OY O\ @UQ_Y3K_ ,_[C__ *C^ MIU_7[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !7Q?_P5=_X+H_!?_@DYH"V?BB\E M\5?$2^@\_3O!VD2J;Z1#PLMPYRMK"3T=P6;#;$?:V,/_ (+X?\%AM/\ ^"2W M[*(O-'^Q:A\5O&YEL/"6G3X9(&4#SK^9.IA@#+\O\KQ_M5_M:_P!H>,%\92_VUH/A_6Y&FD\1;SN74=1W7M5P#B;7_ (*1?\%.?^"W.J7$GP)\,ZC\,?AO,[+%>Z&D>EV:H&*_-K%W MB2:53D,+5EY&?*&.-Y/^#5/]M#XW0M??$[]J#29M0N&\]EN/$>M:Y)YG/+O* MB?-\S<@MU/)SFOV._;D_X*=? /\ X)2>&?"-O\5/$0\&6?B1+BW\/6%AH=U= MK/':" 2JBVT3)$L8N(>'* AL+G! ^/M5_P"#P[]D#3M0CAA/Q2OHY "T\'AM M%CCR2,$23JW'7A3P>,G(H ^,KO\ X-E_V]/V:85U+X2_M.6UQ<:> \5K8^+] M8T2>3&?E1=IA(^9N'=5(8YZD5D^'?^"YW_!0#_@C?XTT_P /_M6?#>]\=>$Y M)A;QWNL6T5O<3*!DK::O9AK:=P/F(E$S]B4[?J]^R7_P<-?LD?MD^*K3P_X9 M^*UAH_B2^E$-MI?B6TFT:6Y<\*D)_#>M0FWOM,U.U2ZM;M#SAXW!4\@$<<$ C!% 'B'_!.+_@JG\' M/^"I/PM?Q'\+O$#37U@B?VQX?U!!;ZOH;MT6>$$@J<'$D;/&V" Q(('T=7\V M?_!6?_@E-\0/^#?']HS1/VI/V6=8U:S^'D-^(KNRFD>Z/AMI6'^A763FXTZ? MA%,A+*VU68OY%?^"H_['GA_P"*7AF,:?=W!:PU[1VD\R31 M-2C"^=;EN-R_,KH^!NCD0D*25 !]%4444 %%%% !1110 4444 %%%% '\O'_ M 75_P"4L7QD_P"PC:_^D%M7R57UK_P75_Y2Q?&3_L(VO_I!;5\E5^Y97_N= M+_#'\D?@6:_[[6_QR_-A1117<< 4444 ?T#?\&I7_*/'QE_V46]_]-FEU^FU M?F3_ ,&I7_*/'QE_V46]_P#39I=?IM7XOQ!_R,:OJ?N7#O\ R+:/^$****\< M]H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJGKWB"Q\+:/<: MAJ=Y:Z?86B;Y[FYE6**%?5F8@ ?6JC%R?+%7;)G.,(N'[?5M#U*RU;3;H9BN;2998W]1D=QT(Z@\&M.B<)0DX35FMT]T32K0JP M52FU*+5TT[II[--;H****DT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH *^2?\ @M__ ,HZO%G_ %_:=_Z615];5\D_\%O_ /E'5XL_Z_M._P#2 MR*O75ZC^P]_P GJ?"#_L=M&_\ 2^&N/,O]TJ_X9?DS MT,H_WZC_ (X_^E(_HWHHHK^0S^^ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "OY(?^#K__ )3:_$?_ +!6B?\ ILMZ_K>K^2'_ (.O_P#E-K\1 M_P#L%:)_Z;+>@#\X:*** "BBB@ K^C[_ (,AO^36?CA_V-5C_P"DAK^<&OZ/ MO^#(;_DUGXX?]C58_P#I(: /V^HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_ /:R_P"36/B9 M_P!BIJG_ *22U_"'7]WG[67_ ":Q\3/^Q4U3_P!)):_A#H **** "BBB@#[_ M /\ @UQ_Y3K_ ,_[C__ *C^IU_7[7\@7_!KC_RG7^!G_UDF7@D \H.,C/J* /YUO%>FR?\ !PO_ ,'-MUX?U29M3^$?PWO9[9HHR6@? M0=(E*OCOMO;QP"W#!;P?W *_I=L;&'3+*&VMH8K>WMT6***) B1(HP%4#@ M #I7\_?_!CY\+[;4/%'[1'CRZ5)=2M8-&T2VE))D6.9[R>XSQT9H;<]>2AS MVS_030!^ /\ P?.?\VN_]S7_ .X6N=_X(Q_\&OWP%_X*(_\ !-OX=?&/QQXP M^+VF^)?&)U/[5:Z'J>G6]C"+;4[NS38LUC*_*6ZL27/S,<8&!71?\'SG_-KO M_*/VK?V<_&'P?\=ZM=:YK7PE^RSZ'J%Y*9;JXTJY,JB!W8EG^SR1[59ND< MT:#A!CU'_@Z[_;*\$? S_@EEXP^&^J:M8OXZ^*OV.QT31A(&N7ABOH)Y[ID' M*PHD+*'/!D9%')./A3_@R'^"NL77QI^-WQ%:&XC\/V.B6?AQ)3Q%:-(%)_NB=?[PH _?[XV?!OPY^T/\(?$O@7Q=IL.K^&?%NG3:5J5I*.)H M)4*-@_PL,Y5ARK $8(!K^>?_ (-]O'GB'_@DG_P77^)'[*/BK4)I/#_B^\NM M"A:9MDZG'RAI[/4Y+9U.,EAY%I #D M'[4'_!1WQQ^T,;C3;.9O"WAB3*_8+*4^;6W_;JWE\M.[1^4\>>,.0<+J5&M/VN(Z4H--I_WWM!>OO6U46?9 MW[4'_!3+P3\!OM&EZ,R>+O$T>4-O:2C[+:../WTPR,@Y^1-S9&#MR#7YY_M M?M6>-OVEM9^T>)M6DDLXWWV^FV^8K*U_W8\G)_VF+-[XKSFBOZ(X9X%RS)DI MT8\]7^>6K^72*]->[9_$W'GB[G_%,G2Q,_9T.E*%U'_MY[S?KI?5)'3^5C#@7Q6S_ (6FHX*IST;ZTIWZ_M[PVA ;2+^0M'&N>?)?EH3UZ97)R5)K M]$OV:OVX? O[3=K'#I=]_9NO;5.0.H6OYWXG\/\SR> M]5KVE+^>*V_Q+>/XKS/[8X!\:,@XG4<.I>QQ+_Y=S:U?]R6BGZ:2_NV/8J** M*^%/UX**** "BBB@ HHHH **** "BBB@ HHHH **** "ODG_ (+?_P#*.KQ9 M_P!?VG?^ED5?6U?)/_!;_P#Y1U>+/^O[3O\ TLBKW.&?^1OAO^OD/_2D?,\9 M_P#(AQG_ %ZG_P"DL_"VBBBOZL/X="BBB@ KU']A[_D]3X0?]CMHW_I?#7EU M>H_L/?\ )ZGP@_[';1O_ $OAKCS+_=*O^&7Y,]#*/]^H_P"./_I2/Z-Z***_ MD,_O@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^2'_@Z__P"4 MVOQ'_P"P5HG_ *;+>OZWJ_DA_P"#K_\ Y3:_$?\ [!6B?^FRWH _.&BBB@ H MHHH *_H^_P"#(;_DUGXX?]C58_\ I(:_G!K^C[_@R&_Y-9^.'_8U6/\ Z2&@ M#]OJ*** "BBB@ HHHH **** "BN?^)/Q9\*_!KPW)K'C#Q-X?\*:/#]^^UC4 M8;&V3OS)*RJ/SKXH_:$_X.:/V,_V>_M$,GQ9M_&>I6^<6?A/3Y]5\[']VX51 M:G\9AF@#[WHK\,_C?_P>]?#_ $:22/X;_ SQAXB4Y"W'B/6K?1]OHWEP)=;O MIO7ZU\D_%O\ X//?VG/&1DA\+^$?A/X-MF'RR+IMUJ%VAS_?EN/*/&./*]?P M /Z@J*_CI^)7_!R=^VQ\42RWGQSUG3(23MBT;2M/TS8/0/!;HYZ_Q,3^0KPO MQY_P4X_:/^*#/_PD'Q\^,FK1R!E,-QXQU!H0& # 1^;L4' R #CF@#^XJJF MLZ_8^'+/[1J%[:6%N6">;<3+$FX]!EB!G@\>U?P7>*?BQXJ\<>?_ &UXE\0: MQ]JV^=]NU&:X\[;C;NWLK^ .NB\)_%WQ9X"6-=#\4>(M%6$,L8L-2FM]@8Y8#8PQDDDXZ MYH _O:HK^)/X6?\ !87]JCX,7$3^'_V@_BW#'"(+AY(^_/ MR\]Z^NOV>O\ @[W_ &N?@_)!%XHOO _Q0LD(60:[H26ER4!_AEL3 V.-SH_ MJ03S0!_5E17XU_LA9VC1+ ME >NU8),#(+'&3^KWP"_:1\ _M4?#VW\6?#?QCX=\;>';D[%O]'ODNHE<=8W MVDE)!GE& 8=P* .VHHHH **** "BBB@ HHHH \__ &LO^36/B9_V*FJ?^DDM M?PAU_=Y^UE_R:Q\3/^Q4U3_TDEK^$.@ HHHH **** /O_P#X-\-I'=?: MK"YLSF4(Y7:+@O\ =.2N.,Y'ZS?\1Q?BK_HW;P__ .%?-_\ (E ']#U%?SP_ M\1Q?BK_HW;P__P"%?-_\B4?\1Q?BK_HW;P__ .%?-_\ (E ']#U%?SP_\1Q? MBK_HW;P__P"%?-_\B4?\1Q?BK_HW;P__ .%?-_\ (E ']#U%?A+^R'_P>,^) M/VG?VL?A?\-9_@/H>CP?$+Q;I7AF2_C\4RS-9+>WD5L9@AME#E!)NVDC.,9' M6OW:H **** "BBB@ HHHH **** "BBO@W]N__@Y"_99_8/NK[2+[QJ?B!XPL MBT;Z#X.1-2EAD&1LFN-RVT1###*TOF+_ '#C% 'WE17\U?[4_P#P>I_&+QW< MW%I\(_AMX-^'^FME$O-:EDUS4L=G7'DP(3UVM'(!TR>I^#?CA_P7?_:__:#E MG/B#X_\ Q!M8;@%7@T&]&@PLI&"I2Q6$%<<$'.>^: /[1JR]6\<:+H%\MK?: MQI=E:_@]\>?&OQE\4YY9?$_B[Q-XCEG.9'U35)[QI# MN+';O[1I]Y=V-QM*>9;S-$^T]1E2#C@ M<5['\+O^"E?[1'P5GC?PI\B\SRVZGAE- ']QU%? MR7_LZ_\ !V/^V)\#+BWCUKQ7X;^)FFPD+]E\3Z'#OV=QY]IY$Q;KAG9\<=0, M5^F7[%__ >=_!OXKW=EI/QG\#^(?A7J$S+&^KZ=)_;>CKT!>0*J7,8[[5BE MP/XJ /V>HKC/@1^T5X#_ &H/A]:^*OAWXO\ #WC3P[> >7?Z1?1W40; )1MI M)1QGE&PRG@@&NSH **** "BBB@ HHHH **** "BBB@ HHHH ***^._VSO^"] MO[*_["]U=:?XN^*6D:MXDM6,6"?*U/QIJ7S,.VZSM3Q^%R:^&/CC_P=4?MH?&>29+/ MXA:/X$L9@5:U\,Z!:P 9S]V:=9IUQGJ)1^= ']U:&8DM;2>++Y;7GKB%9!&/P45X_XH^(6O^.)&;6M M27!+GJWSD_-R>>O- ']Z&M^.-%\-72P:EK&EZ?.R"18[FZCB9E)(R Q!QD$9 M]C5[3]1M]6LH[FUGANK>8;HY8G#HX]01P?PK^ FB@#^_RBOX+?#/QV\<>"G5 MM&\9>*M)94$2FRU:XMRJ#&%&QQP,#CV%>O?#_P#X*X?M1_"^=6T7]H7XR6Z1 MG<()O%M[#2 MM6AFNK<8S^]@SYL1QSAU4T >K4444 %%%% !1110 4444 %%%% !115/Q!XA MT_PEH=WJFJWUGIFFZ?$T]U=W[TOP=J&I_&KQ- "JP>& JZ4D@Z"2_DQ&5/\ >MUGZCCKC\M?VH/^ M#RC]I3XLS7%O\-] \#?";37)\B6*T_MS5(@>FZ:Y'V=L>UL/Z4 ?U#45_$S\ M9/\ @LG^U5\>[B1O$W[0'Q3FBF!$EK8:]-I=G(#@\P6ICB/3C*\=J^?_ !9X M_P!>\>W7GZYK6K:U-N+^9?WDEPVXXR98WARA M!R.Q[4 ?WS45_$7\(?\ @KA^T_\ B>%O"_Q\^*]C#;D&.TF\1W-Y9C "C_1 MYW>(_* .4Z >@K[4_9G_ .#PK]JGX/7$$/CB/P3\6--4@2G4]*73+XKZ)-9^ M7&#CC+PO^)H _J@HK\J/V(?^#NW]FO\ ::OK31_B#!KGP3\0715 VLD7VBL[ M8 47T*@ICG+SPQ(!_%V'ZA^"O'&B_$GPI8:]X=UC2]?T/5(A/9:CIMU'=6EY M&>CQRQDHZGU4D4 :E%%% !1110 4444 %%%% !1110 445Y[\?OVL_A?^RIH M0U+XE?$+P;X%LW0O&^N:O!9-.!Q^[61@TASQA 230!Z%17Y=?M&?\'=_[(WP M6DFM_#.H>-OBE?1Y5?\ A']$:WM0X[-+>M!\N>-T:N/3(KXG^-O_ >_^*+Y MKB'X;_ ?0-+53B"[\2:_-?[QZM!!'!M],"5NF<]@ ?T.T5_)_P#$_P#X.[OV MRO'TDS:3KW@'P0),[5T7PO#,(NOW?MK7!XR.N>@]\^'^-/\ @X5_;0\?23-? M?M ^,X#,&#?V=':Z:!N.3M%M#&%]MN,=!B@#^S"BOXD=;_X+!?M7>()8WN/V MDOCE&T8VC[-XVU&U!^HCE4'ZFJ/_ ]B_:F_Z.6_: _\.'J__P D4 ?V^45_ M%-X<_P""VO[77A5H6M?VC/BY+]G38OVSQ%/>9&,?-YS/N/NV3WZUZW\-_P#@ MY_\ VV_AS-%_Q>(Z]:QE2;;6/#NF72R8QUD^SB7D#!PXZD]>: /Z_J*_FE^! MO_!Z_P#'#PDT,7Q ^%?PW\:6T1^>32IKK0[J9<\[G9KB,-VRL0'3@]_TO_X) M@_\ !SW\&_\ @I;\>O#?PIM/!WCSP5\0_$R7+6=M>QV]YIDIM[66ZD5;F.0/ MD102'YX4!P #DX !^E=%%% !7F/[;'A:Z\<_L9_%S1;%=UYK'@O6;&W&"K#I7IU% 'X&_\&./BZS;0/VCM!+;;^.XT"_52?]9$5U",D?[K*N?] M]:_?*OYI/^"7VMC_ ((B?\'+/C+X/^(M^D^!_'E_=>$K&:X.V(6M[*EWHUQG MH2Q$$!(.%,\N<;2*_I;H _ '_@^<_P";7?\ N:__ '"U\ ?L:_\ !.[_ (*% M?&/]DC0?'/P1C^*$GPFNXKV;1UT/XB6^G0LL-U/'K3*WQ!TNUCP+& MZ=@JZHB@8\N5B%FQC$A$ASYCE?J'_@UQ_P""X"_ME_"NW^ OQ.U@R?%?P39? M\2._O)/^"ZO_*6+XR?]A&U_P#2"VKY*KZU_P""ZO\ REB^,G_81M?_ $@MJ^2J M__^FS2Z_3:OS)_X-2O^4>/C+_LHM[_Z;-+K]-J_%^(/^1C5]3]RX=_Y%M'_ M A1117CGM!1110 4444 %%%% !1110 4444 %%%1WD4D]I*D4GDRNA5)-H; MRR1PV#P<=<&A">BN8/Q/^+?AOX,>&)-8\4:Q9Z-I\? DG?YI6Z[4099V_P!E M03[5\%_M0?\ !6[6O&!N-(^'%O+X?TULHVK7"AKZ<=#Y:\K"#SS\S]""AXKE M_P!N_P#9 ^+OA[Q1>>*M>U*^^(6DC)&J0(=UE$.!AY_Q)KN MIJ\5%_\ 3MOMSM:%C5=6NM=U*:\OKJXO+RZ,J001U!K\KXK\,LMQR> M(PC5&IY+W6_./3UCZM,_HGPU\=N(,MG' 8^+Q=!::O\ >17E-Z-+M/T4HH_? M2BO+/V)?BUJ_QV_91\#>+]>:&36-?TU;JZ:*,1H7+,.%' X Z5"M.A/>+:=NZ=C^[<%BH8K#T\33ORSBI*^]FKJ_GJ%%%%8G2%%%% !1110 M4444 %%%% !1110 5\D_\%O_ /E'5XL_Z_M._P#2R*OK:ODG_@M__P HZO%G M_7]IW_I9%7N<,_\ (WPW_7R'_I2/F>,_^1#C/^O4_P#TEGX6T445_5A_#H44 M44 %>H_L/?\ )ZGP@_[';1O_ $OAKRZO4?V'O^3U/A!_V.VC?^E\-<>9?[I5 M_P ,OR9Z&4?[]1_QQ_\ 2D?T;T445_(9_? 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !7\D/\ P=?_ /*;7XC_ /8*T3_TV6]?UO5_)#_P=?\ M_*;7XC_]@K1/_39;T ?G#1110 4444 %?T??\&0W_)K/QP_[&JQ_])#7\X-? MT??\&0W_ ":S\./'6 MNV/AGPGX=@%QJ.IWC$0VJ%E0$X!)RS*H !)+ $FNJKX?_X.0_\ E"5\?/\ ML%67_ISLZ /D?]L3_@\\^"?PL-WIWP=\$^*/BGJ4>5CU*_/]AZ03T#*75[E\ M==K0QYX&X9)'Y:_M7_\ !T]^U]^TV]U:Z;XTT_X6Z)<,<67@ZQ%I,J_P_P"E MRF2Y# =2DB DDX' 'YRT4 =#\2_BWXK^-'B:76O&/B;Q#XLUFX]+_9N^-6M27GC*S@ M,?@SQ)?W!:;7847/]GW#MRUQ&@)CD8DRHI4_.H,@!^X5%%% !1110 4444 > M?_M9?\FL?$S_ +%35/\ TDEK^$.O[O/VLO\ DUCXF?\ 8J:I_P"DDM?PAT % M%%% !1110 4444 %%%% !1110!] ?\$G?^4IO[-/_95?"_\ Z=[6O[?*_B#_ M ."3O_*4W]FG_LJOA?\ ].]K7]OE !1110 4444 %%%% !7RG_P5 _X+'_!G M_@E'X!2]^(&L/J'BS4H&ET;PGI96;5=4QD!RI.(8-P(,TI"_*P7>PV'YA_X+ MY?\ !Q=X?_X)IZ1??#/X8R:=XF^.M[ OF"11/8>$(Y%R)KD _/,_&_B#5/%'BKQ!<&ZU#4]0G,UQ:RWP]^&=P["/PCX>G:.*>/ MD!;RYPLMV2",JVV(D B)37P=110 4444 %%%% !1110 4444 >J?LC_MN?%7 M]A/XG0^+OA1XVUOP;K$;*9A:39M;]5.1'/_8D5AGD8.#7])'_!%/\ MX.@/ _[?]]I?PW^+D.F?#GXO712VL9D_&W4=(_9W^/GB!KOQ=)LL M_!/BF^=0VL@*%73KN0D;KK@"*5LM-]QB9=IE_,Y_!_@BZ#1KX4\+/)I^G/$?X9V#&6ZR,9$SLF02J)G%?$]%% !11 M10 4444 %%%% !1110 4444 %6='UF\\/:I;WVGW5S8WMJXE@N+>5HI87'1E M92"I'J#5:B@#[X_8W_X.6/VM_P!CN:WMD^(L_P 2/#\+ MI/CA6UA64<86Y9 MA=H . %F"CCY3C%?T'?\$*?^"X%G_P %F? _CEI? -SX#\2?#@ZB\%UY;P/L1UYM)-R.IV[DP[\D?Q\U^_P!_P8Q_\W1?]RI_[FJ /W^HHHH M**** "BBB@ HHK\'?^#@;_@Z!;P%>ZQ\$_V9?$$;:Q'YMAXF\=V1S_9SABCV MNFOT,HPP:Y7(3(\H[_WB 'VE_P %>_\ @XV^#_\ P2[^V>$]-V?$KXNJA \- MZ;=!;?1V(^5M0N &$/KY*AI2,95%8/7\V/\ P4*_X+"_'S_@IIXBFF^)GC6[ M;P[YWFVGA72BUEH5C@Y7;;JQ\QE[23-)(,D;\<5\SZAJ-QJ^H3W=W/-=75U( MTLTTKEY)78Y9F8\EB222>234- !1110 4444 %%%% !1110 5]+?\$[O^"MW MQR_X)A^-4U#X8^+KF'0YI_/U'PQJ):ZT353P#YEN2 KD #S8BD@ WXX/S31 M0!_8E_P1[_X+V?"G_@K/X=72;/'@GXK6%MYVH^$;ZX#O,J@;Y[*7"BXA'? $ MB?Q*!AF^ZJ_@=^'7Q&U_X1>.M)\4>%M8U+P_XBT*Y2\T[4M/N&M[JRF0Y5XW M4@JP/<5_5E_P;R?\%X=/_P""H_PJ;P/X^NK#3?CIX1M0]]$BK#%XHM%POV^! M!PL@) FB485B'4!'VH ?IA1110 4444 %%%% $.HZC;Z1I\]W=SPVMK:QM-- M-,X2.%%&69F/ 4 $DG@ 5^9O_!07_@ZP_9L_8V:]T7P;?3_&WQE;@H+7PS.@ MTB&0=I=1.8R/>!9B.A K"_X/$]H>.=+MKI(961;F+R+ MM_+< _,N]$;:H%?RL4 ?I)^VM_P=2?M6_M9RW5CX?\ $MG\'?#E.=N^_YN+AO[SR.2S'W)K-HH **** "BBB@ HHHH **** "OO_\ X-.6GMF+R(HY9' ME4;F$:GI?^#=;_@OMH?_ 4(^%.D?"OXF:S;Z=\=?#5F+<27-+>)0!=Q M,< W6W_6Q DL0TJC:66/]4:_'/\ X+(_\&MFE_M*>-[SXP?LUZE9?#CXIFY. MIWNBF9K/2]8N@WF?:+>6/FSNBW.0/+=L$^4=SL ?7O\ P5X_X(E^ ?\ @L7_ M ,*]_P"$X\6>,/"__"N?[2^Q?V$;8?:?MOV3S/,\Z)_N_9$V[;.>,>S_\ M$]?V)= _X)T?L@>$?@WX7U;6-M 'ZU^+_ CI?C_PIJ6A:YI]IJVC:S:R65]9740E@NX)%*21 MNIX964D$'J#7Y2>"/^#0GX._![X\67Q"\ _%[XR>"-:T35_[7T0Z?;^+/_!ZI^SOX:TJ3_A#_ (=?%CQ5J00M&E[; MV6EVC-SA3+Y\L@]R(B #WZ5\B?$'_@JQ_P % /\ @OM>77@OX!_#[4_AO\-] M3+6M]=Z$\D,/E-\KI>:Y,(U QN!C@$3.H9=DG(H ]_\ ^#D__@N?'J'AR\_9 M+^ >HS>,/'GBR1-!\8:MHB_:#")&$;Z1:B+/F74S'RY0F1&K-%S(S"+[3_X- MZ/\ @DBO_!*S]C-8?$4%NWQ5^(3Q:MXKF3:QL=JD6^G*X^\L"NY)R0999B"5 MVXX;_@B+_P &X'@?_@EU/:_$#QE?67Q ^-,D#1IJ*PD:;X<#C#I8HXW-(02I MN'"N5)55C#.&_3*@ HHHH **** "BBB@ HHHH **** /Y>/^"ZO_ "EB^,G_ M &$;7_T@MJ^2J^M?^"ZO_*6+XR?]A&U_](+:ODJOW+*_]SI?X8_DC\"S7_?: MW^.7YL****[C@"BBB@#^@;_@U*_Y1X^,O^RBWO\ Z;-+K]-J_,G_ (-2O^4> M/C+_ +*+>_\ ILTNOTVK\7X@_P"1C5]3]RX=_P"1;1_PA1117CGM!1110 44 M44 %%%% !1110 4444 %%%% !7S7^U!_P3*\%?';[1JFAK'X0\22 MY]I$/L M=T_7][",#)/5TP>31X/$/#.5Y[A M7@LVHQJP\UJGWBUK%^::9^,'Q_\ V5O&W[-6M&U\3:3)':R.4M]1M\RV5U_N M28X/^RP5O:O.J_=CQ!X=T_Q9HUQIVJ65KJ-A=+LFM[F)98I5]&5@0:^+/VG_ M /@D58ZPMSK'PRNETZZP9&T2\E)MY3UQ#*>8SZ*^5R?O(*_>N%_%K"XFU#-E M[.?\R^!^O6/XKS1_'G'_ -&_,,!S8SAN3KTM_9NWM%_A>BFONET2DS\^J*VO MB!\.=>^%7B:?1_$6DWNCZG;GYX+F,HQ'9E/1E/9E)![$UBU^PTZD*D%4IM-/ M5-:IKR9_,U>A5H5)4:T7&479IIIIKHT]4PHHJOJFK6VBV;7%W/';PIU=VP*M MM)79G&,I2Y8J[98K)\5>-]-\'6WF7MPJN1E(E^:23Z#^IXKS_P ;?'YYMUOH MJ>6O0W,B_,>/X5[?4_E7FMY>S:C=/-/(\TTARSN;6S!+2GKYGV65\( MU*EJF,?*NRW^?;\_0[#QM\:M2\3%H;0MI]F>,(W[QQ[MV^@_6N+HHKRYU)3= MY,^\PN$HX>'LZ$5%?UOW^9_0=_P2_P#^4?\ \*_^P(G_ *&]>]5X+_P2_P#^ M4?\ \*_^P(G_ *&]>]5_(^=?\C"O_CE_Z4S^]^'?^13A?^O:>R M%%%% !1110 4444 %%%% !1110 5\D_\%O\ _E'5XL_Z_M._]+(J^MJ^2?\ M@M__ ,HZO%G_ %_:=_Z615[G#/\ R-\-_P!?(?\ I2/F>,_^1#C/^O4__26? MA;1117]6'\.A1110 5ZC^P]_R>I\(/\ L=M&_P#2^&O+J]1_8>_Y/4^$'_8[ M:-_Z7PUQYE_NE7_#+\F>AE'^_4?\.5&'*LK*"".A%9E% ']IW_!%K_@H[:?\ !4+]@/PG M\1I&MH_%EJ&T3Q9:0X"VNJVZJ)6"CA4F1HYT7G:DZKDE37U=7\P/_!G)^VW) M\$/V_-<^#^I73+H/QDTIC9QLWR1ZM8))/$1DX7?;?:T..680CG K^GZ@ HHH MH **** //_VLO^36/B9_V*FJ?^DDM?PAU_=Y^UE_R:Q\3/\ L5-4_P#226OX M0Z "BBB@ HHHH **** "BBB@ HHHH ^@/^"3O_*4W]FG_LJOA?\ ].]K7]OE M?Q!_\$G?^4IO[-/_ &57PO\ ^G>UK^WR@ HHHH **** "OSG_P"#AG_@MM9_ M\$JO@#'X>\'W%I>?&SQW;.N@V[A95T*VY5]2F0Y!"G*Q(PP\@)(98W!^ROVR M_P!K'PK^PW^S#XR^*WC2X\CP_P"#=/:\E16"R7DI(2&VCSP9)I62-0>-SCM7 M\4_[;7[8GC']O?\ :?\ %OQ6\=7?VC7O%5X9_)1B8-.MQ\L-K"#TBBC"HO+=4U[7=0O-7UK6KN6^O[Z[E,MQ>3RN7DED<\LS,Q)) MY))K-HHH **** "BBB@ HKVCX!_\$Y/CY^U)8PWGP]^#?Q)\6Z;< &/4-/\ M#]S)8')P/])V"$9YZOV/H:]P3_@W-_;6?31=_P#"@?$_E-%YVTW]@)-N,X\O M[1OW?[.-V>,9XH ^)Z*]R^//_!,K]H;]F'3IK[Q]\%?B7X9TRW7=+J-UH%P; M",8R+X5!99](N)$$[%1RS0LJ3J!@EX%&<$Y /[3**BL;Z'4[*&YMIHKBWN$ M66*6)PZ2HPR&4C@@@@@CK4M !1110 4444 5=:EJ5Y:Z?IVGP/< MW5U,YXVRMU." PMU89BA(Z@2.-^Q8OKS_ (.Z/^"R,^E/)^RG M\.=6:%YHHKKXB7ULV&",%D@TH,.FY=LLV.JM$F<&5*_GYH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ K]_O\ @QC_ .;HO^Y4_P#WG\>^(BVB>#;*0!Q)J$D;$7#H?O0VZ@ROQAB$3(,@- 'P3_ ,'2/_!>J[_9 M\LK[]FWX-:U):^-M3M@/&OB"QFVRZ#;2*"MA Z\KK?$7QAJOB#7M0N]6UO7+N6_U"^NI#)/>7$KEY)78\LS,Q))ZDUF4 M%%%% !1110 44J*TC!5!9F. .M?17P7_P""1/[3_P"T)I\5YX1^ _Q0U+3Y MP&BO9=!GL[28'NDTRI&WX,<4 ?.E%?:^J_\ !N?^VMH]A)<3? 'Q0\<>,B"^ ML)Y#D@<(DY8]>P.!ST%?.WQ]_8I^,'[*SK_PLKX7>/\ P+'(P6.?7-!N;*WF M)Z;)9$"/Z?*3R#0!YC1110 4444 %=M^SE^T-XN_90^.'AGXB^!=6FT7Q7X3 MO4OM/NH^0&7@HZ]'C=2R.AX9693P37$T4 ?V^?\ !,/_ (* >&_^"F?[&7A/ MXL>'5CM)=5B-KK6F"3>VC:G$ +FU)ZD*Q#(Q +1R1M@;L5] 5_+3_P &D'_! M1R;]EK]O!OA!KVHF'P3\; ME;I-+B&RUN-2;210> 9QNMB%&7>2WR<(*_J6H M **** "BBB@#\H/^#R3_ )1(:;_V4#2__2:^K^6*OZG?^#R3_E$AIO\ V4#2 M_P#TFOJ_EBH **** "BBB@ HHHH **** "BBB@ K[_\ ^#7'_E.O\#/^X_\ M^H_J=? %??\ _P &N/\ RG7^!G_M:9I^L:9=#;/:7UNEQ!,.N&1P5;\17S?XZ_X(H_LD_$:^>YU+ M]G?X3K-(_F.UCX?@T_>V,$G[.$SGJ<]3R>>:^H** /F_X8_\$?/V6/@[?0W7 MA_\ 9]^$MK>6YW0W4_ANVO+B$\\K),KNIY(R"#CCI7T5I^GV^D6,-K:P0VMM M;H(XH8D"1QJ. %4< #T%344 %%%% !1110 4444 %%%% !1110 4444 ?R\? M\%U?^4L7QD_["-K_ .D%M7R57UK_ ,%U?^4L7QD_["-K_P"D%M7R57[EE?\ MN=+_ Q_)'X%FO\ OM;_ !R_-A1117<< 4444 ?T#?\ !J5_RCQ\9?\ 91;W M_P!-FEU^FU?F3_P:E?\ */'QE_V46]_]-FEU^FU?B_$'_(QJ^I^Y<._\BVC_ M (0HHHKQSV@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3^,'P- M\*_'KPRVD^*M&M=6M1DQ,XVS6S'^*.089#]#ST.1Q7P%^T__ ,$G_$OPV%QJ MW@.:;Q7HJ9=K%@!J5LOH ,+, .Z@-_L'K7Z4T5]5PYQEF>2S_P!EG>'6$M8O MY='YJWG<_.^./"_(>*:;_M"ERU;652-E-=KO:2\I)KM9ZG\[_COXXVOAZ26U MT^/[9>1DHS-D1Q,/7NQ![#\Z\G\1>*;_ ,57IGOKB29OX5/"H/0#H*D\;_\ M(Z:Q_P!?LW_HQJRZ_J*>*G62E+[C^*<#DN%P+<:*UVN]W_EZ(****S/2"BBB M@#^@[_@E_P#\H_\ X5_]@1/_ $-Z]ZKP7_@E_P#\H_\ X5_]@1/_ $-Z]ZK^ M2I_^DL_"VBBBOZL/X="BBB@ KU' M]A[_ )/4^$'_ &.VC?\ I?#7EU>H_L/?\GJ?"#_L=M&_]+X:X\R_W2K_ (9? MDST,H_WZC_CC_P"E(_HWHHHK^0S^^ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "OY(?^#K_P#Y3:_$?_L%:)_Z;+>OZWJ_DA_X.O\ _E-K\1_^ MP5HG_ILMZ /SAHHHH **** "OZ/O^#(;_DUGXX?]C58_^DAK^<&OZ/O^#(;_ M )-9^.'_ &-5C_Z2&@#]OJ*** "BBB@ KX?_ .#D/_E"5\?/^P59?^G.SK[@ MKX?_ .#D/_E"5\?/^P59?^G.SH _CCHHHH **** "O8OV+OV OB]_P %"_B) M=>%O@_X+O?&.L:? +J]6*X@M8;*$MM#RS3ND: G@9;)[ UX[7[??\&0W_)T_ MQP_[%2R_]*S0!B?L[?\ !E+\;/'$,-Q\2_BAX"^'\,H#&VTNVGUZ\B]0Z_Z/ M$#_NRN/>OLOX1?\ !E=^SMX5A@D\8_$+XK>+KR,+YBVMQ9Z79RGOF,022@'V MFXYY/;]CJ* /SO\ !O\ P:L_L0>%88Q<_"?4=>FC*$3:CXMU;<2O_L5_$JQFC MTWP#XC\#W4S%S=:#XHOFD4G)^5+N2XB4<\ ( ,#C%?G3^WC_ ,&7?C;X=Z1? M:]^S_P"/H?'UO;AI%\->(XX]/U1E X6*Z4BWFD/HZ6X]R>*_HXHH _@@^)GP MQ\1?!CQ]JOA7Q=H>J^&O$FASFUU#3-2MGMKJSE'57C;QN M,)/*2X *I))G^266)H)6CD5DD0E65A@J1U!% #:*** "BBB@#TC]CKX_W7[* MO[6'PW^)5FTJS>!O$MAK3+&>9HX+A))(_<.@9".X8BO[K[&^AU.RAN;>1)K> MX19(I$.5=6&00?0@YK^ BO[?/^"4GQ3;XU?\$S?@'XFDD66ZU/P%H_VMUZ&X M2SBCFQR?^6J/P3D=^: /H"BBB@ HHHH \_\ VLO^36/B9_V*FJ?^DDM?PAU_ M=Y^UE_R:Q\3/^Q4U3_TDEK^$.@ HHHH **** /K#_@A]^R'X-_;R_P""HGPP M^%'Q AU"X\(^*O[5^WQV-T;6X;[/I-[=1[9 "5_>P1D^HR.]?T&_\0AO[&W_ M $!?B!_X4\O_ ,37X@_\&N/_ "G7^!G_ ''_ /U']3K^OV@#\P/^(0W]C;_H M"_$#_P *>7_XFC_B$-_8V_Z OQ _\*>7_P")K]/Z* /S _XA#?V-O^@+\0/_ M IY?_B:/^(0W]C;_H"_$#_PIY?_ (FOT_HH _.CX(?\&M?[)_[/GQH\(>/O M#FD^.(_$/@?6[+7]+>?Q%)+$EU:3I/"70KAE#QKE>XXK]%Z** "BBB@ HHKC M?VB/C?HW[-'P$\:?$3Q#)Y>A^!]$N]%I61<_P 3;=JCJ68 9)H M_GT_X/*/^"D#?$CXW^&_V;?#=\6T?P$(]?\ %7EM\L^J3Q9MH&_ZXVTA?T+7 M6#RE?B!78?M!?&_7OVEOCIXP^(7B>X^T^(/&VL76M7[@G:)IY6D95!Z(N[:J M]%50!P*X^@ HHHH ***]*_8__93\7?MO?M*^$/A7X%LOMOB3QA?K9V^[/E6L M8!>:XE(Y$442O(Y&2%1L G (!VW_ 3F_P"":/Q3_P""H/QVA\#_ ST<3>2 M%FU?6KS='IF@VY./.N)0#C/.V-07<@[5."1_3C_P32_X-K/V=O\ @GWHVG:I MJOA^S^+'Q&A0-/XB\2VB3PP2]U!D59KN8^K;0%7.$144<+7O5 "(@C M0*H"JHP !P!2T44 %? '_!37_@W%_9Y_X**Z'J&IVOA^S^%_Q*F1GM_%'ANT M2W$\V#C[9:KMBN5)P68A9L 2J,@_?\ 10!_#G_P4%_X)[?$K_@FC^T1?_#C MXF:6EGJ4*"ZT^_MF,ECK5HS%4N;>0@;D)4@@@,K*RL P(KP^O[,/^"Y7_!*S M1_\ @JI^Q3K'AN&UM(OB-X8BEU7P5J4@"M!>JN3;,_:&X51&^02VMW:2M#-#*I5XG4D,K \@@@@@^E $%%%% !1110!_7[_P M;,_MG2?MD_\ !)7P&^I7C7GB3X;O)X)U5W;+M]D5#:L<\G-G);98_>';+R](L)'V_VEJ, MS"*U@]=IE=2Y7)6-9&Q\IKWZOYSO^#T[]N&7Q;\:_AY^S_I-X?[-\(VG_"5Z M_$A^62_N0T5JC=PT5N)7'8B\'7 P ?B?\2?B-K?Q@^(>N>+/$NI7.L>(O$M_ M/JFIWUPVZ6\N9I&DED8^K,Q/XUB444 %%%% !116KX'\#ZS\3?&6E^'?#NEW M^N:]KEU'9:?I]E T]S>3R,%2.-%!+,S$ #G- &57Z/?\$[O^#7W]I3]N[3M M/\1:OI=M\(? M\!)'JWBF-X[VZBR/F@L!B9L@[E,OE(XY5R*_7O_ ((3?\&T MW@W]A/PMHOQ+^,VDZ;XP^-MPBW<%G<;;K3/!I(RL<*K+<.9'-UX,TZ5BY!!?<8:4823G*Q12B _\"C(%?CO_P ' G_! MN+\-_P#@EO\ LS6OQ:^'/COQEJ&GW7B&VT1]!U^*WNF3SXYY/,2YB6+"KY. MK1L2&Y;(Y_ITK\H/^#R3_E$AIO\ V4#2_P#TFOJ /Y8J*** "BBB@ K]_O\ M@QC_ .;HO^Y4_P#'(TDW03-&^+R\4="9YU.''W MHH8,]*_HZ_X+L_MOM^P%_P $O_B9XVL;S['XHU*R_P"$<\-LK;91J-[F%)(^ MVZ&,RW&#VMSUZ'^,&@ HHHH **** "OM_P#X(Z?\$+?BA_P5T\;37>ER+X/^ M%^B7(@UKQ;>P&2-7P&-M:19'VBXVD$KN5$# NP+(K\E_P1H_X);:]_P5A_;* MTKP':R7>E^#]*4:IXNUF%1G3=/5@"L98%?/F;$<8(.&8N5*QO7]COP)^!7A' M]F;X1Z#X#\!Z#8>&?"?AFU6ST[3K--L<"#DDDY+.S$LSL2SLS,Q+$D@'SU_P M3\_X(F_LZ_\ !-S1+)O ?@/3]0\56R+YOBS7HTU#7)W&,NLS+B#) )2W6-,@ M';D9KZRHHH *K:QHUGXATNXL=0M;:^L;I#%/;W$2RQ3(>JLK A@?0BK-% 'Y M)?\ !6?_ (-1_A'^UIX ) M+=0@YW1.3N'\SGQU^!7B[]F?XN:]X#\>:#?^&?%GAFZ:SU'3KQ-LD#CD$$9# M(RD,KJ2KJRLI*D$_WH5^0'_!V5_P28L/VG_V6;CX_>$-+C3XC?"FT,NM&WC_ M 'FMZ&IS*'QU>UR9E8](A..?D"@'\P5%%% !1110!I>#?%^I_#[Q?I6O:+>3 M:=K&AWD.H6%W"<26MQ$XDCD7_:5E!'N*_N3_ &%_VG[']M']COX;?%33T2&+ MQSH%KJ +N8 M277PO\5SQ6L8/^JL;Y!=1_G<&\/% 'Z\4444 %%%% 'Y0?\ !Y)_RB0TW_LH M&E_^DU]7\L5?U._\'DG_ "B0TW_LH&E_^DU]7\L5 !1110 4444 6M%T2]\2 M:K;V&G6=UJ%]=.(X;>VB:669CT"JH)8^P%?6W[/_ /P0+_; _:6M8;KPY\"/ M&=G8S%2MUX@2+0(RA_C'VYX6=<!OV@]2DLK234;7 M4-%AANFA4S11O%>%D5\;@K%5) .#M'I7[U4 ?RR^!_\ @S7_ &MO%EB)K_5O M@[X9D*[O)U/Q#=22 YZ9MK29<]^N/>N\_P"()CX_?]%7^#__ 'WJ/_R-7]+U M% '\N>O?\&7_ .U=H]JLEOXJ^!NJN3@Q6NO:BK#CK^]L$7VZ]Z\7^*?_ :W M_ML?#"&6:/X46_B:TA7XS_ %Z44 ?PF_'G M]C/XN?LMW'E_$CX8^/? NYMJ2:YH5S8PRGI\DDB!''NI(-?6O_!KC_RG7^!G M__M9>&OC=X3^%_A_P;\1/"TEW):WWA]#IMO.;JUFM9O.M8BL$A,<\ MAW%-VXYW=<@'TM1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 ?R\?\%U?^4L7QD_["-K_ .D%M7R57UK_ ,%U?^4L7QD_["-K M_P"D%M7R57[EE?\ N=+_ Q_)'X%FO\ OM;_ !R_-A1117<< 4444 ?T#?\ M!J5_RCQ\9?\ 91;W_P!-FEU^FU?F3_P:E?\ */'QE_V46]_]-FEU^FU?B_$' M_(QJ^I^Y<._\BVC_ (0HHHKQSV@HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@#^8OQO_P CIK'_ %^S?^C&K+K4\;_\CIK'_7[-_P"C&K+K M^Q*7P+T/\^ZWQOU84445H9A1110!_0=_P2__ .4?_P *_P#L")_Z&]>]5X+_ M ,$O_P#E'_\ "O\ [ B?^AO7O5?R3G7_ ",*_P#CE_Z4S^[^'?\ D4X7_KW# M_P!)04445YI[(4444 %%%% !1110 4444 %%%% !7R3_ ,%O_P#E'5XL_P"O M[3O_ $LBKZVKY)_X+?\ _*.KQ9_U_:=_Z615[G#/_(WPW_7R'_I2/F>,_P#D M0XS_ *]3_P#26?A;1117]6'\.A1110 5ZC^P]_R>I\(/^QVT;_TOAKRZO4?V M'O\ D]3X0?\ 8[:-_P"E\-<>9?[I5_PR_)GH91_OU'_''_TI']&]%%%?R&?W MP%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_)#_P '7_\ RFU^ M(_\ V"M$_P#39;U_6]7\D/\ P=?_ /*;7XC_ /8*T3_TV6] 'YPT444 %%%% M !7]'W_!D-_R:S\OX_%&FQHFR../4(EN9$1>BHEP\\:@J>%%TO M_@IE\/\ 5HUB5=6^&]I'(%SN:2+4M1!8]ON/&!_NT ?CS1110 4444 %?V+? M\&UGBC_A+_\ @B'\!;O=._DZ?J-EF7[W^CZM>P8')^4>7@?[('3I7\=-?U^_ M\&N/_*"CX&?]Q_\ ]2#4Z /O^BBB@ HHHH \_P#VLO\ DUCXF?\ 8J:I_P"D MDM?PAU_=Y^UE_P FL?$S_L5-4_\ 226OX0Z "BBB@ HHHH ^_P#_ (-3L#UQ MOAMXV ZB8CH2#^JU?S8_\'M'QUD\2_MD?"+X$=A&>G1QZG !^*-%%% !1110 5_1M_P &9G_!.Z'P+\$_%?[2.OV8_MCQ MM++X;\+M(G,&FP2#[5.I_P"FUR@C]0+0]G-?SJ^'M O/%>OV.EZ;;R7FH:E< M1VMK!&/FFED8*B#W+$#\:_NB_8M_9MT[]CW]DKX<_"_2UC^R^!O#]II+2(," MYFCB433'_:DEWR'WG4444 %%%% !1110 5_(/_P<[_LF6_[)_P#P5_\ MB NGVZ6NB_$>&#QQ8QJ,8-YO6Z/IS>PW;#'0$#M7]?%?SQ_\'P_PRCL/B?\ ML]^,HXF,NK:7K6BSR!.%6VEM)HE+8[_:YB!G^%O>@#\'Z*** "BBB@#[W_X- MD_C(WP;_ ."U'P>D:7R[+Q-+?>'KIW4?V"U_#K_P3 M%\=-\,O^"D'P#U_S$C32OB'H,\I>01J8AJ$'F L00H*;@6QP#FO[BJ "BBB@ M K^'O_@J!^U"W[:'_!0KXP?$U;@W5CXH\374FF2$[C_9\3>19C/M;10CCCCC MBO[%/^"F7QK?]G/_ ()X_&[QO!,;>]\.^"=6NK%PVTBZ^RR+;\]LS-&,]>>] M?PYT %%%% !1110 5_1%_P &@O\ P2-L_#7P_D_:F\=Z2DVMZXTVG^ H+F(' M[#:*3%<:BH/225P\*$@$1QR,,K,"/P9_9=^ >J?M4?M(^ _AKHK>7JGCS7[+ M0K>4H76W:XF2(RL!_"@8NQ[*I-?W._!_X4Z)\"?A/X9\$^&K06/AWPCI5MHV MF6X.?)MK>)8HU)[D*@R>YYH Z.BBB@ HHHH **** "OR@_X/)/\ E$AIO_90 M-+_])KZOU?K\H/\ @\D_Y1(:;_V4#2__ $FOJ /Y8J*** "BBB@ K]_O^#&/ M_FZ+_N5/_&+--V[RA:6L4;''*F;*U)ZA8K=E8J?NR3 M3=,XK]":;#$MO$L<:K''& JJHP% Z "G4 %%%% !1110 52\2>'+'QAX=U#2 M=4M(+_3-4MI+.\M9DW1W,,BE'C8=U9201W!J[10!_"O^W)^S=6_T>O*Z_2;_@['^&$?P]_X+2^. M-0BA$,?C#1='UK"IM4M]C2T9A]6M6)/=B>_)_-F@ HHHH *_;#_@R1^,3:!^ MV/\ &3P&TFR'Q3X/M];"E\"22PO%B4 =VVZA(?H&]\?B?7Z6?\&E7CH^$O\ M@M-X+T_S/+_X2C0=:TPKO*^9MLGN\8_B_P"/7.#Z9[4 ?UH4444 %%%% 'Y0 M?\'DG_*)#3?^R@:7_P"DU]7\L5?U._\ !Y)_RB0TW_LH&E_^DU]7\L5 !111 M0 4444 ?T/?\&.G_ "2W]HK_ +"NA?\ HF^K]WJ_"'_@QT_Y);^T5_V%="_] M$WU?N]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% '\O'_!=7_E+%\9/^PC:_\ I!;5\E5]:_\ !=7_ M )2Q?&3_ +"-K_Z06U?)5?N65_[G2_PQ_)'X%FO^^UO\:>R%%%% !1110 4444 %%%% !1110 5\D_\ !;__ )1U>+/^O[3O_2R* MOK:ODG_@M_\ \HZO%G_7]IW_ *615[G#/_(WPW_7R'_I2/F>,_\ D0XS_KU/ M_P!)9^%M%%%?U8?PZ%%%% !7J/[#W_)ZGP@_[';1O_2^&O+J]1_8>_Y/4^$' M_8[:-_Z7PUQYE_NE7_#+\F>AE'^_4?\ ''_TI']&]%%%?R&?WP%%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 5_)#_P=?_\ *;7XC_\ 8*T3_P!- MEO7];U?R0_\ !U__ ,IM?B/_ -@K1/\ TV6] 'YPT444 %%%% !7]'W_ 9# M?\FL_'#_ +&JQ_\ 20U_.#7]'W_!D-_R:S\4 ?C#1110 4444 %?U^_\&N/_*"CX&?]Q_\ M]2#4Z_D"K^OW_@UQ_P"4%'P,_P"X_P#^I!J= 'W_ $444 %%%% 'G_[67_)K M'Q,_[%35/_226OX0Z_N\_:R_Y-8^)G_8J:I_Z22U_"'0 4444 %%%% 'W_\ M\&N/_*=?X&?]Q_\ ]1_4Z_K]K^0+_@UQ_P"4Z_P,_P"X_P#^H_J=?U^T %%% M% !1110 4444 %%%% !7\A7_ =(_$5OB#_P6W^+D8D\RU\/1:3I%OQ]T1Z9 M:O(/PFDEK^O6OXKO^"Y&MS:__P %?/VBIYEC5X_'&H6P" @;8I/*4\D\E4!/ MOGITH ^5**** "BBB@#HOA#\3M2^"?Q8\+^,]&6S?6/".KVFM6*W< GMVGMI MDFC$D9X=-R#*G@C(K]'/^(O']LK_ *#7P_\ _"8B_P#BJ_,&B@#]/O\ B+Q_ M;*_Z#7P__P#"8B_^*H_XB\?VRO\ H-?#_P#\)B+_ .*K\P:* /T^_P"(O']L MK_H-?#__ ,)B+_XJC_B+Q_;*_P"@U\/_ /PF(O\ XJOS!HH _3[_ (B\?VRO M^@U\/_\ PF(O_BJ/^(O']LK_ *#7P_\ _"8B_P#BJ_,&B@#]/O\ B+Q_;*_Z M#7P__P#"8B_^*KYJ_P""C?\ P60^-?\ P5/T7PI8?%J^\.WEOX,GN;C31IFE M)9%6N%C63<5)W<1)CTY]:^5J* "BBB@ HHHH [#]GO7?^$7^/G@?4_*\_P#L M[Q!877E[MOF;+B-MN<'&<8S@U_>97\$?PH_Y*EX:_P"PK:_^CEK^]R@ HHHH M _/K_@Z0\=/X(_X(B?&!86V3ZU)I&F(V1TDU6T:08/7,:2#CGG/:OY"*_JR_ MX/ ]9ATO_@CS=02;]^I>,M)MXMHX##SY>?;;&WXXK^4V@ HHHH **** /TH_ MX--O@I'\7?\ @LSX/U*>+SK?P#H>J^)'0IN7<(/L<;'TVR7D; _WE6OZU*_F MB_X,E_#OVG]OCXL:M]G#"Q\ &T\__GGYVHVC[/\ @7D9_P" 5_2[0 4444 % M%%% !1110 5^4'_!Y)_RB0TW_LH&E_\ I-?5^K]?E!_P>2?\HD--_P"R@:7_ M .DU]0!_+%1110 4444 %?O]_P &,?\ S=%_W*G_ +FJ_ &OW^_X,8_^;HO^ MY4_]S5 '[_4444 %%%9WB_76\,>$]4U)8Q,VGVDMR(R=HV<8H _AB_ M;6^([?&+]LGXM>+I':1O%'C+6-6+-U/GWLTOH/[WH/H*\QI7=I&+,2S,1T&Q M21NS*_/?BO$:** "BBB@ K[K_P"#:#6YM _X+A? >>%8V>2]U2V(<$C;+H]] M$QX(Y"N2/?'7I7PI7V__ ,&WO_*;7X!_]A6]_P#39=T ?V.T444 %%%% 'Y0 M?\'DG_*)#3?^R@:7_P"DU]7\L5?U._\ !Y)_RB0TW_LH&E_^DU]7\L5 !111 M0 4444 ?T/?\&.G_ "2W]HK_ +"NA?\ HF^K]WJ_"'_@QT_Y);^T5_V%="_] M$WU?N]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% '\O'_!=7_E+%\9/^PC:_\ I!;5\E5]:_\ !=7_ M )2Q?&3_ +"-K_Z06U?)5?N65_[G2_PQ_)'X%FO^^UO\:>R%%%% !1110 4444 %%%% !1110 5\D_\ !;__ )1U>+/^O[3O_2R* MOK:ODG_@M_\ \HZO%G_7]IW_ *615[G#/_(WPW_7R'_I2/F>,_\ D0XS_KU/ M_P!)9^%M%%%?U8?PZ%%%% !7J/[#W_)ZGP@_[';1O_2^&O+J]1_8>_Y/4^$' M_8[:-_Z7PUQYE_NE7_#+\F>AE'^_4?\ ''_TI']&]%%%?R&?WP%%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 5_)#_P=?_\ *;7XC_\ 8*T3_P!- MEO7];U?R0_\ !U__ ,IM?B/_ -@K1/\ TV6] 'YPT444 %%%% !7]'W_ 9# M?\FL_'#_ +&JQ_\ 20U_.#7]'W_!D-_R:S\4 ?C#1110 4444 %?U^_\&N/_*"CX&?]Q_\ M]2#4Z_D"K^OW_@UQ_P"4%'P,_P"X_P#^I!J= 'W_ $444 %%%% 'G_[67_)K M'Q,_[%35/_226OX0Z_N\_:R_Y-8^)G_8J:I_Z22U_"'0 4444 %%%% 'W_\ M\&N/_*=?X&?]Q_\ ]1_4Z_K]K^0+_@UQ_P"4Z_P,_P"X_P#^H_J=?U^T %%% M% !1110 4444 %%%% !7\1/_ 5RM[BV_P""JO[2BW2RK(?BAXD=1)G.QM4N M2AY[%"I'MBO[=J_BV_X+M^%YO"'_ 6%_:(M)O,WS>,[N]&^,QG;<;9UX/;; M*,'^(8/>@#Y,HHHH **** "BND^$/PA\3?'SXEZ-X-\&Z->>(/%'B"X%IIVG M6BAIKN4@D(H) S@'OVKZ;_X<$?MD_P#1O?Q _P# >+_XN@#Y HKZ_P#^'!'[ M9/\ T;W\0/\ P'B_^+H_X<$?MD_]&]_$#_P'B_\ BZ /D"BOK_\ X<$?MD_] M&]_$#_P'B_\ BZ/^'!'[9/\ T;W\0/\ P'B_^+H ^0**^O\ _AP1^V3_ -&] M_$#_ ,!XO_BZ/^'!'[9/_1O?Q _\!XO_ (N@#Y HKZ__ .'!'[9/_1O?Q _\ M!XO_ (NC_AP1^V3_ -&]_$#_ ,!XO_BZ /D"BOK_ /X<$?MD_P#1O?Q _P# M>+_XNC_AP1^V3_T;W\0/_ >+_P"+H ^0**^O_P#AP1^V3_T;W\0/_ >+_P"+ MH_X<$?MD_P#1O?Q _P# >+_XN@#Y@^%'_)4O#7_85M?_ $V5\_ _WS[U_3%7\BO_!K#\=H/@C_ M ,%F_AW;WDJP6?CFRU'PQ*[=GFMVE@7_ (%<00I_P*OZZJ "BBB@ HHHH ** M** "OR@_X/)/^42&F_\ 90-+_P#2:^K]7Z_*#_@\D_Y1(:;_ -E TO\ ])KZ M@#^6*BBB@ HHHH *_?[_ (,8_P#FZ+_N5/\ W-5^ -?O]_P8Q_\ -T7_ '*G M_N:H _?ZBBB@ KG_ (L_\DK\3?\ 8*NO_1+UT%4O$FB1^)O#NH:;,SQQ:A;2 M6SLGWE5U*DC/?F@#^!"BIM0L)M)OY[6XC:&XMI&BEC;JC*<$'Z$5#0 4444 M%%%>D?LO_LA?$S]M/Q]>>%OA7X-UCQQXAT_3WU6XL=-16EBM4DBB:4AB!M#S M1+]7% 'F]%?7_P#PX(_;)_Z-[^('_@/%_P#%T?\ #@C]LG_HWOX@?^ \7_Q= M 'R!17U__P ."/VR?^C>_B!_X#Q?_%T?\."/VR?^C>_B!_X#Q?\ Q= 'R!17 MU_\ \."/VR?^C>_B!_X#Q?\ Q='_ X(_;)_Z-[^('_@/%_\70!\@45]?_\ M#@C]LG_HWOX@?^ \7_Q='_#@C]LG_HWOX@?^ \7_ ,70!\@45]?_ /#@C]LG M_HWOX@?^ \7_ ,71_P ."/VR?^C>_B!_X#Q?_%T ?(%%?7__ X(_;)_Z-[^ M('_@/%_\71_PX(_;)_Z-[^('_@/%_P#%T ?(%?;_ /P;>_\ *;7X!_\ 85O? M_39=US__ X(_;)_Z-[^('_@/%_\77UK_P $*?\ @CM^T[^SA_P5C^#?C;QS M\%_&7AGPIH.HW4NH:G>0QK!:(UA2?\HD--_[*!I?_I-?5_+%7]3O_!Y)_P HD--_[*!I?_I-?5_+%0 4444 M%%%% ']#W_!CI_R2W]HK_L*Z%_Z)OJ_=ZOPA_P"#'3_DEO[17_85T+_T3?5^ M[U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 ?R\?\ !=7_ )2Q?&3_ +"-K_Z06U?)5?6O_!=7_E+% M\9/^PC:_^D%M7R57[EE?^YTO\,?R1^!9K_OM;_'+\V%%%%=QP!1110!_0-_P M:E?\H\?&7_91;W_TV:77Z;5^9/\ P:E?\H\?&7_91;W_ --FEU^FU?B_$'_( MQJ^I^Y<._P#(MH_X0HHHKQSV@HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@#^8OQO\ \CIK'_7[-_Z,:LNM3QO_ ,CIK'_7[-_Z,:LNO[$I M? O0_P ^ZWQOU84445H9A1110!_0=_P2_P#^4?\ \*_^P(G_ *&]>]5X+_P2 M_P#^4?\ \*_^P(G_ *&]>]5_).=?\C"O_CE_Z4S^[^'?^13A?^O:>R%%%% !1110 4444 %%%% !1110 5\D_\%O\ _E'5XL_Z_M._]+(J^MJ^ M2?\ @M__ ,HZO%G_ %_:=_Z615[G#/\ R-\-_P!?(?\ I2/F>,_^1#C/^O4_ M_26?A;1117]6'\.A1110 5ZC^P]_R>I\(/\ L=M&_P#2^&O+J]1_8>_Y/4^$ M'_8[:-_Z7PUQYE_NE7_#+\F>AE'^_4?\4 ?C#1110 4444 %?U^_P#!KC_R@H^!G_^*_L:H **** "BBB@ HHHH **** "OY(?^#KOX6-\.?\ M@M5\0;_RUBM_&6E:/KD*J.,?88K5ST'62UD)Z\DG/8?UO5_/'_P>\_L[R6/Q M/^!_Q8MX&>+5-+O?"5_,!\L)MY1=6RD_[?VJ[(_ZYGUH _!^BBB@ HHHH ], M_8Q_: F_93_:X^&?Q*@\QCX%\3Z?KFB@N$DDC_X'&&4^S5_='X;\1V/ MC#P[I^K:7=P7^F:I;1WEG=0MNCN89%#I(I[JRD$'N#7\"%?U.?\ !IW_ ,%0 M+/\ :Y_8EM_@WX@U!&^(?P6M4LH8Y&_>:EH>[;:3J._D9%LV/NA("3F04 ?K M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >$_\ !4+X,/\ M#?\ M$Y/CEX,@A>XO=>\$:M#8QJ,EKI;61[?C!S^^6/CJ?;K7\/-?W]N@D0JP#*PP M01P17\.'_!2+]F:7]CC]O7XN?#-K%L=MU M 'B=%%% !1110!U'P2^+FL? 'XR^$_'7AZ;[/KW@W6+36]/D[)<6TR31D^VY M!D=Q7]S'[+W[0V@?M9_LZ^"OB7X7F6;0?'&CV^KVF'#-")4#-$Y'_+2-MT;# M@AD8$ BOX/Z_>'_@T&_X*[V?@74;C]EGQ]JB6UEK-W)J/@"ZN'VI%=2$O2?\HD--_P"R@:7_ M .DU]7ZOU^4'_!Y)_P HD--_[*!I?_I-?4 ?RQ4444 %%%% !7[_ '_!C'_S M=%_W*G_N:K\ :_?[_@QC_P";HO\ N5/_ '-4 ?O]1110 4444 ?PS_\ !1/X M4M\#/V^OC5X/\H0Q^&_'&LV$"@ *84O9A$P &#'M(P!P1P.E>-U^DG_ => M_L]-\#/^"Q_C+5([?[/I_P 2-)T[Q3:A1\I+0_9)R//^"ZO_ "EB^,G_ &$;7_T@MJ^2J^M?^"ZO_*6+XR?]A&U_ M](+:ODJOW+*_]SI?X8_DC\"S7_?:W^.7YL****[C@"BBB@#^@;_@U*_Y1X^, MO^RBWO\ Z;-+K]-J_,G_ (-2O^4>/C+_ +*+>_\ ILTNOTVK\7X@_P"1C5]3 M]RX=_P"1;1_PA1117CGM!1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% '\Q?C?\ Y'36/^OV;_T8U9=:GC?_ )'36/\ K]F_]&-677]B4O@7 MH?Y]UOC?JPHHHK0S"BBB@#^@[_@E_P#\H_\ X5_]@1/_ $-Z]ZKP7_@E_P#\ MH_\ X5_]@1/_ $-Z]ZK^2I_^DL_ M"VBBBOZL/X="BBB@ KU']A[_ )/4^$'_ &.VC?\ I?#7EU>H_L/?\GJ?"#_L M=M&_]+X:X\R_W2K_ (9?DST,H_WZC_CC_P"E(_HWHHHK^0S^^ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "OY(?^#K_P#Y3:_$?_L%:)_Z;+>O MZWJ_DA_X.O\ _E-K\1_^P5HG_ILMZ /SAHHHH **** "OZ/O^#(;_DUGXX?] MC58_^DAK^<&OZ/O^#(;_ )-9^.'_ &-5C_Z2&@#]OJ*** "BBB@ KX?_ .#D M/_E"5\?/^P59?^G.SK[@KX?_ .#D/_E"5\?/^P59?^G.SH _CCHHHH **** M"OV^_P"#(;_DZ?XX?]BI9?\ I6:_$&OV^_X,AO\ DZ?XX?\ 8J67_I6: /Z/ MJ*** "BBB@ HHHH *_FA_P"#V?\ Y/[^%'_9/U_].-Y7]+U?S0_\'L__ "?W M\*/^R?K_ .G&\H _&&BBB@ HHHH *_K]_P"#7'_E!1\#/^X__P"I!J=?R!5_ M7[_P:X_\H*/@9_W'_P#U(-3H ^_Z*** "BBB@#S_ /:R_P"36/B9_P!BIJG_ M *22U_"'7]\_CKPQ'XW\$:QHLWE>5K%C/9/YL?F)MDC9#N4_>'S!M?L=>M4+;1)):SI,J$_W6*8/L37]SWP-^,_A[]HSX-^%_'OA.^74O M#7C#2[?5]-N!P9()HQ(FX?PL V&4\JP(/(-?P6U^NW_!N]_P<:0_\$[=)C^# MGQD_M'4/A!<733Z1JUK&UQ=>$996S(IB'S26;,6D*H"Z,795?>5 !_4-17#_ M "_:7^'O[5'@:'Q+\-_&GAGQQH4P4_;-&U".[2,G/R2;"3&XP04"['4+=&8Z387HU35&(Z+]EMO,E7) MX!957.>0 2 #Z6JNVK6J:JEBUU;K?21-.EN9!YK1J55G"]2H+*"<8!8#N*_G MW_X* _\ !Z/J&KP7V@_LV^ VTE+XK\71I)<+VWV]C&S1KTRK32/G(W1#! M%8O_ :+_M&^//VJ?^"H_P 9/&7Q&\6:[XT\3ZAX /G:AJMTUQ+M&HVFU%SP MD:]%1 %4< <4 ?T54444 %?G_\ \'-G['TG[7O_ 2+^("Z?:FZU[X;M%XW MTU5 W$68<70]?^/*2Z( Y+!1S7Z 5!J>F6^M:;<6=Y!%=6EW$T,\,JADE1@0 MRL#P002"#ZT ?P%45]*?\%=/V#K[_@F_^W_\0/AA-!.NAV5\VH>&YY#N^V:1 M<$R6K[N-S*A\IR./,BD':OFN@ HHHH *]0_8T_;!\&_BC\.]2&F^ M)?#4_F(L@+V]]"PVRVTZ C?#(A*LN0><@JP5AY?10!_:U_P2K_X*R?#+_@J_ M\!8?%'@F^2Q\2Z9%''XF\,7,G^G:!$?%FC/NM[^QD )4XW1R(P*2Q-@!HY%9&'!! M%?T+?\$Q?^#PSX=_&'3=/\+_ +2&F+\./%7$/_"3:7;R7&@7YZ!I8QNFM&)( M!XDCX+%XQ\H /VJHKG?A9\7?"OQS\%6GB3P7XET'Q;X>OQNMM2T>_BOK2;@' MY9(V93U'&>,UT5 !1110 4444 %%,N+B.SMY)II$BBB4N[NVU442 M,=,D9% 'V57D?[8?[>'PC_8&^&\GBKXM>.=$\'Z;M8VT-S+OO=29>L=M;)F6 M=^1D1J<#DX&37X)?MZ?\'G7Q(^)T-_H?P \%V7PWTN4-%'XAU[R]3UIEYQ)' M!@VUNW3Y6^T#C(/I^.WQG^./C+]HOXA7WBSQ[XHU[QAXEU(YN-2U>]DN[F0< MX7>Y)"KG"J,*HX XH _MB_X)W_MW^&O^"D?[,6G_%CP?IFKZ5X;UC4;ZRL8 MM3"+=2);7,D'FNJ,RIO,98+N. 1DYKW"OS@_X-/_ /E"5\.?^PKK?_ISN*_1 M^@ HHHH *_FT_P"#T3]B-_AW^U#X%^.^EVA&E_$73O[!UN5!\J:E9*/)=SZR MVI55'I9-T[_TEU\R_P#!7_\ 8"L_^"EG_!/_ ,=_"]EA37[JV_M/PU!/%.I:'K%E<:;J^C7)RDD;CLRLI!'8BL^@ HHHH *L:3JUUH&JVM]8W5Q97UE*L]O<02&.6 M"12&5T9<%64@$$'((S5>B@#^F#_@@Q_P<]^&_P!I7PUHOPG_ &B=NMOIWBO^%%G5*LP0_LY7\ =?H%_P3?\ ^#DS]I#_ M ()VZ78^&X]:MOB5\/[(+'%X>\4L]P;&,<;+6Z4B:$ !4)>)<<1\F@#^OJB MOR+_ &7_ /@\H_9J^+%M:V_Q'T'QU\)M4?'GRRVG]N:7%G^[-;#[0V.;_%+_ (.#/V,_A#:RR:G^T!X) MOO*'W-$:?6F<\\ 6<GTZ=!S0!]D5^4'_!Y)_RB0TW_LH&E_\ I-?5Q7[3 M'_!Z1\!?AY;SVWPQ\ ^/?B1J48/ESWPBT+37]")&,L_7J# O'?T_(O\ X*N? M\'"WQF_X*P^!H_!7B;2?"'A+X?VFIQZK;Z/I%H\D[S1I(D;37,K,[D"5_P#5 MB-3D97B@#X+HHHH **** "OW^_X,8_\ FZ+_ +E3_P!S5?@#7[_?\&,?_-T7 M_"T,RQRJ#_%&*_AY^,7PFU[X"_%?Q)X)\4V,FE^)/">IW M&D:G:OU@N()&CD7/<;E.".",$<&@#FZ*** "BBB@#ZT_X([_ /!6;QE_P22_ M:?A\7Z+'+K/@_7!'9>+/#IE*QZM:!LATYPMS%N9HG/0LRGY78'^OG]C_ /;% M^'O[=OP'T;XC_#/Q!;>(/#6L)]Y3MN+&8 ;[:XCSNBF0G#(WL1E2K'^%*O?O M^"?7_!3'XO?\$ROBVOBSX5^))-.^T%1JFCW8,^DZW&N<1W,&0&QDX=2LB9.U MER: /[?J*_+?_@FU_P '6O[/W[8^G:?HGQ*NXO@EX^E"Q20ZU<;M#O)"<;H+ M_ 6,'KMN!'MS@-)C1B:WN;:5989T/(9'4D,I M[$'!H M4444 %%%% !116?XI\6Z5X&T&YU76]2T_1]+LT\RXO+ZX2WMX%]7= MR%4>Y- &A17Y\?MD_P#!SM^R1^R'%>6EOX\;XH>(K7*KI?@F(:DC-VS>%EM MN>#MF9AS\I/%?C9_P4 _X.ZOV@OVH([[0_A;:V/P1\*SDH)M.E^VZ_.G^U>. MH6+/!_<1HZ]/,89R ?OU_P %%/\ @L)\"/\ @F%X8>?XE^+[?_A(Y8//L?"N ME%;O7+\'.TK &'EQL00)9BD9((W$C%>Z_ CXJ0_'7X'^#?&]M9RZ?;^,M"L= MZQKFI:AK.KZE*T]W?7UP M]QO_ "8)\#O^R?Z#_P"FZWH ]@HHHH **** M/R@_X/)/^42&F_\ 90-+_P#2:^K^6*OZG?\ @\D_Y1(:;_V4#2__ $FOJ_EB MH **** "BBB@#^A[_@QT_P"26_M%?]A70O\ T3?5^[U?A#_P8Z?\DM_:*_[" MNA?^B;ZOW>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@#^7C_@NK_REB^,G_81M?\ T@MJ^2J^M?\ M@NK_ ,I8OC)_V$;7_P!(+:ODJOW+*_\ AZA'X7\0Z])KB^([#-Q)ITTD%O R36P&YXMMNK;HR7!)&QLC'[R?"/X MR^%/CYX#L_%'@OQ#I/BCP_J )@O].N5GAO>J\%_X)?_\ */\ ^%?_ &!$_P#0WKWJOY)SK_D85_\ M'+_TIG]W\._\BG"_]>X?^DH****\T]D**** "BBB@ HHHH **** "BBB@ KY M)_X+?_\ *.KQ9_U_:=_Z615]2>+O&.D^ /#EWK&NZG8:/I-@GF7-Y>SK!! O MJSL0 /J:_*7_ (*Q_P#!6WP=^T;\+M2^%_@'3[K5M,NKF"6[\07&;>)_)E$@ M6WB(WL"RKEWV]#A3D-7UG!N5XO%9G1JT(-QA.+D^B2:>^U_+=GPOB%G6!P>2 MXBAB:BC.I"48QZMM-*R6MK[O9=6?G'1117].'\8A1110 5ZC^P]_R>I\(/\ ML=M&_P#2^&O+J]1_8>_Y/4^$'_8[:-_Z7PUQYE_NE7_#+\F>AE'^_4?\4 ?C#1110 4444 M%?U^_P#!KC_R@H^!G_O[;J_FU_X/1OV)YOA_^U%X#^.VFVO_ !*/B%I@\/ZQ(B<1ZE9# M,3N?66U954>ED_M0!^)M%%% !1110 4444 :W@OQ[KGPVUZ/5?#NM:MH&J0@ MK'>:==R6MP@/4!XR&&?K7LFG_P#!5']I_2;*.VM?VC_CU:V\(VQQ1?$#5D1! MZ "? KP6B@#T#XE_M9_%3XT6LD'C'XF?$#Q9#,27CUGQ%>7ZN3G.1+(P.#-,>\^(WP=@EN)H((] MTVL:(>@Y.//4 M(*_ECK^_MT$B%6 96&""."*_E<_X.9?^"(% MQ_P3\^.-Q\6OASI#GX*^/KUI)(+:,^7X1U*0EGM6 X6VE.6A;HOS1$#9&9 # M\IZ*** "BBB@ HHHH [CX$_M,?$3]E_Q6-<^'/CGQ9X%U;@-=:%JLUC)*!_" MYC8;UY(*MD$$C%??'P+_ .#M3]LCX.6L5OJGB;P?\1((5"(OB?P]&6P/62S: MVD8^[,2?6OS/HH _;[P?_P 'O/Q4LHX_^$@^!_P_U-@#YAT_5KNQ#'M@.)L8 M]#G/M6OJW_!\-XVFL66Q_9]\+6]SD;9)_%$\T8&>TL,1M-_%J-\5&.?N7,(SGD<<=,'K7@GQ;_ .#K MW]M+XGP20V/CSP[X*AEX9-!\-6:MC&,![E)G7URK Y[XXK\WZ* /6/VA/V\/ MC5^UA(__ LKXK>/_&T+MN%KJVN7%Q:1G.?D@+>4@SSA5 KR>BB@ HHHH _K M=_X-/_\ E"5\.?\ L*ZW_P"G.XK]'Z_.#_@T_P#^4)7PY_["NM_^G.XK]'Z M"BBB@ HHHH _G3_X.Z?^"/4W@#QY)^U-X TQFT#Q'+%:^/+2VB^73KXXCAU' M"C CGPL[_@AQXA_P""3_QM;6O#MOJ6M_!'Q93_@\0_X)3S>'?&&G?M3>"]++:9K AT;QY';Q\6U MTH$=IJ# ?PR*%@=C@!XX.K2$U_0W7.?%[X2>&_CU\+M?\%^+])M->\+^*+&7 M3M3L+E=T=U!(I5E/<'!R&!!4@$$$ T ?P345]?\ _!9S_@DGXL_X)+?M3WGA M>^6^U;P#KSR7GA#Q%)%A-2M<\PR, %%U#E5D48SE7 "R+7R!0 4444 %%%% M!7L'[,'_ 4 ^-G[%U]YWPL^*'C3P3&9/-DL].U*1;&=_62V8F&3I_&AKQ^B M@#]5/@Q_P>&_M=?#6VAA\0_\*U^(BJ-LDVM>'C:W#C()(-C+;QAL<9\LCGH: M]W\-?\'P'Q"M;=AK'P%\&7TNU0&L_$%S:*&YW'#12\'C SQZGM^&E% '[GZY M_P 'P7CZX2/^S?@#X0M&!/F&Y\1W%P&';&V&/'?KG\*\\\=?\'JW[2&LI)'H M'P[^#>AH[-B2>RU"]F1<@J ?M:)D#()*$'/ 6OQSHH _0'XR_P#!T!^VI\8X M)K?_ (6ROA6QFQFW\.Z'96++QCY9_*:X'<\2]3[#'QM\;?VG/B1^TKK"ZA\1 M/'WC/QU>QL6CFU_6;C46B)Z[/.=MH]EP,5P]% !1110 5_2?\ *)#3?^R@:7_Z37U?RQ5_4[_P>2?\HD--_P"R@:7_ .DU]7\L5 !1 M110 4444 ?T/?\&.G_)+?VBO^PKH7_HF^K]WJ_"'_@QT_P"26_M%?]A70O\ MT3?5^[U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 ?R\?\%U?^4L7QD_["-K_Z06U?)5?6O_!=7_E+ M%\9/^PC:_P#I!;5\E5^Y97_N=+_#'\D?@6:_[[6_QR_-A1117<< 4444 %>L M?LE_MN_$[]B#Q[_PD'PV\57V@W$A7[7:9\VQU%1_!/ V4D'4 D;ER=I4\UY/ M16=2G"I%PJ)-/HS2E5G3DITVTULUHS^A#_@GA_PY1QM*-J6/5U_,M_FN MOJON9_4-17R?_P $^_\ @LG\&_\ @H/8V]CHNK?\(OXX9,S^%]9D6*\+#K]G M?.RY7J04._'+(G2OK"O@<1AJM";IUHN+[,_0\-BJ.(IJK0DI1?5!1116!T!1 M110 4444 %%%% !1110 4444 %%%% !1110!_,7XW_Y'36/^OV;_ -&-676I MXW_Y'36/^OV;_P!&-677]B4O@7H?Y]UOC?JPHHHK0S"BBB@#^@[_ ()?_P#* M/_X5_P#8$3_T-Z]ZKP7_ ()?_P#*/_X5_P#8$3_T-Z]ZK^2B^%6A^('C"$F,P64X&GV3=#YUP,AF']R/<9=1GMX?\ #%*U;-G_ -N) M_P#I4E^2^\_ ^+/&:3OA\BC9?\_)+7_MV+_.7_@)ZQ^U-^VS\1OVQ?$OV_QM MKTUU:PN7M-*MLPZ=8]?]7""1NP<;V+.1P6.!7D]%%?KF'PU+#TU1H148K9)6 M1^$8S&5\55=?$S_Y/4^$'_8[:-_Z7PUY M=7J/[#W_ ">I\(/^QVT;_P!+X:X\R_W2K_AE^3/0RC_?J/\ CC_Z4C^C>BBB MOY#/[X"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_DA_X.O_\ ME-K\1_\ L%:)_P"FRWK^MZOY(?\ @Z__ .4VOQ'_ .P5HG_ILMZ /SAHHHH M**** "OZ/O\ @R&_Y-9^.'_8U6/_ *2&OYP:_H^_X,AO^36?CA_V-5C_ .DA MH _;ZBBB@ HHHH *^'_^#D/_ )0E?'S_ +!5E_Z<[.ON"OA__@Y#_P"4)7Q\ M_P"P59?^G.SH _CCHHHH **** "OV^_X,AO^3I_CA_V*EE_Z5FOQ!K]OO^#( M;_DZ?XX?]BI9?^E9H _H^HHHH **** "BBB@ K^:'_@]G_Y/[^%'_9/U_P#3 MC>5_2]7\T/\ P>S_ /)_?PH_[)^O_IQO* /QAHHHH **** "OZ_?^#7'_E!1 M\#/^X_\ ^I!J=?R!5_7[_P &N/\ R@H^!G_1J"(W/WUQ&QPL93^7OQ3X6U+P/XEU#1=:T^]TG6-)N9+.]L MKR%H;BSFC8J\4B, RNK @J0"""#0!0HHHH **** "BBB@ HHHH *_9[_ (,F M/^3^_BO_ -D_;_TXV=?C#7[/?\&3'_)_?Q7_ .R?M_Z<;.@#^EZBBB@ HHHH M *YOXO\ P@\,?'_X8:YX+\::'I_B3PKXDM'LM2TV]C\R&ZB;J".H(."&!#*P M# @@$=)10!_([_P7;_X("^,/^"5_Q#N_%GA.WU+Q3\"M9N?^);K&WS;C0'TO3]:T75[=[2^L+ZW2X MMKR%P5>.2-P5=6!(((((K^?O_@L/_P &B6HZ#>ZK\0OV55;4M-;?=7GP_O+G M_2;7JS?V=/(?WJXZ02MO&#M=R50 'X,T5J^-_ VM?#/Q;J&@>(](U/0=_X)J?\ !/'P M5\)?%&M:7KWB#19+R\O[C34<6J2W-S).8HRX#.J>9MWE5W8SM%?5% !1110 M4444 %TR LJ@^8 %,C?DS7]_E?F7_P %3_\ @UY^!O\ P4!N=3\6>#53 MX/?$Z\+3R:EI%HK:3JLQ.XM=V0*KO8YS+"T;DL6?S2,4 ?R;T5]F_M\_\$#/ MVF_^">,EY?>*_ -UXE\(6>YCXH\+!]4TM8QUDE*J);=?>>.,9. 37QE0 444 M4 %%%% !1110 4444 %%%% !1110 5^_W_!C'_S=%_W*G_N:K\ :_?[_ (,8 M_P#FZ+_N5/\ W-4 ?O\ 4444 %%%% !1110!XM^WQ^P/\.?^"D'[.>K?#7XE M:2+[2KX>=97L.%OM%NP"([NVD(.R5,GL592R,&5F4_R'?\%4/^"3'Q0_X)0? M'6;POXWL7U#PWJ,LC^&_%-K$1I^OVX/!!R?*G48\R!SN0\C*5010!_"# M17ZW?\%=_P#@U-^)_P"QO33XHA)XCT&/KB2% /M<8_ MYZ0+O R6B55+G\DY8F@E:.1621"596&"I'4$4 -HHHH **** "BBB@ HHHH M**** "BBB@ K^YS_ ()Z_P#)@GP._P"R?Z#_ .FZWK^0/_@G!_P2 ^.'_!4/ MQQ#8?#GPM/%XH^*]41[;1=,&?FW3;3YD@_YY1!Y.^T#)']E7[.GPI;X M$?L^>!/ \E\NIR>#?#VGZ$UXL7DB[-K;1P&0)D[=VS=MR<9QD]: .RHHHH * M*** /R@_X/)/^42&F_\ 90-+_P#2:^K^6*OZG?\ @\D_Y1(:;_V4#2__ $FO MJ_EBH **** "BBB@#^A[_@QT_P"26_M%?]A70O\ T3?5^[U?A#_P8Z?\DM_: M*_["NA?^B;ZOW>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@#^7G_@NNI3_@K'\9,@C_B8VAY_Z\+: MODFOZNOVY/\ @F-\(?\ @H-X:-MX]\.(NM0QE++Q#II%MJUCQ@;9<$2*/^>< MH=,\[<\U^&?_ 41_P"" _Q?_8C^W>(/#]O+\3/A[;AIFU72K8_;-.C&23=6 MH+.H4 DR1EXP!EBF<5^JY#Q#A:U&&&F^6<4EKL[*VC_3?U/R/B#AO%T:T\3! MSQ$4U^*]'T.W YCB M,'4]IAY.+_!^JV9_71^RA^VK\,?VVO *^(OAKXLT[Q%:QJOVNV1O+O=.9LX2 MX@;$D1R#@L-K8)4L.:]4K^.OX/?&KQ;^S[X_L?%/@GQ%JWA?Q!I[9@OM/N&A ME R"5..&1L ,C JPX((XK]B_^"=W_!T!8Z[]A\+_ +0VGQZ;>,5AC\7Z3;'[ M-)VW7=JN3&>Y>$%>?]6@&:_/,UX1KT+U,+[\>WVE_G\M?(_2&-8TWQ!H.JQ":SU#3[A;BWN4/=7 M4D'G(/H00>:V:^/E%IV9]K&2:NM@HHHI#"BBB@ HHHH **** "BBB@ HHHH M_F+\;_\ (Z:Q_P!?LW_HQJRZU/&__(Z:Q_U^S?\ HQJRZ_L2E\"]#_/NM\;] M6%%%%:&84444 ?T'?\$O_P#E'_\ "O\ [ B?^AO7O5>"_P#!+_\ Y1__ K_ M .P(G_H;U[U7\DYU_P C"O\ XY?^E,_N_AW_ )%.%_Z]P_\ 24%%%%>:>R%% M%% !11537=>L?"^CW.HZG>6FG:?9QF6XNKJ9888$'5G=B H'J3BFDV[(4I)* M[V+=#?V-)O$/C3Q!J/B'5IL_O;J3*PJ3G9&@PD:#LB */2OT?A[PY MQF,M6QW[JGV^T_ET]7KY'Y%Q9XN9?E]\/EMJU7O]A/U7Q>D=/[R/N']M;_@O M-XF^(XO- ^$=K<>$=&?,3ZW5@!'?YGZ$%#7Y]ZSK5YXCU:XO] M0N[J_OKR0RSW-Q*TLT[GDLS,26)[DG-5:*_:LIR3!9;2]E@X*/=]7ZO=_EV/ MYQSWB3,WQ]1R[+:*]$M%^;ZMA1117K'AA1110 4444 %%%% !7J7[#H+ M?MJ?"#'/_%;:,?\ R>AKTK]BW_@E+\3OVQGMM4BL_P#A%/!LA!;7-3B95G0\ MYMHN&G]F&$[;P>*_6[]CK_@FW\,?V+["&?0-)&J>)]FV?Q!J2K+>OD881\;8 M5.2-L8&1C<6ZU\+Q3QIE^!I3PR?/4::M'I=6]Y[+TU?D?IW!/AWFN9UZ>-E' MV=&+4N:7VK._NK=^NB\^A[]1117\XG]=!1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %?R_X+4?$6ZL=$U:\MGTO10LL%G))&V--M MP<,H(X-?UCT4 ?P1_P#"J/%/_0M>(/\ P73?_$T?\*H\4_\ 0M>(/_!=-_\ M$U_>Y10!_!'_ ,*H\4_]"UX@_P#!=-_\31_PJCQ3_P!"UX@_\%TW_P 37][E M% '\$?\ PJCQ3_T+7B#_ ,%TW_Q-?T6?\&4/AG4O#/[+WQMCU+3[[3Y)?%-D MR++6SMY[J MYFTNR"10QF21_P#B96AX4(/_ 73?_$T?\*H M\4_]"UX@_P#!=-_\37][E% '\$?_ JCQ3_T+7B#_P %TW_Q-'_"J/%/_0M> M(/\ P73?_$U_>Y10!_!'_P *H\4_]"UX@_\ !=-_\37[8?\ !E%X.UCPS^U% M\;)-2TK4M/CE\+62HUS;/"'/VL\ L!FOZ+** "BBB@ HHHH **** "OYM/\ M@],\%ZQXE_;S^%H11^ 51GMK5Y55O[1NS@E0>>>E?TET4 ?P1_P#" MJ/%/_0M>(/\ P73?_$T?\*H\4_\ 0M>(/_!=-_\ $U_>Y10!_!'_ ,*H\4_] M"UX@_P#!=-_\31_PJCQ3_P!"UX@_\%TW_P 37][E% '\$?\ PJCQ3_T+7B#_ M ,%TW_Q-?UR_\&PVDW6A_P#!#;X(6M[:W%G=1?V]OAGC,ANK=3SU%W!-(1])!T'/7/ MCOB+_@R$^&%REQ_9/QS\>6+,V8#=Z-:70C7/1@K1[CC(R-O/..U '\XM%?T9 M:)_P8_\ P\@M674OCUXTNI]Y*O;>'[:W4+@<%6ETGQ)K_C?XA> M)-.&F:KK=ZHM+3R/,20Q6]HA81J7C0DR/*^5X8 E:^\** "BBB@ HHHH *** M* "BBB@#YQ_;W_X).? ?_@I3X=^R_%7P+I^J:M#%Y-GX@LO]#UJP'.!'=)\Q M4$D^7)OCR:M\ _'&E?$+2=S/%H?B%DTO6(U_A19 M_P#CVG;U9OLX]%K^D>B@#^&/]I[]@#XV?L7ZG+:_%+X7^-/!2Q2>4+O4--D% MA,V>Z.PKQ^O[]M0T^WU>QFM;J"&ZMKA#'+#*@>.13P0RG@@^AKY M?^.W_!$C]DS]I&>:;Q7\ _AW)=7((FNM+T_^Q;F;/&YI;(PR,W^T6R,#G@4 M?Q4T5_5=\2_^#/7]C[QW<2OIQZD_>/MCQW M7_\ @R.^#-Q<*=+^,GQ.LXL'<+#9JX!Z'YR>."*]_P#A+_P;.?L4_"&2&:#X+V.O7D6,SZ]K%_J0 MDQ_>ADF,/Y1C/Y4 ?Q_:+HE[XDU6WL-.L[K4+ZZ<1PV]M$TLLS'H%502Q]@* M^SOV3_\ @WA_:Z_:]FM9M'^$>M^%-&N& .K>,!_85M&IQB01SXN)$YSF*)\] MLU_73\%_V7?AG^SA8?9?A[\/?!'@:W9=K)H&AVVFAQQ][R47.<#.>M=W0!^( M/["7_!EWX!^'MU9:U^T!X\O/B!>Q[9'\.^'!)INDA@1E)+EO])F0\\H+<\_G M^Q7P$_9S\!_LM?#FU\(_#GPCX?\ !7ANS)>/3](LDM82Y^](P49>1L_M->$6DE\,>,O MA+XNM5'RI_:-WI]VQY_@DMS&!T_Y:]3TXS7]/U% '\B7B?\ X-6?VXM NFCM MOA'I^LQKN_?67B_1E7@^DMU&W/4?+^1XKC_^(;S]MK_H@?B#_P &VF?_ "37 M]CM% '\?GA7_ (-A/VXO%C*R?!&:QA,GEM+?>)]&M]G .2C7>\KSU53^AKVG MX6?\&;G[6'CAH7U[4_A3X+A;!E74-=FNIT& 2 MM;RHS#)&"X&5/.,$_U-44 M ?A+^SK_ ,&17A'2+BWNOBQ\;M?UU=_I/B#Q3>>(/*! MZ)96A@W$=N=0P/7YO2@#^<.BBB@ HHHH *_?[_@QC_YNB_[E3_W-5^ -?T+? M\&.'A1K/X??M'ZYMEV:CJ'A^Q!.-A,$>H.<=\_Z0,_5?>@#]YJ*** "BBB@ MHHHH **** "OB?\ X*+_ /!O_P#LW_\ !2:;4-:\3>$SX4\?7RL3XL\,LMCJ M$LAZ/<)M,-T> "9D9]O"NO4?;%% '\N/[;/_ 9Z_M%? 2YO-1^%6I>'_C-X M=C+-%#;2KI.M(@Y^>WG;R6P#QY<[,VTX0$@'\Q_CA^S5\1/V9O$S:-\1/ WB MWP/JBL5%MKFDSV#R8.,IYBKO7T9<@CD$BO[QJS?%O@W1_'V@W&E:]I6FZUI= MT-LUG?VR7-O,/1D<%6_$4 ?P*T5_9E\:?6O@+X-TVZF!_?> M'?/T JQ_CVV,D*%@>?F4@GJ#DY^8OB+_ ,&:?[)_B]II-'UKXO>$Y&R8TL== MM;B%#CC(N+61RO?&\'WH _EJHK^D;5?^#(KX0S7\C6/QJ^)%O:G&R.?3[*:1 M>!G+!4!YR?NC XYZGG])_P"#'GP5#?*U]^T%XHN+;!W1P>%H(9"<<89KAP.? M]D_A0!_.S17])FA_\&1WP:MY9/[2^,WQ.NXR/D%M9V-N5/N623/TP*]4\"_\ M&;_[(OA&X5]0OOB[XH56W&/4_$5O&K#C@_9;6$XX/0@_,>>F #^5^MSX??#+ MQ)\6O$D6C^%?#^N>)M8G_P!78Z382WMS)VXCC5F/X"O[#O@[_P &[O[&'P0E MAETOX"^$]4GA*L7\0RW6NB5@.K)>2RQ\]2H4+[5]8_#?X2>%/@WH7]E^$/#' MA[PKIF0?L>CZ=#8P9' ^2)57]* /Y-OV1?\ @UR_:[_:IFM[F_\ ]M\*]#F M*EK_ ,:W/V"4*>3BS17NMP'9XD!)QN'./UZ_8)_X- /@'^S?-::U\6M4U/XV M>)(2)!:W49TS086'/_'M&[238/'[V4HP S&.17ZX44 9?@KP1HOPV\*6&@^' M='TO0-#TN(066G:;:1VMI9QCHD<48"(H]% %:E%% !1110 4444 ?E7_ ,'A MF@WWB/\ X)-Z;;Z?97=]<#Q]ICF.WA:5]HMKW)PH)QR.?>OY=_\ A5'BG_H6 MO$'_ (+IO_B:_O*?^A:\0?^"Z;_ .)H_P"%4>*?^A:\0?\ @NF_^)K^ M]RB@#\+_ /@R0\+:IX8^%_[0JZEIM_I[3:IH9C%S;O#OQ%>YQN SC(Z>M?NA M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110!\'_\%$/^" ?PA_;:>_\ $/A^%/AG\0;HM,^J M:5;@V.HRGO=6H(5B3DF2,HY+$L7Z5^&7[<7_ 3,^+W_ 3[\2_9?'WAN1=& MN)3%9>(-/)N=*OCV"R@#8YZ^7($?@G;CFOZO:S?&'@[2?B#X8OM$U[2]/UK1 MM3B,%Y8WUNEQ;749ZH\;@JRGT((KZ7*N*,5A+0G[\.SW7H_T>A\OF_"F$QEZ ME/W)]UL_5?JK/U/XU:*_'_'S7WBC]G_4+?PKJSEII?"NIRLVF M7+'DBVG.7MR><(^^,D@ Q**_&;X\?L\>./V8?B'=>%/B!X9U;PKK]F?GM;Z' M;YBY($D;C*2QG!PZ,RMC@FOT?+C+7JGNOE^JT/S',\EQ> E:O'3HU MJG\_T=F<91117J'DA1110 4444 %%%% 'MO[&'_!0_XM?L#^+SJGPY\47.GV MMQ('OM'NLW&E:EC_ )[6Y.TMCC>NV0 G##-?N+_P3O\ ^#B#X3_M?/8>&_'+ M0_"WQ[<%84AO[@-I&IR'@>1=' 1F/2.;:HK2_F6 M_P ^_P _D>YE/$.+P#M3=X?RO;Y=OE\[G]G:L'4,I#*PR".]+7\S/_!/#_@N ME\8OV#/L6AS7C>/_ (>V^V,:!K%PQ:RC':TN.7@P.B$-&/[@)S7[I?L%_P#! M5[X._P#!0K18E\':^NG^*EBWW?AC52MOJEN0,L43.)XQ@G?$6 &-VTG%?F^: M\US0_F7ZKI^7F?J&4\283'6C%\L_Y7^CZ_GY'TI1117@GT 4444 %% M%% !1110 4444 ?S%^-_^1TUC_K]F_\ 1C5EUJ>-_P#D=-8_Z_9O_1C5EU_8 ME+X%Z'^?=;XWZL****T,PHHHH _H._X)?_\ */\ ^%?_ &!$_P#0WKWJO!?^ M"7__ "C_ /A7_P!@1/\ T-Z]ZK^2--=CAOYHR]II%H!/J-]C^Y%D8!Z;W*H M#U85^37[:W_!9SXD?M/M=Z+X;DF\ ^#9-T9M;"<_;[Y.G[^X&" 1UCCVKAB& M+\&OJL@X/S#-6I4H\M/^:6B^75_+3NT?#\4^(&59&G"M+GJ](1U?SZ17KK;9 M,_1#]M7_ (*_?#/]DQ;S1]/N%\;^-(0R#2]-F!@LY!QBYN.5CQSE%W.",%5S MFOR5_:Y_X*!?$O\ ;/UEF\6:TT.B1R^9:Z'89AT^V]#LR3(P_OR%FY."!Q7B M=%?N7#_!N7Y4E."YZG\TM_DME\M>[9_-7%7B%FN>-TZDO9TOY([?]O/>7ST[ M)!1117UA\(%%%% !1110 4444 %%;?P[^&WB#XM^+K30?#&CZCKVLWS;8+.R M@::5_4X'11U+' Y) K]+?V*?^"!"1+:>(/C5>^8WRR)X9TVX^5?]FYN%Z^Z M0G'_ $T/2O#SKB+ Y73Y\7.SZ16LGZ+]79>9])P[PGF>=U?9X&G==9/2*]7^ MBN_(^!?V9/V._B%^UYXK&E^!_#]SJ*1N$N]0D'E6&G@\YFF/RKQD[1EV .U6 M/%?J_P#L4_\ !$?X?_L\?9-<\<&W^(/BR,!PMQ#_ ,2JQ?K^[@;_ %I!XWRY M!P"$0U]A^ _ &A_"_P *6>A^'-)T_0]'L$\NWL[*!888A[*HQD]2>I/)R:V* M_$>(?$''YA>EA_W5/LG[S]7^BMYW/Z2X3\*>EJI MXR:_;G_@X=_X+8:-_P $P?V<+SPKX3U6UN/CEXXLV@T*RC822:#;ON1]4F'\ M(3#"$-]^7!PR1R8_DBN[N6_NI)YY))IIG,DDDC%FD8G)))Y))YR: (Z*** " MBBB@ K^HC_@S(^$;^"?^"7WBCQ/<6_ES^-O'=Y/!+M'[ZUM[:UMTYZG$RW(Y M]^.I/\N]?VN?\$7/V9Y/V0_^"67P1\"W,/V?4K/PU#J6I1%=K17EZ6O;A#ZE M);ATS_LT ?4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !7G7[3'[)GP[_;#^'LGACXD>%-+\4:4P8P_:8]MQ9.<9D@F7 M$D+\#YHV4D#!R.*]%HJJ=24)*<'9KJB*E.-2+A-73W3V/P/_ ."B/_!LYXY^ M"7V[Q-\$;J[^(GAE"TK:%,%77+%.N$QA+H#_ & LAX 1N37Y>:QH]YX>U:ZL M-0M;FQOK*5H+BVN(FBF@D4X9'5@"K @@@C((K^S.OF/]OG_@DG\'/^"AFDR3 M>+-#_LGQWR?3\O0_E?HK[-_X*&_\$.OC'^P-)?:U]A;Q MY\/;W]VRT?('F$G%?&5??X7%4<1#VE"2DO+^M#\ZQ M6#K8:I[*O%Q?G_6OJ@HHHKH.8**** "BBB@ JUH>NWWAC6;74M-O+K3]0L95 MGMKJVE:&:WD4Y5T=2"K \@@@@U5HH#;5'ZJ?\$\/^#FOQI\'CI_ACXY6=SX^ M\-QA84\0VH5=Q>*/ASXJT MKQ5H\FT2/:R?OK1R,B.>)L20R8YV2*K8YQBOY!*[C]G_ /:3\=_LK_$*W\4_ M#WQ1JWA77+<@>?92[5F7^Y+&'_!SMX7^(RV/ACX^6,/@_6VQ M$GB?3XF?2KIN@,\(S);L>/F7?'DDGRU%?JUX8\4Z9XV\/6>KZ+J-CJ^DZE$M MQ:7ME<)<6]U&PRKQR(2K*1T()!K\YQV6XG!SY*\;=GT?HS]+R_-,-C8<^'E? MNNJ]5_2+U%%%<)Z 4444 %%%% '\Q?C?_D=-8_Z_9O\ T8U9=:GC?_D=-8_Z M_9O_ $8U9=?V)2^!>A_GW6^-^K"BBBM#,**** /Z#O\ @E__ ,H__A7_ -@1 M/_0WKWJO /\ @F?J%OI/_!/+X8W5U-#;6UOH*R2RRN$CB4,Y+,QX YR:\$_ M;6_X+L>#?@\+K0OA?!:^.O$4>Z-M2=B-(LVQU#+AK@@]D*I_MGI7\NU5WT7O/=[+^K']JT.(LORC(\+7S"HH+V<++J_=6B2U?Z=;'VM\5 MOB_X7^!O@RZ\0^+M=TWP_HUH/WEU>3"-2<$A%'5W..$4%F/ !-?F+^VO_P % M\]3\1F\\/_!FRDT>Q.Z)_$FH1 WC(@21MMO9H3G9#$N$C7V4#/4Y/-<'7ZOP]X;X3"6K8_\ M>S[?97R^U\]/(_#>+/%['X^^'RM.C3_F^V_G]GY:_P![H:'BKQ;JGCKQ#=:M MK6I7VK:I?.9;B[O)VFGG8]V=B23]36?117Z5&*BK+8_'I2E)N4G=L****9(4 M444 %%%% !117T)^QK_P3.^)W[:-Y#=:+IO]B^%=^)O$&IHT5H0#AA",;IW& M#P@V@C#,N0:Y<9CL/A*3KXF:C%=7_6_EN=V7Y;BL?76&P=-SF^B5_P#AEW;T M1\^P0274Z1QHTDDC!411EF)X [DU]Q?L4?\$/?'GQ^%GKOQ >X^'_A.;;*L M$D8.KWR'^Y$W$((_BE&1D$1L#FOT0_8P_P""6/PQ_8UAM]0L['_A)O&$8!?7 MM4B5IHF[_9X^5@'7EKU\D?OW"? M@S3IVQ.>2YGO[.+T_P"WI+?TC9>;1YO^S;^R1\/_ -DOPG_9/@7P[9Z2LJJ+ MJ\(\V]OB.\TS?._.2%SM7)V@#BO2***_)Z^(JUZCJUI.4GNV[M_,_=,+A:.& MI*AAX*,(Z))62]$@HHHK$Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY0?\ @[Q_ MY3):U_V*NC_^BGK^KZOY0?\ @[Q_Y3):U_V*NC_^BGH _,&OL#]@W_@NU^TU M_P $[DL]/\$?$*[U;PG9D!?"_B53JND!!_!&CL)+=>^+>2+/>OC^B@#^D#]C M[_@]5^&OC2&UT_XW?#3Q#X'U J$DU?PW*NK:<[=W:%_+GA7K\JF<].>>/TJ_ M9N_X+!?LP_M:Q6X\"?&[X?ZE>70!BTZ\U)=,U)\^EI=>5.<=\)QQZU_$K10! M_?U#,MQ$LD;+)'( RLIR&!Z$&G5_"#\)_P!J[XI? 0+_ ,(+\2O'W@ORSE?[ M"\0W>G;3UX\F1:]Z\&_\%YOVQ? BQBQ_:&^(\_E-N7^T;]=2R=H7G[0LFX8' M0Y&>>O- ']HE%?QQ?\1(7[;7_1?/$'_@ITS_ .1JY?XA?\%Y/VQ/B=:O#J7[ M0WQ(MDDQDZ3?C2&& 1PUHL1'7L>>/04 ?V*_&O\ :#\"_LV^#9?$/Q!\8^&? M!6APAB;W6]2BL86(&2JM(PW-Z*N220 "37XW_P#!47_@\/\ !/P[T?4O"?[, M>G/XT\22*T'_ F.K6CV^CZ>>A>WMY );IQS@R+'&#M/[U*?%7B&X-UJ&IZA,9I[ES@#)/154!55<*BJJJ H '+T44 %%%% !1110! M]8?\$1_V%IO^"AO_ 4J^&_@&:S>Z\,VM\->\3G9NCCTJS(EF5_03,([<'L] MPE?VF5^2O_!IG_P2UF_8\_9!NOC%XNTU[7Q_\988I[.*=-LNEZ$IWVR8(RK7 M#'SVYP4^S9 937ZU4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 (RAU*L RL,$'O7YV_\%$?^#=3X5_M9 M+?>(OAW]E^%OCJ;=*QL[?.C:E(22?.MEQY3,>/,AQC))1S7Z)T5U8/'5\+/V ME"3B_P _5=3CQN P^+I^SQ$5)?EZ/=?(_DK_ &RO^"?WQ6_8+\:C1_B1X7NM M+AN'*V.JP?Z1I>I@9YAN%&UC@9*-MD4$;E6O%Z_L@^(WPT\._&#P9?>'?%6A MZ5XBT'4T\NZT_4;5+FWG7.1N1P0<$ @]00",$5^1'_!1'_@U\MK[[=XH_9WU M%;.3#3/X.U>Y+1N>NVTNW)*]@$G)&23YJC K]#RKB^C6M3Q?N2[]'_E^7F?F M^;\%UJ-ZF#?/'M]I?Y_GY'XK45TGQ:^#OBKX#^.KSPSXS\/ZMX9\0:>V)['4 M;9H)D]& 8?,IQD,,JPY!(KFZ^QC)27-'8^)E%Q?+)6844451(4444 %%%% ! M7T-^PO\ \%0?C!_P3X\1+-X%\1R2>'Y9O-O?#FI;KG2;WIN)BR#&YP,R1%'. M "Q'%?/-%95J%.M!TZL5)/HS:AB*M&:J4I.,EU1_2I_P3N_X+W_"#]N(6.@Z MS<)\-_B#/B/^Q]6N5^RW\G_3K=$*LF>R.$D)X"L!N/W17\8=?>W_ 3P_P"# M@?XO?L6K8^'O$\LGQ.\ 0%8QI^J7)&H:='T_T:Z(9@ ,8CD#I@879DFOA,UX M-WJ8%_\ ;K_1_P"?WGZ!E'&VU/'K_MY?JO\ +[C^D:BO!?V(O^"E?PA_X*!> M%_MGP^\30RZM#%YM]H%^!;:MIXXR7@).Y 2!YD9>/)QNSD#WJOA*U&I2FZ=5 M--=&?H-&O3K052E)23ZK4****R-3^8OQO_R.FL?]?LW_ *,:LNM3QO\ \CIK M'_7[-_Z,:LNO[$I? O0_S[K?&_5A1116AF%%%% 'IWCW]L/XA?$7X/>'_A_> M^(;J#P7X;M4M+72+3]Q;RA3D/,%YE;//SD@'[H6O,:**QHX>E1CRTHJ*;;T5 MM7N_5]6=&(Q=;$24Z\W)I)*[;LEHDO)+9= HHHK8YPHHHH **** "BBM'PGX M1U;Q[XBM-'T/3;[6-6OY!%;6=E T\\[GHJHH))^@J9245S2V*C&4FHQ5VS.K MOOV?/V8?'7[4OC%=#\#>';[7+I2OGRHNRVLU)QOFE;"1K_O')QP">*^\/V*O M^"!6H:Z;77_C1>-I=F<2)X;TZ<-=2>@N)URL8]4B+,0?OH017Z&?@ MCX-M?#_A'0]-\/Z-9C]W:V4(C3/=F/5F/4LQ+$\DDU^:\0^)&$PEZ.7VJS[_ M &%\_M?+3S/V+A/P@QV.MB,U;HT_Y?MOY/2/SU_N]3XK_8I_X(6>"_@S]CU[ MXG36WCOQ)'B1=.V'^Q[-O0HW-P1ZR )S_J^ :^\K.SATZSBM[>&."W@01Q11 MJ%2-0,!0!P !P *DHK\7S3.,9F-7VV,FY/IV7HME_5S^BLDX?R_**'U?+Z:@ MNKZOS;>K^>W0****\L]H**** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY M0?\ @[Q_Y3):U_V*NC_^BGK^KZOY0?\ @[Q_Y3):U_V*NC_^BGH _,&BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ K]1O^#;/_@A[>?\ !1KXYV_Q,^(& MERI\$/ E\'G69<+XKOX]KK8IZPKE6F8<%<1CERR9?_!#3_@W5\AZ?X;\*^&[1++3=-LH_+AM8EZ #J23DEB2S,2Q)))(!T4,2V\2Q MQJL<<8"JJC 4#H *=110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DW[6W[#WPO\ VXO M9\/_ !)\*V.NPQ@_9+P#R;_3F_O07"X>/GDJ#M;&&5AQ7XC?\%#_ /@VX^)G M[-'VSQ'\*)+WXI^#(MTK6<4(_M[3D'9H5XN0./FA&XG/[I0,U_0E17L99GF* MP+M2=X_RO;_@?(\7-"5DVP^)]'1I MK, GY?/7&^W8\##C:2<*[5^D95Q'A<;:%^6?9_H^OY^1^89OPSB\#>=N:'\R M_5=/R\SY1HHHKZ ^<"BBB@ HHHH **** -3P9XUUCX<^*;'7/#^K:EH>M:;) MYUI?Z?U\ Y61CFOR(HK@Q^68;&0Y*\;]GU7H_Z1Z.7YKB ML%/GP\K=UT?JOZ9_89\#?C_X+_:7^'MKXJ\ ^)=)\5>'[PE8[RPF$BJPQE'7 M[T;C(RC@,,\@5V%?R%_LP_M>?$?]C;X@Q^)OAOXKU3PSJ?"SK ^ZVOD!SY<\ M+9CF3V=3@\C! -?M=_P3N_X.7_ 7QU^P^&?C5;6?PW\52!8EUN-B=!OWX&79 MB7M"<_\ +0M& "3(O"U^=9KPGB,->IA_?C^*^77Y?S\T?&_\ R.FL?]?LW_HQJRZTO&\F964Y# N<$&LV MOZ8I? O0_BNM_$EZL****T,PHHHH **** "BBB@ HHHH **]N_9%_P"">_Q, M_;/U9?\ A%=%:WT))-ESKNH9@TZWQ]X!\$R.,CY(PS#(R .:_6[]BO\ X)$_ M#/\ 9%^RZM=6Z^-O&<.'_M?4X%\NT<=[:#E8O9B7<=F .*^2X@XSR_*DX3?/ M4_ECO\WLOGKV3/O.%?#O-<\:J4X^SH_SRV_[=6\OEIW:/SM_8J_X(O?$;]IH M6FM>*$F\ >#YB'$]] ?[0O4_Z8VYP0".CR;1@@@.*_63]E?]B+X]FC$=WJUSB;4;[I_K)2,[21G8@5 >BBO6J*_#L_P",,PS5N-67+3_E MCM\^K^>G9(_I;A;@#*LC2G0CSU>LY:OY=(KTU[MA1117RI]L%%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %?@W_P '+_\ P0-^/7[9?[5M M]\=/A/I^C^-M-ET6ST^Z\/078M]8A:W5E:2-)=L4RD'.%D\S/ 1J_>2B@#^" M+XF?"KQ1\%O&=YX<\8^'-=\*>(-/;9=:9K%A+8WEN?1XI%5UZ=Q6!7]VO[2/ M[('PM_;!\)?V'\4/ 'A3QUIJJRQ)J^G1W$EKNQEH9"/,A8X'S1LK>]?F%^U? M_P &9G[/?Q:>ZO?A=XL\9_"74)F+1VKN->TF$>@BF9;C\3H2 =-T=VL<*D^@G8>]?%WQH_X M(X?M4?L_22_\)1\ OBA;00Y\RZLM#EU.T3'K/:B2(?\ ?5 'S516AXE\)ZIX M+U5['6--U#2;Z/.ZWO+=X)5P2IRK 'J".G4$=JSZ "BBB@ HJ2TM);^ZC@@C MDFFF<1QQQJ6:1B< #DDGC KW3X*?\$NOVCOVBI(?^$+^!WQ0URWN "EY'X= MN8K+!.!FXD181GW<< GH#0!X/17ZK?LT_P#!GY^U=\99H9_&@\$_"C36*M)_ M:^K+J%]L/=(;/S4+#^[)+'^=?II^QI_P9T_L[_ B>UU+XH:YXF^,VL0$.;>X M)T71RP.0?L\#F9OXG;$4"9XWRNJYXSFOW\_X)-_\&A?@[X&W6E^./VE;S3OB%XG MA"W$'@^R);0+!^H%TY :\=3C*86'(8$3*0:_8GX0?!7P?^S[X#L_"_@7POH' M@_PY8#_1]-T>PCLK6,\ D)& -QP,L>3U)-=/0!!IFF6VB:;;V=G;P6=G9Q+# M!!#&(XX8U 5451PJ@ < "IZ** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ J*^LH=3LIK:YABN+>X1HI8I4#I(C#!5@>"""00>M2T4 ?F5_P41_X-K?AS M^T2+WQ)\'YK+X8>,),R-IHC)T#4']/*4%K4GCYH04&/]5DEJ_$K]J[]BWXF? ML2_$!O#?Q*\*ZAX>O&+&UN& DLM10?QP3KF.1>1G:'-)\4>'[\?OK'4;=9HR<$!USRCKD[74AE/((-?595Q7B<-: MG7]^'GNO1]?1_>CY'-^$,+BKU*'[N?EL_5=/5?Z]\*?&% M_P"'_$VC:IX?UW2Y/)N]/U"V>VN;9^N'1P&'!!Y'((-?HV7YIAL9#FH2OW75 M>J_I'YGF.4XK SY,1&W9]'Z/^F8]%%%>@>:%%%% !1110 4444 ?64/^J7Z" MG4V'_5+]!3J_1*/P+T1^$XC^++U?YA1116AB%%%% !1110 45:T30[WQ+JUO MI^FV=UJ%]>.(H+:VB:6:9ST544$L3Z 5^A/[%?\ P05\2?$ V>O_ !>NYO"N MCMME30K1U;4[I>#B5^4@!XX^9^H(0\UY.;9Y@LMI>UQDU'LNK]%N_P EU/=R M'AO,QP%-R[O:*]7LOS?1,^'/@I\ _&7[1GC.+P_X)\/:CXBU23YFCMH_ MD@7^_+(V$C3MN=@,\9S7ZC_L5_\ !!;PW\/!:Z]\7;J#Q9K*XD31+1V73+8] M0)6X>E3[_:?SZ>BU\V?T;PGX1Y?E]L1F5JU7 MM]A>B?Q>LM/[J*NBZ+9^&])M]/TZSM;"QLXQ%!;6T2Q0P(. JJH 4#L ,5:H MHK\X;;=V?KL8I*R"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 4?$'AC3?%NG_9-5T^QU.USN\F[@6:/ M.",[6!'0D?0FO,_$?[ WP)\8-,VK?!7X2ZHUQ'Y4IO/"&GS^8F,;6W0G*X)& M#Q7K5% 'S_\ \.G?V6?^C:?V?_\ PWFD?_(]:6@?\$S_ -F_PIO_ ++_ &?O M@CIOF$,_V7P+I<.XCH3M@&<9KVZB@# \%_"GPO\ #<,/#OAO0-!\P$-_9VGP MVNX'!.?+4==J_D/2M^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ KQ#]M/_@G;\)?V^_!XTOXC>&(+Z\MXV2PUFT(M M]5TPG/,,X!.,\^6X:,D LAP*]OHK2C6J4IJI3;375&=:C3JP=.JE)/H]3^(O ZW'Q2\ VX:9Y]/MB-6TV,9)\^U7)=5'62+<, LR MQBOSX92C%6!# X(/:O[.Z^)_^"AW_!"CX._MWI?:Y:V:_#WXA7&Z0:_I%NOE MWDA'!N[;*I-[L"DA_OD<5]UE7&35J>.7_;R_5?Y??S-T5])?MY_\ !*7XQ?\ !/366;QIH)OO"\DOEVGB;2MUQI=QDX4,^ T, MA[)*%)(.WK768=/LO]^4C!..=B!G/9:PQ.*HX>FZU>2C%;MNR M.K!X.OBZRP^&@YSELDKM_<>1U]7_ +%/_!(7XF?M3B7>F:I8V>I:;?Q-!=6EU"LT%S&PPR.C JRD$@@@@BORT_P"" MB'_!LEX-^+[W_BCX%WUKX"\12EII/#UV6;1+MCR1"P!>U).3@!X^@"QCFOU7 MHKNP.98C!SYZ$K>71^J.#,,LPV-A[/$1OV?5>C/Y OVC?V6_B!^R1\09O"_Q M%\*ZKX6UB/)2.[C_ '5T@./,AE7, _VJ_AW=>% M?B%X7TKQ3H=T#F"\BRT#'C?%(,/%(.SQLK#UK\8/^"B/_!L7XH^&?V[Q1\!+ MZX\9:&I::3PQ?R(NK6:\DB"7Y4N5'.%.R3 'FLIA??CV^TOEU^7W'Y-45>\3^%]3\$^(;S2-:TZ^TC5M. ME:"[LKVW>WN+613ADDCO?$Z:Y\"^')0LJ:Q1@5MP?]L%Q_<'6OU4_9^_9D M\"_LN>#ET/P+X=L="LVVF>2-=UQ>,.CS2MEY&Y/+$XS@8'%? <0^(F"P-Z.$ M_>U/+X5ZOKZ+[T?J7"?A-F69VQ&/O0I>:]]KRCT]9>J3/@_]BG_@@7IWA_[) MX@^-%['JUY@2)X;TZ8K:PGKBXG7#2$="D>U_X* M#^'VC\=>'4A\0QQ>59^)-,VVVK6?H/-P1*@[1RJZ#)P 3FOPO_X*'_\ !!7X MP?L-C4/$&DVS?$;X>VI:3^V=)MV^TV,0[W5L,O'@=70O& ,EESBOZ6**]S*^ M(,5@O=B^:'\K_3M^7D>!FW#F$QZ1X/#/AWE63R^L*/M*V_/);/^ZMH^ MNK\PHHHKY ^]"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * ..*** "BBB@ HHHH __]D! end GRAPHIC 13 gb-20211231_g2.jpg begin 644 gb-20211231_g2.jpg M_]C_X 02D9)1@ ! @$ 8 !@ #_[@ .061O8F4 90 !_]L 0P " 0$! M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D* M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\ $0@# MP 50 P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BOS _8^_X)5_&?]I#XZ?'7]I_]KS]MW]H6WT# M6?CQXPL_AK\._#'Q@UC1K"PT6TUJ[MHY66"97 =HG6*.,I&L*(PW"1=GXS_M M-?M#_M;_ U_X+7:Y^QCX1_;C^.\'P_L?CW;^&+?2G^-&O22KIKZE% T7GM= MF0MY;$;]V[OG- ']:]%?E?\ \%1_^"1?Q=^%7P4A_:/_ &$?VXOVD-+USP1K M5AJ&N^#=1^-FNZM9:YI2W,0NU"W%R\B2QQ%Y1ABC+&Z%,LK+^J% !114&J:I MIFB:9<:UK6HP6=G9P//=W=U,L<4$2*69W9B J@ DDG R: )Z*^%_P#@FI_P M5^\,?\%,_P!NSX__ S^!E[;WOPL^%.DZ%9^&]:2$;M;OYIM0%Y?(_7[.WDQ M1Q#NL7F<>;M7[HH ***^.O\ @O9I.JP?\$K?BY\3O"/Q \6>%O$G@KPM+K'A MS7?!_BV_TBYMKF-XS\S6DT?FHRY4I)N7#$X!P0 ?8M%?BI_P9K_M(_M$_M%? M#?X]WG[07Q[\:>.IM*USP^FER^,O%-WJC6:R0WY=8C(1XDTW1OBYKJVDT MEG)8-%*D+796%L7DBD1A5(5>.*^F_P#@CY_P3]T_]N__ ()-?#+]H7XM_MI_ MM-:?X_\ %^EZE)?^+/#_ .T-XAAEAFBU2\MXI(X)+I[<%4AC&#&02N3RFZ+IMQK.LZ MA!:6=I \UW=W,HCCAC4%F=V8@*H ))/ S0!/17PO_P38_X*_>%_^"F/[>/Q M]^%_P*OK:]^%GPIT?0[3P[K4<(W:WJ$T]^+R^1^OV=O)BCB'\2Q&3_EKM7[H MH **** "BBB@ HHHH ***S?&'A/1O'7AJ[\)>(?M?V*^CV7'V#4I[.;&0?EF MMW22,Y Y5@?>@#2HK^3W_@J7\??VL_V\7 MMIT/EV^H2K#%-%>QQ\B(2QR@,@.!)')M"J5 ^Z: "BBB@ HHK^?_ /X+K?\ M!2_]H?XG?\%P?AO_ ,$K_#_Q#UOPW\*-(\>^#-,\<:-X>U2:QD\3OJDME<3K M*6UN$^SVYMV)VSQ2N[!=H"+(RK^EM M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\?_[: M_P#RLK>)_P#LZRT_]/,%?V 5_'Y^VO=6X_X.3_%5R9U\N/\ :LMM[[N%VZS" M&S]"#^5 ']@=?AE_P=I_\%AOCU^SWXM\-?\ !.O]E#X@ZEX5U+7-!36OB!XC MT&\:"^:VGEDBM=.AF0AX WE22RE"&97A7<%,BM^YM?S'?\'A_P"SMXZ^%7_! M3'PA^U9J&D7$_A+QSX1L(K74%0F-+_3I&CN+4GH&\EK>0#C=YK8^Z: /I[_@ MO#^Q5X:_X(R?L3_"7]L+_@G9XX\4_#OXE>%_'.GZ#XG\3Z7XGO)'\413V-S+ M+-J$<\KQW3&XM5;:Z%"LTB%=NU1] _$_X_\ AW_@M)_P;3^,OVH_'NM:]X>U M?2?A/XFU7Q-HWA'6Y;&VN=>T>PNSY-PJ9,UE)-#'DRZ:8I ?/@72]3E,J^JX,?/\ MKZU!_P3 M+_9;^)7P _X-/OBGX>\<:!=6FM^/?@QX_P#$MKI,T3":.WO=)NDLQMZYE@CA ME ZXF'?(H _/O_@U%_8"^$?[=OC'XW:=\5OB!\1-!3PUIF@R6+?#_P =7>B- M,9Y+\.)S;,/. \I=H;[N6Q]XU]U_\'!W[1'_ 4G\!?MI? ;]D;]GOX,?$_7 M?@=>PZ3<>*H/ $VH6UUXVF^WM#QO, /F?_@XNL/!O_!(3_@HC\-/B%_P M2^^)FH_#?Q)<>%OMWBO2/#GC"XN52ZAN,1-=6\TTGRS0D*T4H\N54R4.YRWZ M]_\ !5?XEW_QH_X-\/B7\8M5LXK>Z\6? 2WUFYMX =D4EU:V\[*N23M!<@9) MX%?A!_PXCD:ZU#4(RPNKV1<.^YRR!D&U$V+7[3_MF>+_"?BG_ (-A?$LWAGQ/I^HI M9_LS:-;7C6-XDH@G.E6+B)]I.Q]DD;;3@XD4XPPH ^0O^#'3_DEW[17_ &'_ M W_ .B-0K]WZ_!__@QS=#\,?VBXPPW#7O#1(SR 8=1Q_(_E7[P4 ?S\?\'R M_P#R&/V9/^O;QC_Z%HM=1_P3L_X+_P#P'_X)3_\ !&'X$^"_C5^RQ\8-2O[_ M $;7%\*:O9:'9PZ'KDL>KW0"VBX/Z'\J^EO^"Y4$M'(@(WQ22+D$@@ ^#?\ @D!_P2P^._\ P6X_ M;PU#_@KW^T)X@\,Z/\.)/BU<>(-9T73-72YOKW4(+A;F/2E@0EK:!1Y*L\Y2 M1H=I16\P2#]CO^"_'_!3#Q+_ ,$MO^"?&K?&SX9PVS^.O$FLP>&O [WD(EBM M;ZXCEE:[>,\.(8()G56!4R"-6!5B#^ /_!(_]O;X[?\ !OO_ ,%,/$/[/_[4 M^DW^F^$+S6U\/?%[PYAI%M"C?Z/K%N /WGE"3S5901-;3,%!+1LOZM?\'@7P MHU?]H/\ X)1^$/C_ /"*>/7M"\'^/=/UV_OM+D$\#Z1>6<]NEZCID/'YL]J MPXVS;LX% 'S18?";X'^+_P#@WPU3_@H!X_\ VL;R_P#VM;O3KCQQ:?$63XH3 M+XDL+F/4B(K"W47(>*$V<80P*H&YRX (3;[O\*_VFM<_X+2_\&Q7Q2^*/[1? MCOQ'#XO^%W@_Q5!XINO#&KMIL?B#4](T=[VT>\2( 30R1S6DDL'$;RJQP!A1 MA?\ !L;\9?\ @E1^T5_P3^TOX$_M ?";X*)\5/AQ=7MOK;>-O#6DB^UC3Y+F M6XM[Y9+F/=.B)+]G<[F*& %MH=,_;_QUU?\ 9?\ B1_P2$_:GE_8B^%6AZ1X M/G^&/CC3M-U'PAX=M;'3/$UU%H4T,M[9?90!=1>:&M1.5'F/:/LWQB-V /Q. M_P"#4;]@/X1_MV^-OC9IOQ6^('Q$T%/#6E:%+9-\/_'5WHCS&>2^#"4NT-]W+8ZFO:_\ @\%U'QW^RG\*_"FHP^(1H_C?4( M([YK%K.*"5XTF""01R%6=5!; +9(K'_X,M/BC\.OA-XC_:<\7_$OQKINAZ9I M?@_0=3U"]U*Z6)(+2";4/.F.3]Q/,0$CNZCJP!Z'_@^'TJ^D\9?LW^*DM9/L M-SH_B:".9HR!YBR:8Y4Y'!VN#@\]?0T >S?\%F[_ ,66?_!M1^S_ /M.Z'\2 M?%FE^/=)\!^ /*\4:1XKO;6ZN%O-+MQ?\ @DCK-S\:O'&N>*KB]^)NMV%S>:_K-Q=7#6QM+(&(2R.75<.V ",; MB1@U\T_\%HOC_P#!:/\ X-9_V=?AHOQ+TB3Q#XH\"> !H6C07BR7-T++3H!> M,$4DJL+(TA^RV!_D10!^5' MA']H3]L;X'?\'$^L_L__ +-'Q:\6ZO%IOQ\UWPQX%\)^*O'&I7>DVOFW%U9V MANDDF=IK:U\Q)G4Y9DMR-VX[J_4G]B7_ ((2_P#!2#]F;_@L;8_MY?&;_@HJ M/B=X-33M0?7KW4;B]M=6UN6YLI81926'[RVAM8IY$E0+,546\82-"!M_-7]F M;[+<_P#!X5J7F%'0?M,>+>O(WJ=1Q^(8?F*_J6H _E@_X* ^+OVE/@G_ ,'( M,G[*'[+'[3'C3PGI'_"Z/!UIX5T[4/%FHW^F:;/?)IO@3^VI\8-<\:^*="N=5U'Q=XL\6^?? M)J5K,O &C:Y>1P+A$EN[&&X<*.P#2' ]*[^O$O^":#I)_P3B_9_DC8, MK?!+PH5(/!']CVM>VT ?R(?\%V]2;1O^#B;XE:PNFW5X;3XB>&YA9V48>:?; MI^FMY<:D@,[8P 2,DCD5^G/_ 7.TG_@J%_P6P\"^#/V1/V2_P#@F=\2O!O@ MO3?%*:]XA\5?%F?3-%>XN8X9K>%%B^UN5@19YG8Y:1VV;8QM&_\ ,S_@N%=V MP_X../B#=&=/+C^)WAG>^[A=MEI@;/T(.?I7]=- 'YN?L:_LO^$O^#:C_@C' M\0/'WC_6K7Q=XIT6SN_%OC"XL2\=IJ&LRQPVMII\#. ZVX=;: 2, Q+R2;%W M;!\8_P#!'O3OA'_P6%_9O^.?[7G_ 56_:4L=6^(?B3Q1>>'? -MK7CDZ9'X M+@BL(9TN=(M?/1;7]]=J%<*2?LG)8O+O_3'_ (+Z? 7QO^TM_P $??CI\)OA MSIDU[K,OA:'5;.RMD+2W/]G7UMJ+Q(HY9V2T954/^"=> MIV7C[]C?]M'X;?"Z?Q/J>MQ:_P" ]:^(?A_3YS?HT"075A%<7:':Z>3#*D(; MY_,F91\K9 /K[_@U._X*1?%3_@H;^S%\2/V,_P!KOQ9?^+]3^']M:+INO:K? M2M?:CHE\LT1MYK@,))'@DA($Q;>5N$&3LS7YH_L'_M#?MU>%O^"\EU^SC^SG M\>/%>I77_"Q_%WA/PC8^,_%E_J>FZ3$8]0M([^>WFE870LHSN?#-K:6WC#Q7\//#6GVVGBZE+NNEO=6 MH7SKF-%6:2$;A$LT139:UR/ MP)_.@#]*?^">?_!!+]OK]E/_ (*;>,_VGOV@?^"@=S\1O 7B7PCJ>F7^I-K& MH0Z]KSWD815N8'WQ6X@8M(CI/)M:.+8JY(3\A_\ @HS^R#\.OA!_P<M"*^M-(>5Q?N3*)%-PXC?.8PJ!?NBOZY:_ MEN_X*X21C_@[ELG+@!?C-\,-QST_T#0: /UE_P""U'[9\_\ P0I_X)0Z/\/_ M -F3Q/K5YXPUO43X7\ ZWXNU9]5OK'S?.NKG4)I;C<;AX4W*F_(#RPY#*I4_ M(W[(O_!/+P'^T#_P;N>+O^"DWQ5\9^,]4_:)U3P;XL\<:;\6KGQMJ1UC3[G2 MKB]-I##-Y_R1.EBH<8Y^T.@)K6_8 ^)7ABS_X,_-9\2?VG D> MG_ 'X@:?,&D V7?FZO D1]&>1H\#J?,7U% %S_@US_X*P?%/_@I;^S7XX_9K M_:U\12>(_&OPYBMHSXBNWVW.NZ+>++&AG9<%YXGB>-YN&=982HB!M@3TS,1U4U\S_ B-K<_\'A=WO*.@_:7USKR-ZFZQ^(8?F* / MTF_8]_X(1_\ !2;]GC_@LAI'[?'QD_X*-#XF>$(;.^E\17VH37MIJNKR7%E+ M#]@.G_O+6*T2:1)$"S%46! L:$+M_-7_ (*V^-/VB_@!_P '$&H_LV_LK_M% M^,_"VD2_$+P+F%P+^T%G+'&/"?AJ^73?" M^FVZW$-NPDL44FXNYXS+-+$?\&:L,AE7;_PH6P7.>-WVZ$8^N>/K0!>_P"#/']K[XV_M'?L M,^./A?\ &GQ[J7B4_#CQG#:>'-1UB[>XN(-/N;59%M#(Y+-'')'*4W$E5DV# M"JJCR_\ 9@\4?MG?\%&_^"X7Q<^!'_!4']F?XAWOP=T*QUFW\+>';J]U32/# M/AB*VNE%G=R"W>*#4)+B$$"9V_X+$^&_^"P?_!76(5&]M[@'%?\$K/VLO'O[%7_!Q;JO[$O[,' MQLU+5?@/XE^*VL^&[?PM+XDDU33&L?\ 2#:2P.\CCS876,"=3O=4969@S9^N MO^#RB]\5_!KX'_";X]_![XD>+/"?B:_\7SZ'J-[X;\5WMBMW9?9))U22*&58 MV*NF0Q7<-S#.#BOSG_9H\;? RY_X.GM%\:_!W5=!M/A]+\?;E_#%WI<26FFK M8,LJVY@ "HD)4H$V@*5*[>"*_1#_ (/7-7TK6_V&_@GJ^BZG;WEI>_$F2XL[ MJUF62.>)M,F99$920RD,"&'!!![T ?/?B#]C+XP_M,?\&Q=K^WI^T+^W!\4= M;UOPCH%UJ'@3PI;^(6CT>UM8]=EMY1?1L&EU"ZDW3M]HDD!C4PQH D;"3["_ MX,\?VO\ XW_M'?L-^.?A=\:O'VI>)?\ A6_C*"T\-ZAK%V]QN'\U=O_"M]57.>_P#PE-P,?7/%9/\ MP8_.A_9\^/<88;AXRT8D9Y -I<8_D?RH R_V=?VP]5_X+[_\%ZO%?[._Q6\6 MZI-^SC\*M UN^\/?#:QU:>TT_P 2FRNK>PCO+]8'1KHR2W7VA4<[41$CQ@R> M9UO_ 2N_9"_X*M?\$^_^"YWCCX">%/ GC5/V2]5U;7;JWEU;4);O0;/27BG MGTIK.69V"W:2FVMG5/WI7S/,!"AU_-7_ ()C?&VX_P""&G_!>*\\-?M2BYT? M1-'U_5O!?CF^FA;]UIUTW^CZAC!+0;TL[K< 2T.2H)(S_4%9?MW?L@Z]XV\( M_#?P-^T'X7\5:]XYF9?#.D^$-7BU6:YA2%II+IEM6?RK9(URUP^V,%D7=N=% M8 _'S]L+_@H[K7_!1K_@X"\/?\$N_%OQIF\%?LY?#[Q+?6?CZSM?$3:5'XJO M=.LI[FZAO[A)(V,#74(LQ#O"X#/]]EVYOBS]L_PQ_P $C_\ @X:\$_L__L@_ M%&"\_9X^,UKH,'B/P#I7B,ZCHNC7NH7,M@;FS7S)%M)(YHHKAPA&4D=,;2@7 MXE_:&F\&_P#!-?\ X./Z"[B]_X(R^&W\">(/A;\%/@5XJUOQOKMC;_# M[3_A_P"$M"O=1U*:216^U6RQ*"L5O&'N99RRK#'"[%@0 0#Z_HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P_ MB)\/M!^*'A2X\&>);_7+:SN61I)O#OB:^T>[!5@PV75A-#.@R.0K@,,@Y!(K MXKUG_@V<_P"")_B/Q/=^-_$/['M_?ZU?W[WU]J][\6?%4MU<73N9'GDE;5"[ MR,Y+%R2Q8DDYK[PHH Y?X1_"'PE\$_"8\%>"]2\2W5D)_-63Q5XTU37KD'8B M8%SJ=S<3!,(OR;]H)9L99B<+]J7]DK]G']M?X17OP)_:E^$FE>,O"U](LLFF MZFC PS*"%FAEC99;>50S 21,K@,P!P2#Z+10!\7^'/\ @@A_P3RM-?\ !^J_ M$O0?'7Q*T_X=Q^7X \+_ !0^(VIZYH_AY!MPEO97$IA* (B[)%==L:#'R+C[ M,EL[2>T;3YK6-[=XS&\#("C(1@J5Z$8XQ4E% 'QI\,_^#??_ ()$?"#]HN+] MJ/P#^QSI%GXHM=2&HZ=#)JM[-IMA=A]XF@L))FMHRK@,BB/;&RJ8U0J".N_; M?_X(X?\ !.;_ (*+^/\ 1?BG^US^SM;^)/$.A6@L[35[76K[3IYK0.SBVF:T MFB,T89V90^2NYMI 9@?IVB@#Y3_:#_X(B_\ !+K]IKX,^#_@#\2OV2=!@\+^ M 'F;P?8^&I[C27TWSMGGA9+.2-W$IC0R>86WLHGC:^^('[''P7UCP1J&J0+#JT5I\2/$%S9Z@JK((_M M%I=7\MO.4\V0HTD;&,NQ0J3FOIJBB@#Y$_:3_P""%/\ P3$_;$\:Q_$3]J3X M(>)_'>L6\+0V=YXD^,7BNY^R1,YE>D?L??\$X/V2/V M"=(7PS^RCX0\3^%]%C,QA\.2_$WQ!J.EQ/*P:21+&^OIK='9ADNL8;))SR<^ MYT4 ?+G[9G_!%O\ X)D_\%!/BC;_ !J_:W_9B?L_?L&_LL_LQ? >]_9?\ A-\/+W_A7E_: M26D_@_Q1XJU/7[!;61&22VCBU6YN!# P9MT,>V-MQ)4DDUZ_10!^=O\ Q"N? M\$5A\4!\2Q^S3J?DBZ^T?\(Q_P )IJ/]E[\[L>5YV_9G_EGYFS'R[=O%??\ MX:\%>#_!G@^Q^'OA'PKIVF:#IFGQV&G:+86216MM:H@1((XE 1(U0!0@& !C M%:=% 'QG\-?^#??_ ()#_"/]HN+]J/P'^QSH]GXHM=2&HZ="^JWLNF6-V'WK M-#823&VC*N R*(]D;*I14*@CV?\ ;C_8!_93_P""C'P=_P"%'?M:?#"'Q'HL M-X+S39DN9+:[TVZ"E1/;SQ%7B;:Q! .U@<,K#BO9:* /A[X<_P#!N3_P1\^' M'P*UO]GRV_9/BU/1?$MS;3^(+_5/$VH_VG?-;R>9"AO(9XYHHE\&:)XH#G6-)M?B/K]S;M*Z+&U MQ$ES?2"VN"B(OVB'9+A$&_Y5Q[_10!\3:)_P;M?\$AO#7Q:C^/GA_P#9J\06 M?CB+6FUB/Q?;_&3Q:FIC4&D,C7?VD:KYAF9V9B^[<2Q))R:^TM,T^#2=-M]* MM9)WBMH$BC:YN9)Y"J@ %Y)&9Y&P.68EB>223FIZ* /B;QA_P;M?\$AOB!\5 M[GX[>-_V:=?U7QK=ZJNI7/BR_P#C%XMDU%[Q6#)/]H.J>8)%*J58'*[5QC K MI_VJ/^"'O_!,S]MSQY9_$S]J_P"!&N>.-;T_2+?3+"]UKXJ>)C]FM84"I'&B M:BJ)G&]V"AI)&>1RSNS'ZRHH X7]G#]F_P"$G[)GPBTKX$? O2M5T_PKH<(A MT;3-6\4ZCJYL8%552"*;4)YY4A1554B#B- ,*JBNF\:^#])\?>%[SP?KMWJD M%I?1A)IM%UR[TVZ4!@W[NYLY8IXCD#E'4D9&<$@ZE% 'PKXU_P"#:S_@B]\2 M?&.H_$/XA_LDZGKNOZO>O>:KK>L?%OQ7/ O@&_\37&GK*'C/BKQOJNOW"81(PJW&IW-Q,J!47"!PH.XXRS M$];10 5\!?'W_@V0_P"".W[0_P 6KSXR>)OV<+O1-2U.\:ZU>Q\)>);K3K&] MF9MSL;>-]D.X]1"(P_V??V?X/V7O@/\.HO!?@BV ML);2VTKPKJ%SI\T2R ^9*MU!(MRL[$EC<"3SBWS;]W-?-GP[_P"#=S_@D/\ M"/XI6?QP^%_[-.O^'_&6GWLEW9>*=(^,7BR"_BGD#+)()TU0/N<.X8Y^8.P. M03G[8HH @NM.M[S3)-)FDG$4L!A9XKJ2.4*5VDB16#JV.C@A@>0<\U\7>.O^ M#=S_ ()$?$_XJW7QS^(G[-?B#6_&E[J$=]=>*]3^,?BV;4)+F/;Y')]-ET^]L/%NI7&LM?6T@ M99(KF6_DFENE9693YK/E3@\<5\@7'_!O)_P3;'AC5OA5H>A_$;1OAMK^L+JF MN_"71?BQK-MX9O[I65M\EDMQC[R(<*P \M, ;%Q]Q44 %/".EZ:UAIFB^&PUBEI"P.[RFA*O&Y+,QE5A(78ONW'=7REIW_! MNU_P2&TCXN+\?M+_ &:O$%OXY37&UI?&$7QD\6KJ?]HM*96O/M(U7S/.,A+F M3=N+$DG)K[9HH KZ3IEMHNE6VCV\5RW MLMP@4))YIU3<"@1 F" @10N H ^UJ* /EK]JO_@B]_P3H_;AOO#^I?M:?!WQ M'X[E\*Z4NG: ==^+'B9ULX0J*S!5U$!I9!'&9)V!EF**TCN0#3[K_@C3_P $ M]+W]E.+]AZ[^%?BJ3X30WXNX_ S_ !?\4&S#!_,$?_(2WF$2CS1!N\H2_O F M_P":OJ*B@#YM_8J_X)'?L!?\$[/%&J>+OV-/@WJO@JYUN!(=9M[?XAZ]>6=\ M$W>6TUI=WTL$CIO?8[1ETWMM(W'/%3_\$ /^"0][^TG?_M6ZK^Q?H%]XKU'5 M&U.ZAOKZ[FTMKUW+O/\ V:\QM"68[BIB*9Y"@DD_8]% 'R-\;O\ @A/_ ,$J M?VB_VFQ^UU\8_P!DK2=9\9R3037TDFIWD=AJ$L*JD4EQ8QS+;3D*B@AXRK@? M.'KK/VT?^"3'[!'_ 4,U+1M1_;!^#>I^+T\.VQAT+3CX_UVPL+$'[S16=E> MPVZR, %:01[V554L0J@?1M% 'RO;?\$6?^">)M/MEMK7Q9H6I3:=J/V<$D0R20 ML!.@R=HE5]F3MVY.=W]@?_@E#^PA_P $T-)O[3]D?X&VNAZCJ\2Q:SXEO[N6 M^U2^C!!$;W,[,R1Y /E1[(\J&VYYKZ+HH ^)=.OIK'4[*(L6,2W$#*SQ9+'RI-\89BP4,FRG"W=XD+M#$<$<-(%4\CK7Y ?\$H-2^ G_ 5)NO!^I_$GXU>/KSXXV_PI M\7+\7]6C\)OV< M+#P#I5VVF^,_$UQJR^'/&5Q,'.G6EQ()]7O;X06NGH+N-8T-F97M@%B4#:SL"62=/^SW$T45ND:+!Y,+Q!'7=7Z1? SXM>'?C[\$O!WQV\'HZZ3XU M\*Z?KVEK(06%M>6T=Q$"1QG9(M '5445QGQF^)OB_P"&6F65_P"$/@[K7C&2 MZG:.:VT62-6MU"Y#MO(X)XXH [.BOGWQ)^VK\3/!^A77B?Q5^QOXRT_3K*+S M+N]N[^U2.%/[S,6P!7K^A^.M1UW1;/6[;P=>B.\M8YXQYB'"NH8<]^M '1T5 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M5K2M5O=0D=+K1)[4*N0TI&&]N* +U%%% !1110 4444 %%%% !1110!D^/O& M_ASX9^!=:^(_C"\:WTCP_I-SJ6J7"1-(8K:")I96"J"S$(C' !)Q@5^8/_!5 MG_@G)X8^)'[6NF_MK?L+?%1?@W\9=(^#'B/QS:_$'PJ8X[3Q--87&E>5%J:C M]W/#+!-O#.H^#/%>E17^EZO8366I6,XS'<6 M\J%)(V'=65B#[&OE/_AR]^RC'XET?2XM<\=O\-M)\'7_ (>_X55>?$;7+C2Y M+:XN;*86X:2]+K8J+38U@*YUZRTR::T'F.K1/-;LC"6%)=OFQE7W*LBX8D!J^/?AC^PUH M_P#P3P_X+W>!;3]B76=KZ9)\,KEI_ %]X'\ M57_A^XT(F)(BMO)ITT)1-D4:A>BA!MQ78_!']F'X/?L^RZAJ?@#1]2N-9UB* M&+6O%'B?Q%>ZUK&HQPAO*CGO[^::XDCCWN4B+^7&9'V*NXY -OXF?#3X2_'W MP%K/PE^+'@W1/%GAW4HFL]?!(23M.;'P]\3-< MTW2_$,^,%[VQM;R."X##[T;H8W))926;/T;X=\,^&_"'ARR\'^$_#]EIFDZ; M9QVFG:7I]JD-O:V\:A$BCC0!415 4* * /SI_P""DOQL\+>*/^#935?B M3X9N!=P>-/@;X;L=#M[4;Y+FXU$6%M% B+RTF^;;L R"K#'!K[._80^$'B#] MGS]B#X.? ;Q:FW5O!7PL\/Z%JB[LXN;33H()1D?[<;5SG@__ ()I?L>^!?$& MBZGH'PZOQI7ACQ!)KWA/P7=^)[^?P[H6J.[R&[L]*DF:TMY%>21X]D86!I': M(1EB3[S0 4444 >4?MS_ /)H_CW_ + +_P#H:UW7PN_Y)GX=_P"P%:?^B4KA M?VY_^31_'O\ V 7_ /0UKNOA=_R3/P[_ -@*T_\ 1*4 ;M%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 >4?MS_\FC^/?^P"_P#Z&M=U\+O^29^'?^P%:?\ HE*X7]N? M_DT?Q[_V 7_]#6NZ^%W_ "3/P[_V K3_ -$I0!NT444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110!Y1^W/_P FC^/?^P"__H:UW7PN_P"29^'?^P%:?^B4KA?VY_\ DT?Q M[_V 7_\ 0UKNOA=_R3/P[_V K3_T2E &[1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M'E'[<_\ R:/X]_[ +_\ H:UW7PN_Y)GX=_[ 5I_Z)2N%_;G_ .31_'O_ & 7 M_P#0UKNOA=_R3/P[_P!@*T_]$I0!NT444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y1^ MW/\ \FC^/?\ L O_ .AK7=?"[_DF?AW_ + 5I_Z)2N%_;G_Y-'\>_P#8!?\ M]#6NZ^%W_),_#O\ V K3_P!$I0!NT444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %> ^,_^"H_[ _P]^+;_ ;\8_M.>%K' M4+:&Z;4]3FU2,:9IDUO/;P26MU>;O)MIP]S&#'(P*\AMIP#[%\3O#FO^,?AK MXA\(^$_$DFC:KJNAW=GIFL19W6-Q+"Z1SC'.49@PQ_=K\=?^"27[4&@?L_?' MCX??\$DO^"E'PGLOAAXW\"_"GQ-X(M8_$RH=#^(46HZMIT\$MG,X\N=KB."Y M5PQQ,_W2TDC1( ?KW\2/CM\%O@_\*+KX[?%+XK>'] \%V5C'>7/BG5=6BAL% M@DV^7()F;8P?';6#P]<>)G5[>R%E8K:I?2H_P"Z\Y($?$K#,8DD*E=QKX?_ .":7C+] M@K]HS_@MO^T+^TU^Q]\6_#]GO8[M)[WQ"T$D<8D MC1EM;)94#$NLS/M62)I@#[Z^-7[4O[/G[.USIVG?&;XK:7H=[JZ32:7IDSM+ M>7<4(!FFCMXE:5HHP5,D@79'N&YAD9ZOP5XV\'?$CPEIWC[X>^*].UW0]8LT MN])UC2+U+FUO('&4EBEC)61&!R&4D&OSV_X) _$#5?VH/^"G/["2*TQ_J4MYG>>-5P$>1B.M 'Z]>' M?VVOV2O%OQ17X,>&OV@/#-[XCDU.?3;>Q@U ,ES?P*6GLH9O]5-=1!6,ENCM M*@1MRC:V/4J_,K]NK]GW0/A%_P &RMIX3\"+_8VJ?"[X1^&?$_AG6-//EW.G MZW8-9WQOXI!RD[S"9F<8),\G]XU]U?L8?&K4?VDOV/?A3^T/K,$<5YX[^&^A M^(;R&)=JQS7EA#<.H'8!I",>U 'I=%%<9\9OB;XO^&6F65_X0^#NM>,9+J=H MYK;19(U:W4+D.V\C@GCB@#F_VY_^31_'O_8!?_T-:[KX7?\ ),_#O_8"M/\ MT2E?,W[5O[1_Q8\5_LZ^+O#FM_LD^,-#M+O26CGU:^N(##:KN7YW"G./IZU[ M_P#"OQ/K#?##PXQ\'7H)T&S)!9>/W"4 =O16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PD MNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ M /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+ MJ_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PD MNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ M /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+ MJ_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PD MNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ M /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+ MJ_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PD MNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ M /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+ MJ_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PD MNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ M /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+ MJ_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PD MNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ M /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+ MJ_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PD MNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ M /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+ MJ_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PD MNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ M /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+ MJ_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PD MNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ M /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+ MJ_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PD MNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ M /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+ MJ_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PD MNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ M /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+ MJ_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PD MNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ M /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+ MJ_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ M $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+5K2M5O=0D=+K1)[4*N0TI&&]N* M+U%%% !1110 4444 %%%% !1110!S7QF\<:I\,?@_P"*_B5HGAQ]8O?#WAJ^ MU.STB-F#7TL%N\J0 JK$%V0+P"?FX!Z5^7W_ 4O^+O_ 2=_P""E_@O2_%W MQ4^*/A3Q!H$G[/WBN[\+?9-2B.OZ-XD:]T0V=M;6Z-]HCU3S T0M-N^0AXV1 ME+"OUFKEY_@K\*KGXM6?QVF\#6)\76&CW.E6NNA")DM+B2"26,X.ULM;P_,0 M64*0" S @'R9^R?^VCX5_P""?_\ P3[_ &;O!7_!6GX]P>"/B-XN\+0Z:;WQ MH9QYEW#&K^3>W>QHK>>."2!9'N)$S('RS,&KF+;X2?!W]K+_ (+8?##]O#]D M34M(UC0_A_\ #/7]/^*7Q%\+31SZ5X@N+M8K?2],2[A)BO;F$-=S2[6?R4C@ M60J6B6OO?6=!T/Q%9_V?X@T:TO[?>'\B\MUE3<.AVL",\GFK%M;6]G;I:6EN MD442!(HHT"JB@8 ' ':@#\XOV*['P=_P $Q/\ @I7^U?\ #[]H[QGI'@[P M?\:O$T'Q2^&WBSQ+J,5CI^IF83G6K07$S+&+BVG=&,.[>87$N O->+_#W_@F M1\2_V\_V+?V^?C -!N-*U#]K#QN^I?":RUB%K66^TG0[EI]"NI5E"M MW,"P MW@8B9).0PK]@-3TC2=:@6UUC2[>[C219$CN8%D577D, P.".Q[58H _*;]JK M]IZR_:X_X(5:)^QU\'9H=0^/_P 2O"6A_#^;X4F4)K.D:U%+:V^L"^M?]=9P M6B0W,DD\J*BH(V) E3/Z2?LV?!G2_P!G+]G7P#^SWHEY]HL_ G@O2_#UI<%= MOFQV5I%;*^.V1$#^-=;%I&DP:E+K,.EVZ7D\:I-=K HED4=%9L9('8$U8H * M*** /*/VY_\ DT?Q[_V 7_\ 0UKNOA=_R3/P[_V K3_T2E<+^W/_ ,FC^/?^ MP"__ *&M=U\+O^29^'?^P%:?^B4H W:*** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH *_.'_@I5+^U=\;?^"M/P5_8G^!O[;?CCX.>'O$ M_P )]>UW6+OP9';R27%S:7""/(]+\*^&H[D0?VIJUY?P6]K TK<11[WWNYZ1HY&3@ M$ ]]_P"'/W[=?_2>G]H#_P %.E__ !%'_#G[]NO_ *3T_M ?^"G2_P#XBOBO MQK\6/V)/'6FCXG?\%DO^#@S6]>\8:BOFS_";]FOQS/'X9\/L^/\ 0$BT6*XD MO)$^X9W9226!+?ZP_1OPF_81_:N\&_ [0/VQO^",'_!2?XJZQINKZ:-3T[X1 M_M*WLVL:-KT )!M0;E([K29'V'#CYMV 6C4E@ 3_ /\*?ME_L;?\%I/A7^R MG\3/^"C'Q(^,7A'QO\)_$.NWVG>,X+6*.&YM72.(JL"#.,DY)ZU^GU?CW^S% M^WWI/[?W_!<[X#^*]7^&6J> O'O@OX0^-?#7Q0^'FMY-SX=UN":!I80^!YT+ M*ZO'* RMCAE8#]A* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** /*/VY_^31_'O\ V 7_ /0U MKNOA=_R3/P[_ -@*T_\ 1*5PO[<__)H_CW_L O\ ^AK7=?"[_DF?AW_L!6G_ M *)2@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKR#] MN#]N#X&?\$^/@9)^T-^T-/K">'DUBTTP#0M)>]N7N;ERD2+$ARV6&.*^8/\ MB) _84_Z(]^T!_X9+5/_ (F@#[^HKX!_XB0/V%/^B/?M ?\ ADM4_P#B:2W_ M .#DC_@GS_;>DZ)K?@GXT:-_;.L6NF65[KOPEO[.V^TW$JQ1(TLH"KEF ZT M??\ 1110 4444 %%%% !1110 445S7Q"^,OP?^$=G_:/Q7^*WAKPQ;[=WG^( M==M[)-OKNF=1B@#I:*^3OBI_P76_X(__ ;64^,?^"A?PUN##GS(_#6M_P!M MN".HVZGV>'6?$&K09]=V+5\>V.?:@# M] ZCNKJUL;:2\O;F.&&)"TLLKA511U))X KX!_X=4?\ !3_XKKN_:>_X+T?$ MZ2&4?O=/^$7@'2O"7D@]42XA\R1L=G89J2U_X-M/^"=WBBYCU#]IKQ5\9_CA M<$8]J /H7XQ?\ !4G_ ()O? #S8OB_^W1\ M*]%N8<^9ITWC>RDO!CKBVBD:4_@E?/NJ?\')W_!-'6=0ET/]G27XI?&K4H6* M/IWPE^$VJZA(7_N*T\4$;$\8(8CWKW+X._\ !([_ ()@_ 3RI?A7^P3\*]/N M8,>3J-SX-M;R\3'I<7*22C_OKFOH'2]*TO0]/BTG1=-M[.U@3;!;6L*QQQKZ M*J@ #V% 'P(?^"KG_!3/XO\ R?LJ?\$'OBG)!-_JM3^,OC73/!_D+V>2VF,L MC8[HK;O2C^RO^#EOXW_\?WBO]EOX':9-]W^S;'5?$NLV^?[WF[;1\#&,=3GV MK] Z* /S\_X<\?MS_%\;OVOO^"Z_QXUI)?\ CYL?A'ING>!X6!ZQ_P"B+*2G M4'H6'I7Q%\8_^"/7[$OPY_X.%OV*OAEKVO>*E^)GBR[U MB?6[V"#4?)\V25Q\J-#')L4*I(^8$$BOV._;%_:N\*_L7_ V]^.?B[X;>-O% MT%K>VUE;>'OA[X;DU75+VYN)!'#%% A'WG*KN9E4%@,Y(!_&?_@J9\#_ /@M MQ^W)XPT?_@K)\+OV8=6_9]'P8\,7-KX:T#3O%@O?'NI:71)-NY5WL0: /V?^"O['?[(7[.)2V_9]_9C^'G@J2% 0WA7PA96$N#D M;F:&-6)//S$DGGFO2Z_&3_@G+_P2A\,_M#:#>_MJ_L2_\' GQJU[5_&^FVT' MC#Q C6MSJNZ/+I:7\=S)+-;R1L[XBD.5W$J2K!CZ?^U1^R5\2/V)/AM<_%C] MJ?\ X.5_C#X,T:WB9XWU:VTH3WC*,^7;6ZH9;F0]HXE9CZ4 5/C#X!\(_#7_ M (.WOA'XQ\)Z'!;7OQ"_9XU*7Q+)"@!N+FW%_$EP^.K&&UMXL^D2BOU7K\@O M^"'/[!O[5OQO_:P?_@L+^U]\;_B1J]C::-=>&_@EI7Q1LK=-;U#P[*)"-1NT MBPMFLCS2/%"H)(D=BS(8W?\ 7V@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RC]N?_DT?Q[_ M -@%_P#T-:[KX7?\DS\._P#8"M/_ $2E<+^W/_R:/X]_[ +_ /H:UW7PN_Y) MGX=_[ 5I_P"B4H W:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_C' MXWN_AE\(O%7Q(L+&.ZG\/>&[[4H;:9B$E>"W>4(Q'(!*8)'K6GK7B_PGX;_Y M&+Q1IUAC&?MM['%UZ?>(]#7B?[7W[5?[+VF?LS_$;2]2_:1\ V]S/X$U>*"W MG\8V222.UC+M55,N23D8 Y.: /D+]F+_ (**?\%[?VNO@#X6_:5^#G_!/3X% MS>%_&.EKJ&BRZA\4KF"9H2S*"\90E#E3Q7>?\-#_ /!QQ_TCJ_9__P##NW'_ M ,;KE_\ @BS_ ,%&_P#@GS\$?^"2?P(\$?&+]N7X0^%]X^(?\ @N__ ,$>/# 8ZE_P4/\ AK+M'/\ M9VM?:_R\A7S0!Y%XW_:V_P"#A_X?>"]7\>^(_P#@G;\ UT_0]+N-0OVA^+-R M[B&&-I'*KY?)VJ<#O7U/_P $Y/VI]?\ VV_V'?AK^U?XI\*V>AZAXZ\-IJ=W MI.GS/)#:NSNNQ&?YB/EZGUKY,_:B_P"#CW_@BUJWP'\<>!-#_;=L-1U;6/". MIV&F6FG>#MC]@7]G7_@F ME\'/@%XL;XD:MXH\+^#XK'6++PQ\+M5OHXYQ)(=BS)#Y/YF?NXWR)][M].<4?\/\ %M0^ M7PO_ ,$9_P!N[4 W^JN#^S_Y,#@=<2/><8Y'3J* /O\ HKX _P"'VO[06I\^ M&?\ @AG^US*#\R_VIX+M++Y/4[[@X;I\OU]*/^'P7[=-]SH?_!!?]H&02<6_ MV_5-,MQ9#D^U 'W_ $5\ ?\ M#RS_ (+.?]*\OB#_ ,20\.__ !JC_AXI_P %S)_WUA_P;L3-"W,;7'[6/AF) MR/=# 2I]J /O^BO@#_AX?_P77_Z5U?\ S;GPQ_\ (]'_ \/_P""Z_\ TKJ_ M^;<^&/\ Y'H ^_Z*^ /^'A__ 77_P"E=7_S;GPQ_P#(]'_#P_\ X+K_ /2N MK_YMSX8_^1Z /O\ HKX _P"'AO\ P79?Y%_X-V50G@._[7'ADA?<@6^2*/\ MANW_ (+X?](&O#__ (E%HG_QB@#[_HKX _X;=_X+]W_RVG_!#KPA8%>6:^_: M7TF4/[#RX>/QH_X:\_X.$[_Y;7_@C_\ #&P*\EK[]H"UE#^P\N+C\: /O^BO M@#_AH[_@XSO_ -Y:?\$W/@-IX?A8[[XPS2M&>F6,<>".^!SB@_%/_@Y>U'Y; M+]E7]D[32O!;4/'.M3!L]"/*7C'?/7(Q0!]_T5\ ?:O^#HW5?EATO]A'2D/R MNUQ/XQGD&?XTV_+QV#=QZ4?\*V_X.9M:YU/]I7]D31,\D:-X-UZYVD<8'VAA MD$K_ +4_[?7PSU[09?C!X6M[/1_"7PK%K)!J#WZK:W1EED)9(W/F-&>'VAPE\XL>@/(XY'>@#[_ M *^ ?^#D#_DQ3P=_V*V2WC$"$ASKGBZRM-N.N?-E7%?'0_X-F_^"4^N,&^+/@KXB^/R>7/ MC'XNZY/O/8GR;F+/I7=>"/\ @WY_X(S?#XJ=!_X)]>!;C9C']N)"OACKEXY/8!FM$1L^S&OIGP%_P3U_8' M^%;1O\,_V(_A'X?>+&R71OAQIELX([[HX 2?LZ9I6F:+9)INCZ;!:6\8 MQ';VT*QH@]E4 "@#X%_X?V3>-/W'P!_X)'_MA^,V;_4W\GPA_LS3W]/])N+@ M8_%:/^'B/_!;#XC?)\'_ /@A'+HMJ_\ J]7^(_QYTBSV>FZSBC,WY&OT!HH M_/[[1_PRR&;\UK] :* /S^'_!O]X/\<#S?VE/^"G' M[7'Q)W_\?&F:O\9)+336]=MM:PIL![X>ND^'G_!N5_P1E^'5Y_:T7[$^DZ_J M#OON=0\8Z_J6L27#_P!YUO+F2,GZ*![5]NT4 >7_ K_ &(?V,?@88F^"W[) M/PS\)/!CRI?#?@73[)P1WW0PJ2??.2:]0HHH **** "BBO)OVROVXOV7_P!@ M'X2#XV_M7?$^'POH$M^MA8RM93W,U]>.CNEM!# CR2RLL;D*!T4DD $@ ]9H MK\Z_^&^?^"N/[?O_ !+_ /@G)^PS'\'_ 3=\1_&7]I-&M;B6(_\M;'0X"TS MDCYHY)2T3Y&X+7TC^P5^QS\,9[6?5]0\3PP6 M>E::T*R )IFGPJ5L8V\T[U5V5BB'"D'(!X]\?O\ @LMKS_&CQ+^RC_P3R_8@ M^(_QY^)7A;59=)\1W$.GMH7A?0+U#M>.\U:]54#+D, BE9%'RR<@UR,/_!-? M_@IY^W;*NM?\%1/V_P"Y\&>%;AA(WP2_9L>72+(IG(BO=7ES=70(PKQ ;,@E M'&0:_1%(XXP1&@4$DG:,9)ZFEH BL;1+"QAL(YI9%@B6-9)Y2[L ,99CRQ.. M2>2:EHHH ^._VC/^"#7_ 3(_:2^)MW\;=9^!5UX0\::@[/J'BCX;>)+SP_< MW3L06>5;.1(I'+ ,7:,NS/X/BYX:_9I@\3>+[: M19+;Q1\1-:N_$-U"Z\H\8OI9(HG0C*NB*X/1NE?8-% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110!Y1^W/\ \FC^/?\ L O_ .AK7=?"[_DF?AW_ + 5I_Z)2N%_;G_Y M-'\>_P#8!?\ ]#6NZ^%W_),_#O\ V K3_P!$I0!NT444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !117%Z_P#M'_L\>%-9N/#GBGX\^"]-U"TD\N[L-0\4VD,T M+_W71Y RGV(H [2BN _X:P_99_Z.5^'_ /X65C_\=H_X:P_99_Z.5^'_ /X6 M5C_\=H [^BL/P1\3?AM\3;6>^^&_Q!T/Q#!:R".YFT/5H;M(7(R%8Q,P4D^!_P[OM:E+'[H69EBMW M!]5E85DK^WA_P7#_ &BCM_99_P""1.A_#;2YO^/3Q3^T/\1HX&.>GF:5IX^U M18X)&XYS@=* /T%I))$B1I97"JH)9F. !ZFOS\'[#/\ P73^/A\W]I'_ (*] M^&OAM82\W7AGX"?"R''TCU/46^TQX[':<]^E.C_X-R?V/OB ZW/[87[1?[0G MQ[D8AKB#XI?&._EM6/'"Q69M]B<<+N.!QF@#Z:^+O_!1O]@#X">9'\9OVUOA M9X;GBSNLM5\>6$=R2.H6 R^8Q]@I-?._B?\ X.5/^"/6DZFWAWP5^TIJ?CG5 MU^[I/@3P!K.I2R?[KI:B)O\ ONO5OA%_P1B_X)1? T1/\._^"?GPLCF@ \F\ MU?PI!JES&1W6:]$L@/N&S7T3X7\'^$O!&EKH?@OPMIVD62?)?HD8 M 'Y4 ?!X_P""\NK>-AM_9_\ ^"0/[8?C!7_U&IW7PF72M.F]-MQ<7'YY08R* M4?\ !1__ (+1^..?A3_P0)U.SMG^YJ/CK]H#1-.9/3=;"-I#^!XQ[U^@%% ' MY_\ _"V?^#ESQK\WAG]DK]E/P2&X5?&7CS6-2*9Z$_8%&<=\=>U+_P *O_X. M8O%OS>(?VI/V2_");EE\*>"-;OPGL#>L"0.G/8FOO^B@#X _X8?_ ."_/B7G M6_\ @N3X2\-9ZKX<_9GTF\ ^GVN8>@_,^@H_X=7?\%4-;X\<_P#!P+\2;@-P M_P#8'PCT/2R1TX,9;:<=_7FOO^B@#X _XQY<#;>V/3GUH_P"' FBZE\WC+_@KS^W-K>[_ %D-[^T$RPG/W@$2 MT&U6'!&>E??]% 'P!_Q#F?L?ZA_R.'[3W[2_B$G[YUKXYZ@^\^IV!.WR_2@_ M\&RW_!)C4/\ D;OAMX]\09Z_VS\7->?)[$[+M>@X'L:^_P"B@#X1T;_@V9_X M(=:#_P >/["&G2=?^/WQKKUSU_Z[7[4SX[_\$*_^"1'PW_9U\>^)?!_[ W@& MWU#3?!6JW5C=SV,EP\$T=I*Z.IFD;!5E!!]J^\:Y/X\^$-9^(/P-\9^ O#B1 MMJ&N>$]1T^P6:38AFFMI(T#-V&YAD]J /@/_ ((:_P#!-_\ X)Z_$#_@E7\# MOBK\0?V&/A#X@\3ZUX)BN=6\0Z]\.-,O;V[F,DH,CS30,[,1P3GD8':OM[P] M^QA^QYX1*MX3_90^&FEE3E3IW@33X,=^-D(K\]_V(] _X.&?V)/V3_ O[*'A M;]A3X%ZYI_@70TTRTU;4/BM-'-=(K,V]U2/:#\W0>E>J?\-#_P#!QQ_TCJ_9 M_P#_ [MQ_\ &Z /J[]I+PAX3\*_LJ_$N'PQX7T[34_X5]K*[+"RCA&/L,O& M$ ]!^0KQ#_@@1_RAM_9[_P"R?P_^CI:\D^)OQ0_X.+OB;\-O$/PWOO\ @GQ\ M [6#Q#H=WILUS%\6YR\*3PO$74&/!(#Y /I7TO\ \$I?V#O"<>GZU%I]V)X5F61V(20 !QAAS0!]!T444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 ? '_!R1;ZW_ ,.^=$UO1/"> ML:S_ &-\:/"6IWMEH6F2WES]FM[\2RNL40+-A5)Z4O\ Q$@?L*?]$>_: _\ M#):I_P#$U]_44 ? /_$2!^PI_P!$>_: _P##):I_\37R_P#\%8/^"L'P'_X* M#_ ?P7^SS^SS\%_C0_B%_C1X3U,G7?A/J-E;);6VHH\KM*Z87"G/-?L]10 4 M444 %%%% !1110 4444 %%%% !17#_'[]I;]GS]E;P'-\3OVD/C/X:\$:##D M'4_$NKQ6D099#VC0,QZ $U\3W?\ P6F^/_[8UW)X6_X(W?L&>)OB MC:/(T0^,OQ*BE\->"[<@X\V)YPMSJ 4_>BC6*09!&: /T0KXI_:-_P""[O[& M_P *OB-=?L]?LY:7XI_:$^*\$CPGX??!71VU>2UE5MC?:[Q/]&MD1\B0[V>/ M!W)Q7L_["GPV_;J^'GPZU:?]OW]H[PM\0?%^M:R;ZV@\&^%!IFF^'KM?V!HT M%I_:%[-(TDMS/Y2KYLKN[,SMEB6.30!\0>$?A]_P7A_;<\6:7XU^.'Q5\(?L MF_#ZVU&&\7X?^!(8?$GBK48DD63[/?:C*/LL"M@ FW&2-RO'@FOO;6?#?AWQ M$]G)X@T&ROFTZ]6\T]KRU24VUPH95FCW [) &8!A@@,1GDU=HH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RC]N?_ )-'\>_]@%__ $-: M[KX7?\DS\._]@*T_]$I7"_MS_P#)H_CW_L O_P"AK7=?"[_DF?AW_L!6G_HE M* -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_)7]B7_@G)^P[^VW_ ,%" M_P!M_P 4_M7_ +-7AOQUJ.A_'2WM-)N]<@=WM87TZ-V1=K#@MS7ZU5^:?_!. MOX^?!']FS]J[]O[XI?M _%KP]X,\.V?Q_M!/K/B75HK.W#?V4A"!I6 9S@X1 MWP_P#_ #F_P#CE'_#@C_@C;_TCV^'_P#X!S?_ M !RO,KW_ (+A_$?]JB_G\*?\$@OV!_'7QP43- /B?XFB/ACP9 P.&=;R\59+ MLH02T2(C$8VDY%-'_!.#_@K)^V9_IW_!13_@I]=> _#]US,J5(SAN"?\ !-[]J_\ X)N?\$C/C_\ MI_#_P"*_P 7 M?!_PI\*:7\;[>'PIX6\]WN'MH]-3<+6RB$EQ.JLV"41@"P!(R*]^_P"'S_[4 MO[4/^@_\$P?^"4?Q0\>V4_%M\1/BH\7@[PXRGI<0/=9FO8P.JH(W]!Z^4_\ M!"7]@+]D3X.?MG?M>:3H/P0T35+SX<_&.STGP?XB\46::IJNGVYL%E?R[NY# MRJSRLSNRL"S'T _6&@#\\Q^Q'_P7,_:S;[3^U]_P4[\._!C0;GF?P3^S3X5 M9;G8>@_MG4/])AD X)C#*3R. *Z[X2?\&\?_ 2[^'_B5?B'\4/@_J_QD\7' M'VGQ9\;O$]SXDNKHCG,L5PWV5N#OAIX(TC MP[I%J,6VE:%IL5I;0C_9BB557H.@K7HHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***SO%OB_PGX!\-WGC M+QUXHT[1=(TZ S:AJNK7L=M;6L8ZO)+(0J*/4D"@#1HKX'^(_P#P7R^#'CCQ ME>?!?_@F5\ O&O[4_CFUD\FX_P"%>VOV;PUITIZ?;-;N%%O$AXQ)&)$.<;@: M^G/V+=9_;4\4?!4ZW^WUX%\!>'/&U[JMQ)#H'P_U&XO+2RTY@GD0SRSCY[E? MW@D,9:(X4J1DJ #SW]LK_@L1^P!^PYK \!_%CXV1:QXZFD$.G_#3P+:MK7B& M[G/W819VVXPLW\)G,2G'#5Y=\&_VF_\ @L]^V?\ %GPUXN\$?L>>&?V>/@Q: MZY;76MS_ !CNGO/%_B'35E5I8(=.MB$TQY$W(1<$LA(96.-I^@/V2O\ @F[^ MPS^PO%WT > M>_'3]DW]F;]IS4O#6J_M$_ KPOXWE\'ZA)?>&E\4:1%>QV%PZ!&D2.4%"2 O M4'!56'*@COK2TM;"UBL;&VCA@AC6.&&) J1H!@*H' P *DHH **** "BBB M@ HHHH **** "BBB@ HK\ ?^#D7_ (.1_\\M/^&GQ,UBY M^BQ:7J$K'Z+#<,?2-S]UJ /W^HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** (-4U33=#TRYUK6;^&TL[.!Y[NZN) D<,2*69V M8\*H ))/ KXP\/?\%;_ !G\4=-O&OPOUOP1K7B32-:T^^T M^#6==L=/O;.V:^L-/GN4+P-]I9HXIFBN)AL*1\@-]@^.O!F@_$;P1K/P]\56 MS3:7KVE7&G:E"CE2]O/$T4B@CD$JQ&>U?BM\+OBM^T7_ ,&YW[5/@OX(_MR& M_P#B/^S=I7@_7-(^&?Q6\,Z8TU_X6TB\U73)7&L6Z GRH)TMXP5[76(FEPL$ M8!^G_P 8O^"AWPS^&W[-O@7]H/P/\,_&WQ O/BEIME=_#?P%X-T/[1K>MBZM M!>*?*9E2WCC@/F332LL<0')+,BMYS^Q+_P %B? 7[4O[3&M?L2?&?]F_Q]\$ M/C%I.D?VO:^"?B%;0C^U].!PUQ97$+%)PO)( &0&*%PDFSZ7^%5C\%/$G@KP MA\0O@[;Z'?:##X5C@\$ZQHP22!='GCMW1+:1C?M6>&[-1X8_9M^'VH^%I_$,:?+JWBC4R?/T^-^DL=C9N3*0<) M/>"/[R2A0#U']O[_ (*):3^PK:^&M+T;]F7XI?&+Q5XHDN9;/P3\(/"SZOJ= MO86XC$^H31(?W=NDL]M%O/5[A .^-O\ 9!_;3NOVE_V>=6_:-^*W[-?Q!^!N MFZ1>7:W6D_&/2ETF_2SMH5DEOWA9B8;?!,U\,66D:=\-O$GA.WN="U"SM#)*+.2=BYC\ MR::>0R&)B&E !4(K+\\?MU_\%*OBM^U__P &SOQ^^,7BKX=2^!?B?X5U5/AQ M\5_#-LS>7INK)K6FV6HQ1DDMY4EM>9VDL5$S(6<+O8 ^R=)_X*W^ '^&GA?] MJ/QA\#?%/ASX%>-=>MM+\._%C5[FU2-5NI_L]EJ-Y9;_ #[/3KF8HD5P^6'G M0M+%"C[A]<5^>/\ P4Q\">%=)_X-IO%G@3[+$=,T?]GC18[&/:-JFUM[)K?' MT>*,CZ"OJ3_@FUXU\4?$G_@G;\!?B)XVN99]9UWX,^%]0U:XG)+RW,VDVTDC MMGG+.Q;GGF@#VJBBN,^,WQ-\7_#+3+*_\(?!W6O&,EU.T M1P3QQ0!S?[<__)H_CW_L O\ ^AK7=?"[_DF?AW_L!6G_ *)2OF;]JW]H_P"+ M'BO]G7Q=X' M&/@Z]!.@V9(++Q^X2@#MZ*Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ M (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU? M_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU M?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"] M_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W M_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -B MBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^ M$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_ M^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ MH4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI M: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_O MI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V M**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$E MU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (27 M5_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+ MW_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4 M+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^ MEH V*R/'OC_P+\*_!NI?$7XF^,M+\/:!H]JUSJVMZU?QVMI9PKUDEED(5%'J M2!7S7^W9_P %9O@K^P[=Z5\,[SP1KGCKXM>*_P!WX%^#W@U5NM;UJ5LA&,:! MC;6^0=T\@VA4[&?F+'R@=Z@O&_EJ :NO?\%9/VL?\ @H)X@O?A M9_P1)_9]M]$[!U.V3^SK06Q+2;54,KK&D4:J%(K]HO#?V/P;H%EX3\(?# :5I6G6R6^GZ;IMO% M!;VL*#:D<<: *B* %4 #BOG'XO?\$B_P#@F?\ 'SXEZS\8_C'_ ,$^/#'B M'Q1XAO#=:UK6H6[--=S$ %W(D )P!V[4 >W:;^T]^R1HVGP:3I'[0WPYM;2U MA6*VM;;Q;8)'%&HPJ*JR@*H ' J?_ (:P_99_Z.5^'_\ X65C_P#':^9_ M^'%O_!(3_I&/X+_\!9/_ ([1_P .+?\ @D)_TC'\%_\ @+)_\=H XS_@B_XA MT#Q9^VE^W9XC\+:Y9ZGI]W\?+22TO]/N4FAF3^S(_F1T)5A[@U^A5>)_LL?L MD?LS?L2:!JOA;]E#]ERP\"Z?KEXEWJUIH:;$NID38KMN8\A>*]4_X275_P#H M4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A M0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH M V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^E MH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8H MK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275 M_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7 M_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O? M^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O M?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6 M@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_ MX275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^ MA0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_ M^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ M +Z6@#8HK'_X275_^A0O?^^EKY*_:F_X+;?LZ_LZ_&B7]EOP!\)/B)\9/BU; MPB6_^''P@\/'6+[3$.W#WKJRQ6HPP)#-O52&*@,I(!]FT5^>6I?\%^KGX.PC MQ!^VC_P2V_:2^$7A;(-QXWU3P6-2TC3XR1A[N6T9G@&#G&QCD$8.*^R?@C^T MU\,_VD_AEI?QF^ FMVGBWPMK,/F:;KFAW\<\$P!PRY4_*ZG*LC896!5@""* M/1**QCXGU506;PC> JW[/_ ,6OCO\ MM&?LUV_B/X^?LP^)?A!XE\16=[!>>%X_$\%W?:5"\DL<$R75O@),T/ERXVJT M3L5(RF3XS^R1_P $_\ BI\6]5_X2#7K MBX'_ "W$UQE()/\ :ACC;'!)H I?LU_\%1/VH_VW_CEX<3]F#_@G'XSTSX'R MWK'Q%\8/BQ=IH#W5KY;[)-+TU@T]TK/L82DA2JLK!"01Z]^V5_P3-_9!_;_\ M7>#?$W[67@._\5VG@=[F32O#4^OW4&DW,LQB(ENK6&14N6C\KY-^1B1PP8' M]E_X275_^A0O?^^EH_X275_^A0O?^^EH C^''PQ^&WP<\'67P[^$GP_T3POH M&G1^7I^B>'M+BLK2V7T2&%511]!6Y6/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H M7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ MT*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*% M[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_] M"A>_]]+7E?[2?_!0;]E3]CS2/[9_:A^,_ACP,AB\R"V\0^(;>"ZN5_Z8VY;S MIC[1HQH ]LHK\=/VIO\ @\X_8(^%JW&C_LQ?!OQC\4]2CR(+V;&AZ7(>Q\VX M1[GKV^S#CO7SC/\ \%+?^#J7_@JNAM_V./V7;OX3^#=0&(-#]#@_UVL>*-;@ ML+5.,X,L[JH/MFOQ!_X.)_\ @XZ^#GBS]G8_LO\ _!,7]JZTU/6/$%]+9?$+ M7M TJ]C>'3#&08;*^=$BS(WRR/$7.PX5URU%/V(H/%^MVV#_ ,)#\29AKD[..CB&?_18G!Y#10H0?H, '\?=%?O5 M_P '%?\ P;FRDZU^WS_P3T^#<]C#'')>_$;X9Z-9KY: M)J6G0Q]!C+2VZC M'61!]Y:?_P &Y?\ P;JWME<:#_P4$_X* ?"*ZN0!%J'PU^'&J6H"YX>+4]0B M?KV:&W8>DCC[JT ?HA_P;=_\/'/^'<>@_P##PO\ Z9?\*T_MCS/[=_L+RQY7 M]H;OP\G=^]\K'F?PU]_UC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1 M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_ MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45 MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+ M5K2M5O=0D=+K1)[4*N0TI&&]N* +U%%% !1110 4444 %%%% !1110!S7QFL M?B%J?P?\5Z;\)-02T\5W'AJ^B\,74C*%AU!K=Q;.2P*@"4H>01QR#7P-\;OC M'^U1\>O&EA\*_'O_ 3<\4CXC^)?V:+%)=&_6^ M='TY6!9CL^T[70"W+G:/T>HH _/;7OA+_P %%_\ @G+_ ,$U?@[^PQ^PG^S? MJOQB\2Z/H$6F>-/&NE>.M&T)=(@#>9=FR;59@QN':62.W+O ?[.+?\$:-/^!'PRLKL#7O&VJ?';1O$9L;*,//*BV=F1<7% MS=2#RS<.[,)+AII-YW&ONNB@#Y?NOVPOV\="_:$\9?![5O\ @EIXHU;P]9WX M7X?_ !#\-?$31&TS5[4H");Y;N>">PPV0RQQ7#CG:CX#/F6O_!+SPMX\_8-^ M,/[*/QLUBR;6_C[K.N^)/B#JVAPLUK9:YJ;J\'[4__!,?PS_P23^(7P3U#PQKTNG:+X3^)/Q?.KZ? M-H7]A:9/;F;4K#9<-=7-Q>06J*EO);Q>6\\GFF-45G_0WP%X(\-?#/P-HOPW M\%Z:MGH_A_2;;3=)LT.1!;01+%%&/9411^%:U% !1110!Y1^W/\ \FC^/?\ ML O_ .AK7=?"[_DF?AW_ + 5I_Z)2N%_;G_Y-'\>_P#8!?\ ]#6NZ^%W_),_ M#O\ V K3_P!$I0!NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1102 ,DX ZDT %?!'[87_ 4\ M^-/Q>^.FH_\ !.G_ ()"^'M+\9_%NT_=?$'XF:DOF^&/AC"Q*M)=2@,MS?## M!+50V'4AUO#IWQP_: MF?L]_LR^ M (-#T'3QYES,2)+O5+H@"2\NYB-T\[X&YVZ !5"HJJ #S3_@GE_P2P^"O[!L M6J_$K4/$&H_$?XR^,#YWQ"^,WC$^?K&M3-@O'&S%OLEJ" %MXS@*B;F-;EO-OO$VO2CS+J[GG;YY%\UY!&&)VI@ M ?V&KKX1ZG\?/"[_ !,TCQSX;\0Z1\.X-36?4KY;/4X)I5D@BW- GD>;('F" M(?+P"6P*^Y_A?\:-4_;I_8!7OO!&L>)?#L$M[H*8*Q24)N9)$QAL,&H [?XT_&GX*? /X?WOQ%_:!^)_ASPEX9M MD*WNK>*=5AL[0 @_(7F8*Q89 3DMT -?B]\"O^"@/[)O[+W_ 5E\._$[_@F M+X9\<^%]?\&_LT?L)_#;3[2'Q5\0?VB_##>&]!TN)( MVL-*TN4W-]?)&N/+AMXQ&"5' DX'!P >Y?MV?\$O_#7_ 4*\?Z+)\;OVG?B MEIOPVT[2/LNL_"/P;XD.E:5XBG\UW\Z_DA43S*48(8@ZC]VC*5.[=ZM^S%^Q MM^RO^Q?X(7X=_LK_ $\,^!M**J+B/0=,2.6[*\![BH(!SSG_#LC_@Z>_X*N_Z7^VI^U-/ M\*/!VH0#]?_VL_P#@L1_P3._8 MC^TV7[1/[8?A#3-6M,B;PWI=Z=4U56'16L[(2S1Y/ +JJ^I !(_-']I/_@]" M^&]YK1^'O_!/W]B[Q1XYUF[D,&FZGXRG%I'++V,5C9^=-<*>RF2%L=ATKT7] MDS_@S3_X)Y?"'[-K7[47Q,\8_%S4XL&>Q\_^PM)D/4_N;5VN>O\ T]8QVK]+ MOV;?V)/V0OV/=$&@_LO?LV^#? T)B$I'UY]4_9I_X,N_A M3)K ^('[?G[9?BGQWK%U*+C4=,\'P"RBEE[B6]N_/GN >[!(6]QUK]P:* /F MW]DS_@D#_P $U/V(A;7G[.7['W@_2-5M,&'Q)J-B=2U56'5EO;PRSID\D(ZK MGH!@8^DJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*/VY_P#DT?Q[ M_P!@%_\ T-:[KX7?\DS\._\ 8"M/_1*5PO[<_P#R:/X]_P"P"_\ Z&M=U\+O M^29^'?\ L!6G_HE* -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-3]I#X\_&;_@M%\:M>_8 M_8/\?7_AGX#^%[\Z?^T'\?-$DP^K2#'F^&M#EY61V4[9[E$O#-BMKI6F6:]!U: M21C\TLKL6=Y&)9W9F8DDF@!W[.O[.GP6_9-^#6A?L_\ [/?P_L?#/A+PY9BW MTO2;!,*HZM(['+2RNQ+O(Y+NS%F)))KMJ** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\>_:Y_X* _L8_L(>%? M^$N_:T_:+\->"X7A,EI8ZC>[[^]49S]GLX@UQ<PU0\4>*?#' M@CP]>>+?&GB.PTC2M/@,U_J>J7B6]O;1CJ\DDA"HH[DD"O.?B+XX^+_QR_9% M?XD_L(^*O"]KXI\6^&+/4_ &K^/M,NFTU$N1%*LES!%MF4^0[87&5DV[E8!E M/R?X8_X(/Z?\?/$%G\3O^"M_[7WCG]I/7K>9;FW\)7ERVA^#M-E'(\C2;)E5 MROW2[OB0*-\?44 >Z?LX?\%9OV'/VP/VD=5_9B_9<^*5SX]U70M'FO\ 6?$7 MAK1;FXT&T,5Q)N3RV9&6-_GW *>9_;6_8*_;#_;0^,JZ.G_!1 MSQ7\+O@A_8\":AX*^%VE0V&OZI=[G$_F:PVZ2& IL 1%(;%/#^GIML=#\.:3#96EN/]B*%51?P'-=!0!\W_LK_ M /!(S_@G7^QOX5U'PS\$_P!EWPXEQK=A/9^(?$.OVYU35=7AG1DN$N+RZ,DK MI*&??&&$9W$; .*^8_ ?[/?_ 5,_P""-UY>_#C]B'X4:=^TK^SE)?S7?ACX M<:KXOCTCQ7X&260O):6MW<@PWMFK.[(C9E_A&W!:3]+** /S[O?^"CG_ 64 M^+T)\*?LZ?\ !$;4O"NJSC8WBCXQ_%#3[32M-;IYCV]M_I%V@;/RQ,K$#(ZU MWO[!?_!,;X@_"7XY:K^WI^WK\#],)R=-T:V8 MQQDDAIV59) 3D*9)3)]CT4 %%%% !1110 45Y=^TE^VS^R'^Q[HAU_\ :@_: M2\&^!H3$9((?$6O0P7%R/^F,!;S9SP>(U8\'BOS2_:S_ .#RO_@GC\(/M.B_ MLO?#3QC\7-3BR(+[R/["TF0]/]==(USU_P"G7&.] 'Z_5SGQ1^,'PE^!_A.; MQY\:?BAX=\(:';_Z_6/$^M06%K'QGYI9W5!^=?@;_P /.O\ @Z<_X*N_Z)^Q M5^RQ/\*?!VH<0:_IGAU+".2 _P 7]JZTVV0@<[K14?@87)YZ+X6_\&A_[7?[ M3_BN'XL?\%6/^"CNIZSJDOS75AH-Y=:[?E&P2G]HZD56$CIA8)4ST) &0#[" M_:S_ .#L3_@DK^S=]IT;X>>/]>^+6MP906?@#1R;19.VZ]NC#"R?[<)FZ]#7 MQ'JW_!R#_P %P_\ @I#J<_A+_@E3_P $]Y-!TR64PIXDMM"F\07%JVF6]E9VL0CMK2TA6.*% M,!550 H Z #% '\_6E?\&X'_ 7%_P""D.I0>+?^"JW_ 4(DT#3)95F?PW< MZ[-X@GM6SDK'8VSQ:=;^QBE(!YVG'/VW^R9_P:=?\$E?V;OLVL_$3P%KWQ:U MN##F\\?:P3:+)WVV5H(863_8F$WU-?IE10!SGPM^#WPD^!WA.'P'\%OA=X=\ M(:';_P"HT?PQHL%A:Q\8XB@14'Y5T=%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% 'E'[<__ ":/X]_[ +_^AK7=?"[_ ))GX=_[ M 5I_Z)2N%_;G_P"31_'O_8!?_P!#6NZ^%W_),_#O_8"M/_1*4 ;M%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !7P'_P %(?VROCU\??CS'_P2'_X)K>(Q9?$W6].2Z^+WQ1@!>W^%_AZ7 M :3U#@B*TMU#N"XQ(T9&"J2E>Y_X)I?\ !/+P+_P3 MO^!,O@FU\17'BOQYXJU!]<^*GQ'U7+W_ (JUN4EIKF5V)81JS,L49)V*23EW MD=@#L_V*/V+_ ($_L!_L[:'^S1^SUX:-CH>CQE[F\N"'N]6O7P9[Z[E !EN) M6&6;@ !54*B*H]7HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BN)^//[27[/_P"RYX'D^)7[1WQG\,^"-!B)7^T_$^LP MV<4CXSY:&1@9'/9$RQ[ UA?M;>-?VIO#GP!O?$W[#?PP\*>.?'=Q-:IHFG>* M_$+6.F^3+(JO=O+&"94B1O-,:LC.JD*V[:K 'J,LL4$33SR*B(I9W4?!W]N[]CG]H;XS>(?V??@3^T=X4\8>+_ IIR7WB'2/#>J+>?8H6D\K+ M2Q9B+"3"L@,K=ZD@YP\ACD&<;B*^T/VYH ^=/VL/V>/\ @KY^U+\>-:^' M?PW_ &QO!_P*^!D MUL=>\$:#)?^-=:5H(VN$:6Y(@T\"4R(DL)\P! Q!SBM MO]D?_@BA_P $_OV0_%7_ M?2?A==>/_ (CS2B>^^*?Q7U)O$&OW-P/^6XGN M04@D_P!J!(R>^:^LJ* "BBB@ HHHH *Y_P"*OQ5^''P.^'&M?%[XO>--/\.^ M&?#NGR7VMZWJEP(H+2!!EG9C^0 R22 20*/BK\5?AQ\#OAQK7Q>^+WC33_# MOAGP[I\E]K>MZI<"*"T@099V8_D ,DD@ $D"OY0O^"^'_!?#XC_\%5/B/+\( M/A! YDB!4G M()(^WZ_@C^%7Q5^(_P #?B/HOQ>^$/C34/#OB?P[J$=]HFMZ7<&*>TG0Y5U8 M?D0QAO\ M5QJEPH(:XMM)LTC>$[0'(,TB*Q/ 48H _HOKYN_:S_X*^?\ !-7]B$7-G^T= M^V#X/TC5;3(F\-Z??'4M55AT5K*S$LZ9/ +HJYZD8./Q[_X=N?\ !U1_P5>_ MTO\ ;&_:=N/A)X-U'F?0M2\1)IDO<7(X[4 <'^TM_P> MB?"=]8/P_P#V!/V-?%/CO6+J7[/IVI^,)Q8Q2R_PF*RM?/GN%/92\+>PKRK[ M9_P=]?\ !6G_ (]X+_X ^"M2_B"_\(;# C=\GS-9="OIO4CZ\_N!^S5^PW^Q MW^QSHXT7]EW]FGP9X'0Q>7->=-<*>[".%L=QUK M]+OV3/\ @CK_ ,$S?V(_LU[^SO\ L>>$--U:TP8?$FJV1U3558=66\O3+-'D M\D(RKTP /I>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH \H_;G_Y-'\>_P#8!?\ ]#6NZ^%W_),_ M#O\ V K3_P!$I7"_MS_\FC^/?^P"_P#Z&M=U\+O^29^'?^P%:?\ HE* -VBB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "O!_P#@HQ^WU\,/^"=/[-][\;_'>GW&M:S>74>D^ _!6F9:_P#%&N3Y M6UT^V106+.W+,%;8BLV&("GU+XS_ !D^&?[/7PH\0?&_XR^+[30?"WA;2I=1 MUS5[U\1VUO&N6/'+,>%5%!9F(5020#\#_P#!.SX,?$S_ (*8_M+VW_!9W]LG MPC=Z9X=LH9K7]E7X7ZNG'A_1I#@^(+F+D&_O Z'G9'M92P$#( >H?\ !*'] M@/XG?!B7Q-^W3^W#?VVO?M)_&,)=>-+Y,/#X6T[Y6MO#UCRPC@@54#[20\B# M+2"-'/V=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M15+7_$GAWPII_P#:WBG7[+3;0S1P_:=0NDAC\R1PB)N<@;F9@H'4D@#DT 7: M*\:_;A^/W[1G[/7PGLO$?[+/[(&K?&GQ=JVN1:78^&=-\06VEPVGF12O]LN[ MFX^6*W0QA68 G=(@X!W#Y0_X=X_\%7?V]Q_:/_!2W]O8_#+P;=\R_!?]FDOI MXDB/_+*]UN<-<39&%DB0-$WS;&6@#[U\*_%;X7>.O$^N>"O!/Q(T'6-9\,31 M1>)=)TO5X;BYTF24,8TN8XV+0,P1RH< D*<=*^.OC_>_\%S_ -I?XT>)?@W^ MSGHOPX_9U^&6E:K)96WQ=U^Y3Q-X@UVV!^6[T_3E"P6P8'F.ZPP(RKU[_P#L M9_\ !/K]CG_@GYX*NO O[(WP)T?PA;:CY1UF^M@\]_JC1[MC75W,SSW!4O(5 M#N0OF/M"[C7LM 'Q%\ _^""7[%W@/QW#\=?VIK_Q/^T=\3QAI/&_QPU9M8$# M9SMMK%_]%@C5L%%*.T> %?BOMJWM[>TMTM+2!(HHD"111J%5% P . .U/H MH **** "BBO&/VHO^"BG[#'[%=E)<_M2?M5>"O!L\J%= M"TR0GA60R++=/Z[6@C)X&1G(\ _X;L_X.Q_^"KG[C]F']GJZ^#?@S4.(]7T_ MP^FAQ-;GI(-1UAFGEQW>SVDD<+U% '[V?%WXY?!7]G_PI)X[^.WQ=\,^#-%B MSOU;Q5KMOI]L"!DCS)W5<^V7AAC9/\ ;A$PYZ'G'R=\(O\ @ST_:%_: \5Q_%?_ (*E M?\%&-7\0ZS<8.H6GAB>YU:^E4\D'5-4Y4CIC[.XST/'/Z(_LG_\ !N[_ ,$B MOV0OLVI>#OV2M'\5:U;8(\0?$9SKEPSCI((KG-M$XZAHH4(/- 'Y5_&;_@O! M_P %C?\ @LIX(\0?L]?L'?\ !,2R/@3Q1:2Z;J]S=>&9?$@,3@J5FO;M(M.A M]?WD658 ALKFOSJ_;U_X(=?\%%_^";?PB\/_ !P_:B^$%K9>'M=N#;7%YH>K MQ:BNC7)^Y!>O!N2)I.=C*SHQ4J&W<5_9YINFZ=HVGPZ3I%A!:6MM$L=O;6T0 MCCB0# 554 * . !Q6-\5?A5\./CC\.-:^$/Q>\%Z?XB\,^(M/DL=;T35+<2P M7<#C#(RG\P1@@@$$$ T ?PA_"KX5?$?XY?$?1?A#\(?!>H>(O$_B+4(['1-$ MTNW,L]W.YPJ*H_,DX"@$D@ FOZO?^"!__! _X*+7Q M!?>&?CEX.U&#PG,(O%,UAXFM)DT:0YPEV4D(MV.#@2;3P:\=_P""N>B^,-?_ M ."?WCO3O"^G>-+ZR/\ 9S^,=.^&\RQ^(+WPXFH6[:Q!IY;@W#Z>+I0O!<%D M4AF4C\??V2/^"WW_ 0Q_P""4NG?%_0_V)_A7\0M=\->,]%T6;2/!NH64SM> M:K%'?QW274]_*WDPE9+96*B08WE4?D$ _H4!# ,I!!'!%%?%W_!OC??M"ZI_ MP26^%FK?M)Z1>:?K-Y!J$^C:=J".LUIHKW]PVG18D^81K:F(1 \B 0CM7VC0 M 4444 %%%% !1110 4444 %%%% 'E'[<_P#R:/X]_P"P"_\ Z&M=U\+O^29^ M'?\ L!6G_HE*X7]N?_DT?Q[_ -@%_P#T-:[KX7?\DS\._P#8"M/_ $2E &[1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %'3K17Y]?\ !4[]I3XP_M0?&W3O^"+O["7BN73O''C/3!>_&[X@V&7'P\\( MO@2G<;Y)9"J(N2.20.:^=-* M_P""U7_!)36O%@\%:=_P44^$;7S2"-#)XTM4MW8D@!;AF$+9([/Z>HH ^GJ* MJZ)KFB^)M'MO$/AO6+74-/O8%FL[ZQN%EAGC895T=2592.002#5J@ HHKP/] MO+]N34OV+/#7AX^$/V4_B;\7_%'B^^FLO#?ACX;Z#]IS/&BN6O+AB$LH,-GS M6#8"L=I"G ![Y3([B"9Y(X9D=HGV2JK E&P&P?0X(./0@]Z_.[_A0W_!=7_@ MH/\ Z1^TC^T%H7[)'P]N^7\"_!Z==7\83PG_ )9W&M/^YM).>);0'I@I7U3^ MPS^P#^SS_P $]/AIJ7PT_9_MO$$JZ]J[:OXFUOQ3XEN=3U#6M1:-(WO+B29B MOFLD:*?+5%.P?+0!\X?$;]K_ /X+(?M4?$+7?A'^P?\ L*V/PA\.:1K-UI=Y M\9?VA[G89C#*T4DVG:/:L\DZDH7AG=G@E4J3M!J3X8_\$'OASXT\>:9\=?\ M@IC^TYX^_:;\>:7=)>:DW*G<'L=&M&$,.#GY79T/!V U][44 % M%%% !16)\0OB7\.?A)X6N/''Q6\?Z)X8T6T&;K6/$.JPV5K"/5Y9F5%Z'J>U M?G]^UA_P=1?\$AOV8_M.D^&OC'J?Q3UJWRO]F_#323=P[N@_TV=HK5ESU, 0#]'*;--#;PO<7$JQQHI9W=L!0.223T%?S]^)?^#HC_@K7^WOKMSX M_P""4?\ P3BFMHS(86UMM(N_$MY:^DCNB0V=IU!/G+(HSC<>M4X?^"$'_!Q3 M_P %0)EU?_@IE^W8W@KP]>L'NO#.H^(CJ)C!.=R:3I;1Z<#C_IJC= 1Z 'ZI M_M8?\%Y_^"3W[&WVG3_BK^V+X:U+6;;*MX<\%2MKE]Y@_P"63K9B1(']IFC' MOR*_.+XZ_P#!Y9XG^)?B<_"[_@FC_P $_P#7O%>MW;%=*O?&9DN)YFZ#;I6F M%Y)!DYXN0>G'/'T-^R?_ ,&@G_!+;X#_ &;6?CDWBWXOZO%AI1XDU8Z?IOF# MH4M;(QOMS_!+-*#WR.*_1WX%?LR?LZ?LP>&!X,_9S^!?A+P-I>T![+PIX?M[ M%)2/XI/)13(WJS9)/).: /PD'[/O_!W;_P %8#YGQ7^)E]\"O!>H];*[U-?" MD:1'[T36M@KZE(,?PW((/0MC./9_V7?^#+?]F'PU>1^+OVU_VI?%_P 1=5ED M\^\TOPS FD64DA.666:0SW$XSGYU:%B><"OVMHH \ _93_X)8?\ !._]B-+> M7]F/]D3P7X:U"V $6O\ ]EB\U7CUOKHR7)]<>9C->_T44 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >'_P#! M2']LT?\ !/C]BSQM^U__ ,*QG\9GP?'8,GABUU+[')?M.IOCKXG_ .#:?19/$T,C7L_C*_M+(WR,/G:= MKM]!\P$8W%RW;.:_9?\ X*D_$_\ :"^#7[#?C#XD_LI?"'2_'GQ'TV_T3_A# M/"NLZ,]_;WE_)K-C%&QA22-BT9?S4<.OEO$LF1LK\P)_^"B?_!X%J,+Z>?\ M@EE\/E\]3'N;PX^!NXYWZT5[_P 7'K0!^GW_ 2T_;'\9?\ !0#]A;P7^U]X M[^%W_"%W_C.YUF6/PQYTDIL+6#5[VUM5:21$,C&W@A=I-B!RY9552 /H*OE[ M_@C9\"?VJ/V;O^"=W@/X3?MF75D/'MF=0N-0TK3IHY(-&@N+Z>>WTY'B)C*0 M12)$JQDQQJHC0E(U)^H: (-4U33=#TRYUK6;^&TL[.!Y[NZN) D<,2*69V8\ M*H ))/ KXP\/?\ !6_QG\4=-O&OPOUOP1K7B32-:T^^T^# M6==L=/O;.V:^L-/GN4+P-]I9HXIFBN)AL*1\@-]@^.O!F@_$;P1K/P]\56S3 M:7KVE7&G:E"CE2]O/$T4B@CD$JQ&>U?BM\+OBM^T7_P;G?M4^"_@C^W(;_XC M_LW:5X/US2/AG\5O#.F--?\ A;2+S5=,E<:Q;H"?*@G2WC!7M=8B:7"P1@'Z M?_&+_@H=\,_AM^S;X%_:#\#_ S\;?$"\^*6FV5W\-_ 7@W0_M&MZV+JT%XI M\IF5+>.. ^9--*RQQ C?M6>&[-1X8_9M^'VH^%I_$,:?+JWBC4R?/T^-^DL=C9N3*0<)/>"/[R M2A0#V3XF?MR6NF_M'7W[(O[/WPDU'XD_$'0?#D.O>,+"PU:VL+'P[93L5M5N MKJ=L+6$;7QU YXH _5O2?\ @K?X M ?X:>%_VH_&'P-\4^'/@5XUUZVTOP[\6-7N;5(U6ZG^SV6HWEEO\^STZYF*) M%-%CL8]HVJ M;6WLFM\?1XHR/H*^I/\ @FUXU\4?$G_@G;\!?B)XVN99]9UWX,^%]0U:XG)+ MRW,VDVTDCMGG+.Q;GGF@#VJBBN,^,VB?'+6],LHO@=XWT70[M)V-]+K6F--_P#H-V7_ (#'_&C[%XW_ .@W9?\ M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V** MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#' M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ MZ#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK' M^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\ M:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#' M_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W M9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H M-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[ M%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH M^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\ M: -BBL?[%XW_ .@W9?\ @,?\:\\_:M_:6\(?L7?L^>*/VFOC_P#$2PTCPMX3 MTUKO4)_LN9)FR%CMX4)'F32R%8XTS\SNHXZT >;_ /!5/_@H<_["/P;TO1/A M5X3_ .$Q^-/Q+U,>'O@Q\/X/FEU?5I,+Y\J@@K:6^]9)7)5<;$+)Y@82?\$L M/^">B?L%_!+4+KXD>+/^$P^,7Q&U0^(OC-\0KCYIM;UF7+-&C$ BU@WM'"F% M &Y]JF1A7A'_ 2S_97_ &B_VCOC%?\ _!9K]NC28=.^(WCG2?L?PC\":E"T MB_#WPF^3#$JG 2\N48R2O@.%E8'899(U^_OL7C?_ *#=E_X#'_&@#8HK'^Q> M-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ M *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q> M-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ M *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q> M-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ M *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q> M-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ M *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q> M-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ M *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q> M-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ M *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:YOXQZ'\5M5^$7BK2_"FM6QU2Y\ M-WT6FB*V.[[0UNXCQSUW$8H _/#]GSX&Z;_P7]^/'B?]M#]K:YO-8_9H\#>, MKS0/@)\)ENY(M+\2R6,IAN?$FHJA7[6'F5TAB8[5"R(RD!O-^Y]6_P""=7_! M/_7/!7_"N-6_8@^$%O 7AGP]-J6N:YJ,&J7,=W#;VL( MR7^T,)G#RP;BKKU(108>ZE_P""O_[8O[;$C:#_ M ,$??^"?>N>)='G)2+XW?&Y)?#?A1!G GMH&Q>:E'TR(Q&ZGJA%>D>./V4(_ MV._^"5/QD^$WQ,_:.\6_$;1S\._%.H^*O%7Q2UC^TM0NA/ITS7(,KA0D7#;( M\$+NQD]:T?\ @BC9_%5O^"2G[/#>(]6@CF/PHTC[.D]NQ86OV=?LV2?^F'E8 M]L4 <9\%?^"3G[37C[XN^&OVE_\ @IA_P46\#M)O()!)%FUMR)+_P ME&))BA=25D5P3G[LK'^Q>-_^@W9?^ Q_QH^Q>-_^ M@W9?^ Q_QH V**^1OVL/^"R?_!/?]BK[39?'S]N+P):ZM:Y$OAO0G;5M35QT M1[6R$LD1)X!D"+ZD#)K\W?V@_P#@\TTO4]>_X5[^P1^R'X@\;ZO=RF#3=0\7 M1BU$TG8Q6-F9IIP>P,D38Z@=* /W;KR_]I#]M?\ 9%_9 T4Z]^T_^TEX,\#0 MF(R0P^(M?@M[BY _YXP%O-G/!^6-6/'2OPYCM?\ @\ _X*P+B>YU#X">#-1[ MN5\&Q0*WLHDUAU*^N]--8NY!/J6 MG^$[8VR2R]Q)>W?G37 /=A'$V.XZT >L?M8?\'DW_!.7X/?:=&_9F^'OC+XN MZG%D07D-K_8>DR$>L]VIN!SZ6I&.]?,7_#V+_@Z'_P""JG^A_L)?LB2_#'PC MJ'%KXBTSPTMNCPMU)U;6B('('.ZV5'Z8&2,_K#^RA_P1<_X)]_L4FVOOV?OV M4O =CJUK@P^(]9TEM5U1''.Y;N]:66(D\XC95] *^G/L7C?_H-V7_@,?\ M&@#\'?A[_P &E7[>7[77BBW^*?\ P5:_X*1WVH7S'?)IVE7UYXBOU1L9B%W? MM'%;$=,1QS(, #CI^@/[)_\ P;._\$?_ -E#[-J=O^S3'\0M:ML'^V_BC>?V MP9".YM&5+('/.1;@^]?#O#MCI.F640CL].TRT2""!!T5(T 51[ 5>K'^Q>-_\ H-V7 M_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X# M'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7 M_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X# M'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7 M_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X# M'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7 M_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X# M'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7 M_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X# M'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7 M_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X# M'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7 M_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X# M'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7 M_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X# M'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7 M_@,?\:M:5!K\,CG6+^"92OR"*+:0: +U%%% !1110 4444 ?B?\ %>[_ .#Q MOQ;\7_&>N_L]ZQH-EX"D\9ZNG@JWU?3_ E!<+I*7TT=H62YB\X9A6,@R?.R MD$\FL'^QO^#WK_H;/!__ '[\%?\ QJOU+_X*B?&;]I3X'_L9:_XB_8\T;3KS MXH:WK.B>&?!#ZQL^R6FH:MJMKIL5S+YGR8C-UO <%2RJ&5@2I_'S5/!O_!V# MIGQEU/X#ZI_P4Z^'MOXGM/";>)+"RGUC384UBQ26:*X:SD?2E21K>2$I.A*^ M3YL)?:LBL0#]=/\ @D=;_MDVO[ WA*#_ (*"27K_ !A&N>)3XV>^\CSY<5])5\D_\$*?^$\F_P""3GP8U7XD_'VS^)FJ MZEX=FOW\66,TLD;Q3WD\L5H&E1'S;1NEJRLJ[&MV0 !0*^MJ .:^,UC\0M3^ M#_BO3?A)J"6GBNX\-7T7ABZD90L.H-;N+9R6!4 2E#R"..0:^!OC=\8_VJ/C MUXTL/A7X]_X)N>*1\1_$O[.'B[P[JG@_5M:T2309;J[O-%BDNC?K?.CZ-=*\=:-H2Z1 &\R[-DVJS!C<.TLD=NY@D2%5$CJS*(FWOV2/C9_P5 M*B\7> _V<6_X(T:?\"/AE978&O>-M4^.VC>(S8V48>>5%L[,BXN+FZD'EFX= MV827#32;SN-?==% 'Q+X _9O^+O_ 3[_;\^-O[0WPE^"&O?$/X:_M Q:?KN MHZ1X0NK!=1\.^*;1)8IP8;VYMTDMKU)1)YRR,8YD*NJ1D25SWP$_X(_2^-?V M/OVE/ _[6\EI8^.?VM/%&K^(/&<>DS"[C\+K.S'2K&*7Y5N6L?DD+\*TI< L M@5C]]T4 ?FY\4_V;?V\/VI_^"8_AG_@DG\0O@GJ'AC7I=.T7PG\2?B^=7T^; M0O["TR>W,VI6&RX:ZN;B\@M45+>2WB\MYY/-,:HK/^AO@+P1X:^&?@;1?AOX M+TU;/1_#^DVVFZ39HRHBC\*UJ* "BBB@#RC]N?_DT?Q[_ -@% M_P#T-:[KX7?\DS\._P#8"M/_ $2E<+^W/_R:/X]_[ +_ /H:UW7PN_Y)GX=_ M[ 5I_P"B4H W:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** (KZ^L=+L9M3U.\BMK:WB:6XN)Y B1(HRS,QX4 DD\ "OS ^&^F MWW_!?O\ ;3MOV@?%=E+)^Q[\"/$TB_#C2+N,B#XH>*K=BDFKRQGB73[8[DB5 M@5+KS3/!^DK#<_M7?$[1WP-'T MISE?#=K+RIO;O:5D'.Q RL&"SHOW_P#"'X1_#?X"?"_0/@O\'_"-GH/A?PQI M<.G:'H]BFV*UMXE"JHSR3QDL268DL222: .CHHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M ***CNKJUL;62]O;F.&&&,O--*X544#)8D\ #]FW1O MB%<_L\?L)_#OQ+^T]\58LHWA;X20BXTW3WS@-?ZN0;6UBW JSJ92A&&5:^B/ MV.-:_;#\?_ <:M^WW\+/ _A;QEJ5_/?M<_\ !;7]BC]EWQR?@1X0U?6OC!\6YW:&P^$WP>TPZYK# M3#@I/Y),5IM)!82NKA3N"-BN9_9T/_!;K]J;XW^&_CG^T-<>!_VTN"/Q'XC\0V^UAY&I7YVPVBD,&!M\.I7#ID9KZ,_90_87_9"_8:\'R>!O MV3?V??#?@BQGQ]MDTBRS=7I!R#<7,A:>X([&1VP.!@5ZQ0!^//[0?QKA_P"# M:?\ :(\3_$CQS\'K;Q[^SI\5_$6KZ[\,X=(N+)->\!>*+N%9;_3+=+AE8Z;= MM#$Q:$[80B[E9AB;\B/^(D7_ (*.?\/'/^'A7_">_P#4/_X5G]ID_L+^PO,W M?V7Y6?\ @7VC'F^;^\S_ US/_!P-\:?VN_BQ_P4O\=:-^UQ\5_#?B2\\,W[ MV/A>U\$:Y'>:-I6EEMT,%NJ.Q@D*X,R2XF\S.\?=KXFH _ILF_;K\<_\'(W@ M&7X6_"G3Q\$OV5M!N[&3]H;QUXN\3V4.LZNRB.X;0+2.*4_9;=V&&O)2HD09 MPNUH)?H7]HC_ (.0_P#@B_\ L.>&;?X<^%OCU;^-9= L8[+3/"WPDT_^U8X8 M(4$<<4=T&2R"JJA0//R .E?S*?\ !-#_ ()S?M&?\%._VD=._9S^ FA3/:-+ M%=>+]>F9DL=#T]7PUU<.%(#8++&F"SN=J@_,1_2]^R?_ ,&LG_!(3]F'[-JO MB'X*ZA\4M:M\-_:?Q,U4WL1;J?\ 0H5BM&4GH)(G('&3R2 ?#GC_ /X.S?V_ M_P!L'Q/9!@D\=, M8_\ !([_ (.?O^"J9^V?M[?M@R_#3PEJ'-WX;U/Q*L2/"W0#2-% MW('\-P\ M;CG)R37[]^ ?AS\/?A3X7M_!'PN\!Z-X:T6T&+32- TN&SM81TPD4*JB]!T' M:MF@#\BOV3_^#-W_ ()P?!O[-K/[2OCOQE\7M4BP9[2YN_[$TJ0CN+>T;[0. M>QNF&.,=<_I1^SE^Q?\ LE?LAZ'_ ,(_^S#^SCX-\"V[1".>3PWX?@MI[@>L MTRKYDQX'S2,QX'->FT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% 'S[I/Q0_8Q_X*L? ?XA? O2/&D&N:;#JFH^&/&^A6FIK;ZOH5_9WDD. M]ECYN99[F5-:MI(9HR\[N77S=KD;7 M5NE?F_\ $3_@ZR_9U_8\^.UA\&OAU\5O$O[4?@9K@V]]XDC\+PZ7J^E'( 6* M['DP:US\J@6EMD#<;J8M0!^IW_!/S]B3X:?\$ZOV1?"'['OPDUW5M4T3PC!< MB+4];E5KFZFN+J6ZGD;8JJH,L\A"J,*N!R02?9JX?]G#X]^&OVG/@QH7QP\( M>$/%>@Z?KUKY]OI7C;PS<:1J5N,D8EMKA0PSU#+N1U(9692#7<4 %%%% !11 M10 4444 %%%% !1110!Y1^W/_P FC^/?^P"__H:UW7PN_P"29^'?^P%:?^B4 MKA?VY_\ DT?Q[_V 7_\ 0UKNOA=_R3/P[_V K3_T2E &[1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !7Q9_P %7/V]OBM\+-2\-?L M_L)VMOK/[2/QAC>'PQ&^'M_!VD\K<^(K[AA'%"H?R@P.^1#A9/+,;>C?\%,/ M^"B'@G_@GC\#K?Q7_P (U<>+OB'XOU%=#^%'PVTO+WWBG6Y2%B@C1)OVK_VOO$\'B_]I'XONE]\3/%"X:'2 MH>#!H=AU$5G;*$3"\2-&#RJ1!0#TO_@G?^P3\*?^"=7[-NG? 7X;W5QJNH2W M$FI^-/&&IY:_\3ZU/AKK4;ER2S.[<*"S;$5%R=N3[I110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!117*?&GX[?!?]G'P!>?%3X^?%7P_P"#?#E@/]*UKQ)JL5G;H<$A \C ,YP0 MJ#+,> ": .KK-\8>,O"'P]\,7OC;Q]XJTW0]&TV SZCJ^L7T=M:VL0ZO)+(0 MB*.Y8@5YQ^R!^VE^S]^WQ\(+GXX?LM^,+O6?#":U=Z5;:U=:)98O+ M8H$>,@RM\QX%>X> OA[X"^%7A"Q^'_PP\$Z1X+_ +:W_!4G]@G_ ()ZZ,^H?M7?M):!X=O_ "/-M?#44YN]7NP1 ME?+L8 \Y4G \PJ(QD;F YH ],^ O[.?P&_9<^'MM\*?V=/A!X>\%>';3F+2? M#FEQVL3-C!D?8 9)#CYI')9CR236I\4/BS\+?@CX*O/B1\9?B/H7A/P]IZ;K M[7/$>K0V5I /]N69E1?;)YK\,/V@?^#L7]KO]K[QY+^SW_P1C_8?US4M6N\I M;>(]?T5]6U3RR<>?'IUJ6AM@IY\V>29 #\R+BL7X7_\ !M+_ ,%8/^"F7C2S M^.G_ 6=_;8U71H&?S8_"T6IIK&J0(W+111QD:?IBG.1Y/F@'.8A0!]'_MW? M\'@_["_P&ENO W[&G@K5_C3XF5C##J40?3-"CESM_P!?*AGN"#VCAV./NRC( M-?*'_"K?^#H?_@O;^^^).MW'P(^$&K6@ M8X(=OV$?^")?_!-K_@G7%::I^S[^SKIL_B>V49\=>*\:GK+..KI/*,6 MQ/&5MUB4X^[7U?0!^/7P4_X,R_\ @GSX-^!^M>$/C1\6/&GC/QWJ^DO;V?C. M"<:;;:)=$ I<6MC&S!R&'*7$LRLI( 0X8?D/_P 0W7_!1S_AXY_P[U_X0+_J M(?\ "S/LTG]A?V%YFW^U/-Q_P'[/GS?-_=X_BK^OVB@#P#_@F[_P3=_9Q_X) M?_LXV'[/7[/6@?W;CQ-XFO(E^W^(+_;A[JX\*6,R1W^MKHMY>PV9%M"O?$_B+4H;+3].M)+J_O+A]L<$,:EWD8]E5023Z"C0-> MT;Q3H5EXG\.ZE#>Z?J-I'=6%Y;ONCGAD4.DBGNK*00?0U^.?_!;G_@XV_P"" M>?C[_@FW\3/@G^Q1^U#;^+/B!XWTQ/#MO9Z?H.IVXM[&Z<)?3&6XMHXR/LOG M1C#[MTJD X-)_P $1/\ @XX_X)Z> _\ @FY\-/@E^VQ^T]!X2^('@;37\.3V MFH:!J5P+FPM6*6,XEM[:2/'V7R8SN<-OA@4 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110!^ VF_\ !L]^W-_P4?\ MVC_&7Q8_;D_:VU[PE\)(OB7XBG\ >#IM1N-4U.+2WU:Z:,6UO._V;3(I%;>A M'F'# F$ BOU._8-_X(J_\$XO^"#/'/@_XBZ(_B3P+XCM-5L$U&\L&O+&821BYM+J6T MN8LCC='/#+$P[-&P[5JT %%%% !1110 4444 %%%% !1110!Y1^W/_R:/X]_ M[ +_ /H:UW7PN_Y)GX=_[ 5I_P"B4KA?VY_^31_'O_8!?_T-:[KX7?\ ),_# MO_8"M/\ T2E &[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%>6_MF_MC? K]@W]G?7_ -IG]H?Q0--\/Z%!\D,0#W6I739$-E:QDCS9Y6&U M5X'5F*JK,.D^/7QX^$G[,7P>\0?'OX[>.++PYX3\+Z>][K6L7[X2&-> !EG M=F*HD:@L[LJJ"S 'X-_8_P#@3\5_^"MG[0^@_P#!4S]N#P->Z#\,/"\YN?V8 M?@IK23 *UO&_'+X]_'*Y_X+ ?\ M%'O#!LOB?XDT]K7X1_#2[)>'X8>&Y,[(0K 8U&=&+3R$!U#LA"%WC3[]HHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBD=BB,RH6(&0JXR?;GB@!:YGQU\:?@_\ ##7M \*_$?XI>'M! MU3Q7J2Z?X8TW6-8AM[C5[MND%M'(P:>3_90$U\*:K\>_^"V__!0[5+GPW^RS M\ [3]DSX;-F?LE?\$1OV M0/V;_B3!^TA\4KGQ'\;OC*LL=Q)\6/C!JK:OJ,$Z'+?B%\1KZ9X_#$*"+RGM M[&%";N:3=+MW$HK1*'4J^Y?&O@M_P0<^!=[X_M/V@_\ @HS\7O$_[4OQ-MV\ MR'5?B:R_V#ICD@LEAHD9-K;Q9&?+<2J#R IKZN_:+_:J_9M_9&\"2?$O]IOX MW^&O VB)N$=[XCU:.W^T,!DQPHQWSR>D<89CV!K\C?VT/^#QOX2V.O-\(O\ M@F/^SAK7Q3\37D_V72_$/B2QN+6PFF/W#;V$0^V7F>FQOLS>F>X!^TJ)H'A+ M01'&EGIFEZ;:8"@)#!:P1K^"HBJ/8 "OSQ_;T_X.A_\ @EU^Q7]M\+>$/B-+ M\7O&%MN0:#\.'CN;2*4< 3ZBQ%L@R"#Y332*1S'7Y[6'_!+C_@X]_P""X][# MXH_X*'?'J\^$'PVO95F3POKB&T58LY7RM M&3>Z=C?/'+_MGO^BG[!G_ ;% M_P#!+?\ 8C^Q>*-<^%K_ !8\86VUSXC^)*QWD$4HYW06 46L8!P5+I)(N!B3 MO0!^=-W_ ,%(?^#D[_@NE=2^'_V#/@K>?!OX87\C1-XFT21M/B$)."9-=N@L MDSKW%@B/C&8S7OG[%/\ P9Q_ KP[K*?%?_@I/^T!K/Q8\374_P!JU+P]H%Y/ M9:9+,QRXGO'/VR\R>=ZFV)SR#7[2VMK:V-K'8V-M'###&$AAB0*J*!@* . M. !4E '"_L_?LQ_L\?LI>!(OAE^S9\%O#7@?08L$Z=X:TB*U25@,>9*4 ::0 M]Y'+,-_L!?!-KKPO^R1\/O$GQDUR, ME(=06-M&T;?T_P!=<1FXDP>RV^U@.).0:^4M(_:._P"#J'_@N3;//\!M$?X) M?##4)GA_M?2&;PU9; =I;[=,9-2N<ZQDJ:TDEA;7GCRQ=K:_WJ59(])M"\]W&ZDC:\D+$9!3 MFJO_ 3G_P"#/OP1XE\'V_QG_P""J_Q \7ZAXYU&\NI=4\!Z-K=N+:(B=U1[ MC4(7FEO#)&$E)C>!E,FTEMI+?ZC6XCMX[+<[VP\N1& M6 X9%8#:!@5[Q_P0:\$_L7_$+_@J+\-_AE^WIX(_MOPEXAO38Z18WEWY5BVM M2!3IXO$QF>WDD B\K(5GFB+[HPZ-_0Y_P02_X(W_ K_ &,/V:=%_:&^/7PR MM]7^//Q&TAM2\9:[XD5KR[T>WNUW+I,)N"S1!(&5)SDO+(9 [L@15ZK_ (*B M?\$#?V-/V^/A1]L^'OPVTCX.?B79-I_Q*\(WUQX0^+>AS($FT[Q)I MS"&[5T'">9A)PHX43A)M8\&^']4\-ZAKFG^#=:; M3M4DCB\0Z:ZFVN49&BD5PC!E>-OEPLD9(=?QJO?VM?\ @X*_X*^?"5[/X/GQ MM\)OV9XK]K?4/B9*?V>?!?['?BCQ-^U'\,+_ ,<>$;.\TJ9_ ^DZ4;^Z\1Z@FIVKZ=IT-J/^ M/EY[Y;:,1-\C[B'^0M7D?_!-G_@H)^UK^VCX>^*>D_$_]@:?X'>(_ AT[_A# MO!/C34[B*34+2YBN#"\[_9$:WC9K9D#1PN$YPK[,$ VO^"&OP7^''[.__!,' MX>?!7X1_M :/\4_#GA[5/$UMI?C_ $& QVFL(?$>IN9(UWN!M9FC.UW4M&Q5 MW4AC]:5X;_P3D^,G[/?Q_P#V2M#^+W[,GAUM%\-:]K.MWUUH;5KN M75('\LE"1?R71RA*,"&4E64U[E0 4444 %%%% !1110 4444 %%%% 'E'[<_ M_)H_CW_L O\ ^AK7=?"[_DF?AW_L!6G_ *)2N%_;G_Y-'\>_]@%__0UKNOA= M_P DS\._]@*T_P#1*4 ;M%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !7/_%?XK_#?X&?#?6OC!\7_ !II_AWPQX=T^2^UO6]4G$<%I @RSLQ_( 9+ M$@ $D"H?C)\9?A9^SU\+M;^-7QL\=:=X:\*^'+![S6M;U6?RX;6%>Y/5F)(5 M44%G9E506(!_.3X(B1H(XT M"JHPJ@8 'I4=A86.EV,.F:99Q6UM;1+%;V\$81(D48554<*H ' J6@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HH) &2:^+_ -I__@N;^Q]\%OB!)^SW^S[9^(/V@/BZY9+?X:_!BP.KSPR MX)O+J/-O9HC$"0L[/&,DQX% 'VA7S_\ MZ_\%)OV=O\ @GAH/AZ?XQ6/BS7/ M$7C.YGM/ O@?P-X6N-5U;Q%=0JC206T<:[ RB2,GS'0?,,$GBO$?@9\-?^"V MG[5?QC\,_';]K7XP^&/V=_A]H>M0:G!\#_AU##K6K:Q%&X;[+K&K2@QJK#*N MMJ-K*WW4._%WP[^''A^X^(_P 3?$^BZ#I6CP/)=Z]KU[#:V]C$<;F> M>4JL2G R20.!0!\ ?8O^"Z'_ 4NYU"\T[]BOX3WG_+"U:/6OB%J=N?5_EM] M*W+Z;;B%C@[Q7US^Q'^Q/\*/V"_@U)\&?A-XD\7:Y#>ZS/K&MZ_XY\3SZMJ6 MJZC,L:S7,TTIP&<1)E8U1,@MMW,Q/P%^WG_P=U?\$[/V8OMOA#]F2RU+XW>* M8-R+)H,AL=#BD'&'OY4)E'0@V\4J,,C>*^,_^$G_ .#HS_@O;\GARRN/@/\ M"#5N!/$9_#.G3VS=_-._4M25EX.S=;L0>$SB@#]'M+BLK2V7TCAA M540?04 ?AE^SI_P:5?M-_M3^.X_VA?\ @LM^V[KNMZU>[9+OP[X=UF34]2=, MY$,VIW8:.$+]WRH(I$ /R2+@5^N/[%__ 3)_83_ ."?6@KHW[)O[-WA[PO< MM!Y5WX@%N;G5KQ>XFOIR\[J3SLW[ 2=J@<5[Q10 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%<=X0_:!^#'C[XO>,/@'X M.^(FGZAXQ\ 0Z=+XR\/0.?M&DI?1--:&4$8_>QHSC!/&,XR,@'8T5Y_\-_CC MK/Q ^-?Q#^$-_P# WQGX>M? ]? OQV_X+!_\$X/^"8WQ ^).N_'W_@HQJ7Q%UCQ/KR7VE_##0I8M:N/# M CA$;:?;):C9:JS R$74L?)&,9Y_-&'_ (.)/VFOC5\5?'7@/_@A!_P2]N=) MUSXB^)'UOQ?XFN].NO$&JW]](H0W\EK"?LE@VU0"9&FBPI)]0 ?O)\-?VQOV M:_BU;?$*_P#!OQ4L_LOPJ\77?AGQ]>:M!-IT&D:E;)&\\;R7:1JZ*)4_?(6B M;G:YP:_/#XO_ /!W1_P3[^"8\&_&VHZ-X9TSP'JUGJ]GXA MTZ#8(-8&H(ZV\$$[&0"(-+,@C#,F'6ODKPM_P;I?\%N?^"H6NVOQ%_X*X?MR M7'A;27G^TKX7N-3&LW=LQ.YA%86CQZ;9[L_>C']1UR[-GXQT'PG'']@LGDQ'9RZMJ#?8@ M\<8P9$5)F;>RX^55]+^ G_!H5^T?^T=XPC^-/_!6_P#;YUK7-7NR'OM)\,ZG M/JVHR*3G9)JNH@B,CH52"5>?E?C)_>C3M.T_1]/@TG2;"&UM;:)8K:VMH@D< M2*,*JJH 4 <"IJ /EW]B[_@C%_P $T_V!5M=2_9V_97\/6^OVH!7QAK\1 MU35]XZNEU=%W@)ZE8?+3_9%?45%% !7YX?\ !;O]EO\ X**_M;_$[X*>'?V7 MO@CX-\9?#;X?>*HO&7C#0?%_C :=!XAU:W. M="\&>//M\=MX@LXMMOJL43H)OBF5?O/*)"3MQ7Z7T44 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110!YG^V!^SFW[5?[/FN?!BP^(VJ^#=6NW MM;WPWXPT/'VO0M5L[F*[LKV,$@/Y=Q#$S1D@2(&0D!B:_'SXM_\ !,C_ (.Q M?B/\0_$_A"]_X* ?#[^QO&>GVFD>(O'&AW-OH\E[I]J9Q!O^R:8EU X6ZGW+ M#C<7(+L IKB/^"C7_!!S]K[X9>'OB!^VWX[_ ."K_B#PJ/%'Q.==%\%*+T66 MGR:SX@%IIT,U_P#VDD=O;I]K@>:;RL0QK)A'*!6ZJZ_X--/VTK3PU)KT_P#P M7'\1(8[$SL\NBZBMLN$W9,W]K\1_[>WISCM0!^JG_!*K]B/P'_P3N_86\%?L MG> /'T?BN+PXEV=6\2Q!574-2ENI9+MU5681JLS/$J9)18@K$L&)^B*^*/\ M@WGM+/0?^"4'P]\"6WQBA\=R>&-4\0:1>^(;>#;')B9(Y!+(+F%9"PB MN P$T/E2;4+%!]KT %%%% !1110 4444 %%%% !1110!Y1^W/_R:/X]_[ +_ M /H:UW7PN_Y)GX=_[ 5I_P"B4KA?VY_^31_'O_8!?_T-:[KX7?\ ),_#O_8" MM/\ T2E &[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?,'[.-0\0^+-'GU/1].\&>#KC5I'MH9!'([+#DKAB.W2O(/^(D#]A3_ M *(]^T!_X9+5/_B:/VA_^5CC]G7_ +-_\7?^E$5??U 'P#_Q$@?L*?\ 1'OV M@/\ PR6J?_$TFF_\'+/_ 3#35-0TOX@:[X_\#-IWAVZUEI?'?P_N]+6X@@* MJ4@$HW32N[HB1H"69@*]Y_X*"_\ !2[]GC_@G;X'L-0^)4U_XA\:>)IOL?P^ M^%_A6W-WKWBF^8A4AMK=,L$WE0TS#8N0/F=D1OS+^'WP!_:I_:5_X+X? 3XL M?\%;_!WA>YU;7OAGX@\2^"_A!:Q"ZT_P);V?#]^NI?!S]G#4R5N/ M$$@YAUOQ&@.'RIW169RH5L$;"YN?TPMK:VLK:.SL[=(H8D"111(%5% P% ' M '&*?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445\ MY_\ !1/_ (*/_#C_ ()^^#O#]K-X%UGQ]\2/'VIG2OAA\*_"J[M3\2WP"[@I MP1#!&&5I9V!6,,.&)"D ^C**_/C2]$_X.8/B[9KX^O?'?[+_ ,(A.!+9> I= M'U/7+BV4@8AO;Q7\LR#)RUN2G QU-0:=_P %7?VROV%?&VD> ?\ @M/^S%X= M\*^%M;OX]/TK]H7X1W]Q?>$5NW(6.+4(+@&ZTP,>!++\I+?="J[J ?H=17/^ M.?BU\+/AC\/[GXL?$CXDZ#H'A>SM1\1^/;W]G_ /X)F_!+Q/\ M3?$BV;R MKFW^'@6+PWI+G(5K[7)1]FBC)Z/'YBD_*64U[Q^W-_P3G_9G_P""AEEX5T;] MJE?$NI^&O".HS7[^$]/\5W6GZ5K#NJ8_M"&!T^TK&8PR98%"7YVNX/RO^TK_ M ,%Y_P#@BQ_P23\!?\*(^">JZ!K=[HBM'9?#CX(Z7;26]M*.")IXBEI"VX#S M,R--G)*,>* /K[]A^X_;JU'X/7&L_P#!0C3_ (>6'C;4-:FN;+1OAM)!D^=^/_C3_ ,$D_P#@BQ\,KFW\0ZW\,_@O MINH.]\^AZ-8Q1ZEK$A+$RK:6RM=7C9)&[:^T8&0,"OR'UG_@L/\ \'#/_!;' M5KGP/_P3&_9JO?A;X!N9F@G\5:* 'C3.&$VO7JQPQNH^;;:)',,$#?TKV']C M[_@SK\-:SXG_ .%U_P#!5/\ :IUSXD^)[^87.K>'O"^I7"P7,QQN^U:G<_Z7 M=9Z$HL# CAS0!@?M.?\ !W=\8?CWXW;]G[_@CQ^Q7KWBOQ!?LT.G^(/$VCS7 MUY-_"9+;2;(L<#.Y9)92!QOB'(KBO!'_ ;X_P#!;'_@K7XJLOC!_P %A/VQ MM0\(:&TPN;;PK=7B:C?0 \D0:=:LFGZ?N4XW!C(I^_$2,5^Y'[,?[&_[+'[& M'@A?AW^RQ\!/#/@;2MJB>+0=,2*6[*\![B*(X/)-? M9E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117R__ ,%??VV];_87 M_8IUOQS\-+)M0^)7BZ^M_"'PDT.% \VH^)-18PVBHAX?R\O.5/#" KG+"@#L M?V6?^"@G[.7[8/QB^,/P/^#/B@7NM_!7Q?'X?\51EEVR2M &,T6"=T8G6ZMB M3@^99R<;2I;V^OQMU']BJU_X-Z==_9O_ &[/"^I2W>@+I\7P]_:[U99'==1_ MM6Z-PGB*5FY(M]2E93(V9##]GB'&:_7^Z\:^#;'6],\-7OBW3(=2UI)'T?3Y M;^-9[]8TWN88RVZ4*GS$J#@#/V8/$>IZA'XO\ M?:=J5]X;M8M&N)+>:"Q17N6>Y5##$5#KA68,VX8!S2>)OB/\;M*_:,\,?#'P M]^SS)JG@/5="O;OQ%\25\3VT*Z'>1%1;V9L7'G7'G9)$L;$)M^9<'- 'H%%< M!K/A3]H>Y_:5T7QGHGQ:T>V^&%MX6N;76_!;@8HTC!4Q MX(8DGT(2\_9U\,7O[3UE^U8_C3Q6FLV/@J7PQ'H$>OR#17M9+H7+3M98V&YW MJJ^=][8JKT% &^/BU\+&^*A^!B_$C0CXU&@G7&\(KJT)U-=,$P@^VFVW>:+? MSF$8E*["_P H.016#9_M#Z!>?M/7G[*R^ /&":I9>"H_$S^)I/#SC0GMWNC; M+;+?9V&[W*S>1@-L4MT%= WPJ^&#?$X?&QOASH1\9+H8T5?%ATF$ZD--\XS? M8A<[?-$'FDR>5NV;SNQGFM^@#S_1_$_[1<_[2VL^$=;^%^AV_P +;?PK;7.B M>+X=<+ZA=ZLTS+-:26FW]W$D8#"3)R2!ZX7PU\-?C/I/[1GB;XIZ]^T/<:IX M'U;0;*ST#X;/X;MH8]#NXBQGO%O4/G3F;<,QR A-ORG' M_'/]HWX!?LQ^"Y M/B)^T3\9_#'@C0X\C^T_%&MP643L!G8AE9?,?T1,_VH_#6A7D/C/Q_INFV'B?4'U>Y>&XM[%&2V5;=I##&5#O\RH& M.XY)S7 ?M6_M_P#_ 3L_P""?JI\1O^"A/[3'B/XGZ]IMVR?S ,;]J/_@\GT+Q#XD_X5)_P3&_ M8U\0>/O$-[*8-*UCQA;RJEQ+V\C3+(O<7(/4!I86XY6O*/\ A@7_ (.C_P#@ MM ?MG[8?QLN_@Q\.M2YE\.ZQ=G1H6MVZQ_V/8#SYR,\+?E3_ +=?N/\ LM_L M+_L>_L4>&_\ A%?V4_VW>(1W-QHFDHMW=J,8\^Z;,]P>!S*['@!SCFNCHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@#SG]KKX"_ 7]I[]FGQG\"?VGK"UG\!>(=$D MB\2F\O1;);P(1*+GSB0(6A>-)5D)PC1JW:OP(UK_ (("_P#!&EO%[:/!_P ' M)'@"W\$0W9_XI.\\<^'I+N.(-_J_M/\ ::PAQR-WV7&?X>U?K/\ \'$/AGP- MXJ_X(\_&&R^)7Q%OO"^A6]KI-UJ.H6$KV3"SQ&CL//8+!NVLJ&4.P* MJP/XU:)X2_X,QY_#UM<7_P 3_C;!V^JFXA=ER8W,-J8BZD[3L)3( MX)') /WS_P""9G@7]C;X9_L3>#/A]^P'X@L]8^%6B?VAIWA[6[&_%VFIS6^H M7,%Y=?:% 6X,EY'<,94_=N3E/D*BO>*^1O\ @A7:_LQ6/_!+SX>VO[&6J>([ MWX7)K'BD>#+KQ;$J:A):?\)+JG^M"@<;]X4D!B@4L Q('US0!C?$7QQI'PQ^ M'VN_$GQ!%/)8>'M&NM3O4M8]\K0P1-*X1 ;KP)XA\5>/?V>_$5^QMK+2H;W2QJ/\ M8DG+0R-YEO*$ W 6@7_2!L@ !^KWPL\?_&7XC_LM^$_BA-\/]+TOQWXA\%:9 MJ5]X:UB]FMK73]0N+:*2>WDD6*20+$[NN-A8[ I*Y+#P/_@BO^VM^T%^W?\ MLR>+_BU^TOI_AVS\2:+\7=>\-?8?"MK)%96T%BT,:I'YK-(_S%R7_%;_LYSQO_P"E<5 'I/\ P4 _:=_;-O/CCX>_8M_X M)H^-/@QI_P 4FT)O%'BN?XQZC=+:6^DM(UO:VUO#9J\TMS/*EQ("%*QQV+[B M#)'GI?AK\:_VK_V-_P!AGQQ^TA_P5J\>?#G4=<\&VVH:U?O\([&[CT^/3(85 M,-O']M"2374DBN!E44M+&@Z%FYC]OG_@A=_P3Y_X*&>(=5^*WQ6^'.HZ+\3+ MZ"$6/Q.\+Z]=6NJ:?-!&L=O*B^88'\L(F%>,CC(PWS5\%?M0>.OVQ?B5_P & MS/[4_P "?VDO%EQXL\>_ WXFOX!OO&6&,WB33-*UO1[@W[L22Q-K,ZLS99A M3(2Y=B ?5_C#]O?]N'X$_L!>%_\ @K7\9V\.7?@[4XM(U_QI\'-(\/L)]"\+ M:G-"D,EK?F7S)]1MHKF">;S4$,N)D6.'"N/OWPUXCT+QCX%]4AOM, MU6RBO-.O;=MT=Q!*@>.13W5E8$'T-? W_!3O6O"]K_P;;>,]4M)8CID_[/>D MII[#&PB6VLT@Q]2Z8_"OI;_@F1HOB7PY_P $W/V??#WC*.5-6L?@EX5M]3CF MSO2=-(M5=6SSN# @^X- 'N%%%<9\9M$^.6MZ991? [QOHNAW:3L;Z76M,:Y6 M6/;PJ@$;3GG- '-_MS_\FC^/?^P"_P#Z&M=U\+O^29^'?^P%:?\ HE*^9OVK M?!O[:=A^SKXNO/B!\9_!^H:+'I+'4;*Q\./%--'N7*HY;Y3G'->__"NQ\' ^N61;^P;/)%J>OD)[T =O16/]B\;_P#0;LO_ &/^-'V+QO_ -!NR_\ M 8_XT ;%%8_V+QO_ -!NR_\ 8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ MT&[+_P !C_C1]B\;_P#0;LO_ &/^- &Q16/]B\;_P#0;LO_ &/^-'V+QO_ M -!NR_\ 8_XT ;%%8_V+QO_ -!NR_\ 8_XT?8O&_\ T&[+_P !C_C0!L45 MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_ &/^- &Q16/]B\;_P#0;LO_ &/ M^-'V+QO_ -!NR_\ 8_XT ;%%8_V+QO_ -!NR_\ 8_XT?8O&_\ T&[+_P ! MC_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_ &/^- &Q16/]B\;_P#0 M;LO_ &/^-'V+QO_ -!NR_\ 8_XT ;%%8_V+QO_ -!NR_\ 8_XT?8O&_\ MT&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_ &/^- &Q16/ M]B\;_P#0;LO_ &/^-'V+QO_ -!NR_\ 8_XT ;%%8_V+QO_ -!NR_\ 8_X MT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_ &/ M^- &Q16/]B\;_P#0;LO_ &/^-'V+QO_ -!NR_\ 8_XT ;%%8_V+QO_ -!N MR_\ 8_XUP_[1'[0OP__ &3/A1J?QQ_:0^-WAOP?X5TE-U[K&L_NTW$';%&H MRTTK8(6*,,[GA5)XH ^4?VA_^5CC]G7_ +-_\7?^E$5:?[7W_!6SQ?KGQEOO MV"O^"4GPVLOC%\65E)#@1/\ MEO\ \%#/VS?B_P#MW_M\_#+]I"_\!?'KX*_ RZ\ :MH.D_$;P?X&N9_$?BC1 MIIE>XDMX(06L(;HA(HY6))BWOA@QB'V9^R+_ ,%9O^"6O["GP=LO@3^RU^S) M\8O"OAZT/F31VOP&U9[B^G( :YNIW!DN)FP,R2,3@ #"@ 'U7_P3^_X)/\ MA7]EOQUJ'[67[2WQ+N_C-^T7XHAQXF^*WB2 9L48$&QTFW^YI]HH)0+& S+D M':A6)//?VA_^5CC]G7_LW_Q=_P"E$58W_$1G^R7_ -$Y^.?_ (8C5?\ XFO) MO@[^V-I?_!0;_@N[\'?B[\$? ?CZPT;PI\&O$VF:KJOC/X>7ND11SS21R(@, MRX;('KUXH _7"BL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW M_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_QH^Q>-_\ MH-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW M_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_QH^Q>-_\ MH-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW M_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL#4I?$VC6$NJ:OXKTRUM8$+SW- MS&$CC4=2S,0 /9)+7XK_\%$/A+9W4)Q-IVG:_%J-W M$?1K>S:65?Q44 ?5E%>0_M3_ !K^*W[.7P)U?XS>#_A#XD^)][IS6RVO@[X? MZ2ESJ=^9[B.$-$CR*"B>9YCMD[8T=L$*:^2[;]L3_@X,^.)V_!+_ ()6> _A ME92\6FN?&OXI0W&X=FDL=,'GQ8[J23Z4 ?HE7YY_L6Z'9_M1_P#!*(LIQ*N3M^#GB3X%?LO\ MQ=M;+P_X@E\^VMM;TF/4/[#NB?GN;%9LQPNXP'5E>-L!MF[YJ /UJ_X)P_L, M?L,Z+8_%JR_X+'_M*7_C?3/V4_BM<^!/ ^E?%GQZ8?"-CI,%O%)83P:=(ZH\ M\D;R*8',JE41%1L"NQ_:Y_X.\/V-?@)I\'P&_P""8O[.UU\1]0M0NGZ#=_V8 M^C>'[#K'_ (*+?M\_ MM97]CI'Q)O[C6H['3 MWK>M*TIC:YEGD!@L]YC^51'*=BH"L> H_:[]B#_@D M+^Q=_P $[]/B'[+GP'\+Z1K*1;)_%VHV37^LSY&&S>7!:5%;J8XRD?H@H _( M"/\ 8E_X.:?^"\$BZI^U[\3;KX)?"C4R';P]J\*_BEX0N?C1XNMMKMJGC^)&TV.0=3#IB M?N-IP#BX-PP/1J_1;[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&@"_H^C:/X=TJ MVT'P_I5M8V-G"L-I96<"Q101J,*B(H 50. ,"K-8_V+QO\ ]!NR_P# 8_XT M?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^ M- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR M_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0; MLO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+ MQO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1] MB\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT M ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ M ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR M_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O& M_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+ MQO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0! ML45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ MP&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XUR'QO^-WA']FS MP%)\4?CQ\8?#_A7P]#>6]I)J^KJ8X5GGE6*&//\ >=V50.Y- 'H]%>4?M'?% MOXP? KP-9>+_ C\)->^(5S=^(;#39-%\'Z?')!]-U"+Q;82^)9/%NE7$T<^B*Y-Y#;^2MQ:/X8M=7U2*W MDU;4) 2EK;*[ S2D D(@)P"<8%<9\>_V;]>_: 7P>NL?&+Q-X=_X0WQS8>*+ M7_A#M9DT\:G-:;REG?!01=63LX:2W8;7,:9/'/1^,_A+IWQ&N=&O/B%X9\+Z M]+XH1JZQWEN9%8PSJLCA94PX#L 1DT 4_C)\>IOA!XT M\!>#8_@OXZ\4#QUXE_LAM6\):$+RS\/#RFD^V:F^\&VMOEV>:%8;R <9S7Y[ M23?''_@J#_P70TCXL_"C3_"^I? ?]C?Q'/X>U2;Q%_&+]A?]@OQK\:_AGI=UKWC2>U&D>!] M+T70I;N9]5N@R13&-%;Y(5$EPV1@B KG+#/P_P#\$T/^"K7[%/\ P3[_ &,? M!W[-6E> ?CE>:II]HU]XOUEO@;JTDFK:WR\2 MWT1-V-&O(%CLM4MR3D1WEA%'&6;+,(&8X\PYIZ?_ ,')7[&NK^?_ &3X,^-= MU]EN&M[G[/\ _4W\J5<;HVP#M89&5/(S7RO\4O^"IGPLM_^"M7PF_;O_9<^ M&WQ9MT\3:BL M;['XV(R->'-9\1VFY7\'^!;? M^V=2$@ZQ2+ QBMG]KB2+MSR* /MRJ/B;Q1X:\%Z!=^*O&/B*QTG2["$RWVI: MG=I!;V\8ZO)(Y"HH]20*_ 7XB?\ !U-_P4?_ &VO&5S\&/\ @D;^PKJ5S>2' M8FMW^A2:YJ<4;$[9S;6X^S6>.[3//& "2?2IX?\ ^#=;_@N'_P %1=;M?B-_ MP5K_ &Y9_#.F/,)T\,7FK?VQ=6Q/)$5A9M'IUGD'&8W)!ZH<8(!]Y?MI_P#! MT]_P2B_9*^U^'_!7Q/O?B]XDM]R+I?PV@6YLU?MOU"1DMBF>K0O,P_NGBO@C M4?\ @N'_ ,'#'_!7>_G\*?\ !+G]CJ?X?>$[J5H1XHTO3ENWB4G#++K6I+'9 M1L!DXBCCE'.TD@8_03]C+_@V5_X)F_L;O::]#\&['XC^)+;:P\0?$]!JN''. MY+0JMHF#RK>277CYR1FOO73M!\3Z/I\&DZ3>:9:VMM$L5M;6UCLCB11A555P M% ' H _#/X&?\&B?[2W[3'C2/XW?\%=OV_=;U[6+K#7ND>&=3FU;470G= MY;ZIJ(*Q$=-B02(,_*^ ,_J3^Q=_P1B_X)I_L"K:ZE^SM^ROX>M]?M0"OC#7 MXCJFK[QU=+JZ+O 3U*P^6G^R*^BOL7C?_H-V7_@,?\:/L7C?_H-V7_@,?\: M-BBL?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&@#8HK'^Q>-_^@W9?^ Q_QH^Q M>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\: -BBL?[%X MW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&@#8HK'^Q>-_^@W9?^ Q_QH^Q>-_^@W9? M^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\: -BBL?[%XW_Z#=E_X M#'_&C[%XW_Z#=E_X#'_&@#8HK'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QH V M**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\: -BBL?[%XW_Z#=E_X#'_&C[%X MW_Z#=E_X#'_&@#8HK'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C? M_H-V7_@,?\:/L7C?_H-V7_@,?\: -BBL?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X M#'_&@#8HK'^Q>-_^@W9?^ Q_QJUI4&OPR.=8OX)E*_((HMI!H O4444 %%%% M !1110!\ _'+_@KA_P $2OVF_A=XE_9G_;(_:0\&6$$'BA]-\:> O$=Q<*1= M:3JP;R9AY*B6)IK-&(&4="5R037CQ^)?_!GZ!DZ;^S!QZ>$XO_C%;&N?\&FG M_!-OXM>+_$7Q<^/.H^/;_P 7^+O%6JZYKEQHWBQ8+42WE]-@#[+_P""6WB']DOQ5^Q1X>UW]A;P M[9Z7\*)O$GB=?!]KIPD%LT2>(M2266!9$1HX9)UFE2/: B2*@R%!/T'7B7_! M.S]B_P +?\$]OV1_#W[(7@75[F^T+PGJ^NOH<][<":<65YK-[?P)*X1 TB17 M2(Q"@%E.,CD^VT HRV=MXI\.7VD7%W;J#) ES \+ M.H/!90Y(!XR*^-]?_8D_X*:^)O%^A_#GQ1^UOX-OM(B^#VN>#]2^+MK\/)(= M9\B[NM+ZVCZFT1U"2*VD9;M5,",CLT&61#]UT4 ><_ _]G#PM^RM^S+X;_9C M_9I-KHFE^#?#\&E>&YM:M'OU18P 99TCE@:9W.YW(=,NY/'2O'O^"6/_ 3W M^*7_ 3F^''BSX6^+OVC=$^(&F^)_'6J>*Q-9?#Z71;BUO;]XWFCW-J5TKP@ MHVU=JL-_+''/U/10!\OW7[.7_!3S3?VA/&7B;PC_ ,%%O"[_ U\47XN-(\, M>)?@Y%>:GX5C*!6M[&[@O;>.3D95[J*<#(W1N=Q?U'P9^R!\#_"7[.&J_LLW MWAV77?"_B6SU.+Q@=>F\ZY\13:DTKZC=7DBA?,FN))Y7=E"@%\($555?3Z* M/B9_^"3?C[QG^S3X2_X)\_&S]I2T\3? #P??V 30_P#A%7@U_P 0:1ITZ3Z= MHVH7WVIH&MXFB@222&WCDG2WC7]R=[/]KPPPV\*6]O$L<:*%1$7 4#@ =!3 MJ* "BBB@#RC]N?\ Y-'\>_\ 8!?_ -#6NZ^%W_),_#O_ & K3_T2E<+^W/\ M\FC^/?\ L O_ .AK7=?"[_DF?AW_ + 5I_Z)2@#=HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHKQW]M']OC]D_P#X)]_"]OBQ^U9\7].\-6,NY-*T]B9M0U>< ?N+.U3,MQ)D M@':N%R"Y5-^ #U_]LK_@LAX*^%GQ6D_8W_8;^%E]^T#^T#.K)_P@OA&Y7^S_ Z< M[3<:UJ'^IL8T)&Y"V_.U6\H.KUS'[/7_ 1]\=?&?XLZ;^V9_P %D/BK8?&? MXEV#_:/"WP^LK=D\$>!22"$LK%^+N9< &XG!+%5)5F19:^H/V-_V%_V5_P!@ M3X51_![]E/X0Z;X7THE9-1N(5,M[JDX&/M%WVP("?$WQCHO@Q)?1D6YN)IF3W\H'VKYWU#_ (.Z_CKJ7Q$T74]; MUCX%^$?!]KK=M+XG\/:'I7B+Q#X@GL5F5I[>WNC#;:<7>+<@DWD!B"#P: /Z M!:R?&?CSP-\.=$D\3?$+QGI.@Z;%_K=0UG48K6!/K)*RJ/SK^?\ _P""EG_! MV'^RO^U?\*;?X2_ /P-^TIX-2WUV*_N/$/@SX@6'A#4[V%(IHS9M(OC!KI^,O'MP5/ M5F^S2VEJW8EFA*\=,4 ?U,_!7]O']B[]I+XFZG\'/V>?VI/ OCKQ+HVF'4-4 MTOPAXDM]1:UMA*D1D=[=G08DD12-V06&17EG[9/_ 4E^+/[-_Q@7X#?!/\ MX)H_'3XQZZ^DP7Z:YX4T."W\.*)6=5A?5)I=DPWMS)J.L?";3+B\LC$SDQ0 M11:>EP6V+\N_JV 3SDU\:?#3_@R)^'$EV-7_ &A?^"A/B779YVWWD7AGP9#9 M.6[_ +^YN;DN?]HQCZ5]*_"?_@T'_P"".GP[$9\9>%_B'X\*8+_\)3XYD@$G MU&FQVF!]#^- 'YZ_&']N3_@V&7Q1=^*?C+=?M7?M2ZB]Y)![35\XL-7O6M M&U)B.F5M]/EGD/?_ (^./QS7[7?"?_@A]_P2+^"IC?P/_P $]OAC))#CRI_$ M/AU-8E0CH0^H>

_ 3]KWQ!K_Q0M+3S] MM?TFVL=(U"1>6MI%3?)"T@^59 M?,*HV-RD9(_>ZB@#^"/XJ_"KXC_ WXCZU\(?B]X+U#P[XG\.ZA)8ZWHFJ6YB MGM)T.&1E/Y@C(8$$$@@U]_\ _! __@@?\1_^"JGQ'B^+_P 7[;4/#OP+\.Z@ M%UO6XP8I_$4Z$%M.L6(_"6<9$0.!ER /W^_X*C?\$#_V*O\ @JI\1_"'Q>^+ M]MJ'AWQ-X=U"!=;UOPT$BG\1:2ARVG7+$?@DXS)$"P&00!]?_"KX5?#CX'?# MC1?A#\(?!>G^'?#/AW3X['1-$TNW$4%I @PJ*H_,DY))))))- !\*OA5\./@ M=\.-%^$/PA\%Z?X=\,^'=/CL=$T32[<106D"#"HJC\R3DDDDDDDUT%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !116?JWBG0-%\,WOC"^U%6T[3[6:YNKBV1I]L<08R$+ M&&9R-K?*H+$C !/% &A17G'PO_:6\%?M%_LQ6O[4/[+J-XTTC7?#UQJ?@Z"0 M2::=89!((H2;F,/;^9(FS=(F5SDKQBCPMJO[0?Q@_96CU+Q!X7'P?^)WB'P= M*&TZ6\M==7PGJ\L#*A,B?N+Y8)2K] L@7! R0 #T>N:^,?Q@^&_[/_PMU[XU M_&#Q1%HGA?PQIDNH:]J\T,DB6EM&,O(RQJSD <_*I/M7.)\!-1^(G[)__#-' M[4GCM_'=UK/@;_A'O'7B:RL/['?7'DM?(NKM(K=S]C>4EY (F C9OD(P,=-X M!^$_@#X9_"?1/@?X3T +X7\/>'[;1-+TR_N)+P+8V\"P112/.SO-B-%4M(S, MV,L2230!S?Q/^.^L:9^S'=_M$_LZ_#*[^*<]QX<@UCPEX;T2_CM)?$$4ZH\( MBEG&V/=&X<%QT'3-)\(*P#9*,RD\Y MKLO%'@WPEXXT,^&?''AC3]:TYI8I7L=7LH[F%Y(G62-RD@*EE=5=3C(901@@ M59UC6M&\/:?)J^OZM:V-I",RW5Y.L4:#U+,0!7A_Q0_X*E?\$V/@QYD7Q._; MS^$6DW$6=]C-\0-/>ZXZX@25I#^"T >\T5^??Q0_X.BO^")WPS$D$7[6TOB2 M[CSFT\+^#-5N=WTE:V2$_P#?ROG3XG_\'JO_ 3M\.>9;?"O]G7XM^)IDSME MO[+3M-MY/3#&ZEDQ]8Q0!^Q]%?@)J?\ P>7_ +3GQAOY=$_9)_X)8/J-RK;( MC<^)+W6I&)Z%H+*RA*G_ &=Y^M5S_P %8?\ @[A_::^7X-?\$Z7\#PS\6URG MPCNK$;3T;S==N&C;_>P%]J /WV\2:_I_A3P_>^)M62Z:UT^UDN+E;&PFNIBB M*6;9# CR2M@'"(K,QX ).*^&?B+_ ,','_!&#P#H>JW<7[8]GJ>JZ=9W$D.A M6GA76!/!_8]_X//OVG/\ DIO[4$GP^CN> MI_X3G1](\M3_ -@")W7\/F_&O@G_ (+'?\$5/VK/^";7@+0_VD/VVOVM?#7C MWQS\2/%,MK]DTS4M1U*]O6C@,MQ>SWE]'$\FP^0A)4L3.O.!0!]=_P#!NK_P M<&? _P#9MU_X_:=_P4?^-/O$-[*8-*UCQA;RJEQ+ MV\C3+(O<7(/4!I86XY6OPM^!7[/%EHO[4?PE\"_MK>"?&'@SP+XX\0:/)J=_ M<:>^G7$V@W5TD;W]J]S$5>/8782A64[3C-?V=_LD_L$?L<_L*>#8_ W[)W[/ M'AKP7:K (KB\TVP#7UZ!SFYO)-UQ !P * /P__P"&!?\ @Z/_ ."T M!^V?MA_&R[^#'PZU+F7P[K%V=&A:W;K'_8]@//G(SPM^5/\ MU]B?L6?\&A7 M_!-+]G/[)XC_ &B;W7_C3X@@VLX\03'3M'60?Q)8VS[F'JLT\RG^[7ZM44 < MY\*_@_\ ";X%^#;;X=_!3X8^'_".@68_T71?#.CPV-I%P!E8H550>!SCFNCH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@#RC]N?_ )-'\>_]@%__ $-:[KX7?\DS\._]@*T_ M]$I7"_MS_P#)H_CW_L O_P"AK7=?"[_DF?AW_L!6G_HE* -VBBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIE MQ<06D#W5U.D442%Y))&"JB@9))/ '>OA+X[_P#!-=*\.>'](MC<:KK>N:A':VEG$.KR2RD(B^Y(ZU^?_B3_ (*R M?M5?\%!M?O/A'_P1&^!$>M:-#UA086..- %1 % '% 'R#^QM_P1C^#'P'^*(_:R_:E^(>L_M ?'NX" MO<_%'XB1K(-,89(CTJQR8=-B4D[ FYTR0KJIVU]ET44 %%%% 'SW_P %+_V] M]#_X)Z_LX?\ "TX?!-UXO\9>(]=M?#7PR\!Z>Q%SXE\07C%;6S0@$JO#.[8) M"(0,L54_BA_P6P^,WQ;_ &5_A;$?^"@G_!1'XA^.?VF?&E@+S3/@?\)/%\GA M_P %> ;64##WL=I^]O"@&V,M(DDQW$DH/-?W3_@Z7_X* >+/V)?VX?VJ7!EGNYW.6=F/Y # 4 M4 ?M;_P1$_:6_:?_ &E?AS)!^P/_ ,%'?&.D?'_PC9->:Y^S[\>/$+>(/"?C MFTCP6DTJ:?%SIQ( \Q5=WC8@F18F+K^T7_!-?_@H=X8_X*!_"?6-2U+X?W_@ M3XD> ]:;0/BM\,]:?-YX:U9,YC+8'FP2!6:*8 !U##AD8#^+#X5?%7XC_ WX MCZ+\7OA#XTU#P[XG\.ZA'?:)K>EW!BGM)T.5=6'Y$'(8$@@@D5]__LC_ +17 M_!=K_@H_^V_J7CO]F#XP3^&?B3\7O";0:SXFTJWL_#MMK6G:1Y<9F9XH5#/" M72/SD'F9S&&^4J #^MVO*?BI^W?^Q!\"];E\,_&S]LCX5^$-3@SYVF^)_B#I MMA<(0,D&*>96R,'C%?B/=_\ !K9_P6I_:H2(?MR_\%6K6_M6Y^RWWC'7O$[0 M ]1Y=V((P?96Q[UZ?\)O^#(?]ES1_*;XY_MO^/O$1&/.7PIX>LM&#>P^T&]Q M^M 'V#^TK_P/[YBX73/AKIS:HYVX_Y;$QVXSGC,HS@ M^E?%'QO_ .#WWX)Z9YMK^S=^PKXIUO=D07WC?Q3;:7L]&:"UCN]W^Z)5^M?6 M'PG_ .#3K_@BW\-1')XA^!OB;QM-%@K-XL\=7PR1W*63VT;?0J1[5]-_"?\ MX)%_\$O?@@8Y?AK^P'\)[*XAQY5_<^"+.\NDQZ3W"22C_OJ@#\5OAC_P>/\ M_!1WXF:KK&B^"O\ @GQX,\57UP\(\/V7AFWU>:2R W^8)TC>5KDL3'M*>2%V M-PV[*^3?'#7O^#K/_@IQ\1=4\::?\%OCMX)T'6Y$^S>"] FU+PEH5O&(U3:B MWMS$9$;&\F61P6=B,+A1_4!H/A[0/"VEQ:)X8T.STZRA&(;.PMDABC'HJ( ! M^ JY0!_*O\/?^#2K_@M1\8KN34OBE8^ /"=S?2"2]O/&_CE+VY+=R9+"*\8G MZ-@^M?3_ (!_X,KOC]XRL-/LOVE?^"E5I%:Z=&$M]*T#PK=:I'"O=(I+JZ@$ M0Y/(B/TYK^@FB@#\?OA/_P &77_!-7PEY5W\5/C7\6?%]RA'F0IJUCIUI)_P M"*U:4?A-7TU\)_\ @VQ_X(J_"'RY](_8@T?6;E,;[GQ9KFHZKYA'XN)5CC12S MN[8"@.='U/5/ M#MQ'!X@TW3]3BFN-,ED7>D=Q&C%H69?F < D!OBA\;='^'4_P //$(TC4;WXDZM::):ZG(8A)YUA+V_[4G[8'PNM[*P\97,'P[?X:2ZIX@EU+0PB>3-=_ M9;:5(KEG\S*JVP KTP20#]%:HZ%XG\->*8;BX\,^(;'48[2[>UNGL+M)A#.F M-\3E"=KKD94\C/(K\;?"7_!U_P#\$T?V:3XWB'Q8^/7QND\3>.M0UW1'N?!] ME:PZ#:3[!#I-NUQ$^$?^#N_P#9]^!,.M^!OV$/^"3U MU9CQ7XJOO$.HQWGCCR&O=5O'#W%TUM;VDQ9Y"%RJR* * /W7_9Q_:5^ M&O[4_@F_^('PLCUE=/TWQ'?Z)._A5'KO[3WP>TSP'XL;4[V*70-&\1)JL$=JMPZVTHN%50S/"(V9=HVL M2,#I7X>?\1!O_!R)^T>?)_9@_P""38TZPN/]3JQ_M.C$US+X TJXZ?/X5T?RL_[N^]'Z_G0!^W_P"S=\)/BC\+O@1I M_P *_P!H/X]7?Q9\00_;!K'C/5M MM.DU1)[B614>VM_W2!(Y%A 7 *QC(R3 M65\,O"/['W_!/+X$:#\!_!VN>&OAQX%\,VLL>AZ;KOBG9';1/-),_P"^OIFD M<&21VRSGKCH *_%;_B'=_P"#B[]HW]]^U+_P5I%I97'^MTV3XI>(=3,8/4?9 MEBBMQ]%?%=%\/_\ @R)\(75[_;7Q]_X*+:]K5Q.V^[C\/^!8[9RW?]_$B>,/^"AGPMD:'(DA\/^)HM7=2.Q2P\Y ML^V,U\Z_$_\ X.W?^",7P_\ ,'ACXJ>,_&K1YPOA?P%=Q[SZ Z@+4?CG%!_+E\9ZK\5/&OHOX8?\&\ M/_!%[X2>6WAG]@/PA>M'CYO$]S>ZSN/J1?SS _3&/:@#X1^)_P#P>\_LKZ3Y MG_"F/V(/B!K^,^5_PD_B&QTC=Z9\@7FW]:\Z_P"(K#_@KQ^T*=O[&?\ P2.C MOA/_ ,>I7P]KWB8X/0YLDM@WUQBOV^^&'[('[)GP1$8^#'[+WP[\(^3CRO\ MA&/!5A8;,>GD1+BO1: /Y_#^U9_P>C?M.#'PW_9QE^'T-QU'_"&:'I'EJ>O. MNR/(O'I\WIS2_P##HC_@[0_:8^?XU?\ !21O!EO/_P ?5F_Q>OK0%3U7R=%M MVB;_ '20OO7] 5% 'X#:-_P9B?M!_%?4(]?_ &L/^"I,NHW8.Z5;/PK=ZM(Q M/7%Q>7L97ZF,_2OBSQ8V7MI\/M/^T\=,SM"9&_%C M7N=% $&F:5IFB6,>EZ-IL%I;0KMAMK6%8XT'H%4 ?2IZ** "O _V@?^";O[ M,/[5O[3_ (*_:?\ VDO"/_"9W?PXTB6V\#^&-;"RZ3IMW-,)9]0:W(Q/.PCM MT7S-R)Y"L%WX9??** /&?VW_ -@']E'_ (*(_!R;X)?M6?"JS\0:9AWTN_4> M5?Z/.1C[19W"C?!(,#./E<#:ZNI*GT_X?^&;WP5X#T3P;J7B6[UJYTG2+:RN M-8OPHGOWBB5&GDV@+O4?MS_\FC^/?^P"_P#Z&M=U\+O^29^'?^P%:?\ HE*X7]N?_DT?Q[_V 7_] M#6NZ^%W_ "3/P[_V K3_ -$I0!NT444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !117QG^U7_P7 _9.^!7Q#?]G/X Z3K_ ,?O MC)(6CMOA?\'[/^T[BWD!P3?729@L8T)'F%V9XQ\QCQ0!]F5\7_M6?\%N_P!F MCX+_ !(E_9G_ &8O">O?M#?&IMR0_#/X31"]-E(#@MJ-\H:WL(U/$A8N\?5H MP.:\R_X8<_X*K_\ !3?_ (FO_!2S]H?_ (47\+[SYO\ A0'P-U;_ (F-[ ?^ M6.L:YR9,CY7BM\Q.IX\MA7V=^RG^Q?\ LL_L/?#>/X3_ +*7P/T'P5HB[3<1 M:3:_O[UU&!+5N :-TY6ONWX$?L]? M W]E_P"&]C\(/V>/A1H7@WPSIR_Z+HWA_3DMH0V #(P49DD; +2.2['EB3S7 M8U@_$CXJ_"_X-^%I_'/Q?^)&@^%-$MO^/G6/$FL06-K%QGYI9V5%Z'J>U &] M17YO_M6_\'57_!(;]FC[3I7A3XNZM\5-9@RO]G?#?1VN8-W;-Y<-#;,N>K1R M2$#L> ?AGQ)_P=%?\%:OV]-? M\%0'&I_\%)OVZ6\#^'+X[KSPSJ7B0WNP-SN32-)*:?G'9I48< CKCZS_ &4O M^#/;_@F!\$/LVL?'W5?&/Q?U6+#31:WJATO3"XZ%;:R*2XSU62>13T(QG(!X M;^T!_P 'GFG^+/$/_"MO^"=?["/B/QAK-XYBTN_\:S%7ED'39ING^;+,#U \ M^-L=0">//3X/_P"#P#_@JY_R']'K>R:?'>5XT#2 MMQRSEB>YKT*@#^;S]IS_ (-+?BY^S-\ )/VNO'7QMU?X\^)O#_B&RU;XB?#W MPQILMK=:MH*OG44LKR626:>\$?SJS1KE5?",P56^#_\ @I5_P3A^%_P6\/6/ M[9G[ 7Q2_P"%F?LY^+;A%T[6DE635/!M[(-W]CZU"N&MIQR(Y'51*!ZXW?V9 MU\7?M7_\$ O^"4W[67B_5OBG\1_V=4\/>(=8CD.O:[X'UVZT1K]6PTC7,5M( ML$Q8@,SO&68C+$\T ?S2_P#!+?\ X)M_"/X\K+^UO_P4&^,UA\*OVVWPZ_9C^&-Y8BVN=-\(13BZEU*X@!(BENY\.H/S["Y+ M.K)(_I'[$'_!#S_@C7\%[3PW^T1^SK^SUH7C*2\TZVU#PIXT\3:U<>(4-JZ+ M);SVHNI)((P%(9)(HU89R#7W!0 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !17G?QS_:Z_96_9BL&U+]HO]I#P-X&B$>]?^$K\56E@\@[; M$FD5G)[!02>PKX>_:$_X.OO^".'P,\^S\,?&'Q'\2+^#(>S\ ^%)Y%W=@)[W M[- X_P!I)&'\J /TEHK\$/B!_P 'E'QV^,WB"3P#_P $^O\ @FA?Z[JK_P#' MC-X@U"ZU6XER<+G3]-B5A^%P<]*P_P#A.?\ @\O_ ."@[8T/PE>_!CP[>_ZP M?V=IWA;[-GH,_$EAI&FVJ[KG4- M3O$MX(E]6DD(51]37R)^T)_P<$?\$>?V:GGL_''[-/B7<6Z^9-+ MXS\6O;VP8O*0Q:X%C'/*R7!;:3(/*#Y _$'B2T^&'PKGEFLK M26Q\*6-PL^L^(DM]ZR7=W?RPI:Q/(R/Y$TT;2!%%?9G_ X=_P"#?'_ACG_A MD_\ X3;P5_:?_'Q_PM?_ (3S3_\ A)OM^S;]H^T;]GE_].NS[/CGR]_ST ?B M+_P3]_X)9_\ !4_XV_M :+\(OV>_B#I_@#Q;_P *]TWXA^$Y=:\=?9DFT*]* MFWU.QDM!/DJ[H&,8$L,APP5U8+]\Z#_P9_?\%(OBUK>K>)_VI_\ @IYHJ:EX MFG2?Q1J%C+K'B&?4I478KW$EV]JUPRK\H,AR!P"!7IWQ0^"MS_P3!_8Z^"_[ M3?@?]J/X??$3X@?L=^-[ZVLKKPUXGM1>>-_AIJ%SNN["6W\TE+B!+EPD>Z18 MEMW="Q8&OVL^%OQ,\$?&CX:^'_B]\--?AU7P[XHT:VU70]2MS\EU:7$2RQ2# MZHRG'49H _&7X7_\&17[)&D&,_&?]M;XB^(,8\T>&=%L-(#?3SQ>8_6OHOX8 M?\&E?_!%WX?^6WB7X.^+O&CQX^?Q/X]O4W$=R+!K93],8]J_2VB@#Y>^&'_! M$_\ X)*?"#RV\%_\$\_A4TD./*GUOPI!JLJ$=Q)>B5@??.:^@_ GPJ^%_P + M;#^ROAC\-]!\.6NW'V;0='@LX\>FV)5%;U% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 > M4?MS_P#)H_CW_L O_P"AK7=?"[_DF?AW_L!6G_HE*X7]N?\ Y-'\>_\ 8!?_ M -#6NZ^%W_),_#O_ & K3_T2E &[1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !161X]^(/@+X5^$K[Q_\ $_QMI'AS0M,A,NHZUKNI16EI M:QCJ\DTK*B+[D@5\)^-/^"ZUK\>?%-[\(/\ @D-^RIXK_:2\2VLYMKWQ?:1G M1_!>D2]";C5KI564KG<(XAB50=DF<4 ?H!<7$%I ]U=3I%%$A>221@JHH&22 M3T '>OB#]H#_ (+N_LU>&_B%<_L[?L/> /$G[3GQ8BRI\(_".$7-AI[YP&U# M5L&UM(@P*LX,I0C#JM<1)_P25_:\_;B4^-?^"TW[<-SJ_AK!N)O@+\&;J?0/ M"-O&/F,=[=Y6[U% ,\R,A0CY9"*V?%W_ 5I_P"""O\ P22^'I^#'PV^,/P\ MT2WTS(7P3\(=.74[B2<#!$QL5=%G./F>YD5B?O,2: ,7_AWU_P %1_\ @I%_ MQ-?^"HW[5O\ PJCX>7?S']G[X :@T#W,)_Y8ZMK9W27&1\LD,.Z%NJ-&:^RO MV5/V+?V5?V(/AXGPM_91^!?A_P $Z, OVB/2+/$]ZRC DN;ARTUS)CC?*[MC MC-?CA\;_ /@\J\;?%/Q0?A=_P3/_ ."?&N^*=;NR5TJ\\9&6ZN9CG QI6E[W M?J.ER/3%<5_PS]_P=X_\%6OG^*OQ-OO@7X,U'_ESN]43PI&D1^]&UM8*^I2# M'\-R"#T+8S@ _;+]IW_@H/\ L0_L8V+WG[4?[4W@KP7*D?F+IFKZY$+^9<9S M%9H6N)?^ 1M7YJ_M6?\ !YU^P/\ "\W&B_LJ_!GQG\5M1CR(-0O$&@Z7+V!$ MDZR71]<&V7MSZ4SW$X)S\ZF%CGMW_2K]E/_ (),_P#!.#]B86US^S7^Q[X+T'4K7'D> M(;C3?M^JJ1W%]=F6X'/.!(!GM0!^.8_X*4?\'5W_ 52_P!%_8[_ &6I_A-X M0U#B#7-.\,IIDP J]10 4444 %%117M ME/=2V4-W$\T 4SPK("T8;)7<.HS@XSUQ7+>&OC[\$_&7BWQ=X$\+?%30K_6/ M 5Q;P>-=/M]2C:31)9XS+"ER,_NF>,;@&QQS0!UU?GC_ ,'(7[<>H_LS_L2O M^SO\-/$9L/'?QK2^T:TO(,M+H_AZWMFN-=U8J"&*P60=*/B59>%Y-962$RL=(GO%:/4 MG1<;DC('5=V_:C?SK_\ !3#_ (+=:Y_P44^,'Q0^+FJ_!VXT.X\5^#]+\'> M;>3Q"+A?">A172WFHH ($\ZYO9XT#3#R]D#RPD2*X( /W$_X-U_CU:_"NQ\0 M?\$OM<\9W>LZ3X=\/6/Q$_9]U_577[1KO@#656XB4E0 TMG,7]O>$-0>2 M2\\/W<1A;.&E?R)]["$'B(G##]Y?^"?_ /P="?L"?M;^&-9U3]H;Q9X9^!>I MV&H11:7I/BOQQ#=#4K=XE?SEE$,2QE6)1D89!&02* /TLHKYH^ 7_!87_@FY M^TIXF\5>%?AC^UQX)>?PGK8TNXFU'Q+9VT6HR% XEL7DE NX.<>;'E=P(SD5 MZ[\&OVFOV?\ ]H;4?$ND_ _XN:)XIG\'ZP=*\2IHUX)A87@4/Y3D<$[6!R"0 M<]: .ZHK.T+Q=X3\47%_9^&O$^G:C+I=XUIJ<5C>QS-9W"\M#*$),;C(RK8( MSTK1H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBN:^*'QG^#WP1T!O%?QH^*_AKPAI:@EM2\4:[;Z?;C' M7,D[JO'UH Z6BO@C]H3_ (.9_P#@C/\ L]>?97'[6=OXSU&'.--^'NCW.J^; MC^[>M '[MTRYN;>SMY+N[G2**)"\LLC!510,DDG@ #O7\^=S^ MWQ_P=_?M^($^ '[)MY\*M'OVVQ7%IX%M]$4PG^,7/B*1W(QSOB*D_P /4"I$ M_P"#8'_@M)^VS?3+CQ'JOB:6U7J0MM(UO:H0<86.3 M;SG/8@'ZX_M"?\%F?^"6'[+?GP_&?]NKX>6=W;9%QI6CZV-6OHB.S6M@)IE/ ML4%?"_[0G_!YY_P3D^'1GT[X!_![XC?$>\CSY-T]E!HVGR^G[VX=IQ^-O_A5 M_P" '_!FC_P3(^&S6NI?&[XA_$CXD7<3AKJTNM8BTK3YP ?E\JTC%P@).>+C M/ YZY^Z/V?\ _@D9_P $R/V73;7'P0_8:^'&E7MFP:UUBZ\-Q7^H1$="MY=B M6<'_ ('0!^/\G_!R7_P7>_;G;[%_P3L_X)BC3=+O6Q;ZW:>$]3\0M;@_=)OG M$%D@_P!J2+!]J/\ AV9_P=M?\% 3Y_[47[:$OPPTB\YNM,N?'T>FH\)_A^Q^ M'(VC?C^"4K[D&OZ"E544(B@*!@ #@"EH _#CX&?\&3OP52^7Q'^UY^W+XQ\6 M7MQ)YU]:^#=%@TSQYK[B_9[_X-N_^"-7[.GD7FC?L M::-XJU"'&_4?B#>W&MF4CH6M[EVMA_P&%17W+10!A_#_ .&7PV^$WAZ/PE\* M_A[H?AG2H?\ 5:9X?TF&RMT^D<*JH_*MRBB@ K-\8^$?#OC_ ,(ZKX$\7Z8M M[I.MZ=/8:I9N[*)[>:-HY(R5(8!D9AD$'G@UI44 ?('_ X(_P""-O\ TCV^ M'_\ X!S?_'*/^'!'_!&W_I'M\/\ _P YO\ XY7U_10!\@?\."/^"-O_ $CV M^'__ (!S?_'*^E?@G\$OA7^SE\+M(^"OP1\%VOAWPKH,+PZ-HEDSF&TC:1I" MB;V)"[G8@9P,X& *ZJB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \H_;G M_P"31_'O_8!?_P!#6NZ^%W_),_#O_8"M/_1*5PO[<_\ R:/X]_[ +_\ H:UW M7PN_Y)GX=_[ 5I_Z)2@#=HHHH **** "BBB@ HHHH ***^8/^"N'[,?LK?\'8'_!5O]I_QEXE\'_!_P#8%^'7Q#U; M3[&35[7PWX9OKRWU!;")8TE%O;R3O-J#*V9"D*-*%=CLV(2H!_0K17XS?#[_ M (.'O^"BGC#X&Z#^U4?V4O@E>?#V\^(^E^#?$4NC^/KYM6T34+NY2 P7%C-$ MDL,J[B<. ",$%E(-?LO//#;0O_'OPI)XD_88_9GT+X3_#B;*C]HS]K M764\,Z&8\?ZZQT]W%Q>@KEDDSMR 'C&<5^.7[*?[$'_!=3]J_P 8_P#"V_V< M_P!CO6]$UG591-=?&CXIVH?6;D?PW2:IKY:19!G'G:;'$QYXQD5]O?"C_@SV M_:!^//B=?BU_P5+_ ."CVK:_JTHW:C;>&I[G5KQUZD'5-4.5(YX^SN,]\#D M\X^.7[=/_!&7PGXNC^)O_!1O]M;XI?M[_$C39C+9>&=&TEM+\"Z1<\X%O8L\ M%JRZ?X)\*V2FTTRY\/ M>$Y-872D!PH$WE0:;9KD_=DA*@D#/K]T?!K_ ()B_P#!M#_P3EO8U\9:Q\%) M_$=A&)9=4^-'Q&T[4+S@X$GV:]F%O&V1PT<"'/3G%>J>,?\ @X?_ ."'OP.4 M>$)?VX_"0BTZU46]IX0T'4-2MDC'"I&^GVLL7_ 5;@<\#F@#\TK7_@WM_P"" M_G_!2ZZCU[_@J%_P4 ;PMHMU())_#5]XADUJ2W;.24TRP>+38_JDPY XXK[% M_92_X-$O^"5'P#^S:S\8].\5_%W5XL/(WBS66M-/$@[I:6/E97_8FDF![YZ5 MF_$;_@\?_P""2'@O4[C3?"VA_%KQ?'%$&AO]!\'6T,$S$XVC[=>6\@QU)* 8 MZ9/%?/\ \0/^#X7X8VNM7%C\(/\ @G=XAUFS,:BQNO$'Q"AT^:20G!#P06=R M !QC$A+=/EZT ?M1\$/V;OV?/V:/# \%_L\? _PGX'TD !K#PIX?M[".0C^) MQ"B[VZY9LDDDDY-=K7\^4'_!SU_P79^/6LSR_LH?\$F;*\TNYB5=/BB^'7B7 M7IHF_B=I[:6"-QCI^[4+U.X4RV_:'_X/6/VBM?N=:\ _![4O!-I?PI''IDGA M'PWI-O9J/O,G]L[I@Q[EG9ACY<=* /Z$*I-XE\.)?W.E/K]D+JR@6:\MC=)Y MD$;9VNZYRJG!P3@'!K^?BS_X([?\'9?[0'B:\\8_%'_@HA<>";O5H(XM1$OQ MIU"S3RDSA%@T6%X5ZG(0*&)^8]ZM:9_P9C_M7_%W7I_%O[5'_!3^SN-4O_+. MIWMMXG:@#]E/&O\ P5!_X)R?#;QGK/P\^(O[ MPUOQO96C0B92T8!ED4.Q )V(68<9 R*^>O%__ (M!TVV!UAWC+7'F6]Y-;O:+$^U 29#)DG:N! MGY^UK_@]UUF+XF>)[;P)^P,NO^&+DV2>!+>]\5MIVIP,(C]J-Z8XKJ.XW2E? M*6(1;5!#,Y8%?U=^&W_!$O\ X)(?"?RSX1_X)X?"F1XL>7+KGA.#59%(Z$/> MB5L^^R4#TQ"BC% '\_?A/_ M (.*?^#B?XQ?$?Q7XK_9R_X)U:AKWAWQ&UE_PC/AV?X2ZOJT'AE(H2DQAN[- M+9YS.Y$C-KS7,@7;EI[N]A M);' 8J3@8Q7] E% '\T/_!2[_@VS_8U_8.\._##X1^%OVKO%OB#XO?&/QU;: M#X3&O3:?INC:;9(R/J.K7B&-I#;V\++PLR'?,A^8*RGYN_;M_P""67P5\6_\ M%/G_ &#/^"6FH6-[X;\)^'M+M?%7Q#\8^.(/[+;498OM%Q>3WS%8(T5)HH_) MA4L7AD"([96OZ?OVH_\ @FM^PI^VOXNT_P =_M6_LT>'?'.K:3IWV#3+S74E M6@5PJ@N[$G&3QD\#'E\/_! +_@C7"A1/^">_@$@LS?/;3L!T X' H _GS_X)B_\$Z/V=/@O_P %8X?V)/\ @KG\//"?B3P;XL\.ZE:> M'/%6G>/I8M%:_A475O>6^I6%S""'C@FA\J1E8-<('C5L"OJ_]@__ ((-_P#! M*/XX_MI?';_@GS\:=>UJ_P#$7@S4U\3_ N\7>"/'B%->\'W>T1JPVS1-<6< MK+#,P5=S2#Y<*2?U=F_X(!?\$:YD"/\ \$]_ ( 96^2VG4Y!!'(EZ< M#7FI;G\ ?M/_ !CTEFR0NIW>E7R+Z8"64)Q] M23[UY3XE_P"#(&TTZ[&K?";_ (*6ZCI]Q%DVZZE\- SANW[Z'44*_4(:_>VB M@#^?#1O^#43_ (+ _ 2[OM0_93_X*NZ=HT]_J>+[6]O6N91?W?A36 MEWD#(B593-#'QQ&H1!V4$\RZ1_P6$_X.T_@1+>'XH?\ !-6^\:0RWC2[[WX' MZI.MI'_SRC?2)HUV#LTF]N>6-?T&T4 ?S\6'_!VU_P %0OA(TS?M-_\ !)VV MC59RRB"QUO03'",?*QNX[G+#G+<#_9XYZKP1_P 'Q/PLO7"?$O\ X)W>(=*P M^&;0_B+!?G&.N);*WYSGC/XU^[MA\U&R* /RD\%?\'I?_ 3%US9!XR^!_P :-"E;[\@T'3+J!?\ @2:@'/\ MW[KUSP5_P=C?\$3_ !5L_MO]H'Q)X;+#)&M?#W5'VGT/V2&?].*^H_&O_!*# M_@F%\1-[^,?^">GP7NY9/OW0^&FF13G_ +:QPJ_ZUY%XV_X-PO\ @B=X^WG6 M_P!@GP[;%SDG1--?^#17_@C/XJ+_ -A?#SQWX:W$E?[%\>7$FSV'VL3_ *YKR+QI M_P &3W_!/34MS^ /VG_C'I+-DA=4N]*OD7TP$LH3CZDGWH _83PUXT\'>-+3 M[?X.\6:9JT'_ #VTR_CG3\T)%:=?@CXC_P"#("VTZ[_M;X4?\%+M0T^XB):W M74OAF&<'M^^AU)"OU"&LQ?\ @UO_ ."U?PGS_P ,[?\ !7]+3R<_9<>-/$>B MX_\ ;SMOX9H _H!HK^?Y?\ @F#_ ,'@'P8R/ W_ 4)?Q7Y'$>?BY-?^:/7 M_B;VZY_X%@U':^-?^#WWX00[]:\'S^)+6$[4CELO!.H,P'?-HPF;(]3G\: / MZ!:*_GST/_@MK_P=^(+=)6CFDO\ X ^(0XV$AF_T.XCV M@]G*E3P1D57\(?\ !XK^WWI.CCQ%\3/^"7^DZCIZ7$D,U]H]UJNG0[XV*RIO MEAN%5E8%2"25(P1Q0!_0I17X1^"O^#XCX3WI1?B/_P $\O$6E\XD;1/B'!?8 M]P);.W_+/XUZ[X*_X/2_^"8NN;(/&7P/^-&A2M]^0:#IEU O_ DU .?^_= ' MZ_T5^;G@K_@[&_X(G^*MG]M_M ^)/#989(UKX>ZH^T^A^R0S_IQ7=2?\'+7_ M 1 B,8;]O+23YL0D7;X1UPX'H<6/RGC[IP?:@#[%^)OQ@^%WP9T_2]6^*OC MO3= MM;\066AZ3/J=R(EN]1NY1%;6J$]9)'(51W-=)7\Q?\ P=$_\%N_@I^W MQK'PQ^ O[#/Q=N==\#^$9W\3ZWXBL[*[L!<:Z2T-JB)X M!S'7Z+_L6_\ !UQ_P32UG]C'P5XI_;%_:$GT#XK6_A^.W\:>&K3P9JMU)/J$ M.8GGBDM[5K?;/L$ZKY@""78Q!4T ?J[17XH?M!?\'L7[(GA9YM-_9B_9'\>> M-KE24AN_%&I6NAVTC=F3R_M'ZI_P75_X.8_VY/!]YXT_8M_8 M1/@WPDEC-=V_BG0_AS<7@:"-69RE[JK-:7# *<+'%N)& I) H _H?KQ/]H3_ M (*1_L"?LI">']H?]L3X=^%;NWSYFDZCXIMC?\==MHC-.^/]E#7X8>&_^"/' M_!R1_P %0?@='\,M3LI[MVC9HH9-,@@CM;0 MNP"DR;2@8$J0*]Q_9N_X,I_V=3\%;6^_:G_:6\;-\0-0\.?Z5:>%?L<>EZ/J M2]CBE/!WP^8%Y"YP #W;]H3_ (/!?^"3/PD,]C\)Y/'WQ/NTRL,G MAOPN;*T9A_>EU%[=PO\ M+$_L".:^/\ XF_\'@7[?_QOTG5;_P#85_X)LV=K MIFFQL;W7-8BU+Q(;2,?\M9!9QVT/H,>GZWXG\5VDE]?ZC+Y0CFNEDGD^ M%_\ P>5_M]>"7\:ZEXWUOP#H5_:QSZ7I6D^*-(\*S3Q2;2%06;I=K\K;C]H= M3@$ DX%=5X4_X,NOC+\6K63QU^UY_P %,;FY\6WJ1M<&Q\*SZN8VW!G#W=W> MQO,=NY1\BX8ALL!M/[]44 ?F[\&_^#4#_@BY\+-'2P\4? ?Q#X]NUV$ZIXP\ M<7XE)5@W^KL)+:'D@9'E\C(Z$@_=7P:_9D_9O_9TTD:#\ /@#X+\$684 VWA M/PQ::>C8]1!&NX^YR2:[BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH QOB+XXTCX8_#[7?B3X@BGDL/#VC76IWJ6L>^5H8(FE<(N1N M;:AP.YK\\OV6_P!J[_@H3^WK:_#G]ICX*?M#> ?#0^(?PE\3^)O#7P[N/"3Y3-($@8 AOTAOTL9+&>/5%A:V:%A< M+< &,QX.[=GC;C.<\8K\8_V@OV)_VD/^")'[:DG[3/\ P20TL^+O -UX$\0^ M*O'O[/?B*_8VUEI4-[I8U'^Q).6AD;S+>4(!N M O^D#9 #]7OA9X_^,OQ' M_9;\)_%";X?Z7I?COQ#X*TS4K[PUK%[-;6NGZA<6T4D]O)(L4D@6)W=<;"QV M!25R6'@?_!%?]M;]H+]N_P#9D\7_ !:_:7T_P[9^)-%^+NO>&OL/A6UDBLK: M"Q:&-4C\UFD?YBY+N.;G0%U2ZU'Q!?I)+ M!IMI%)(L20011,UQ(P:1I&6)?*VF1JO[.G_!67PGJ?[)OQN^+W[5-A9:%XM_ M9FU_6M!^+VFZ$&^SW5QIX9HKNP25B_DWJ!&AC=BP=FC+-MWMXK_P0-T_4-%_ M;&_X*":/XG5EUK_AJ;4;J991AS8SRW4EFW/.PQ$E>V.E?"?[8WA_QUXJ^$__ M 6.U_P/!.^EOX_\ P*8 2K26.J%]2QC@%8>7]CS0!^BOC#]O?\ ;A^!/[ 7 MA?\ X*U_&=O#EWX.U.+2-?\ &GP,]4M)8CID_[/>DII[#&PB6VLT@Q]2Z8_"OI M;_@F1HOB7PY_P3<_9]\/>,HY4U:Q^"7A6WU..;.])TTBU5U;/.X,"#[@T >X M445QGQF^!GA#XYZ99:3XOU36K6.QG::%M%U:2T9F*[2&*?>&.QH YO\ ;G_Y M-'\>_P#8!?\ ]#6NZ^%W_),_#O\ V K3_P!$I7S-^U;^Q3\)_A]^SKXN\::) MXD\837>G:2TT$=]XIGFA9@RC#HQPPYZ&O?\ X5^!='3X8>'$%U>X&@V8&;MO M^>"4 =O16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1_P _ M-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!; M4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%?F+_P=N^)KOPK_ ,$D MWU'2=5>QU'_A:?AXZ9=QOL,-PDDLRN&_AV^66SVQ7Z1?\(/I'_/S>_\ @6U? MF/\ \':WP^L9/^"3#7]A:W-[=6?Q1T"2TLY)&D$\C/-$$V]3D2$<<\T ?@!^ MV7_P4\\2?'7]FSP%^PA\ _!(^'?P5^'^GPM+X:LM1,\_BO6\9N-:U.81QF>6 M64M(D17;%NP,D*1\Y?"KXJ_$?X&_$?1?B]\(?&FH>'?$_AW4([[1-;TNX,4] MI.ARKJP_(@Y# D$$$BO1OVM?@;X4\*7<'[0WP(\+ZOI7P?\ B#XEUJ/X76_B M74(IM4:RL);>.5IECY\M9;CR4D8#>89 ?F1J\:1'D.U%)."< =@,F@#[%_:] M_P""P'C3]I[XF:?\=_#/P5TGP1XSUG3=&?XNRZ1J!?2/&VMZ5?)=6>LM8+%' M]EN $,;XDDW+(^TIN;=Q?[97_!7G_@H_^WV9M/\ VGOVKO$VLZ-. &\*Z=,N MFZ.0"2NZQM%C@E9<\/(KOZL:]:^(_P"Q)X,_8HU[1/V%?VC_ (-1:E\9=<^* M7@O7T\?Z7J1O=&E\$WUJ%EM;<8"EOMTZ1O,5(D,6U3M7+_UA_#G]C7]E_P"# M_ECX2? WPOX6\K'E?\(YH-M8[/IY,:XH _B__9]_9<_:!\=W-KJO@'_@G_\ M$/XHSA\K96GA[6+G3[D'H&338HYS]4N%K]%?V6?@;_P#O M@O=;-D.L6_PMT6RU-5/]Z_\ $TL]V<#^_*>I[U_3!_P@^D?\_-[_ .!;4?\ M"#Z1_P _-[_X%M0!^"7_ [$_P"#O_\ :0G^T_%/]OV;P+YZ;9HS\6Y--5 3 MD_)H,#K^7TZ41_\ !GO^WG\<[X:I^UU_P5:@OKF1 MS.MCJGB*0KG.W?>W-N M2,\\]^<5^]O_ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ?C1\-O\ @R/_ &,M M)\L_%[]L?XFZ\5QY@\.Z=I^E!_IYT=V0/QKZ!^&W_!I1_P $7? GEGQ)\'_% M_C%H\9;Q+X^O8]Y]2+!K8?IBOT6_X0?2/^?F]_\ MJ/^$'TC_GYO?\ P+:@ M#YI^&W_!#'_@D%\*/+/A3_@GA\,)S%C8_B'P\FKL".^;\S$GW-?0'PZ_9_\ M@-\'XUB^$GP2\(^%E081?#GANUL0H] (8UQ6M_P@^D?\_-[_ .!;4?\ "#Z1 M_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I' M_/S>_P#@6U'_ @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[ M_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/ MS>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X M%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@ M6U'_ @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ; M%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4? M\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C M_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_ @^ MD?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z M1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S M>_\ @6U ',6G[*/[+>G^'#X.L/V:_ $&D-/-,VE0^#K%;8RRN9)7\H1;=SNS M,QQEF8DY)KQO0O\ @B9_P21\/>$!X(M?^">/PJN;,7,\_P!HU;PG!?7N^61I M7'VRY#W&W#?^#7+_@BQX<\ Q>!O$W[+-QXHECNKB8Z]K/BS4+>_?S96D",]A-;)LC#! M$ 081%!+')/R%^U)_P &S/\ P2"_X)\_\$^_&7[1'[3_ (N\=>(-1\$:5?7T MNO:-KO\ 93ZK/+.PT^PCMY/M$:.SRV]L&YW'YVQD@?M9_P (/I'_ #\WO_@6 MU?EK_P %+M1^%G_!07_@IQX1_P""96M?'>R\(?#CX.:.?'GQ>UJ_U^W@\[7I M8BFAZ;&+A@DDD1E%X\;!D=&P<%!0!_,;X3^"GQ?^(.I:[I7P\^%^O^()_#%A M/?>(DT'29KW^S;2$XEN)C"K".%#UD;"CUK[8_P""%W[,?[$OQ=_:,\"ZC^W5 M\-AXK\ >.?%%UX"'O$\T$=UH\\K6TD>^*\"W5M'$^X&6WD9OE7%? MTB_L7_ G_@D_^P!\)(?@U^R[\3?A]X?TTA'U2^'CJRDOM7G Q]HNYS)NGD.3 MU^50=J*B@*/G3]K'_@DW_P $FOBGX&^,<_[//Q^\"^ /$?Q1\-Q2-::1XXL8 M=,C\3V,YNM+UE(EDS;31RM-'(82HDCNI?E#L68 ^K?V%_P#@D]^QE^P5\"-* M^"WPW^$GA_6+VSL;BVU;QOK/A334UG6A-)([_:KBVMXO, 63RE&.(T126(+' MW3X4_"?X9_ SX=Z3\)/@YX%TOPSX8T*U^SZ/H6BV:V]K:1;BVU(U "Y9F8^I M8D\DU\P?\$;OVN]._P""A'["WAOXK^+KZ:/QYX>GE\+_ !0TZ&_!^RZ_8XCN M#\A*A9AY=PH4D!9P,G!KZH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ M (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\ MJ/^$'TC_GYO?\ P+:@#8HK M'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_ +:C_A! M](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ MGYO?_ MJ -BBL?\ X0?2/^?F]_\ MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^ M?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_ +:C_A!](_Y^;W_ M ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W M_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ M -BBL?\ X0?2/^?F]_\ MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH M_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_ +:C_A!](_Y^;W_ ,"VH V* M*Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ MX0?2/^?F]_\ MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ M )^;W_P+:@#8HK'_ .$'TC_GYO?_ +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC M_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F] M_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F M]_\ MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+ M:@#8HK'_ .$'TC_GYO?_ +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ M MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ - MBBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\ MJ/ M^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ M .$'TC_GYO?_ +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!]( M_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!] M(_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\ MJ/^$'TC_GY MO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_G MYO?_ +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\ M"VH V**Q_P#A!](_Y^;W_P "VJUI6@66CR/):RSL77!\V8L/UH O4444 %%% M% !1110 4444 %%%% '.?&#X=6/Q@^$OBGX2:GJ,MG;>*?#E]I%Q=VZ@R0)< MP/"SJ#P64.2 >,BOC?7_ -B3_@IKXF\7Z'\.?%'[6_@V^TB+X/:YX/U+XNVO MP\DAUGR+NZTOK:/J;1'4)(K:1ENU4P(R.S099$/W710!YS\#_P!G#PM^RM^S M+X;_ &8_V:3:Z)I?@WP_!I7AN;6K1[]46, &6=(Y8&F=SN=R'3+N3QTKQ[_@ MEC_P3W^*7_!.;X<>+/A;XN_:-T3X@:;XG\=:IXK$UE\/I=%N+6]OWC>:/+=3U;=_:$\R1X6)'5O+2-#^ M[C1%W,P+M[_10!\3/_P2;\?>,_V:?"7_ 3Y^-G[2EIXF^ '@^_L FA_\(J\ M&O\ B#2-.G2?3M&U"^^U- UO$T4"220V\&&&WA2WMXECC1 M0J(BX"@< #H*=10 4444 >4?MS_ /)H_CW_ + +_P#H:UW7PN_Y)GX=_P"P M%:?^B4KA?VY_^31_'O\ V 7_ /0UKNOA=_R3/P[_ -@*T_\ 1*4 ;M%%% !1 M110 4444 %%%% !7PG_P<2?L:_M2_MX_\$\6_9[_ &0_!-MKGBNZ\=Z5?O'= M:[!IXMK6W\Z1IEDG95+!Q$H4$'YR1]VONRB@#^-_AIXI\::?K>BZY;K&JR.WVF\^UVTDSH)I#;W$0,H M5@%"(%H?L0?\$A?^"^7[!-SX[U?X!_\ !,KX)CQ!XWL;C3AXI\;>*--UF?0] M.F!$EE8Q3:FT B8':QN(IFD4!79ER#_2710!_,G'_P $!/\ @MQXA\8^"O'O MCK]CSP[?>*M \8V>JZ[XYNOB]9R7NJV5N]MY.F&$77V:"T@6UC$$<,*^6!M! M*A57^FP=.E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 5\O?%'_@BQ_P2O^-?Q%UKXM_%G]B;P;K_ (E\1:C+?ZWK6I0S M23WEQ(Q9Y';S.I)Z#@# %?4-% 'R!_P ."/\ @C;_ -(]OA__ . 3?LJ_L*_LC?L0:?K.D_LF_ G1? M MIXAFAFUJVT02+'=21!UC=E9V&X!V&1@D$9S@8]9HHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** /*/VY_^31_'O\ V 7_ /0UKNOA=_R3/P[_ -@* MT_\ 1*5PO[<__)H_CW_L O\ ^AK7=?"[_DF?AW_L!6G_ *)2@#=HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@#RC]N?_DT?Q[_V 7_]#6NZ^%W_ "3/P[_V K3_ -$I M7"_MS_\ )H_CW_L O_Z&M=U\+O\ DF?AW_L!6G_HE* -VBBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** /*/VY_\ DT?Q[_V 7_\ 0UKNOA=_R3/P[_V K3_T2E<+^W/_ M ,FC^/?^P"__ *&M=U\+O^29^'?^P%:?^B4H W:*** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJOI>K:5K=I]OT M74[>\@\V2+SK699$WQNT_]@%__0UKNOA=_P DS\._]@*T_P#1*5PO[<__ ":/X]_[ +_^AK7= M?"[_ ))GX=_[ 5I_Z)2@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** /@G_ (+O_M5^*OV6/"OP.U+Q1XC\1^'/ M@QXC^,=GIGQS\5>%+BYM[NRT,/"&M?!;5YFN%\+75CJFHQ0:CI;L2Z1);VR&;=DD1MYC2%XVA M/0_^"TO[UCNK>4%03')&P(#896'0C((QP M:_';Q+^Q+\19/^#<;]KS]E+X2WVI:]X.\.?%_P 27GP2$D[7#S>%-'UJQO3% M"W)G7S[+4U5ER)&^9<[A0![%\>? 7QD_90_X(W:%_P %-O"?Q5\3:C^T-X6\ M+Z'\0/%_B?6/$%U+#XC:Y>VFU/2+NV\SR3I_V>XFBBMTC18/)A>((Z[J_2+X M&?%KP[\??@EX.^.W@]'72?&OA73]>TM9""PMKRVCN(@2.,[)%KX%_P""DOQL M\+>*/^#935?B3X9N!=P>-/@;X;L=#M[4;Y+FXU$6%M% B+RTF^;;L R"K#'! MK[._80^$'B#]GS]B#X.? ;Q:FW5O!7PL\/Z%JB[LXN;33H()1D?[<;4 >K44 M5QGQF^!GA#XYZ99:3XOU36K6.QG::%M%U:2T9F*[2&*?>&.QH YO]N?_ )-' M\>_]@%__ $-:[KX7?\DS\._]@*T_]$I7S-^U;^Q3\)_A]^SKXN\::)XD\837 M>G:2TT$=]XIGFA9@RC#HQPPYZ&O?_A7X%T=/AAX<075[@:#9@9NV_P">"4 = MO16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U' M_"#Z1_S\WO\ X%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ M /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/ MI'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P ( M/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\ MWO\ X%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S M\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^ M!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\W MO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0 M!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M M1_P@^D?\_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8 M_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_" M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ M"#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\ M_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D? M\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO M_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1_P _ M-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!; M4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"! M;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q1 M6/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1_P _-[_X%M1_ MP@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__ M @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I' M_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I M'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_- M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__ @^D?\ M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@ M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ M@6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L M45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4 M?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/ M_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z M1_S\WO\ X%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"# MZ1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/ MS>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ M (%M1_P@^D?\_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 M;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6 MU'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45 MC_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@ M^D?\_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P M@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_ MS\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1 M_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ M .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[ M_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U M &Q16/\ \(/I'_/S>_\ @6U6M*T"RT>1Y+66=BZX/FS%A^M %ZBBB@ HHHH M**** "BBB@ HHHH **** /,OVC?V0?@3^U3+X;U+XNZ!JC:KX-U&2_\ "/B# MP]XFO]'U+1KF2/RY)+>ZL9HI4WI\C*6*.ORLK D5PO[*7_!-GX'?LQ:_;_$B M_O\ 6/&_CBPN=;_LCQ?XNU>[O9M*M-2U&>\EM[.&>>2*S9A*J32PJCW!0M(3 MD(OT/10!\R:E_P $@_V&[_\ :!\6?M)VG@WQ9I6O^/;H77CFQ\/?$S7--TOQ M#/C!>]L;6\C@N P^]&Z&-R264EFS]&^'?#/AOPAX@?#J_ M&E>&/$$FO>$_!=WXGOY_#NA:H[O(;NSTJ29K2WD5Y)'CV1A8&D=HA&6)/O-% M% !1110!Y1^W/_R:/X]_[ +_ /H:UW7PN_Y)GX=_[ 5I_P"B4KA?VY_^31_' MO_8!?_T-:[KX7?\ ),_#O_8"M/\ T2E &[1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M 'E'[<__ ":/X]_[ +_^AK7=?"[_ ))GX=_[ 5I_Z)2N%_;G_P"31_'O_8!? M_P!#6NZ^%W_),_#O_8"M/_1*4 ;M%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >4?MS M_P#)H_CW_L O_P"AK7=?"[_DF?AW_L!6G_HE*X7]N?\ Y-'\>_\ 8!?_ -#6 MNZ^%W_),_#O_ & K3_T2E &[1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E'[<_P#R M:/X]_P"P"_\ Z&M=U\+O^29^'?\ L!6G_HE*X7]N?_DT?Q[_ -@%_P#T-:[K MX7?\DS\._P#8"M/_ $2E &[1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !15?4M6TK1H8[C5]3M[2.6XC@B M>YF6,/+(X2.,%B,LSLJJO4D@#DU8H **** "BBB@#RC]N?\ Y-'\>_\ 8!?_ M -#6NZ^%W_),_#O_ & K3_T2E<+^W/\ \FC^/?\ L O_ .AK7=?"[_DF?AW_ M + 5I_Z)2@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@#\<_C%^T+X+_:%_X*>?%O]CC]N3Q/K-GXJT?X MU?#RW^!_@2^UN\L=+O?"TFIV)NKJQAAD2.YO)"SRRS-OF1/EB95AD"?7OQX\ M?>+/^".O_!/7]H7X\ZKX^UWQGH_A/4KC5OA1:>-/$=SJMQ8075GIUK9Z9+(K?3[U()B,C!9V".&C;,L;9U!;S+V.WMB'Y9R98U M8NX,C@'MGQY\!?&3]E#_ ((W:%_P4V\)_%7Q-J/[0WA;POH?Q \7^)]8\074 ML/B-KE[:;4](N[;S/).G_9[B:**W2-%@\F%X@CKNK](O@9\6O#OQ]^"7@[X[ M>#T==)\:^%=/U[2UD(+"VO+:.XB!(XSLD6O@7_@I+\;/"WBC_@V4U7XD^&;@ M7<'C3X&^&['0[>U&^2YN-1%A;10(B\M)OFV[ ,@JPQP:^SOV$/A!X@_9\_8@ M^#GP&\6IMU;P5\+/#^A:HN[.+FTTZ""49'^W&U 'JU^T[38+:\@:SNV,?_&:]3_X9?\ V:?^ MC>/ O_A)6?\ \:H_X9?_ &:?^C>/ O\ X25G_P#&J /+/^'MW_!.C_HZ31?_ M O/_C-'_#V[_@G1_T=)HO_ ( 7G_QFO4_^&7_V:?\ HWCP+_X25G_\:H_X M9?\ V:?^C>/ O_A)6?\ \:H \L_X>W?\$Z/^CI-%_P# "\_^,T?\/;O^"='_ M $=)HO\ X 7G_P 9KU/_ (9?_9I_Z-X\"_\ A)6?_P :H_X9?_9I_P"C>/ O M_A)6?_QJ@#RS_A[=_P $Z/\ HZ31?_ "\_\ C-'_ ]N_P""='_1TFB_^ %Y M_P#&:]3_ .&7_P!FG_HWCP+_ .$E9_\ QJC_ (9?_9I_Z-X\"_\ A)6?_P : MH \L_P"'MW_!.C_HZ31?_ "\_P#C--'_ 5R_P""/ O_A)6?_QJO%? _P"S_P# :X_;K\<^'+CX)>$9-/MO M!6F2V]@_ANU,,4C.VYU0Q[58]R!DT :__#V[_@G1_P!'2:+_ . %Y_\ &:/^ M'MW_ 3H_P"CI-%_\ +S_P",UZG_ ,,O_LT_]&\>!?\ PDK/_P"-4?\ #+_[ M-/\ T;QX%_\ "2L__C5 'EG_ ]N_P""='_1TFB_^ %Y_P#&:/\ A[=_P3H_ MZ.DT7_P O/\ XS7J?_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)* MS_\ C5 'EG_#V[_@G1_T=)HO_@!>?_&:/^'MW_!.C_HZ31?_ O/_C->I_\ M,O\ [-/_ $;QX%_\)*S_ /C5'_#+_P"S3_T;QX%_\)*S_P#C5 'EG_#V[_@G M1_T=)HO_ ( 7G_QFC_A[=_P3H_Z.DT7_ , +S_XS7J?_ R_^S3_ -&\>!?_ M DK/_XU1_PR_P#LT_\ 1O'@7_PDK/\ ^-4 >6?\/;O^"='_ $=)HO\ X 7G M_P 9H_X>W?\ !.C_ *.DT7_P O/_ (S7J?\ PR_^S3_T;QX%_P#"2L__ (U1 M_P ,O_LT_P#1O'@7_P )*S_^-4 >6?\ #V[_ ()T?]'2:+_X 7G_ ,9H_P"' MMW_!.C_HZ31?_ "\_P#C->I_\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\> M!?\ PDK/_P"-4 >6?\/;O^"='_1TFB_^ %Y_\9H_X>W?\$Z/^CI-%_\ "\_ M^,UZG_PR_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_ +-/_1O'@7_PDK/_ .-4 >6? M\/;O^"='_1TFB_\ @!>?_&:/^'MW_!.C_HZ31?\ P O/_C->I_\ #+_[-/\ MT;QX%_\ "2L__C5'_#+_ .S3_P!&\>!?_"2L_P#XU0!Y9_P]N_X)T?\ 1TFB M_P#@!>?_ !FC_A[=_P $Z/\ HZ31?_ "\_\ C->I_P##+_[-/_1O'@7_ ,)* MS_\ C5'_ R_^S3_ -&\>!?_ DK/_XU0!Y9_P /;O\ @G1_T=)HO_@!>?\ MQFC_ (>W?\$Z/^CI-%_\ +S_ .,UZG_PR_\ LT_]&\>!?_"2L_\ XU1_PR_^ MS3_T;QX%_P#"2L__ (U0!Y9_P]N_X)T?]'2:+_X 7G_QFC_A[=_P3H_Z.DT7 M_P +S_XS7J?_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\ LT_]&\>!?_"2L_\ MXU0!Y9_P]N_X)T?]'2:+_P" %Y_\9H_X>W?\$Z/^CI-%_P# "\_^,UZG_P , MO_LT_P#1O'@7_P )*S_^-4?\,O\ [-/_ $;QX%_\)*S_ /C5 'E4?_!7+_@G M-*NY?VH]''./FTZ]'\X*=_P]N_X)T?\ 1TFB_P#@!>?_ !FLC]A']G_X#>(_ M@]JE]XA^"7A&_G3QKJ\237OANUE=8UN"%0%HR0H' '05[5_PR_\ LT_]&\>! M?_"2L_\ XU0!Y9_P]N_X)T?]'2:+_P" %Y_\9H_X>W?\$Z/^CI-%_P# "\_^ M,UZG_P ,O_LT_P#1O'@7_P )*S_^-4?\,O\ [-/_ $;QX%_\)*S_ /C5 'EG M_#V[_@G1_P!'2:+_ . %Y_\ &:/^'MW_ 3H_P"CI-%_\ +S_P",UZG_ ,,O M_LT_]&\>!?\ PDK/_P"-4?\ #+_[-/\ T;QX%_\ "2L__C5 'EG_ ]N_P"" M='_1TFB_^ %Y_P#&:/\ A[=_P3H_Z.DT7_P O/\ XS7J?_#+_P"S3_T;QX%_ M\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\ C5 'EG_#V[_@G1_T=)HO_@!>?_&: M/^'MW_!.C_HZ31?_ O/_C->I_\,O\ [-/_ $;QX%_\)*S_ /C5'_#+_P"S M3_T;QX%_\)*S_P#C5 'EG_#V[_@G1_T=)HO_ ( 7G_QFC_A[=_P3H_Z.DT7_ M , +S_XS7J?_ R_^S3_ -&\>!?_ DK/_XU1_PR_P#LT_\ 1O'@7_PDK/\ M^-4 >6?\/;O^"='_ $=)HO\ X 7G_P 9H_X>W?\ !.C_ *.DT7_P O/_ (S7 MJ?\ PR_^S3_T;QX%_P#"2L__ (U1_P ,O_LT_P#1O'@7_P )*S_^-4 >6?\ M#V[_ ()T?]'2:+_X 7G_ ,9H_P"'MW_!.C_HZ31?_ "\_P#C->I_\,O_ +-/ M_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-4 >6?\/;O^"='_1TFB_^ M %Y_\9H_X>W?\$Z/^CI-%_\ "\_^,UZG_PR_P#LT_\ 1O'@7_PDK/\ ^-4? M\,O_ +-/_1O'@7_PDK/_ .-4 >6?\/;O^"='_1TFB_\ @!>?_&:/^'MW_!.C M_HZ31?\ P O/_C->I_\ #+_[-/\ T;QX%_\ "2L__C5'_#+_ .S3_P!&\>!? M_"2L_P#XU0!Y9_P]N_X)T?\ 1TFB_P#@!>?_ !FC_A[=_P $Z/\ HZ31?_ " M\_\ C->I_P##+_[-/_1O'@7_ ,)*S_\ C5'_ R_^S3_ -&\>!?_ DK/_XU M0!Y9_P /;O\ @G1_T=)HO_@!>?\ QFC_ (>W?\$Z/^CI-%_\ +S_ .,UZG_P MR_\ LT_]&\>!?_"2L_\ XU1_PR_^S3_T;QX%_P#"2L__ (U0!Y4__!7#_@G- M&A=OVH]'P/[NGWI/Y""E'_!6_P#X)SD C]J/1N?6PO/_ (S4G[:'[._[/^@? MLL>-]9T+X&>#K*\M]$=[>ZM/#%I')$VY>598P5/N*[7X;?LS_LX7?P[T"ZNO MV?O!$LLNBVKR22>%+-F=C"I)),>22>] '#_\/;O^"='_ $=)HO\ X 7G_P 9 MH_X>W?\ !.C_ *.DT7_P O/_ (S7J?\ PR_^S3_T;QX%_P#"2L__ (U1_P , MO_LT_P#1O'@7_P )*S_^-4 >6?\ #V[_ ()T?]'2:+_X 7G_ ,9H_P"'MW_! M.C_HZ31?_ "\_P#C->I_\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ MPDK/_P"-4 >6?\/;O^"='_1TFB_^ %Y_\9H_X>W?\$Z/^CI-%_\ "\_^,UZ MG_PR_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_ +-/_1O'@7_PDK/_ .-4 >6?\/;O M^"='_1TFB_\ @!>?_&:/^'MW_!.C_HZ31?\ P O/_C->I_\ #+_[-/\ T;QX M%_\ "2L__C5'_#+_ .S3_P!&\>!?_"2L_P#XU0!Y9_P]N_X)T?\ 1TFB_P#@ M!>?_ !FC_A[=_P $Z/\ HZ31?_ "\_\ C->I_P##+_[-/_1O'@7_ ,)*S_\ MC5'_ R_^S3_ -&\>!?_ DK/_XU0!Y9_P /;O\ @G1_T=)HO_@!>?\ QFC_ M (>W?\$Z/^CI-%_\ +S_ .,UZG_PR_\ LT_]&\>!?_"2L_\ XU1_PR_^S3_T M;QX%_P#"2L__ (U0!Y9_P]N_X)T?]'2:+_X 7G_QFC_A[=_P3H_Z.DT7_P M+S_XS7J?_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\ LT_]&\>!?_"2L_\ XU0! MY9_P]N_X)T?]'2:+_P" %Y_\9H_X>W?\$Z/^CI-%_P# "\_^,UZG_P ,O_LT M_P#1O'@7_P )*S_^-4?\,O\ [-/_ $;QX%_\)*S_ /C5 'EG_#V[_@G1_P!' M2:+_ . %Y_\ &:/^'MW_ 3H_P"CI-%_\ +S_P",UZG_ ,,O_LT_]&\>!?\ MPDK/_P"-4?\ #+_[-/\ T;QX%_\ "2L__C5 'EG_ ]N_P""='_1TFB_^ %Y M_P#&:/\ A[=_P3H_Z.DT7_P O/\ XS7J?_#+_P"S3_T;QX%_\)*S_P#C5'_# M+_[-/_1O'@7_ ,)*S_\ C5 'EG_#V[_@G1_T=)HO_@!>?_&:/^'MW_!.C_HZ M31?_ O/_C->I_\,O\ [-/_ $;QX%_\)*S_ /C5'_#+_P"S3_T;QX%_\)*S M_P#C5 'EG_#V[_@G1_T=)HO_ ( 7G_QFFO\ \%W?\$Z/^CI-%_\ "\_^,T? M\/;O^"='_1TFB_\ @!>?_&:]3_X9?_9I_P"C>/ O_A)6?_QJC_AE_P#9I_Z- MX\"_^$E9_P#QJ@#RS_A[=_P3H_Z.DT7_ , +S_XS1_P]N_X)T?\ 1TFB_P#@ M!>?_ !FO4_\ AE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J M/+/^'MW_ 3H_P"CI-%_\ +S_P",T?\ #V[_ ()T?]'2:+_X 7G_ ,9KU/\ MX9?_ &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !J@#RS_ (>W M?\$Z/^CI-%_\ +S_ .,T?\/;O^"='_1TFB_^ %Y_\9KU/_AE_P#9I_Z-X\"_ M^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:H \L_X>W?\$Z/^CI-%_\ "\_ M^,T?\/;O^"='_1TFB_\ @!>?_&:]3_X9?_9I_P"C>/ O_A)6?_QJC_AE_P#9 MI_Z-X\"_^$E9_P#QJ@#RS_A[=_P3H_Z.DT7_ , +S_XS1_P]N_X)T?\ 1TFB M_P#@!>?_ !FO4_\ AE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9_ M_&J /+/^'MW_ 3H_P"CI-%_\ +S_P",T?\ #V[_ ()T?]'2:+_X 7G_ ,9K MU/\ X9?_ &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !J@#RS_ M (>W?\$Z/^CI-%_\ +S_ .,T?\/;O^"='_1TFB_^ %Y_\9KU/_AE_P#9I_Z- MX\"_^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:H \L_X>W?\$Z/^CI-%_\ M "\_^,T?\/;O^"='_1TFB_\ @!>?_&:]3_X9?_9I_P"C>/ O_A)6?_QJC_AE M_P#9I_Z-X\"_^$E9_P#QJ@#RS_A[=_P3H_Z.DT7_ , +S_XS1_P]N_X)T?\ M1TFB_P#@!>?_ !FO4_\ AE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^ M$E9__&J /+/^'MW_ 3H_P"CI-%_\ +S_P",T?\ #V[_ ()T?]'2:+_X 7G_ M ,9KU/\ X9?_ &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !J@ M#RS_ (>W?\$Z/^CI-%_\ +S_ .,T?\/;O^"='_1TFB_^ %Y_\9KU/_AE_P#9 MI_Z-X\"_^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:H \J'_!7+_@G,9#&/ MVH]'R!DG^SKW'Y^1BG?\/;O^"='_ $=)HO\ X 7G_P 9K(\#_L__ &N/VZ_ M'/ARX^"7A&33[;P5IDMO8/X;M3#%(SMN=4,>U6/<@9->U?\ #+_[-/\ T;QX M%_\ "2L__C5 'EG_ ]N_P""='_1TFB_^ %Y_P#&:/\ A[=_P3H_Z.DT7_P MO/\ XS7J?_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\ C5 ' MEG_#V[_@G1_T=)HO_@!>?_&:/^'MW_!.C_HZ31?_ O/_C->I_\,O\ [-/_ M $;QX%_\)*S_ /C5'_#+_P"S3_T;QX%_\)*S_P#C5 'EG_#V[_@G1_T=)HO_ M ( 7G_QFC_A[=_P3H_Z.DT7_ , +S_XS7J?_ R_^S3_ -&\>!?_ DK/_XU M1_PR_P#LT_\ 1O'@7_PDK/\ ^-4 >6?\/;O^"='_ $=)HO\ X 7G_P 9H_X> MW?\ !.C_ *.DT7_P O/_ (S7J?\ PR_^S3_T;QX%_P#"2L__ (U1_P ,O_LT M_P#1O'@7_P )*S_^-4 >6?\ #V[_ ()T?]'2:+_X 7G_ ,9H_P"'MW_!.C_H MZ31?_ "\_P#C->I_\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/ M_P"-4 >6?\/;O^"='_1TFB_^ %Y_\9H_X>W?\$Z/^CI-%_\ "\_^,UZG_PR M_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_ +-/_1O'@7_PDK/_ .-4 >6?\/;O^"=' M_1TFB_\ @!>?_&:/^'MW_!.C_HZ31?\ P O/_C->I_\ #+_[-/\ T;QX%_\ M"2L__C5'_#+_ .S3_P!&\>!?_"2L_P#XU0!Y9_P]N_X)T?\ 1TFB_P#@!>?_ M !FC_A[=_P $Z/\ HZ31?_ "\_\ C->I_P##+_[-/_1O'@7_ ,)*S_\ C5'_ M R_^S3_ -&\>!?_ DK/_XU0!Y9_P /;O\ @G1_T=)HO_@!>?\ QFC_ (>W M?\$Z/^CI-%_\ +S_ .,UZG_PR_\ LT_]&\>!?_"2L_\ XU1_PR_^S3_T;QX% M_P#"2L__ (U0!Y9_P]N_X)T?]'2:+_X 7G_QFC_A[=_P3H_Z.DT7_P +S_X MS7J?_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\ LT_]&\>!?_"2L_\ XU0!Y9_P M]N_X)T?]'2:+_P" %Y_\9H_X>W?\$Z/^CI-%_P# "\_^,UZG_P ,O_LT_P#1 MO'@7_P )*S_^-4?\,O\ [-/_ $;QX%_\)*S_ /C5 'EG_#V[_@G1_P!'2:+_ M . %Y_\ &:;'_P %/ O_ M (25G_\ &J\5_81_9_\ @-XC^#VJ7WB'X)>$;^=/&NKQ)->^&[65UC6X(5 6 MC)"@< =!0!K_ /#V[_@G1_T=)HO_ ( 7G_QFC_A[=_P3H_Z.DT7_ , +S_XS M7J?_ R_^S3_ -&\>!?_ DK/_XU1_PR_P#LT_\ 1O'@7_PDK/\ ^-4 >6?\ M/;O^"='_ $=)HO\ X 7G_P 9H_X>W?\ !.C_ *.DT7_P O/_ (S7J?\ PR_^ MS3_T;QX%_P#"2L__ (U1_P ,O_LT_P#1O'@7_P )*S_^-4 >6?\ #V[_ ()T M?]'2:+_X 7G_ ,9H_P"'MW_!.C_HZ31?_ "\_P#C->I_\,O_ +-/_1O'@7_P MDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-4 >6?\/;O^"='_1TFB_^ %Y_\9H_ MX>W?\$Z/^CI-%_\ "\_^,UZG_PR_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_ +-/ M_1O'@7_PDK/_ .-4 >6?\/;O^"='_1TFB_\ @!>?_&:/^'MW_!.C_HZ31?\ MP O/_C->I_\ #+_[-/\ T;QX%_\ "2L__C5'_#+_ .S3_P!&\>!?_"2L_P#X MU0!Y9_P]N_X)T?\ 1TFB_P#@!>?_ !FNZ^ W[:O[+G[3NO7OACX#__$=_ MIUH+J]M;2"=&BA+!-Y\R-01N('&>M;/_ R_^S3_ -&\>!?_ DK/_XU6QX- M^$GPI^'5W-?_ ^^&/A[0I[B,1W$VC:+!:O*@.0K&)%+#/.#0!T-%%% !111 M0 4444 %%%% !1110 4444 %%%% 'R_\:?\ @E%^S[\2?$^J>.OAYXI\9_#[ M6/$WCS2O%/C&3PGXUU6WL]:N[2\@N'E>S2Z6WANI%@""[B194.Q\ML KVOX# M?L[?!C]F3X>CX7? _P "6^AZ,U[/?7<8GEN)[Z\G;?/=W5Q.SS7=Q(W+S3.\ MCG&YC@5VM% '@W@__@FE^Q[X%\0:+J>@?#J_&E>&/$$FO>$_!=WXGOY_#NA: MH[O(;NSTJ29K2WD5Y)'CV1A8&D=HA&6)/O-%% !1110 4444 %%%% !1110 M4444 %%<9X7_ &BO@1XW^+FM_ 3P9\7?#^K^,_#-C'=^(_#>F:I'/=Z5$[E$ M-RB$F LP.%?#$'9)V@.J^'-3CN8XIE +12;3F*0 J2C@, P.,$5M>*?BGX#\%^,O#'P^\2 M:[Y&L^,KVYM?#EBEK+*UU);VLEU,244B)$BB8F20JFXHF[?)&K '05S>F?"G MPCI'Q1U3XP6<,XUK5]-@L;UVG)C,,1)0!.QR>O>O+$_X*??\$\I/VB?^&3(_ MVR?A\?B+_:/]G#PJ/$R^,/&/A+X>^% MM0\<^/?%&G:)HNDVCW6JZOJ][';6MG @+/+++(0D:* 268@ #F@#2HKS_P"" MG[57[/'[1=W?Z;\%_BQI6NWFEP0W%_I\#M'=0V\V?)N##*JR>1)M;RYMOER; M6VL<''0?$GXI^ _A#H5IXC^(6N_8+2_UW3M&LF6UEG>>^O[N*SM852)6H6OVJQ\(Z:DE_J\]OG:9TL;59+AH@W!D$>P'C.:[R@ HHHH **** " MBBB@ HHHH **** "BBB@ HJ'4-0L-)L)M4U2]AMK6VB:6XN;B0)'%&HRSLQX M50 22> !7,?!?X]?!;]HSPE-X^^ WQ0T3Q?H4&IW&GMK7AZ_2ZM'N8&V2QI- M&2DFUN"5)&>] '6T5X?^TC_P4K_8%_8_\;V/PU_:;_:V\#^"_$&HPK-;:-K> MMQQW(B8X662,9,,;$'#R!5.TX/!Q[%X9\3^&_&OAVQ\7^#?$-CJVDZI:1W6F MZIIEVD]O=P.H9)8I$)61&4@AE)!!!!H O45QVI_M!?!?0]=\7^'_ !!\1-/T MV7P!H]IJOC.ZU-VMK/2+2Y6=XI)KJ4+ OR6TKLN_=&FQG"K)&6X/]F;_ (*1 M?L&_MD^*=0\#?LO?M8>"?&NMZ9"9KS1]%UE'NEA!"M,L38>2,$@&1 5!9\.S^%_!<,Z6EQJ5Q?2"XG,C>=,^]SD]L]!VKI*XOXQ_M%? M!+]G^'37^+_Q&L-%FUJ>2'1=/D+2WFI/&N^1;>VB5IIRB?,_EHVQ?F; YJY\ M'/C;\(OVA/ 5K\4/@?\ $C1_%7A^\=XX-6T.^2XA,B,5DB8J?DD1@59&PRL" M& (Q0!U%%<_?_%/P'IGQ2TOX+7FNX\3:SH5[K.GZ8EK*Y>QM)K6&>9I%4QQ M27ENH#LK.7;8&V/MS-,_:*^!&M?&Z[_9KT3XN^'[WQ_I^B/K&I>$+/5(Y;^R ML5EBB,\\*$M"I>>(#?M+;OER < '9T5YW^T5^UO^S#^R+H&G^*OVG_CUX5\! M:=JUX;33+SQ5K45G'=3A"YCC,A&Y@H)('05Q?P9_X*A?\$[/VB?B1IWP>^!/ M[:?PX\6^*M7\W^R_#^@>*;>YN[KRHGFDV1HQ9ML<;N<=%0GM0![Q1110 444 M4 %%%% !1110 4444 %%%% !117+_&+XV_!_]GKP!>_%7XZ_$_0?"'AO3EW7 MNM^(]4BL[:+KA=\C %CC 499CP 3Q0!U%%5- UW2/%.A67B;P_?)=6&HVD=U M97,8.V6&10Z.,\X*D'GUKPS2/^"J7_!.'7_CW_PR_HW[:_PYN?'G]HG3U\.Q M>)H#*]X&VFU5\^6\^[Y/)5B^X%=N>* /?J**\@\>_M]_L:_"GX&Q?M)_%+]H MCPYX9\#W.JW6FV7B#Q#8A:,AR >B M?$CX?>'/BKX%U/X=^+HI7TW5K8P7BP2E'*$@\,.AXK2T;2K30='M-#T]6$%E M;1P0!VR0B*%7)[G %<3^SC^U3^S?^U[X!_X6A^S%\;/#GCG05N3;S:CX( MK2%9;DZ);R+N2:_:!'6QC9?F#SF-2HW XYH ]1HJIX?\0:#XLT*R\4^%M;L] M3TS4K6.ZT[4=/N4F@NH)%#)+'(A*NC*0P920000:R/"/Q9^'OCO5_%6B>%?$ M2W4_@G6QI'B8FWDCCL[W[';WAB\QU"28@NX&9HRRJ7*,0Z.J@'145QWP9_:$ M^!W[1>E:OK_P&^+&@^,-/T'79=%U;4?#FI1W=O;ZA%'%)+;^;&2C.BS1[@I. M"V#R"!2^*_[4/P$^"7B*Q\&?$CXD6EGKNIV'[6"6\U&>UC;;)ZBAW!?.\EL.T6X@>8H*98#.2*](^*WQ3\!_!+X=:Q\6/B=KO]F:!H-DUU MJ=Z+66=DC&!A(H5>25R2%6.-6=V8*JDD @'05S?C?X4^$?B#XB\.>*/$<,[7 M?A;4FOM),,Y15F*%"6'\0P>E>=?M-_\ !1C]A7]C/Q+IG@S]J7]JGP9X'UC6 M81-IVE:[K"1W,D)8J)C&,LD18,!(P"$JPSP<>M^&?$WAOQIX=L/%_@[Q!9:M MI.J6<=WIFJ:;=)/;W=O(H>.6*1"5D1E(964D$$$&@"]17&:'^T5\"/%'QFU/ M]G;PS\7?#^I>.=$TH:EK?A73]4CFO=.M3(L8DN(T),&6=0 ^TMG(! )KK[R[ MM-/M);^_N8X(((VDFFE<*D: 9+,3P ,DF@"2BN%7]IGX!Q? +3_ -J36_BI MI.B?#[4]!MM:M?%/B68Z7;"QN(EEAFD^V"-H=R.I"R!6Y (!XKI/ ?CGPE\3 M_ ^C?$KP#KL&J:%XATFWU/1=3MB?+N[2>)989DR =KHZL,CH: -:BO(O&?[> M_P"QK\._'4WPY\;_ +1WA?3-4M=7BTF_^U7X6VL=0EP8[*XN<>1;7+[DVP2N MLC;TPIW+GUV@ HHHH **** "BBB@ HHHH **** "BBB@ HHKC/"_[17P(\;_ M !#/B[X?U?QGX9L8[OQ'X;TS5(Y[O2HG4)_P4^_X)Y2?M$_\ #)D?[9/P M^/Q%_M'^SAX5'B.'[1]MSM^R9SL^T;OE\G=YF[Y=N[B@#U/3/A3X1TCXHZI\ M8+.&<:UJ^FP6-Z[3DQF&(DH G8Y/7O725'=75K8VLE]?7,<,,,9>::5PJHH& M2Q)X Y)-O_%WP%^*FA^,-(TS6)]*O-6\.ZBEW:I>0A#+ M")8R4=EWJ#M) )QG(( !U]%<_P#$GXI^ _A#H5IXC^(6N_8+2_UW3M&LF6UE MG>>^O[N*SM852)6:_"O]M;]D[XW>-E^'?PF^/OAO M7M8F@GGL+6POPPU*&!]D\MG(<)>QQ,0LCP-(J$@,02* /4:*** "BBB@ HHH MH **** "BBB@ HHHH ***AU#4+#2;";5-4O8;:UMHFEN+FXD"1Q1J,L[,>%4 M $DG@ 4 345R7P7^/7P6_:,\)3>/O@-\4-$\7Z%!J=QI[:UX>OTNK1[F!MDL M:31DI)M;@E21GO7GG[2/_!2O]@7]C_QO8_#7]IO]K;P/X+\0:C"LUMHVMZW' M'WNX'4,DL4B$K(C*00RD@@@@USU[\?/@[I?B'Q?X9UCQ_8V$_@+ M1[75?&5QJ):WM-(M+A9WBDFN9 L"_);2NR[]T:!'<*LD98 Z^N;^%OPI\(_! M[P[/X7\%PSI:7&I7%](+BA:PDEQ%#N"&81G#/%N*KYB@IEE&?F&?1?BO\ %_X5 M? GP)??%#XU?$C0_"?AS3(]^H:YXBU2*SM8!VW2RLJ@GH!G)/ R: .CHK.\( M^+/#OCSPII?CGPAJL=_I.M:=!?Z7?0YV7%M-&LD)-7T&^UJQTT6TK9L+.6UAN)WD53'$%DO+=0'92Y=M@;RWV@ M'0T5X%\+_P#@J=_P3D^-7QJ;]G7X3_MJ?#K7_&OVAX(- TWQ+#)+=3)G=' P M.RX<8)*Q,QPI..#7N/B'Q%X?\):'=^)_%>N6>F:;86[3WVHZA=)#!;1*,M)) M(Y"HH'))( H N45S'P<^-/PG_:%^'5A\7?@?\0=+\5>%]4DN$TS7]$NEGM+O MR)Y+>4Q2+\LBB6*1=RDJ=N02,&NGH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D959 M2K*"",$$=:6B@#\V_P!ASX>^ _AI_P '$7[6'AWX=>#-+T'3G^$G@N07]S#$GG00E7(ED3S$#(N64GD"O8/^"H/_!9S M]DO]A7QEI'[+_B[]I31/!?CWQ5;>==ZW>:71WE=MH4U[M^QY:2?L]?L2Q?&'X_!](U?5K'4_B'\2W>WDFDL+N_>75 M+N$K&K/(+5)/LR*JEO+M450< 4 ?#?\ P7!?A5 MXJU/XB:&?#'B2#2# / UE!/'/=7C74,16WDEMQY""1UWR7<4DA6-7F3T+_@N M9\0M3\:_M3_L4?L'RS>9X5^+?QP&L>-; ',6K:?H;6=R+*8=)())+A'9#P3 MA[59_P""B7[5/_!.S_@J[_P33\+?'6@26_PT\&^'KA)] M;BUX_+97363@7-@D,Q22:>9(DBA$AD8(QSB?\%*_V1OB-\$?AW^Q5^UJGVSQ M3/\ LC^)](M_B3GM;.RU;5$0 O+Y/V2*=E R(S(YP$- &S_P % MAOB'J?[,O_!1K]AO]I/P3<&TU'Q#\6)_AGXE\D[1J>C:T;:,P3X_UB0S*LZ MY"2#<.:^EOC#_P 7F_;P^&7P8C_>Z5\,]&N_B+XF0<@7TRS:3HL3CNK^9K-P M,])-.B8 D K\Q?MMZ3X1_P""G/\ P4E_9.\!_LX^,M*\8^$/@MXLN/B=\2_% M?AO4([W3M*:!;=M&M&N(6:)KFYG1F$.[>(5,NW9@GZ=_8._XN9-\2OVN[K]X M/B;X\N4\-RG^'P[I.=+T_8>\4[6]UJ"?]A,].@ /ES_@NU\._ 5M^TC^P]\3 M;;P7I47B.?\ ;&\*65QKL>GQK>2VQ\QO)>8+O9,Q1G:3@;!Z5]%_\%@/V\G_ M .";?_!/CQ_^U3I&GP7OB#3+.*P\(V-RNZ.?5KN5;>V+KQN2-G,SKD%DA8 @ MD5\R_P#!P-\:_@]X,^-W[%.@^+OBGX>TR^TG]KKPOK&JVE]K,$4MEIT?FK)> M3*S Q0*73,K80;N37IO_ < ?LL>/_VZ_P#@ECXATC]G"PB\4^(-"U+2_&?A MC2].D$RZZEG*)7AA*$B4R6SRM&%SYC!%'WA0!YC^PC^U5^SS_P $U? ?P^\# M_MC> ?BMH/Q ^.^I6T_C;]H#XB^#3;V'BCQ90+Y3'RSAW53^F>E63Z;I=MITEY) M<-;VZ1M<3'+RE5 W-[G&3]: )Z*** "BBB@ HHHH **** "BBB@ HHHH S?% MO@[PCX^T"?PIX[\*Z;K6EW6W[3INKV,=S;S;6#KNCD!5L,JL,C@@'M7Y_?\ M!K]IEAHO_!,*31]*M4@M;3XM^+8;:"-<+'&NI.JJ .@ %?H%XM\8>$O /AV MZ\7^.O%&G:+I-B@>]U35KV.VMK=20H9Y)"%09(&21R0*_.;_ (-;?BG\-?&/ M_!/'5O"WA7Q]H^H:I9_%CQ3=7>F6>I127$$$VH&2*5X@VY4='1E8C!##!H ^ ML]>_8%_8AM_!OQ#O_C5\&/"7B.#QS>:EJ_Q#\1^,M*M[BXO(I2[[9KF1=Z06 MT 2&$!AY,5O'M(*[CX+_ ,&XGPL\;_!'_@DYX0L/'E_J,.BZCK6M:WX'MM=< MK-8^&[B]EEL-^_&Q9(O]) [+&_P#!17]C/X72 M_P#!5K]BWQ;^RG\.=(\+?$RP\;:CJ?BO4?"NG1V9?P78VR?;OMOD*H,1::*T MC+]6O&C4_,0/K+]N+]NC]EC_ ():_LR'XO\ QSU^UT30M-BBTOPOX?LP!<:E M<"/;!96L8ZX5>3]V-%9V(537QK^S%_P7#_X).+\0)?&Z?M3Q_%']H/XK7MAH MUOHOA/P3K8!9IMFG^'M-DN[**."TBEG8F69H_.EDFN) I<1Q@'6? 7XO75[_ M ,'+_P >/A;\9+L17UI\"?#L?P;BOSM$FCYBN-4^R[N&+WLC%]O+"UYR(OES M_P!B3Q;)\,?^#C#]K']FCX=703P=XH^'F@^.];TBW8?9K'Q%Y=G;S2JHXCEN M8[@RRGK(RJ6SM&/H/_@H[X%_X)HZQ:Z+\2/VVOAWHGB/Q7X:WGP'8:8)6\5W MMPP)%CI<5DZ7ER\IX\B,E#DLX"AF'SO^P/\ LJ^(O^":?P _:$_X*<_&WX-Z M1X<^*/Q4#ZMIGPPT-8C%X?L8$:'0_#BO%A)+N662%)I%.))I$R25+L ?5?[+ M7_%WOVFOC-^T_-^]L;?68/AUX/EZJ;'1&E.H2K_=9M7N]1MWQ]X:=#D_* /E MSX,?#OP%\./^#H?Q]8?#[P7I6AV^H?LV^D:?';1S7+>(X$:9EC4 N5C M0%CR=HSTK[B_90^"3_LY?LW^#/@K=ZK_ &A?Z#H4,6MZKCG4M2<>;>WC=/FG MN7FF;@?-*:^!O G[0?P(NO\ @Z8\66]M\9O"TC7/[)EGH%MLU^W(FU8>(8I3 MIZ'?AKGRV#>2/GQD[>#0!]S_ !L_8H_9>_:6^(>C_$;]H[X,:!X_G\.Z7/9> M'=+\9Z1!J6GZ9Y[JUQ/#;3HT8GE$<*-*P9@D"JFP-)O^7?V;/V6OV9KS_@LI MXX\>_ +]G7P+X,T+X ?#2S\,>9X0\(V6F"\\3:Z5OKMV:UB3S&M]-AL8P&SL M_M&4#&XU]O\ C_QSX8^&'@36_B5XVU1+'1?#VD7.IZO>R?=M[6")I99#[*B, M?PKYU_X)!>!/$^D_L9V/QT^(^EO:>,/CAXAU'XF^*K>7[\$NL2_:+6V(ZK]G MT\6-MM/3[/CCI0!]0T444 %%%% !1110 4444 %%%% !1110 5\)?\')?P[\ M!>+_ /@CA\:O$GBGP7I6HZEH?ANWFT74;W3XY9["0ZE9EFAD92T1.Q<[2,[0 M#FONVOA/_@Y-^(7@/P=_P1L^-.@>+/&FE:;?Z]X>M[;0[&^U".*;4)AJ%IF. M!&(:5@""0H) .3Q0!]-?"_P5'\2?V*O#GP[FU_4-*37OA?9Z=)J>D7'E7=HL M^G)&989,'9*H8LK?PL >U?$__!>+_@GW^QQIO_!)O6_AQ\)OV8_"FC^*M-U# M1=+^"]OX3T""UU)->N-1MK>UM[1XU$C/+O99 2=R;W;E-X^NO@+^TS^SWX6_ M8&\+?M%:W\9_#.349XF>.,(S+:V\C(K;YIS0!]U_M$>/\ XJ_LV_L$221>(5U7XF#POI?A M?P_J$K%A?^*K\P:99RMD996O[B*1SC(3<3C!JQX)_P"">?[,OA>7P%+XB\!6 M/BA?AE\/[/PGX&MO$UC%>0Z/#$-L]W DBL$NKE4MUEFY%](\*2_%S4;'5X!%FW. MHP^%]/.X-JEU;6D!_#VE>+M&T2$0:7+XRE"7CB") (Q)#:,'E50-CZ@<@&0B MO'_ 7_!0K6/^"*/[6_QQ_8]_;;^&5UJ:_&;XHZS\0?@9X]M[^VALO%+:I-%& MFDW]U<.D=BT#"*%IYB(XD1MP6,0F3Z;_ .":W_!33_@EQ\7_ !;I?[%?_!/# MXJ:M\0]5CL]0\0^+M8_X1W489%W.)+K5]2N[VW@%Q<7-Y/&K&/ M-_L[_#_]E7]HGP7^UG^S]_P5\O?#-MX[USXPZM/XFM_'>JPV-S;>%XE5?#][ MI OV@/B!9:@/A MKX3U;7?%NK::6-G:1M/=:G/#;;\$V]NDK0Q$A/!]E=^(/')NO%7Q#TC5+5+B+^UM6N7U&ZM760$.D$D_V= 1Q';Q@ !0! M\6?L+>!_CM_P[-^ W[ _QKUO6-5/COXG7MEI=UXAMWBU";X;:1?S:DDEU'( MZ17-G:VEB$896+58%PN/E_3CQ!XAT#PGHMSXD\4ZY9Z9IUE$9;R_U"Y2&&!! MU9WQT[3?VR?'5K865I$(XK>", M6*)&BJ %55 X %'/"'Q+T'4]1NOVN/&VM6VGV.K0RSS:9.UEY-ZL:L6:W<\+*!L8@@$D5 MTVG2_#OQ!_P5Q_:-^'?_ 4>BT!O#WB'X=>']+^!%AX\,2Z/J7AE[9VUZ"S, M^(I)VOQ$;I/];MBMC@QHI !ZS_P26^#/BWP?\-_B1^TCXKU72XT_: ^*=_\ M$71_#F@ZQ#?V6BV%[#;QV\0N+=F@GN)(X%FGEA9HFEE(1G"^8_UA7P!_P0?^ M FH?LUVWQ^^$_P (_%NH:U^SQ8_%DO\ *_O[QKB(VDEI')J,=E,Y)GLH[QV MACE4E)'AG<,S,['[_H **** "BBB@ HHHH **** "BBB@ HHHH _-O\ X*U? M#OP%I/\ P5=_8*^(FE>"]*M=>U/XN:W#J>LVVGQQW5Y&NEPA5EE50T@4(H&X MG &!BONCX^_LX?"S]IO1]"\)?&?0(M;\/:-XCAUFX\-W\22V&K301RK!'=PN M"L\4X#3:[=NH*1P[ Q\L AWF *QQY8Y)56 /E3]MW M]CGX9P_\%IOV._&_[)_P^TKPKX]TZ;Q#JOQ'O_"NGQVBOX1M;6*$F^6%0"KS MW M(F898W#KDA/D^J/VP/^+L?&SX-_LGV_[RVUCQ4WC?Q?".1_8WAYX+F('_ M ']8GT5=IX:,3#G!%?(_[)G_ 6O_P""4#_$877AO]J@?%C]H3XQ:SIVESV? MACP-K40N)FE\JRT>RDN[2..TTZU,[D-*Z;BUQ<29DE<5]I:4=0U#Q1K?\%2O^"8?B7QGX\_9V\CZ?'; M1/,;Z-3(4C4+N(103C)P*^J_^"B^K:GJG[/2?L_>&+^6WUOXS>(;/P%ITMLY M66&VO]YU.XC(Y$D&DPZE'%NM,BD_LN2&S8Q/;EE)A9?+3!3!&T>E;?[)VM>/_ W_ ,$6 MOAIXB^$]BUUXIL/V7M&N?#5LD6]IM03PY"UN@7^(F4(,=\UF_P#!<[XA> _ M?_!)GX^P>-O&FE:1)K/PLUK3](CU+4(X&OKN6T=(X(0Y!DD9F "+DG/2NJ_X M)+_$/P%\0?\ @F7\!]2\">-=*UFWT[X/>&;#49=+U".=;2[ATBU6:WE*,?+E M0\/&V&4\$"@#Y+_X)4?\*'_:C_X-IG\,>,-0LM2L-3^'GBVU^)4]_*LD\>KM M->S7ES=,_P PN3(ZW0D<[_GCD!^Z:]L_X-X_CA\1_P!HC_@C;\#_ (E_%C4[ MF^UO^PK[2I;^\78P6T66/+,"23G)\#_X**_L@_L=?&^[ M\9?LQ_\ !-C]F[P3K/QO^,-P;/X@>+M$1IM!\"V:WJB1.;.'4#$TGV= MHO))9!,@/EEJ_0K]DS]FKX>_L<_LU>"/V7?A7%(-!\#^';?2K&6<#S;DQK^\ MN),<>9+(7E?'&Z1L8H ]#HHHH **** "BBB@ HHHH **** "BBB@!&564JR@ M@C!!'6OS<_8<^'O@/X:?\'$7[6'AWX=>#-+T'3G^$G@N(/^#D+]IRUT+XS>%KQ]8^%?A"RT<6NOV\ M@O[F&)/.@A*N1+(GF(&1

  •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�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end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Cover - USD ($)
    $ in Billions
    		 12 Months Ended
    Dec. 31, 2021
    Feb. 16, 2022
    Jul. 02, 2021
    Cover [Abstract]      
    Document Type 10-K    
    Document Annual Report true    
    Document Period End Date Dec. 31, 2021    
    Current Fiscal Year End Date --12-31    
    Document Transition Report false    
    Entity File Number 1-16137    
    Entity Registrant Name INTEGER HOLDINGS CORPORATION    
    Entity Incorporation, State or Country Code DE    
    Entity Tax Identification Number 16-1531026    
    Entity Address, Address Line One 5830 Granite Parkway,    
    Entity Address, Address Line Two Suite 1150    
    Entity Address, City or Town Plano,    
    Entity Address, State or Province TX    
    Entity Address, Postal Zip Code 75024    
    City Area Code 214    
    Local Phone Number 618-5243    
    Title of 12(b) Security Common Stock, Par Value $0.001 Per Share    
    Trading Symbol ITGR    
    Security Exchange Name NYSE    
    Entity Well-known Seasoned Issuer Yes    
    Entity Voluntary Filers No    
    Entity Current Reporting Status Yes    
    Entity Interactive Data Current Yes    
    Entity Filer Category Large Accelerated Filer    
    Entity Small Business false    
    Entity Emerging Growth Company false    
    ICFR Auditor Attestation Flag true    
    Entity Shell Company false    
    Entity Public Float     $ 3.1
    Entity Common Stock, Shares Outstanding (in shares)   33,097,540  
    Documents Incorporated by Reference
    Portions of the following document are specifically incorporated by reference into the indicated parts of this report:
     
    DocumentPart
    Proxy Statement for the 2022 Annual Meeting of Stockholders
    Part III, Item 10
    “Directors, Executive Officers and Corporate Governance”
    Part III, Item 11
    “Executive Compensation”
    Part III, Item 12
    “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters”
    Part III, Item 13
    “Certain Relationships and Related Transactions, and Director Independence”
    Part III, Item 14
    “Principal Accounting Fees and Services”
    		    
    Entity Central Index Key 0001114483    
    Amendment Flag false    
    Document Fiscal Year Focus 2021    
    Document Fiscal Period Focus FY    
    XML 15 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Audit Information
    		 12 Months Ended
    Dec. 31, 2021
    Auditor Information [Abstract]  
    Auditor Name Deloitte & Touche LLP
    Auditor Location Williamsville, New York
    Auditor Firm ID 34
    XML 16 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Balance Sheets - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Current assets:    
    Cash and cash equivalents $ 17,885 $ 49,206
    Accounts receivable, net of provision for credit losses of $0.1 million and $0.2 million as of December 31, 2021 and 2020, respectively 182,310 156,207
    Inventories 155,699 149,323
    Refundable income taxes 4,735 2,087
    Contract assets 64,743 40,218
    Prepaid expenses and other current assets 27,610 15,896
    Total current assets 452,982 412,937
    Property, plant and equipment, net 277,099 253,964
    Goodwill 924,704 859,442
    Other intangible assets, net 807,810 757,224
    Deferred income taxes 5,711 4,398
    Operating lease assets 70,053 45,153
    Other long-term assets 43,856 38,739
    Total assets 2,582,215 2,371,857
    Current liabilities:    
    Current portion of long-term debt 15,250 37,500
    Accounts payable 76,859 51,570
    Income taxes payable 725 1,847
    Operating lease liabilities 9,862 8,431
    Accrued expenses and other current liabilities 56,933 56,843
    Total current liabilities 159,629 156,191
    Long-term debt 812,876 693,758
    Deferred income taxes 171,505 182,304
    Operating lease liabilities 59,767 37,861
    Other long-term liabilities 23,741 30,688
    Total liabilities 1,227,518 1,100,802
    Commitments and contingencies (Note 13)
    Stockholders’ equity:    
    Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding as of December 31, 2021 and 2020 0 0
    Common stock, $0.001 par value; 100,000,000 shares authorized; 33,063,336 and 32,908,178 shares issued and outstanding as of December 31, 2021 and 2020, respectively 33 33
    Additional paid-in capital 713,150 700,814
    Retained earnings 614,324 517,516
    Accumulated other comprehensive income 27,190 52,692
    Total stockholders’ equity 1,354,697 1,271,055
    Total liabilities and stockholders’ equity $ 2,582,215 $ 2,371,857
    XML 17 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Balance Sheets (Parenthetical) - USD ($)
    $ in Millions
    Dec. 31, 2021
    Dec. 31, 2020
    Current assets:    
    Allowance for doubtful accounts $ 0.1 $ 0.2
    Stockholders’ equity:    
    Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
    Preferred stock, shares authorized (in shares) 100,000,000 100,000,000
    Preferred stock, shares issued (in shares) 0 0
    Preferred stock, shares outstanding (in shares) 0 0
    Common stock, par value (in dollars per share) $ 0.001 $ 0.001
    Common stock, shares authorized (in shares) 100,000,000 100,000,000
    Common stock, shares issued (in shares) 33,063,336 32,908,178
    Common stock, shares outstanding (in shares) 33,063,336 32,908,178
    XML 18 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statements of Operations - USD ($)
    shares in Thousands, $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Income Statement [Abstract]      
    Sales $ 1,221,079 $ 1,073,442 $ 1,258,094
    Cost of sales 884,109 787,735 903,084
    Gross profit 336,970 285,707 355,010
    Operating expenses:      
    Selling, general and administrative 141,418 109,006 138,695
    Research, development and engineering 51,985 48,468 46,529
    Other operating expenses 7,856 7,621 12,151
    Total operating expenses 201,259 165,095 197,375
    Operating income 135,711 120,612 157,635
    Interest expense 31,628 38,220 52,545
    (Gain) loss on equity investments, net 3,143 (5,337) 475
    Other (income) loss, net (123) 1,522 (578)
    Income from continuing operations before taxes 101,063 86,207 105,193
    Provision for income taxes 8,043 8,949 13,975
    Income from continuing operations 93,020 77,258 91,218
    Discontinued operations:      
    Income from discontinued operations before taxes 4,931 0 5,296
    Provision for income taxes 1,143 0 178
    Income from discontinued operations 3,788 0 5,118
    Net income $ 96,808 $ 77,258 $ 96,336
    Basic earnings per share:      
    Income from continuing operations (in dollars per share) $ 2.82 $ 2.35 $ 2.80
    Income from discontinued operations (in dollars per share) 0.11 0 0.16
    Basic earnings per share (in dollars per share) 2.93 2.35 2.95
    Diluted earnings per share:      
    Income from continuing operations (in dollars per share) 2.80 2.33 2.76
    Income from discontinued operations (in dollars per share) 0.11 0 0.15
    Diluted earnings per share (in dollars per share) $ 2.91 $ 2.33 $ 2.92
    Weighted average shares outstanding:      
    Basic (in shares) 32,993 32,845 32,627
    Diluted (in shares) 33,258 33,113 33,037
    XML 19 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statements of Comprehensive Income - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Comprehensive Income      
    Net income $ 96,808 $ 77,258 $ 96,336
    Other comprehensive income (loss):      
    Foreign currency translation gain (loss) (27,826) 34,907 (7,900)
    Net change in cash flow hedges, net of tax 2,105 (2,052) (4,580)
    Defined benefit plan liability adjustment, net of tax 219 (151) (536)
    Other comprehensive income (loss), net (25,502) 32,704 (13,016)
    Comprehensive income $ 71,306 $ 109,962 $ 83,320
    XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statements of Cash Flows - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Cash flows from operating activities:      
    Net income $ 96,808 $ 77,258 $ 96,336
    Adjustments to reconcile net income to net cash provided by operating activities:      
    Depreciation and amortization 81,369 79,324 77,895
    Debt related charges included in interest expense 6,954 4,774 7,772
    Stock-based compensation 16,185 9,163 9,294
    Non-cash (gains) charges related to customer bankruptcy (348) 554 21,695
    Non-cash lease expense 8,235 7,810 7,443
    Non-cash (gain) loss on equity investments 3,143 (5,337) 475
    Contingent consideration fair value adjustment 133 (2,000) 0
    Other non-cash (gains) losses 2,202 600 (162)
    Deferred income taxes (10,270) (6,966) (10,285)
    Gain on sale of discontinued operations 0 0 (4,974)
    Changes in operating assets and liabilities, net of acquisitions:      
    Accounts receivable (17,539) 38,153 (6,976)
    Inventories 4,700 18,441 3,724
    Prepaid expenses and other assets (2,409) (864) (6,293)
    Contract assets (24,923) (15,451) (24,767)
    Accounts payable 19,525 (9,055) 1,887
    Accrued expenses and other liabilities (22,984) (10,721) (2,744)
    Income taxes payable (4,115) (4,342) (4,962)
    Net cash provided by operating activities 156,666 181,341 165,358
    Cash flows from investing activities:      
    Acquisition of property, plant and equipment (53,463) (46,832) (48,198)
    Purchase of intangible asset 0 (4,607) 0
    Proceeds from sale of property, plant and equipment 443 82 28
    Purchase of equity investments 0 0 (417)
    Proceeds from sale of discontinued operations 0 0 4,734
    Acquisitions, net (217,978) (5,219) (15,009)
    Net cash used in investing activities (270,998) (56,576) (58,862)
    Cash flows from financing activities:      
    Principal payments of term loans (741,786) (87,500) (111,500)
    Proceeds from issuance of term loans 818,250 0 0
    Proceeds from revolving credit facility 82,300 185,000 34,000
    Payments of revolving credit facility (63,000) (185,000) (39,000)
    Proceeds from the exercise of stock options 743 3,263 3,242
    Payment of debt issuance costs (8,139) (515) (1,385)
    Tax withholdings related to net share settlements of restricted stock awards (4,592) (3,820) (3,283)
    Contingent consideration payments (1,621) 0 0
    Principal payments on finance leases (169) (6) 0
    Net cash provided by (used in) financing activities 81,986 (88,578) (117,926)
    Effect of foreign currency exchange rates on cash and cash equivalents 1,025 (516) (604)
    Net increase (decrease) in cash and cash equivalents (31,321) 35,671 (12,034)
    Cash and cash equivalents, beginning of year 49,206 13,535 25,569
    Cash and cash equivalents, end of year $ 17,885 $ 49,206 $ 13,535
    XML 21 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statement of Stockholders' Equity - USD ($)
    $ in Thousands
    Total
    Common stock and additional paid-in capital
    Treasury stock
    Retained earnings
    Retained earnings
    Cumulative Effect, Period of Adoption, Adjustment
    Accumulated other comprehensive income
    Total stockholders’ equity, beginning balance at Dec. 28, 2018 $ 1,060,493 $ 691,116 $ (8,125) $ 344,498 $ (576) $ 33,004
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Stock awards exercised or vested   641        
    Stock-based compensation   9,294        
    Treasury shares purchased     (2,961)      
    Treasury shares reissued     2,277      
    Net income 96,336     96,336    
    Other comprehensive income (loss) (13,016)         (13,016)
    Total stockholders’ equity, ending balance at Dec. 31, 2019 1,152,488 701,051 (8,809) 440,258   19,988
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Stock awards exercised or vested   (9,367)        
    Stock-based compensation   9,163        
    Treasury shares reissued     8,809      
    Net income 77,258     77,258    
    Other comprehensive income (loss) 32,704         32,704
    Total stockholders’ equity, ending balance at Dec. 31, 2020 1,271,055 700,847 0 517,516   52,692
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Stock awards exercised or vested   (3,849)        
    Stock-based compensation   16,185        
    Net income 96,808     96,808    
    Other comprehensive income (loss) (25,502)         (25,502)
    Total stockholders’ equity, ending balance at Dec. 31, 2021 $ 1,354,697 $ 713,183 $ 0 $ 614,324   $ 27,190
    XML 22 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Summary of Significant Accounting Policies
    		 12 Months Ended
    Dec. 31, 2021
    Accounting Policies [Abstract]  
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition to medical technologies, the Company develops batteries for high-end niche applications in the energy, military, and environmental markets. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries.
    Basis of Presentation and Principles of Consolidation
    The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of Integer Holdings Corporation and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
    In July 2018, the Company completed the sale of its Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC). For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&O Product Line. The Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s (parent) centralized treasury and cash management processes. See Note 20 “Discontinued Operations” for the financial results and cash flow amounts for discontinued operations. All results and information in the consolidated financial statements are presented as continuing operations and exclude the AS&O Product Line unless otherwise noted specifically as discontinued operations.
    The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. The discontinued operations of the AS&O Product Line were reported in the Medical segment. Refer to Note 18 “Segment and Geographic Information,” for additional information on the Company’s reportable segments.
    Use of Estimates
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting periods. Actual results could differ materially from those estimates.
    Risks and Uncertainties
    Beginning in early March 2020, the global spread of the novel coronavirus (“COVID-19”) created significant uncertainty and worldwide economic disruption. Specific impacts to the Company’s business included and continue to include labor shortages, disruptions in the supply chain, delayed or reduced customer orders and sales, restrictions on associates’ ability to travel or work, and delays in shipments to and from certain countries. The extent to which COVID-19 will continue to impact the Company’s operations depends on future developments, which remain highly uncertain and difficult to predict, including, among others, the duration of the outbreak, the effectiveness and utilization of vaccines for COVID-19 and its variants, new information that may emerge concerning the severity of COVID-19 and the actions, especially those taken by governmental authorities to contain the pandemic or treat its impact. As pandemic-related events continue to evolve, additional impacts may arise that the Company is not aware of currently. Any prolonged material disruption of the Company’s labor force, suppliers, manufacturing, or customers could materially impact its consolidated financial position, results of operations or cash flows.
    Cash and Cash Equivalents
    Cash and cash equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three months or less.
    (1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
    Concentration of Credit Risk
    Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and accounts receivable are to three customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 19 “Revenue from Contracts with Customers” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks.
    Trade Accounts Receivable and Provision for Current Expected Credit Losses
    The Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains a provision for those customer receivables that it does not expect to collect. In accordance with Accounting Standards Codification (“ASC”) Topic 326, the Company accrues its estimated losses from uncollectable accounts receivable to the provision based upon recent historical experience, the length of time the receivable has been outstanding, other specific information as it becomes available, and reasonable and supportable forecasts not already reflected in the historical loss information. Provisions for current expected credit losses are charged to current operating expenses. Actual losses are charged against the provision when incurred. In 2020, the Company wrote-off $2.3 million of outstanding receivables that were previously reserved for as of December 31, 2019, in connection with a customer bankruptcy in the fourth quarter of 2019.
    Supplier Financing Arrangements
    The Company utilizes supplier financing arrangements with financial institutions to sell certain accounts receivable on a non-recourse basis. These transactions are treated as a sale of, and are accounted for as a reduction to, accounts receivable. The agreements transfer control and risk related to the receivables to the financial institutions. The Company has no continuing involvement in the transferred receivables subsequent to the sale. During the years ended December 31, 2021 and December 31, 2020, the Company sold and de-recognized accounts receivable and collected cash of $116.1 million and $73.3 million, respectively. The costs associated with the supplier financing arrangements were not material for the years ended December 31, 2021 and December 31, 2020.
    Inventories
    Inventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held, historical sales volume, and estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4 “Inventories” contains additional information on the Company’s inventory. In connection with a customer bankruptcy in the fourth quarter of 2019, the Company wrote-down inventory by $19.0 million.
    Leases
    The Company determines if an arrangement is, or contains, a lease at inception and classifies it at as finance or operating.  The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Finance lease assets and corresponding liabilities are included in Other long-term assets, Accrued expenses and other current liabilities, and Other long-term liabilities, respectively, on the Consolidated Balance Sheets.
    Lease right-of-use (“ROU”) assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term at commencement date. When discount rates implicit in leases cannot be readily determined, the Company uses its incremental borrowing rate based on information available at commencement date in determining the present value of future payments.  The incremental borrowing rate is determined based on the Company’s recent debt issuances, the Company’s specific credit rating, lease term and the currency in which lease payments are made.
    (1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
    Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such option. Costs associated with operating leases are recognized within operating expenses on a straight-line basis over the lease term. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. The interest component of a finance lease is included in Interest expense and recognized using the effective interest method over the lease term. The Company combines lease and non-lease components for all asset classes. For certain leases where rent escalates based upon a change in a financial index, such as the Consumer Price Index, the difference between the rate at lease inception and the subsequent fluctuations in that rate are included in variable lease costs.  Additionally, because the Company does not separate lease and non-lease components, variable costs also include payments to the landlord for common area maintenance, real estate taxes, insurance and other operating expenses.  The Company does not apply the recognition requirements to leases with lease terms of 12 months or less. Note 14 “Leases” contains additional information on the Company’s leases.
    Property, Plant and Equipment (“PP&E”)
    PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 12-30 years; machinery and equipment 3-10 years; office equipment 3-10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, whichever is shorter. The costs of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. The Company also reviews its PP&E for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its fixed assets exceeds the related undiscounted future cash flows. In cases where the carrying value of the Company's long-lived assets or asset groups (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. Note 5 “Property, Plant and Equipment, Net” contains additional information on the Company’s PP&E.
    Fair Value Measurements
    Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. the “exit price”) in an orderly transaction between market participants at the measurement date. ASC 820, Fair Value Measurements, establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows:
    Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment.
    Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market.
    Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations.
    Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements.
    Acquisitions
    The Company accounts for acquisitions under the acquisition method of accounting for business combinations. Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill.
    (1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
    All direct acquisition-related costs are expensed as incurred and are recognized as a component of Other operating expenses. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.
    Contingent Consideration
    In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable performance target. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect.
    The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The Company determines the initial fair value of contingent consideration liabilities using a Monte Carlo (“Monte Carlo”) valuation model, which involves a simulation of future revenues during the earn out-period using management’s best estimates, or a probability-weighted discounted cash flow analysis.
    In periods subsequent to the initial measurement, contingent consideration liabilities are remeasured to fair value each reporting period until the contingent consideration is settled using various assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, revenue volatility and projected payment dates. The current portion of contingent consideration liabilities is included in Accrued expenses and other current liabilities and the non-current portion is included in Other long-term liabilities on the Consolidated Balance Sheets. Adjustments to the fair value of contingent consideration liabilities are included in Other operating expenses in the Consolidated Statements of Operations, and cash flows from operating activities in the Consolidated Statements of Cash Flows. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on contingent consideration recorded at fair value in the consolidated financial statements.
    Goodwill
    Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired and is assigned to one or more reporting units. The Company’s reporting units are the same as its reportable segments, Medical and Non-Medical. The Company tests each reporting unit’s goodwill for impairment at least annually as of the last day of the fiscal year and between annual tests if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of a reporting unit below its carrying amount. In conducting its goodwill test, the Company either performs a qualitative assessment or a quantitative assessment. A qualitative assessment requires that the Company consider events or circumstances including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, changes in strategy, changes in customers, changes in the Company’s stock price, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair values of its reporting units are greater than the carrying amounts, then the quantitative goodwill impairment test is not performed. The Company may elect to bypass the qualitative analysis and perform a quantitative analysis.
    If the qualitative assessment indicates that the quantitative analysis should be performed or if management elects to bypass a qualitative analysis to perform a quantitative analysis, the Company then evaluates goodwill for impairment by comparing the fair value of each of its reporting units to its carrying value, including the associated goodwill. To determine the fair values, the Company uses a weighted combination of the market approach based on comparable publicly traded companies and the income approach based on estimated discounted future cash flows. The cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors.
    (1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
    The Company completed its annual goodwill impairment test as of December 31, 2021 and determined, after performing a qualitative review of its Medical reporting unit, that it is more likely than not that the fair value of the Medical reporting unit exceeds its carrying amount. Accordingly, there was no indication of impairment and the quantitative goodwill impairment test was not performed for the Medical reporting unit. The Company bypassed the qualitative analysis for its Non-Medical reporting unit and performed a quantitative analysis. The fair value of the Non-Medical reporting unit exceeded its carrying amount as of December 31, 2021.
    Other Intangible Assets
    Other intangible assets consist of purchased technology and patents, customer lists and trademarks. Definite-lived intangible assets are amortized on an accelerated or straight-line basis, which approximates the projected cash flows used to determine the fair value of those definite-lived intangible assets at the time of acquisition, as follows: purchased technology and patents 5-20 years; customer lists 7-20 years and other intangible assets 1-20 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized. The Company expenses the costs incurred to renew or extend the term of intangible assets.
    The Company reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets or asset groups exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted future cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis.
    The Company assesses its indefinite-lived intangible assets for impairment periodically to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment at least annually by comparing the fair value of the indefinite-lived intangible asset to its carrying value. The fair value is determined using the relief from royalty method.
    Refer to Note 6 “Goodwill and Other Intangible Assets, Net” for further details of the Company’s goodwill and other intangible assets.
    Equity Investments
    The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other long-term assets on the Consolidated Balance Sheets. Equity investments are measured and recorded as follows:
    •Non-marketable equity securities are equity securities without readily determinable fair value that are measured and recorded at fair value with changes in fair value recognized within net income. The Company measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. If an impairment is recognized on the Company’s non-marketable equity securities during the period, these assets are classified as Level 3 within the fair value hierarchy based on the nature of the fair value inputs.
    •Equity method investments are equity securities in investees the Company does not control but over which it has the ability to exercise influence. Equity method investments are recorded at cost and are adjusted to recognize (1) the Company’s share, based on percentage ownership or other contractual basis, of the investee’s income or loss, (2) additional contributions made and dividends or other distributions received, and (3) impairments resulting from other-than-temporary declines in fair value.
    Realized and unrealized gains and losses resulting from changes in fair value or the sale of these equity investments are recorded through (Gain) loss on equity investments, net. For some investments, the Company records its share of the investee’s income or loss one quarter in arrears due to the timing of our receipt of such information. The carrying value of the Company’s non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities by the same issuer. Determining whether an observed transaction is similar to a security within the Company’s portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of the Company’s equity securities as a result of observable price changes requires quantitative assessments of the fair value of these securities using various valuation methodologies and involves the use of estimates.
    (1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
    Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. The Company’s quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee’s fair value. Qualitative factors considered include the investee’s financial condition and business outlook, market for technology, operational and financing cash flow activities, technology and regulatory approval progress, and other relevant events and factors affecting the investee. When indicators of impairment exist, quantitative assessments of the fair value of the Company’s non-marketable equity investments are prepared.
    To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security’s fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and the Company’s ability and intent to hold the investment for a sufficient period of time to allow for recovery.
    The Company has determined that its investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant. Refer to Note 17 “Financial Instruments and Fair Value Measurements” for additional information on the Company’s equity investments.
    Debt Issuance Costs and Discounts
    Debt issuance costs and discounts associated with the issuance of debt by the Company are deferred and amortized over the lives of the related debt. Debt issuance costs incurred in connection with the Company’s issuance of its revolving credit facility are classified within Other long-term assets and amortized to Interest expense on a straight-line basis over the contractual term of the revolving credit facility. Debt issuance costs and discounts related to the Company’s term-debt are recorded as a reduction of the carrying value of the related debt and are amortized to Interest expense using the effective interest method over the period from the date of issuance to the maturity date. Upon prepayment of the related debt, the Company also recognizes a proportionate amount of the costs as extinguishment of debt. Costs treated as extinguishment of debt are expensed and included in Interest expense in the accompanying Consolidated Statements of Operations. The amortization of debt issuance costs and discounts, and debt extinguishment charges are included in Debt related charges included in interest expense in the Consolidated Statements of Cash Flows. Note 8 “Debt” contains additional information on the Company’s debt issuance costs and discounts.
    Income Taxes
    The consolidated financial statements of the Company have been prepared using the asset and liability approach to account for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined, within each taxing jurisdiction, that it is more likely than not that the asset will not be realized.
    The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision for income taxes. Penalties, if incurred, are recognized as a component of Selling, general and administrative (“SG&A”) expenses.
    The Company and its subsidiaries file a consolidated United States (“U.S.”) federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where the tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates.
    (1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
    Derivative Financial Instruments
    The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. The Company’s use of derivative instruments is generally limited to cash flow hedges of certain interest rate risks and minimizing foreign currency exposure on foreign currency transactions, which are typically designated in hedging relationships, and intercompany balances, which are not designated as hedging instruments. Under master agreements with the respective counterparties to our derivative contracts, subject to applicable requirements, we have the right of set-off and are allowed to net settle transactions of the same type with a single net amount payable by one party to the other. Gains and losses on cash flow hedges are recorded in Accumulated Other Comprehensive Income in the Consolidated Balance Sheets until the underlying transaction is recorded in earnings. When the hedged item is realized, gains or losses are reclassified from Accumulated Other Comprehensive Income (“AOCI”) to the Consolidated Statement of Operations on the same line item as the underlying transaction. In the event the forecasted transactions do not occur, or it becomes probable that they will not occur, the Company reclassifies any gain or loss on the related cash flow hedge to earnings in the respective period. Cash flows related to these derivative financial instruments are included in cash flows from operating activities. Foreign currency contracts not designated as hedging relationships are recorded at fair value in Accrued expenses and other current liabilities in the Consolidated Balance Sheets and resulting gains or losses are recorded in the Consolidated Statement of Operations.
    Revenue Recognition
    The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The majority of contracts have an original expected duration of one year or less. Consideration payable to customers is included in the transaction price. In accordance with ASC 340-40-25-4, the Company expenses incremental costs of obtaining a contract when incurred because the amortization period is less than one year.
    The Company evaluates revenue recognition in contracts with customers as performance obligations are satisfied and as the customer obtains control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits of the products. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Most of the Company’s revenues are recognized at the point in time when the products are shipped to customers. When contracts with customers for products, which do not have an alternative use to the Company, contain provisions that provide the Company with an enforceable right to payment for performance completed to date for costs incurred plus a reasonable profit throughout the duration of the contract, revenue is recognized over time as control is transferred to the customer. In contracts with customers where revenue is recognized over time, the Company uses an input measure to determine progress towards completion and total estimated costs at completion. Under this method, sales and gross profit are recognized as work is performed generally based on actual costs incurred. Revenue is recognized net of sales tax, value-added taxes and other taxes.
    Performance Obligations
    The Company considers each shipment of an individual product included on a purchase order to be a separate performance obligation, as each shipment is separately identifiable and the customer can benefit from each individual product separately from the other products included on the purchase order. Accordingly, a contract can have one or more performance obligations to manufacture products. Standard payment terms range from 30 to 90 days and may include a discount for early payment.
    The Company does not offer its customers a right of return. Rather, the Company warrants that each unit received by the customer will meet the agreed upon technical and quality specifications and requirements. Only when the delivered units do not meet these requirements can the customer return the non-compliant units as a corrective action under the warranty. The remedy offered to the customer is repair of the returned units or replacement if repair is not viable. Accordingly, the Company records a warranty reserve and any warranty activities are not considered to be a separate performance obligation.
    (1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
    Contract Balances
    The timing of revenue recognition, billings and cash collections results in billed accounts receivable and less frequently, unearned revenue. Accounts receivable are recorded when the right to consideration becomes unconditional. Unearned revenue is recorded when customers pay or are billed in advance of the Company’s satisfaction of performance obligations. Contract liabilities are classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. For contracts with customers where revenue is recognized over time, the Company records a contract asset for unbilled revenue associated with non-cancellable customer orders, which is recorded within Contract assets on the Consolidated Balance Sheets.
    Transaction Price
    Generally, the transaction price of the Company’s contracts consists of a unit price for each individual product included in the contract, which can be fixed or variable based on the number of units ordered. In some instances, the transaction price also includes a rebate for meeting certain volume-based targets over a specified period of time. The transaction price of a contract is determined based on the unit price and the number of units ordered, reduced by the rebate expected to be earned on those units. Rebates are estimated based on the expected achievement of the volume-based target using the most likely amount method and are updated quarterly. Adjustments to these estimates are recognized under the cumulative catch-up method and in the period in which they are identified. When contracts with customers include consideration payable at the beginning of the contract, the transaction price is reduced at the later of when the Company recognizes revenue for the transfer of the related goods to the customer or when the Company pays or promises to pay the consideration. Volume discounts and rebates and other pricing reductions earned by customers are offset against their receivable balances.
    The transaction price is allocated to each performance obligation on a relative standalone selling price basis. As the majority of products sold to customers are manufactured to meet the specific requirements and technical specifications of that customer, the products are considered unique to that customer and the unit price stated in the contract is considered the standalone selling price.
    Contract Modifications
    Contract modifications, which can include a change in scope, price, or both, most often occur related to contracts that are governed by a long-term arrangement. Contract modifications typically relate to the same products already governed by the long-term arrangement, and therefore, are accounted for as part of the existing contract. If a contract modification is for additional products, it is accounted for as a separate contract.
    Environmental Costs
    Environmental expenditures that relate to an existing condition caused by past operations and that do not provide future benefits are expensed as incurred. Liabilities are recorded when environmental assessments are made, the requirement for remedial efforts is probable and the amount of the liability can be reasonably estimated. Liabilities are recorded generally no later than the completion of feasibility studies. The Company has a process in place to monitor, identify, and assess how the current activities for known exposures are progressing against the recorded liabilities. The process is also designed to identify other potential remediation sites that are not presently known.
    Restructuring Expenses
    The Company continually evaluates alternatives to align its resources with the changing needs of its customers and markets, and to lower its operating costs. This includes realignment of existing manufacturing capacity, facility closures, process optimization, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in voluntary or involuntary employee termination benefits. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. All other exit costs are expensed as incurred. Refer to Note 11 “Other Operating Expenses” for additional information.
    Research, Development and Engineering (“RD&E”)
    RD&E costs are expensed as incurred. The primary costs are salary and benefits for personnel, material costs used in development projects and subcontracting costs.
    (1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
    Product Warranties
    The Company allows customers to return defective or damaged products for credit, replacement, or repair. The Company warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The Company accrues its estimated exposure to warranty claims, through Cost of Sales, based upon experience and other specific information as it becomes available. The product warranty liability is classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. Adjustments to pre-existing estimated exposure for warranties are made as changes to the obligations become reasonably estimable. Note 13 “Commitments and Contingencies” contains additional information on the Company’s product warranties.
    Stock-Based Compensation
    The Company recognizes stock-based compensation expense for its compensation plans. These plans include stock options, restricted stock units (“RSUs”) and performance-based restricted stock units (“PRSUs”). For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares to be earned depends on the achievement of targets based on market conditions, such as total shareholder return, or performance conditions based on the Company’s operating results. The Company records forfeitures of equity awards in the period in which they occur.
    The fair value of the stock-based compensation is determined at the grant date. The Company uses the Black-Scholes standard option pricing model (“Black-Scholes model”) to determine the fair value of stock options. The fair value of each RSU is determined based on the Company’s closing stock price on the date of grant. The fair value of each PRSU is determined based on either the Company’s closing stock price on the date of grant or through a Monte Carlo valuation model for those awards that include a market-based condition. In addition to the closing stock price on the date of grant, the determination of the fair value of awards using both the Black-Scholes and Monte Carlo valuation models is affected by other assumptions, including the following:
    Expected Term - The Company analyzes historical employee exercise and termination data to estimate the expected term assumption for stock options. For market-based awards, the term is commensurate with the performance period remaining as of the grant date.
    Risk-free Interest Rate - A risk-free rate is based on the U.S. Treasury rates in effect on the grant date for a maturity equal to or approximating the expected term of the award.
    Expected Volatility - For stock options, expected volatility is calculated using historical volatility based on the daily closing prices of the Company’s common stock over a period equal to the expected term. For market-based awards, a combination of historical and implied volatility for the Company and members of its peer group are used in developing the expected volatility assumption.
    Dividend Yield - The dividend yield assumption is based on the Company’s expected annual dividend yield on the grant date.
    The Company recognizes compensation expense over the required service or vesting period based on the fair value of the award on the date of grant. Certain executive stock-based awards contain market, performance and service conditions. Compensation expense for awards with market conditions is recognized over the service period and is not reversed if the market condition is not met. Compensation expense for awards with performance conditions is reassessed each reporting period and recognized based upon the probability that the performance targets will be achieved.
    All stock option awards granted under the Company’s compensation plans have an exercise price equal to the closing stock price on the date of grant, a ten-year contractual life and generally, vest annually over a three-year vesting term. RSUs typically vest in equal annual installments over a three or four year period. RSUs issued to members of the Company’s Board of Directors as a portion of their annual retainer vest quarterly over a one-year vesting term. Earned PRSUs typically vest three years from the date of grant.
    The Company records deferred tax assets for awards that result in deductions on the Company’s income tax returns, based on the amount of stock-based compensation expense recognized and the statutory tax rate in the jurisdiction in which it will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported on the income tax return are recorded as a component of Provision for income taxes in the Consolidated Statements of Operations. Note 10 “Stock-Based Compensation” contains additional information on the Company’s stock-based compensation.
    (1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
    Defined Benefit Plans
    The Company recognizes in its balance sheet as an asset or liability the overfunded or underfunded status of its defined benefit plans provided to its employees located in Mexico and Switzerland. This asset or liability is measured as the difference between the fair value of plan assets, if any, and the benefit obligation of those plans. For these plans, the benefit obligation is the projected benefit obligation, which is calculated based on actuarial computations of current and future benefits for employees. Actuarial gains or losses and prior service costs or credits that arise during the period, but are not included as components of net periodic benefit expense, are recognized as a component of AOCI on the Consolidated Balance Sheets. The Company records the service cost component of net benefit costs in Cost of sales and SG&A expenses. The interest cost component of net benefit costs is recorded in Interest expense and the remaining components of net benefit costs, amortization of net losses and expected return on plan assets, are recorded in Other (income) loss, net.
    Foreign Currency Translation and Remeasurement
    The Company translates all assets and liabilities of its foreign subsidiaries, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translates income and expenses at the average exchange rates in effect during the period. The net effect of this translation is recorded in the consolidated financial statements as a component of AOCI. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in the Company’s foreign subsidiaries.
    The Company has foreign operations in the Dominican Republic, Germany, Ireland, Israel, Malaysia, Mexico, Switzerland, and Uruguay, which expose the Company to foreign currency exchange rate fluctuations due to transactions denominated in Dominican pesos, Euros, Israeli shekels, Malaysian ringgits, Mexican pesos, Swiss francs, and Uruguayan pesos. To the extent that monetary assets and liabilities, including short-term and long-term intercompany loans, are recorded in a currency other than the functional currency of the subsidiary, these amounts are remeasured each period at the period-end exchange rate, with the resulting gain or loss being recorded in Other (income) loss, net in the Consolidated Statements of Operations. Net foreign currency transaction (gains) losses included in Other (income) loss, net amounted to ($0.1 million), $1.6 million and $0.1 million for fiscal years 2021, 2020 and 2019, respectively, and primarily related to the fluctuation of the U.S. dollar relative to the Euro and the remeasurement of certain intercompany loans.
    Earnings Per Share (“EPS”)
    Basic EPS is calculated by dividing Net Income by the weighted average number of shares outstanding during the period. Diluted EPS is calculated by adjusting the weighted average number of shares outstanding for potential common shares if dilutive to the EPS calculation. Note 15 “Earnings Per Share” contains additional information on the computation of the Company’s EPS.
    Comprehensive Income
    The Company’s comprehensive income as reported in the Consolidated Statements of Comprehensive Income includes net income, foreign currency translation adjustments, the net change in cash flow hedges, net of tax, and defined benefit plan liability adjustments, net of tax. The Consolidated Statements of Comprehensive Income and Note 16 “Stockholders’ Equity” contain additional information on the computation of the Company’s comprehensive income.
    Recent Accounting Pronouncements
    In the normal course of business, management evaluates all new Accounting Standards Updates (“ASU”) and other accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements.
    Accounting Guidance Not Yet Elected or Adopted
    In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company will early adopt ASU 2021-08 as of January 1, 2022 on a prospective basis. The impact of the adoption of ASU 2021-08 cannot currently be determined, as it is dependent on future business combinations that the Company may enter into.
    XML 23 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Business Acquisition
    		 12 Months Ended
    Dec. 31, 2021
    Business Combination and Asset Acquisition [Abstract]  
    BUSINESS ACQUISITIONS BUSINESS ACQUISITIONS
    2021 Acquisition
    On December 1, 2021, the Company acquired 100% of the equity interests of Oscor Inc., Oscor Caribe, LLC and Oscor Europe GmbH (collectively “Oscor”), privately-held companies with operations in Florida, the Dominican Republic and Germany that design, develop, manufacture and market a comprehensive portfolio of highly specialized medical devices, venous access systems and diagnostic catheters and implantable devices for a cash purchase price of $220.4 million, of which $2.6 million is net cash acquired subject to payment in connection with working capital and other closing adjustments. Serving the Company’s current markets, Oscor broadens the Company’s product portfolio, expands its research and development capabilities, and adds low-cost manufacturing capacity. The Company used proceeds from its Senior Secured Credit Facilities to fund the acquisition. See Note 8 “Debt” for additional information. Oscor is included in the Company’s Medical segment.
    The Oscor acquisition was structured as a stock purchase, however the parties agreed to coordinate the election of Section 338(h)(10) of the Internal Revenue Code relative to this transaction for tax purposes. Therefore, the excess purchase price over the fair value of net assets acquired was recorded as goodwill, which will be amortized over 15 years for income tax filing purposes.
    The Company has provisionally estimated fair values for the assets purchased, liabilities assumed and purchase consideration as of the date of the acquisition. The determination of estimated fair value required management to make significant estimates and assumptions based on information that was available at the time the consolidated financial statements were prepared. The amounts reported are considered provisional as the Company is completing the valuations that are required to allocate the purchase price in areas such as property and equipment, intangible assets, lease-related assets and liabilities, deferred taxes and goodwill. As a result, the allocation of the provisional purchase price may change in the future, which could be material.
    The preliminary purchase price allocation was as follows (in thousands):
    Fair value of net assets acquired
    Current assets (excluding inventory)$12,148 
    Inventory12,212 
    Property, plant and equipment17,977 
    Goodwill77,887 
    Intangible assets105,300 
    Operating lease assets15,142 
    Other noncurrent assets695 
    Current liabilities(8,875)
    Operating lease liabilities(12,044)
    Fair value of net assets acquired$220,442 
    The preliminary fair values of the assets acquired were determined using one of three valuation approaches: market, income or cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations.
    The market approach estimates the value for a subject asset based on available market pricing for comparable assets. The income approach estimates the value for a subject asset based on the present value of cash flows projected to be generated by the asset. The projected cash flows were discounted at a required rate of return that reflects the relative risk of the asset and the time value of money. The projected cash flows for each asset considered multiple factors from the perspective of a marketplace participant including revenue projections from existing customers, attrition trends, technology life-cycle assumptions, marginal tax rates and expected profit margins giving consideration to historical and expected margins. The cost approach estimates the value for a subject asset based on the cost to replace the asset and reflects the estimated reproduction or replacement cost for the asset, less an allowance for loss in value due to depreciation or obsolescence, with specific consideration given to economic obsolescence if indicated. These fair value measurement approaches are based on significant unobservable inputs, including management estimates and assumptions.
    (2.)    BUSINESS ACQUISITIONS (Continued)
    Current Assets and Liabilities
    The fair value of current assets and liabilities, excluding inventory, was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities.
    The fair value of in-process and finished goods inventory acquired was estimated by applying a version of the income approach called the comparable sales method. This approach estimates the fair value of the assets by calculating the potential revenue generated from selling the inventory and subtracting from it the costs related to the completion and sale of that inventory and a reasonable profit allowance for these remaining efforts. Based upon this methodology, the Company recorded the inventory acquired at fair value resulting in an increase in inventory of $1.0 million.
    Property, Plant and Equipment
    The fair value of PP&E acquired was estimated by applying the cost approach for personal property and leasehold improvements. The cost approach was applied by developing a replacement cost and adjusting for economic depreciation and obsolescence.
    Leases
    The Company recognized operating lease liabilities and operating lease right-of-use assets for office and manufacturing facilities in the U.S., Dominican Republic, and Germany in accordance with ASC 842, Leases. Additionally, the Company recorded favorable lease terms associated with the operating leases in the U.S. of $3.1 million. The favorable lease terms were recorded as an increase to the ROU lease asset.
    Goodwill
    The excess of the purchase price over the fair value of net tangible and intangible assets acquired and liabilities assumed was allocated to goodwill. Various factors contributed to the establishment of goodwill, including the value of Oscors’s highly trained assembled work force and management team, the incremental value resulting from Oscor’s industry leading capabilities and services to OEMs, enhanced synergies, and the expected revenue growth over time that is attributable to increased market penetration from future products and customers. The goodwill acquired in connection with the acquisition was allocated to the Medical segment and is deductible for tax purposes.
    Intangible Assets
    The purchase price was allocated to intangible assets as follows (dollars in thousands):
    Definite-lived Intangible AssetsFair Value AssignedWeighted Average Amortization Period
    (Years)    		Weighted Average Discount Rate
    Customer lists$73,800 20.09.5%
    Technology15,200 15.09.5%
    Tradenames16,300 20.09.5%

    Customer Lists - Customer lists represent the estimated fair value of contractual and non-contractual customer relationships Oscor had as of the acquisition date. The primary customers of Oscor include large original equipment manufacturers in various geographic locations around the world. These relationships were valued separately from goodwill at the amount that an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The estimated useful life of the existing customer base was based upon the historical customer annual attrition rate of 5%, as well as management’s understanding of the industry and product life cycles.
    Technology - Technology consists of technical processes, patented and unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by Oscor and that will be leveraged in current and future products. The fair value of technology acquired was determined utilizing the relief from royalty method, a form of the income approach, with a royalty rate that ranged from 4.0% to 4.5%. The estimated useful life of the technology is based upon management’s estimate of the product life cycle associated with the technology before they will be replaced by new technologies.
    (2.)    BUSINESS ACQUISITIONS (Continued)
    Tradenames - Tradenames represents the estimated fair value of Oscor’s corporate and product names. The acquired tradenames were valued separately from goodwill at the amount that an independent third party would be willing to pay for use of these names. The fair value of the tradenames was determined by utilizing the relief from royalty method, a form of the income approach, with a royalty rate of 2.0%. Tradenames were assumed to have a definite useful life based upon long-term management expectations and future operating plans.
    2020 Acquisition
    On February 19, 2020, the Company acquired certain assets and liabilities of InoMec Ltd. (“InoMec”), a privately-held company based in Israel that specializes in the research, development and manufacturing of medical devices, including minimally invasive tools, delivery systems, tubing and catheters, surgery tools, drug-device combination, laser combined devices, and tooling and production. The acquisition enabled the Company to create a research and development center in Israel, closer to the customer base in the region. The fair value of the consideration transferred was $7.0 million, which included an initial cash payment of $5.3 million and $1.7 million in estimated fair value of contingent consideration. The contingent consideration represented the estimated fair value of the Company’s obligation, under the asset purchase agreement, to make additional payments of up to $3.5 million if specified conditions are met through February 2024. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration.
    Based on the final purchase price allocation, the assets acquired principally comprise $2.0 million of intangible assets, $4.8 million of goodwill, $0.3 million of acquired property, plant and equipment, and a net liability for other working capital items of $0.1 million. Intangible assets included developed technology, customer relationships and non-compete provisions, which are being amortized over a weighted average period of 5.9 years. Goodwill for the InoMec acquisition is deductible for income tax purposes.
    2019 Acquisition
    On October 7, 2019, the Company acquired certain assets and liabilities of US BioDesign, LLC (“USB”), a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The acquisition added a differentiated capability related to the complex development and manufacture of braided and formed biomedical structures to the Company’s broad portfolio. The fair value of the consideration transferred was $19.1 million, which included a cash payment of $14.9 million and $4.2 million in estimated fair value of contingent consideration. The contingent consideration represents the estimated fair value of the Company’s obligation, under the asset purchase agreement, to make additional payments of up to $5.5 million if certain revenue goals are met through 2023. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration.
    Based on the final purchase price allocation, the assets acquired principally consist of $7.4 million of developed technology, $10.4 million of goodwill, $0.7 million of acquired property, plant and equipment, and $0.6 million of other working capital items. The $10.4 million of goodwill reflects a $0.1 million decrease resulting from a favorable working capital adjustment recorded in 2020. The technology intangible asset is being amortized over a useful life of 8 years. Goodwill for the USB acquisition is deductible for income tax purposes.
    Actual and Pro Forma (unaudited) disclosures
    For segment reporting purposes, the results of operations and assets from the Oscor, InoMec and USB acquisitions have been included in the Company’s Medical segment since the respective acquisition dates. For the year ended December 31, 2021, sales related to Oscor, InoMec and USB were $4.7 million, $3.5 million and $4.8 million, respectively. For the year ended December 31, 2020, sales related to InoMec and USB were $3.4 million and $4.5 million, respectively. For the year ended December 31, 2019, sales related to USB were $0.8 million. Earnings related to the operations of Oscor, InoMec and USB for the fiscal years 2021, 2020 and 2019 were not material. Pro forma financial information has not been presented for the InoMec and USB acquisitions as the net effects were not significant or material to the Company’s results of operations or financial position.
    (2.)    BUSINESS ACQUISITIONS (Continued)
    The following unaudited pro forma information presents the consolidated results of operations of the Company and Oscor as if the acquisition occurred as of the beginning of fiscal year 2020 (in thousands):
     20212020
    Sales$1,274,148 $1,128,137 
    Income from continuing operations$91,844 $67,529 
    The unaudited pro forma results are presented for illustrative purposes only and do not reflect the realization of potential cost savings, and any related integration costs. Certain costs savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These unaudited pro forma results do not purport to be indicative of the results that would have been obtained, or to be a projection of results that may be obtained in the future. These unaudited pro forma results include certain adjustments, primarily due to increases in amortization expense due to the fair value adjustments of intangible assets, the increases to interest expense reflecting the amount borrowed in connection with the acquisition, acquisition related costs and the impact of income taxes on the pro forma adjustments.
    Acquisition costs
    During the fiscal years 2021, 2020 and 2019, direct costs of these acquisitions of $2.0 million, $0.9 million and $0.4 million, respectively, were expensed as incurred and included in Other Operating Expenses in the Consolidated Statements of Operations.
    XML 24 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Supplemental Cash Flow Information
    		 12 Months Ended
    Dec. 31, 2021
    Supplemental Cash Flow Elements [Abstract]  
    SUPPLEMENTAL CASH FLOW INFORMATION SUPPLEMENTAL CASH FLOW INFORMATION
    The following represents supplemental cash flow information for fiscal years 2021, 2020 and 2019 (in thousands):
     202120202019
    Non-cash investing and financing activities:
    Property, plant and equipment purchases included in accounts payable$5,556 $3,597 $8,646 
    Cash paid during the year for:
    Interest24,740 33,933 44,784 
    Income taxes19,649 18,477 30,034 
    XML 25 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Inventories
    		 12 Months Ended
    Dec. 31, 2021
    Inventory Disclosure [Abstract]  
    INVENTORIES INVENTORIES
    Inventories comprise the following (in thousands):
    December 31,
    2021    		December 31,
    2020
    Raw materials$70,956 $72,477 
    Work-in-process74,152 58,806 
    Finished goods10,591 18,040 
    Total$155,699 $149,323 
    XML 26 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Property, Plant and Equipment, Net
    		 12 Months Ended
    Dec. 31, 2021
    Property, Plant and Equipment [Abstract]  
    PROPERTY, PLANT AND EQUIPMENT, NET PROPERTY, PLANT AND EQUIPMENT, NET
    PP&E comprises the following (in thousands):
    December 31, 2021December 31,
    2020
    Manufacturing machinery and equipment$352,391 $320,807 
    Buildings and building improvements98,007 102,037 
    Information technology hardware and software72,752 69,969 
    Leasehold improvements85,931 77,382 
    Furniture and fixtures17,099 16,250 
    Land and land improvements13,980 11,598 
    Construction work in process41,813 26,389 
    Other1,431 1,238 
    683,404 625,670 
    Accumulated depreciation(406,305)(371,706)
    Total$277,099 $253,964 
    Depreciation expense for PP&E was as follows for fiscal years 2021, 2020 and 2019 (in thousands):
    202120202019
    Depreciation expense$39,772 $38,193 $37,819 
    XML 27 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Goodwill and Other Intangible Assets, Net
    		 12 Months Ended
    Dec. 31, 2021
    Goodwill and Intangible Assets Disclosure [Abstract]  
    GOODWILL AND OTHER INTANGIBLE ASSETS, NET GOODWILL AND OTHER INTANGIBLE ASSETS, NET
    Goodwill
    The change in the carrying amount of goodwill by reportable segment during fiscal years 2021 and 2020 was as follows (in thousands):
    MedicalNon-MedicalTotal
    December 31, 2019$822,617 $17,000 $839,617 
    Acquisition4,800 — 4,800 
    Acquisition-related adjustments (Note 2)(85)— (85)
    Foreign currency translation15,110 — 15,110 
    December 31, 2020842,442 17,000 859,442 
    Acquisition (Note 2)77,887 — 77,887 
    Foreign currency translation(12,625)— (12,625)
    December 31, 2021$907,704 $17,000 $924,704 
    As of December 31, 2021, no accumulated impairment loss has been recognized for the goodwill allocated to the Company’s Medical or Non-Medical segments.
    (6.)     GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Continued)
    Intangible Assets
    Intangible assets comprise the following (in thousands):
    Gross
    Carrying
    Amount    		Accumulated
    Amortization    		Net
    Carrying
    Amount
    December 31, 2021
    Definite-lived:
    Purchased technology, tradenames and patents$285,659 $(164,371)$121,288 
    Customer lists783,618 (187,412)596,206 
    Other4,162 (4,134)28 
    Total amortizing intangible assets$1,073,439 $(355,917)$717,522 
    Indefinite-lived:
    Trademarks and tradenames$90,288 
    December 31, 2020
    Definite-lived:
    Purchased technology and patents$257,453 $(152,798)$104,655 
    Customer lists723,791 (161,856)561,935 
    Other4,142 (3,796)346 
    Total amortizing intangible assets$985,386 $(318,450)$666,936 
    Indefinite-lived:
    Trademarks and tradenames$90,288 
    See Note 2 “Business Acquisitions” for additional details regarding intangible assets acquired during 2021 and 2020. Included in the Company’s indefinite-lived intangible assets are the Lake Region Medical and Greatbatch Medical tradenames with carrying values of $70.0 million and $20.3 million, respectively.
    When acquiring certain assets, the Company assesses whether the acquired assets are a result of a business combination or a purchase of an asset. During 2020, the Company acquired a set of similar identifiable intangible assets relating to a license to use technology within its Non-Medical segment. The Company purchased the technology for $4.5 million, which includes $1.0 million of contingent consideration paid during 2020 upon completion of certain milestones, and capitalized $0.1 million of costs associated with acquiring the license as an intangible asset. The intangible asset of $4.6 million is being amortized over 11 years, the remaining useful life of the patented technology.
    Aggregate intangible asset amortization expense comprises the following for fiscal years 2021, 2020 and 2019 (in thousands):
    202120202019
    Cost of sales$13,090 $12,860 $13,111 
    SG&A28,507 28,271 26,965 
    Total intangible asset amortization expense$41,597 $41,131 $40,076 
    Estimated future intangible asset amortization expense based upon the carrying value as of December 31, 2021 is as follows (in thousands):
    20222023202420252026After 2026
    Amortization expense$46,594 $48,490 $47,576 $45,946 $43,612 $485,304 
    XML 28 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Accrued Expenses and Other Current Liabilities
    		 12 Months Ended
    Dec. 31, 2021
    Accounts Payable and Accrued Liabilities [Abstract]  
    ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
    Accrued expenses and other current liabilities comprise the following (in thousands):
    December 31, 2021December 31,
    2020
    Salaries and benefits$27,733 $24,512 
    Profit sharing and bonuses18,325 19,204 
    Contract liabilities3,776 2,498 
    Product warranties509 163 
    Accrued interest76 1,644 
    Other6,514 8,822 
    Total$56,933 $56,843 
    XML 29 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt
    		 12 Months Ended
    Dec. 31, 2021
    Debt Disclosure [Abstract]  
    DEBT DEBT
    Long-term debt comprises the following (in thousands):
     December 31, 2021December 31,
    2020
    Senior secured term loan A $467,062 $229,687 
    Senior secured term loan B 349,125 508,286 
    Senior secured revolving credit facility19,300 — 
    Unamortized discount on term loan B and deferred debt issuance costs(7,361)(6,715)
    Total debt828,126 731,258 
    Current portion of long-term debt(15,250)(37,500)
    Total long-term debt$812,876 $693,758 
    Senior Secured Credit Facilities
    On September 2, 2021, the Company entered into a new credit agreement (the “2021 Credit Agreement”), which permits borrowings and other extensions of credit in an initial aggregate principal amount of up to $1 billion (as may be increased from time to time in accordance with the terms). The 2021 Credit Agreement governs the Company’s senior secured credit facilities (the “Senior Secured Credit Facilities”), which consist of a five-year $400 million revolving credit facility (the “Revolving Credit Facility”), a five-year $250 million “term A” loan (the “TLA Facility”) and a seven-year $350 million “term B” loan (the “TLB Facility” and, together with the TLA Facility, the “Term Loan Facilities”). The TLB Facility was issued at a 0.50% discount. The 2021 Credit Agreement also includes an alternative benchmark rate as a replacement to the London Interbank Offered Rate (“LIBOR”) in the event LIBOR is no longer available. In connection with closing of the Oscor acquisition, on December 1, 2021, the Company amended the 2021 Credit Agreement to provide for, among other things, the incurrence of an additional $220 million aggregate principal amount of term A loans. As of December 31, 2021, the weighted average interest rate on all outstanding borrowings is 2.04%.
    The obligations under the 2021 Credit Agreement are guaranteed by certain specified subsidiaries of the Company. Among other things, the 2021 Credit Agreement contains covenants that restrict the Company’s and certain of its subsidiaries’ ability to incur liens on certain assets, incur indebtedness, make material changes in corporate structure or materially alter the nature of its business, dispose of material assets, engage in mergers, consolidations and certain other fundamental changes, or engage in certain transactions with affiliates. The 2021 Credit Agreement contains customary default provisions, including, but not limited to, failure to pay interest or principal when due and failure to comply with covenants.
    (8.)     DEBT (Continued)
    Prior to September 2, 2021, the Company was party to an amended and restated credit agreement (the “2015 Credit Agreement”), dated as of October 27, 2015. The 2015 Credit Agreement provided for certain credit facilities to the Company in an aggregate principal amount not to initially exceed $1.6 billion. At the time of the refinancing on September 2, 2021, the 2015 Credit Agreement provided for a $200 million revolving credit facility with no outstanding borrowings, a term loan A facility and a term loan B facility with outstanding principal balances of $210.9 million and $462.3 million, respectively. The term loan B facility under the 2015 Credit Agreement was issued at a 1% discount. The 2015 Credit Agreement was terminated concurrently with entering into the 2021 Credit Agreement. Details of our Long-term debt as of December 31, 2020 can be found within our 2020 Form 10-K.
    Revolving Credit Facility
    The Revolving Credit Facility matures on September 2, 2026 and includes a $40 million sublimit for swingline loans and standby letters of credit. As of December 31, 2021, the Company had available borrowing capacity on the Revolving Credit Facility of $375.0 million after giving effect to $19.3 million of outstanding borrowings and $5.7 million of outstanding standby letters of credit.
    Interest rates on the Revolving Credit Facility are at the Company’s option, either at: (i) the applicable LIBOR (or an applicable benchmark replacement) plus the applicable margin, which will range between 1.25% and 2.25%, based on the Company’s Total Net Leverage Ratio (as defined in the 2021 Credit Agreement), or (ii) the Base Rate (as defined below) plus the applicable margin, which will range between 0.25% and 1.25%, based on the Company’s Total Net Leverage Ratio. The Base Rate is defined, for any day, as the per annum rate equal to the highest of (i) the prime rate (as defined in the 2021 Credit Agreement), (ii) the Federal Funds Rate, as published by the Federal Reserve Bank of New York, plus 0.50%, and (iii) one-month LIBOR plus 1.00%. As of December 31, 2021, the weighted average interest rate on outstanding borrowings under the Revolving Credit Facility was 1.35%.
    The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.15% and 0.25%, depending on the Company’s Total Net Leverage Ratio. As of December 31, 2021, the commitment fee on the unused portion of the Revolving Credit Facility was 0.15%.
    Term Loan Facilities
    The TLA Facility and TLB Facility mature on September 2, 2026 and September 2, 2028, respectively, and require quarterly principal installments. The quarterly principal installments under the TLA Facility increase over the term of the loan. The interest rate terms for the TLA Facility are the same as those outlined above for the Revolving Credit Facility. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the applicable LIBOR rate plus 2.50%, with LIBOR subject to a 0.50% floor, or (ii) the Base Rate plus 1.50%. As of December 31, 2021, the interest rates on the TLA Facility and TLB Facility were 1.35% and 3.00%, respectively.
    Covenants
    The 2021 Credit Agreement contains customary terms and conditions, including representations and warranties and affirmative and negative covenants, as well as financial covenants for the benefit of the lenders under the Revolving Credit Facility and the TLA Facility, which require that (i) the Company maintain a Total Net Leverage Ratio not to exceed 5.50:1.00 (stepping down to 5.00:1.00 for the third fiscal quarter of 2023 through maturity and subject to increase in certain circumstances following qualified acquisitions, but shall not exceed 5.50:1.00) and (ii) the Company maintain an interest coverage ratio of at least 2.50:1.00. The TLB Facility does not contain any financial maintenance covenants. As of December 31, 2021, the Company was in compliance with these financial covenants.
    Contractual maturities under the Senior Secured Credit Facilities for the next five years and thereafter, as of December 31, 2021, are as follows (in thousands):
    20222023202420252026After 2026
    Future minimum principal payments$15,250 $18,188 $29,938 $38,750 $401,739 $331,622 
    (8.)     DEBT (Continued)
    Deferred Debt Issuance Costs and Discounts
    The change in deferred debt issuance costs related to the Company’s Revolving Credit Facility is as follows (in thousands):
    December 31, 2020891 
    Financing costs incurred2,762 
    Write-off of deferred debt issuance costs(72)
    Amortization during the period(542)
    December 31, 2021$3,039 
    The change in unamortized discount and deferred debt issuance costs related to the Term Loan Facilities is as follows (in thousands):
    Deferred Debt Issuance CostsUnamortized Discount on TLB FacilityTotal
    December 31, 20205,258 1,457 6,715 
    Financing costs incurred5,236 1,750 6,986 
    Write-off of deferred debt issuance costs and unamortized discount(2,677)(954)(3,631)
    Amortization during the period(2,143)(566)(2,709)
    December 31, 2021$5,674 $1,687 $7,361 

    In connection with the 2021 Credit Agreement, the Company incurred and capitalized $8.8 million of issuance costs, including an original issue discount on the TLB Facility of $1.8 million. In connection with December 1, 2021 amendment to the TLA Facility, the Company incurred and capitalized $1.0 million of issuance costs. An aggregate of $7.0 million of original issue discount and debt issuance costs have been recorded as a reduction of the carrying value of the related debt and $2.8 million of debt issuance costs attributable to the Revolving Credit Facility have been recorded as a component of Other long-term assets on the Consolidated Balance Sheets as of December 31, 2021.
    In connection with terminating the 2015 Credit Agreement and entering into the 2021 Credit Agreement, for each separate debt instrument on a lender by lender basis, in accordance with ASC 470-50, Debt Modifications and Extinguishment, the Company performed an assessment of whether the transaction was deemed to be new debt, a modification of existing debt, or an extinguishment of existing debt. Debt issuance costs are either deferred and amortized over the term of the associated debt or expensed as incurred.
    Based on this assessment, $1.2 million of unamortized deferred debt issuance costs and unamortized discount related to the 2015 Credit Agreement were deemed to be related to the issuance of new debt, or the modification of existing debt, and therefore will continue to be deferred and amortized over the term of the associated debt. The remaining $3.3 million of unamortized deferred debt issuance costs and unamortized discount related to the 2015 Credit Agreement were deemed to be related to the extinguishment of debt and were expensed. Additionally, in connection with prepayments on the TLB Facility made during 2021 under the 2015 Credit Agreement, $0.3 million of unamortized deferred debt issuance costs and unamortized discount were treated as extinguishment of debt and were expensed.
    XML 30 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Benefit Plans
    		 12 Months Ended
    Dec. 31, 2021
    Retirement Benefits [Abstract]  
    BENEFIT PLANS BENEFIT PLANS
    Savings Plan
    The Company sponsors a defined contribution 401(k) plan (the “Plan”) for its U.S. based employees. The Plan provides for the deferral of employee compensation under Internal Revenue Code §401(k) and a Company match. The Company matches $0.50 per dollar of each participant’s deferral made to the Plan up to 6% of their compensation, subject to Internal Revenue Service guidelines. The Company temporarily suspended the Company match beginning in August 2020 through the end of 2020 as part of its cost reduction actions to reduce discretionary spending in response to the effect of the COVID-19 pandemic on its operations. Contributions from employees, as well as those matched by the Company, vest immediately. Net costs related to defined contribution plans were $7.9 million in 2021, $5.0 million in 2020 and $7.2 million in 2019.
    Defined Benefit Plans
    The Company is required to provide its employees located in Switzerland and Mexico certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age and compensation. The defined benefit pension plan provided to the Company’s employees located in Switzerland is a funded contributory plan, while the plans that provide benefits to the Company’s employees located in Mexico are unfunded and noncontributory. The assets of the Switzerland plan are held at an AA- rated insurance carrier who bears the pension risk and longevity risk, and will be used to cover the pension liability for the remaining retirees of the Swiss plan, as well as the remaining employees at that location. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees. The aggregated projected benefit obligation for these plans was $3.9 million and $3.7 million as of December 31, 2021 and December 31, 2020, respectively. Net periodic pension cost for fiscal years 2021, 2020 and 2019 was $0.5 million, $0.4 million and $0.3 million, respectively. Over the next ten years, we expect gross benefit payments to be $1.0 million in total for the years 2022 through 2026, and $1.8 million in total for the years 2027 through 2031.
    XML 31 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock-Based Compensation
    		 12 Months Ended
    Dec. 31, 2021
    Share-based Payment Arrangement [Abstract]  
    STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
    Stock-based Compensation Plans
    The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors (the “Board”) or the Compensation and Organization Committee of the Board. The stock-based compensation plans provide for the granting of stock options, RSAs, RSUs, stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers.
    On March 25, 2021, the Company’s Board adopted, subject to stockholder approval, the Integer Holdings Corporation 2021 Omnibus Incentive Plan (the “2021 Plan”). The Company’s stockholders approved the 2021 Plan at the Company’s 2021 annual meeting of stockholders on May 19, 2021, at which time the 2021 Plan replaced the Company’s 2016 Stock Incentive Plan (the “2016 Plan”) and the Company ceased granting any new awards under the 2016 Plan. The number of shares initially reserved for issuance under the 2021 Plan is (i) 1,450,000 plus (ii) the total number of shares of common stock available for issuance under the 2016 Plan, plus (iii) any shares of common stock that are subject to awards forfeited, cancelled, expired, terminated or otherwise lapsed or settled in cash, in whole or in part, without the delivery of shares under the 2016 Plan. Each of the Company’s 2011 Stock Incentive Plan, the 2009 Stock Incentive Plan and the 2005 Stock Incentive Plan have expired, and no awards are available for issuance under these expired plans. As of December 31, 2021, there were 1,636,980 shares available for future grants under the 2021 Plan.
    The Company recognized an excess net tax benefit from the exercise of stock options and vesting of RSUs of $1.1 million, $1.5 million and $2.8 million for fiscal years 2021, 2020 and 2019, respectively. These amounts are recorded as a component of Provision for income taxes.
    (10.)     STOCK-BASED COMPENSATION (Continued)
    Stock-based Compensation Expense
    The components and classification of stock-based compensation expense for fiscal years 2021, 2020 and 2019 were as follows (in thousands):
    202120202019
    Stock options$— $43 $410 
    RSUs and PRSUs16,185 9,120 8,884 
    Total stock-based compensation expense$16,185 $9,163 $9,294 
    Cost of sales$3,365 $1,658 $1,011 
    SG&A11,579 6,942 7,827 
    RD&E969 563 269 
    OOE272 — 187 
    Total stock-based compensation expense$16,185 $9,163 $9,294 
    Stock Options
    There were no stock options granted in fiscal years 2021, 2020 or 2019. The following table summarizes stock option activity during the fiscal year ended December 31, 2021:
    Number of
    Stock
    Options    		Weighted
    Average
    Exercise
    Price    		Weighted
    Average
    Remaining
    Contractual
    Term
    (in years)    		Aggregate
    Intrinsic
    Value
    (in millions)
    Outstanding at December 31, 2020281,873 $36.05 
    Exercised(34,233)21.72 
    Outstanding at December 31, 2021247,640 $38.03 4.2$11.8 
    Vested and exercisable at December 31, 2021247,640 $38.03 4.2$11.8 
    Intrinsic value is calculated for in-the-money options (exercise price less than market price) as the difference between the market price of the Company’s common stock as of December 31, 2021 ($85.59) and the weighted average exercise price of the underlying stock options, multiplied by the number of options outstanding and/or exercisable. Shares are distributed from the Company’s authorized but unissued reserve upon the exercise of stock options.
    The following table provides certain information relating to the exercise of stock options during fiscal years 2021, 2020 and 2019 (in thousands):
    202120202019
    Intrinsic value$2,370 $4,773 $7,998 
    Cash received743 3,263 3,242 
    Restricted Stock Units
    The following table summarizes RSU activity during the fiscal year ended December 31, 2021:
    Time-Vested
    Activity    		Weighted
    Average Grant Date
    Fair Value
    Nonvested at December 31, 2020207,923 $75.38 
    Granted208,624 81.98 
    Vested(149,464)74.47 
    Forfeited(18,952)79.84 
    Nonvested at December 31, 2021248,131 $81.14 
    (10.)     STOCK-BASED COMPENSATION (Continued)
    As of December 31, 2021, there was $13.9 million of total unrecognized compensation cost related to RSUs, which is expected to be recognized over a weighted-average period of approximately 1.6 years. The fair value of RSU shares vested in fiscal years 2021, 2020 and 2019 was $12.9 million, $9.9 million and $2.4 million, respectively. The weighted average grant date fair value of RSUs granted during fiscal years 2021, 2020 and 2019 was $81.98, $83.94 and $82.31, respectively.
    Performance Restricted Stock Units
    The following table summarizes PRSU activity during the fiscal year ended December 31, 2021:
    Performance-
    Vested
    Activity    		Weighted
    Average Grant Date
    Fair Value
    Nonvested at December 31, 2020219,391 $72.33 
    Granted92,384 85.16 
    Vested(38,882)37.75 
    Forfeited(74,024)53.45 
    Nonvested at December 31, 2021198,869 $92.07 
    For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares earned depends on the achievement of financial or market-based performance conditions. The financial performance condition is based on the Company’s sales targets. The market conditions are based on the Company’s achievement of a relative total shareholder return (“TSR”) performance requirement, on a percentile basis, compared to a defined group of peer companies over three year performance periods. All PRSUs awarded during the 2021 fiscal year were subject to market-based performance conditions.
    At December 31, 2021, there was $6.0 million of total unrecognized compensation cost related to unvested PRSUs, which is expected to be recognized over a weighted-average period of approximately 1.9 years. The fair value of PRSU shares vested in fiscal years 2021, 2020 and 2019 was $3.1 million, $2.9 million and $6.7 million, respectively. The weighted average grant date fair value of PRSUs granted during fiscal years 2021, 2020 and 2019 was $85.16, $95.06 and $101.17, respectively.
    The grant-date fair value of the market-based portion of the PRSUs granted during fiscal years 2021, 2020 and 2019 was determined using the Monte Carlo valuation model on the date of grant. The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows:
     202120202019
    Weighted average fair value$85.16 $107.27 $117.03 
    Risk-free interest rate0.19 %1.29 %2.46 %
    Expected volatility41 %30 %40 %
    Expected life (in years)3.02.92.8
    Expected dividend yield— %— %— %

    The valuation of the TSR portion of the PRSUs granted during fiscal years 2021 and 2020 also reflects a weighted average illiquidity discount of 8.19% and 8.00%, respectively, related to the six-month period that recipients are restricted from selling, transferring, pledging or assigning the underlying shares, in the event of vesting.
    XML 32 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Other Operating Expenses
    		 12 Months Ended
    Dec. 31, 2021
    Other Income and Expenses [Abstract]  
    OTHER OPERATING EXPENSES OTHER OPERATING EXPENSES
    The Company continuously evaluates the business and identifies opportunities to realign its resources to better serve its customers and markets, improve operational efficiency and capabilities, and lower its operating costs. To realize the benefits associated with these opportunities, the Company undertakes restructuring-type activities to transform its business. In addition, from time to time, the Company incurs cost associated with acquiring and integrating businesses and certain other general expenses, including asset impairments. The Company classifies costs associated with these items as OOE.
    The following tables summarize OOE by program in each of the preceding three years (in thousands):
    202120202019
    Operational excellence initiatives$3,893 $2,791 $— 
    Strategic reorganization and alignment911 686 5,812 
    Manufacturing alignment to support growth— 241 2,145 
    Acquisition and integration costs (adjustments)2,544 (776)377 
    Other general expenses508 4,679 3,817 
    Total other operating expenses$7,856 $7,621 $12,151 
    Operational excellence initiatives
    The Company’s operational excellence (“OE”) initiatives mainly consist of costs associated with executing on its sales force, manufacturing, business process, and performance excellence operational strategic imperatives. These projects focus on changing the Company’s organizational structure to match product line growth strategies and customer needs, transitioning its manufacturing process into a competitive advantage and standardizing and optimizing its business processes.
    2021 OE Initiatives - Costs related to the Company’s 2021 OE initiatives are primarily recorded within the Medical segment or unallocated operating expenses and mainly include termination benefits. The Company estimates that it will incur aggregate pre-tax charges in connection with the 2021 OE initiatives of between approximately $4 million to $5 million, the majority of which are expected to be cash expenditures. As of December 31, 2021, total restructuring and related charges incurred since inception were $3.6 million. These actions are expected to be substantially complete by the end of 2022.
    2020 Initiatives - Costs related to the Company’s 2020 initiatives are primarily recorded within the Medical segment and mainly include termination benefits. As of December 31, 2021, total restructuring and related charges incurred since inception were $3.1 million. These actions were substantially complete at the end of 2020.
    Strategic reorganization and alignment
    The Company’s strategic reorganization and alignment (“SRA”) initiatives primarily include those that align resources with market conditions and the Company’s strategic direction in order to enhance the profitability of its portfolio of products.
    2021 SRA Initiatives - During the fourth quarter of 2021, the Company initiated plans to exit certain markets served in our Medical segment to enhance profitability and reallocate manufacturing capacity needed to support our overall growth plans. The Company estimates that it will incur a range of pre-tax charges in connection with the 2021 SRA initiatives of approximately $5 million and $8 million, the majority of which are expected to be cash expenditures. Costs related to the Company’s 2021 SRA Initiatives are primarily recorded within the Medical segment and mainly include termination benefits. As of December 31, 2021, total charges incurred since inception were $0.9 million. These actions are expected to be completed by the end of 2025.
    2017 SRA Initiatives - In 2017, to better align its resources to enhance the profitability of its portfolio of products, the Company began aligning resources with its strategic direction, improving profitability to invest in accelerated growth and the expansion of a facility. These actions began in 2017 and were completed during the second quarter of 2020. The Company recorded, primarily within the Medical segment, $23.0 million of restructuring and related charges since inception.
    (11.)     OTHER OPERATING EXPENSES (Continued)
    Manufacturing alignment to support growth
    In 2017, the Company commenced several initiatives designed to reduce costs, increase manufacturing capacity to accommodate growth and improve operating efficiencies.  The plan involved the relocation of certain manufacturing operations and expansion of certain of the Company’s facilities. Costs related to the Company’s manufacturing alignment to support growth initiative were primarily recorded within the Medical segment. As of December 31, 2021, total restructuring and related charges incurred for this initiative since inception were $5.8 million. These actions were completed during 2020.
    The following table summarizes the change in accrued liabilities, presented within Accrued expenses and other current liabilities on the Consolidated Balance Sheets, related to the initiatives described above (in thousands):
    Operational excellence initiatives
    Strategic reorganization and alignment
    		Total
    December 31, 2020$291 $— $291 
    Charges incurred, net of reversals3,893 911 4,804 
    Cash payments(3,886)(777)(4,663)
    December 31, 2021$298 $134 $432 
    Acquisition and integration costs
    During 2021, acquisition and integration costs included $2.4 million of expenses primarily related to the acquisition of Oscor, and a net $0.1 million adjustment to increase the fair value of acquisition-related contingent consideration liability associated with the Company’s other acquisitions. During 2020, acquisition and integration costs included $1.2 million of expenses primarily related to the acquisition of certain assets and liabilities of InoMec, and a $2.0 million adjustment to reduce the fair value of acquisition-related contingent consideration liability associated with the Company’s acquisition of USB. During 2019, acquisition and integration costs primarily related to direct acquisition costs incurred in connection with the acquisition of USB. Acquisition and integration costs primarily consist of professional fees and other costs. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration.
    Other general expenses
    During 2021, 2020 and 2019, the Company recorded expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce future costs and improve efficiencies. The 2021, 2020 and 2019 amounts primarily include severance, information technology systems conversion expenses, expenses incurred in connection with a customer filing Chapter 11 bankruptcy, and expenses related to the restructuring of certain legal entities of the Company.
    XML 33 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes
    		 12 Months Ended
    Dec. 31, 2021
    Income Tax Disclosure [Abstract]  
    INCOME TAXES INCOME TAXES
    Income from continuing operations before taxes for fiscal years 2021, 2020 and 2019 consisted of the following (in thousands):
    202120202019
    U.S.$48,293 $35,337 $40,203 
    International52,770 50,870 64,990 
    Total income from continuing operations before taxes$101,063 $86,207 $105,193 
    The provision for income taxes from continuing operations for fiscal years 2021, 2020 and 2019 comprises the following (in thousands):
    202120202019
    Current:
    Federal$9,511 $7,784 $14,090 
    State1,553 1,233 87 
    International8,459 6,898 10,083 
    19,523 15,915 24,260 
    Deferred:
    Federal(8,665)(4,648)(8,813)
    State(393)(1,245)332 
    International(2,422)(1,073)(1,804)
    (11,480)(6,966)(10,285)
    Total provision for income taxes$8,043 $8,949 $13,975 
    The provision for income taxes from continuing operations differs from the U.S. statutory rate for fiscal years 2021, 2020 and 2019 due to the following:
    202120202019
    Statutory rate$21,223 21.0 %$18,103 21.0 %$22,091 21.0 %
    Federal tax credits (including R&D)(11,929)(11.8)(7,009)(8.1)(4,797)(4.6)
    Foreign rate differential(5,165)(5.1)(5,333)(6.2)(5,479)(5.2)
    Stock-based compensation(1,084)(1.1)(1,459)(1.7)(2,422)(2.3)
    Uncertain tax positions18 — 1,208 1.4 (920)(0.9)
    State taxes, net of federal benefit1,183 1.2 553 0.6 1,106 1.1 
    U.S. tax on foreign earnings, net of §250 deduction1,913 1.9 3,216 3.7 5,201 4.9 
    Valuation allowance524 0.5 (345)(0.4)(1,606)(1.5)
    Other1,360 1.4 15 0.1 801 0.8 
    Effective tax rate$8,043 8.0 %$8,949 10.4 %$13,975 13.3 %
    The difference between the Company’s effective tax rate and the U.S. federal statutory income tax rate in the current year is primarily attributable to the availability of Foreign Tax Credits, R&D Credits, the impact of the Company’s earnings realized in foreign jurisdictions with statutory rates that are different than the U.S. federal statutory rate, and the provision for Global Intangible Low Taxed income (“GILTI”), net of the statutory deduction of 50% of the GILTI inclusion and the Foreign Derived Intangible Income (“FDII”) deduction (collectively “Section 250 deduction”). The Company’s foreign earnings are primarily derived from Switzerland, Mexico, Uruguay, Ireland and Malaysia. The Company currently has a tax holiday in Malaysia through April 2023 provided certain conditions continue to be met. In addition, the Company acquired manufacturing operations in the Dominican Republic as part of the acquisition of Oscor and is operating under a free trade zone agreement in the Dominican Republic through March 2034.
    (12.)     INCOME TAXES (Continued)
    Difference Attributable to Foreign Investment: Certain foreign subsidiary earnings are subject to U.S. taxation under the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”) . The Company intends to permanently reinvest substantially all of our foreign subsidiary earnings, as well as our capital in our foreign subsidiaries, with the exception of planned distributions made out of current year earnings and profits (“E&P”) and E&P previously taxed as of and for the year ended December 29, 2017, including E&P subject to the toll charge under the Tax Reform Act. The Company accrues for withholding taxes on distributions in the year associated with earnings that are intended to be distributed.
    The net deferred tax liability consists of the following (in thousands):
    December 31,
    2021    		December 31,
    2020
    Tax credit carryforwards$11,394 $13,449 
    Inventories14,147 14,099 
    Net operating loss carryforwards11,721 10,436 
    Operating lease liabilities17,950 11,969 
    Stock-based compensation3,724 3,276 
    Accrued expenses9,348 8,058 
    Gross deferred tax assets68,284 61,287 
    Less valuation allowance(19,456)(20,739)
    Net deferred tax assets48,828 40,548 
    Property, plant and equipment(7,354)(5,824)
    Intangible assets(186,150)(197,048)
    Operating lease assets(17,974)(11,290)
    Other(3,144)(4,292)
    Gross deferred tax liabilities(214,622)(218,454)
    Net deferred tax liability$(165,794)$(177,906)
    Presented as follows:
    Noncurrent deferred tax asset$5,711 $4,398 
    Noncurrent deferred tax liability(171,505)(182,304)
    Net deferred tax liability$(165,794)$(177,906)
    As of December 31, 2021, the Company has the following carryforwards available:
    JurisdictionTax
    Attribute    		Amount
    (in millions)    		Begin to Expire
    U.S. State
    Net operating losses(1)
    		$120.7 2022
    International
    Net operating losses(1)
    		12.2 2022
    U.S. FederalForeign tax credits6.7 2022
    U.S. StateR&D tax credits1.4 2022
    U.S. StateState tax credits4.9 2022
    __________
    (1)     Net operating losses (“NOLs”) are presented as pre-tax amounts.
    (12.)     INCOME TAXES (Continued)
    In assessing the realizability of deferred tax assets, management considers, within each taxing jurisdiction, whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the consideration of the weight of both positive and negative evidence, management has determined it is more likely than not that a portion of the deferred tax assets as of December 31, 2021 and December 31, 2020 related to certain foreign tax credits, state investment tax credits, and foreign and state net operating losses will not be realized.
    The Company files annual income tax returns in the U.S., various state and local jurisdictions, and in various foreign jurisdictions. A number of years may elapse before an uncertain tax position, for which the Company has unrecognized tax benefits, is examined and finally settled. While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that its unrecognized tax benefits reflect the most probable outcome. The Company adjusts these unrecognized tax benefits, as well as the related interest, in light of changing facts and circumstances. The resolution of an uncertain tax position, if recognized, would be recorded as an adjustment to the provision for income taxes and the effective tax rate in the period of resolution.
    Below is a summary of changes to the unrecognized tax benefit for fiscal years 2021, 2020 and 2019 (in thousands):
    202120202019
    Balance, beginning of year$5,484 $4,446 $5,369 
    Additions based upon tax positions related to the current year3,324 300 300 
    Additions (reductions) related to prior period tax returns(3,271)738 (1,223)
    Balance, end of year$5,537 $5,484 $4,446 
    The tax years that remain open and subject to tax audits vary depending on the tax jurisdiction. During 2021, the Internal Revenue Service (“IRS”) effectively concluded its examination of the U.S. subsidiaries of the Company for the taxable years 2017 and 2018. Taxable years 2019 and forward remain subject to examination by the IRS.
    The balance of unrecognized tax benefits is not expected to materially change over the course of the next twelve months as a result of the lapse of the statute of limitations and/or audit settlements. As of December 31, 2021, approximately $5.5 million of unrecognized tax benefits would favorably impact the effective tax rate (net of federal impact on state issues), if recognized.
    The Company recognizes interest related to unrecognized tax benefits as a component of Provision for income taxes on the Consolidated Statements of Operations. During 2021, 2020 and 2019, the recorded amounts for interest and penalties, respectively, were not significant.
    In response to the COVID-19 pandemic, many governments have enacted or are contemplating measures to provide aid and economic stimulus. These measures may include deferring the due dates of tax payments or other changes to their income and non-income-based tax laws. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020 in the U.S., includes measures to assist companies, including temporary changes to income and non-income-based tax laws. The CARES Act provided for deferred payment of the employer portion of social security taxes through the end of 2020. As of December 31, 2020, the Company had deferred a total of $9.7 million of payroll taxes, of which it paid $4.9 million in December 2021. As of December 31, 2021, the Company had a remaining deferred amount of $4.8 million, which the Company expects to pay withing the next twelve months. The deferred payroll taxes are included within Accrued expenses and other current liabilities on the Consolidated Balance Sheets.
    See Note 20 “Discontinued Operations” for additional information pertaining to income taxes from discontinued operations.
    XML 34 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Commitments And Contingencies
    		 12 Months Ended
    Dec. 31, 2021
    Commitments and Contingencies Disclosure [Abstract]  
    COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
    Contingent Consideration Arrangements
    The Company records contingent consideration liabilities related to the earn-out provisions for certain acquisitions. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information.
    Litigation
    The Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action will not become material in the future.
    The Company records a contingent gain for litigation when all of the following conditions have been met: (a) the amount to be paid to the Company is known, (b) there is no potential for appeal or reversal, and (c) collectability is reasonably assured.
    In April 2013, the Company commenced an action against AVX Corporation and AVX Filters Corporation (collectively “AVX”) alleging that AVX had infringed on the Company’s patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate the Company’s patented technology. Following four trials and an appeal, the United States Court of Appeals for the Federal Circuit affirmed, in all respects, a judgment in favor of the Company. The Company received the payment of $28.9 million in October 2020, and after recognizing certain related expenses, recognized a net gain of $28.2 million.
    Selling, general and administrative expenses
    The net gain on patent litigation of $28.2 million is recorded in Selling, general and administrative expenses in the Company’s Consolidated Statements of Operations for the year ended December 31, 2020.
    Environmental Matters
    The Company acquired Lake Region Medical Holdings, Inc. (“LRM”) in 2015. At the direction of the New Jersey Department of Environmental Protection (“NJDEP”), LRM has been performing, and has agreed to fund approximately $0.3 million for, environmental investigations of a manufacturing facility LRM owned in South Plainfield, New Jersey from 1971 to 2004, and where it conducted operations from 1971 to 2007. NJDEP required LRM to perform and fund these environmental investigations due to concerns that prior investigations by LRM at the property were inadequate and because NJDEP concluded that the property was a source of local ground water contamination during LRM’s operations, including the Franklin Street Regional Groundwater Contamination Area, which has been designated as an immediate environmental concern by NJDEP. LRM funded the environmental investigation undertaken by NJDEP’s contractor by placing approximately $0.3 million in escrow for the environmental investigation. As of December 31, 2021, approximately $0.2 million had been drawn down from the escrow account by NJDEP to pay for the environmental investigation, and approximately $0.1 million remains in escrow for anticipated future costs associated with the environmental investigation. These environmental investigations may conclude that remediation of the property by LRM, and the reimbursement of costs and damages, including natural resource damages, associated with the groundwater immediate environmental concern, are necessary. Further, the current owner of the property claims to have been financially impacted by LRM’s inadequate environmental investigations. While the Company does not expect this environmental matter will have a material effect on its consolidated results of operations, financial position or cash flows, there can be no assurance that this environmental matter will not become material in the future. As of December 31, 2021, there was $0.1 million recorded in Accrued expenses and other current liabilities in the Consolidated Balance Sheets in connection with this environmental matter.
    License Agreements
    The Company is a party to various license agreements for technology that is utilized in certain of its products. The most significant of these agreements are the licenses for basic technology used in the production of wet tantalum capacitors, filtered feedthroughs and MRI compatible lead systems. Expenses related to license agreements were $1.3 million, $1.2 million, and $1.4 million, for 2021, 2020 and 2019, respectively, and are primarily included in Cost of Sales.
    (13.)     COMMITMENTS AND CONTINGENCIES (Continued)
    Product Warranties
    The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The change in product warranty liability for fiscal years 2021 and 2020 comprises the following (in thousands):
    20212020
    Beginning balance$163 $1,933 
    Additions to warranty reserve, net of reversals(15)(156)
    Adjustments to pre-existing warranties (71)(119)
    Warranty claims settled— (1,495)
    Acquisitions$432 — 
    Ending balance$509 $163 
    Self-Insurance Liabilities
    As of December 31, 2021, and at various times in the past, the Company self-funded certain of its workers’ compensation and employee medical and dental expenses. The Company has established reserves to cover these self-insured liabilities and also maintains stop-loss insurance to limit its exposures under these programs. Claims reserves represent accruals for the estimated uninsured portion of reported claims, including adverse development of reported claims, as well as estimates of incurred but not reported claims. Claims incurred but not reported are estimated based on the Company’s historical experience, which is continually monitored, and accruals are adjusted when warranted by changes in facts and circumstances. The Company’s actual experience may be different than its estimates, sometimes significantly. Changes in assumptions, as well as changes in actual experience could cause these estimates to change. Insurance and claims expense will vary from period to period based on the severity and frequency of claims incurred in a given period.  The Company’s self-insurance reserves totaled $5.6 million and $5.4 million as of December 31, 2021 and December 31, 2020, respectively. These accruals are recorded in Accrued expenses and other current liabilities and Other long-term liabilities on the Consolidated Balance Sheets.
    XML 35 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases
    		 12 Months Ended
    Dec. 31, 2021
    Leases [Abstract]  
    Leases LEASES
    The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Gross assets acquired under finance leases are recorded in Other long-term assets and were $8.3 million as of December 31, 2021. Accumulated amortization associated with finance leases was $0.2 million as of December 31, 2021. Finance leases were not material as of December 31, 2020.
    The components and classification of lease cost are as follows (in thousands):
    December 31,
    2021    		December 31,
    2020
    Finance lease cost:
    Amortization of lease assets$223 $7 
    Interest on lease liabilities59 1 
    Finance lease cost282 8 
    Operating lease cost10,729 10,425 
    Short-term lease cost (leases with initial term of 12 months or less)137 86 
    Variable lease cost2,619 2,615 
    Sublease income(1,392)(1,495)
    Total lease cost$12,375 $11,639 
    Cost of sales$9,642 $9,141 
    SG&A1,817 1,803 
    RD&E857 694 
    Interest expense$59 $1 
    Total lease cost$12,375 $11,639 
    (14.)     LEASES (Continued)
    The Company’s sublease income is derived primarily from certain real estate leases to several non-affiliated tenants under operating sublease arrangements.
    At December 31, 2021, the maturities of operating and finance lease liabilities were as follows (in thousands):
    Operating Leases Finance Leases
    2022$12,423 $876 
    202311,317 888 
    202410,809 896 
    202510,634 787 
    20269,856 640 
    Thereafter25,652 5,807 
    Gross lease liabilities80,691 9,894 
    Less: imputed interest(11,062)(1,836)
    Present value of lease liabilities69,629 8,058 
    Less: current portion of lease liabilities(9,862)(608)
    Total long-term lease liabilities$59,767 $7,450 
    As of December 31, 2021, the Company did not have any leases that have not yet commenced.
    The following table presents the weighted average remaining lease term and discount rate.
    December 31,
    2021    		December 31,
    2020
    Weighted-average remaining lease term - operating leases (in years)7.07.0
    Weighted-average remaining lease term - finance leases (in years)12.23.8
    Weighted-average discount rate - operating leases3.9 %5.3 %
    Weighted-average discount rate - finance leases3.5 %2.2 %

    Supplemental cash flow information related to leases for fiscal years 2021 and 2020 is as follows (in thousands):
    20212020
    Cash paid for operating leases$10,808 $10,385 
    Cash paid for interest on finance leases59 1 
    Assets acquired under operating leases32,466 9,059 
    Assets acquired under finance leases8,154 127 
    During the fiscal year ended December 31, 2021, the Company extended the lease terms for three of its manufacturing facilities. As a result of these lease modifications, the Company re-measured the lease liability and adjusted the ROU asset on the modification dates.
    XML 36 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Earnings Per Share
    		 12 Months Ended
    Dec. 31, 2021
    Earnings Per Share [Abstract]  
    EARNINGS PER SHARE EARNINGS PER SHARE
    The following table sets forth a reconciliation of the information used in computing basic and diluted EPS for fiscal years 2021, 2020 and 2019 (in thousands, except per share amounts):
    202120202019
    Numerator for basic and diluted EPS:
    Income from continuing operations$93,020 $77,258 $91,218 
    Income from discontinued operations3,788 — 5,118 
    Net income$96,808 $77,258 $96,336 
    Denominator for basic EPS:
    Weighted average shares outstanding32,993 32,845 32,627 
    Effect of dilutive securities:
    Stock options, restricted stock and restricted stock units265 268 410 
    Denominator for diluted EPS33,258 33,113 33,037 
    Basic earnings per share:
    Income from continuing operations$2.82 $2.35 $2.80 
    Income from discontinued operations0.11 — 0.16 
    Basic earnings per share2.93 2.35 2.95 
    Diluted earnings per share:
    Income from continuing operations$2.80 $2.33 $2.76 
    Income from discontinued operations0.11 — 0.15 
    Diluted earnings per share2.91 2.33 2.92 
    The diluted weighted average share calculations do not include the following securities for fiscal years 2021, 2020 and 2019, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):
    202120202019
    Time-vested stock options, restricted stock and restricted stock units4 98 30 
    Performance-vested restricted stock units92 89 47 
    XML 37 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stockholders' Equity
    		 12 Months Ended
    Dec. 31, 2021
    Equity [Abstract]  
    STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
    Common Stock
    The following table sets forth the changes in the number of shares of common stock for fiscal years 2021 and 2020:
    IssuedTreasury StockOutstanding
    Shares outstanding at December 31, 201932,847,017 (146,546)32,700,471 
    Stock options exercised27,544 74,596 102,140 
    Vesting of RSUs, net of shares withheld to cover taxes33,617 71,950 105,567 
    Shares outstanding at December 31, 202032,908,178 — 32,908,178 
    Stock options exercised34,233 — 34,233 
    Vesting of RSUs, net of shares withheld to cover taxes120,925 — 120,925 
    Shares outstanding at December 31, 202133,063,336 — 33,063,336 
    Accumulated Other Comprehensive Income
    Accumulated other comprehensive income comprises the following (in thousands): 
    Defined
    Benefit
    Plan
    Liability    		Cash
    Flow
    Hedges    		Foreign
    Currency
    Translation
    Adjustment    		Total
    Pre-Tax
    Amount    		TaxNet-of-Tax
    Amount
    December 31, 2019$(912)$(2,358)$22,639 $19,369 $619 $19,988 
    Unrealized loss on cash flow hedges— (6,683)— (6,683)1,404 (5,279)
    Realized loss on foreign currency hedges— 638 — 638 (134)504 
    Realized loss on interest rate swap hedges— 3,447 — 3,447 (724)2,723 
    Net defined benefit plan adjustments(183)— — (183)32 (151)
    Foreign currency translation gain— — 34,907 34,907 — 34,907 
    December 31, 2020$(1,095)$(4,956)$57,546 $51,495 $1,197 $52,692 
    Unrealized gain on cash flow hedges— 91 — 91 (19)72 
    Realized gain on foreign currency hedges— (832)— (832)175 (657)
    Realized loss on interest rate swap hedges— 3,406 — 3,406 (716)2,690 
    Net defined benefit plan adjustments205 — — 205 14 219 
    Foreign currency translation loss— — (27,826)(27,826)— (27,826)
    December 31, 2021$(890)$(2,291)$29,720 $26,539 $651 $27,190 
    XML 38 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Instruments and Fair Value Measurements
    		 12 Months Ended
    Dec. 31, 2021
    Fair Value Disclosures [Abstract]  
    FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
    Assets and Liabilities Measured at Fair Value on a Recurring Basis
    Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments and contingent consideration. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis.
    The Company is exposed to global market risks, including the effect of changes in interest rates and foreign currency exchange rates, and uses derivatives to manage these exposures that occur in the normal course of business. The Company does not hold or issue derivatives for trading or speculative purposes. All derivatives are recorded at fair value on the balance sheet.
    The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):
    Fair ValueQuoted
    Prices in
    Active
    Markets
    (Level 1)    		Significant
    Other
    Observable
    Inputs
    (Level 2)    		Significant
    Unobservable
    Inputs
    (Level 3)
    December 31, 2021
    Assets: Foreign currency hedging contracts$687 $— $687 $— 
    Liabilities: Interest rate swap2,978 — 2,978 — 
    Liabilities: Contingent consideration2,415 — — 2,415 
    December 31, 2020
    Assets: Foreign currency hedging contracts$2,070 $— $2,070 $— 
    Liabilities: Interest rate swaps7,026 — 7,026 — 
    Liabilities: Contingent consideration3,900 — — 3,900 
    Derivatives Designated as Hedging Instruments
    Interest Rate Swaps
    The Company periodically enters into interest rate swap agreements to reduce the cash flow risk caused by interest rate changes on its outstanding floating rate borrowings. Under these swap agreements, the Company pays a fixed rate of interest and receives a floating rate equal to one-month LIBOR. The variable rate received from the swap agreements and the variable rate paid on the outstanding debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The Company has designated these swap agreements as cash flow hedges based on concluding the hedged forecasted transaction is probable of occurring within the period the cash flow hedge is anticipated to affect earnings.
    The Company receives fair value estimates from the swap agreement counterparties. The fair value of the Company’s swap agreements are determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. The Company’s interest rate swap agreements are categorized in Level 2 of the fair value hierarchy. The estimated fair value of the swap agreements represents the amount the Company would receive (pay) to terminate the contracts.
    Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of December 31, 2021 is as follows (dollars in thousands):
    Notional AmountStart DateEnd
    Date    		Pay Fixed RateReceive Current Floating RateFair ValueBalance Sheet Location
    $150,000 Jun 2020Jun 20232.1785 %0.1013 %$(2,978)Other long-term liabilities
    (17.)     FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
    Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands):
    Notional AmountMaturity
    Date    		Pay Fixed RateReceive Current Floating RateFair ValueBalance Sheet Location
    $200,000 Jun 20232.1785 %0.1480 %$(7,026)Other long-term liabilities
    Foreign Currency Contracts
    The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations. The Company has designated these foreign currency forward contracts as cash flow hedges.
    The Company receives fair value estimates from the foreign currency contract counterparties. The fair value of foreign currency contracts are determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rate and credit spread curves. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as Sales or Cost of Sales as the inventory, which the contracts are hedging, is sold.
    Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2021 is as follows (dollars in thousands):
    Notional AmountMaturity
    Date    		$/Foreign CurrencyFair ValueBalance Sheet Location
    $22,201 Dec 20220.0463MXN Peso$408 Prepaid expenses and other current assets
    17,017 Dec 20221.1344Euro130 Prepaid expenses and other current assets
    9,020 Dec 20220.0220UYU Peso149 Prepaid expenses and other current assets
    Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands):
    Notional AmountMaturity
    Date    		$/Foreign CurrencyFair ValueBalance Sheet Location
    $16,132 Sep 20211.1949Euro$399 Prepaid expenses and other current assets
    10,224 Sep 20210.0454MXN Peso922 Prepaid expenses and other current assets
    2,656 Mar 20210.0443MXN Peso341 Prepaid expenses and other current assets
    7,269 Dec 20210.0485MXN Peso77 Prepaid expenses and other current assets
    3,252 Aug 20210.0232UYU Peso165 Prepaid expenses and other current assets
    3,966 Nov 20210.0227UYU Peso166 Prepaid expenses and other current assets
    The following table presents the impact of cash flow hedge derivative instruments on other comprehensive income (“OCI”), AOCI and the Company’s Consolidated Statement of Operations for fiscal years 2021, 2020 and 2019 (in thousands):
    Gain (Loss) Recognized in OCIGain (Loss) Reclassified from AOCI
    Derivative202120202019Location in Statement of Operations 202120202019
    Interest rate swaps$642 $(7,405)$(5,618)Interest expense$(3,406)$(3,447)$1,621 
    Foreign exchange contracts(943)1,017 (1,044)Sales(674)618 (1,334)
    Foreign exchange contracts399 (355)2,634 Cost of sales1,437 (1,177)1,482 
    Foreign exchange contracts(7)60 — Operating expenses69 (79)— 
    The Company expects to reclassify net losses totaling $1.8 million related to its cash flow hedges from AOCI into earnings during the next twelve months.
    (17.)     FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
    Derivatives Not Designated as Hedging Instruments
    The Company also has foreign currency exposure on balances, primarily intercompany, that are denominated in a foreign currency and are adjusted to current values using period-end exchange rates. To minimize foreign currency exposure, the Company enters into foreign currency contracts with a one month maturity. At December 31, 2021, the Company had one contract outstanding, with a notional amount of $15.0 million and a fair value of $0.1 million. The Company recorded a net gain on foreign currency contracts not designated as hedging instruments of $0.4 million for fiscal year 2021, which are included in Other (income) loss, net and generally offset the gains or losses from the foreign currency adjustments on the intercompany balances that are also included in Other (income) loss, net.
    Contingent Consideration
    The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for fiscal years 2021 and 2020 (in thousands):
    December 31, 2019$4,200 
    Amount recorded for current year acquisitions
    		2,700 
    Fair value measurement adjustment(2,000)
    Payments
    		(1,000)
    December 31, 20203,900 
    Fair value measurement adjustment133 
    Payments
    		(1,621)
    Foreign currency translation3 
    December 31, 2021$2,415 
    On February 19, 2020, the Company acquired certain assets and liabilities of InoMec. On October 7, 2019, the Company acquired certain assets and liabilities of USB, a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The contingent consideration at December 31, 2021 is the estimated fair value of the Company’s obligations, under the asset purchase agreements for InoMec and USB, to make additional payments if certain revenue goals are met. See Note 2 “Business Acquisitions” for additional information about the InoMec and USB acquisitions.
    During 2021, the Company made payments associated with the InoMec and USB acquisitions, resulting from achievement of revenue-based goals for the period from March 1, 2020 to February 28, 2021 for InoMec and January 1, 2020 to December 31, 2020 for USB. During 2020, the Company made payments to settle a portion of a contingent consideration arrangement relating to a license to use technology.
    As of December 31, 2021 and December 31, 2020, the current portion of contingent consideration liabilities included in Accrued expenses and other current liabilities was $0.9 million and $1.7 million, respectively, and the non-current portion included in Other long-term liabilities on the Consolidated Balance Sheets was $1.5 million and $2.2 million, respectively.
    The following table provides quantitative information associated with the fair value measurement of the Company’s liabilities for contingent consideration:
    December 31, 2021
    Contingency TypeRemaining Maximum Payout (undiscounted)Fair ValueValuation TechniqueUnobservable InputsWeighted Average or Range
    Revenue-based payments$6,750 $2,415 Monte CarloRevenue volatility29.0 %
    Discount rate1.8 %
    Projected year(s) of payment2022-2024
    (17.)     FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
    December 31, 2020
    Contingency TypeRemaining Maximum Payout (undiscounted)Fair ValueValuation TechniqueUnobservable InputsWeighted Average or Range
    Revenue-based payments$9,000 $3,900 Monte CarloRevenue volatility35.0 %
    Discount rate4.0 %
    Projected year(s) of payment2021-2024

    Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
    Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, contract assets, accounts payable and accrued expenses approximate fair value due to the short-term nature of these items.
    Borrowings under the Company’s Revolving Credit Facility, TLA Facility and TLB Facility accrue interest at a floating rate tied to a standard short-term borrowing index, selected at the Company’s option, plus an applicable margin. The carrying amount of this floating rate debt approximates fair value based upon the respective interest rates adjusting with market rate adjustments.
    Equity Investments
    Equity investments comprise the following (in thousands):
    December 31,
    2021    		December 31,
    2020
    Equity method investment$16,192 $21,470 
    Non-marketable equity securities5,637 5,723 
    Total equity investments
    		$21,829 $27,193 
    The components of (Gain) loss on equity investments, net for each period were as follows (in thousands):
    202120202019
    Equity method investment (income) loss$3,057 $(5,706)$(1,100)
    Impairment charges86 369 1,575 
    Total (gain) loss on equity investments, net
    		$3,143 $(5,337)$475 
    During 2021, 2020 and 2019, the Company determined that certain non-marketable equity securities were impaired. In both 2021 and 2020, new equity financings by two of the Company’s non-marketable equity securities indicated new values for the investments. During the fourth quarters of 2021 and 2020, the Company recorded impairment charges of $0.1 million and $0.4 million, respectively, to reduce the carrying value of these non-marketable equity securities to their estimated fair value of zero and $2.2 million, respectively. The fair values of these investments were derived from observable price changes of similar securities of the investees. In 2019, the Company determined the fair value for one of its non-marketable equity securities to be zero based upon available market information. This assessment was based on qualitative indications of impairment. Factors that significantly influenced the determination of the impairment loss included the equity security’s investee’s financial condition, priority claims to the equity security, distributions rights and preferences, and status of the regulatory approval required to bring its product to market. During 2021, 2020 and 2019, the Company received cash distributions representing a return on equity method investments of $2.2 million, $0.4 million and $0.1 million, respectively.
    The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. As of December 31, 2021, the Company owned 6.7% of this fund.
    XML 39 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Segment and Geographic Information
    		 12 Months Ended
    Dec. 31, 2021
    Segment Reporting [Abstract]  
    SEGMENT AND GEOGRAPHIC INFORMATION SEGMENT AND GEOGRAPHIC INFORMATION
    The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker, to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting.
    The Company defines segment income from operations as sales less cost of sales including amortization and expenses attributable to segment-specific selling, general, administrative, research, development, engineering and other operating activities. The remaining unallocated operating and other expenses are primarily administrative corporate headquarter expenses and capital costs that are not allocated to reportable segments. Transactions between the two segments are not significant.
    The following table presents sales by product line for fiscal years 2021, 2020 and 2019 (in thousands).
    202120202019
    Segment sales by product line:
    Medical
    Cardio & Vascular $626,013 $569,948 $610,056 
    Cardiac & Neuromodulation446,569 346,242 457,194 
    Advanced Surgical, Orthopedics & Portable Medical110,044 121,788 132,429 
    Total Medical1,182,626 1,037,978 1,199,679 
    Non-Medical38,453 35,464 58,415 
    Total sales$1,221,079 $1,073,442 $1,258,094 
    Geographic Area Information
    The following table presents sales by significant country for fiscal years 2021, 2020 and 2019. In these tables, sales are allocated based on where the products are shipped (in thousands).
    202120202019
    Sales by geographic area:
    United States$671,502 $596,804 $698,474 
    Non-Domestic locations:
    Puerto Rico110,162 96,048 154,644 
    Costa Rica66,975 58,853 63,634 
    Rest of world372,440 321,737 341,342 
    Total sales$1,221,079 $1,073,442 $1,258,094 
    The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues for fiscal years 2021 and 2020.
    20212020
    CustomerMedicalNon-MedicalMedicalNon-Medical
    Customer A19%*19%*
    Customer B17%*17%*
    Customer C14%*15%*
    Customer D*36%*22%
    Customer E***10%
    All other customers50%64%49%68%
    __________
    * Less than 10% of segment’s total revenues for the period.
    (18.)     SEGMENT AND GEOGRAPHIC INFORMATION (Continued)
    The following table presents revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped for fiscal years 2021 and 2020.
    20212020
    Ship to LocationMedicalNon-MedicalMedicalNon-Medical
    United States54%71%55%60%
    Rest of world46%29%45%40%
    The following table presents income from continuing operations for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).
    202120202019
    Segment income from continuing operations:
    Medical$213,600 $169,396 $223,873 
    Non-Medical8,022 4,848 16,289 
    Total segment income from continuing operations221,622 174,244 240,162 
    Unallocated operating expenses(85,911)(53,632)(82,527)
    Operating income135,711 120,612 157,635 
    Unallocated expenses, net(34,648)(34,405)(52,442)
    Income from continuing operations before taxes$101,063 $86,207 $105,193 
    The following table presents depreciation and amortization expense for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).
     202120202019
    Segment depreciation and amortization:
    Medical$75,366 $72,338 $68,867 
    Non-Medical1,167 996 1,039 
    Total depreciation and amortization included in segment
       income from continuing operations
    		76,533 73,334 69,906 
    Unallocated depreciation and amortization4,836 5,990 7,989 
    Total depreciation and amortization$81,369 $79,324 $77,895 
    The following table presents total assets for the Company’s reportable segments as of December 31, 2021 and December 31, 2020 (in thousands).
    December 31,
    2021    		December 31,
    2020
    Identifiable assets:
    Medical$2,448,123 $2,212,489 
    Non-Medical 56,158 52,682 
    Total reportable segments2,504,281 2,265,171 
    Unallocated assets77,934 106,686 
    Total assets$2,582,215 $2,371,857 
    (18.)     SEGMENT AND GEOGRAPHIC INFORMATION (Continued)
    The following table presents capital expenditures for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).
     202120202019
    Expenditures for tangible long-lived assets:
    Medical$48,364 $42,435 $44,026 
    Non-Medical628 1,038 397 
    Total reportable segments48,992 43,473 44,423 
    Unallocated long-lived tangible assets4,471 3,359 3,775 
    Total expenditures$53,463 $46,832 $48,198 
    The following table presents PP&E by geographic area as of December 31, 2021 and December 31, 2020. In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands).
    December 31,
    2021    		December 31,
    2020
    Long-lived tangible assets by geographic area:
    United States$184,474 $170,871 
    Mexico33,877 32,723 
    Ireland41,501 38,526 
    Rest of world17,247 11,844 
    Total$277,099 $253,964 
    XML 40 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Revenue From Contracts With Customers
    		 12 Months Ended
    Dec. 31, 2021
    Revenue from Contract with Customer [Abstract]  
    REVENUE FROM CONTRACTS WITH CUSTOMERS REVENUE FROM CONTRACTS WITH CUSTOMERS
    Disaggregated Revenue
    In general, the Company’s business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. For a summary by disaggregated product line sales for each segment, refer to Note 18, “Segment and Geographic Information.”
    A significant portion of the Company’s sales for fiscal years 2021, 2020 and 2019 and accounts receivable at December 31, 2021 and December 31, 2020 were to three customers as follows:
     SalesAccounts Receivable
    202120202019December 31,
    2021    		December 31,
    2020
    Customer A18%18%21%15%15%
    Customer B16%16%17%19%19%
    Customer C13%14%12%10%13%
    47%48%50%44%47%
    Revenue recognized from products and services transferred to customers over time during fiscal years 2021 and 2020 represented 33% and 29%, respectively, of total revenue. Substantially all of the revenue recognized from products and services transferred to customers over time during fiscal years 2021 and 2020 was within the Medical segment.
    (19.)     REVENUE FROM CONTRACTS WITH CUSTOMERS (Continued)
    Contract Balances
    The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands):
    December 31,
    2021    		December 31,
    2020
    Contract assets$64,743 $40,218 
    Contract liabilities3,776 2,498 
    Contract assets at December 31, 2021, increased $24.5 million from December 31, 2020, primarily due to a contract modification to add existing products and extend the contractual term. During the fiscal year ended December 31, 2021, the Company recognized $1.9 million of revenue that was included in the contract liability balance as of December 31, 2020. During the fiscal year ended December 31, 2020, the Company recognized $1.3 million of revenue that was included in the contract liability balance as of December 31, 2019.
    XML 41 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Discontinued Operations
    		 12 Months Ended
    Dec. 31, 2021
    Discontinued Operations and Disposal Groups [Abstract]  
    DISCONTINUED OPERATIONS DISCONTINUED OPERATIONS
    Divestiture of AS&O Product Line
    In July 2018, the Company completed the sale of its AS&O Product Line within its Medical segment to Viant (formerly MedPlast, LLC). For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&O Product Line.
    During the fourth quarter of 2021, the Company recognized other income from discontinued operations of $4.9 million for the release of pre-divestiture indemnified tax liabilities resulting from the lapse of the statute of limitations and the effective settlement of tax audits. During 2019, the Company received, and recognized as gain on sale from discontinued operations, $4.8 million due to the final net working capital adjustment agreed to with Viant.
    Income from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands):
    202120202019
    Gain on sale of discontinued operations$— $— $(4,974)
    Other income, net(4,931)— (322)
    Income from discontinued operations before taxes4,931 — 5,296 
    Provision for income taxes1,143 — 178 
    Income from discontinued operations$3,788 $— $5,118 
    Cash flow information from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands):
    202120202019
    Cash used in operating activities$— $— $(78)
    Cash provided by investing activities— — 4,734 
    XML 42 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule II - Valuation and Qualifying Accounts
    		 12 Months Ended
    Dec. 31, 2021
    SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
    Schedule II - Valuation and Qualifying Accounts
    Schedule II—Valuation and Qualifying Accounts
     Col. C—Additions    
    Column A
    Description    		Col. B Balance at Beginning
    of Period    		Charged to Costs &
    Expenses    		Charged to Other Accounts- Describe Col. D Deductions
    - Describe    		 Col. E Balance at End of
    Period
    December 31, 2021
    Provision for credit losses
    		$155 $20 
    (1)
    		$— $(43)
    (4)
    		$132 
    Valuation allowance for deferred tax assets$20,739 $(941)
    (2)
    		$26 
    (3)
    		$(368)
    (2)
    		$19,456 
    December 31, 2020
    Provision for credit losses
    		$2,443 $28 
    (1)
    		$— $(2,316)
    (4)
    		$155 
    Valuation allowance for deferred tax assets$22,229 $(275)
    (2)
    		$— $(1,215)
    (2)(4)(5)
    		$20,739 
    December 31, 2019
    Allowance for doubtful accounts$592 $1,884 
    (1)
    		$2 
    (3)
    		$(35)
    (4)
    		$2,443 
    Valuation allowance for deferred tax assets$34,339 $736 
    (2)
    		$— $(12,846)
    (2)(4)(5)
    		$22,229 
    (1)Valuation allowance recorded in the provision for credit losses (allowance for doubtful accounts in years prior to 2020). The 2019 amount includes a $2.3 million reserve recorded in connection with a customer bankruptcy, net of adjustments to the Company’s general and specific reserves.
    (2)Valuation allowance recorded in the provision for income taxes for certain net operating losses and tax credits. The 2021, 2020 and 2019 deductions include the expiration of certain net operating losses and tax credits.
    (3)Includes foreign currency translation effect.
    (4)Accounts written off and reductions to allowances existing at the beginning of the year. The 2020 amount includes $2.3 million of accounts receivable recorded during 2019 in connection with a customer bankruptcy.
    (5)The 2020 and 2019 deductions include releases of the allowance for net operating losses utilized during that year and return to provision adjustments for prior years.
    Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.
    (3)See exhibits listed under Part (b) below.
    XML 43 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Summary of Significant Accounting Policies (Policies)
    		 12 Months Ended
    Dec. 31, 2021
    Accounting Policies [Abstract]  
    Basis of Presentation and Principles of Consolidation
    Basis of Presentation and Principles of Consolidation
    The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of Integer Holdings Corporation and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
    In July 2018, the Company completed the sale of its Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC). For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&O Product Line. The Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s (parent) centralized treasury and cash management processes. See Note 20 “Discontinued Operations” for the financial results and cash flow amounts for discontinued operations. All results and information in the consolidated financial statements are presented as continuing operations and exclude the AS&O Product Line unless otherwise noted specifically as discontinued operations.
    The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. The discontinued operations of the AS&O Product Line were reported in the Medical segment. Refer to Note 18 “Segment and Geographic Information,” for additional information on the Company’s reportable segments.
    Use of Estimates
    Use of Estimates
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting periods. Actual results could differ materially from those estimates.
    Cash and Cash Equivalents Cash and Cash EquivalentsCash and cash equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three months or less.
    Concentration of Credit Risk
    Concentration of Credit Risk
    Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and accounts receivable are to three customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 19 “Revenue from Contracts with Customers” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks.
    Trade Accounts Receivable and Provision for Current Expected Credit Losses Trade Accounts Receivable and Provision for Current Expected Credit LossesThe Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains a provision for those customer receivables that it does not expect to collect. In accordance with Accounting Standards Codification (“ASC”) Topic 326, the Company accrues its estimated losses from uncollectable accounts receivable to the provision based upon recent historical experience, the length of time the receivable has been outstanding, other specific information as it becomes available, and reasonable and supportable forecasts not already reflected in the historical loss information. Provisions for current expected credit losses are charged to current operating expenses. Actual losses are charged against the provision when incurred.
    Supplier Financing Arrangements Supplier Financing ArrangementsThe Company utilizes supplier financing arrangements with financial institutions to sell certain accounts receivable on a non-recourse basis. These transactions are treated as a sale of, and are accounted for as a reduction to, accounts receivable. The agreements transfer control and risk related to the receivables to the financial institutions. The Company has no continuing involvement in the transferred receivables subsequent to the sale.
    Inventories InventoriesInventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held, historical sales volume, and estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4 “Inventories” contains additional information on the Company’s inventory.
    Leases
    Leases
    The Company determines if an arrangement is, or contains, a lease at inception and classifies it at as finance or operating.  The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Finance lease assets and corresponding liabilities are included in Other long-term assets, Accrued expenses and other current liabilities, and Other long-term liabilities, respectively, on the Consolidated Balance Sheets.
    Lease right-of-use (“ROU”) assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term at commencement date. When discount rates implicit in leases cannot be readily determined, the Company uses its incremental borrowing rate based on information available at commencement date in determining the present value of future payments.  The incremental borrowing rate is determined based on the Company’s recent debt issuances, the Company’s specific credit rating, lease term and the currency in which lease payments are made.
    (1.)     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
    Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such option. Costs associated with operating leases are recognized within operating expenses on a straight-line basis over the lease term. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. The interest component of a finance lease is included in Interest expense and recognized using the effective interest method over the lease term. The Company combines lease and non-lease components for all asset classes. For certain leases where rent escalates based upon a change in a financial index, such as the Consumer Price Index, the difference between the rate at lease inception and the subsequent fluctuations in that rate are included in variable lease costs.  Additionally, because the Company does not separate lease and non-lease components, variable costs also include payments to the landlord for common area maintenance, real estate taxes, insurance and other operating expenses.  The Company does not apply the recognition requirements to leases with lease terms of 12 months or less. Note 14 “Leases” contains additional information on the Company’s leases.
    Property, Plant and Equipment
    Property, Plant and Equipment (“PP&E”)
    PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 12-30 years; machinery and equipment 3-10 years; office equipment 3-10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, whichever is shorter. The costs of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. The Company also reviews its PP&E for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its fixed assets exceeds the related undiscounted future cash flows. In cases where the carrying value of the Company's long-lived assets or asset groups (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. Note 5 “Property, Plant and Equipment, Net” contains additional information on the Company’s PP&E.
    Fair Value Measurements
    Fair Value Measurements
    Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. the “exit price”) in an orderly transaction between market participants at the measurement date. ASC 820, Fair Value Measurements, establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows:
    Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment.
    Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market.
    Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations.
    Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements.
    Acquisitions and Contingent Consideration
    Acquisitions
    The Company accounts for acquisitions under the acquisition method of accounting for business combinations. Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill.
    All direct acquisition-related costs are expensed as incurred and are recognized as a component of Other operating expenses. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.
    Contingent Consideration
    In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable performance target. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect.
    The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The Company determines the initial fair value of contingent consideration liabilities using a Monte Carlo (“Monte Carlo”) valuation model, which involves a simulation of future revenues during the earn out-period using management’s best estimates, or a probability-weighted discounted cash flow analysis.
    In periods subsequent to the initial measurement, contingent consideration liabilities are remeasured to fair value each reporting period until the contingent consideration is settled using various assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, revenue volatility and projected payment dates. The current portion of contingent consideration liabilities is included in Accrued expenses and other current liabilities and the non-current portion is included in Other long-term liabilities on the Consolidated Balance Sheets. Adjustments to the fair value of contingent consideration liabilities are included in Other operating expenses in the Consolidated Statements of Operations, and cash flows from operating activities in the Consolidated Statements of Cash Flows. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on contingent consideration recorded at fair value in the consolidated financial statements.
    Goodwill
    Goodwill
    Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired and is assigned to one or more reporting units. The Company’s reporting units are the same as its reportable segments, Medical and Non-Medical. The Company tests each reporting unit’s goodwill for impairment at least annually as of the last day of the fiscal year and between annual tests if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of a reporting unit below its carrying amount. In conducting its goodwill test, the Company either performs a qualitative assessment or a quantitative assessment. A qualitative assessment requires that the Company consider events or circumstances including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, changes in strategy, changes in customers, changes in the Company’s stock price, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair values of its reporting units are greater than the carrying amounts, then the quantitative goodwill impairment test is not performed. The Company may elect to bypass the qualitative analysis and perform a quantitative analysis.
    If the qualitative assessment indicates that the quantitative analysis should be performed or if management elects to bypass a qualitative analysis to perform a quantitative analysis, the Company then evaluates goodwill for impairment by comparing the fair value of each of its reporting units to its carrying value, including the associated goodwill. To determine the fair values, the Company uses a weighted combination of the market approach based on comparable publicly traded companies and the income approach based on estimated discounted future cash flows. The cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors.
    The Company completed its annual goodwill impairment test as of December 31, 2021 and determined, after performing a qualitative review of its Medical reporting unit, that it is more likely than not that the fair value of the Medical reporting unit exceeds its carrying amount. Accordingly, there was no indication of impairment and the quantitative goodwill impairment test was not performed for the Medical reporting unit. The Company bypassed the qualitative analysis for its Non-Medical reporting unit and performed a quantitative analysis. The fair value of the Non-Medical reporting unit exceeded its carrying amount as of December 31, 2021.
    Other Intangible Assets
    Other Intangible Assets
    Other intangible assets consist of purchased technology and patents, customer lists and trademarks. Definite-lived intangible assets are amortized on an accelerated or straight-line basis, which approximates the projected cash flows used to determine the fair value of those definite-lived intangible assets at the time of acquisition, as follows: purchased technology and patents 5-20 years; customer lists 7-20 years and other intangible assets 1-20 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized. The Company expenses the costs incurred to renew or extend the term of intangible assets.
    The Company reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets or asset groups exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted future cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis.
    The Company assesses its indefinite-lived intangible assets for impairment periodically to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment at least annually by comparing the fair value of the indefinite-lived intangible asset to its carrying value. The fair value is determined using the relief from royalty method.
    Refer to Note 6 “Goodwill and Other Intangible Assets, Net” for further details of the Company’s goodwill and other intangible assets.
    Equity Investments
    Equity Investments
    The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other long-term assets on the Consolidated Balance Sheets. Equity investments are measured and recorded as follows:
    •Non-marketable equity securities are equity securities without readily determinable fair value that are measured and recorded at fair value with changes in fair value recognized within net income. The Company measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. If an impairment is recognized on the Company’s non-marketable equity securities during the period, these assets are classified as Level 3 within the fair value hierarchy based on the nature of the fair value inputs.
    •Equity method investments are equity securities in investees the Company does not control but over which it has the ability to exercise influence. Equity method investments are recorded at cost and are adjusted to recognize (1) the Company’s share, based on percentage ownership or other contractual basis, of the investee’s income or loss, (2) additional contributions made and dividends or other distributions received, and (3) impairments resulting from other-than-temporary declines in fair value.
    Realized and unrealized gains and losses resulting from changes in fair value or the sale of these equity investments are recorded through (Gain) loss on equity investments, net. For some investments, the Company records its share of the investee’s income or loss one quarter in arrears due to the timing of our receipt of such information. The carrying value of the Company’s non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities by the same issuer. Determining whether an observed transaction is similar to a security within the Company’s portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of the Company’s equity securities as a result of observable price changes requires quantitative assessments of the fair value of these securities using various valuation methodologies and involves the use of estimates.
    Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. The Company’s quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee’s fair value. Qualitative factors considered include the investee’s financial condition and business outlook, market for technology, operational and financing cash flow activities, technology and regulatory approval progress, and other relevant events and factors affecting the investee. When indicators of impairment exist, quantitative assessments of the fair value of the Company’s non-marketable equity investments are prepared.
    To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security’s fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and the Company’s ability and intent to hold the investment for a sufficient period of time to allow for recovery.
    The Company has determined that its investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant. Refer to Note 17 “Financial Instruments and Fair Value Measurements” for additional information on the Company’s equity investments.
    Debt Issuance Costs and Discounts
    Debt Issuance Costs and Discounts
    Debt issuance costs and discounts associated with the issuance of debt by the Company are deferred and amortized over the lives of the related debt. Debt issuance costs incurred in connection with the Company’s issuance of its revolving credit facility are classified within Other long-term assets and amortized to Interest expense on a straight-line basis over the contractual term of the revolving credit facility. Debt issuance costs and discounts related to the Company’s term-debt are recorded as a reduction of the carrying value of the related debt and are amortized to Interest expense using the effective interest method over the period from the date of issuance to the maturity date. Upon prepayment of the related debt, the Company also recognizes a proportionate amount of the costs as extinguishment of debt. Costs treated as extinguishment of debt are expensed and included in Interest expense in the accompanying Consolidated Statements of Operations. The amortization of debt issuance costs and discounts, and debt extinguishment charges are included in Debt related charges included in interest expense in the Consolidated Statements of Cash Flows. Note 8 “Debt” contains additional information on the Company’s debt issuance costs and discounts.
    Income Taxes
    Income Taxes
    The consolidated financial statements of the Company have been prepared using the asset and liability approach to account for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined, within each taxing jurisdiction, that it is more likely than not that the asset will not be realized.
    The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision for income taxes. Penalties, if incurred, are recognized as a component of Selling, general and administrative (“SG&A”) expenses.
    The Company and its subsidiaries file a consolidated United States (“U.S.”) federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where the tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates.
    Derivative Financial Instruments Derivative Financial InstrumentsThe Company recognizes all derivative financial instruments in its consolidated financial statements at fair value. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. The Company’s use of derivative instruments is generally limited to cash flow hedges of certain interest rate risks and minimizing foreign currency exposure on foreign currency transactions, which are typically designated in hedging relationships, and intercompany balances, which are not designated as hedging instruments. Under master agreements with the respective counterparties to our derivative contracts, subject to applicable requirements, we have the right of set-off and are allowed to net settle transactions of the same type with a single net amount payable by one party to the other. Gains and losses on cash flow hedges are recorded in Accumulated Other Comprehensive Income in the Consolidated Balance Sheets until the underlying transaction is recorded in earnings. When the hedged item is realized, gains or losses are reclassified from Accumulated Other Comprehensive Income (“AOCI”) to the Consolidated Statement of Operations on the same line item as the underlying transaction. In the event the forecasted transactions do not occur, or it becomes probable that they will not occur, the Company reclassifies any gain or loss on the related cash flow hedge to earnings in the respective period. Cash flows related to these derivative financial instruments are included in cash flows from operating activities. Foreign currency contracts not designated as hedging relationships are recorded at fair value in Accrued expenses and other current liabilities in the Consolidated Balance Sheets and resulting gains or losses are recorded in the Consolidated Statement of Operations.
    Revenue Recognition
    Revenue Recognition
    The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The majority of contracts have an original expected duration of one year or less. Consideration payable to customers is included in the transaction price. In accordance with ASC 340-40-25-4, the Company expenses incremental costs of obtaining a contract when incurred because the amortization period is less than one year.
    The Company evaluates revenue recognition in contracts with customers as performance obligations are satisfied and as the customer obtains control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits of the products. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Most of the Company’s revenues are recognized at the point in time when the products are shipped to customers. When contracts with customers for products, which do not have an alternative use to the Company, contain provisions that provide the Company with an enforceable right to payment for performance completed to date for costs incurred plus a reasonable profit throughout the duration of the contract, revenue is recognized over time as control is transferred to the customer. In contracts with customers where revenue is recognized over time, the Company uses an input measure to determine progress towards completion and total estimated costs at completion. Under this method, sales and gross profit are recognized as work is performed generally based on actual costs incurred. Revenue is recognized net of sales tax, value-added taxes and other taxes.
    Performance Obligations
    The Company considers each shipment of an individual product included on a purchase order to be a separate performance obligation, as each shipment is separately identifiable and the customer can benefit from each individual product separately from the other products included on the purchase order. Accordingly, a contract can have one or more performance obligations to manufacture products. Standard payment terms range from 30 to 90 days and may include a discount for early payment.
    The Company does not offer its customers a right of return. Rather, the Company warrants that each unit received by the customer will meet the agreed upon technical and quality specifications and requirements. Only when the delivered units do not meet these requirements can the customer return the non-compliant units as a corrective action under the warranty. The remedy offered to the customer is repair of the returned units or replacement if repair is not viable. Accordingly, the Company records a warranty reserve and any warranty activities are not considered to be a separate performance obligation.
    Contract Balances
    The timing of revenue recognition, billings and cash collections results in billed accounts receivable and less frequently, unearned revenue. Accounts receivable are recorded when the right to consideration becomes unconditional. Unearned revenue is recorded when customers pay or are billed in advance of the Company’s satisfaction of performance obligations. Contract liabilities are classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. For contracts with customers where revenue is recognized over time, the Company records a contract asset for unbilled revenue associated with non-cancellable customer orders, which is recorded within Contract assets on the Consolidated Balance Sheets.
    Transaction Price
    Generally, the transaction price of the Company’s contracts consists of a unit price for each individual product included in the contract, which can be fixed or variable based on the number of units ordered. In some instances, the transaction price also includes a rebate for meeting certain volume-based targets over a specified period of time. The transaction price of a contract is determined based on the unit price and the number of units ordered, reduced by the rebate expected to be earned on those units. Rebates are estimated based on the expected achievement of the volume-based target using the most likely amount method and are updated quarterly. Adjustments to these estimates are recognized under the cumulative catch-up method and in the period in which they are identified. When contracts with customers include consideration payable at the beginning of the contract, the transaction price is reduced at the later of when the Company recognizes revenue for the transfer of the related goods to the customer or when the Company pays or promises to pay the consideration. Volume discounts and rebates and other pricing reductions earned by customers are offset against their receivable balances.
    The transaction price is allocated to each performance obligation on a relative standalone selling price basis. As the majority of products sold to customers are manufactured to meet the specific requirements and technical specifications of that customer, the products are considered unique to that customer and the unit price stated in the contract is considered the standalone selling price.
    Contract Modifications
    Contract modifications, which can include a change in scope, price, or both, most often occur related to contracts that are governed by a long-term arrangement. Contract modifications typically relate to the same products already governed by the long-term arrangement, and therefore, are accounted for as part of the existing contract. If a contract modification is for additional products, it is accounted for as a separate contract.
    Environmental Costs
    Environmental Costs
    Environmental expenditures that relate to an existing condition caused by past operations and that do not provide future benefits are expensed as incurred. Liabilities are recorded when environmental assessments are made, the requirement for remedial efforts is probable and the amount of the liability can be reasonably estimated. Liabilities are recorded generally no later than the completion of feasibility studies. The Company has a process in place to monitor, identify, and assess how the current activities for known exposures are progressing against the recorded liabilities. The process is also designed to identify other potential remediation sites that are not presently known.
    Restructuring Expenses
    Restructuring Expenses
    The Company continually evaluates alternatives to align its resources with the changing needs of its customers and markets, and to lower its operating costs. This includes realignment of existing manufacturing capacity, facility closures, process optimization, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in voluntary or involuntary employee termination benefits. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. All other exit costs are expensed as incurred. Refer to Note 11 “Other Operating Expenses” for additional information.
    Research, Development and Engineering (RD&E) Research, Development and Engineering (“RD&E”)RD&E costs are expensed as incurred. The primary costs are salary and benefits for personnel, material costs used in development projects and subcontracting costs.
    Product Warranties
    Product Warranties
    The Company allows customers to return defective or damaged products for credit, replacement, or repair. The Company warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The Company accrues its estimated exposure to warranty claims, through Cost of Sales, based upon experience and other specific information as it becomes available. The product warranty liability is classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. Adjustments to pre-existing estimated exposure for warranties are made as changes to the obligations become reasonably estimable. Note 13 “Commitments and Contingencies” contains additional information on the Company’s product warranties.
    Stock-Based Compensation
    Stock-Based Compensation
    The Company recognizes stock-based compensation expense for its compensation plans. These plans include stock options, restricted stock units (“RSUs”) and performance-based restricted stock units (“PRSUs”). For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares to be earned depends on the achievement of targets based on market conditions, such as total shareholder return, or performance conditions based on the Company’s operating results. The Company records forfeitures of equity awards in the period in which they occur.
    The fair value of the stock-based compensation is determined at the grant date. The Company uses the Black-Scholes standard option pricing model (“Black-Scholes model”) to determine the fair value of stock options. The fair value of each RSU is determined based on the Company’s closing stock price on the date of grant. The fair value of each PRSU is determined based on either the Company’s closing stock price on the date of grant or through a Monte Carlo valuation model for those awards that include a market-based condition. In addition to the closing stock price on the date of grant, the determination of the fair value of awards using both the Black-Scholes and Monte Carlo valuation models is affected by other assumptions, including the following:
    Expected Term - The Company analyzes historical employee exercise and termination data to estimate the expected term assumption for stock options. For market-based awards, the term is commensurate with the performance period remaining as of the grant date.
    Risk-free Interest Rate - A risk-free rate is based on the U.S. Treasury rates in effect on the grant date for a maturity equal to or approximating the expected term of the award.
    Expected Volatility - For stock options, expected volatility is calculated using historical volatility based on the daily closing prices of the Company’s common stock over a period equal to the expected term. For market-based awards, a combination of historical and implied volatility for the Company and members of its peer group are used in developing the expected volatility assumption.
    Dividend Yield - The dividend yield assumption is based on the Company’s expected annual dividend yield on the grant date.
    The Company recognizes compensation expense over the required service or vesting period based on the fair value of the award on the date of grant. Certain executive stock-based awards contain market, performance and service conditions. Compensation expense for awards with market conditions is recognized over the service period and is not reversed if the market condition is not met. Compensation expense for awards with performance conditions is reassessed each reporting period and recognized based upon the probability that the performance targets will be achieved.
    All stock option awards granted under the Company’s compensation plans have an exercise price equal to the closing stock price on the date of grant, a ten-year contractual life and generally, vest annually over a three-year vesting term. RSUs typically vest in equal annual installments over a three or four year period. RSUs issued to members of the Company’s Board of Directors as a portion of their annual retainer vest quarterly over a one-year vesting term. Earned PRSUs typically vest three years from the date of grant.
    The Company records deferred tax assets for awards that result in deductions on the Company’s income tax returns, based on the amount of stock-based compensation expense recognized and the statutory tax rate in the jurisdiction in which it will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported on the income tax return are recorded as a component of Provision for income taxes in the Consolidated Statements of Operations. Note 10 “Stock-Based Compensation” contains additional information on the Company’s stock-based compensation.
    Defined Benefit Plans
    Defined Benefit Plans
    The Company recognizes in its balance sheet as an asset or liability the overfunded or underfunded status of its defined benefit plans provided to its employees located in Mexico and Switzerland. This asset or liability is measured as the difference between the fair value of plan assets, if any, and the benefit obligation of those plans. For these plans, the benefit obligation is the projected benefit obligation, which is calculated based on actuarial computations of current and future benefits for employees. Actuarial gains or losses and prior service costs or credits that arise during the period, but are not included as components of net periodic benefit expense, are recognized as a component of AOCI on the Consolidated Balance Sheets. The Company records the service cost component of net benefit costs in Cost of sales and SG&A expenses. The interest cost component of net benefit costs is recorded in Interest expense and the remaining components of net benefit costs, amortization of net losses and expected return on plan assets, are recorded in Other (income) loss, net.
    Foreign Currency Translation and Remeasurement
    Foreign Currency Translation and Remeasurement
    The Company translates all assets and liabilities of its foreign subsidiaries, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translates income and expenses at the average exchange rates in effect during the period. The net effect of this translation is recorded in the consolidated financial statements as a component of AOCI. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in the Company’s foreign subsidiaries.
    The Company has foreign operations in the Dominican Republic, Germany, Ireland, Israel, Malaysia, Mexico, Switzerland, and Uruguay, which expose the Company to foreign currency exchange rate fluctuations due to transactions denominated in Dominican pesos, Euros, Israeli shekels, Malaysian ringgits, Mexican pesos, Swiss francs, and Uruguayan pesos. To the extent that monetary assets and liabilities, including short-term and long-term intercompany loans, are recorded in a currency other than the functional currency of the subsidiary, these amounts are remeasured each period at the period-end exchange rate, with the resulting gain or loss being recorded in Other (income) loss, net in the Consolidated Statements of Operations.
    Earnings Per Share (EPS)
    Earnings Per Share (“EPS”)
    Basic EPS is calculated by dividing Net Income by the weighted average number of shares outstanding during the period. Diluted EPS is calculated by adjusting the weighted average number of shares outstanding for potential common shares if dilutive to the EPS calculation. Note 15 “Earnings Per Share” contains additional information on the computation of the Company’s EPS.
    Comprehensive Income
    Comprehensive Income
    The Company’s comprehensive income as reported in the Consolidated Statements of Comprehensive Income includes net income, foreign currency translation adjustments, the net change in cash flow hedges, net of tax, and defined benefit plan liability adjustments, net of tax. The Consolidated Statements of Comprehensive Income and Note 16 “Stockholders’ Equity” contain additional information on the computation of the Company’s comprehensive income.
    Recently Accounting Pronouncements Adopted, Accounting Guidance Not Yet Elected or Adopted
    Recent Accounting Pronouncements
    In the normal course of business, management evaluates all new Accounting Standards Updates (“ASU”) and other accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements.
    Accounting Guidance Not Yet Elected or Adopted
    In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company will early adopt ASU 2021-08 as of January 1, 2022 on a prospective basis. The impact of the adoption of ASU 2021-08 cannot currently be determined, as it is dependent on future business combinations that the Company may enter into.
    XML 44 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Business Acquisition (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Business Combination and Asset Acquisition [Abstract]  
    Schedule of Summary of Final Allocation of Purchase Consideration As a result, the allocation of the provisional purchase price may change in the future, which could be material.
    The preliminary purchase price allocation was as follows (in thousands):
    Fair value of net assets acquired
    Current assets (excluding inventory)$12,148 
    Inventory12,212 
    Property, plant and equipment17,977 
    Goodwill77,887 
    Intangible assets105,300 
    Operating lease assets15,142 
    Other noncurrent assets695 
    Current liabilities(8,875)
    Operating lease liabilities(12,044)
    Fair value of net assets acquired$220,442 
    Schedule of Indefinite-Lived Intangible Assets
    The purchase price was allocated to intangible assets as follows (dollars in thousands):
    Definite-lived Intangible AssetsFair Value AssignedWeighted Average Amortization Period
    (Years)    		Weighted Average Discount Rate
    Customer lists$73,800 20.09.5%
    Technology15,200 15.09.5%
    Tradenames16,300 20.09.5%
    Intangible assets comprise the following (in thousands):
    Gross
    Carrying
    Amount    		Accumulated
    Amortization    		Net
    Carrying
    Amount
    December 31, 2021
    Definite-lived:
    Purchased technology, tradenames and patents$285,659 $(164,371)$121,288 
    Customer lists783,618 (187,412)596,206 
    Other4,162 (4,134)28 
    Total amortizing intangible assets$1,073,439 $(355,917)$717,522 
    Indefinite-lived:
    Trademarks and tradenames$90,288 
    December 31, 2020
    Definite-lived:
    Purchased technology and patents$257,453 $(152,798)$104,655 
    Customer lists723,791 (161,856)561,935 
    Other4,142 (3,796)346 
    Total amortizing intangible assets$985,386 $(318,450)$666,936 
    Indefinite-lived:
    Trademarks and tradenames$90,288 
    Schedule of Business Acquisition, Pro Forma Information
    The following unaudited pro forma information presents the consolidated results of operations of the Company and Oscor as if the acquisition occurred as of the beginning of fiscal year 2020 (in thousands):
     20212020
    Sales$1,274,148 $1,128,137 
    Income from continuing operations$91,844 $67,529 
    XML 45 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Supplemental Cash Flow Information (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Supplemental Cash Flow Elements [Abstract]  
    Schedule of Supplemental Cash Flow Information
    The following represents supplemental cash flow information for fiscal years 2021, 2020 and 2019 (in thousands):
     202120202019
    Non-cash investing and financing activities:
    Property, plant and equipment purchases included in accounts payable$5,556 $3,597 $8,646 
    Cash paid during the year for:
    Interest24,740 33,933 44,784 
    Income taxes19,649 18,477 30,034 
    XML 46 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Inventories (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Inventory Disclosure [Abstract]  
    Schedule of Inventory, Current
    Inventories comprise the following (in thousands):
    December 31,
    2021    		December 31,
    2020
    Raw materials$70,956 $72,477 
    Work-in-process74,152 58,806 
    Finished goods10,591 18,040 
    Total$155,699 $149,323 
    XML 47 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Property, Plant and Equipment, Net (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Property, Plant and Equipment [Abstract]  
    Schedule of Property, Plant and Equipment
    PP&E comprises the following (in thousands):
    December 31, 2021December 31,
    2020
    Manufacturing machinery and equipment$352,391 $320,807 
    Buildings and building improvements98,007 102,037 
    Information technology hardware and software72,752 69,969 
    Leasehold improvements85,931 77,382 
    Furniture and fixtures17,099 16,250 
    Land and land improvements13,980 11,598 
    Construction work in process41,813 26,389 
    Other1,431 1,238 
    683,404 625,670 
    Accumulated depreciation(406,305)(371,706)
    Total$277,099 $253,964 
    Schedule of Depreciation Expense
    Depreciation expense for PP&E was as follows for fiscal years 2021, 2020 and 2019 (in thousands):
    202120202019
    Depreciation expense$39,772 $38,193 $37,819 
    XML 48 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Goodwill and Other Intangible Assets, Net (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Schedule of Goodwill
    The change in the carrying amount of goodwill by reportable segment during fiscal years 2021 and 2020 was as follows (in thousands):
    MedicalNon-MedicalTotal
    December 31, 2019$822,617 $17,000 $839,617 
    Acquisition4,800 — 4,800 
    Acquisition-related adjustments (Note 2)(85)— (85)
    Foreign currency translation15,110 — 15,110 
    December 31, 2020842,442 17,000 859,442 
    Acquisition (Note 2)77,887 — 77,887 
    Foreign currency translation(12,625)— (12,625)
    December 31, 2021$907,704 $17,000 $924,704 
    Schedule of Finite-Lived Intangible Assets
    Intangible assets comprise the following (in thousands):
    Gross
    Carrying
    Amount    		Accumulated
    Amortization    		Net
    Carrying
    Amount
    December 31, 2021
    Definite-lived:
    Purchased technology, tradenames and patents$285,659 $(164,371)$121,288 
    Customer lists783,618 (187,412)596,206 
    Other4,162 (4,134)28 
    Total amortizing intangible assets$1,073,439 $(355,917)$717,522 
    Indefinite-lived:
    Trademarks and tradenames$90,288 
    December 31, 2020
    Definite-lived:
    Purchased technology and patents$257,453 $(152,798)$104,655 
    Customer lists723,791 (161,856)561,935 
    Other4,142 (3,796)346 
    Total amortizing intangible assets$985,386 $(318,450)$666,936 
    Indefinite-lived:
    Trademarks and tradenames$90,288 
    Schedule of Indefinite-Lived Intangible Assets
    The purchase price was allocated to intangible assets as follows (dollars in thousands):
    Definite-lived Intangible AssetsFair Value AssignedWeighted Average Amortization Period
    (Years)    		Weighted Average Discount Rate
    Customer lists$73,800 20.09.5%
    Technology15,200 15.09.5%
    Tradenames16,300 20.09.5%
    Intangible assets comprise the following (in thousands):
    Gross
    Carrying
    Amount    		Accumulated
    Amortization    		Net
    Carrying
    Amount
    December 31, 2021
    Definite-lived:
    Purchased technology, tradenames and patents$285,659 $(164,371)$121,288 
    Customer lists783,618 (187,412)596,206 
    Other4,162 (4,134)28 
    Total amortizing intangible assets$1,073,439 $(355,917)$717,522 
    Indefinite-lived:
    Trademarks and tradenames$90,288 
    December 31, 2020
    Definite-lived:
    Purchased technology and patents$257,453 $(152,798)$104,655 
    Customer lists723,791 (161,856)561,935 
    Other4,142 (3,796)346 
    Total amortizing intangible assets$985,386 $(318,450)$666,936 
    Indefinite-lived:
    Trademarks and tradenames$90,288 
    Schedule of Finite-Lived Intangible Assets, Amortization Expense
    Aggregate intangible asset amortization expense comprises the following for fiscal years 2021, 2020 and 2019 (in thousands):
    202120202019
    Cost of sales$13,090 $12,860 $13,111 
    SG&A28,507 28,271 26,965 
    Total intangible asset amortization expense$41,597 $41,131 $40,076 
    Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
    Estimated future intangible asset amortization expense based upon the carrying value as of December 31, 2021 is as follows (in thousands):
    20222023202420252026After 2026
    Amortization expense$46,594 $48,490 $47,576 $45,946 $43,612 $485,304 
    XML 49 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Accrued Expenses and Other Current Liabilities (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Accounts Payable and Accrued Liabilities [Abstract]  
    Schedule of Accrued Liabilities and Other Current Liabilities
    Accrued expenses and other current liabilities comprise the following (in thousands):
    December 31, 2021December 31,
    2020
    Salaries and benefits$27,733 $24,512 
    Profit sharing and bonuses18,325 19,204 
    Contract liabilities3,776 2,498 
    Product warranties509 163 
    Accrued interest76 1,644 
    Other6,514 8,822 
    Total$56,933 $56,843 
    XML 50 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Debt Disclosure [Abstract]  
    Schedule of Debt
    Long-term debt comprises the following (in thousands):
     December 31, 2021December 31,
    2020
    Senior secured term loan A $467,062 $229,687 
    Senior secured term loan B 349,125 508,286 
    Senior secured revolving credit facility19,300 — 
    Unamortized discount on term loan B and deferred debt issuance costs(7,361)(6,715)
    Total debt828,126 731,258 
    Current portion of long-term debt(15,250)(37,500)
    Total long-term debt$812,876 $693,758 
    Schedule of Maturities of Long-term Debt for the next five years and thereafter, as of December 31, 2021, are as follows (in thousands):
    20222023202420252026After 2026
    Future minimum principal payments$15,250 $18,188 $29,938 $38,750 $401,739 $331,622 
    Schedule of Deferred Financing Costs
    The change in deferred debt issuance costs related to the Company’s Revolving Credit Facility is as follows (in thousands):
    December 31, 2020891 
    Financing costs incurred2,762 
    Write-off of deferred debt issuance costs(72)
    Amortization during the period(542)
    December 31, 2021$3,039 
    The change in unamortized discount and deferred debt issuance costs related to the Term Loan Facilities is as follows (in thousands):
    Deferred Debt Issuance CostsUnamortized Discount on TLB FacilityTotal
    December 31, 20205,258 1,457 6,715 
    Financing costs incurred5,236 1,750 6,986 
    Write-off of deferred debt issuance costs and unamortized discount(2,677)(954)(3,631)
    Amortization during the period(2,143)(566)(2,709)
    December 31, 2021$5,674 $1,687 $7,361 
    XML 51 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock-Based Compensation (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Share-based Payment Arrangement [Abstract]  
    Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs
    The components and classification of stock-based compensation expense for fiscal years 2021, 2020 and 2019 were as follows (in thousands):
    202120202019
    Stock options$— $43 $410 
    RSUs and PRSUs16,185 9,120 8,884 
    Total stock-based compensation expense$16,185 $9,163 $9,294 
    Cost of sales$3,365 $1,658 $1,011 
    SG&A11,579 6,942 7,827 
    RD&E969 563 269 
    OOE272 — 187 
    Total stock-based compensation expense$16,185 $9,163 $9,294 
    Schedule of Share-based Compensation, Stock Options, Activity The following table summarizes stock option activity during the fiscal year ended December 31, 2021:
    Number of
    Stock
    Options    		Weighted
    Average
    Exercise
    Price    		Weighted
    Average
    Remaining
    Contractual
    Term
    (in years)    		Aggregate
    Intrinsic
    Value
    (in millions)
    Outstanding at December 31, 2020281,873 $36.05 
    Exercised(34,233)21.72 
    Outstanding at December 31, 2021247,640 $38.03 4.2$11.8 
    Vested and exercisable at December 31, 2021247,640 $38.03 4.2$11.8 
    Schedule Of Stock Option Exercise Information
    The following table provides certain information relating to the exercise of stock options during fiscal years 2021, 2020 and 2019 (in thousands):
    202120202019
    Intrinsic value$2,370 $4,773 $7,998 
    Cash received743 3,263 3,242 
    Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
    The following table summarizes RSU activity during the fiscal year ended December 31, 2021:
    Time-Vested
    Activity    		Weighted
    Average Grant Date
    Fair Value
    Nonvested at December 31, 2020207,923 $75.38 
    Granted208,624 81.98 
    Vested(149,464)74.47 
    Forfeited(18,952)79.84 
    Nonvested at December 31, 2021248,131 $81.14 
    The following table summarizes PRSU activity during the fiscal year ended December 31, 2021:
    Performance-
    Vested
    Activity    		Weighted
    Average Grant Date
    Fair Value
    Nonvested at December 31, 2020219,391 $72.33 
    Granted92,384 85.16 
    Vested(38,882)37.75 
    Forfeited(74,024)53.45 
    Nonvested at December 31, 2021198,869 $92.07 
    Schedule of Share-based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows:
     202120202019
    Weighted average fair value$85.16 $107.27 $117.03 
    Risk-free interest rate0.19 %1.29 %2.46 %
    Expected volatility41 %30 %40 %
    Expected life (in years)3.02.92.8
    Expected dividend yield— %— %— %
    XML 52 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Other Operating Expenses (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Other Income and Expenses [Abstract]  
    Schedule of Other Operating Cost and Expense, by Component
    The following tables summarize OOE by program in each of the preceding three years (in thousands):
    202120202019
    Operational excellence initiatives$3,893 $2,791 $— 
    Strategic reorganization and alignment911 686 5,812 
    Manufacturing alignment to support growth— 241 2,145 
    Acquisition and integration costs (adjustments)2,544 (776)377 
    Other general expenses508 4,679 3,817 
    Total other operating expenses$7,856 $7,621 $12,151 
    Schedule of Restructuring Reserve by Type of Cost
    The following table summarizes the change in accrued liabilities, presented within Accrued expenses and other current liabilities on the Consolidated Balance Sheets, related to the initiatives described above (in thousands):
    Operational excellence initiatives
    Strategic reorganization and alignment
    		Total
    December 31, 2020$291 $— $291 
    Charges incurred, net of reversals3,893 911 4,804 
    Cash payments(3,886)(777)(4,663)
    December 31, 2021$298 $134 $432 
    XML 53 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Income Tax Disclosure [Abstract]  
    Schedule of Income before Income Tax, Domestic and Foreign
    Income from continuing operations before taxes for fiscal years 2021, 2020 and 2019 consisted of the following (in thousands):
    202120202019
    U.S.$48,293 $35,337 $40,203 
    International52,770 50,870 64,990 
    Total income from continuing operations before taxes$101,063 $86,207 $105,193 
    Schedule of Components of Income Tax Expense (Benefit)
    The provision for income taxes from continuing operations for fiscal years 2021, 2020 and 2019 comprises the following (in thousands):
    202120202019
    Current:
    Federal$9,511 $7,784 $14,090 
    State1,553 1,233 87 
    International8,459 6,898 10,083 
    19,523 15,915 24,260 
    Deferred:
    Federal(8,665)(4,648)(8,813)
    State(393)(1,245)332 
    International(2,422)(1,073)(1,804)
    (11,480)(6,966)(10,285)
    Total provision for income taxes$8,043 $8,949 $13,975 
    Schedule of Effective Income Tax Rate Reconciliation
    The provision for income taxes from continuing operations differs from the U.S. statutory rate for fiscal years 2021, 2020 and 2019 due to the following:
    202120202019
    Statutory rate$21,223 21.0 %$18,103 21.0 %$22,091 21.0 %
    Federal tax credits (including R&D)(11,929)(11.8)(7,009)(8.1)(4,797)(4.6)
    Foreign rate differential(5,165)(5.1)(5,333)(6.2)(5,479)(5.2)
    Stock-based compensation(1,084)(1.1)(1,459)(1.7)(2,422)(2.3)
    Uncertain tax positions18 — 1,208 1.4 (920)(0.9)
    State taxes, net of federal benefit1,183 1.2 553 0.6 1,106 1.1 
    U.S. tax on foreign earnings, net of §250 deduction1,913 1.9 3,216 3.7 5,201 4.9 
    Valuation allowance524 0.5 (345)(0.4)(1,606)(1.5)
    Other1,360 1.4 15 0.1 801 0.8 
    Effective tax rate$8,043 8.0 %$8,949 10.4 %$13,975 13.3 %
    Schedule of Deferred Tax Assets and Liabilities
    The net deferred tax liability consists of the following (in thousands):
    December 31,
    2021    		December 31,
    2020
    Tax credit carryforwards$11,394 $13,449 
    Inventories14,147 14,099 
    Net operating loss carryforwards11,721 10,436 
    Operating lease liabilities17,950 11,969 
    Stock-based compensation3,724 3,276 
    Accrued expenses9,348 8,058 
    Gross deferred tax assets68,284 61,287 
    Less valuation allowance(19,456)(20,739)
    Net deferred tax assets48,828 40,548 
    Property, plant and equipment(7,354)(5,824)
    Intangible assets(186,150)(197,048)
    Operating lease assets(17,974)(11,290)
    Other(3,144)(4,292)
    Gross deferred tax liabilities(214,622)(218,454)
    Net deferred tax liability$(165,794)$(177,906)
    Presented as follows:
    Noncurrent deferred tax asset$5,711 $4,398 
    Noncurrent deferred tax liability(171,505)(182,304)
    Net deferred tax liability$(165,794)$(177,906)
    Schedule of Operating Loss and Tax Credit Carryforwards
    As of December 31, 2021, the Company has the following carryforwards available:
    JurisdictionTax
    Attribute    		Amount
    (in millions)    		Begin to Expire
    U.S. State
    Net operating losses(1)
    		$120.7 2022
    International
    Net operating losses(1)
    		12.2 2022
    U.S. FederalForeign tax credits6.7 2022
    U.S. StateR&D tax credits1.4 2022
    U.S. StateState tax credits4.9 2022
    __________
    (1)     Net operating losses (“NOLs”) are presented as pre-tax amounts.
    Schedule of Income Tax Contingencies
    Below is a summary of changes to the unrecognized tax benefit for fiscal years 2021, 2020 and 2019 (in thousands):
    202120202019
    Balance, beginning of year$5,484 $4,446 $5,369 
    Additions based upon tax positions related to the current year3,324 300 300 
    Additions (reductions) related to prior period tax returns(3,271)738 (1,223)
    Balance, end of year$5,537 $5,484 $4,446 
    XML 54 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Commitments and Contingencies (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Commitments and Contingencies Disclosure [Abstract]  
    Schedule of Product Warranty Liability The change in product warranty liability for fiscal years 2021 and 2020 comprises the following (in thousands):
    20212020
    Beginning balance$163 $1,933 
    Additions to warranty reserve, net of reversals(15)(156)
    Adjustments to pre-existing warranties (71)(119)
    Warranty claims settled— (1,495)
    Acquisitions$432 — 
    Ending balance$509 $163 
    XML 55 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Leases [Abstract]  
    Schedule of Lease Term, Discount Rate, Lease Costs and Supplemental Cash Flow Information
    The components and classification of lease cost are as follows (in thousands):
    December 31,
    2021    		December 31,
    2020
    Finance lease cost:
    Amortization of lease assets$223 $7 
    Interest on lease liabilities59 1 
    Finance lease cost282 8 
    Operating lease cost10,729 10,425 
    Short-term lease cost (leases with initial term of 12 months or less)137 86 
    Variable lease cost2,619 2,615 
    Sublease income(1,392)(1,495)
    Total lease cost$12,375 $11,639 
    Cost of sales$9,642 $9,141 
    SG&A1,817 1,803 
    RD&E857 694 
    Interest expense$59 $1 
    Total lease cost$12,375 $11,639 
    The following table presents the weighted average remaining lease term and discount rate.
    December 31,
    2021    		December 31,
    2020
    Weighted-average remaining lease term - operating leases (in years)7.07.0
    Weighted-average remaining lease term - finance leases (in years)12.23.8
    Weighted-average discount rate - operating leases3.9 %5.3 %
    Weighted-average discount rate - finance leases3.5 %2.2 %

    Supplemental cash flow information related to leases for fiscal years 2021 and 2020 is as follows (in thousands):
    20212020
    Cash paid for operating leases$10,808 $10,385 
    Cash paid for interest on finance leases59 1 
    Assets acquired under operating leases32,466 9,059 
    Assets acquired under finance leases8,154 127 
    Schedule of Operating Lease Liability Maturities (Topic 842)
    At December 31, 2021, the maturities of operating and finance lease liabilities were as follows (in thousands):
    Operating Leases Finance Leases
    2022$12,423 $876 
    202311,317 888 
    202410,809 896 
    202510,634 787 
    20269,856 640 
    Thereafter25,652 5,807 
    Gross lease liabilities80,691 9,894 
    Less: imputed interest(11,062)(1,836)
    Present value of lease liabilities69,629 8,058 
    Less: current portion of lease liabilities(9,862)(608)
    Total long-term lease liabilities$59,767 $7,450 
    XML 56 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Earnings Per Share (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Earnings Per Share [Abstract]  
    Schedule of Earnings Per Share, Basic and Diluted
    The following table sets forth a reconciliation of the information used in computing basic and diluted EPS for fiscal years 2021, 2020 and 2019 (in thousands, except per share amounts):
    202120202019
    Numerator for basic and diluted EPS:
    Income from continuing operations$93,020 $77,258 $91,218 
    Income from discontinued operations3,788 — 5,118 
    Net income$96,808 $77,258 $96,336 
    Denominator for basic EPS:
    Weighted average shares outstanding32,993 32,845 32,627 
    Effect of dilutive securities:
    Stock options, restricted stock and restricted stock units265 268 410 
    Denominator for diluted EPS33,258 33,113 33,037 
    Basic earnings per share:
    Income from continuing operations$2.82 $2.35 $2.80 
    Income from discontinued operations0.11 — 0.16 
    Basic earnings per share2.93 2.35 2.95 
    Diluted earnings per share:
    Income from continuing operations$2.80 $2.33 $2.76 
    Income from discontinued operations0.11 — 0.15 
    Diluted earnings per share2.91 2.33 2.92 
    Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
    The diluted weighted average share calculations do not include the following securities for fiscal years 2021, 2020 and 2019, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):
    202120202019
    Time-vested stock options, restricted stock and restricted stock units4 98 30 
    Performance-vested restricted stock units92 89 47 
    XML 57 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stockholders' Equity (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Equity [Abstract]  
    Schedule of Changes in Number of Shares of Common Stock
    The following table sets forth the changes in the number of shares of common stock for fiscal years 2021 and 2020:
    IssuedTreasury StockOutstanding
    Shares outstanding at December 31, 201932,847,017 (146,546)32,700,471 
    Stock options exercised27,544 74,596 102,140 
    Vesting of RSUs, net of shares withheld to cover taxes33,617 71,950 105,567 
    Shares outstanding at December 31, 202032,908,178 — 32,908,178 
    Stock options exercised34,233 — 34,233 
    Vesting of RSUs, net of shares withheld to cover taxes120,925 — 120,925 
    Shares outstanding at December 31, 202133,063,336 — 33,063,336 
    Schedule of Accumulated Other Comprehensive Income (Loss)
    Accumulated other comprehensive income comprises the following (in thousands): 
    Defined
    Benefit
    Plan
    Liability    		Cash
    Flow
    Hedges    		Foreign
    Currency
    Translation
    Adjustment    		Total
    Pre-Tax
    Amount    		TaxNet-of-Tax
    Amount
    December 31, 2019$(912)$(2,358)$22,639 $19,369 $619 $19,988 
    Unrealized loss on cash flow hedges— (6,683)— (6,683)1,404 (5,279)
    Realized loss on foreign currency hedges— 638 — 638 (134)504 
    Realized loss on interest rate swap hedges— 3,447 — 3,447 (724)2,723 
    Net defined benefit plan adjustments(183)— — (183)32 (151)
    Foreign currency translation gain— — 34,907 34,907 — 34,907 
    December 31, 2020$(1,095)$(4,956)$57,546 $51,495 $1,197 $52,692 
    Unrealized gain on cash flow hedges— 91 — 91 (19)72 
    Realized gain on foreign currency hedges— (832)— (832)175 (657)
    Realized loss on interest rate swap hedges— 3,406 — 3,406 (716)2,690 
    Net defined benefit plan adjustments205 — — 205 14 219 
    Foreign currency translation loss— — (27,826)(27,826)— (27,826)
    December 31, 2021$(890)$(2,291)$29,720 $26,539 $651 $27,190 
    XML 58 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Instruments and Fair Value Measurements (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Fair Value Disclosures [Abstract]  
    Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
    The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):
    Fair ValueQuoted
    Prices in
    Active
    Markets
    (Level 1)    		Significant
    Other
    Observable
    Inputs
    (Level 2)    		Significant
    Unobservable
    Inputs
    (Level 3)
    December 31, 2021
    Assets: Foreign currency hedging contracts$687 $— $687 $— 
    Liabilities: Interest rate swap2,978 — 2,978 — 
    Liabilities: Contingent consideration2,415 — — 2,415 
    December 31, 2020
    Assets: Foreign currency hedging contracts$2,070 $— $2,070 $— 
    Liabilities: Interest rate swaps7,026 — 7,026 — 
    Liabilities: Contingent consideration3,900 — — 3,900 
    Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of December 31, 2021 is as follows (dollars in thousands):
    Notional AmountStart DateEnd
    Date    		Pay Fixed RateReceive Current Floating RateFair ValueBalance Sheet Location
    $150,000 Jun 2020Jun 20232.1785 %0.1013 %$(2,978)Other long-term liabilities
    (17.)     FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
    Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands):
    Notional AmountMaturity
    Date    		Pay Fixed RateReceive Current Floating RateFair ValueBalance Sheet Location
    $200,000 Jun 20232.1785 %0.1480 %$(7,026)Other long-term liabilities
    Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2021 is as follows (dollars in thousands):
    Notional AmountMaturity
    Date    		$/Foreign CurrencyFair ValueBalance Sheet Location
    $22,201 Dec 20220.0463MXN Peso$408 Prepaid expenses and other current assets
    17,017 Dec 20221.1344Euro130 Prepaid expenses and other current assets
    9,020 Dec 20220.0220UYU Peso149 Prepaid expenses and other current assets
    Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands):
    Notional AmountMaturity
    Date    		$/Foreign CurrencyFair ValueBalance Sheet Location
    $16,132 Sep 20211.1949Euro$399 Prepaid expenses and other current assets
    10,224 Sep 20210.0454MXN Peso922 Prepaid expenses and other current assets
    2,656 Mar 20210.0443MXN Peso341 Prepaid expenses and other current assets
    7,269 Dec 20210.0485MXN Peso77 Prepaid expenses and other current assets
    3,252 Aug 20210.0232UYU Peso165 Prepaid expenses and other current assets
    3,966 Nov 20210.0227UYU Peso166 Prepaid expenses and other current assets
    Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)
    The following table presents the impact of cash flow hedge derivative instruments on other comprehensive income (“OCI”), AOCI and the Company’s Consolidated Statement of Operations for fiscal years 2021, 2020 and 2019 (in thousands):
    Gain (Loss) Recognized in OCIGain (Loss) Reclassified from AOCI
    Derivative202120202019Location in Statement of Operations 202120202019
    Interest rate swaps$642 $(7,405)$(5,618)Interest expense$(3,406)$(3,447)$1,621 
    Foreign exchange contracts(943)1,017 (1,044)Sales(674)618 (1,334)
    Foreign exchange contracts399 (355)2,634 Cost of sales1,437 (1,177)1,482 
    Foreign exchange contracts(7)60 — Operating expenses69 (79)— 
    Schedule of Rollforward of Contingent Consideration
    The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for fiscal years 2021 and 2020 (in thousands):
    December 31, 2019$4,200 
    Amount recorded for current year acquisitions
    		2,700 
    Fair value measurement adjustment(2,000)
    Payments
    		(1,000)
    December 31, 20203,900 
    Fair value measurement adjustment133 
    Payments
    		(1,621)
    Foreign currency translation3 
    December 31, 2021$2,415 
    Schedule of Contingent Consideration Measurement Inputs
    The following table provides quantitative information associated with the fair value measurement of the Company’s liabilities for contingent consideration:
    December 31, 2021
    Contingency TypeRemaining Maximum Payout (undiscounted)Fair ValueValuation TechniqueUnobservable InputsWeighted Average or Range
    Revenue-based payments$6,750 $2,415 Monte CarloRevenue volatility29.0 %
    Discount rate1.8 %
    Projected year(s) of payment2022-2024
    (17.)     FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
    December 31, 2020
    Contingency TypeRemaining Maximum Payout (undiscounted)Fair ValueValuation TechniqueUnobservable InputsWeighted Average or Range
    Revenue-based payments$9,000 $3,900 Monte CarloRevenue volatility35.0 %
    Discount rate4.0 %
    Projected year(s) of payment2021-2024
    Schedule of Equity Method Investments
    Equity investments comprise the following (in thousands):
    December 31,
    2021    		December 31,
    2020
    Equity method investment$16,192 $21,470 
    Non-marketable equity securities5,637 5,723 
    Total equity investments
    		$21,829 $27,193 
    The components of (Gain) loss on equity investments, net for each period were as follows (in thousands):
    202120202019
    Equity method investment (income) loss$3,057 $(5,706)$(1,100)
    Impairment charges86 369 1,575 
    Total (gain) loss on equity investments, net
    		$3,143 $(5,337)$475 
    XML 59 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Segment and Geographic Information (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Segment Reporting [Abstract]  
    Schedule of Segment Sales by Product Line
    The following table presents sales by product line for fiscal years 2021, 2020 and 2019 (in thousands).
    202120202019
    Segment sales by product line:
    Medical
    Cardio & Vascular $626,013 $569,948 $610,056 
    Cardiac & Neuromodulation446,569 346,242 457,194 
    Advanced Surgical, Orthopedics & Portable Medical110,044 121,788 132,429 
    Total Medical1,182,626 1,037,978 1,199,679 
    Non-Medical38,453 35,464 58,415 
    Total sales$1,221,079 $1,073,442 $1,258,094 
    Schedule of Sales by Geographic Area
    The following table presents sales by significant country for fiscal years 2021, 2020 and 2019. In these tables, sales are allocated based on where the products are shipped (in thousands).
    202120202019
    Sales by geographic area:
    United States$671,502 $596,804 $698,474 
    Non-Domestic locations:
    Puerto Rico110,162 96,048 154,644 
    Costa Rica66,975 58,853 63,634 
    Rest of world372,440 321,737 341,342 
    Total sales$1,221,079 $1,073,442 $1,258,094 
    The following table presents revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped for fiscal years 2021 and 2020.
    20212020
    Ship to LocationMedicalNon-MedicalMedicalNon-Medical
    United States54%71%55%60%
    Rest of world46%29%45%40%
    Schedule of Revenue by Major Customers by Reporting Segments
    The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues for fiscal years 2021 and 2020.
    20212020
    CustomerMedicalNon-MedicalMedicalNon-Medical
    Customer A19%*19%*
    Customer B17%*17%*
    Customer C14%*15%*
    Customer D*36%*22%
    Customer E***10%
    All other customers50%64%49%68%
    __________
    * Less than 10% of segment’s total revenues for the period.
    Schedule of Segment Income (Loss) from Operations
    The following table presents income from continuing operations for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).
    202120202019
    Segment income from continuing operations:
    Medical$213,600 $169,396 $223,873 
    Non-Medical8,022 4,848 16,289 
    Total segment income from continuing operations221,622 174,244 240,162 
    Unallocated operating expenses(85,911)(53,632)(82,527)
    Operating income135,711 120,612 157,635 
    Unallocated expenses, net(34,648)(34,405)(52,442)
    Income from continuing operations before taxes$101,063 $86,207 $105,193 
    Schedule of Segment Depreciation and Amortization
    The following table presents depreciation and amortization expense for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).
     202120202019
    Segment depreciation and amortization:
    Medical$75,366 $72,338 $68,867 
    Non-Medical1,167 996 1,039 
    Total depreciation and amortization included in segment
       income from continuing operations
    		76,533 73,334 69,906 
    Unallocated depreciation and amortization4,836 5,990 7,989 
    Total depreciation and amortization$81,369 $79,324 $77,895 
    Schedule of Long-Lived Tangible Assets and Identifiable Assets by Geographic Area
    The following table presents total assets for the Company’s reportable segments as of December 31, 2021 and December 31, 2020 (in thousands).
    December 31,
    2021    		December 31,
    2020
    Identifiable assets:
    Medical$2,448,123 $2,212,489 
    Non-Medical 56,158 52,682 
    Total reportable segments2,504,281 2,265,171 
    Unallocated assets77,934 106,686 
    Total assets$2,582,215 $2,371,857 
    The following table presents PP&E by geographic area as of December 31, 2021 and December 31, 2020. In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands).
    December 31,
    2021    		December 31,
    2020
    Long-lived tangible assets by geographic area:
    United States$184,474 $170,871 
    Mexico33,877 32,723 
    Ireland41,501 38,526 
    Rest of world17,247 11,844 
    Total$277,099 $253,964 
    Schedule of Expenditures for Tangible Long-Lived Assets, Excluding Acquisitions
    The following table presents capital expenditures for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).
     202120202019
    Expenditures for tangible long-lived assets:
    Medical$48,364 $42,435 $44,026 
    Non-Medical628 1,038 397 
    Total reportable segments48,992 43,473 44,423 
    Unallocated long-lived tangible assets4,471 3,359 3,775 
    Total expenditures$53,463 $46,832 $48,198 
    XML 60 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Revenue From Contracts With Customers (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Revenue from Contract with Customer [Abstract]  
    Schedules of Concentration of Risk by Reveune and Accounts Receivable
    A significant portion of the Company’s sales for fiscal years 2021, 2020 and 2019 and accounts receivable at December 31, 2021 and December 31, 2020 were to three customers as follows:
     SalesAccounts Receivable
    202120202019December 31,
    2021    		December 31,
    2020
    Customer A18%18%21%15%15%
    Customer B16%16%17%19%19%
    Customer C13%14%12%10%13%
    47%48%50%44%47%
    Schedule of Contract Assets and Contract Liabilities
    The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands):
    December 31,
    2021    		December 31,
    2020
    Contract assets$64,743 $40,218 
    Contract liabilities3,776 2,498 
    XML 61 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Discontinued Operations (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Discontinued Operations and Disposal Groups [Abstract]  
    Schedule of Discontinued Operations
    Income from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands):
    202120202019
    Gain on sale of discontinued operations$— $— $(4,974)
    Other income, net(4,931)— (322)
    Income from discontinued operations before taxes4,931 — 5,296 
    Provision for income taxes1,143 — 178 
    Income from discontinued operations$3,788 $— $5,118 
    Cash flow information from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands):
    202120202019
    Cash used in operating activities$— $— $(78)
    Cash provided by investing activities— — 4,734 
    XML 62 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Summary of Significant Accounting Policies (Narrative) (Details)
    $ in Millions
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2019
    USD ($)
    Dec. 31, 2021
    USD ($)
    segment
    customer
    Dec. 31, 2020
    USD ($)
    Dec. 31, 2019
    USD ($)
    Schedule of Assets Useful Life [Line Items]        
    Number of reportable segments | segment   2    
    Number of customers | customer   3    
    Outstanding receivables previously reserved, written off     $ 2.3  
    Sale of accounts receivable   $ 116.1 73.3  
    Costs incurred from sale of accounts receivable   $ 0.0 0.0  
    Increase in inventory valuation reserves $ 19.0      
    Description of payment terms   Standard payment terms range from 30 to 90 days and may include a discount for early payment.    
    Net foreign currency transaction gains (losses)   $ 0.1 $ (1.6) $ (0.1)
    Stock options        
    Schedule of Assets Useful Life [Line Items]        
    Contractual life   10 years    
    Award vesting period   3 years    
    Restricted Stock And Unit Awards | Director        
    Schedule of Assets Useful Life [Line Items]        
    Award vesting period   1 year    
    Minimum | Restricted Stock And Unit Awards        
    Schedule of Assets Useful Life [Line Items]        
    Award vesting period   3 years    
    Minimum | Patents        
    Schedule of Assets Useful Life [Line Items]        
    Intangible asset, useful life   5 years    
    Minimum | Customer lists        
    Schedule of Assets Useful Life [Line Items]        
    Intangible asset, useful life   7 years    
    Minimum | Other        
    Schedule of Assets Useful Life [Line Items]        
    Intangible asset, useful life   1 year    
    Maximum | Restricted Stock And Unit Awards        
    Schedule of Assets Useful Life [Line Items]        
    Award vesting period   4 years    
    Maximum | Performance Based Restricted Stock And Restricted Stock Units        
    Schedule of Assets Useful Life [Line Items]        
    Award vesting period   3 years    
    Maximum | Patents        
    Schedule of Assets Useful Life [Line Items]        
    Intangible asset, useful life   20 years    
    Maximum | Customer lists        
    Schedule of Assets Useful Life [Line Items]        
    Intangible asset, useful life   20 years    
    Maximum | Other        
    Schedule of Assets Useful Life [Line Items]        
    Intangible asset, useful life   20 years    
    Buildings and building improvements | Minimum        
    Schedule of Assets Useful Life [Line Items]        
    Property, plant and equipment, useful life   12 years    
    Buildings and building improvements | Maximum        
    Schedule of Assets Useful Life [Line Items]        
    Property, plant and equipment, useful life   30 years    
    Manufacturing machinery and equipment | Minimum        
    Schedule of Assets Useful Life [Line Items]        
    Property, plant and equipment, useful life   3 years    
    Manufacturing machinery and equipment | Maximum        
    Schedule of Assets Useful Life [Line Items]        
    Property, plant and equipment, useful life   10 years    
    Office Equipment | Minimum        
    Schedule of Assets Useful Life [Line Items]        
    Property, plant and equipment, useful life   3 years    
    Office Equipment | Maximum        
    Schedule of Assets Useful Life [Line Items]        
    Property, plant and equipment, useful life   10 years    
    XML 63 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Business Acquisition (Acquisition of Assets from Oscor Inc Narrative) (Details)
    $ in Millions
    		 1 Months Ended
    Dec. 01, 2021
    USD ($)
    Dec. 31, 2021
    USD ($)
    $ / €
    Measurement Input, Annual Attrition Rate | Customer lists | Valuation, Income Approach    
    Asset Acquisition, Contingent Consideration [Line Items]    
    Measurement input | $ / €   0.05
    Measurement Input, Royalty Rate | Technology | Valuation, Income Approach | Maximum    
    Asset Acquisition, Contingent Consideration [Line Items]    
    Measurement input | $ / €   0.040
    Measurement Input, Royalty Rate | Technology | Valuation, Income Approach | Minimum    
    Asset Acquisition, Contingent Consideration [Line Items]    
    Measurement input | $ / €   0.045
    Measurement Input, Royalty Rate | Tradenames | Valuation, Income Approach    
    Asset Acquisition, Contingent Consideration [Line Items]    
    Measurement input | $ / €   0.020
    Oscor Inc    
    Asset Acquisition, Contingent Consideration [Line Items]    
    Percentage of business acquired 100.00%  
    Consideration transferred | $ $ 220.4  
    Cash acquired from acquisition | $ $ 2.6  
    Inventory adjustments | $   $ 1.0
    Oscor Inc | Office And Manufacturing Facilities    
    Asset Acquisition, Contingent Consideration [Line Items]    
    Lease ROU asset, adjustment | $   $ 3.1
    XML 64 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Business Acquisition (Allocation Of The Provisional Purchase Price ) (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 01, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Fair value of net assets acquired        
    Goodwill $ 924,704   $ 859,442 $ 839,617
    Oscor Inc        
    Fair value of net assets acquired        
    Current assets (excluding inventory)   $ 12,148    
    Inventory   12,212    
    Property, plant and equipment   17,977    
    Goodwill   77,887    
    Intangible assets   105,300    
    Operating lease assets   15,142    
    Other noncurrent assets   695    
    Current liabilities   (8,875)    
    Operating lease liabilities   (12,044)    
    Fair value of net assets acquired   $ 220,442    
    XML 65 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Business Acquisition (Acquisition of Assets from InoMec Ltd Narrative) (Details) - USD ($)
    $ in Thousands
    Feb. 19, 2020
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
    Goodwill acquired   $ 924,704 $ 859,442 $ 839,617
    InoMec Ltd        
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
    Consideration transferred $ 7,000      
    Cash paid 5,300      
    Contingent consideration 1,700      
    Revenue-based payments 3,500 $ 6,750 $ 9,000  
    Intangible assets 2,000      
    Goodwill acquired 4,800      
    Property, plant and equipment 300      
    Other noncurrent assets $ 100      
    Weighted Average Amortization Period (Years) 5 years 10 months 24 days      
    XML 66 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Business Acquisition (Acquisition of Assets from US BioDesign LLC Narrative) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 01, 2021
    Feb. 19, 2020
    Oct. 07, 2019
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
    Goodwill acquired       $ 924,704 $ 859,442 $ 839,617
    Acquisition-related adjustments (Note 2)         85  
    Sales       1,221,079 1,073,442 1,258,094
    Acquisition related costs       2,000 900 400
    US BioDesign LLC            
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
    Consideration transferred     $ 19,100      
    Cash paid     14,900      
    Fair value of contingent consideration     4,200      
    Revenue-based payments     5,500      
    Goodwill acquired     10,400      
    Property, plant and equipment     700      
    Other noncurrent assets     600      
    Acquisition-related adjustments (Note 2)         100  
    Sales       4,800 4,500  
    US BioDesign LLC | Technology            
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
    Acquired finite lived intangible assets     $ 7,400      
    Intangible asset, useful life     8 years      
    Oscor Inc            
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
    Consideration transferred $ 220,400          
    Sales       4,700    
    Acquisition related costs       2,400    
    InoMec Ltd            
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
    Consideration transferred   $ 7,000        
    Cash paid   5,300        
    Revenue-based payments   3,500   6,750 9,000  
    Goodwill acquired   4,800        
    Property, plant and equipment   300        
    Other noncurrent assets   $ 100        
    Sales       $ 3,500 3,400  
    Acquisition related costs         $ 1,200  
    US BioDesign LLC            
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
    Sales           $ 800
    XML 67 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Business Acquisition (Indefinite-Lived Intangible Assets) (Details)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2021
    USD ($)
    Customer lists  
    Acquired Finite-Lived Intangible Assets [Line Items]  
    Fair Value Assigned $ 73.8
    Weighted Average Amortization Period (Years) 20 years
    Weighted Average Discount Rate 9.50%
    Technology  
    Acquired Finite-Lived Intangible Assets [Line Items]  
    Fair Value Assigned $ 15.2
    Weighted Average Amortization Period (Years) 15 years
    Weighted Average Discount Rate 9.50%
    Tradenames  
    Acquired Finite-Lived Intangible Assets [Line Items]  
    Fair Value Assigned $ 16.3
    Weighted Average Amortization Period (Years) 20 years
    Weighted Average Discount Rate 9.50%
    XML 68 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Business Acquisition ( Pro Forma Information) (Details) - Oscor Inc - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Business Combination and Asset Acquisition [Abstract]    
    Sales $ 1,274,148 $ 1,128,137
    Income from continuing operations 91,844 67,529
    Business Combination, Separately Recognized Transactions [Line Items]    
    Sales 1,274,148 1,128,137
    Income from continuing operations $ 91,844 $ 67,529
    XML 69 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Supplemental Cash Flow Information (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Non-cash investing and financing activities:      
    Property, plant and equipment purchases included in accounts payable $ 5,556 $ 3,597 $ 8,646
    Cash paid during the year for:      
    Interest 24,740 33,933 44,784
    Income taxes $ 19,649 $ 18,477 $ 30,034
    XML 70 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Inventories (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Inventory Disclosure [Abstract]    
    Raw materials $ 70,956 $ 72,477
    Work-in-process 74,152 58,806
    Finished goods 10,591 18,040
    Total $ 155,699 $ 149,323
    XML 71 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Property, Plant and Equipment, Net (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross $ 683,404 $ 625,670
    Accumulated depreciation (406,305) (371,706)
    Total 277,099 253,964
    Manufacturing machinery and equipment    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross 352,391 320,807
    Buildings and building improvements    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross 98,007 102,037
    Information technology hardware and software    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross 72,752 69,969
    Leasehold improvements    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross 85,931 77,382
    Furniture and fixtures    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross 17,099 16,250
    Land and land improvements    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross 13,980 11,598
    Construction work in process    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross 41,813 26,389
    Other    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross $ 1,431 $ 1,238
    XML 72 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Property, Plant and Equipment, Net (Depreciation Expense) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Property, Plant and Equipment [Abstract]      
    Depreciation expense $ 39,772 $ 38,193 $ 37,819
    XML 73 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Goodwill and Other Intangible Assets, Nets (Schedule of Goodwill) (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Goodwill [Roll Forward]    
    Beginning balance $ 859,442,000 $ 839,617,000
    Acquisition 77,887,000 4,800,000
    Acquisition-related adjustments (Note 2)   (85,000)
    Foreign currency translation (12,625,000) 15,110,000
    Ending balance 924,704,000 859,442,000
    Medical    
    Goodwill [Roll Forward]    
    Beginning balance 842,442,000 822,617,000
    Acquisition 77,887,000 4,800,000
    Acquisition-related adjustments (Note 2)   (85,000)
    Foreign currency translation (12,625,000) 15,110,000
    Ending balance 907,704,000 842,442,000
    Accumulated impairment loss 0  
    Non-Medical    
    Goodwill [Roll Forward]    
    Beginning balance 17,000,000 17,000,000
    Acquisition 0 0
    Acquisition-related adjustments (Note 2)   0
    Foreign currency translation 0 0
    Ending balance 17,000,000 $ 17,000,000
    Accumulated impairment loss $ 0  
    XML 74 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Goodwill and Other Intangible Assets, Net (Schedule of Intangible Assets) (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Finite-Lived Intangible Assets [Line Items]    
    Gross Carrying Amount $ 1,073,439 $ 985,386
    Accumulated Amortization (355,917) (318,450)
    Net Carrying Amount 717,522 666,936
    Trademarks and tradenames    
    Finite-Lived Intangible Assets [Line Items]    
    Indefinite-lived intangible assets (excluding goodwill) 90,288 90,288
    Purchased technology, tradenames and patents    
    Finite-Lived Intangible Assets [Line Items]    
    Gross Carrying Amount 285,659 257,453
    Accumulated Amortization (164,371) (152,798)
    Net Carrying Amount 121,288 104,655
    Customer lists    
    Finite-Lived Intangible Assets [Line Items]    
    Gross Carrying Amount 783,618 723,791
    Accumulated Amortization (187,412) (161,856)
    Net Carrying Amount 596,206 561,935
    Other    
    Finite-Lived Intangible Assets [Line Items]    
    Gross Carrying Amount 4,162 4,142
    Accumulated Amortization (4,134) (3,796)
    Net Carrying Amount $ 28 $ 346
    XML 75 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Goodwill and Other Intangible Assets, Net (Narrative) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Finite-Lived Intangible Assets [Line Items]      
    Payments to acquire intangible asset $ 0 $ 4,607 $ 0
    License | Non-Medical | Similar Identifiable Assets Relating To A License To Use Technology      
    Finite-Lived Intangible Assets [Line Items]      
    Payments to acquire intangible asset   4,500  
    Asset acquisition contingent consideration liability paid   1,000  
    Asset acquisition transaction costs capitalized   100  
    Fair Value Assigned   $ 4,600  
    Intangible asset, useful life   11 years  
    Trademarks and tradenames      
    Finite-Lived Intangible Assets [Line Items]      
    Indefinite-lived intangible assets (excluding goodwill) 90,288 $ 90,288  
    Lake Region Medical | Trademarks and tradenames      
    Finite-Lived Intangible Assets [Line Items]      
    Indefinite-lived intangible assets (excluding goodwill) $ 70,000 $ 20,300  
    XML 76 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Goodwill and Other Intangible Assets, Net (Amortization Expense by categories) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Finite-Lived Intangible Assets [Line Items]      
    Total intangible asset amortization expense $ 41,597 $ 41,131 $ 40,076
    Cost of sales      
    Finite-Lived Intangible Assets [Line Items]      
    Total intangible asset amortization expense 13,090 12,860 13,111
    SG&A      
    Finite-Lived Intangible Assets [Line Items]      
    Total intangible asset amortization expense $ 28,507 $ 28,271 $ 26,965
    XML 77 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Goodwill and Other Intangible Assets, Net (Future Amortization Expense) (Details)
    $ in Thousands
    Dec. 31, 2021
    USD ($)
    Goodwill and Intangible Assets Disclosure [Abstract]  
    2022 $ 46,594
    2023 48,490
    2024 47,576
    2025 45,946
    2026 43,612
    After 2026 $ 485,304
    XML 78 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Accrued Expenses and Other Current Liabilities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Accounts Payable and Accrued Liabilities [Abstract]      
    Salaries and benefits $ 27,733 $ 24,512  
    Profit sharing and bonuses 18,325 19,204  
    Contract liabilities 3,776 2,498  
    Product warranties 509 163 $ 1,933
    Accrued interest 76 1,644  
    Other 6,514 8,822  
    Total $ 56,933 $ 56,843  
    XML 79 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt (Schedule of Long-Term Debt) (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Sep. 02, 2021
    Dec. 31, 2020
    Debt Instrument [Line Items]      
    Unamortized discount on term loan B and deferred debt issuance costs $ (7,361)   $ (6,715)
    Total debt 828,126   731,258
    Current portion of long-term debt (15,250)   (37,500)
    Long-term debt 812,876   693,758
    Loans Payable | Secured Debt | Senior secured term loan A      
    Debt Instrument [Line Items]      
    Long-term debt, gross 467,062   229,687
    Total debt   $ 210,900  
    Loans Payable | Secured Debt | Senior secured term loan B      
    Debt Instrument [Line Items]      
    Long-term debt, gross 349,125   508,286
    Total debt   $ 462,300  
    Line of Credit | Revolving Credit Facility      
    Debt Instrument [Line Items]      
    Long-term debt, gross 19,300   $ 0
    Unamortized discount on term loan B and deferred debt issuance costs $ (1,200)    
    XML 80 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt (Senior Secured Credit Facilities) (Details) - USD ($)
    		 12 Months Ended
    Sep. 02, 2021
    Dec. 31, 2021
    Sep. 01, 2021
    Dec. 31, 2020
    Debt Instrument [Line Items]        
    Credit facility maximum borrowing capacity $ 1,000,000,000      
    Long-term Debt   $ 828,126,000   $ 731,258,000
    Secured Debt | Senior secured term loan A        
    Debt Instrument [Line Items]        
    Credit facility maximum borrowing capacity $ 250,000,000      
    Debt instrument term 5 years      
    Weighted average interest rate   1.35%    
    Secured Debt | Senior secured term loan B        
    Debt Instrument [Line Items]        
    Credit facility maximum borrowing capacity $ 350,000,000      
    Debt instrument term 7 years      
    Discount percent 0.50%      
    Weighted average interest rate   3.00%    
    Secured Debt | Loans Payable | Senior secured term loan A        
    Debt Instrument [Line Items]        
    Debt instrument increase   $ 220,000,000    
    Weighted average interest rate   2.04%    
    Long-term Debt $ 210,900,000      
    Secured Debt | Loans Payable | Senior secured term loan B        
    Debt Instrument [Line Items]        
    Discount percent 1.00%      
    Long-term Debt $ 462,300,000      
    Revolving Credit Facility        
    Debt Instrument [Line Items]        
    Weighted average interest rate   1.35%    
    Revolving Credit Facility | Line of Credit        
    Debt Instrument [Line Items]        
    Credit facility maximum borrowing capacity $ 400,000,000   $ 1,600,000,000  
    Debt instrument term 5 years      
    Outstanding amount   $ 19,300,000    
    XML 81 R68.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt (Revolving Credit Facility) (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2021
    Sep. 02, 2021
    Sep. 01, 2021
    Jul. 13, 2020
    Debt Instrument [Line Items]        
    Credit facility maximum borrowing capacity   $ 1,000,000,000    
    Secured Debt | Swingline Loans | New Revolving Credit Facility 2015        
    Debt Instrument [Line Items]        
    Credit facility maximum borrowing capacity       $ 40,000,000
    Revolving Credit Facility        
    Debt Instrument [Line Items]        
    Weighted average interest rate 1.35%      
    Revolving Credit Facility | Line of Credit        
    Debt Instrument [Line Items]        
    Credit facility maximum borrowing capacity   400,000,000 $ 1,600,000,000  
    Remaining borrowing capacity $ 375,000,000      
    Outstanding amount $ 19,300,000      
    Unused capacity commitment fee 0.15%      
    Revolving Credit Facility | Line of Credit | Minimum        
    Debt Instrument [Line Items]        
    Unused capacity commitment fee 0.15%      
    Revolving Credit Facility | Line of Credit | Maximum        
    Debt Instrument [Line Items]        
    Unused capacity commitment fee 0.25%      
    Revolving Credit Facility | Line of Credit | London Interbank Offered Rate One - Month (LIBOR) | Minimum        
    Debt Instrument [Line Items]        
    Spread on variable rate 1.25%      
    Revolving Credit Facility | Line of Credit | London Interbank Offered Rate One - Month (LIBOR) | Maximum        
    Debt Instrument [Line Items]        
    Spread on variable rate 2.25%      
    Revolving Credit Facility | Line of Credit | New Revolving Credit Facility 2015        
    Debt Instrument [Line Items]        
    Credit facility maximum borrowing capacity   $ 200,000,000    
    Revolving Credit Facility | Line of Credit | Senior secured term loan A | London Interbank Offered Rate One - Month (LIBOR)        
    Debt Instrument [Line Items]        
    Spread on variable rate 1.00%      
    Revolving Credit Facility | Line of Credit | Senior secured term loan A | Base Rate | Minimum        
    Debt Instrument [Line Items]        
    Spread on variable rate 0.25%      
    Revolving Credit Facility | Line of Credit | Senior secured term loan A | Base Rate | Maximum        
    Debt Instrument [Line Items]        
    Spread on variable rate 1.25%      
    Revolving Credit Facility | Line of Credit | Senior secured term loan A | Fed Funds Effective Rate Overnight Index Swap Rate        
    Debt Instrument [Line Items]        
    Spread on variable rate 0.50%      
    Standby Letters of Credit        
    Debt Instrument [Line Items]        
    Outstanding standby letters of credit $ 5,700,000      
    XML 82 R69.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt (Term Loan Facilities) (Details) - Secured Debt
    		 12 Months Ended
    Dec. 31, 2021
    Senior secured term loan B  
    Debt Instrument [Line Items]  
    Weighted average interest rate 3.00%
    Senior secured term loan B | London Interbank Offered Rate (LIBOR)  
    Debt Instrument [Line Items]  
    Spread on variable rate 2.50%
    Interest rate floor 0.50%
    Senior secured term loan B | Base Rate  
    Debt Instrument [Line Items]  
    Spread on variable rate 1.50%
    Senior secured term loan A  
    Debt Instrument [Line Items]  
    Weighted average interest rate 1.35%
    XML 83 R70.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt (Covenants) (Details) - Revolving Credit Facility - Secured Debt
    		 12 Months Ended
    Dec. 31, 2021
    $ / €
    Senior secured term loan A  
    Debt Instrument [Line Items]  
    Net leverage ratio incremental increase option 5.50
    ITGRTerm Loan A T L A Facility  
    Debt Instrument [Line Items]  
    Net leverage ratio incremental increase option 5.00
    Interest expense ratio 2.50
    XML 84 R71.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt (Long-term Debt Maturity Schedule) (Details)
    $ in Thousands
    Dec. 31, 2021
    USD ($)
    Debt Disclosure [Abstract]  
    2022 $ 15,250
    2023 18,188
    2024 29,938
    2025 38,750
    2026 401,739
    After 2026 $ 331,622
    XML 85 R72.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt (Deferred Financing Fees) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Deferred Finance Costs [Roll Forward]      
    Total, Beginning Balance $ 6,715    
    Total, Amortization during the period (6,954) $ (4,774) $ (7,772)
    Total, Ending Balance 7,361 6,715  
    Revolving Credit Facility      
    Deferred Finance Costs [Roll Forward]      
    Debt issuance costs, Beginning Balance 891    
    Financing costs incurred 2,762    
    Write-off of debt issuance costs and unamortized discount (72)    
    Amortization during the period (542)    
    Debt issuance costs, Ending Balance 3,039 891  
    Term Loan And Senior Notes      
    Deferred Finance Costs [Roll Forward]      
    Debt issuance costs, Beginning Balance 5,258    
    Financing costs incurred 5,236    
    Write-off of debt issuance costs and unamortized discount (2,677)    
    Amortization during the period (2,143)    
    Debt issuance costs, Ending Balance 5,674 5,258  
    Total, Beginning Balance 6,715    
    Total, Financing costs incurred 6,986    
    Total, Write-off during the period (3,631)    
    Total, Amortization during the period (2,709)    
    Total, Ending Balance 7,361 6,715  
    Senior secured term loan B      
    Deferred Finance Costs [Roll Forward]      
    Unamortized discount on TLB Facility, Beginning Balance 1,457    
    Unamortized discount on TLB Facility, Financing costs incurred 1,750    
    Unamortized discount on TLB Facility, Write-off during the period (954)    
    Unamortized discount on TLB Facility, Amortization during the period (566)    
    Unamortized discount on TLB Facility, Ending Balance $ 1,687 $ 1,457  
    XML 86 R73.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt (Deferred Debt Issuance Costs and Discounts) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Debt Instrument [Line Items]    
    Unamortized debt issuance costs $ 7,361 $ 6,715
    Other Assets | Revolving Credit Facility    
    Debt Instrument [Line Items]    
    Debt issuance costs 2,800  
    Loans Payable    
    Debt Instrument [Line Items]    
    Debt issuance costs 8,800  
    Loans Payable | Long-term Debt    
    Debt Instrument [Line Items]    
    Debt issuance costs 7,000  
    Secured Debt | Senior secured term loan B    
    Debt Instrument [Line Items]    
    Original issue discount 1,800  
    Write off of debt issuance cost 300  
    Secured Debt | Senior secured term loan A    
    Debt Instrument [Line Items]    
    Debt issuance costs 1,000  
    Line of Credit | Revolving Credit Facility    
    Debt Instrument [Line Items]    
    Unamortized debt issuance costs 1,200  
    Write off of debt issuance cost $ 3,300  
    XML 87 R74.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Benefit Plans (Savings Plan Narrative) (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Defined Contribution And Benefit Plan Disclosure [Line Items]      
    Net costs recognized $ 7,900,000 $ 5,000,000 $ 7,200,000
    Maximum      
    Defined Contribution And Benefit Plan Disclosure [Line Items]      
    Employer matching contribution, per dollar $ 0.50    
    Employer matching contribution, percentage of employees' gross pay 6.00%    
    XML 88 R75.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Benefit Plans (Defined Benefit Plans Narrative) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Retirement Benefits [Abstract]      
    Aggregated projected benefit obligation $ 3.9 $ 3.7  
    Net periodic pension cost 0.5 $ 0.4 $ 0.3
    Expected future benefit payments first five years 1.0    
    Expected future benefit payments next five years $ 1.8    
    XML 89 R76.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock-Based Compensation (Narratives) (Details) - USD ($)
    $ / shares in Units, $ in Millions
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Number of shares authorized (in shares) 1,450,000    
    Number of shares available for grant (in shares) 1,636,980    
    Restricted Stock and Restricted Stock Units      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Compensation expense tax benefit $ 1.1 $ 1.5 $ 2.8
    Total unrecognized compensation cost $ 13.9    
    Period for recognition 1 year 7 months 6 days    
    Fair value of shares vested $ 12.9 $ 9.9 $ 2.4
    Granted (in dollars per share) $ 81.98 $ 83.94 $ 82.31
    Stock options      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Grants in period (in shares) 0 0  
    Closing stock price (in dollars per share) $ 85.59    
    Performance Based Restricted Stock And Restricted Stock Units      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Total unrecognized compensation cost $ 6.0    
    Period for recognition 1 year 10 months 24 days    
    Fair value of shares vested $ 3.1 $ 2.9 $ 6.7
    Granted (in dollars per share) $ 85.16 $ 95.06 $ 101.17
    Performance period (over) 3 years    
    Illiquidity discount percent 8.19% 8.00%  
    XML 90 R77.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock-Based Compensation (Components of Stock-Based Compensation Expense) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Total stock-based compensation expense $ 16,185 $ 9,163 $ 9,294
    Cost of sales      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Total stock-based compensation expense 3,365 1,658 1,011
    SG&A      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Total stock-based compensation expense 11,579 6,942 7,827
    RD&E      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Total stock-based compensation expense 969 563 269
    OOE      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Total stock-based compensation expense 272 0 187
    Stock options      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Total stock-based compensation expense 0 43 410
    RSUs and PRSUs      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Total stock-based compensation expense $ 16,185 $ 9,120 $ 8,884
    XML 91 R78.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock-Based Compensation (Weighted-Average Fair Value and Assumptions) (Details) - Performance Based Restricted Stock And Restricted Stock Units - $ / shares
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Weighted average fair value(in dollars per share) $ 85.16 $ 107.27 $ 117.03
    Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]      
    Risk-free interest rate 0.19% 1.29% 2.46%
    Expected volatility 41.00% 30.00% 40.00%
    Expected life (in years) 3 years 2 years 10 months 24 days 2 years 9 months 18 days
    Expected dividend yield 0.00% 0.00% 0.00%
    XML 92 R79.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock-Based Compensation (Stock Option Activity) (Details)
    $ / shares in Units, $ in Millions
    		 12 Months Ended
    Dec. 31, 2021
    USD ($)
    $ / shares
    shares
    Number of Stock Options  
    Beginning balance (in shares) | shares 281,873
    Exercised (in shares) | shares (34,233)
    Ending balance (in shares) | shares 247,640
    Vested and exercisable (in shares) | shares 247,640
    Weighted Average Exercise Price  
    Beginning balance (in dollars per share) | $ / shares $ 36.05
    Exercised (in dollars per share) | $ / shares 21.72
    Ending balance (in dollars per share) | $ / shares 38.03
    Vested and exercisable (in dollars per share) | $ / shares $ 38.03
    Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value  
    Outstanding, weighted average remaining contractual term 4 years 2 months 12 days
    Vested and exercisable , weighted average remaining contractual term 4 years 2 months 12 days
    Outstanding, aggregate intrinsic value | $ $ 11.8
    Vested and exercisable , aggregate intrinsic value | $ $ 11.8
    XML 93 R80.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock-Based Compensation (Exercise of Stock Option) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Share-based Payment Arrangement [Abstract]      
    Intrinsic value $ 2,370 $ 4,773 $ 7,998
    Cash received $ 743 $ 3,263 $ 3,242
    XML 94 R81.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock-Based Compensation (Restricted Stock and Restricted Stock Units) (Details) - $ / shares
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Performance Based Restricted Stock And Restricted Stock Units      
    Weighted Average Grant Date Fair Value      
    Granted (in dollars per share) $ 85.16 $ 95.06 $ 101.17
    Restricted Stock And Restricted Stock Units Time Based      
    Time-Vested and Performance-Vested Restricted Stock Units and Awards      
    Beginning balance (in shares) 207,923    
    Granted (in shares) 208,624    
    Vested (in shares) (149,464)    
    Forfeited (in shares) (18,952)    
    Ending balance (in shares) 248,131 207,923  
    Weighted Average Grant Date Fair Value      
    Beginning balance (in dollars per share) $ 75.38    
    Granted (in dollars per share) 81.98    
    Vested (in dollars per share) 74.47    
    Forfeited (in dollars per share) 79.84    
    Ending balance (in dollars per share) $ 81.14 $ 75.38  
    Performance Based Restricted Stock And Restricted Stock Units      
    Time-Vested and Performance-Vested Restricted Stock Units and Awards      
    Beginning balance (in shares) 219,391    
    Granted (in shares) 92,384    
    Vested (in shares) (38,882)    
    Forfeited (in shares) (74,024)    
    Ending balance (in shares) 198,869 219,391  
    Weighted Average Grant Date Fair Value      
    Beginning balance (in dollars per share) $ 72.33    
    Granted (in dollars per share) 85.16    
    Vested (in dollars per share) 37.75    
    Forfeited (in dollars per share) 53.45    
    Ending balance (in dollars per share) $ 92.07 $ 72.33  
    XML 95 R82.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Other Operating Expenses (Schedule of Other Operating Expenses) (Details) - USD ($)
    $ in Thousands
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Other Operating Income Expense Detail [Line Items]        
    Acquisition and integration costs (adjustments) $ 2,544   $ (776) $ 377
    Other general expenses 508   4,679 3,817
    Total other operating expenses 7,856 $ 7,856 7,621 12,151
    Operational Excellence Initiatives        
    Other Operating Income Expense Detail [Line Items]        
    Restructuring Costs 3,893   2,791 0
    Strategic reorganization and alignment        
    Other Operating Income Expense Detail [Line Items]        
    Restructuring Costs 911   686 5,812
    Manufacturing alignment to support growth        
    Other Operating Income Expense Detail [Line Items]        
    Restructuring Costs $ 0   $ 241 $ 2,145
    XML 96 R83.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Other Operating Expenses (Narrative) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Jul. 03, 2020
    Restructuring Cost and Reserve [Line Items]        
    Charges incurred, net of reversals $ 4,804      
    Acquisition related costs 2,000 $ 900 $ 400  
    Strategic reorganization and alignment        
    Restructuring Cost and Reserve [Line Items]        
    Charges incurred, net of reversals 911      
    Strategic reorganization and alignment | Medical        
    Restructuring Cost and Reserve [Line Items]        
    Costs incurred since inception       $ 23,000
    Manufacturing alignment to support growth        
    Restructuring Cost and Reserve [Line Items]        
    Costs incurred since inception 5,800      
    Operational Excellence Initiatives Two Thousand Twenty One Initiatives | Employee Severance        
    Restructuring Cost and Reserve [Line Items]        
    Costs incurred since inception 3,600      
    Minimum | Employee Severance | Operational Excellence Initiatives Two Thousand Twenty One Initiatives        
    Restructuring Cost and Reserve [Line Items]        
    Expected costs 4,000      
    Maximum | Employee Severance | Operational Excellence Initiatives Two Thousand Twenty One Initiatives        
    Restructuring Cost and Reserve [Line Items]        
    Expected costs 5,000      
    Oscor Inc        
    Restructuring Cost and Reserve [Line Items]        
    Acquisition related costs 2,400      
    InoMec Ltd        
    Restructuring Cost and Reserve [Line Items]        
    Acquisition related costs   1,200    
    Fair value reduction adjustment for acquisition-related contingent consideration liability 100      
    US BioDesign LLC        
    Restructuring Cost and Reserve [Line Items]        
    Fair value reduction adjustment for acquisition-related contingent consideration liability   $ 2,000    
    Operational excellence initiatives        
    Restructuring Cost and Reserve [Line Items]        
    Charges incurred, net of reversals 3,100      
    Strategic Reorganization And Alignment Initiatives Two Thousand Twenty One Initiatives        
    Restructuring Cost and Reserve [Line Items]        
    Capital investments expended 900      
    Strategic Reorganization And Alignment Initiatives Two Thousand Twenty One Initiatives | Minimum        
    Restructuring Cost and Reserve [Line Items]        
    Capital investments expended 5,000      
    Strategic Reorganization And Alignment Initiatives Two Thousand Twenty One Initiatives | Maximum        
    Restructuring Cost and Reserve [Line Items]        
    Capital investments expended $ 8,000      
    XML 97 R84.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Other Operating Expenses (Changes in Accrued Liabilities) (Details)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    USD ($)
    Restructuring Reserve [Roll Forward]  
    Restructuring reserve, beginning balance $ 291
    Charges incurred, net of reversals 4,804
    Cash payments (4,663)
    Restructuring reserve, ending balance 432
    Operational excellence initiatives  
    Restructuring Reserve [Roll Forward]  
    Restructuring reserve, beginning balance 291
    Charges incurred, net of reversals 3,893
    Cash payments (3,886)
    Restructuring reserve, ending balance 298
    Strategic reorganization and alignment  
    Restructuring Reserve [Roll Forward]  
    Restructuring reserve, beginning balance 0
    Charges incurred, net of reversals 911
    Cash payments (777)
    Restructuring reserve, ending balance $ 134
    XML 98 R85.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes (Narrative) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Income Tax Disclosure [Abstract]    
    Unrecognized tax benefit $ 5.5  
    Deferred payroll taxes 4.8 $ 9.7
    Payment for employment taxes $ 4.9  
    XML 99 R86.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes (Income Before Income Tax Domestic And Foreign) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Income Tax Disclosure [Line Items]      
    Income (loss) from continuing operations before income taxes $ 101,063 $ 86,207 $ 105,193
    U.S.      
    Income Tax Disclosure [Line Items]      
    Income (loss) from continuing operations before income taxes 48,293 35,337 40,203
    International      
    Income Tax Disclosure [Line Items]      
    Income (loss) from continuing operations before income taxes $ 52,770 $ 50,870 $ 64,990
    XML 100 R87.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes (Provision Benefit of Income Taxes) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Current:      
    Federal $ 9,511 $ 7,784 $ 14,090
    State 1,553 1,233 87
    International 8,459 6,898 10,083
    Total 19,523 15,915 24,260
    Deferred:      
    Federal (8,665) (4,648) (8,813)
    State (393) (1,245) 332
    International (2,422) (1,073) (1,804)
    Total (11,480) (6,966) (10,285)
    Total provision for income taxes $ 8,043 $ 8,949 $ 13,975
    XML 101 R88.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes (Effect Tax Rate Reconciliation) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Effective Income Tax Rate Reconciliation, Amount [Abstract]      
    Statutory rate $ 21,223 $ 18,103 $ 22,091
    Federal tax credits (including R&D) (11,929) (7,009) (4,797)
    Foreign rate differential (5,165) (5,333) (5,479)
    Stock-based compensation (1,084) (1,459) (2,422)
    Uncertain tax positions 18 1,208 (920)
    State taxes, net of federal benefit 1,183 553 1,106
    U.S. tax on foreign earnings, net of §250 deduction 1,913 3,216 5,201
    Valuation allowance 524 (345) (1,606)
    Other 1,360 15 801
    Total provision for income taxes $ 8,043 $ 8,949 $ 13,975
    Effective Income Tax Rate Reconciliation, Percent [Abstract]      
    Statutory rate 21.00% 21.00% 21.00%
    Federal tax credits (including R&D) (11.80%) (8.10%) (4.60%)
    Foreign rate differential (5.10%) (6.20%) (5.20%)
    Stock-based compensation (1.10%) (1.70%) (2.30%)
    Uncertain tax positions 0.00% 1.40% (0.90%)
    State taxes, net of federal benefit 1.20% 0.60% 1.10%
    U.S. tax on foreign earnings, net of §250 deduction 1.90% 3.70% 4.90%
    Valuation allowance 0.50% (0.40%) (1.50%)
    Other 1.40% 0.10% 0.80%
    Effective tax rate 8.00% 10.40% 13.30%
    XML 102 R89.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes (Deferred Tax Assets and Liabilities) (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Components of Deferred Tax Assets and Liabilities [Abstract]    
    Tax credit carryforwards $ 11,394 $ 13,449
    Inventories 14,147 14,099
    Net operating loss carryforwards 11,721 10,436
    Operating lease liabilities 17,950 11,969
    Stock-based compensation 3,724 3,276
    Accrued expenses 9,348 8,058
    Gross deferred tax assets 68,284 61,287
    Less valuation allowance (19,456) (20,739)
    Net deferred tax assets 48,828 40,548
    Property, plant and equipment (7,354) (5,824)
    Intangible assets (186,150) (197,048)
    Operating lease assets (17,974) (11,290)
    Other (3,144) (4,292)
    Gross deferred tax liabilities (214,622) (218,454)
    Net deferred tax liability (165,794) (177,906)
    Noncurrent deferred tax asset 5,711 4,398
    Noncurrent deferred tax liability $ (171,505) $ (182,304)
    XML 103 R90.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes (Income Tax Carry Forward) (Details)
    $ in Millions
    Dec. 31, 2021
    USD ($)
    U.S. State  
    Operating Loss Carryforwards [Line Items]  
    Net operating loss $ 120.7
    U.S. State | R&D tax credits  
    Operating Loss Carryforwards [Line Items]  
    Tax Credit 1.4
    U.S. State | State tax credits  
    Operating Loss Carryforwards [Line Items]  
    Tax Credit 4.9
    International  
    Operating Loss Carryforwards [Line Items]  
    Net operating loss 12.2
    U.S. Federal | Foreign tax credits  
    Operating Loss Carryforwards [Line Items]  
    Tax Credit $ 6.7
    XML 104 R91.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes (Unrecognized Tax Benefits) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
    Balance, beginning of year $ 5,484 $ 4,446 $ 5,369
    Additions based upon tax positions related to the current year 3,324 300 300
    Additions (reductions) related to prior period tax returns (3,271) 738 (1,223)
    Balance, end of year $ 5,537 $ 5,484 $ 4,446
    XML 105 R92.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Commitments and Contingencies (Narrative) (Details) - USD ($)
    $ in Thousands
    		 1 Months Ended 12 Months Ended
    Oct. 31, 2020
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Gain Contingencies [Line Items]        
    Proceeds from legal settlements $ 28,900      
    Gain on litigation settlement $ 28,200   $ 28,200  
    Loss contingency damages sought   $ 300    
    Drawn down from the escrow   200    
    Anticipated future costs remaining   100    
    Accrued environmental loss contingencies, current   100    
    Expenses related to license agreements   884,109 787,735 $ 903,084
    Self insurance reserve   5,600 5,400  
    Royalty        
    Gain Contingencies [Line Items]        
    Expenses related to license agreements   $ 1,300 $ 1,200 $ 1,400
    XML 106 R93.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Commitments and Contingencies (Change in Product Warranty Liability) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Movement in Standard Product Warranty Accrual [Roll Forward]    
    Beginning balance $ 163 $ 1,933
    Additions to warranty reserve, net of reversals (15) (156)
    Adjustments to pre-existing warranties (71) (119)
    Warranty claims settled 0 (1,495)
    Acquisitions 432 0
    Ending balance $ 509 $ 163
    XML 107 R94.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases (Narrative) (Details)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2021
    USD ($)
    facility
    Dec. 31, 2020
    USD ($)
    Leases [Abstract]    
    Gross assets acquired $ 8.3  
    Finance lease accumulated amortization $ 0.2  
    Finance lease right-of-use asset   $ 0.0
    Number of facilities in which lease terms were extended | facility 3  
    XML 108 R95.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases (Schedule of Lease Costs) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Lessor, Lease, Description [Line Items]    
    Amortization of lease assets $ 223 $ 7
    Finance lease cost 59 1
    Finance lease cost 282 8
    Operating lease cost 10,729 10,425
    Short-term lease cost (leases with initial term of 12 months or less) 137 86
    Variable lease cost 2,619 2,615
    Sublease income (1,392) (1,495)
    Total lease cost 12,375 11,639
    Cost of sales    
    Lessor, Lease, Description [Line Items]    
    Total lease cost 9,642 9,141
    SG&A    
    Lessor, Lease, Description [Line Items]    
    Total lease cost 1,817 1,803
    RD&E    
    Lessor, Lease, Description [Line Items]    
    Total lease cost 857 694
    Interest expense    
    Lessor, Lease, Description [Line Items]    
    Total lease cost $ 59 $ 1
    XML 109 R96.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases (Schedule of Operating Lease Liability Maturities) (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Operating Leases    
    2022 $ 12,423  
    2023 11,317  
    2024 10,809  
    2025 10,634  
    2026 9,856  
    Thereafter 25,652  
    Gross lease liabilities 80,691  
    Less: imputed interest (11,062)  
    Present value of lease liabilities $ 69,629  
    Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accrued Liabilities, Current Accrued Liabilities, Current
    Less: current portion of lease liabilities $ (9,862) $ (8,431)
    Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Noncurrent Other Liabilities, Noncurrent
    Operating lease liabilities $ 59,767 $ 37,861
    Finance Leases    
    2022 876  
    2023 888  
    2024 896  
    2025 787  
    2026 640  
    Thereafter 5,807  
    Gross lease liabilities 9,894  
    Less: imputed interest (1,836)  
    Present value of lease liabilities 8,058  
    Less: current portion of lease liabilities (608)  
    Total long-term lease liabilities $ 7,450  
    XML 110 R97.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases (Lease Term and Discount Rate) (Details)
    Dec. 31, 2021
    Dec. 31, 2020
    Leases [Abstract]    
    Weighted-average remaining lease term - operating leases (in years) 7 years 7 years
    Weighted-average remaining lease term - finance leases (in years) 12 years 2 months 12 days 3 years 9 months 18 days
    Weighted-average discount rate - operating leases 3.90% 5.30%
    Weighted-average discount rate - finance leases 3.50% 2.20%
    XML 111 R98.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases (Schedule of Operating Lease Supplemental Cash Flow Information) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Leases [Abstract]    
    Cash paid for operating leases $ 10,808 $ 10,385
    Interest on lease liabilities 59 1
    Assets acquired under operating leases 32,466 9,059
    Assets acquired under finance leases $ 8,154 $ 127
    XML 112 R99.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Earnings Per Share (Details) - USD ($)
    $ / shares in Units, shares in Thousands, $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Numerator for basic and diluted EPS:      
    Income from continuing operations $ 93,020 $ 77,258 $ 91,218
    Income from discontinued operations 3,788 0 5,118
    Net income $ 96,808 $ 77,258 $ 96,336
    Denominator for basic EPS:      
    Weighted average shares outstanding (in shares) 32,993 32,845 32,627
    Effect of dilutive securities stock options, restricted stock and restricted stock units (in shares) 265 268 410
    Denominator for diluted EPS (in shares) 33,258 33,113 33,037
    Basic earnings per share:      
    Income from continuing operations (in dollars per share) $ 2.82 $ 2.35 $ 2.80
    Income from discontinued operations (in dollars per share) 0.11 0 0.16
    Basic earnings per share (in dollars per share) 2.93 2.35 2.95
    Diluted earnings per share:      
    Income from continuing operations (in dollars per share) 2.80 2.33 2.76
    Income from discontinued operations (in dollars per share) 0.11 0 0.15
    Diluted earnings per share (in dollars per share) $ 2.91 $ 2.33 $ 2.92
    XML 113 R100.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Earnings Per Share (Antidilutive Securities) (Details) - shares
    shares in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Time-vested stock options, restricted stock and restricted stock units      
    Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
    Securities excluded (in shares) 4 98 30
    Performance-vested restricted stock units      
    Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
    Securities excluded (in shares) 92 89 47
    XML 114 R101.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stockholders' Equity (Schedule of Changes in Number of Shares of Common Stock) (Details) - shares
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Increase (Decrease) in Stockholders' Equity [Roll Forward]    
    Shares outstanding at beginning of year (in shares) 32,908,178  
    Shares outstanding at beginning of year (in shares) 32,908,178 32,700,471
    Stock options exercised (in shares) 34,233 102,140
    Shares outstanding at end of year (in shares) 33,063,336 32,908,178
    Shares outstanding at beginning of year (in shares) 33,063,336 32,908,178
    Common Stock    
    Increase (Decrease) in Stockholders' Equity [Roll Forward]    
    Shares outstanding at beginning of year (in shares) 32,908,178 32,847,017
    Stock options exercised (in shares) 34,233 27,544
    Shares outstanding at end of year (in shares) 33,063,336 32,908,178
    Treasury Stock, Common    
    Increase (Decrease) in Stockholders' Equity [Roll Forward]    
    Shares outstanding at beginning of year (in shares) 0 (146,546)
    Stock options exercised (in shares) 0 74,596
    Shares outstanding at beginning of year (in shares) 0 0
    RSUs    
    Increase (Decrease) in Stockholders' Equity [Roll Forward]    
    Vesting of RSUs, net of shares withheld to cover taxes (in shares) 120,925 105,567
    RSUs | Common Stock    
    Increase (Decrease) in Stockholders' Equity [Roll Forward]    
    Vesting of RSUs, net of shares withheld to cover taxes (in shares) 120,925 33,617
    RSUs | Treasury Stock, Common    
    Increase (Decrease) in Stockholders' Equity [Roll Forward]    
    Vesting of RSUs, net of shares withheld to cover taxes (in shares) 0 71,950
    XML 115 R102.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stockholders' Equity (Schedule of Accumulated Other Comprehensive Income) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Accumulated Other Comprehensive Income [Roll Forward]    
    Total stockholders’ equity, beginning balance $ 1,271,055 $ 1,152,488
    Total stockholders’ equity, ending balance 1,354,697 1,271,055
    Defined Benefit Plan Liability    
    Accumulated Other Comprehensive Income [Roll Forward]    
    Total stockholders’ equity, beginning balance (1,095) (912)
    Reclassification from AOCI, current period, before tax, attributable to parent 205 (183)
    Reclassification from AOCI, current period, tax 14 32
    Reclassification from AOCI, current period, net of tax, attributable to parent 219 (151)
    Total stockholders’ equity, ending balance (890) (1,095)
    Cash Flow Hedges    
    Accumulated Other Comprehensive Income [Roll Forward]    
    Total stockholders’ equity, beginning balance (4,956) (2,358)
    Reclassification from AOCI, current period, before tax, attributable to parent 91 (6,683)
    Reclassification from AOCI, current period, tax (19) 1,404
    Reclassification from AOCI, current period, net of tax, attributable to parent 72 (5,279)
    Total stockholders’ equity, ending balance (2,291) (4,956)
    Cash Flow Hedges | Foreign Exchange Contract    
    Accumulated Other Comprehensive Income [Roll Forward]    
    Reclassification from AOCI, current period, before tax, attributable to parent (832) 638
    Reclassification from AOCI, current period, tax 175 (134)
    Reclassification from AOCI, current period, net of tax, attributable to parent (657) 504
    Cash Flow Hedges | Interest rate swaps    
    Accumulated Other Comprehensive Income [Roll Forward]    
    Reclassification from AOCI, current period, before tax, attributable to parent 3,406 3,447
    Reclassification from AOCI, current period, tax (716) (724)
    Reclassification from AOCI, current period, net of tax, attributable to parent 2,690 2,723
    Foreign Currency Translation Adjustment    
    Accumulated Other Comprehensive Income [Roll Forward]    
    Total stockholders’ equity, beginning balance 57,546 22,639
    Reclassification from AOCI, current period, before tax, attributable to parent (27,826) 34,907
    Reclassification from AOCI, current period, tax 0 0
    Reclassification from AOCI, current period, net of tax, attributable to parent (27,826) 34,907
    Total stockholders’ equity, ending balance 29,720 57,546
    Total Pre-Tax Amount    
    Accumulated Other Comprehensive Income [Roll Forward]    
    Total stockholders’ equity, beginning balance 51,495 19,369
    Total stockholders’ equity, ending balance 26,539 51,495
    Tax    
    Accumulated Other Comprehensive Income [Roll Forward]    
    Total stockholders’ equity, beginning balance 1,197 619
    Total stockholders’ equity, ending balance 651 1,197
    Net-of-Tax Amount    
    Accumulated Other Comprehensive Income [Roll Forward]    
    Total stockholders’ equity, beginning balance 52,692 19,988
    Total stockholders’ equity, ending balance $ 27,190 $ 52,692
    XML 116 R103.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Instruments and Fair Value Measurements (Assets and Liabilities Recorded at Fair Value on a Recurring Basis) (Details) - Fair Value, Recurring - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets: Foreign currency hedging contracts $ 687 $ 2,070
    Liabilities: Interest rate swaps 2,978 7,026
    Liabilities: Contingent consideration 2,415 3,900
    Quoted Prices in Active Markets (Level 1)    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets: Foreign currency hedging contracts 0 0
    Liabilities: Interest rate swaps 0 0
    Liabilities: Contingent consideration 0 0
    Significant Other Observable Inputs (Level 2)    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets: Foreign currency hedging contracts 687 2,070
    Liabilities: Interest rate swaps 2,978 7,026
    Liabilities: Contingent consideration 0 0
    Significant Unobservable Inputs (Level 3)    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets: Foreign currency hedging contracts 0 0
    Liabilities: Interest rate swaps 0 0
    Liabilities: Contingent consideration $ 2,415 $ 3,900
    XML 117 R104.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Instruments and Fair Value Measurements (Schedule of Interest Rate Swaps) (Details) - Designated as Hedging Instrument - Interest Rate Swap Maturing June 2023 - Other long-term liabilities - USD ($)
    Dec. 31, 2021
    Dec. 31, 2020
    Derivatives, Fair Value [Line Items]    
    Notional Amount $ 150,000,000 $ 200,000,000
    Pay Fixed Rate 2.1785% 2.1785%
    Receive Current Floating Rate 0.1013% 0.148%
    Fair Value $ (2,978,000) $ (7,026,000)
    XML 118 R105.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Instruments and Fair Value Measurements (Schedule of Foreign Currency Contracts) (Details) - Prepaid Expenses and Other Current Assets - Designated as Hedging Instrument
    $ in Thousands
    Dec. 31, 2021
    USD ($)
    $ / $
    $ / $
    Dec. 31, 2020
    USD ($)
    $ / €
    $ / $
    $ / $
    Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract One    
    Derivatives, Fair Value [Line Items]    
    Notional Amount $ 22,201  
    Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $ 0.0463  
    Fair Value $ 408  
    Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Two    
    Derivatives, Fair Value [Line Items]    
    Notional Amount $ 17,017  
    Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $ 1.1344  
    Fair Value $ 130  
    Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Three    
    Derivatives, Fair Value [Line Items]    
    Notional Amount $ 9,020  
    Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $ 0.0220  
    Fair Value $ 149  
    Foreign Exchange Contract Maturing September 2021, Contract One    
    Derivatives, Fair Value [Line Items]    
    Notional Amount   $ 16,132
    Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / €   1.1949
    Fair Value   $ 399
    Foreign Exchange Contract Maturing September 2021, Contract Two    
    Derivatives, Fair Value [Line Items]    
    Notional Amount   $ 10,224
    Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $   0.0454
    Fair Value   $ 922
    Foreign Exchange Contract Maturing March 2021    
    Derivatives, Fair Value [Line Items]    
    Notional Amount   $ 2,656
    Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $   0.0443
    Fair Value   $ 341
    Foreign Exchange Contract Maturing December 2021    
    Derivatives, Fair Value [Line Items]    
    Notional Amount   $ 7,269
    Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $   0.0485
    Fair Value   $ 77
    Foreign Exchange Contract Maturing August 2021    
    Derivatives, Fair Value [Line Items]    
    Notional Amount   $ 3,252
    Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $   0.0232
    Fair Value   $ 165
    Foreign Exchange Contract Maturing November 2021    
    Derivatives, Fair Value [Line Items]    
    Notional Amount   $ 3,966
    Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $   0.0227
    Fair Value   $ 166
    XML 119 R106.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Instruments and Fair Value Measurements (Schedule of Derivative Instruments with Hedge Accounting Designation) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Interest expense      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Gain (Loss) Reclassified from AOCI $ (3,406) $ (3,447) $ 1,621
    Interest expense | Interest rate swaps      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Gain (Loss) Recognized in OCI 642 (7,405) (5,618)
    Sales      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Gain (Loss) Reclassified from AOCI (674) 618 (1,334)
    Sales | Foreign exchange contracts      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Gain (Loss) Recognized in OCI (943) 1,017 (1,044)
    Cost of sales      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Gain (Loss) Reclassified from AOCI 1,437 (1,177) 1,482
    Cost of sales | Foreign exchange contracts      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Gain (Loss) Recognized in OCI 399 (355) 2,634
    Operating expenses      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Gain (Loss) Reclassified from AOCI 69 (79) 0
    Operating expenses | Foreign exchange contracts      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Gain (Loss) Recognized in OCI $ (7) $ 60 $ 0
    XML 120 R107.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Instruments and Fair Value Measurements (Narratives) (Details) - USD ($)
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 28, 2018
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]        
    Gain (loss) reclassification from accumulated OCI to income, estimated net amount to be transferred   $ 1,800,000    
    Contingent consideration liability, current $ 1,700,000 900,000 $ 1,700,000  
    Contingent consideration liability, noncurrent 2,200,000 1,500,000 2,200,000  
    Non-marketable securities impairment 400,000 100,000    
    Non-marketable securities fair value $ 2,200,000 0 2,200,000  
    Equity method investment, return of capital   2,200,000 $ 400,000 $ 100,000
    Foreign Exchange Contract | Not Designated as Hedging Instrument        
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]        
    Notional amount   15,000,000    
    Fair value   100,000    
    Foreign exchange contracts | Not Designated as Hedging Instrument        
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]        
    Gain (loss) recognized in OCI   $ 400,000    
    Chinese Venture Capital Fund        
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]        
    Percentage of ownership interest   6.70%    
    XML 121 R108.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Instruments and Fair Value Measurements (Estimated Fair Values for Contingent Consideration) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
    Balance at beginning of period $ 3,900 $ 4,200
    Amount recorded for current year acquisitions   2,700
    Fair value measurement adjustment 133 (2,000)
    Payments (1,621) (1,000)
    Foreign currency translation 3  
    Balance at end of period $ 2,415 $ 3,900
    XML 122 R109.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Instruments and Fair Value Measurements (Contingent Consideration Measurement Inputs) (Details)
    $ in Thousands
    Dec. 31, 2021
    USD ($)
    Dec. 31, 2020
    USD ($)
    Feb. 19, 2020
    USD ($)
    InoMec Ltd      
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
    Remaining Maximum Payout (undiscounted) $ 6,750 $ 9,000 $ 3,500
    Fair Value, Recurring      
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
    Fair Value $ 2,415 $ 3,900  
    Fair Value, Recurring | Revenue volatility | Weighted Average      
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
    Unobservable Inputs 0.290 0.350  
    Fair Value, Recurring | Discount rate | Weighted Average      
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
    Unobservable Inputs 0.018 0.040  
    XML 123 R110.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Instruments and Fair Value Measurements (Equity Method Investments) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Fair Value Disclosures [Abstract]      
    Equity method investment $ 16,192 $ 21,470  
    Non-marketable equity securities 5,637 5,723  
    Total equity investments 21,829 27,193  
    Equity method investment (income) loss 3,057 (5,706) $ (1,100)
    Impairment charges 86 369 1,575
    Total (gain) loss on equity investments, net $ 3,143 $ (5,337) $ 475
    XML 124 R111.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Segment and Geographic Information (Narrative) (Details)
    		 12 Months Ended
    Dec. 31, 2021
    segment
    Segment Reporting [Abstract]  
    Number of reportable segments 2
    XML 125 R112.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Segment and Geographic Information (Sales by Product Lines) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Sales $ 1,221,079 $ 1,073,442 $ 1,258,094
    Medical      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Sales 1,182,626 1,037,978 1,199,679
    Medical | Cardio & Vascular      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Sales 626,013 569,948 610,056
    Medical | Cardiac & Neuromodulation      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Sales 446,569 346,242 457,194
    Medical | Advanced Surgical, Orthopedics & Portable Medical      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Sales 110,044 121,788 132,429
    Non-Medical      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Sales $ 38,453 $ 35,464 $ 58,415
    XML 126 R113.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Segment and Geographic Information (Sales by Geographic Information) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total sales $ 1,221,079 $ 1,073,442 $ 1,258,094
    U.S.      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total sales 671,502 596,804 698,474
    Puerto Rico      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total sales 110,162 96,048 154,644
    Costa Rica      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total sales 66,975 58,853 63,634
    Rest of world      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total sales $ 372,440 $ 321,737 $ 341,342
    XML 127 R114.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Segment and Geographic Information (Significant Customers) (Details) - Customer Concentration Risk - Sales
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Customer A      
    Revenue, Major Customer [Line Items]      
    Concentration risk percentage 18.00% 18.00% 21.00%
    Customer B      
    Revenue, Major Customer [Line Items]      
    Concentration risk percentage 16.00% 16.00% 17.00%
    Customer C      
    Revenue, Major Customer [Line Items]      
    Concentration risk percentage 13.00% 14.00% 12.00%
    Medical | Customer A      
    Revenue, Major Customer [Line Items]      
    Concentration risk percentage 19.00% 19.00%  
    Medical | Customer B      
    Revenue, Major Customer [Line Items]      
    Concentration risk percentage 17.00% 17.00%  
    Medical | Customer C      
    Revenue, Major Customer [Line Items]      
    Concentration risk percentage 14.00% 15.00%  
    Medical | All other customers      
    Revenue, Major Customer [Line Items]      
    Concentration risk percentage 50.00% 49.00%  
    Non-Medical | Customer D      
    Revenue, Major Customer [Line Items]      
    Concentration risk percentage 36.00% 22.00%  
    Non-Medical | Customer E      
    Revenue, Major Customer [Line Items]      
    Concentration risk percentage   10.00%  
    Non-Medical | All other customers      
    Revenue, Major Customer [Line Items]      
    Concentration risk percentage 64.00% 68.00%  
    XML 128 R115.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Segment and Geographic Information (Schedule of Revenue by Ship To Location) (Details) - Sales - Geographic Concentration Risk
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    United States | Medical    
    Segment Reporting Information [Line Items]    
    Concentration risk percentage 54.00% 55.00%
    United States | Non-Medical    
    Segment Reporting Information [Line Items]    
    Concentration risk percentage 71.00% 60.00%
    Rest of world | Medical    
    Segment Reporting Information [Line Items]    
    Concentration risk percentage 46.00% 45.00%
    Rest of world | Non-Medical    
    Segment Reporting Information [Line Items]    
    Concentration risk percentage 29.00% 40.00%
    XML 129 R116.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Segment and Geographic Information (Reconciliation of Segment Information) (Details 1) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Segment Reporting Information [Line Items]      
    Operating income as reported $ 135,711 $ 120,612 $ 157,635
    Unallocated other income (expense), net (34,648) (34,405) (52,442)
    Income from continuing operations before taxes 101,063 86,207 105,193
    Total depreciation and amortization 81,369 79,324 77,895
    Total assets 2,582,215 2,371,857  
    Expenditures for tangible long-lived assets, excluding acquisitions 53,463 46,832 48,198
    Operating Segments      
    Segment Reporting Information [Line Items]      
    Operating income as reported 221,622 174,244 240,162
    Total depreciation and amortization 76,533 73,334 69,906
    Total assets 2,504,281 2,265,171  
    Expenditures for tangible long-lived assets, excluding acquisitions 48,992 43,473 44,423
    Operating Segments | Medical      
    Segment Reporting Information [Line Items]      
    Operating income as reported 213,600 169,396 223,873
    Total depreciation and amortization 75,366 72,338 68,867
    Total assets 2,448,123 2,212,489  
    Expenditures for tangible long-lived assets, excluding acquisitions 48,364 42,435 44,026
    Operating Segments | Non-Medical      
    Segment Reporting Information [Line Items]      
    Operating income as reported 8,022 4,848 16,289
    Total depreciation and amortization 1,167 996 1,039
    Total assets 56,158 52,682  
    Expenditures for tangible long-lived assets, excluding acquisitions 628 1,038 397
    Unallocated Amount to Segment      
    Segment Reporting Information [Line Items]      
    Operating income as reported (85,911) (53,632) (82,527)
    Total depreciation and amortization 4,836 5,990 7,989
    Total assets 77,934 106,686  
    Expenditures for tangible long-lived assets, excluding acquisitions $ 4,471 $ 3,359 $ 3,775
    XML 130 R117.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Segment and Geographic Information (Long lived Tangible Assets by Region) (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Segment Reporting, Asset Reconciling Item [Line Items]    
    Long-lived tangible assets $ 277,099 $ 253,964
    United States    
    Segment Reporting, Asset Reconciling Item [Line Items]    
    Long-lived tangible assets 184,474 170,871
    Mexico    
    Segment Reporting, Asset Reconciling Item [Line Items]    
    Long-lived tangible assets 33,877 32,723
    Ireland    
    Segment Reporting, Asset Reconciling Item [Line Items]    
    Long-lived tangible assets 41,501 38,526
    Rest of world    
    Segment Reporting, Asset Reconciling Item [Line Items]    
    Long-lived tangible assets $ 17,247 $ 11,844
    XML 131 R118.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Revenue From Contracts With Customers (Disaggregated Revenue) (Details)
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Disaggregation of Revenue [Line Items]      
    Percent of revenue from contract with customer compared to total revenue 33.00% 29.00%  
    Sales | Customer Concentration Risk | Customer A      
    Disaggregation of Revenue [Line Items]      
    Concentration risk percentage 18.00% 18.00% 21.00%
    Sales | Customer Concentration Risk | Customer B      
    Disaggregation of Revenue [Line Items]      
    Concentration risk percentage 16.00% 16.00% 17.00%
    Sales | Customer Concentration Risk | Customer C      
    Disaggregation of Revenue [Line Items]      
    Concentration risk percentage 13.00% 14.00% 12.00%
    Sales | Customer Concentration Risk | Top Customers      
    Disaggregation of Revenue [Line Items]      
    Concentration risk percentage 47.00% 48.00% 50.00%
    Accounts Receivable | Customer Concentration Risk | Customer A      
    Disaggregation of Revenue [Line Items]      
    Concentration risk percentage 15.00% 15.00%  
    Accounts Receivable | Customer Concentration Risk | Customer B      
    Disaggregation of Revenue [Line Items]      
    Concentration risk percentage 19.00% 19.00%  
    Accounts Receivable | Customer Concentration Risk | Customer C      
    Disaggregation of Revenue [Line Items]      
    Concentration risk percentage 10.00% 13.00%  
    Accounts Receivable | Customer Concentration Risk | Top Customers      
    Disaggregation of Revenue [Line Items]      
    Concentration risk percentage 44.00% 47.00%  
    XML 132 R119.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Revenue From Contracts With Customers (Contract Balances) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Revenue from Contract with Customer [Abstract]    
    Contract assets $ 64,743 $ 40,218
    Contract liabilities 3,776 2,498
    Increase in contract assets 24,500  
    Contract with customer, liability, revenue recognized $ 1,900 $ 1,300
    XML 133 R120.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Discontinued Operations (AS&O Business Narrative) (Details) - USD ($)
    $ in Millions
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2019
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
    Proceeds from sale of discontinued operations, gross   $ 4.8
    Discontinued Operations, Held-for-sale | AS&O Product Line    
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
    Discontinued operation, gain (loss) on disposal of discontinued operation, net of tax $ 4.9  
    XML 134 R121.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Discontinued Operations (Income from Discontinued Operations) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
    Income from discontinued operations before taxes $ 4,931 $ 0 $ 5,296
    Provision for income taxes 1,143 0 178
    Income from discontinued operations 3,788 0 5,118
    AS&O Product Line | Discontinued Operations, Held-for-sale      
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
    Gain on sale of discontinued operations 0 0 (4,974)
    Other income, net (4,931) 0 (322)
    Income from discontinued operations before taxes 4,931 0 5,296
    Provision for income taxes 1,143 0 178
    Income from discontinued operations $ 3,788 $ 0 $ 5,118
    XML 135 R122.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Discontinued Operations (Cash Flow Information from Discontinued Operations) (Details) - AS&O Product Line - Discontinued Operations, Held-for-sale - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
    Cash used in operating activities $ 0 $ 0 $ (78)
    Cash provided by investing activities $ 0 $ 0 $ 4,734
    XML 136 R123.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
    SEC Schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense, customer bankruptcy     $ 2,300
    Provision for credit losses      
    SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
    Balance at beginning of period $ 155 $ 2,443 592
    Charged to Costs & Expenses 20 28 1,884
    Charged to Other Accounts- Describe 0 0 2
    Deductions (43) (2,316) (35)
    Balance at end of period 132 155 2,443
    Valuation allowance for deferred tax assets      
    SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
    Balance at beginning of period 20,739 22,229 34,339
    Charged to Costs & Expenses (941) (275) 736
    Charged to Other Accounts- Describe 26 0 0
    Deductions (368) (1,215) (12,846)
    Balance at end of period $ 19,456 $ 20,739 $ 22,229
    XML 137 R9999.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Label Element Value
    Accounting Standards Update [Extensible Enumeration] us-gaap_AccountingStandardsUpdateExtensibleList Accounting Standards Update 2016-02 [Member]
    XML 138 gb-20211231_htm.xml IDEA: XBRL DOCUMENT 0001114483 2021-01-01 2021-12-31 0001114483 2021-07-02 0001114483 2022-02-16 0001114483 2021-12-31 0001114483 2020-12-31 0001114483 2020-01-01 2020-12-31 0001114483 2018-12-29 2019-12-31 0001114483 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001114483 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001114483 us-gaap:RetainedEarningsMember 2018-12-29 2019-12-31 0001114483 2019-12-31 0001114483 2018-12-28 0001114483 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-12-31 0001114483 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-12-31 0001114483 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-12-28 0001114483 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001114483 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001114483 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-12-29 2019-12-31 0001114483 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-12-31 0001114483 us-gaap:TreasuryStockMember 2019-12-31 0001114483 us-gaap:TreasuryStockMember 2018-12-28 0001114483 us-gaap:TreasuryStockMember 2018-12-29 2019-12-31 0001114483 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0001114483 us-gaap:TreasuryStockMember 2021-12-31 0001114483 us-gaap:TreasuryStockMember 2020-12-31 0001114483 us-gaap:RetainedEarningsMember 2020-12-31 0001114483 us-gaap:RetainedEarningsMember 2019-12-31 0001114483 us-gaap:RetainedEarningsMember 2018-12-28 0001114483 2017-12-30 2018-12-28 0001114483 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-12-28 0001114483 us-gaap:RetainedEarningsMember 2021-12-31 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-28 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-29 2019-12-31 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001114483 2019-09-28 2019-12-31 0001114483 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-01-01 2021-12-31 0001114483 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-01-01 2021-12-31 0001114483 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2021-01-01 2021-12-31 0001114483 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2021-01-01 2021-12-31 0001114483 srt:MinimumMember us-gaap:OfficeEquipmentMember 2021-01-01 2021-12-31 0001114483 srt:MaximumMember us-gaap:OfficeEquipmentMember 2021-01-01 2021-12-31 0001114483 srt:MinimumMember us-gaap:PatentsMember 2021-01-01 2021-12-31 0001114483 srt:MaximumMember us-gaap:PatentsMember 2021-01-01 2021-12-31 0001114483 srt:MinimumMember us-gaap:CustomerListsMember 2021-01-01 2021-12-31 0001114483 srt:MaximumMember us-gaap:CustomerListsMember 2021-01-01 2021-12-31 0001114483 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2021-01-01 2021-12-31 0001114483 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2021-01-01 2021-12-31 0001114483 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001114483 srt:MinimumMember gb:RestrictedStockAndUnitAwardsMember 2021-01-01 2021-12-31 0001114483 srt:MaximumMember gb:RestrictedStockAndUnitAwardsMember 2021-01-01 2021-12-31 0001114483 srt:DirectorMember gb:RestrictedStockAndUnitAwardsMember 2021-01-01 2021-12-31 0001114483 srt:MaximumMember gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember 2021-01-01 2021-12-31 0001114483 gb:OscorIncMember 2021-12-01 0001114483 gb:OscorIncMember 2021-12-01 2021-12-01 0001114483 gb:OscorIncMember 2021-12-01 0001114483 gb:OscorIncMember 2021-12-01 2021-12-31 0001114483 gb:OscorIncMember gb:OfficeAndManufacturingFacilitiesMember 2021-12-31 0001114483 us-gaap:CustomerListsMember 2021-01-01 2021-12-31 0001114483 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-01-01 2021-12-31 0001114483 us-gaap:TradeNamesMember 2021-01-01 2021-12-31 0001114483 us-gaap:CustomerListsMember gb:MeasurementInputAnnualAttritionRateMember us-gaap:IncomeApproachValuationTechniqueMember 2021-12-31 0001114483 srt:MaximumMember us-gaap:TechnologyBasedIntangibleAssetsMember gb:MeasurementInputRoyaltyRateMember us-gaap:IncomeApproachValuationTechniqueMember 2021-12-31 0001114483 srt:MinimumMember us-gaap:TechnologyBasedIntangibleAssetsMember gb:MeasurementInputRoyaltyRateMember us-gaap:IncomeApproachValuationTechniqueMember 2021-12-31 0001114483 us-gaap:TradeNamesMember gb:MeasurementInputRoyaltyRateMember us-gaap:IncomeApproachValuationTechniqueMember 2021-12-31 0001114483 gb:InoMecLtdMember 2020-02-19 2020-02-19 0001114483 gb:InoMecLtdMember 2020-02-19 0001114483 gb:USBioDesignLLCMember 2019-10-07 2019-10-07 0001114483 gb:USBioDesignLLCMember 2019-10-07 0001114483 gb:USBioDesignLLCMember gb:TechnologyMember 2019-10-07 0001114483 gb:USBioDesignLLCMember 2020-01-01 2020-12-31 0001114483 gb:USBioDesignLLCMember gb:TechnologyMember 2019-10-07 2019-10-07 0001114483 gb:OscorIncMember 2021-01-01 2021-12-31 0001114483 gb:InoMecLtdMember 2021-01-01 2021-12-31 0001114483 gb:USBioDesignLLCMember 2021-01-01 2021-12-31 0001114483 gb:InoMecLtdMember 2020-01-01 2020-12-31 0001114483 gb:USBioDesignLLCMember 2018-12-29 2019-12-31 0001114483 gb:OscorIncMember 2020-01-01 2020-12-31 0001114483 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001114483 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001114483 us-gaap:BuildingAndBuildingImprovementsMember 2021-12-31 0001114483 us-gaap:BuildingAndBuildingImprovementsMember 2020-12-31 0001114483 us-gaap:ComputerEquipmentMember 2021-12-31 0001114483 us-gaap:ComputerEquipmentMember 2020-12-31 0001114483 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001114483 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001114483 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001114483 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001114483 us-gaap:LandAndLandImprovementsMember 2021-12-31 0001114483 us-gaap:LandAndLandImprovementsMember 2020-12-31 0001114483 us-gaap:ConstructionInProgressMember 2021-12-31 0001114483 us-gaap:ConstructionInProgressMember 2020-12-31 0001114483 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2021-12-31 0001114483 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2020-12-31 0001114483 gb:MedicalSegmentMember 2019-12-31 0001114483 gb:NonMedicalSegmentMember 2019-12-31 0001114483 gb:MedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:NonMedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:MedicalSegmentMember 2020-12-31 0001114483 gb:NonMedicalSegmentMember 2020-12-31 0001114483 gb:MedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:NonMedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:MedicalSegmentMember 2021-12-31 0001114483 gb:NonMedicalSegmentMember 2021-12-31 0001114483 gb:PurchasedTechnologyTradenamesAndPatentsMember 2021-12-31 0001114483 us-gaap:CustomerListsMember 2021-12-31 0001114483 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0001114483 us-gaap:TrademarksAndTradeNamesMember 2021-12-31 0001114483 gb:PurchasedTechnologyTradenamesAndPatentsMember 2020-12-31 0001114483 us-gaap:CustomerListsMember 2020-12-31 0001114483 us-gaap:OtherIntangibleAssetsMember 2020-12-31 0001114483 us-gaap:TrademarksAndTradeNamesMember 2020-12-31 0001114483 gb:LakeRegionMedicalMember us-gaap:TrademarksAndTradeNamesMember 2021-12-31 0001114483 gb:LakeRegionMedicalMember us-gaap:TrademarksAndTradeNamesMember 2020-12-31 0001114483 gb:SimilarIdentifiableAssetsRelatingToALicenseToUseTechnologyMember us-gaap:LicenseMember gb:NonMedicalSegmentMember 2020-01-01 2020-12-31 0001114483 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001114483 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001114483 us-gaap:CostOfSalesMember 2018-12-29 2019-12-31 0001114483 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001114483 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001114483 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-12-29 2019-12-31 0001114483 us-gaap:SecuredDebtMember gb:TermLoanATLAFacilityMember us-gaap:LoansPayableMember 2021-12-31 0001114483 us-gaap:SecuredDebtMember gb:TermLoanATLAFacilityMember us-gaap:LoansPayableMember 2020-12-31 0001114483 us-gaap:SecuredDebtMember gb:TermLoanBTLBFacilityMember us-gaap:LoansPayableMember 2021-12-31 0001114483 us-gaap:SecuredDebtMember gb:TermLoanBTLBFacilityMember us-gaap:LoansPayableMember 2020-12-31 0001114483 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-12-31 0001114483 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-12-31 0001114483 2021-09-02 0001114483 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-09-02 2021-09-02 0001114483 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-09-02 0001114483 gb:TermLoanATLAFacilityMember us-gaap:SecuredDebtMember 2021-09-02 2021-09-02 0001114483 gb:TermLoanATLAFacilityMember us-gaap:SecuredDebtMember 2021-09-02 0001114483 gb:TermLoanBTLBFacilityMember us-gaap:SecuredDebtMember 2021-09-02 2021-09-02 0001114483 gb:TermLoanBTLBFacilityMember us-gaap:SecuredDebtMember 2021-09-02 0001114483 us-gaap:SecuredDebtMember gb:TermLoanATLAFacilityMember us-gaap:LoansPayableMember 2021-01-01 2021-12-31 0001114483 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-09-01 0001114483 us-gaap:RevolvingCreditFacilityMember gb:NewRevolvingCreditFacility2015Member us-gaap:LineOfCreditMember 2021-09-02 0001114483 us-gaap:SecuredDebtMember gb:TermLoanATLAFacilityMember us-gaap:LoansPayableMember 2021-09-02 0001114483 us-gaap:SecuredDebtMember gb:TermLoanBTLBFacilityMember us-gaap:LoansPayableMember 2021-09-02 0001114483 us-gaap:SecuredDebtMember gb:TermLoanBTLBFacilityMember us-gaap:LoansPayableMember 2021-09-02 2021-09-02 0001114483 us-gaap:SecuredDebtMember gb:NewRevolvingCreditFacility2015Member gb:SwinglineLoansMember 2020-07-13 0001114483 us-gaap:StandbyLettersOfCreditMember 2021-12-31 0001114483 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember gb:LondonInterbankOfferedRateOneMonthLIBORMember 2021-01-01 2021-12-31 0001114483 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember gb:LondonInterbankOfferedRateOneMonthLIBORMember 2021-01-01 2021-12-31 0001114483 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember gb:TermLoanATLAFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2021-01-01 2021-12-31 0001114483 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember gb:TermLoanATLAFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2021-01-01 2021-12-31 0001114483 us-gaap:RevolvingCreditFacilityMember gb:TermLoanATLAFacilityMember us-gaap:LineOfCreditMember us-gaap:FederalFundsEffectiveSwapRateMember 2021-01-01 2021-12-31 0001114483 us-gaap:RevolvingCreditFacilityMember gb:TermLoanATLAFacilityMember us-gaap:LineOfCreditMember gb:LondonInterbankOfferedRateOneMonthLIBORMember 2021-01-01 2021-12-31 0001114483 us-gaap:RevolvingCreditFacilityMember 2021-12-31 0001114483 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-01-01 2021-12-31 0001114483 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-01-01 2021-12-31 0001114483 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-01-01 2021-12-31 0001114483 gb:TermLoanBTLBFacilityMember us-gaap:SecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-12-31 0001114483 gb:TermLoanBTLBFacilityMember us-gaap:SecuredDebtMember us-gaap:BaseRateMember 2021-01-01 2021-12-31 0001114483 gb:TermLoanATLAFacilityMember us-gaap:SecuredDebtMember 2021-12-31 0001114483 gb:TermLoanBTLBFacilityMember us-gaap:SecuredDebtMember 2021-12-31 0001114483 us-gaap:RevolvingCreditFacilityMember gb:TermLoanATLAFacilityMember us-gaap:SecuredDebtMember 2021-01-01 2021-12-31 0001114483 us-gaap:RevolvingCreditFacilityMember gb:ITGRTermLoanATLAFacilityMember us-gaap:SecuredDebtMember 2021-01-01 2021-12-31 0001114483 us-gaap:RevolvingCreditFacilityMember 2020-12-31 0001114483 us-gaap:RevolvingCreditFacilityMember 2021-01-01 2021-12-31 0001114483 us-gaap:RevolvingCreditFacilityMember 2021-12-31 0001114483 gb:TermLoanAndSeniorNotesMember 2020-12-31 0001114483 gb:TermLoanBTLBFacilityMember 2020-12-31 0001114483 gb:TermLoanAndSeniorNotesMember 2021-01-01 2021-12-31 0001114483 gb:TermLoanBTLBFacilityMember 2021-01-01 2021-12-31 0001114483 gb:TermLoanAndSeniorNotesMember 2021-12-31 0001114483 gb:TermLoanBTLBFacilityMember 2021-12-31 0001114483 us-gaap:LoansPayableMember 2021-12-31 0001114483 us-gaap:LongTermDebtMember us-gaap:LoansPayableMember 2021-12-31 0001114483 us-gaap:OtherAssetsMember us-gaap:RevolvingCreditFacilityMember 2021-12-31 0001114483 gb:TermLoanBTLBFacilityMember us-gaap:SecuredDebtMember 2021-01-01 2021-12-31 0001114483 srt:MaximumMember 2021-01-01 2021-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsMember 2021-01-01 2021-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsMember 2018-12-29 2019-12-31 0001114483 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001114483 us-gaap:EmployeeStockOptionMember 2018-12-29 2019-12-31 0001114483 gb:RSUsAndPRSUsMember 2021-01-01 2021-12-31 0001114483 gb:RSUsAndPRSUsMember 2020-01-01 2020-12-31 0001114483 gb:RSUsAndPRSUsMember 2018-12-29 2019-12-31 0001114483 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001114483 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001114483 us-gaap:CostOfSalesMember 2018-12-29 2019-12-31 0001114483 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001114483 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001114483 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-12-29 2019-12-31 0001114483 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001114483 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001114483 us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-29 2019-12-31 0001114483 gb:OtherOperatingExpensesNetMember 2021-01-01 2021-12-31 0001114483 gb:OtherOperatingExpensesNetMember 2020-01-01 2020-12-31 0001114483 gb:OtherOperatingExpensesNetMember 2018-12-29 2019-12-31 0001114483 us-gaap:EmployeeStockOptionMember 2021-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsTimeBasedMember 2020-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsTimeBasedMember 2021-01-01 2021-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsTimeBasedMember 2021-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsMember 2021-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember 2020-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember 2021-01-01 2021-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember 2021-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember 2021-01-01 2021-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember 2021-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember 2020-01-01 2020-12-31 0001114483 gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember 2018-12-29 2019-12-31 0001114483 gb:OperationalExcellenceInitiativesMember 2021-10-02 2021-12-31 0001114483 gb:OperationalExcellenceInitiativesMember 2020-01-01 2020-12-31 0001114483 gb:OperationalExcellenceInitiativesMember 2018-12-29 2019-12-31 0001114483 gb:StrategicReorganizationAndAlignmentMember 2021-10-02 2021-12-31 0001114483 gb:StrategicReorganizationAndAlignmentMember 2020-01-01 2020-12-31 0001114483 gb:StrategicReorganizationAndAlignmentMember 2018-12-29 2019-12-31 0001114483 gb:ManufacturingAlignmentToSupportGrowthMember 2021-10-02 2021-12-31 0001114483 gb:ManufacturingAlignmentToSupportGrowthMember 2020-01-01 2020-12-31 0001114483 gb:ManufacturingAlignmentToSupportGrowthMember 2018-12-29 2019-12-31 0001114483 2021-10-02 2021-12-31 0001114483 srt:MinimumMember us-gaap:EmployeeSeveranceMember gb:OperationalExcellenceInitiativesTwoThousandTwentyOneInitiativesMember 2021-12-31 0001114483 srt:MaximumMember us-gaap:EmployeeSeveranceMember gb:OperationalExcellenceInitiativesTwoThousandTwentyOneInitiativesMember 2021-12-31 0001114483 gb:OperationalExcellenceInitiativesTwoThousandTwentyOneInitiativesMember us-gaap:EmployeeSeveranceMember 2021-12-31 0001114483 gb:TwoThousandTwentyTwoRestructuringPlanMember 2021-01-01 2021-12-31 0001114483 srt:MinimumMember gb:StrategicReorganizationAndAlignmentInitiativesTwoThousandTwentyOneInitiativesMember 2021-12-31 0001114483 srt:MaximumMember gb:StrategicReorganizationAndAlignmentInitiativesTwoThousandTwentyOneInitiativesMember 2021-12-31 0001114483 gb:StrategicReorganizationAndAlignmentInitiativesTwoThousandTwentyOneInitiativesMember 2021-12-31 0001114483 gb:StrategicReorganizationAndAlignmentMember gb:MedicalSegmentMember 2020-07-03 0001114483 gb:ManufacturingAlignmentToSupportGrowthMember 2021-12-31 0001114483 gb:TwoThousandTwentyTwoRestructuringPlanMember 2020-12-31 0001114483 gb:StrategicReorganizationAndAlignmentMember 2020-12-31 0001114483 gb:TwoThousandTwentyTwoRestructuringPlanMember 2021-01-01 2021-12-31 0001114483 gb:StrategicReorganizationAndAlignmentMember 2021-01-01 2021-12-31 0001114483 gb:TwoThousandTwentyTwoRestructuringPlanMember 2021-12-31 0001114483 gb:StrategicReorganizationAndAlignmentMember 2021-12-31 0001114483 country:US 2021-01-01 2021-12-31 0001114483 country:US 2020-01-01 2020-12-31 0001114483 country:US 2018-12-29 2019-12-31 0001114483 gb:InternationalMember 2021-01-01 2021-12-31 0001114483 gb:InternationalMember 2020-01-01 2020-12-31 0001114483 gb:InternationalMember 2018-12-29 2019-12-31 0001114483 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001114483 gb:InternationalJurisdictionMember 2021-12-31 0001114483 us-gaap:DomesticCountryMember gb:ForeignTaxCreditCarryforwardMember 2021-12-31 0001114483 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2021-12-31 0001114483 us-gaap:StateAndLocalJurisdictionMember gb:StateTaxCreditCarryforwardMember 2021-12-31 0001114483 2020-10-01 2020-10-31 0001114483 us-gaap:RoyaltyMember 2021-01-01 2021-12-31 0001114483 us-gaap:RoyaltyMember 2020-01-01 2020-12-31 0001114483 us-gaap:RoyaltyMember 2018-12-29 2019-12-31 0001114483 us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0001114483 us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0001114483 gb:TimeVestedStockOptionsRestrictedStockAndRestrictedStockUnitsMember 2021-01-01 2021-12-31 0001114483 gb:TimeVestedStockOptionsRestrictedStockAndRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001114483 gb:TimeVestedStockOptionsRestrictedStockAndRestrictedStockUnitsMember 2018-12-29 2019-12-31 0001114483 gb:PerformanceVestedRestrictedStockUnitsMember 2021-01-01 2021-12-31 0001114483 gb:PerformanceVestedRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001114483 gb:PerformanceVestedRestrictedStockUnitsMember 2018-12-29 2019-12-31 0001114483 us-gaap:CommonStockMember 2019-12-31 0001114483 us-gaap:TreasuryStockCommonMember 2019-12-31 0001114483 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001114483 us-gaap:TreasuryStockCommonMember 2020-01-01 2020-12-31 0001114483 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001114483 us-gaap:RestrictedStockUnitsRSUMember us-gaap:TreasuryStockCommonMember 2020-01-01 2020-12-31 0001114483 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001114483 us-gaap:CommonStockMember 2020-12-31 0001114483 us-gaap:TreasuryStockCommonMember 2020-12-31 0001114483 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001114483 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0001114483 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001114483 us-gaap:RestrictedStockUnitsRSUMember us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0001114483 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001114483 us-gaap:CommonStockMember 2021-12-31 0001114483 us-gaap:TreasuryStockCommonMember 2021-12-31 0001114483 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0001114483 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0001114483 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001114483 gb:AccumulatedAdjustmentAttributableToParentMember 2019-12-31 0001114483 gb:AccumulatedOtherComprehensiveIncomeTaxMember 2019-12-31 0001114483 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-12-31 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-12-31 0001114483 us-gaap:InterestRateSwapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-12-31 0001114483 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-12-31 0001114483 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-12-31 0001114483 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0001114483 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0001114483 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001114483 gb:AccumulatedAdjustmentAttributableToParentMember 2020-12-31 0001114483 gb:AccumulatedOtherComprehensiveIncomeTaxMember 2020-12-31 0001114483 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-12-31 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-12-31 0001114483 us-gaap:InterestRateSwapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-12-31 0001114483 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-12-31 0001114483 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-12-31 0001114483 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0001114483 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0001114483 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0001114483 gb:AccumulatedAdjustmentAttributableToParentMember 2021-12-31 0001114483 gb:AccumulatedOtherComprehensiveIncomeTaxMember 2021-12-31 0001114483 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001114483 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001114483 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001114483 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001114483 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001114483 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001114483 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001114483 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001114483 us-gaap:OtherNoncurrentLiabilitiesMember gb:InterestRateSwapMaturingJuneTwoThousandTwentyThreeMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001114483 us-gaap:OtherNoncurrentLiabilitiesMember gb:InterestRateSwapMaturingJuneTwoThousandTwentyThreeMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001114483 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember gb:ForeignExchangeContractMaturingDecemberTwoThousandTwentyTwoContractOneMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001114483 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember gb:ForeignExchangeContractMaturingDecemberTwoThousandTwentyTwoContractTwoMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001114483 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember gb:ForeignExchangeContractMaturingDecemberTwoThousandTwentyTwoContractThreeMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001114483 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember gb:ForeignExchangeContractMaturingSeptemberTwoThousandTwentyOneContractOneMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001114483 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember gb:ForeignExchangeContractMaturingSeptemberTwoThousandTwentyOneContractTwoMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001114483 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember gb:ForeignExchangeContractMaturingMarchTwoThousandTwentyOneMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001114483 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember gb:ForeignExchangeContractMaturingDecemberTwoThousandTwentyOneMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001114483 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember gb:ForeignExchangeContractMaturingAugustTwoThousandTwentyOneMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001114483 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember gb:ForeignExchangeContractMaturingNovemberTwoThousandTwentyOneMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001114483 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0001114483 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0001114483 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2018-12-29 2019-12-31 0001114483 us-gaap:InterestExpenseMember 2018-12-29 2019-12-31 0001114483 us-gaap:ForeignExchangeForwardMember us-gaap:SalesMember 2021-01-01 2021-12-31 0001114483 us-gaap:ForeignExchangeForwardMember us-gaap:SalesMember 2020-01-01 2020-12-31 0001114483 us-gaap:ForeignExchangeForwardMember us-gaap:SalesMember 2018-12-29 2019-12-31 0001114483 us-gaap:SalesMember 2021-01-01 2021-12-31 0001114483 us-gaap:SalesMember 2020-01-01 2020-12-31 0001114483 us-gaap:SalesMember 2018-12-29 2019-12-31 0001114483 us-gaap:ForeignExchangeForwardMember us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001114483 us-gaap:ForeignExchangeForwardMember us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001114483 us-gaap:ForeignExchangeForwardMember us-gaap:CostOfSalesMember 2018-12-29 2019-12-31 0001114483 us-gaap:ForeignExchangeForwardMember us-gaap:OperatingExpenseMember 2021-01-01 2021-12-31 0001114483 us-gaap:ForeignExchangeForwardMember us-gaap:OperatingExpenseMember 2020-01-01 2020-12-31 0001114483 us-gaap:ForeignExchangeForwardMember us-gaap:OperatingExpenseMember 2018-12-29 2019-12-31 0001114483 us-gaap:OperatingExpenseMember 2021-01-01 2021-12-31 0001114483 us-gaap:OperatingExpenseMember 2020-01-01 2020-12-31 0001114483 us-gaap:OperatingExpenseMember 2018-12-29 2019-12-31 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0001114483 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2021-01-01 2021-12-31 0001114483 gb:InoMecLtdMember 2021-12-31 0001114483 srt:WeightedAverageMember us-gaap:FairValueMeasurementsRecurringMember gb:MeasurementInputRevenueVolatilityMember 2021-12-31 0001114483 srt:WeightedAverageMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001114483 gb:InoMecLtdMember 2020-12-31 0001114483 srt:WeightedAverageMember us-gaap:FairValueMeasurementsRecurringMember gb:MeasurementInputRevenueVolatilityMember 2020-12-31 0001114483 srt:WeightedAverageMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember 2020-12-31 0001114483 2020-10-03 2020-12-31 0001114483 gb:ChineseVentureCapitalFundMember 2021-12-31 0001114483 gb:CardioAndVascularMember gb:MedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:CardioAndVascularMember gb:MedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:CardioAndVascularMember gb:MedicalSegmentMember 2018-12-29 2019-12-31 0001114483 gb:CardiacNeuromodulationMember gb:MedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:CardiacNeuromodulationMember gb:MedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:CardiacNeuromodulationMember gb:MedicalSegmentMember 2018-12-29 2019-12-31 0001114483 gb:AdvancedSurgicalOrthopedicsandPortableMedicalMember gb:MedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:AdvancedSurgicalOrthopedicsandPortableMedicalMember gb:MedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:AdvancedSurgicalOrthopedicsandPortableMedicalMember gb:MedicalSegmentMember 2018-12-29 2019-12-31 0001114483 gb:MedicalSegmentMember 2018-12-29 2019-12-31 0001114483 gb:NonMedicalSegmentMember 2018-12-29 2019-12-31 0001114483 country:US 2021-01-01 2021-12-31 0001114483 country:US 2020-01-01 2020-12-31 0001114483 country:US 2018-12-29 2019-12-31 0001114483 country:PR 2021-01-01 2021-12-31 0001114483 country:PR 2020-01-01 2020-12-31 0001114483 country:PR 2018-12-29 2019-12-31 0001114483 country:CR 2021-01-01 2021-12-31 0001114483 country:CR 2020-01-01 2020-12-31 0001114483 country:CR 2018-12-29 2019-12-31 0001114483 gb:RestOfWorldMember 2021-01-01 2021-12-31 0001114483 gb:RestOfWorldMember 2020-01-01 2020-12-31 0001114483 gb:RestOfWorldMember 2018-12-29 2019-12-31 0001114483 gb:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:MedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:MedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:CustomerBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:MedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:CustomerBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:MedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:CustomerCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:MedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:CustomerCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:MedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:CustomerDMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:NonMedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:CustomerDMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:NonMedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:CustomerEMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:NonMedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:AllOtherCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:MedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:AllOtherCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:NonMedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:AllOtherCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:MedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:AllOtherCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember gb:NonMedicalSegmentMember 2020-01-01 2020-12-31 0001114483 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember gb:MedicalSegmentMember 2021-01-01 2021-12-31 0001114483 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember gb:NonMedicalSegmentMember 2021-01-01 2021-12-31 0001114483 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember gb:MedicalSegmentMember 2020-01-01 2020-12-31 0001114483 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember gb:NonMedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:AllOtherCountriesMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember gb:MedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:AllOtherCountriesMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember gb:NonMedicalSegmentMember 2021-01-01 2021-12-31 0001114483 gb:AllOtherCountriesMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember gb:MedicalSegmentMember 2020-01-01 2020-12-31 0001114483 gb:AllOtherCountriesMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember gb:NonMedicalSegmentMember 2020-01-01 2020-12-31 0001114483 us-gaap:OperatingSegmentsMember gb:MedicalSegmentMember 2021-01-01 2021-12-31 0001114483 us-gaap:OperatingSegmentsMember gb:MedicalSegmentMember 2020-01-01 2020-12-31 0001114483 us-gaap:OperatingSegmentsMember gb:MedicalSegmentMember 2018-12-29 2019-12-31 0001114483 us-gaap:OperatingSegmentsMember gb:NonMedicalSegmentMember 2021-01-01 2021-12-31 0001114483 us-gaap:OperatingSegmentsMember gb:NonMedicalSegmentMember 2020-01-01 2020-12-31 0001114483 us-gaap:OperatingSegmentsMember gb:NonMedicalSegmentMember 2018-12-29 2019-12-31 0001114483 us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0001114483 us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0001114483 us-gaap:OperatingSegmentsMember 2018-12-29 2019-12-31 0001114483 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-12-31 0001114483 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-12-31 0001114483 us-gaap:MaterialReconcilingItemsMember 2018-12-29 2019-12-31 0001114483 us-gaap:OperatingSegmentsMember gb:MedicalSegmentMember 2021-12-31 0001114483 us-gaap:OperatingSegmentsMember gb:MedicalSegmentMember 2020-12-31 0001114483 us-gaap:OperatingSegmentsMember gb:NonMedicalSegmentMember 2021-12-31 0001114483 us-gaap:OperatingSegmentsMember gb:NonMedicalSegmentMember 2020-12-31 0001114483 us-gaap:OperatingSegmentsMember 2021-12-31 0001114483 us-gaap:OperatingSegmentsMember 2020-12-31 0001114483 us-gaap:MaterialReconcilingItemsMember 2021-12-31 0001114483 us-gaap:MaterialReconcilingItemsMember 2020-12-31 0001114483 country:US 2021-12-31 0001114483 country:US 2020-12-31 0001114483 country:MX 2021-12-31 0001114483 country:MX 2020-12-31 0001114483 country:IE 2021-12-31 0001114483 country:IE 2020-12-31 0001114483 gb:RestOfWorldMember 2021-12-31 0001114483 gb:RestOfWorldMember 2020-12-31 0001114483 gb:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001114483 gb:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001114483 gb:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-12-29 2019-12-31 0001114483 gb:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001114483 gb:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001114483 gb:CustomerBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001114483 gb:CustomerBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001114483 gb:CustomerBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-12-29 2019-12-31 0001114483 gb:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001114483 gb:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001114483 gb:CustomerCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001114483 gb:CustomerCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001114483 gb:CustomerCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-12-29 2019-12-31 0001114483 gb:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001114483 gb:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001114483 gb:TopCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001114483 gb:TopCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001114483 gb:TopCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-12-29 2019-12-31 0001114483 gb:TopCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001114483 gb:TopCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001114483 us-gaap:DiscontinuedOperationsHeldforsaleMember gb:ASOBusinessMember 2021-10-02 2021-12-31 0001114483 us-gaap:DiscontinuedOperationsHeldforsaleMember gb:ASOBusinessMember 2021-01-01 2021-12-31 0001114483 us-gaap:DiscontinuedOperationsHeldforsaleMember gb:ASOBusinessMember 2020-01-01 2020-12-31 0001114483 us-gaap:DiscontinuedOperationsHeldforsaleMember gb:ASOBusinessMember 2018-12-29 2019-12-31 0001114483 us-gaap:AllowanceForCreditLossMember 2020-12-31 0001114483 us-gaap:AllowanceForCreditLossMember 2021-01-01 2021-12-31 0001114483 us-gaap:AllowanceForCreditLossMember 2021-12-31 0001114483 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2020-12-31 0001114483 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-01-01 2021-12-31 0001114483 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-12-31 0001114483 us-gaap:AllowanceForCreditLossMember 2019-12-31 0001114483 us-gaap:AllowanceForCreditLossMember 2020-01-01 2020-12-31 0001114483 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0001114483 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2020-01-01 2020-12-31 0001114483 us-gaap:AllowanceForCreditLossMember 2018-12-28 0001114483 us-gaap:AllowanceForCreditLossMember 2018-12-29 2019-12-31 0001114483 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-28 0001114483 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-29 2019-12-31 iso4217:USD shares iso4217:USD shares gb:segment gb:customer pure iso4217:USD iso4217:EUR gb:facility iso4217:USD iso4217:MXN iso4217:USD iso4217:UYU 0001114483 false 2021 FY http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member P3Y http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent 10-K true 2021-12-31 --12-31 false 1-16137 INTEGER HOLDINGS CORPORATION DE 16-1531026 5830 Granite Parkway, Suite 1150 Plano, TX 75024 214 618-5243 Common Stock, Par Value $0.001 Per Share ITGR NYSE Yes No Yes Yes Large Accelerated Filer false false true false 3100000000 33097540 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the following document are specifically incorporated by reference into the indicated parts of this report:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.861%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proxy Statement for the 2022 Annual Meeting of Stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part III, Item 10</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">“Directors, Executive Officers and Corporate Governance”</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part III, Item 11<br/>“Executive Compensation”</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part III, Item 12<br/>“Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters”</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part III, Item 13<br/>“Certain Relationships and Related Transactions, and Director Independence”</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part III, Item 14<br/>“Principal Accounting Fees and Services”</span></td></tr></table></div> Deloitte & Touche LLP Williamsville, New York 17885000 49206000 100000 200000 182310000 156207000 155699000 149323000 4735000 2087000 64743000 40218000 27610000 15896000 452982000 412937000 277099000 253964000 924704000 859442000 807810000 757224000 5711000 4398000 70053000 45153000 43856000 38739000 2582215000 2371857000 15250000 37500000 76859000 51570000 725000 1847000 9862000 8431000 56933000 56843000 159629000 156191000 812876000 693758000 171505000 182304000 59767000 37861000 23741000 30688000 1227518000 1100802000 0.001 0.001 100000000 100000000 0 0 0 0 0 0 0.001 0.001 100000000 100000000 33063336 33063336 32908178 32908178 33000 33000 713150000 700814000 614324000 517516000 27190000 52692000 1354697000 1271055000 2582215000 2371857000 1221079000 1073442000 1258094000 884109000 787735000 903084000 336970000 285707000 355010000 141418000 109006000 138695000 51985000 48468000 46529000 -7856000 -7621000 -12151000 201259000 165095000 197375000 135711000 120612000 157635000 31628000 38220000 52545000 -3143000 5337000 -475000 123000 -1522000 578000 101063000 86207000 105193000 8043000 8949000 13975000 93020000 77258000 91218000 4931000 0 5296000 1143000 0 178000 3788000 0 5118000 96808000 77258000 96336000 2.82 2.35 2.80 0.11 0 0.16 2.93 2.35 2.95 2.80 2.33 2.76 0.11 0 0.15 2.91 2.33 2.92 32993000 32845000 32627000 33258000 33113000 33037000 96808000 96808000 77258000 77258000 96336000 96336000 -27826000 34907000 -7900000 2105000 -2052000 -4580000 -219000 151000 536000 -25502000 32704000 -13016000 71306000 109962000 83320000 96808000 77258000 96336000 81369000 79324000 77895000 6954000 4774000 7772000 16185000 9163000 9294000 -348000 554000 21695000 8235000 7810000 7443000 -3143000 5337000 -475000 -133000 2000000 0 -2202000 -600000 162000 -10270000 -6966000 -10285000 0 0 4974000 17539000 -38153000 6976000 -4700000 -18441000 -3724000 2409000 864000 6293000 24923000 15451000 24767000 19525000 -9055000 1887000 -22984000 -10721000 -2744000 -4115000 -4342000 -4962000 156666000 181341000 165358000 53463000 46832000 48198000 0 4607000 0 443000 82000 28000 0 0 417000 0 0 4734000 217978000 5219000 15009000 -270998000 -56576000 -58862000 741786000 87500000 111500000 818250000 0 0 82300000 185000000 34000000 63000000 185000000 39000000 743000 3263000 3242000 8139000 515000 1385000 4592000 3820000 3283000 1621000 0 0 169000 6000 0 81986000 -88578000 -117926000 1025000 -516000 -604000 -31321000 35671000 -12034000 49206000 13535000 25569000 17885000 49206000 13535000 1271055000 1152488000 1060493000 700847000 701051000 691116000 -3849000 -9367000 641000 16185000 9163000 9294000 713183000 700847000 701051000 -8809000 -8125000 2961000 8809000 2277000 0 0 -8809000 517516000 440258000 344498000 -576000 96808000 96808000 77258000 77258000 96336000 96336000 614324000 517516000 440258000 52692000 19988000 33004000 -25502000 32704000 -13016000 27190000 52692000 19988000 1354697000 1271055000 1152488000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition to medical technologies, the Company develops batteries for high-end niche applications in the energy, military, and environmental markets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of Integer Holdings Corporation and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company completed the sale of its Advanced Surgical and Orthopedic product lines (the “AS&amp;O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC). For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&amp;O Product Line. The Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s (parent) centralized treasury and cash management processes. See Note 20 “Discontinued Operations” for the financial results and cash flow amounts for discontinued operations. All results and information in the consolidated financial statements are presented as continuing operations and exclude the AS&amp;O Product Line unless otherwise noted specifically as discontinued operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. The discontinued operations of the AS&amp;O Product Line were reported in the Medical segment. Refer to Note 18 “Segment and Geographic Information,” for additional information on the Company’s reportable segments.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting periods. Actual results could differ materially from those estimates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in early March 2020, the global spread of the novel coronavirus (“COVID-19”) created significant uncertainty and worldwide economic disruption. Specific impacts to the Company’s business included and continue to include labor shortages, disruptions in the supply chain, delayed or reduced customer orders and sales, restrictions on associates’ ability to travel or work, and delays in shipments to and from certain countries. The extent to which COVID-19 will continue to impact the Company’s operations depends on future developments, which remain highly uncertain and difficult to predict, including, among others, the duration of the outbreak, the effectiveness and utilization of vaccines for COVID-19 and its variants, new information that may emerge concerning the severity of COVID-19 and the actions, especially those taken by governmental authorities to contain the pandemic or treat its impact. As pandemic-related events continue to evolve, additional impacts may arise that the Company is not aware of currently. Any prolonged material disruption of the Company’s labor force, suppliers, manufacturing, or customers could materially impact its consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three months or less. </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and accounts receivable are to three customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 19 “Revenue from Contracts with Customers” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Accounts Receivable and Provision for Current Expected Credit Losses</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains a provision for those customer receivables that it does not expect to collect. In accordance with Accounting Standards Codification (“ASC”) Topic 326, the Company accrues its estimated losses from uncollectable accounts receivable to the provision based upon recent historical experience, the length of time the receivable has been outstanding, other specific information as it becomes available, and reasonable and supportable forecasts not already reflected in the historical loss information. Provisions for current expected credit losses are charged to current operating expenses. Actual losses are charged against the provision when incurred. In 2020, the Company wrote-off $2.3 million of outstanding receivables that were previously reserved for as of December 31, 2019, in connection with a customer bankruptcy in the fourth quarter of 2019.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplier Financing Arrangements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes supplier financing arrangements with financial institutions to sell certain accounts receivable on a non-recourse basis. These transactions are treated as a sale of, and are accounted for as a reduction to, accounts receivable. The agreements transfer control and risk related to the receivables to the financial institutions. The Company has no continuing involvement in the transferred receivables subsequent to the sale. During the years ended December 31, 2021 and December 31, 2020, the Company sold and de-recognized accounts receivable and collected cash of $116.1 million and $73.3 million, respectively. The costs associated with the supplier financing arrangements were not material for the years ended December 31, 2021 and December 31, 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held, historical sales volume, and estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4 “Inventories” contains additional information on the Company’s inventory. In connection with a customer bankruptcy in the fourth quarter of 2019, the Company wrote-down inventory by $19.0 million.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is, or contains, a lease at inception and classifies it at as finance or operating.  The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Finance lease assets and corresponding liabilities are included in Other long-term assets, Accrued expenses and other current liabilities, and Other long-term liabilities, respectively, on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease right-of-use (“ROU”) assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term at commencement date. When discount rates implicit in leases cannot be readily determined, the Company uses its incremental borrowing rate based on information available at commencement date in determining the present value of future payments.  The incremental borrowing rate is determined based on the Company’s recent debt issuances, the Company’s specific credit rating, lease term and the currency in which lease payments are made.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such option. Costs associated with operating leases are recognized within operating expenses on a straight-line basis over the lease term. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. The interest component of a finance lease is included in Interest expense and recognized using the effective interest method over the lease term. The Company combines lease and non-lease components for all asset classes. For certain leases where rent escalates based upon a change in a financial index, such as the Consumer Price Index, the difference between the rate at lease inception and the subsequent fluctuations in that rate are included in variable lease costs.  Additionally, because the Company does not separate lease and non-lease components, variable costs also include payments to the landlord for common area maintenance, real estate taxes, insurance and other operating expenses.  The Company does not apply the recognition requirements to leases with lease terms of 12 months or less. Note 14 “Leases” contains additional information on the Company’s leases.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment (“PP&amp;E”)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PP&amp;E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 12-30 years; machinery and equipment 3-10 years; office equipment 3-10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, whichever is shorter. The costs of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. The Company also reviews its PP&amp;E for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its fixed assets exceeds the related undiscounted future cash flows. In cases where the carrying value of the Company's long-lived assets or asset groups (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. Note 5 “Property, Plant and Equipment, Net” contains additional information on the Company’s PP&amp;E.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the “exit price”) in an orderly transaction between market participants at the measurement date. ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows:</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment.</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market.</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions under the acquisition method of accounting for business combinations. Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All direct acquisition-related costs are expensed as incurred and are recognized as a component of Other operating expenses. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable performance target. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The Company determines the initial fair value of contingent consideration liabilities using a Monte Carlo (“Monte Carlo”) valuation model, which involves a simulation of future revenues during the earn out-period using management’s best estimates, or a probability-weighted discounted cash flow analysis. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In periods subsequent to the initial measurement, contingent consideration liabilities are remeasured to fair value each reporting period until the contingent consideration is settled using various assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, revenue volatility and projected payment dates. The current portion of contingent consideration liabilities is included in Accrued expenses and other current liabilities and the non-current portion is included in Other long-term liabilities on the Consolidated Balance Sheets. Adjustments to the fair value of contingent consideration liabilities are included in Other operating expenses in the Consolidated Statements of Operations, and cash flows from operating activities in the Consolidated Statements of Cash Flows. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on contingent consideration recorded at fair value in the consolidated financial statements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired and is assigned to one or more reporting units. The Company’s reporting units are the same as its reportable segments, Medical and Non-Medical. The Company tests each reporting unit’s goodwill for impairment at least annually as of the last day of the fiscal year and between annual tests if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of a reporting unit below its carrying amount. In conducting its goodwill test, the Company either performs a qualitative assessment or a quantitative assessment. A qualitative assessment requires that the Company consider events or circumstances including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, changes in strategy, changes in customers, changes in the Company’s stock price, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair values of its reporting units are greater than the carrying amounts, then the quantitative goodwill impairment test is not performed. The Company may elect to bypass the qualitative analysis and perform a quantitative analysis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the qualitative assessment indicates that the quantitative analysis should be performed or if management elects to bypass a qualitative analysis to perform a quantitative analysis, the Company then evaluates goodwill for impairment by comparing the fair value of each of its reporting units to its carrying value, including the associated goodwill. To determine the fair values, the Company uses a weighted combination of the market approach based on comparable publicly traded companies and the income approach based on estimated discounted future cash flows. The cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed its annual goodwill impairment test as of December 31, 2021 and determined, after performing a qualitative review of its Medical reporting unit, that it is more likely than not that the fair value of the Medical reporting unit exceeds its carrying amount. Accordingly, there was no indication of impairment and the quantitative goodwill impairment test was not performed for the Medical reporting unit. The Company bypassed the qualitative analysis for its Non-Medical reporting unit and performed a quantitative analysis. The fair value of the Non-Medical reporting unit exceeded its carrying amount as of December 31, 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consist of purchased technology and patents, customer lists and trademarks. Definite-lived intangible assets are amortized on an accelerated or straight-line basis, which approximates the projected cash flows used to determine the fair value of those definite-lived intangible assets at the time of acquisition, as follows: purchased technology and patents 5-20 years; customer lists 7-20 years and other intangible assets 1-20 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized. The Company expenses the costs incurred to renew or extend the term of intangible assets. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets or asset groups exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted future cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its indefinite-lived intangible assets for impairment periodically to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment at least annually by comparing the fair value of the indefinite-lived intangible asset to its carrying value. The fair value is determined using the relief from royalty method.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6 “Goodwill and Other Intangible Assets, Net” for further details of the Company’s goodwill and other intangible assets.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other long-term assets on the Consolidated Balance Sheets. Equity investments are measured and recorded as follows:</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Non-marketable equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are equity securities without readily determinable fair value that are measured and recorded at fair value with changes in fair value recognized within net income. The Company measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. If an impairment is recognized on the Company’s non-marketable equity securities during the period, these assets are classified as Level 3 within the fair value hierarchy based on the nature of the fair value inputs.</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Equity method investments are equity securities in investees the Company does not control but over which it has the ability to exercise influence. Equity method investments are recorded at cost and are adjusted to recognize (1) the Company’s share, based on percentage ownership or other contractual basis, of the investee’s income or loss, (2) additional contributions made and dividends or other distributions received, and (3) impairments resulting from other-than-temporary declines in fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized and unrealized gains and losses resulting from changes in fair value or the sale of these equity investments are recorded through (Gain) loss on equity investments, net. For some investments, the Company records its share of the investee’s income or loss one quarter in arrears due to the timing of our receipt of such information. The carrying value of the Company’s non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities by the same issuer. Determining whether an observed transaction is similar to a security within the Company’s portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of the Company’s equity securities as a result of observable price changes requires quantitative assessments of the fair value of these securities using various valuation methodologies and involves the use of estimates.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. The Company’s quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee’s fair value. Qualitative factors considered include the investee’s financial condition and business outlook, market for technology, operational and financing cash flow activities, technology and regulatory approval progress, and other relevant events and factors affecting the investee. When indicators of impairment exist, quantitative assessments of the fair value of the Company’s non-marketable equity investments are prepared. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security’s fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and the Company’s ability and intent to hold the investment for a sufficient period of time to allow for recovery.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that its investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant. Refer to Note 17 “Financial Instruments and Fair Value Measurements” for additional information on the Company’s equity investments.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs and Discounts</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs and discounts associated with the issuance of debt by the Company are deferred and amortized over the lives of the related debt. Debt issuance costs incurred in connection with the Company’s issuance of its revolving credit facility are classified within Other long-term assets and amortized to Interest expense on a straight-line basis over the contractual term of the revolving credit facility. Debt issuance costs and discounts related to the Company’s term-debt are recorded as a reduction of the carrying value of the related debt and are amortized to Interest expense using the effective interest method over the period from the date of issuance to the maturity date. Upon prepayment of the related debt, the Company also recognizes a proportionate amount of the costs as extinguishment of debt. Costs treated as extinguishment of debt are </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expensed and included in Interest expense in the accompanying Consolidated Statements of Operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization of debt issuance costs and discounts, and debt extinguishment charges are included in Debt related charges included in interest expense in the Consolidated Statements of Cash Flows. Note 8 “Debt” contains additional information on the Company’s debt issuance costs and discounts.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company have been prepared using the asset and liability approach to account for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined, within each taxing jurisdiction, that it is more likely than not that the asset will not be realized.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision for income taxes. Penalties, if incurred, are recognized as a component of Selling, general and administrative (“SG&amp;A”) expenses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries file a consolidated United States (“U.S.”) federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where the tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. The Company’s use of derivative instruments is generally limited to cash flow hedges of certain interest rate risks and minimizing foreign currency exposure on foreign currency transactions, which are typically designated in hedging relationships, and intercompany balances, which are not designated as hedging instruments. Under master agreements with the respective counterparties to our derivative contracts, subject to applicable requirements, we have the right of set-off and are allowed to net settle transactions of the same type with a single net amount payable by one party to the other. Gains and losses on cash flow hedges are recorded in Accumulated Other Comprehensive Income in the Consolidated Balance Sheets until the underlying transaction is recorded in earnings. When the hedged item is realized, gains or losses are reclassified from Accumulated Other Comprehensive Income (“AOCI”) to the Consolidated Statement of Operations on the same line item as the underlying transaction. In the event the forecasted transactions do not occur, or it becomes probable that they will not occur, the Company reclassifies any gain or loss on the related cash flow hedge to earnings in the respective period. Cash flows related to these derivative financial instruments are included in cash flows from operating activities. Foreign currency contracts not designated as hedging relationships are recorded at fair value in Accrued expenses and other current liabilities in the Consolidated Balance Sheets and resulting gains or losses are recorded in the Consolidated Statement of Operations. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The majority of contracts have an original expected duration of one year or less. Consideration payable to customers is included in the transaction price. In accordance with ASC 340-40-25-4, the Company expenses incremental costs of obtaining a contract when incurred because the amortization period is less than one year.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates revenue recognition in contracts with customers as performance obligations are satisfied and as the customer obtains control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits of the products. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Most of the Company’s revenues are recognized at the point in time when the products are shipped to customers. When contracts with customers for products, which do not have an alternative use to the Company, contain provisions that provide the Company with an enforceable right to payment for performance completed to date for costs incurred plus a reasonable profit throughout the duration of the contract, revenue is recognized over time as control is transferred to the customer. In contracts with customers where revenue is recognized over time, the Company uses an input measure to determine progress towards completion and total estimated costs at completion. Under this method, sales and gross profit are recognized as work is performed generally based on actual costs incurred. </span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized net of sales tax, value-added taxes and other taxes.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers each shipment of an individual product included on a purchase order to be a separate performance obligation, as each shipment is separately identifiable and the customer can benefit from each individual product separately from the other products included on the purchase order. Accordingly, a contract can have one or more performance obligations to manufacture products. Standard payment terms range from 30 to 90 days and may include a discount for early payment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not offer its customers a right of return. Rather, the Company warrants that each unit received by the customer will meet the agreed upon technical and quality specifications and requirements. Only when the delivered units do not meet these requirements can the customer return the non-compliant units as a corrective action under the warranty. The remedy offered to the customer is repair of the returned units or replacement if repair is not viable. Accordingly, the Company records a warranty reserve and any warranty activities are not considered to be a separate performance obligation.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable and less frequently, unearned revenue. Accounts receivable are recorded when the right to consideration becomes unconditional. Unearned revenue is recorded when customers pay or are billed in advance of the Company’s satisfaction of performance obligations. Contract liabilities are classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. For contracts with customers where revenue is recognized over time, the Company records a contract asset for unbilled revenue associated with non-cancellable customer orders, which is recorded within Contract assets on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Price</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the transaction price of the Company’s contracts consists of a unit price for each individual product included in the contract, which can be fixed or variable based on the number of units ordered. In some instances, the transaction price also includes a rebate for meeting certain volume-based targets over a specified period of time. The transaction price of a contract is determined based on the unit price and the number of units ordered, reduced by the rebate expected to be earned on those units. Rebates are estimated based on the expected achievement of the volume-based target using the most likely amount method and are updated quarterly. Adjustments to these estimates are recognized under the cumulative catch-up method and in the period in which they are identified. When contracts with customers include consideration payable at the beginning of the contract, the transaction price is reduced at the later of when the Company recognizes revenue for the transfer of the related goods to the customer or when the Company pays or promises to pay the consideration. Volume discounts and rebates and other pricing reductions earned by customers are offset against their receivable balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is allocated to each performance obligation on a relative standalone selling price basis. As the majority of products sold to customers are manufactured to meet the specific requirements and technical specifications of that customer, the products are considered unique to that customer and the unit price stated in the contract is considered the standalone selling price.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Modifications</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract modifications, which can include a change in scope, price, or both, most often occur related to contracts that are governed by a long-term arrangement. Contract modifications typically relate to the same products already governed by the long-term arrangement, and therefore, are accounted for as part of the existing contract. If a contract modification is for additional products, it is accounted for as a separate contract. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Costs</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Environmental expenditures that relate to an existing condition caused by past operations and that do not provide future benefits are expensed as incurred. Liabilities are recorded when environmental assessments are made, the requirement for remedial efforts is probable and the amount of the liability can be reasonably estimated. Liabilities are recorded generally no later than the completion of feasibility studies. The Company has a process in place to monitor, identify, and assess how the current activities for known exposures are progressing against the recorded liabilities. The process is also designed to identify other potential remediation sites that are not presently known.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Expenses</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates alternatives to align its resources with the changing needs of its customers and markets, and to lower its operating costs. This includes realignment of existing manufacturing capacity, facility closures, process optimization, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in voluntary or involuntary employee termination benefits. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. All other exit costs are expensed as incurred. Refer to Note 11 “Other Operating Expenses” for additional information.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research, Development and Engineering (“RD&amp;E”)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RD&amp;E costs are expensed as incurred. The primary costs are salary and benefits for personnel, material costs used in development projects and subcontracting costs. </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranties</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows customers to return defective or damaged products for credit, replacement, or repair. The Company warrants that its products will meet customer specifications and will be free from defects in materials and workmanship</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accrues its estimated exposure to warranty claims, through Cost of Sales, based upon experience and other specific information as it becomes available. The product warranty liability is classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. Adjustments to pre-existing estimated exposure for warranties are made as changes to the obligations become reasonably estimable. Note 13 “Commitments and Contingencies” contains additional information on the Company’s product warranties.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for its compensation plans. These plans include stock options, restricted stock units (“RSUs”) and performance-based restricted stock units (“PRSUs”). For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares to be earned depends on the achievement of targets based on market conditions, such as total shareholder return, or performance conditions based on the Company’s operating results. The Company records forfeitures of equity awards in the period in which they occur.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock-based compensation is determined at the grant date. The Company uses the Black-Scholes standard option pricing model (“Black-Scholes model”) to determine the fair value of stock options. The fair value of each RSU is determined based on the Company’s closing stock price on the date of grant. The fair value of each PRSU is determined based on either the Company’s closing stock price on the date of grant or through a Monte Carlo valuation model for those awards that include a market-based condition. In addition to the closing stock price on the date of grant, the determination of the fair value of awards using both the Black-Scholes and Monte Carlo valuation models is affected by other assumptions, including the following:</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company analyzes historical employee exercise and termination data to estimate the expected term assumption for stock options. For market-based awards, the term is commensurate with the performance period remaining as of the grant date.</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk-free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - A risk-free rate is based on the U.S. Treasury rates in effect on the grant date for a maturity equal to or approximating the expected term of the award.</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - For stock options, expected volatility is calculated using historical volatility based on the daily closing prices of the Company’s common stock over a period equal to the expected term. For market-based awards, a combination of historical and implied volatility for the Company and members of its peer group are used in developing the expected volatility assumption.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The dividend yield assumption is based on the Company’s expected annual dividend yield on the grant date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense over the required service or vesting period based on the fair value of the award on the date of grant. Certain executive stock-based awards contain market, performance and service conditions. Compensation expense for awards with market conditions is recognized over the service period and is not reversed if the market condition is not met. Compensation expense for awards with performance conditions is reassessed each reporting period and recognized based upon the probability that the performance targets will be achieved.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock option awards granted under the Company’s compensation plans have an exercise price equal to the closing stock price on the date of grant, a ten-year contractual life and generally, vest annually over a three-year vesting term. RSUs typically vest in equal annual installments over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2VhYmVlYWE2ODQxYWZhMmZjZWJlMzY2NDZjMjc3L3NlYzo5NWNlYWJlZWFhNjg0MWFmYTJmY2ViZTM2NjQ2YzI3N18xMjQvZnJhZzo1YmI5ODhiZjIxMjc0ZGVkOTVhY2E3MTAxMzUzZmVmNS90ZXh0cmVnaW9uOjViYjk4OGJmMjEyNzRkZWQ5NWFjYTcxMDEzNTNmZWY1XzQ1MDgx_3c442f08-8f0a-4cb3-9be0-e32e0f98e98c">three</span> or four year period. RSUs issued to members of the Company’s Board of Directors as a portion of their annual retainer vest quarterly over a one-year vesting term. Earned PRSUs typically vest three years from the date of grant.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records deferred tax assets for awards that result in deductions on the Company’s income tax returns, based on the amount of stock-based compensation expense recognized and the statutory tax rate in the jurisdiction in which it will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported on the income tax return are recorded as a component of Provision for income taxes in the Consolidated Statements of Operations. Note 10 “Stock-Based Compensation” contains additional information on the Company’s stock-based compensation.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Benefit Plans</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes in its balance sheet as an asset or liability the overfunded or underfunded status of its defined benefit plans provided to its employees located in Mexico and Switzerland. This asset or liability is measured as the difference between the fair value of plan assets, if any, and the benefit obligation of those plans. For these plans, the benefit obligation is the projected benefit obligation, which is calculated based on actuarial computations of current and future benefits for employees. Actuarial gains or losses and prior service costs or credits that arise during the period, but are not included as components of net periodic benefit expense, are recognized as a component of AOCI on the Consolidated Balance Sheets. The Company records the service cost component of net benefit costs in Cost of sales and SG&amp;A expenses. The interest cost component of net benefit costs is recorded in Interest expense and the remaining components of net benefit costs, amortization of net losses and expected return on plan assets, are recorded in Other (income) loss, net.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Remeasurement</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company translates all assets and liabilities of its foreign subsidiaries, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translates income and expenses at the average exchange rates in effect during the period. The net effect of this translation is recorded in the consolidated financial statements as a component of AOCI. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in the Company’s foreign subsidiaries.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has foreign operations in the Dominican Republic, Germany, Ireland, Israel, Malaysia, Mexico, Switzerland, and Uruguay, which expose the Company to foreign currency exchange rate fluctuations due to transactions denominated in Dominican pesos, Euros, Israeli shekels, Malaysian ringgits, Mexican pesos, Swiss francs, and Uruguayan pesos. To the extent that monetary assets and liabilities, including short-term and long-term intercompany loans, are recorded in a currency other than the functional currency of the subsidiary, these amounts are remeasured each period at the period-end exchange rate, with the resulting gain or loss being recorded in Other (income) loss, net in the Consolidated Statements of Operations. Net foreign currency transaction (gains) losses included in Other (income) loss, net amounted to ($0.1 million), $1.6 million and $0.1 million for fiscal years 2021, 2020 and 2019, respectively, and primarily related to the fluctuation of the U.S. dollar relative to the Euro and the remeasurement of certain intercompany loans.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share (“EPS”)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic EPS is calculated by dividing Net Income by the weighted average number of shares outstanding during the period. Diluted EPS is calculated by adjusting the weighted average number of shares outstanding for potential common shares if dilutive to the EPS calculation. Note 15 “Earnings Per Share” contains additional information on the computation of the Company’s EPS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s comprehensive income as reported in the Consolidated Statements of Comprehensive Income includes net income, foreign currency translation adjustments, the net change in cash flow hedges, net of tax, and defined benefit plan liability adjustments, net of tax. The Consolidated Statements of Comprehensive Income and Note 16 “Stockholders’ Equity” contain additional information on the computation of the Company’s comprehensive income.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, management evaluates all new Accounting Standards Updates (“ASU”) and other accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Guidance Not Yet Elected or Adopted</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company will early adopt ASU 2021-08 as of January 1, 2022 on a prospective basis. The impact of the adoption of ASU 2021-08 cannot currently be determined, as it is dependent on future business combinations that the Company may enter into.</span></div> <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of Integer Holdings Corporation and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company completed the sale of its Advanced Surgical and Orthopedic product lines (the “AS&amp;O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC). For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&amp;O Product Line. The Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s (parent) centralized treasury and cash management processes. See Note 20 “Discontinued Operations” for the financial results and cash flow amounts for discontinued operations. All results and information in the consolidated financial statements are presented as continuing operations and exclude the AS&amp;O Product Line unless otherwise noted specifically as discontinued operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. The discontinued operations of the AS&amp;O Product Line were reported in the Medical segment. Refer to Note 18 “Segment and Geographic Information,” for additional information on the Company’s reportable segments.</span></div> 2 <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting periods. Actual results could differ materially from those estimates.</span></div> Cash and Cash EquivalentsCash and cash equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three months or less. <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and accounts receivable are to three customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 19 “Revenue from Contracts with Customers” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks.</span></div> 3 Trade Accounts Receivable and Provision for Current Expected Credit LossesThe Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains a provision for those customer receivables that it does not expect to collect. In accordance with Accounting Standards Codification (“ASC”) Topic 326, the Company accrues its estimated losses from uncollectable accounts receivable to the provision based upon recent historical experience, the length of time the receivable has been outstanding, other specific information as it becomes available, and reasonable and supportable forecasts not already reflected in the historical loss information. Provisions for current expected credit losses are charged to current operating expenses. Actual losses are charged against the provision when incurred. 2300000 Supplier Financing ArrangementsThe Company utilizes supplier financing arrangements with financial institutions to sell certain accounts receivable on a non-recourse basis. These transactions are treated as a sale of, and are accounted for as a reduction to, accounts receivable. The agreements transfer control and risk related to the receivables to the financial institutions. The Company has no continuing involvement in the transferred receivables subsequent to the sale. 116100000 73300000 0 0 InventoriesInventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held, historical sales volume, and estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4 “Inventories” contains additional information on the Company’s inventory. 19000000 <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is, or contains, a lease at inception and classifies it at as finance or operating.  The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Finance lease assets and corresponding liabilities are included in Other long-term assets, Accrued expenses and other current liabilities, and Other long-term liabilities, respectively, on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease right-of-use (“ROU”) assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term at commencement date. When discount rates implicit in leases cannot be readily determined, the Company uses its incremental borrowing rate based on information available at commencement date in determining the present value of future payments.  The incremental borrowing rate is determined based on the Company’s recent debt issuances, the Company’s specific credit rating, lease term and the currency in which lease payments are made.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such option. Costs associated with operating leases are recognized within operating expenses on a straight-line basis over the lease term. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. The interest component of a finance lease is included in Interest expense and recognized using the effective interest method over the lease term. The Company combines lease and non-lease components for all asset classes. For certain leases where rent escalates based upon a change in a financial index, such as the Consumer Price Index, the difference between the rate at lease inception and the subsequent fluctuations in that rate are included in variable lease costs.  Additionally, because the Company does not separate lease and non-lease components, variable costs also include payments to the landlord for common area maintenance, real estate taxes, insurance and other operating expenses.  The Company does not apply the recognition requirements to leases with lease terms of 12 months or less. Note 14 “Leases” contains additional information on the Company’s leases.</span></div> <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment (“PP&amp;E”)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PP&amp;E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 12-30 years; machinery and equipment 3-10 years; office equipment 3-10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, whichever is shorter. The costs of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. The Company also reviews its PP&amp;E for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its fixed assets exceeds the related undiscounted future cash flows. In cases where the carrying value of the Company's long-lived assets or asset groups (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. Note 5 “Property, Plant and Equipment, Net” contains additional information on the Company’s PP&amp;E.</span></div> P12Y P30Y P3Y P10Y P3Y P10Y <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the “exit price”) in an orderly transaction between market participants at the measurement date. ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows:</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment.</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market.</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements.</span></div> <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions under the acquisition method of accounting for business combinations. Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All direct acquisition-related costs are expensed as incurred and are recognized as a component of Other operating expenses. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable performance target. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The Company determines the initial fair value of contingent consideration liabilities using a Monte Carlo (“Monte Carlo”) valuation model, which involves a simulation of future revenues during the earn out-period using management’s best estimates, or a probability-weighted discounted cash flow analysis. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In periods subsequent to the initial measurement, contingent consideration liabilities are remeasured to fair value each reporting period until the contingent consideration is settled using various assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, revenue volatility and projected payment dates. The current portion of contingent consideration liabilities is included in Accrued expenses and other current liabilities and the non-current portion is included in Other long-term liabilities on the Consolidated Balance Sheets. Adjustments to the fair value of contingent consideration liabilities are included in Other operating expenses in the Consolidated Statements of Operations, and cash flows from operating activities in the Consolidated Statements of Cash Flows. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on contingent consideration recorded at fair value in the consolidated financial statements.</span></div> <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired and is assigned to one or more reporting units. The Company’s reporting units are the same as its reportable segments, Medical and Non-Medical. The Company tests each reporting unit’s goodwill for impairment at least annually as of the last day of the fiscal year and between annual tests if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of a reporting unit below its carrying amount. In conducting its goodwill test, the Company either performs a qualitative assessment or a quantitative assessment. A qualitative assessment requires that the Company consider events or circumstances including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, changes in strategy, changes in customers, changes in the Company’s stock price, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair values of its reporting units are greater than the carrying amounts, then the quantitative goodwill impairment test is not performed. The Company may elect to bypass the qualitative analysis and perform a quantitative analysis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the qualitative assessment indicates that the quantitative analysis should be performed or if management elects to bypass a qualitative analysis to perform a quantitative analysis, the Company then evaluates goodwill for impairment by comparing the fair value of each of its reporting units to its carrying value, including the associated goodwill. To determine the fair values, the Company uses a weighted combination of the market approach based on comparable publicly traded companies and the income approach based on estimated discounted future cash flows. The cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors.</span></div>The Company completed its annual goodwill impairment test as of December 31, 2021 and determined, after performing a qualitative review of its Medical reporting unit, that it is more likely than not that the fair value of the Medical reporting unit exceeds its carrying amount. Accordingly, there was no indication of impairment and the quantitative goodwill impairment test was not performed for the Medical reporting unit. The Company bypassed the qualitative analysis for its Non-Medical reporting unit and performed a quantitative analysis. The fair value of the Non-Medical reporting unit exceeded its carrying amount as of December 31, 2021. <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consist of purchased technology and patents, customer lists and trademarks. Definite-lived intangible assets are amortized on an accelerated or straight-line basis, which approximates the projected cash flows used to determine the fair value of those definite-lived intangible assets at the time of acquisition, as follows: purchased technology and patents 5-20 years; customer lists 7-20 years and other intangible assets 1-20 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized. The Company expenses the costs incurred to renew or extend the term of intangible assets. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets or asset groups exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted future cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its indefinite-lived intangible assets for impairment periodically to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment at least annually by comparing the fair value of the indefinite-lived intangible asset to its carrying value. The fair value is determined using the relief from royalty method.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6 “Goodwill and Other Intangible Assets, Net” for further details of the Company’s goodwill and other intangible assets.</span></div> P5Y P20Y P7Y P20Y P1Y P20Y <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other long-term assets on the Consolidated Balance Sheets. Equity investments are measured and recorded as follows:</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Non-marketable equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are equity securities without readily determinable fair value that are measured and recorded at fair value with changes in fair value recognized within net income. The Company measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. If an impairment is recognized on the Company’s non-marketable equity securities during the period, these assets are classified as Level 3 within the fair value hierarchy based on the nature of the fair value inputs.</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Equity method investments are equity securities in investees the Company does not control but over which it has the ability to exercise influence. Equity method investments are recorded at cost and are adjusted to recognize (1) the Company’s share, based on percentage ownership or other contractual basis, of the investee’s income or loss, (2) additional contributions made and dividends or other distributions received, and (3) impairments resulting from other-than-temporary declines in fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized and unrealized gains and losses resulting from changes in fair value or the sale of these equity investments are recorded through (Gain) loss on equity investments, net. For some investments, the Company records its share of the investee’s income or loss one quarter in arrears due to the timing of our receipt of such information. The carrying value of the Company’s non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities by the same issuer. Determining whether an observed transaction is similar to a security within the Company’s portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of the Company’s equity securities as a result of observable price changes requires quantitative assessments of the fair value of these securities using various valuation methodologies and involves the use of estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. The Company’s quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee’s fair value. Qualitative factors considered include the investee’s financial condition and business outlook, market for technology, operational and financing cash flow activities, technology and regulatory approval progress, and other relevant events and factors affecting the investee. When indicators of impairment exist, quantitative assessments of the fair value of the Company’s non-marketable equity investments are prepared. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security’s fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and the Company’s ability and intent to hold the investment for a sufficient period of time to allow for recovery.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that its investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant. Refer to Note 17 “Financial Instruments and Fair Value Measurements” for additional information on the Company’s equity investments.</span></div> <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs and Discounts</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs and discounts associated with the issuance of debt by the Company are deferred and amortized over the lives of the related debt. Debt issuance costs incurred in connection with the Company’s issuance of its revolving credit facility are classified within Other long-term assets and amortized to Interest expense on a straight-line basis over the contractual term of the revolving credit facility. Debt issuance costs and discounts related to the Company’s term-debt are recorded as a reduction of the carrying value of the related debt and are amortized to Interest expense using the effective interest method over the period from the date of issuance to the maturity date. Upon prepayment of the related debt, the Company also recognizes a proportionate amount of the costs as extinguishment of debt. Costs treated as extinguishment of debt are </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expensed and included in Interest expense in the accompanying Consolidated Statements of Operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization of debt issuance costs and discounts, and debt extinguishment charges are included in Debt related charges included in interest expense in the Consolidated Statements of Cash Flows. Note 8 “Debt” contains additional information on the Company’s debt issuance costs and discounts.</span></div> <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company have been prepared using the asset and liability approach to account for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined, within each taxing jurisdiction, that it is more likely than not that the asset will not be realized.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision for income taxes. Penalties, if incurred, are recognized as a component of Selling, general and administrative (“SG&amp;A”) expenses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries file a consolidated United States (“U.S.”) federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where the tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates.</span></div> Derivative Financial Instruments<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span> The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. The Company’s use of derivative instruments is generally limited to cash flow hedges of certain interest rate risks and minimizing foreign currency exposure on foreign currency transactions, which are typically designated in hedging relationships, and intercompany balances, which are not designated as hedging instruments. Under master agreements with the respective counterparties to our derivative contracts, subject to applicable requirements, we have the right of set-off and are allowed to net settle transactions of the same type with a single net amount payable by one party to the other. Gains and losses on cash flow hedges are recorded in Accumulated Other Comprehensive Income in the Consolidated Balance Sheets until the underlying transaction is recorded in earnings. When the hedged item is realized, gains or losses are reclassified from Accumulated Other Comprehensive Income (“AOCI”) to the Consolidated Statement of Operations on the same line item as the underlying transaction. In the event the forecasted transactions do not occur, or it becomes probable that they will not occur, the Company reclassifies any gain or loss on the related cash flow hedge to earnings in the respective period. Cash flows related to these derivative financial instruments are included in cash flows from operating activities. Foreign currency contracts not designated as hedging relationships are recorded at fair value in Accrued expenses and other current liabilities in the Consolidated Balance Sheets and resulting gains or losses are recorded in the Consolidated Statement of Operations. <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The majority of contracts have an original expected duration of one year or less. Consideration payable to customers is included in the transaction price. In accordance with ASC 340-40-25-4, the Company expenses incremental costs of obtaining a contract when incurred because the amortization period is less than one year.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates revenue recognition in contracts with customers as performance obligations are satisfied and as the customer obtains control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits of the products. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Most of the Company’s revenues are recognized at the point in time when the products are shipped to customers. When contracts with customers for products, which do not have an alternative use to the Company, contain provisions that provide the Company with an enforceable right to payment for performance completed to date for costs incurred plus a reasonable profit throughout the duration of the contract, revenue is recognized over time as control is transferred to the customer. In contracts with customers where revenue is recognized over time, the Company uses an input measure to determine progress towards completion and total estimated costs at completion. Under this method, sales and gross profit are recognized as work is performed generally based on actual costs incurred. </span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized net of sales tax, value-added taxes and other taxes.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers each shipment of an individual product included on a purchase order to be a separate performance obligation, as each shipment is separately identifiable and the customer can benefit from each individual product separately from the other products included on the purchase order. Accordingly, a contract can have one or more performance obligations to manufacture products. Standard payment terms range from 30 to 90 days and may include a discount for early payment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not offer its customers a right of return. Rather, the Company warrants that each unit received by the customer will meet the agreed upon technical and quality specifications and requirements. Only when the delivered units do not meet these requirements can the customer return the non-compliant units as a corrective action under the warranty. The remedy offered to the customer is repair of the returned units or replacement if repair is not viable. Accordingly, the Company records a warranty reserve and any warranty activities are not considered to be a separate performance obligation.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable and less frequently, unearned revenue. Accounts receivable are recorded when the right to consideration becomes unconditional. Unearned revenue is recorded when customers pay or are billed in advance of the Company’s satisfaction of performance obligations. Contract liabilities are classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. For contracts with customers where revenue is recognized over time, the Company records a contract asset for unbilled revenue associated with non-cancellable customer orders, which is recorded within Contract assets on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Price</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the transaction price of the Company’s contracts consists of a unit price for each individual product included in the contract, which can be fixed or variable based on the number of units ordered. In some instances, the transaction price also includes a rebate for meeting certain volume-based targets over a specified period of time. The transaction price of a contract is determined based on the unit price and the number of units ordered, reduced by the rebate expected to be earned on those units. Rebates are estimated based on the expected achievement of the volume-based target using the most likely amount method and are updated quarterly. Adjustments to these estimates are recognized under the cumulative catch-up method and in the period in which they are identified. When contracts with customers include consideration payable at the beginning of the contract, the transaction price is reduced at the later of when the Company recognizes revenue for the transfer of the related goods to the customer or when the Company pays or promises to pay the consideration. Volume discounts and rebates and other pricing reductions earned by customers are offset against their receivable balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is allocated to each performance obligation on a relative standalone selling price basis. As the majority of products sold to customers are manufactured to meet the specific requirements and technical specifications of that customer, the products are considered unique to that customer and the unit price stated in the contract is considered the standalone selling price.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Modifications</span></div>Contract modifications, which can include a change in scope, price, or both, most often occur related to contracts that are governed by a long-term arrangement. Contract modifications typically relate to the same products already governed by the long-term arrangement, and therefore, are accounted for as part of the existing contract. If a contract modification is for additional products, it is accounted for as a separate contract. Standard payment terms range from 30 to 90 days and may include a discount for early payment. <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Costs</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Environmental expenditures that relate to an existing condition caused by past operations and that do not provide future benefits are expensed as incurred. Liabilities are recorded when environmental assessments are made, the requirement for remedial efforts is probable and the amount of the liability can be reasonably estimated. Liabilities are recorded generally no later than the completion of feasibility studies. The Company has a process in place to monitor, identify, and assess how the current activities for known exposures are progressing against the recorded liabilities. The process is also designed to identify other potential remediation sites that are not presently known.</span></div> <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Expenses</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates alternatives to align its resources with the changing needs of its customers and markets, and to lower its operating costs. This includes realignment of existing manufacturing capacity, facility closures, process optimization, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in voluntary or involuntary employee termination benefits. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. All other exit costs are expensed as incurred. Refer to Note 11 “Other Operating Expenses” for additional information.</span></div> Research, Development and Engineering (“RD&amp;E”)RD&amp;E costs are expensed as incurred. The primary costs are salary and benefits for personnel, material costs used in development projects and subcontracting costs. <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranties</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows customers to return defective or damaged products for credit, replacement, or repair. The Company warrants that its products will meet customer specifications and will be free from defects in materials and workmanship</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accrues its estimated exposure to warranty claims, through Cost of Sales, based upon experience and other specific information as it becomes available. The product warranty liability is classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. Adjustments to pre-existing estimated exposure for warranties are made as changes to the obligations become reasonably estimable. Note 13 “Commitments and Contingencies” contains additional information on the Company’s product warranties.</span></div> <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for its compensation plans. These plans include stock options, restricted stock units (“RSUs”) and performance-based restricted stock units (“PRSUs”). For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares to be earned depends on the achievement of targets based on market conditions, such as total shareholder return, or performance conditions based on the Company’s operating results. The Company records forfeitures of equity awards in the period in which they occur.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock-based compensation is determined at the grant date. The Company uses the Black-Scholes standard option pricing model (“Black-Scholes model”) to determine the fair value of stock options. The fair value of each RSU is determined based on the Company’s closing stock price on the date of grant. The fair value of each PRSU is determined based on either the Company’s closing stock price on the date of grant or through a Monte Carlo valuation model for those awards that include a market-based condition. In addition to the closing stock price on the date of grant, the determination of the fair value of awards using both the Black-Scholes and Monte Carlo valuation models is affected by other assumptions, including the following:</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company analyzes historical employee exercise and termination data to estimate the expected term assumption for stock options. For market-based awards, the term is commensurate with the performance period remaining as of the grant date.</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk-free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - A risk-free rate is based on the U.S. Treasury rates in effect on the grant date for a maturity equal to or approximating the expected term of the award.</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - For stock options, expected volatility is calculated using historical volatility based on the daily closing prices of the Company’s common stock over a period equal to the expected term. For market-based awards, a combination of historical and implied volatility for the Company and members of its peer group are used in developing the expected volatility assumption.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The dividend yield assumption is based on the Company’s expected annual dividend yield on the grant date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense over the required service or vesting period based on the fair value of the award on the date of grant. Certain executive stock-based awards contain market, performance and service conditions. Compensation expense for awards with market conditions is recognized over the service period and is not reversed if the market condition is not met. Compensation expense for awards with performance conditions is reassessed each reporting period and recognized based upon the probability that the performance targets will be achieved.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock option awards granted under the Company’s compensation plans have an exercise price equal to the closing stock price on the date of grant, a ten-year contractual life and generally, vest annually over a three-year vesting term. RSUs typically vest in equal annual installments over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2VhYmVlYWE2ODQxYWZhMmZjZWJlMzY2NDZjMjc3L3NlYzo5NWNlYWJlZWFhNjg0MWFmYTJmY2ViZTM2NjQ2YzI3N18xMjQvZnJhZzo1YmI5ODhiZjIxMjc0ZGVkOTVhY2E3MTAxMzUzZmVmNS90ZXh0cmVnaW9uOjViYjk4OGJmMjEyNzRkZWQ5NWFjYTcxMDEzNTNmZWY1XzQ1MDgx_3c442f08-8f0a-4cb3-9be0-e32e0f98e98c">three</span> or four year period. RSUs issued to members of the Company’s Board of Directors as a portion of their annual retainer vest quarterly over a one-year vesting term. Earned PRSUs typically vest three years from the date of grant.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records deferred tax assets for awards that result in deductions on the Company’s income tax returns, based on the amount of stock-based compensation expense recognized and the statutory tax rate in the jurisdiction in which it will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported on the income tax return are recorded as a component of Provision for income taxes in the Consolidated Statements of Operations. Note 10 “Stock-Based Compensation” contains additional information on the Company’s stock-based compensation.</span></div> P10Y P3Y P4Y P1Y P3Y <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Benefit Plans</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes in its balance sheet as an asset or liability the overfunded or underfunded status of its defined benefit plans provided to its employees located in Mexico and Switzerland. This asset or liability is measured as the difference between the fair value of plan assets, if any, and the benefit obligation of those plans. For these plans, the benefit obligation is the projected benefit obligation, which is calculated based on actuarial computations of current and future benefits for employees. Actuarial gains or losses and prior service costs or credits that arise during the period, but are not included as components of net periodic benefit expense, are recognized as a component of AOCI on the Consolidated Balance Sheets. The Company records the service cost component of net benefit costs in Cost of sales and SG&amp;A expenses. The interest cost component of net benefit costs is recorded in Interest expense and the remaining components of net benefit costs, amortization of net losses and expected return on plan assets, are recorded in Other (income) loss, net.</span></div> <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Remeasurement</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company translates all assets and liabilities of its foreign subsidiaries, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translates income and expenses at the average exchange rates in effect during the period. The net effect of this translation is recorded in the consolidated financial statements as a component of AOCI. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in the Company’s foreign subsidiaries.</span></div>The Company has foreign operations in the Dominican Republic, Germany, Ireland, Israel, Malaysia, Mexico, Switzerland, and Uruguay, which expose the Company to foreign currency exchange rate fluctuations due to transactions denominated in Dominican pesos, Euros, Israeli shekels, Malaysian ringgits, Mexican pesos, Swiss francs, and Uruguayan pesos. To the extent that monetary assets and liabilities, including short-term and long-term intercompany loans, are recorded in a currency other than the functional currency of the subsidiary, these amounts are remeasured each period at the period-end exchange rate, with the resulting gain or loss being recorded in Other (income) loss, net in the Consolidated Statements of Operations. 100000 -1600000 -100000 <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share (“EPS”)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic EPS is calculated by dividing Net Income by the weighted average number of shares outstanding during the period. Diluted EPS is calculated by adjusting the weighted average number of shares outstanding for potential common shares if dilutive to the EPS calculation. Note 15 “Earnings Per Share” contains additional information on the computation of the Company’s EPS.</span></div> <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s comprehensive income as reported in the Consolidated Statements of Comprehensive Income includes net income, foreign currency translation adjustments, the net change in cash flow hedges, net of tax, and defined benefit plan liability adjustments, net of tax. The Consolidated Statements of Comprehensive Income and Note 16 “Stockholders’ Equity” contain additional information on the computation of the Company’s comprehensive income.</span></div> <div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, management evaluates all new Accounting Standards Updates (“ASU”) and other accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Guidance Not Yet Elected or Adopted</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company will early adopt ASU 2021-08 as of January 1, 2022 on a prospective basis. The impact of the adoption of ASU 2021-08 cannot currently be determined, as it is dependent on future business combinations that the Company may enter into.</span></div> BUSINESS ACQUISITIONS<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Acquisition</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2021, the Company acquired 100% of the equity interests of Oscor Inc., Oscor Caribe, LLC and Oscor Europe GmbH (collectively “Oscor”), privately-held companies with operations in Florida, the Dominican Republic and Germany that design, develop, manufacture and market a comprehensive portfolio of highly specialized medical devices, venous access systems and diagnostic catheters and implantable devices for a cash purchase price of $220.4 million, of which $2.6 million is net cash acquired subject to payment in connection with working capital and other closing adjustments. Serving the Company’s current markets, Oscor broadens the Company’s product portfolio, expands its research and development capabilities, and adds low-cost manufacturing capacity. The Company used proceeds from its Senior Secured Credit Facilities to fund the acquisition. See Note 8 “Debt” for additional information. Oscor is included in the Company’s Medical segment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oscor acquisition was structured as a stock purchase, however the parties agreed to coordinate the election of Section 338(h)(10) of the Internal Revenue Code relative to this transaction for tax purposes. Therefore, the excess purchase price over the fair value of net assets acquired was recorded as goodwill, which will be amortized over 15 years for income tax filing purposes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provisionally estimated fair values for the assets purchased, liabilities assumed and purchase consideration as of the date of the acquisition. The determination of estimated fair value required management to make significant estimates and assumptions based on information that was available at the time the consolidated financial statements were prepared. The amounts reported are considered provisional as the Company is completing the valuations that are required to allocate the purchase price in areas such as property and equipment, intangible assets, lease-related assets and liabilities, deferred taxes and goodwill. As a result, the allocation of the provisional purchase price may change in the future, which could be material.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary purchase price allocation was as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets (excluding inventory)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,977 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,442 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary fair values of the assets acquired were determined using one of three valuation approaches: market, income or cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market approach estimates the value for a subject asset based on available market pricing for comparable assets. The income approach estimates the value for a subject asset based on the present value of cash flows projected to be generated by the asset. The projected cash flows were discounted at a required rate of return that reflects the relative risk of the asset and the time value of money. The projected cash flows for each asset considered multiple factors from the perspective of a marketplace participant including revenue projections from existing customers, attrition trends, technology life-cycle assumptions, marginal tax rates and expected profit margins giving consideration to historical and expected margins. The cost approach estimates the value for a subject asset based on the cost to replace the asset and reflects the estimated reproduction or replacement cost for the asset, less an allowance for loss in value due to depreciation or obsolescence, with specific consideration given to economic obsolescence if indicated. These fair value measurement approaches are based on significant unobservable inputs, including management estimates and assumptions.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2.)    BUSINESS ACQUISITIONS (Continued)</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current Assets and Liabilities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of current assets and liabilities, excluding inventory, was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of in-process and finished goods inventory acquired was estimated by applying a version of the income approach called the comparable sales method. This approach estimates the fair value of the assets by calculating the potential revenue generated from selling the inventory and subtracting from it the costs related to the completion and sale of that inventory and a reasonable profit allowance for these remaining efforts. Based upon this methodology, the Company recorded the inventory acquired at fair value resulting in an increase in inventory of $1.0 million. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of PP&amp;E acquired was estimated by applying the cost approach for personal property and leasehold improvements. The cost approach was applied by developing a replacement cost and adjusting for economic depreciation and obsolescence.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized operating lease liabilities and operating lease right-of-use assets for office and manufacturing facilities in the U.S., Dominican Republic, and Germany in accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, the Company recorded favorable lease terms associated with the operating leases in the U.S. of $3.1 million. The favorable lease terms were recorded as an increase to the ROU lease asset. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the purchase price over the fair value of net tangible and intangible assets acquired and liabilities assumed was allocated to goodwill. Various factors contributed to the establishment of goodwill, including the value of Oscors’s highly trained assembled work force and management team, the incremental value resulting from Oscor’s industry leading capabilities and services to OEMs, enhanced synergies, and the expected revenue growth over time that is attributable to increased market penetration from future products and customers. The goodwill acquired in connection with the acquisition was allocated to the Medical segment and is deductible for tax purposes.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to intangible assets as follows (dollars in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.953%"><tr><td style="width:1.0%"/><td style="width:41.184%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.136%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.138%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Assigned</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period <br/>(Years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer lists</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customer Lists - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer lists represent the estimated fair value of contractual and non-contractual customer relationships Oscor had as of the acquisition date. The primary customers of Oscor include large original equipment manufacturers in various geographic locations around the world. These relationships were valued separately from goodwill at the amount that an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The estimated useful life of the existing customer base was based upon the historical customer annual attrition rate of 5%, as well as management’s understanding of the industry and product life cycles.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Technology - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology consists of technical processes, patented and unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by Oscor and that will be leveraged in current and future products. The fair value of technology acquired was determined utilizing the relief from royalty method, a form of the income approach, with a royalty rate that ranged from 4.0% to 4.5%. The estimated useful life of the technology is based upon management’s estimate of the product life cycle associated with the technology before they will be replaced by new technologies.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2.)    BUSINESS ACQUISITIONS (Continued)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tradenames - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradenames represents the estimated fair value of Oscor’s corporate and product names. The acquired tradenames were valued separately from goodwill at the amount that an independent third party would be willing to pay for use of these names. The fair value of the tradenames was determined by utilizing the relief from royalty method, a form of the income approach, with a royalty rate of 2.0%. Tradenames were assumed to have a definite useful life based upon long-term management expectations and future operating plans.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Acquisition</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2020, the Company acquired certain assets and liabilities of InoMec Ltd. (“InoMec”), a privately-held company based in Israel that specializes in the research, development and manufacturing of medical devices, including minimally invasive tools, delivery systems, tubing and catheters, surgery tools, drug-device combination, laser combined devices, and tooling and production. The acquisition enabled the Company to create a research and development center in Israel, closer to the customer base in the region. The fair value of the consideration transferred was $7.0 million, which included an initial cash payment of $5.3 million and $1.7 million in estimated fair value of contingent consideration. The contingent consideration represented the estimated fair value of the Company’s obligation, under the asset purchase agreement, to make additional payments of up to $3.5 million if specified conditions are met through February 2024. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the final purchase price allocation, the assets acquired principally comprise $2.0 million of intangible assets, $4.8 million of goodwill, $0.3 million of acquired property, plant and equipment, and a net liability for other working capital items of $0.1 million. Intangible assets included developed technology, customer relationships and non-compete provisions, which are being amortized over a weighted average period of 5.9 years. Goodwill for the InoMec acquisition is deductible for income tax purposes.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019 Acquisition</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2019, the Company acquired certain assets and liabilities of US BioDesign, LLC (“USB”), a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The acquisition added a differentiated capability related to the complex development and manufacture of braided and formed biomedical structures to the Company’s broad portfolio. The fair value of the consideration transferred was $19.1 million, which included a cash payment of $14.9 million and $4.2 million in estimated fair value of contingent consideration. The contingent consideration represents the estimated fair value of the Company’s obligation, under the asset purchase agreement, to make additional payments of up to $5.5 million if certain revenue goals are met through 2023. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the final purchase price allocation, the assets acquired principally consist of $7.4 million of developed technology, $10.4 million of goodwill, $0.7 million of acquired property, plant and equipment, and $0.6 million of other working capital items. The $10.4 million of goodwill reflects a $0.1 million decrease resulting from a favorable working capital adjustment recorded in 2020. The technology intangible asset is being amortized over a useful life of 8 years. Goodwill for the USB acquisition is deductible for income tax purposes.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actual and Pro Forma (unaudited) disclosures</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For segment reporting purposes, the results of operations and assets from the Oscor, InoMec and USB acquisitions have been included in the Company’s Medical segment since the respective acquisition dates. For the year ended December 31, 2021, sales related to Oscor, InoMec and USB were $4.7 million, $3.5 million and $4.8 million, respectively. For the year ended December 31, 2020, sales related to InoMec and USB were $3.4 million and $4.5 million, respectively. For the year ended December 31, 2019, sales related to USB were $0.8 million. Earnings related to the operations of Oscor, InoMec and USB for the fiscal years 2021, 2020 and 2019 were not material. Pro forma financial information has not been presented for the InoMec and USB acquisitions as the net effects were not significant or material to the Company’s results of operations or financial position.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2.)    BUSINESS ACQUISITIONS (Continued)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information presents the consolidated results of operations of the Company and Oscor as if the acquisition occurred as of the beginning of fiscal year 2020 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma results are presented for illustrative purposes only and do not reflect the realization of potential cost savings, and any related integration costs. Certain costs savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These unaudited pro forma results do not purport to be indicative of the results that would have been obtained, or to be a projection of results that may be obtained in the future. These unaudited pro forma results include certain adjustments, primarily due to increases in amortization expense due to the fair value adjustments of intangible assets, the increases to interest expense reflecting the amount borrowed in connection with the acquisition, acquisition related costs and the impact of income taxes on the pro forma adjustments.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Acquisition costs</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years 2021, 2020 and 2019, direct costs of these acquisitions of $2.0 million, $0.9 million and $0.4 million, respectively, were expensed as incurred and included in Other Operating Expenses in the Consolidated Statements of Operations.</span></div> 1 220400000 2600000 As a result, the allocation of the provisional purchase price may change in the future, which could be material.<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary purchase price allocation was as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets (excluding inventory)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,977 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,442 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12148000 12212000 17977000 77887000 105300000 15142000 695000 8875000 12044000 220442000 1000000 3100000 <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to intangible assets as follows (dollars in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.953%"><tr><td style="width:1.0%"/><td style="width:41.184%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.136%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.138%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Assigned</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period <br/>(Years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer lists</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets comprise the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology, tradenames and patents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,659 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer lists</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizing intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073,439 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355,917)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer lists</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizing intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,386 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318,450)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,288 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 73800000 P20Y 0.095 15200000 P15Y 0.095 16300000 P20Y 0.095 0.05 0.040 0.045 0.020 7000000 5300000 1700000 3500000 2000000 4800000 300000 100000 P5Y10M24D 19100000 14900000 4200000 5500000 7400000 10400000 700000 600000 10400000 100000 P8Y 4700000 3500000 4800000 3400000 4500000 800000 <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information presents the consolidated results of operations of the Company and Oscor as if the acquisition occurred as of the beginning of fiscal year 2020 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div> 1274148000 1128137000 91844000 67529000 2000000 900000 400000 SUPPLEMENTAL CASH FLOW INFORMATION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information for fiscal years 2021, 2020 and 2019 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment purchases included in accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid during the year for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information for fiscal years 2021, 2020 and 2019 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment purchases included in accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid during the year for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 5556000 3597000 8646000 24740000 33933000 44784000 19649000 18477000 30034000 INVENTORIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,152 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,806 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,040 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,699 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,323 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,152 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,806 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,040 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,699 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,323 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 70956000 72477000 74152000 58806000 10591000 18040000 155699000 149323000 PROPERTY, PLANT AND EQUIPMENT, NET<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PP&amp;E comprises the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,391 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information technology hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,752 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction work in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683,404 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,099 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,964 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for PP&amp;E was as follows for fiscal years 2021, 2020 and 2019 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PP&amp;E comprises the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,391 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information technology hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,752 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction work in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683,404 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,099 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,964 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 352391000 320807000 98007000 102037000 72752000 69969000 85931000 77382000 17099000 16250000 13980000 11598000 41813000 26389000 1431000 1238000 683404000 625670000 406305000 371706000 277099000 253964000 <div style="margin-bottom:6pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for PP&amp;E was as follows for fiscal years 2021, 2020 and 2019 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 39772000 38193000 37819000 GOODWILL AND OTHER INTANGIBLE ASSETS, NET<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill by reportable segment during fiscal years 2021 and 2020 was as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822,617 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839,617 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related adjustments (Note 2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842,442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859,442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition (Note 2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,704 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,704 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, no accumulated impairment loss has been recognized for the goodwill allocated to the Company’s Medical or Non-Medical segments.</span></div><div style="margin-bottom:9pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Continued)</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets comprise the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology, tradenames and patents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,659 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer lists</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizing intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073,439 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355,917)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer lists</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizing intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,386 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318,450)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,288 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 “Business Acquisitions” for additional details regarding intangible assets acquired during 2021 and 2020. Included in the Company’s indefinite-lived intangible assets are the Lake Region Medical and Greatbatch Medical tradenames with carrying values of $70.0 million and $20.3 million, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When acquiring certain assets, the Company assesses whether the acquired assets are a result of a business combination or a purchase of an asset. During 2020, the Company acquired a set of similar identifiable intangible assets relating to a license to use technology within its Non-Medical segment. The Company purchased the technology for $4.5 million, which includes $1.0 million of contingent consideration paid during 2020 upon completion of certain milestones, and capitalized $0.1 million of costs associated with acquiring the license as an intangible asset. The intangible asset of $4.6 million is being amortized over 11 years, the remaining useful life of the patented technology.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intangible asset amortization expense comprises the following for fiscal years 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,860 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,111 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible asset amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,597 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,131 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,076 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future intangible asset amortization expense based upon the carrying value as of December 31, 2021 is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">After 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,304 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill by reportable segment during fiscal years 2021 and 2020 was as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822,617 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839,617 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related adjustments (Note 2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842,442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859,442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition (Note 2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,704 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,704 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 822617000 17000000 839617000 4800000 0 4800000 85000 0 85000 15110000 0 15110000 842442000 17000000 859442000 77887000 0 77887000 -12625000 0 -12625000 907704000 17000000 924704000 0 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets comprise the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology, tradenames and patents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,659 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer lists</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizing intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073,439 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355,917)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer lists</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizing intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,386 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318,450)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,288 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 285659000 164371000 121288000 783618000 187412000 596206000 4162000 4134000 28000 1073439000 355917000 717522000 90288000 257453000 152798000 104655000 723791000 161856000 561935000 4142000 3796000 346000 985386000 318450000 666936000 90288000 70000000 20300000 4500000 1000000 100000 4600000 P11Y <div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intangible asset amortization expense comprises the following for fiscal years 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,860 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,111 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible asset amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,597 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,131 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,076 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 13090000 12860000 13111000 28507000 28271000 26965000 41597000 41131000 40076000 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future intangible asset amortization expense based upon the carrying value as of December 31, 2021 is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">After 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,304 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 46594000 48490000 47576000 45946000 43612000 485304000 ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities comprise the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profit sharing and bonuses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,933 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,843 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities comprise the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profit sharing and bonuses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,933 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,843 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 27733000 24512000 18325000 19204000 3776000 2498000 509000 163000 76000 1644000 6514000 8822000 56933000 56843000 DEBT<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt comprises the following (in thousands):</span></div><div style="padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured term loan A </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,062 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,687 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured term loan B </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount on term loan B and deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828,126 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812,876 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,758 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt;padding-right:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2, 2021, the Company entered into a new credit agreement (the “2021 Credit Agreement”), which permits borrowings and other extensions of credit in an initial aggregate principal amount of up to $1 billion (as may be increased from time to time in accordance with the terms). The 2021 Credit Agreement governs the Company’s senior secured credit facilities (the “Senior Secured Credit Facilities”), which consist of a five-year $400 million revolving credit facility (the “Revolving Credit Facility”), a five-year $250 million “term A” loan (the “TLA Facility”) and a seven-year $350 million “term B” loan (the “TLB Facility” and, together with the TLA Facility, the “Term Loan Facilities”). The TLB Facility was issued at a 0.50% discount. The 2021 Credit Agreement also includes an alternative benchmark rate as a replacement to the London Interbank Offered Rate (“LIBOR”) in the event LIBOR is no longer available. In connection with closing of the Oscor acquisition, on December 1, 2021, the Company amended the 2021 Credit Agreement to provide for, among other things, the incurrence of an additional $220 million aggregate principal amount of term A loans. As of December 31, 2021, the weighted average interest rate on all outstanding borrowings is 2.04%.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations under the 2021 Credit Agreement are guaranteed by certain specified subsidiaries of the Company. Among other things, the 2021 Credit Agreement contains covenants that restrict the Company’s and certain of its subsidiaries’ ability to incur liens on certain assets, incur indebtedness, make material changes in corporate structure or materially alter the nature of its business, dispose of material assets, engage in mergers, consolidations and certain other fundamental changes, or engage in certain transactions with affiliates. The 2021 Credit Agreement contains customary default provisions, including, but not limited to, failure to pay interest or principal when due and failure to comply with covenants.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEBT (Continued)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to September 2, 2021, the Company was party to an amended and restated credit agreement (the “2015 Credit Agreement”), dated as of October 27, 2015. The 2015 Credit Agreement provided for certain credit facilities to the Company in an aggregate principal amount not to initially exceed $1.6 billion. At the time of the refinancing on September 2, 2021, the 2015 Credit Agreement provided for a $200 million revolving credit facility with no outstanding borrowings, a term loan A facility and a term loan B facility with outstanding principal balances of $210.9 million and $462.3 million, respectively. The term loan B facility under the 2015 Credit Agreement was issued at a 1% discount. The 2015 Credit Agreement was terminated concurrently with entering into the 2021 Credit Agreement. Details of our Long-term debt as of December 31, 2020 can be found within our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1114483/000111448321000006/gb-20201231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Form 10-K</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-bottom:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility matures on September 2, 2026 and includes a $40 million sublimit for swingline loans and standby letters of credit. As of December 31, 2021, the Company had available borrowing capacity on the Revolving Credit Facility of $375.0 million after giving effect to $19.3 million of outstanding borrowings and $5.7 million of outstanding standby letters of credit.</span></div><div style="margin-bottom:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rates on the Revolving Credit Facility are at the Company’s option, either at: (i) the applicable LIBOR (or an applicable benchmark replacement) plus the applicable margin, which will range between 1.25% and 2.25%, based on the Company’s Total Net Leverage Ratio (as defined in the 2021 Credit Agreement), or (ii) the Base Rate (as defined below) plus the applicable margin, which will range between 0.25% and 1.25%, based on the Company’s Total Net Leverage Ratio. The Base Rate is defined, for any day, as the per annum rate equal to the highest of (i) the prime rate (as defined in the 2021 Credit Agreement), (ii) the Federal Funds Rate, as published by the Federal Reserve Bank of New York, plus 0.50%, and (iii) one-month LIBOR plus 1.00%. As of December 31, 2021, the weighted average interest rate on outstanding borrowings under the Revolving Credit Facility was 1.35%.</span></div><div style="margin-bottom:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.15% and 0.25%, depending on the Company’s Total Net Leverage Ratio. As of December 31, 2021, the commitment fee on the unused portion of the Revolving Credit Facility was 0.15%. </span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan Facilities</span></div><div style="margin-bottom:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TLA Facility and TLB Facility mature on September 2, 2026 and September 2, 2028, respectively, and require quarterly principal installments. The quarterly principal installments under the TLA Facility increase over the term of the loan. The interest rate terms for the TLA Facility are the same as those outlined above for the Revolving Credit Facility. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the applicable LIBOR rate plus 2.50%, with LIBOR subject to a 0.50% floor, or (ii) the Base Rate plus 1.50%. As of December 31, 2021, the interest rates on the TLA Facility and TLB Facility were 1.35% and 3.00%, respectively.</span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Covenants</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Credit Agreement contains customary terms and conditions, including representations and warranties and affirmative and negative covenants, as well as financial covenants for the benefit of the lenders under the Revolving Credit Facility and the TLA Facility, which require that (i) the Company maintain a Total Net Leverage Ratio not to exceed 5.50:1.00 (stepping down to 5.00:1.00 for the third fiscal quarter of 2023 through maturity and subject to increase in certain circumstances following qualified acquisitions, but shall not exceed 5.50:1.00) and (ii) the Company maintain an interest coverage ratio of at least 2.50:1.00. The TLB Facility does not contain any financial maintenance covenants. As of December 31, 2021, the Company was in compliance with these financial covenants.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities under the Senior Secured Credit Facilities for the next five years and thereafter, as of December 31, 2021, are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"/><td style="width:29.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">After 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum principal payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,739 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,622 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEBT (Continued)</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Debt Issuance Costs and Discounts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in deferred debt issuance costs related to the Company’s Revolving Credit Facility is as follows (in thousands):</span></div><div style="margin-top:12pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%"><tr><td style="width:1.0%"/><td style="width:83.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.272%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing costs incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-off of deferred debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,039 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in unamortized discount and deferred debt issuance costs related to the Term Loan Facilities is as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unamortized Discount on TLB Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing costs incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-off of deferred debt issuance costs and unamortized discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,677)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,709)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,361 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2021 Credit Agreement, the Company incurred and capitalized $8.8 million of issuance costs, including an original issue discount on the TLB Facility of $1.8 million. In connection with December 1, 2021 amendment to the TLA Facility, the Company incurred and capitalized $1.0 million of issuance costs. An aggregate of $7.0 million of original issue discount and debt issuance costs have been recorded as a reduction of the carrying value of the related debt and $2.8 million of debt issuance costs attributable to the Revolving Credit Facility have been recorded as a component of Other long-term assets on the Consolidated Balance Sheets as of December 31, 2021.</span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with terminating the 2015 Credit Agreement and entering into the 2021 Credit Agreement, for each separate debt instrument on a lender by lender basis, in accordance with ASC 470-50, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Modifications and Extinguishment</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company performed an assessment of whether the transaction was deemed to be new debt, a modification of existing debt, or an extinguishment of existing debt. Debt issuance costs are either deferred and amortized over the term of the associated debt or expensed as incurred. </span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this assessment, $1.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of unamortized deferred debt issuance costs and unamortized discount related to the 2015 Credit Agreement were deemed to be related to the issuance of new debt, or the modification of existing debt, and therefore will continue to be deferred and amortized over the term of the associated debt. The remaining </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of unamortized deferred debt issuance costs and unamortized discount related to the 2015 Credit Agreement were deemed to be related to the extinguishment of debt and were expensed. Additionally, in connection with prepayments on the TLB Facility made during 2021 under the 2015 Credit Agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of unamortized deferred debt issuance costs and unamortized discount were treated as extinguishment of debt and were expensed.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt comprises the following (in thousands):</span></div><div style="padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured term loan A </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,062 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,687 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured term loan B </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount on term loan B and deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828,126 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812,876 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,758 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 467062000 229687000 349125000 508286000 19300000 0 7361000 6715000 828126000 731258000 15250000 37500000 812876000 693758000 1000000000 P5Y 400000000 P5Y 250000000 P7Y 350000000 0.0050 220000000 0.0204 1600000000 200000000 210900000 462300000 0.01 40000000 375000000 19300000 5700000 0.0125 0.0225 0.0025 0.0125 0.0050 0.0100 0.0135 0.0015 0.0025 0.0015 0.0250 0.0050 0.0150 0.0135 0.0300 5.50 5.00 5.50 2.50 for the next five years and thereafter, as of December 31, 2021, are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"/><td style="width:29.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">After 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum principal payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,739 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,622 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 15250000 18188000 29938000 38750000 401739000 331622000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in deferred debt issuance costs related to the Company’s Revolving Credit Facility is as follows (in thousands):</span></div><div style="margin-top:12pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%"><tr><td style="width:1.0%"/><td style="width:83.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.272%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing costs incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-off of deferred debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,039 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in unamortized discount and deferred debt issuance costs related to the Term Loan Facilities is as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unamortized Discount on TLB Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing costs incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-off of deferred debt issuance costs and unamortized discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,677)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,709)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,361 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 891000 2762000 72000 542000 3039000 5258000 1457000 6715000 5236000 1750000 6986000 2677000 954000 3631000 2143000 566000 2709000 5674000 1687000 7361000 8800000 1800000 1000000 7000000 2800000 1200000 3300000 300000 BENEFIT PLANS<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Savings Plan</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a defined contribution 401(k) plan (the “Plan”) for its U.S. based employees. The Plan provides for the deferral of employee compensation under Internal Revenue Code §401(k) and a Company match. The Company matches $0.50 per dollar of each participant’s deferral made to the Plan up to 6% of their compensation, subject to Internal Revenue Service guidelines. The Company temporarily suspended the Company match beginning in August 2020 through the end of 2020 as part of its cost reduction actions to reduce discretionary spending in response to the effect of the COVID-19 pandemic on its operations. Contributions from employees, as well as those matched by the Company, vest immediately. Net costs related to defined contribution plans were $7.9 million in 2021, $5.0 million in 2020 and $7.2 million in 2019.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Benefit Plans</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to provide its employees located in Switzerland and Mexico certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age and compensation. The defined benefit pension plan provided to the Company’s employees located in Switzerland is a funded contributory plan, while the plans that provide benefits to the Company’s employees located in Mexico are unfunded and noncontributory. The assets of the Switzerland plan are held at an AA- rated insurance carrier who bears the pension risk and longevity risk, and will be used to cover the pension liability for the remaining retirees of the Swiss plan, as well as the remaining employees at that location. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees. The aggregated projected benefit obligation for these plans was $3.9 million and $3.7 million as of December 31, 2021 and December 31, 2020, respectively. Net periodic pension cost for fiscal years 2021, 2020 and 2019 was $0.5 million, $0.4 million and $0.3 million, respectively. Over the next ten years, we expect gross benefit payments to be $1.0 million in total for the years 2022 through 2026, and $1.8 million in total for the years 2027 through 2031.</span></div> 0.50 0.06 7900000 5000000 7200000 3900000 3700000 500000 400000 300000 1000000 1800000 STOCK-BASED COMPENSATION<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Plans</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors (the “Board”) or the Compensation and Organization Committee of the Board. The stock-based compensation plans provide for the granting of stock options, RSAs, RSUs, stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company’s Board adopted, subject to stockholder approval, the Integer Holdings Corporation 2021 Omnibus Incentive Plan (the “2021 Plan”). The Company’s stockholders approved the 2021 Plan at the Company’s 2021 annual meeting of stockholders on May 19, 2021, at which time the 2021 Plan replaced the Company’s 2016 Stock Incentive Plan (the “2016 Plan”) and the Company ceased granting any new awards under the 2016 Plan. The number of shares initially reserved for issuance under the 2021 Plan is (i) 1,450,000 plus (ii) the total number of shares of common stock available for issuance under the 2016 Plan, plus (iii) any shares of common stock that are subject to awards forfeited, cancelled, expired, terminated or otherwise lapsed or settled in cash, in whole or in part, without the delivery of shares under the 2016 Plan. Each of the Company’s 2011 Stock Incentive Plan, the 2009 Stock Incentive Plan and the 2005 Stock Incentive Plan have expired, and no awards are available for issuance under these expired plans. As of December 31, 2021, there were 1,636,980 shares available for future grants under the 2021 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an excess net tax benefit from the exercise of stock options and vesting of RSUs of $1.1 million, $1.5 million and $2.8 million for fiscal years 2021, 2020 and 2019, respectively. These amounts are recorded as a component of Provision for income taxes.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCK-BASED COMPENSATION (Continued)</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and classification of stock-based compensation expense for fiscal years 2021, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PRSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RD&amp;E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OOE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,163 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,294 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no stock options granted in fiscal years 2021, 2020 or 2019. The following table summarizes stock option activity during the fiscal year ended December 31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,873 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.05 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.03 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,640 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.03 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intrinsic value is calculated for in-the-money options (exercise price less than market price) as the difference between the market price of the Company’s common stock as of December 31, 2021 ($85.59) and the weighted average exercise price of the underlying stock options, multiplied by the number of options outstanding and/or exercisable. Shares are distributed from the Company’s authorized but unissued reserve upon the exercise of stock options.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information relating to the exercise of stock options during fiscal years 2021, 2020 and 2019 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,263 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,242 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the fiscal year ended December 31, 2021: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Time-Vested<br/>Activity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,923 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,131 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCK-BASED COMPENSATION (Continued)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, there was $13.9 million of total unrecognized compensation cost related to RSUs, which is expected to be recognized over a weighted-average period of approximately 1.6 years. The fair value of RSU shares vested in fiscal years 2021, 2020 and 2019 was $12.9 million, $9.9 million and $2.4 million, respectively. The weighted average grant date fair value of RSUs granted during fiscal years 2021, 2020 and 2019 was $81.98, $83.94 and $82.31, respectively.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Restricted Stock Units</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes PRSU activity during the fiscal year ended December 31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance-<br/>Vested<br/>Activity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,391 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,384 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,882)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,024)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,869 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares earned depends on the achievement of financial or market-based performance conditions. The financial performance condition is based on the Company’s sales targets. The market conditions are based on the Company’s achievement of a relative total shareholder return (“TSR”) performance requirement, on a percentile basis, compared to a defined group of peer companies over three year performance periods. All PRSUs awarded during the 2021 fiscal year were subject to market-based performance conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, there was $6.0 million of total unrecognized compensation cost related to unvested PRSUs, which is expected to be recognized over a weighted-average period of approximately 1.9 years. The fair value of PRSU shares vested in fiscal years 2021, 2020 and 2019 was $3.1 million, $2.9 million and $6.7 million, respectively. The weighted average grant date fair value of PRSUs granted during fiscal years 2021, 2020 and 2019 was $85.16, $95.06 and $101.17, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of the market-based portion of the PRSUs granted during fiscal years 2021, 2020 and 2019 was determined using the Monte Carlo valuation model on the date of grant. The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.03 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of the TSR portion of the PRSUs granted during fiscal years 2021 and 2020 also reflects a weighted average illiquidity discount of 8.19% and 8.00%, respectively, related to the six-month period that recipients are restricted from selling, transferring, pledging or assigning the underlying shares, in the event of vesting.</span></div> 1450000 1636980 1100000 1500000 2800000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and classification of stock-based compensation expense for fiscal years 2021, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PRSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RD&amp;E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OOE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,163 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,294 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 43000 410000 16185000 9120000 8884000 16185000 9163000 9294000 3365000 1658000 1011000 11579000 6942000 7827000 969000 563000 269000 272000 0 187000 16185000 9163000 9294000 0 0 The following table summarizes stock option activity during the fiscal year ended December 31, 2021:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,873 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.05 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.03 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,640 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.03 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 281873 36.05 34233 21.72 247640 38.03 P4Y2M12D 11800000 247640 38.03 P4Y2M12D 11800000 85.59 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information relating to the exercise of stock options during fiscal years 2021, 2020 and 2019 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,263 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,242 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2370000 4773000 7998000 743000 3263000 3242000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the fiscal year ended December 31, 2021: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Time-Vested<br/>Activity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,923 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,131 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes PRSU activity during the fiscal year ended December 31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance-<br/>Vested<br/>Activity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,391 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,384 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,882)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,024)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,869 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 207923 75.38 208624 81.98 149464 74.47 18952 79.84 248131 81.14 13900000 P1Y7M6D 12900000 9900000 2400000 81.98 83.94 82.31 219391 72.33 92384 85.16 38882 37.75 74024 53.45 198869 92.07 P3Y 6000000 P1Y10M24D 3100000 2900000 6700000 85.16 95.06 101.17 The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.03 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 85.16 107.27 117.03 0.0019 0.0129 0.0246 0.41 0.30 0.40 P3Y P2Y10M24D P2Y9M18D 0 0 0 0.0819 0.0800 OTHER OPERATING EXPENSES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously evaluates the business and identifies opportunities to realign its resources to better serve its customers and markets, improve operational efficiency and capabilities, and lower its operating costs. To realize the benefits associated with these opportunities, the Company undertakes restructuring-type activities to transform its business. In addition, from time to time, the Company incurs cost associated with acquiring and integrating businesses and certain other general expenses, including asset impairments. The Company classifies costs associated with these items as OOE.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize OOE by program in each of the preceding three years (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operational excellence initiatives</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic reorganization and alignment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing alignment to support growth</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs (adjustments)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other general expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,856 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operational excellence initiatives</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operational excellence (“OE”) initiatives mainly consist of costs associated with executing on its sales force, manufacturing, business process, and performance excellence operational strategic imperatives. These projects focus on changing the Company’s organizational structure to match product line growth strategies and customer needs, transitioning its manufacturing process into a competitive advantage and standardizing and optimizing its business processes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 OE Initiatives - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to the Company’s 2021 OE initiatives are primarily recorded within the Medical segment or unallocated operating expenses and mainly include termination benefits. The Company estimates that it will incur aggregate pre-tax charges in connection with the 2021 OE initiatives of between approximately $4 million to $5 million, the majority of which are expected to be cash expenditures. As of December 31, 2021, total restructuring and related charges incurred since inception were $3.6 million. These actions are expected to be substantially complete by the end of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Initiatives - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to the Company’s 2020 initiatives are primarily recorded within the Medical segment and mainly include termination benefits. As of December 31, 2021, total restructuring and related charges incurred since inception were $3.1 million. These actions were substantially complete at the end of 2020.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic reorganization and alignment</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s strategic reorganization and alignment (“SRA”) initiatives primarily include those that align resources with market conditions and the Company’s strategic direction in order to enhance the profitability of its portfolio of products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 SRA Initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - During the fourth quarter of 2021, the Company initiated plans to exit certain markets served in our Medical segment to enhance profitability and reallocate manufacturing capacity needed to support our overall growth plans. The Company estimates that it will incur a range of pre-tax charges in connection with the 2021 SRA initiatives of approximately $5 million and $8 million, the majority of which are expected to be cash expenditures. Costs related to the Company’s 2021 SRA Initiatives are primarily recorded within the Medical segment and mainly include termination benefits. As of December 31, 2021, total charges incurred since inception were $0.9 million. These actions are expected to be completed by the end of 2025.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 SRA Initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2017, to better align its resources to enhance the profitability of its portfolio of products, the Company began aligning resources with its strategic direction, improving profitability to invest in accelerated growth and the expansion of a facility. These actions began in 2017 and were completed during the second quarter of 2020. The Company recorded, primarily within the Medical segment, $23.0 million of restructuring and related charges since inception.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER OPERATING EXPENSES (Continued)</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing alignment to support growth </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company commenced several initiatives designed to reduce costs, increase manufacturing capacity to accommodate growth and improve operating efficiencies.  The plan involved the relocation of certain manufacturing operations and expansion of certain of the Company’s facilities. Costs related to the Company’s manufacturing alignment to support growth initiative were primarily recorded within the Medical segment. As of December 31, 2021, total restructuring and related charges incurred for this initiative since inception were $5.8 million. These actions were completed during 2020.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in accrued liabilities, presented within Accrued expenses and other current liabilities on the Consolidated Balance Sheets, related to the initiatives described above (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operational excellence initiatives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Strategic reorganization and alignment</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges incurred, net of reversals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition and integration costs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, acquisition and integration costs included $2.4 million of expenses primarily related to the acquisition of Oscor, and a net $0.1 million adjustment to increase the fair value of acquisition-related contingent consideration liability associated with the Company’s other acquisitions. During 2020, acquisition and integration costs included $1.2 million of expenses primarily related to the acquisition of certain assets and liabilities of InoMec, and a $2.0 million adjustment to reduce the fair value of acquisition-related contingent consideration liability associated with the Company’s acquisition of USB. During 2019, acquisition and integration costs primarily related to direct acquisition costs incurred in connection with the acquisition of USB. Acquisition and integration costs primarily consist of professional fees and other costs. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration. </span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other general expenses</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, 2020 and 2019, the Company recorded expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce future costs and improve efficiencies. The 2021, 2020 and 2019 amounts primarily include severance, information technology systems conversion expenses, expenses incurred in connection with a customer filing Chapter 11 bankruptcy, and expenses related to the restructuring of certain legal entities of the Company.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize OOE by program in each of the preceding three years (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operational excellence initiatives</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic reorganization and alignment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing alignment to support growth</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs (adjustments)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other general expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,856 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 3893000 2791000 0 911000 686000 5812000 0 241000 2145000 2544000 -776000 377000 508000 4679000 3817000 -7856000 -7621000 -12151000 4000000 5000000 3600000 3100000 5000000 8000000 900000 23000000 5800000 <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in accrued liabilities, presented within Accrued expenses and other current liabilities on the Consolidated Balance Sheets, related to the initiatives described above (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operational excellence initiatives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Strategic reorganization and alignment</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges incurred, net of reversals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 291000 0 291000 3893000 911000 4804000 3886000 777000 4663000 298000 134000 432000 2400000 100000 1200000 2000000 INCOME TAXES<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from continuing operations before taxes for fiscal years 2021, 2020 and 2019 consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,293 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,337 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,203 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,870 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,990 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income from continuing operations before taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,063 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,207 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,193 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes from continuing operations for fiscal years 2021, 2020 and 2019 comprises the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,511 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,784 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,090 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,459 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,898 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,083 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,523 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,648)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,813)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,245)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,480)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,966)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,285)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,043 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,975 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes from continuing operations differs from the U.S. statutory rate for fiscal years 2021, 2020 and 2019 due to the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax credits (including R&amp;D)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,929)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings, net of §250 deduction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,043 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,949 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,975 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the Company’s effective tax rate and the U.S. federal statutory income tax rate in the current year is primarily attributable to the availability of Foreign Tax Credits, R&amp;D Credits, the impact of the Company’s earnings realized in foreign jurisdictions with statutory rates that are different than the U.S. federal statutory rate, and the provision for Global Intangible Low Taxed income (“GILTI”), net of the statutory deduction of 50% of the GILTI inclusion and the Foreign Derived Intangible Income (“FDII”) deduction (collectively “Section 250 deduction”). The Company’s foreign earnings are primarily derived from Switzerland, Mexico, Uruguay, Ireland and Malaysia. The Company currently has a tax holiday in Malaysia through April 2023 provided certain conditions continue to be met. In addition, the Company acquired manufacturing operations in the Dominican Republic as part of the acquisition of Oscor and is operating under a free trade zone agreement in the Dominican Republic through March 2034.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCOME TAXES (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Difference Attributable to Foreign Investment: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain foreign subsidiary earnings are subject to U.S. taxation under the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”) . The Company intends to permanently reinvest substantially all of our foreign subsidiary earnings, as well as our capital in our foreign subsidiaries, with the exception of planned distributions made out of current year earnings and profits (“E&amp;P”) and E&amp;P previously taxed as of and for the year ended December 29, 2017, including E&amp;P subject to the toll charge under the Tax Reform Act. The Company accrues for withholding taxes on distributions in the year associated with earnings that are intended to be distributed. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability consists of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,394 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,284 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,828 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,548 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,354)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,824)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,974)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214,622)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218,454)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165,794)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,906)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Presented as follows:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent deferred tax asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165,794)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,906)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company has the following carryforwards available:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.929%"><tr><td style="width:1.0%"/><td style="width:32.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax<br/>Attribute</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Begin to Expire</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Net operating losses (“NOLs”) are presented as pre-tax amounts.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCOME TAXES (Continued)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers, within each taxing jurisdiction, whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the consideration of the weight of both positive and negative evidence, management has determined it is more likely than not that a portion of the deferred tax assets as of December 31, 2021 and December 31, 2020 related to certain foreign tax credits, state investment tax credits, and foreign and state net operating losses will not be realized. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files annual income tax returns in the U.S., various state and local jurisdictions, and in various foreign jurisdictions. A number of years may elapse before an uncertain tax position, for which the Company has unrecognized tax benefits, is examined and finally settled. While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that its unrecognized tax benefits reflect the most probable outcome. The Company adjusts these unrecognized tax benefits, as well as the related interest, in light of changing facts and circumstances. The resolution of an uncertain tax position, if recognized, would be recorded as an adjustment to the provision for income taxes and the effective tax rate in the period of resolution.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of changes to the unrecognized tax benefit for fiscal years 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,369 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based upon tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions (reductions) related to prior period tax returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,537 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,484 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,446 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax years that remain open and subject to tax audits vary depending on the tax jurisdiction. During 2021, the Internal Revenue Service (“IRS”) effectively concluded its examination of the U.S. subsidiaries of the Company for the taxable years 2017 and 2018. Taxable years 2019 and forward remain subject to examination by the IRS.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of unrecognized tax benefits is not expected to materially change over the course of the next twelve months as a result of the lapse of the statute of limitations and/or audit settlements. As of December 31, 2021, approximately $5.5 million of unrecognized tax benefits would favorably impact the effective tax rate (net of federal impact on state issues), if recognized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest related to unrecognized tax benefits as a component of Provision for income taxes on the Consolidated Statements of Operations. During 2021, 2020 and 2019, the recorded amounts for interest and penalties, respectively, were not significant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, many governments have enacted or are contemplating measures to provide aid and economic stimulus. These measures may include deferring the due dates of tax payments or other changes to their income and non-income-based tax laws. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020 in the U.S., includes measures to assist companies, including temporary changes to income and non-income-based tax laws. The CARES Act provided for deferred payment of the employer portion of social security taxes through the end of 2020. As of December 31, 2020, the Company had deferred a total of $9.7 million of payroll taxes, of which it paid $4.9 million in December 2021. As of December 31, 2021, the Company had a remaining deferred amount of $4.8 million, which the Company expects to pay withing the next twelve months. The deferred payroll taxes are included within Accrued expenses and other current liabilities on the Consolidated Balance Sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20 “Discontinued Operations” for additional information pertaining to income taxes from discontinued operations.</span></div> <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from continuing operations before taxes for fiscal years 2021, 2020 and 2019 consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,293 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,337 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,203 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,870 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,990 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income from continuing operations before taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,063 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,207 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,193 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 48293000 35337000 40203000 52770000 50870000 64990000 101063000 86207000 105193000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes from continuing operations for fiscal years 2021, 2020 and 2019 comprises the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,511 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,784 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,090 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,459 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,898 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,083 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,523 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,648)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,813)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,245)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,480)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,966)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,285)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,043 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,975 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9511000 7784000 14090000 1553000 1233000 87000 8459000 6898000 10083000 19523000 15915000 24260000 -8665000 -4648000 -8813000 -393000 -1245000 332000 -2422000 -1073000 -1804000 -11480000 -6966000 -10285000 8043000 8949000 13975000 <div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes from continuing operations differs from the U.S. statutory rate for fiscal years 2021, 2020 and 2019 due to the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax credits (including R&amp;D)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,929)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings, net of §250 deduction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,043 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,949 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,975 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 21223000 0.210 18103000 0.210 22091000 0.210 11929000 0.118 7009000 0.081 4797000 0.046 -5165000 -0.051 -5333000 -0.062 -5479000 -0.052 1084000 0.011 1459000 0.017 2422000 0.023 18000 0 1208000 0.014 -920000 -0.009 1183000 0.012 553000 0.006 1106000 0.011 1913000 0.019 3216000 0.037 5201000 0.049 524000 0.005 -345000 -0.004 -1606000 -0.015 1360000 0.014 15000 0.001 801000 0.008 8043000 0.080 8949000 0.104 13975000 0.133 <div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability consists of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,394 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,284 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,828 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,548 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,354)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,824)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,974)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214,622)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218,454)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165,794)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,906)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Presented as follows:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent deferred tax asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165,794)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,906)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11394000 13449000 14147000 14099000 11721000 10436000 17950000 11969000 3724000 3276000 9348000 8058000 68284000 61287000 19456000 20739000 48828000 40548000 7354000 5824000 186150000 197048000 17974000 11290000 3144000 4292000 214622000 218454000 165794000 177906000 5711000 4398000 171505000 182304000 165794000 177906000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company has the following carryforwards available:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.929%"><tr><td style="width:1.0%"/><td style="width:32.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax<br/>Attribute</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Begin to Expire</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Net operating losses (“NOLs”) are presented as pre-tax amounts.</span></div> 120700000 12200000 6700000 1400000 4900000 <div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of changes to the unrecognized tax benefit for fiscal years 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,369 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based upon tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions (reductions) related to prior period tax returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,537 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,484 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,446 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5484000 4446000 5369000 3324000 300000 300000 3271000 -738000 1223000 5537000 5484000 4446000 5500000 9700000 4900000 4800000 COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration Arrangements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records contingent consideration liabilities related to the earn-out provisions for certain acquisitions. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action will not become material in the future.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a contingent gain for litigation when all of the following conditions have been met: (a) the amount to be paid to the Company is known, (b) there is no potential for appeal or reversal, and (c) collectability is reasonably assured.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2013, the Company commenced an action against AVX Corporation and AVX Filters Corporation (collectively “AVX”) alleging that AVX had infringed on the Company’s patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate the Company’s patented technology. Following four trials and an appeal, the United States Court of Appeals for the Federal Circuit affirmed, in all respects, a judgment in favor of the Company. The Company received the payment of $28.9 million in October 2020, and after recognizing certain related expenses, recognized a net gain of $28.2 million.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gain on patent litigation of $28.2 million is recorded in Selling, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eneral and administrative expenses in the Company’s Consolidated Statements of Operations for the year ended December 31, 2020.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired Lake Region Medical Holdings, Inc. (“LRM”) in 2015. At the direction of the New Jersey Department of Environmental Protection (“NJDEP”), LRM has been performing, and has agreed to fund approximately $0.3 million for, environmental investigations of a manufacturing facility LRM owned in South Plainfield, New Jersey from 1971 to 2004, and where it conducted operations from 1971 to 2007. NJDEP required LRM to perform and fund these environmental investigations due to concerns that prior investigations by LRM at the property were inadequate and because NJDEP concluded that the property was a source of local ground water contamination during LRM’s operations, including the Franklin Street Regional Groundwater Contamination Area, which has been designated as an immediate environmental concern by NJDEP. LRM funded the environmental investigation undertaken by NJDEP’s contractor by placing approximately $0.3 million in escrow for the environmental investigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, approximately $0.2 million had been drawn down from the escrow account by NJDEP to pay for the environmental investigation, and approximately $0.1 million remains in escrow for anticipated future costs associated with the environmental investigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These environmental investigations may conclude that remediation of the property by LRM, and the reimbursement of costs and damages, including natural resource damages, associated with the groundwater immediate environmental concern, are necessary. Further, the current owner of the property claims to have been financially impacted by LRM’s inadequate environmental investigations. While the Company does not expect this environmental matter will have a material effect on its consolidated results of operations, financial position or cash flows, there can be no assurance that this environmental matter will not become material in the future. As of December 31, 2021, there was $0.1 million recorded in Accrued expenses and other current liabilities in the Consolidated Balance Sheets in connection with this environmental matter</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various license agreements for technology that is utilized in certain of its products. The most significant of these agreements are the licenses for basic technology used in the production of wet tantalum capacitors, filtered feedthroughs and MRI compatible lead systems. Expenses related to license agreements were $1.3 million, $1.2 million, and $1.4 million, for 2021, 2020 and 2019, respectively, and are primarily included in Cost of Sales.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMITMENTS AND CONTINGENCIES (Continued)</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Warranties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The change in product warranty liability for fiscal years 2021 and 2020 comprises the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to warranty reserve, net of reversals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to pre-existing warranties </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty claims settled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Self-Insurance Liabilities</span></div>As of December 31, 2021, and at various times in the past, the Company self-funded certain of its workers’ compensation and employee medical and dental expenses. The Company has established reserves to cover these self-insured liabilities and also maintains stop-loss insurance to limit its exposures under these programs. Claims reserves represent accruals for the estimated uninsured portion of reported claims, including adverse development of reported claims, as well as estimates of incurred but not reported claims. Claims incurred but not reported are estimated based on the Company’s historical experience, which is continually monitored, and accruals are adjusted when warranted by changes in facts and circumstances. The Company’s actual experience may be different than its estimates, sometimes significantly. Changes in assumptions, as well as changes in actual experience could cause these estimates to change. Insurance and claims expense will vary from period to period based on the severity and frequency of claims incurred in a given period.  The Company’s self-insurance reserves totaled $5.6 million and $5.4 million as of December 31, 2021 and December 31, 2020, respectively. These accruals are recorded in Accrued expenses and other current liabilities and Other long-term liabilities on the Consolidated Balance Sheets. 28900000 28200000 28200000 300000 300000 200000 100000 100000 1300000 1200000 1400000 The change in product warranty liability for fiscal years 2021 and 2020 comprises the following (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to warranty reserve, net of reversals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to pre-existing warranties </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty claims settled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 163000 1933000 -15000 -156000 -71000 -119000 0 1495000 432000 0 509000 163000 5600000 5400000 LEASES<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Gross assets acquired under finance leases are recorded in Other long-term assets and were $8.3 million as of December 31, 2021. Accumulated amortization associated with finance leases was $0.2 million as of December 31, 2021. Finance leases were not material as of December 31, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and classification of lease cost are as follows (in thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost (leases with initial term of 12 months or less)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,375 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,639 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RD&amp;E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,375 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,639 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEASES (Continued)</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s sublease income is derived primarily from certain real estate leases to several non-affiliated tenants under operating sublease arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the maturities of operating and finance lease liabilities were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,894 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,058 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2VhYmVlYWE2ODQxYWZhMmZjZWJlMzY2NDZjMjc3L3NlYzo5NWNlYWJlZWFhNjg0MWFmYTJmY2ViZTM2NjQ2YzI3N18xNjMvZnJhZzozMjlhZTdmYThjMmE0MmM1OWYyMTdiNTUxOGJkMzA2Ny90YWJsZTpiOGQ2MzNjOTJmMTI0YjE1OGU1NGJhYTcyZjI2YmRkNS90YWJsZXJhbmdlOmI4ZDYzM2M5MmYxMjRiMTU4ZTU0YmFhNzJmMjZiZGQ1XzEwLTAtMS0xLTM2MTA2_7b28cdd9-75f4-4d34-92b7-c5fd8d5989e4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2VhYmVlYWE2ODQxYWZhMmZjZWJlMzY2NDZjMjc3L3NlYzo5NWNlYWJlZWFhNjg0MWFmYTJmY2ViZTM2NjQ2YzI3N18xNjMvZnJhZzozMjlhZTdmYThjMmE0MmM1OWYyMTdiNTUxOGJkMzA2Ny90YWJsZTpiOGQ2MzNjOTJmMTI0YjE1OGU1NGJhYTcyZjI2YmRkNS90YWJsZXJhbmdlOmI4ZDYzM2M5MmYxMjRiMTU4ZTU0YmFhNzJmMjZiZGQ1XzEwLTAtMS0xLTM2MTA2_b4273ea5-d15a-410c-83ac-2a939bf4b6e1">Less: current portion of lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,862)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2VhYmVlYWE2ODQxYWZhMmZjZWJlMzY2NDZjMjc3L3NlYzo5NWNlYWJlZWFhNjg0MWFmYTJmY2ViZTM2NjQ2YzI3N18xNjMvZnJhZzozMjlhZTdmYThjMmE0MmM1OWYyMTdiNTUxOGJkMzA2Ny90YWJsZTpiOGQ2MzNjOTJmMTI0YjE1OGU1NGJhYTcyZjI2YmRkNS90YWJsZXJhbmdlOmI4ZDYzM2M5MmYxMjRiMTU4ZTU0YmFhNzJmMjZiZGQ1XzExLTAtMS0xLTM1ODYy_61c8b3ad-cc7b-4f8c-a8e9-dfc645a6895b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2VhYmVlYWE2ODQxYWZhMmZjZWJlMzY2NDZjMjc3L3NlYzo5NWNlYWJlZWFhNjg0MWFmYTJmY2ViZTM2NjQ2YzI3N18xNjMvZnJhZzozMjlhZTdmYThjMmE0MmM1OWYyMTdiNTUxOGJkMzA2Ny90YWJsZTpiOGQ2MzNjOTJmMTI0YjE1OGU1NGJhYTcyZjI2YmRkNS90YWJsZXJhbmdlOmI4ZDYzM2M5MmYxMjRiMTU4ZTU0YmFhNzJmMjZiZGQ1XzExLTAtMS0xLTM1ODYy_d60d2025-5144-4bc4-ac1f-82e3366b9b94">Total long-term lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,767 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company did not have any leases that have not yet commenced.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term and discount rate.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - finance leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for fiscal years 2021 and 2020 is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest on finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired under operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired under finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended December 31, 2021, the Company extended the lease terms for three of its manufacturing facilities. As a result of these lease modifications, the Company re-measured the lease liability and adjusted the ROU asset on the modification dates.</span></div> 8300000 200000 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and classification of lease cost are as follows (in thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost (leases with initial term of 12 months or less)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,375 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,639 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RD&amp;E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,375 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,639 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term and discount rate.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - finance leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for fiscal years 2021 and 2020 is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest on finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired under operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired under finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 223000 7000 59000 1000 282000 8000 10729000 10425000 137000 86000 2619000 2615000 1392000 1495000 12375000 11639000 9642000 9141000 1817000 1803000 857000 694000 59000 1000 12375000 11639000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the maturities of operating and finance lease liabilities were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,894 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,058 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2VhYmVlYWE2ODQxYWZhMmZjZWJlMzY2NDZjMjc3L3NlYzo5NWNlYWJlZWFhNjg0MWFmYTJmY2ViZTM2NjQ2YzI3N18xNjMvZnJhZzozMjlhZTdmYThjMmE0MmM1OWYyMTdiNTUxOGJkMzA2Ny90YWJsZTpiOGQ2MzNjOTJmMTI0YjE1OGU1NGJhYTcyZjI2YmRkNS90YWJsZXJhbmdlOmI4ZDYzM2M5MmYxMjRiMTU4ZTU0YmFhNzJmMjZiZGQ1XzEwLTAtMS0xLTM2MTA2_7b28cdd9-75f4-4d34-92b7-c5fd8d5989e4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2VhYmVlYWE2ODQxYWZhMmZjZWJlMzY2NDZjMjc3L3NlYzo5NWNlYWJlZWFhNjg0MWFmYTJmY2ViZTM2NjQ2YzI3N18xNjMvZnJhZzozMjlhZTdmYThjMmE0MmM1OWYyMTdiNTUxOGJkMzA2Ny90YWJsZTpiOGQ2MzNjOTJmMTI0YjE1OGU1NGJhYTcyZjI2YmRkNS90YWJsZXJhbmdlOmI4ZDYzM2M5MmYxMjRiMTU4ZTU0YmFhNzJmMjZiZGQ1XzEwLTAtMS0xLTM2MTA2_b4273ea5-d15a-410c-83ac-2a939bf4b6e1">Less: current portion of lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,862)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2VhYmVlYWE2ODQxYWZhMmZjZWJlMzY2NDZjMjc3L3NlYzo5NWNlYWJlZWFhNjg0MWFmYTJmY2ViZTM2NjQ2YzI3N18xNjMvZnJhZzozMjlhZTdmYThjMmE0MmM1OWYyMTdiNTUxOGJkMzA2Ny90YWJsZTpiOGQ2MzNjOTJmMTI0YjE1OGU1NGJhYTcyZjI2YmRkNS90YWJsZXJhbmdlOmI4ZDYzM2M5MmYxMjRiMTU4ZTU0YmFhNzJmMjZiZGQ1XzExLTAtMS0xLTM1ODYy_61c8b3ad-cc7b-4f8c-a8e9-dfc645a6895b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2VhYmVlYWE2ODQxYWZhMmZjZWJlMzY2NDZjMjc3L3NlYzo5NWNlYWJlZWFhNjg0MWFmYTJmY2ViZTM2NjQ2YzI3N18xNjMvZnJhZzozMjlhZTdmYThjMmE0MmM1OWYyMTdiNTUxOGJkMzA2Ny90YWJsZTpiOGQ2MzNjOTJmMTI0YjE1OGU1NGJhYTcyZjI2YmRkNS90YWJsZXJhbmdlOmI4ZDYzM2M5MmYxMjRiMTU4ZTU0YmFhNzJmMjZiZGQ1XzExLTAtMS0xLTM1ODYy_d60d2025-5144-4bc4-ac1f-82e3366b9b94">Total long-term lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,767 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 12423000 876000 11317000 888000 10809000 896000 10634000 787000 9856000 640000 25652000 5807000 80691000 9894000 11062000 1836000 69629000 8058000 9862000 608000 59767000 7450000 P7Y P7Y P12Y2M12D P3Y9M18D 0.039 0.053 0.035 0.022 10808000 10385000 59000 1000 32466000 9059000 8154000 127000 3 EARNINGS PER SHARE<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a reconciliation of the information used in computing basic and diluted EPS for fiscal years 2021, 2020 and 2019 (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for basic and diluted EPS:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,808 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,258 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,336 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic EPS:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, restricted stock and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,037 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diluted weighted average share calculations do not include the following securities for fiscal years 2021, 2020 and 2019, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-vested stock options, restricted stock and restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-vested restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a reconciliation of the information used in computing basic and diluted EPS for fiscal years 2021, 2020 and 2019 (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for basic and diluted EPS:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,808 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,258 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,336 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic EPS:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, restricted stock and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,037 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 93020000 77258000 91218000 3788000 0 5118000 96808000 77258000 96336000 32993000 32845000 32627000 265000 268000 410000 33258000 33113000 33037000 2.82 2.35 2.80 0.11 0 0.16 2.93 2.35 2.95 2.80 2.33 2.76 0.11 0 0.15 2.91 2.33 2.92 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diluted weighted average share calculations do not include the following securities for fiscal years 2021, 2020 and 2019, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-vested stock options, restricted stock and restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-vested restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4000 98000 30000 92000 89000 47000 STOCKHOLDERS’ EQUITY<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the changes in the number of shares of common stock for fiscal years 2021 and 2020:</span></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,847,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,546)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of RSUs, net of shares withheld to cover taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,908,178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,908,178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of RSUs, net of shares withheld to cover taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,063,336 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,063,336 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income comprises the following (in thousands): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined<br/>Benefit<br/>Plan<br/>Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash<br/>Flow<br/>Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Pre-Tax<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net-of-Tax<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(912)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,358)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,639 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,369 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on foreign currency hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on interest rate swap hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net defined benefit plan adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,095)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,956)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,692 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gain on foreign currency hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on interest rate swap hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(716)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net defined benefit plan adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,291)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,720 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,539 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the changes in the number of shares of common stock for fiscal years 2021 and 2020:</span></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,847,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,546)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of RSUs, net of shares withheld to cover taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,908,178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,908,178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of RSUs, net of shares withheld to cover taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,063,336 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,063,336 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 32847017 -146546 32700471 27544 74596 102140 33617 71950 105567 32908178 0 32908178 34233 0 34233 120925 0 120925 33063336 0 33063336 <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income comprises the following (in thousands): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined<br/>Benefit<br/>Plan<br/>Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash<br/>Flow<br/>Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Pre-Tax<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net-of-Tax<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(912)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,358)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,639 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,369 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on foreign currency hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on interest rate swap hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net defined benefit plan adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,095)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,956)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,692 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gain on foreign currency hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on interest rate swap hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(716)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net defined benefit plan adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,291)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,720 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,539 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -912000 -2358000 22639000 19369000 619000 19988000 6683000 6683000 1404000 5279000 -638000 -638000 -134000 -504000 -3447000 -3447000 -724000 -2723000 183000 183000 32000 151000 -34907000 -34907000 0 -34907000 -1095000 -4956000 57546000 51495000 1197000 52692000 -91000 -91000 -19000 -72000 832000 832000 175000 657000 -3406000 -3406000 -716000 -2690000 -205000 -205000 14000 -219000 27826000 27826000 0 27826000 -890000 -2291000 29720000 26539000 651000 27190000 FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments and contingent consideration. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to global market risks, including the effect of changes in interest rates and foreign currency exchange rates, and uses derivatives to manage these exposures that occur in the normal course of business. The Company does not hold or issue derivatives for trading or speculative purposes. All derivatives are recorded at fair value on the balance sheet.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets: Foreign currency hedging contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: Interest rate swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets: Foreign currency hedging contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Derivatives Designated as Hedging Instruments</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Swaps</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically enters into interest rate swap agreements to reduce the cash flow risk caused by interest rate changes on its outstanding floating rate borrowings. Under these swap agreements, the Company pays a fixed rate of interest and receives a floating rate equal to one-month LIBOR. The variable rate received from the swap agreements and the variable rate paid on the outstanding debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The Company has designated these swap agreements as cash flow hedges based on concluding the hedged forecasted transaction is probable of occurring within the period the cash flow hedge is anticipated to affect earnings.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives fair value estimates from the swap agreement counterparties. The fair value of the Company’s swap agreements are determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. The Company’s interest rate swap agreements are categorized in Level 2 of the fair value hierarchy. The estimated fair value of the swap agreements represents the amount the Company would receive (pay) to terminate the contracts.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of December 31, 2021 is as follows (dollars in thousands):</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:8.270%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Start Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pay Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Receive Current Floating Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1785 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1013 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,978)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pay Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Receive Current Floating Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1785 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,026)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Contracts</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations. The Company has designated these foreign currency forward contracts as cash flow hedges.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives fair value estimates from the foreign currency contract counterparties. The fair value of foreign currency contracts are determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rate and credit spread curves. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as Sales or Cost of Sales as the inventory, which the contracts are hedging, is sold.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2021 is as follows (dollars in thousands):</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$/Foreign Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0463</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MXN Peso</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1344</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0220</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UYU Peso</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands):</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$/Foreign Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sep 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1949</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sep 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0454</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MXN Peso</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0443</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MXN Peso</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0485</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MXN Peso</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aug 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UYU Peso</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0227</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UYU Peso</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact of cash flow hedge derivative instruments on other comprehensive income (“OCI”), AOCI and the Company’s Consolidated Statement of Operations for fiscal years 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Recognized in OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Reclassified from AOCI</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location in Statement of Operations </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,405)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,618)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,447)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,044)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to reclassify net losses totaling $1.8 million related to its cash flow hedges from AOCI into earnings during the next twelve months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Derivatives Not Designated as Hedging Instruments</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has foreign currency exposure on balances, primarily intercompany, that are denominated in a foreign currency and are adjusted to current values using period-end exchange rates. To minimize foreign currency exposure, the Company enters into foreign currency contracts with a one month maturity. At December 31, 2021, the Company had one contract outstanding, with a notional amount of $15.0 million and a fair value of $0.1 million. The Company recorded a net gain on foreign currency contracts not designated as hedging instruments of $0.4 million for fiscal year 2021, which are included in Other (income) loss, net and generally offset the gains or losses from the foreign currency adjustments on the intercompany balances that are also included in Other (income) loss, net.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for fiscal years 2021 and 2020 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Amount recorded for current year acquisitions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value measurement adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value measurement adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Payments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2020, the Company acquired certain assets and liabilities of InoMec. On October 7, 2019, the Company acquired certain assets and liabilities of USB, a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The contingent consideration at December 31, 2021 is the estimated fair value of the Company’s obligations, under the asset purchase agreements for InoMec and USB, to make additional payments if certain revenue goals are met. See Note 2 “Business Acquisitions” for additional information about the InoMec and USB acquisitions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company made payments associated with the InoMec and USB acquisitions, resulting from achievement of revenue-based goals for the period from March 1, 2020 to February 28, 2021 for InoMec and January 1, 2020 to December 31, 2020 for USB. During 2020, the Company made payments to settle a portion of a contingent consideration arrangement relating to a license to use technology.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and December 31, 2020, the current portion of contingent consideration liabilities included in Accrued expenses and other current liabilities was $0.9 million and $1.7 million, respectively, and the non-current portion included in Other long-term liabilities on the Consolidated Balance Sheets was $1.5 million and $2.2 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides quantitative information associated with the fair value measurement of the Company’s liabilities for contingent consideration:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingency Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Maximum Payout (undiscounted)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average or Range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue-based payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year(s) of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022-2024</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingency Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Maximum Payout (undiscounted)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average or Range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue-based payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year(s) of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021-2024</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, contract assets, accounts payable and accrued expenses approximate fair value due to the short-term nature of these items.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Company’s Revolving Credit Facility, TLA Facility and TLB Facility accrue interest at a floating rate tied to a standard short-term borrowing index, selected at the Company’s option, plus an applicable margin. The carrying amount of this floating rate debt approximates fair value based upon the respective interest rates adjusting with market rate adjustments.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments comprise the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-marketable equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,829 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,193 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of (Gain) loss on equity investments, net for each period were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment (income) loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,057 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,706)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (gain) loss on equity investments, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,143 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,337)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, 2020 and 2019, the Company determined that certain non-marketable equity securities were impaired. In both 2021 and 2020, new equity financings by two of the Company’s non-marketable equity securities indicated new values for the investments. During the fourth quarters of 2021 and 2020, the Company recorded impairment charges of $0.1 million and $0.4 million, respectively, to reduce the carrying value of these non-marketable equity securities to their estimated fair value of zero and $2.2 million, respectively. The fair values of these investments were derived from observable price changes of similar securities of the investees. In 2019, the Company determined the fair value for one of its non-marketable equity securities to be zero based upon available market information. This assessment was based on qualitative indications of impairment. Factors that significantly influenced the determination of the impairment loss included the equity security’s investee’s financial condition, priority claims to the equity security, distributions rights and preferences, and status of the regulatory approval required to bring its product to market. During 2021, 2020 and 2019, the Company received cash distributions representing a return on equity method investments of $2.2 million, $0.4 million and $0.1 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. As of December 31, 2021, the Company owned</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.7% of this fund.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets: Foreign currency hedging contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: Interest rate swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets: Foreign currency hedging contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of December 31, 2021 is as follows (dollars in thousands):</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:8.270%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Start Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pay Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Receive Current Floating Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1785 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1013 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,978)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pay Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Receive Current Floating Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1785 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,026)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2021 is as follows (dollars in thousands):</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$/Foreign Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0463</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MXN Peso</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1344</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0220</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UYU Peso</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands):</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$/Foreign Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sep 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1949</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sep 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0454</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MXN Peso</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0443</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MXN Peso</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0485</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MXN Peso</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aug 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UYU Peso</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0227</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UYU Peso</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 687000 0 687000 0 2978000 0 2978000 0 2415000 0 0 2415000 2070000 0 2070000 0 7026000 0 7026000 0 3900000 0 0 3900000 150000000 0.021785 0.001013 2978000 200000000 0.021785 0.001480 7026000 22201000 0.0463 408000 17017000 1.1344 130000 9020000 0.0220 149000 16132000 1.1949 399000 10224000 0.0454 922000 2656000 0.0443 341000 7269000 0.0485 77000 3252000 0.0232 165000 3966000 0.0227 166000 <div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact of cash flow hedge derivative instruments on other comprehensive income (“OCI”), AOCI and the Company’s Consolidated Statement of Operations for fiscal years 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Recognized in OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Reclassified from AOCI</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location in Statement of Operations </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,405)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,618)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,447)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,044)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 642000 -7405000 -5618000 -3406000 -3447000 1621000 -943000 1017000 -1044000 -674000 618000 -1334000 399000 -355000 2634000 1437000 -1177000 1482000 -7000 60000 0 69000 -79000 0 1800000 15000000 100000 400000 <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for fiscal years 2021 and 2020 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Amount recorded for current year acquisitions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value measurement adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value measurement adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Payments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4200000 2700000 -2000000 1000000 3900000 133000 1621000 3000 2415000 900000 1700000 1500000 2200000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides quantitative information associated with the fair value measurement of the Company’s liabilities for contingent consideration:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingency Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Maximum Payout (undiscounted)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average or Range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue-based payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year(s) of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022-2024</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingency Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Maximum Payout (undiscounted)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average or Range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue-based payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year(s) of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021-2024</span></td></tr></table></div> 6750000 2415000 0.290 0.018 9000000 3900000 0.350 0.040 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments comprise the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-marketable equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,829 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,193 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of (Gain) loss on equity investments, net for each period were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment (income) loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,057 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,706)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (gain) loss on equity investments, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,143 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,337)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 16192000 21470000 5637000 5723000 21829000 27193000 -3057000 5706000 1100000 86000 369000 1575000 -3143000 5337000 -475000 100000 400000 0 2200000 0 2200000 400000 100000 0.067 SEGMENT AND GEOGRAPHIC INFORMATION<div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker, to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines segment income from operations as sales less cost of sales including amortization and expenses attributable to segment-specific selling, general, administrative, research, development, engineering and other operating activities. The remaining unallocated operating and other expenses are primarily administrative corporate headquarter expenses and capital costs that are not allocated to reportable segments. Transactions between the two segments are not significant.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents sales by product line for fiscal years 2021, 2020 and 2019 (in thousands).</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment sales by product line:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardio &amp; Vascular </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610,056 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiac &amp; Neuromodulation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Surgical, Orthopedics &amp; Portable Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medical</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182,626 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037,978 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199,679 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,464 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221,079 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073,442 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258,094 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Area Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents sales by significant country for fiscal years 2021, 2020 and 2019. In these tables, sales are allocated based on where the products are shipped (in thousands).</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by geographic area:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Domestic locations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221,079 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073,442 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258,094 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues for fiscal years 2021 and 2020.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Customer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Medical</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer E</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other customers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Less than 10% of segment’s total revenues for the period.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(18.)     SEGMENT AND GEOGRAPHIC INFORMATION (Continued)</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped for fiscal years 2021 and 2020.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ship to Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Medical</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents income from continuing operations for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment income from continuing operations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment income from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,622 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,244 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,162 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,711 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,612 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,635 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated expenses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,648)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,442)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,063 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,207 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,193 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents depreciation and amortization expense for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment depreciation and amortization:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,867 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization included in segment</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   income from continuing operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,533 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,334 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,906 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,369 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,324 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,895 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for the Company’s reportable segments as of December 31, 2021 and December 31, 2020 (in thousands).</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medical </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504,281 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265,171 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,934 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,582,215 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371,857 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(18.)     SEGMENT AND GEOGRAPHIC INFORMATION (Continued)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents capital expenditures for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenditures for tangible long-lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,992 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,473 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,423 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated long-lived tangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenditures</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,463 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,832 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,198 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents PP&amp;E by geographic area as of December 31, 2021 and December 31, 2020. In these tables, PP&amp;E is aggregated based on the physical location of the tangible long-lived assets (in thousands).</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived tangible assets by geographic area:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,099 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,964 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2 2 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents sales by product line for fiscal years 2021, 2020 and 2019 (in thousands).</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment sales by product line:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardio &amp; Vascular </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610,056 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiac &amp; Neuromodulation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Surgical, Orthopedics &amp; Portable Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medical</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182,626 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037,978 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199,679 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,464 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221,079 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073,442 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258,094 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 626013000 569948000 610056000 446569000 346242000 457194000 110044000 121788000 132429000 1182626000 1037978000 1199679000 38453000 35464000 58415000 1221079000 1073442000 1258094000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents sales by significant country for fiscal years 2021, 2020 and 2019. In these tables, sales are allocated based on where the products are shipped (in thousands).</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by geographic area:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Domestic locations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221,079 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073,442 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258,094 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped for fiscal years 2021 and 2020.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ship to Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Medical</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%</span></td></tr></table></div> 671502000 596804000 698474000 110162000 96048000 154644000 66975000 58853000 63634000 372440000 321737000 341342000 1221079000 1073442000 1258094000 <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues for fiscal years 2021 and 2020.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Customer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Medical</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer E</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other customers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Less than 10% of segment’s total revenues for the period.</span></div> 0.19 0.19 0.17 0.17 0.14 0.15 0.36 0.22 0.10 0.50 0.64 0.49 0.68 0.54 0.71 0.55 0.60 0.46 0.29 0.45 0.40 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents income from continuing operations for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment income from continuing operations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment income from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,622 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,244 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,162 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,711 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,612 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,635 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated expenses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,648)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,442)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,063 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,207 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,193 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 213600000 169396000 223873000 8022000 4848000 16289000 221622000 174244000 240162000 -85911000 -53632000 -82527000 135711000 120612000 157635000 34648000 34405000 52442000 101063000 86207000 105193000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents depreciation and amortization expense for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment depreciation and amortization:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,867 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization included in segment</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   income from continuing operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,533 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,334 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,906 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,369 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,324 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,895 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 75366000 72338000 68867000 1167000 996000 1039000 76533000 73334000 69906000 4836000 5990000 7989000 81369000 79324000 77895000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for the Company’s reportable segments as of December 31, 2021 and December 31, 2020 (in thousands).</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medical </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504,281 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265,171 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,934 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,582,215 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371,857 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents PP&amp;E by geographic area as of December 31, 2021 and December 31, 2020. In these tables, PP&amp;E is aggregated based on the physical location of the tangible long-lived assets (in thousands).</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived tangible assets by geographic area:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,099 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,964 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2448123000 2212489000 56158000 52682000 2504281000 2265171000 77934000 106686000 2582215000 2371857000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents capital expenditures for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands).</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenditures for tangible long-lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,992 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,473 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,423 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated long-lived tangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenditures</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,463 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,832 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,198 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 48364000 42435000 44026000 628000 1038000 397000 48992000 43473000 44423000 4471000 3359000 3775000 53463000 46832000 48198000 184474000 170871000 33877000 32723000 41501000 38526000 17247000 11844000 277099000 253964000 REVENUE FROM CONTRACTS WITH CUSTOMERS<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregated Revenue</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the Company’s business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. For a summary by disaggregated product line sales for each segment, refer to Note 18, “Segment and Geographic Information.”</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company’s sales for fiscal years 2021, 2020 and 2019 and accounts receivable at December 31, 2021 and December 31, 2020 were to three customers as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from products and services transferred to customers over time during fiscal years 2021 and 2020 represented 33% and 29%, respectively, of total revenue. Substantially all of the revenue recognized from products and services transferred to customers over time during fiscal years 2021 and 2020 was within the Medical segment.</span></div><div style="margin-bottom:3pt;margin-top:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19.)     REVENUE FROM CONTRACTS WITH CUSTOMERS (Continued)</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.184%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets at December 31, 2021, increased $24.5 million from December 31, 2020, primarily due to a contract modification to add existing products and extend the contractual term. During the fiscal year ended December 31, 2021, the Company recognized $1.9 million of revenue that was included in the contract liability balance as of December 31, 2020. During the fiscal year ended December 31, 2020, the Company recognized $1.3 million of revenue that was included in the contract liability balance as of December 31, 2019.</span></div> <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company’s sales for fiscal years 2021, 2020 and 2019 and accounts receivable at December 31, 2021 and December 31, 2020 were to three customers as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td></tr></table></div> 0.18 0.18 0.21 0.15 0.15 0.16 0.16 0.17 0.19 0.19 0.13 0.14 0.12 0.10 0.13 0.47 0.48 0.50 0.44 0.47 0.33 0.29 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.184%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 64743000 40218000 3776000 2498000 24500000 1900000 1300000 DISCONTINUED OPERATIONS<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestiture of AS&amp;O Product Line</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company completed the sale of its AS&amp;O Product Line within its Medical segment to Viant (formerly MedPlast, LLC). For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&amp;O Product Line.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, the Company recognized other income from discontinued operations of $4.9 million for the release of pre-divestiture indemnified tax liabilities resulting from the lapse of the statute of limitations and the effective settlement of tax audits. During 2019, the Company received, and recognized as gain on sale from discontinued operations, $4.8 million due to the final net working capital adjustment agreed to with Viant.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,974)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,931 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,788 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,118 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow information from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 4900000 4800000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,974)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,931 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,788 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,118 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow information from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 0 0 4974000 4931000 0 322000 4931000 0 5296000 1143000 0 178000 3788000 0 5118000 0 0 -78000 0 0 4734000 34 <div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule II—Valuation and Qualifying Accounts</span></div><div style="margin-bottom:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.551%"><tr><td style="width:1.0%"/><td style="width:35.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.513%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.279%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Col. C—Additions</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Column A<br/>Description</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Col. B Balance at Beginning<br/>of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged to Costs &amp;<br/>Expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged to Other Accounts- Describe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Col. D Deductions<br/>- Describe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Col. E Balance at End of<br/>Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(4)(5)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(4)(5)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Valuation allowance recorded in the provision for credit losses (allowance for doubtful accounts in years prior to 2020). The 2019 amount includes a $2.3 million reserve recorded in connection with a customer bankruptcy, net of adjustments to the Company’s general and specific reserves.</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Valuation allowance recorded in the provision for income taxes for certain net operating losses and tax credits. The 2021, 2020 and 2019 deductions include the expiration of certain net operating losses and tax credits.</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes foreign currency translation effect.</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Accounts written off and reductions to allowances existing at the beginning of the year. The 2020 amount includes $2.3 million of accounts receivable recorded during 2019 in connection with a customer bankruptcy.</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The 2020 and 2019 deductions include releases of the allowance for net operating losses utilized during that year and return to provision adjustments for prior years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">See exhibits listed under Part (b) below.</span></div> 155000 20000 0 43000 132000 20739000 -941000 26000 368000 19456000 2443000 28000 0 2316000 155000 22229000 -275000 0 1215000 20739000 592000 1884000 2000 35000 2443000 34339000 736000 0 12846000 22229000 2300000 2300000 EXCEL 139 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

    #72;=*4:Y5;4M= M"Z,6KPXN)S^_F=%X'O![J>YL\K>@D\RU_DX_KHM7!V,B2%4J;V@%B?]NU96J M*EH(9/S3KWG0;4D3T[_#ZN_Y[#C+7%IUI:N_ET6S>G5P<2 *M9!MU7S1=W]5 M_CQGM%ZN*\O_BCLW]FQV(/+6-GKM)X."=5F[_^6]YT,RX6+\P(2IGS!ENMU& M3.5;VY7^6-6V7ZP"J3J?BHZV9EQ;NZ4$5_@1.0U-$U#72]F3ZZXEN5 MC\3I)!/3\73RR'JGW3E/>;W3/SKGE5[/RUHZE:@+<6DM5#\YO?COR[EM#-3E M?Q[9=];M.^-]9P_M^^WF^K=W-S?B\NIOWZYOKK]>?_KM9A^#?V 9YDV/]$^U M ./4>JZ,\+S+1+-2=.J-K+

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�[$ MG;,4&_4H83T+*[[X)]*@%WA!V'>?=LO48.?YH=?NU7:O>'5J7IVCO.CYR QA MJ60&$2G/1<[%"JA)*5N;1LZER^X.EPLO#((WC/>MNKV.?]',MUOS[?ZU?F

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end XML 140 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 141 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 142 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 454 654 1 false 156 0 false 10 false false R1.htm 000010001 - Document - Cover Sheet http://www.greatbatchmedical.com/role/Cover Cover Cover 1 false false R2.htm 000020002 - Document - Audit Information Sheet http://www.greatbatchmedical.com/role/AuditInformation Audit Information Notes 2 false false R3.htm 100010003 - Statement - Consolidated Balance Sheets Sheet http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Uncategorized 3 false false R4.htm 100020004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Cover 4 false false R5.htm 100030005 - Statement - Consolidated Statements of Operations Sheet http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 5 false false R6.htm 100040006 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 6 false false R7.htm 100050007 - Statement - Consolidated Statements of Cash Flows Sheet http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 100060008 - Statement - Consolidated Statement of Stockholders' Equity Sheet http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity Consolidated Statement of Stockholders' Equity Statements 8 false false R9.htm 210011001 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 210041002 - Disclosure - Business Acquisition Sheet http://www.greatbatchmedical.com/role/BusinessAcquisition Business Acquisition Notes 10 false false R11.htm 210121003 - Disclosure - Supplemental Cash Flow Information Sheet http://www.greatbatchmedical.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 11 false false R12.htm 210151004 - Disclosure - Inventories Sheet http://www.greatbatchmedical.com/role/Inventories Inventories Notes 12 false false R13.htm 210181005 - Disclosure - Property, Plant and Equipment, Net Sheet http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNet Property, Plant and Equipment, Net Notes 13 false false R14.htm 210221006 - Disclosure - Goodwill and Other Intangible Assets, Net Sheet http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNet Goodwill and Other Intangible Assets, Net Notes 14 false false R15.htm 210291007 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 15 false false R16.htm 210321008 - Disclosure - Debt Sheet http://www.greatbatchmedical.com/role/Debt Debt Notes 16 false false R17.htm 210421009 - Disclosure - Benefit Plans Sheet http://www.greatbatchmedical.com/role/BenefitPlans Benefit Plans Notes 17 false false R18.htm 210451010 - Disclosure - Stock-Based Compensation Sheet http://www.greatbatchmedical.com/role/StockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 210531011 - Disclosure - Other Operating Expenses Sheet http://www.greatbatchmedical.com/role/OtherOperatingExpenses Other Operating Expenses Notes 19 false false R20.htm 210581012 - Disclosure - Income Taxes Sheet http://www.greatbatchmedical.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 210671013 - Disclosure - Commitments And Contingencies Sheet http://www.greatbatchmedical.com/role/CommitmentsAndContingencies Commitments And Contingencies Notes 21 false false R22.htm 210711014 - Disclosure - Leases Sheet http://www.greatbatchmedical.com/role/Leases Leases Notes 22 false false R23.htm 210781015 - Disclosure - Earnings Per Share Sheet http://www.greatbatchmedical.com/role/EarningsPerShare Earnings Per Share Notes 23 false false R24.htm 210821016 - Disclosure - Stockholders' Equity Sheet http://www.greatbatchmedical.com/role/StockholdersEquity Stockholders' Equity Notes 24 false false R25.htm 210861017 - Disclosure - Financial Instruments and Fair Value Measurements Sheet http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurements Financial Instruments and Fair Value Measurements Notes 25 false false R26.htm 210961018 - Disclosure - Segment and Geographic Information Sheet http://www.greatbatchmedical.com/role/SegmentandGeographicInformation Segment and Geographic Information Notes 26 false false R27.htm 211051019 - Disclosure - Revenue From Contracts With Customers Sheet http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomers Revenue From Contracts With Customers Notes 27 false false R28.htm 211091020 - Disclosure - Discontinued Operations Sheet http://www.greatbatchmedical.com/role/DiscontinuedOperations Discontinued Operations Notes 28 false false R29.htm 211141021 - Disclosure - Schedule II - Valuation and Qualifying Accounts Sheet http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccounts Schedule II - Valuation and Qualifying Accounts Notes 29 false false R30.htm 220022001 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPolicies 30 false false R31.htm 230053001 - Disclosure - Business Acquisition (Tables) Sheet http://www.greatbatchmedical.com/role/BusinessAcquisitionTables Business Acquisition (Tables) Tables http://www.greatbatchmedical.com/role/BusinessAcquisition 31 false false R32.htm 230133002 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://www.greatbatchmedical.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://www.greatbatchmedical.com/role/SupplementalCashFlowInformation 32 false false R33.htm 230163003 - Disclosure - Inventories (Tables) Sheet http://www.greatbatchmedical.com/role/InventoriesTables Inventories (Tables) Tables http://www.greatbatchmedical.com/role/Inventories 33 false false R34.htm 230193004 - Disclosure - Property, Plant and Equipment, Net (Tables) Sheet http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetTables Property, Plant and Equipment, Net (Tables) Tables http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNet 34 false false R35.htm 230233005 - Disclosure - Goodwill and Other Intangible Assets, Net (Tables) Sheet http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetTables Goodwill and Other Intangible Assets, Net (Tables) Tables http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNet 35 false false R36.htm 230303006 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilities 36 false false R37.htm 230333007 - Disclosure - Debt (Tables) Sheet http://www.greatbatchmedical.com/role/DebtTables Debt (Tables) Tables http://www.greatbatchmedical.com/role/Debt 37 false false R38.htm 230463008 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.greatbatchmedical.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.greatbatchmedical.com/role/StockBasedCompensation 38 false false R39.htm 230543009 - Disclosure - Other Operating Expenses (Tables) Sheet http://www.greatbatchmedical.com/role/OtherOperatingExpensesTables Other Operating Expenses (Tables) Tables http://www.greatbatchmedical.com/role/OtherOperatingExpenses 39 false false R40.htm 230593010 - Disclosure - Income Taxes (Tables) Sheet http://www.greatbatchmedical.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.greatbatchmedical.com/role/IncomeTaxes 40 false false R41.htm 230683011 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.greatbatchmedical.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables 41 false false R42.htm 230723012 - Disclosure - Leases (Tables) Sheet http://www.greatbatchmedical.com/role/LeasesTables Leases (Tables) Tables http://www.greatbatchmedical.com/role/Leases 42 false false R43.htm 230793013 - Disclosure - Earnings Per Share (Tables) Sheet http://www.greatbatchmedical.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.greatbatchmedical.com/role/EarningsPerShare 43 false false R44.htm 230833014 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.greatbatchmedical.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.greatbatchmedical.com/role/StockholdersEquity 44 false false R45.htm 230873015 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) Sheet http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables Financial Instruments and Fair Value Measurements (Tables) Tables http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurements 45 false false R46.htm 230973016 - Disclosure - Segment and Geographic Information (Tables) Sheet http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables Segment and Geographic Information (Tables) Tables http://www.greatbatchmedical.com/role/SegmentandGeographicInformation 46 false false R47.htm 231063017 - Disclosure - Revenue From Contracts With Customers (Tables) Sheet http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersTables Revenue From Contracts With Customers (Tables) Tables http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomers 47 false false R48.htm 231103018 - Disclosure - Discontinued Operations (Tables) Sheet http://www.greatbatchmedical.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.greatbatchmedical.com/role/DiscontinuedOperations 48 false false R49.htm 240034001 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies (Narrative) (Details) Details http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies 49 false false R50.htm 240064002 - Disclosure - Business Acquisition (Acquisition of Assets from Oscor Inc Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails Business Acquisition (Acquisition of Assets from Oscor Inc Narrative) (Details) Details http://www.greatbatchmedical.com/role/BusinessAcquisitionTables 50 false false R51.htm 240074003 - Disclosure - Business Acquisition (Allocation Of The Provisional Purchase Price ) (Details) Sheet http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails Business Acquisition (Allocation Of The Provisional Purchase Price ) (Details) Details http://www.greatbatchmedical.com/role/BusinessAcquisitionTables 51 false false R52.htm 240084004 - Disclosure - Business Acquisition (Acquisition of Assets from InoMec Ltd Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails Business Acquisition (Acquisition of Assets from InoMec Ltd Narrative) (Details) Details http://www.greatbatchmedical.com/role/BusinessAcquisitionTables 52 false false R53.htm 240094005 - Disclosure - Business Acquisition (Acquisition of Assets from US BioDesign LLC Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails Business Acquisition (Acquisition of Assets from US BioDesign LLC Narrative) (Details) Details http://www.greatbatchmedical.com/role/BusinessAcquisitionTables 53 false false R54.htm 240104006 - Disclosure - Business Acquisition (Indefinite-Lived Intangible Assets) (Details) Sheet http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails Business Acquisition (Indefinite-Lived Intangible Assets) (Details) Details http://www.greatbatchmedical.com/role/BusinessAcquisitionTables 54 false false R55.htm 240114007 - Disclosure - Business Acquisition ( Pro Forma Information) (Details) Sheet http://www.greatbatchmedical.com/role/BusinessAcquisitionProFormaInformationDetails Business Acquisition ( Pro Forma Information) (Details) Details http://www.greatbatchmedical.com/role/BusinessAcquisitionTables 55 false false R56.htm 240144008 - Disclosure - Supplemental Cash Flow Information (Details) Sheet http://www.greatbatchmedical.com/role/SupplementalCashFlowInformationDetails Supplemental Cash Flow Information (Details) Details http://www.greatbatchmedical.com/role/SupplementalCashFlowInformationTables 56 false false R57.htm 240174009 - Disclosure - Inventories (Details) Sheet http://www.greatbatchmedical.com/role/InventoriesDetails Inventories (Details) Details http://www.greatbatchmedical.com/role/InventoriesTables 57 false false R58.htm 240204010 - Disclosure - Property, Plant and Equipment, Net (Details) Sheet http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails Property, Plant and Equipment, Net (Details) Details http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetTables 58 false false R59.htm 240214011 - Disclosure - Property, Plant and Equipment, Net (Depreciation Expense) (Details) Sheet http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails Property, Plant and Equipment, Net (Depreciation Expense) (Details) Details http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetTables 59 false false R60.htm 240244012 - Disclosure - Goodwill and Other Intangible Assets, Nets (Schedule of Goodwill) (Details) Sheet http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails Goodwill and Other Intangible Assets, Nets (Schedule of Goodwill) (Details) Details http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetTables 60 false false R61.htm 240254013 - Disclosure - Goodwill and Other Intangible Assets, Net (Schedule of Intangible Assets) (Details) Sheet http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails Goodwill and Other Intangible Assets, Net (Schedule of Intangible Assets) (Details) Details http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetTables 61 false false R62.htm 240264014 - Disclosure - Goodwill and Other Intangible Assets, Net (Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails Goodwill and Other Intangible Assets, Net (Narrative) (Details) Details http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetTables 62 false false R63.htm 240274015 - Disclosure - Goodwill and Other Intangible Assets, Net (Amortization Expense by categories) (Details) Sheet http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetAmortizationExpensebycategoriesDetails Goodwill and Other Intangible Assets, Net (Amortization Expense by categories) (Details) Details http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetTables 63 false false R64.htm 240284016 - Disclosure - Goodwill and Other Intangible Assets, Net (Future Amortization Expense) (Details) Sheet http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetFutureAmortizationExpenseDetails Goodwill and Other Intangible Assets, Net (Future Amortization Expense) (Details) Details http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetTables 64 false false R65.htm 240314017 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities (Details) Details http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables 65 false false R66.htm 240344018 - Disclosure - Debt (Schedule of Long-Term Debt) (Details) Sheet http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails Debt (Schedule of Long-Term Debt) (Details) Details http://www.greatbatchmedical.com/role/DebtTables 66 false false R67.htm 240354019 - Disclosure - Debt (Senior Secured Credit Facilities) (Details) Sheet http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails Debt (Senior Secured Credit Facilities) (Details) Details http://www.greatbatchmedical.com/role/DebtTables 67 false false R68.htm 240364020 - Disclosure - Debt (Revolving Credit Facility) (Details) Sheet http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails Debt (Revolving Credit Facility) (Details) Details http://www.greatbatchmedical.com/role/DebtTables 68 false false R69.htm 240374021 - Disclosure - Debt (Term Loan Facilities) (Details) Sheet http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails Debt (Term Loan Facilities) (Details) Details http://www.greatbatchmedical.com/role/DebtTables 69 false false R70.htm 240384022 - Disclosure - Debt (Covenants) (Details) Sheet http://www.greatbatchmedical.com/role/DebtCovenantsDetails Debt (Covenants) (Details) Details http://www.greatbatchmedical.com/role/DebtTables 70 false false R71.htm 240394023 - Disclosure - Debt (Long-term Debt Maturity Schedule) (Details) Sheet http://www.greatbatchmedical.com/role/DebtLongtermDebtMaturityScheduleDetails Debt (Long-term Debt Maturity Schedule) (Details) Details http://www.greatbatchmedical.com/role/DebtTables 71 false false R72.htm 240404024 - Disclosure - Debt (Deferred Financing Fees) (Details) Sheet http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails Debt (Deferred Financing Fees) (Details) Details http://www.greatbatchmedical.com/role/DebtTables 72 false false R73.htm 240414025 - Disclosure - Debt (Deferred Debt Issuance Costs and Discounts) (Details) Sheet http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails Debt (Deferred Debt Issuance Costs and Discounts) (Details) Details http://www.greatbatchmedical.com/role/DebtTables 73 false false R74.htm 240434026 - Disclosure - Benefit Plans (Savings Plan Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/BenefitPlansSavingsPlanNarrativeDetails Benefit Plans (Savings Plan Narrative) (Details) Details http://www.greatbatchmedical.com/role/BenefitPlans 74 false false R75.htm 240444027 - Disclosure - Benefit Plans (Defined Benefit Plans Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/BenefitPlansDefinedBenefitPlansNarrativeDetails Benefit Plans (Defined Benefit Plans Narrative) (Details) Details http://www.greatbatchmedical.com/role/BenefitPlans 75 false false R76.htm 240474028 - Disclosure - Stock-Based Compensation (Narratives) (Details) Sheet http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails Stock-Based Compensation (Narratives) (Details) Details http://www.greatbatchmedical.com/role/StockBasedCompensationTables 76 false false R77.htm 240484029 - Disclosure - Stock-Based Compensation (Components of Stock-Based Compensation Expense) (Details) Sheet http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails Stock-Based Compensation (Components of Stock-Based Compensation Expense) (Details) Details http://www.greatbatchmedical.com/role/StockBasedCompensationTables 77 false false R78.htm 240494030 - Disclosure - Stock-Based Compensation (Weighted-Average Fair Value and Assumptions) (Details) Sheet http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails Stock-Based Compensation (Weighted-Average Fair Value and Assumptions) (Details) Details http://www.greatbatchmedical.com/role/StockBasedCompensationTables 78 false false R79.htm 240504031 - Disclosure - Stock-Based Compensation (Stock Option Activity) (Details) Sheet http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails Stock-Based Compensation (Stock Option Activity) (Details) Details http://www.greatbatchmedical.com/role/StockBasedCompensationTables 79 false false R80.htm 240514032 - Disclosure - Stock-Based Compensation (Exercise of Stock Option) (Details) Sheet http://www.greatbatchmedical.com/role/StockBasedCompensationExerciseofStockOptionDetails Stock-Based Compensation (Exercise of Stock Option) (Details) Details http://www.greatbatchmedical.com/role/StockBasedCompensationTables 80 false false R81.htm 240524033 - Disclosure - Stock-Based Compensation (Restricted Stock and Restricted Stock Units) (Details) Sheet http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails Stock-Based Compensation (Restricted Stock and Restricted Stock Units) (Details) Details http://www.greatbatchmedical.com/role/StockBasedCompensationTables 81 false false R82.htm 240554034 - Disclosure - Other Operating Expenses (Schedule of Other Operating Expenses) (Details) Sheet http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails Other Operating Expenses (Schedule of Other Operating Expenses) (Details) Details http://www.greatbatchmedical.com/role/OtherOperatingExpensesTables 82 false false R83.htm 240564035 - Disclosure - Other Operating Expenses (Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails Other Operating Expenses (Narrative) (Details) Details http://www.greatbatchmedical.com/role/OtherOperatingExpensesTables 83 false false R84.htm 240574036 - Disclosure - Other Operating Expenses (Changes in Accrued Liabilities) (Details) Sheet http://www.greatbatchmedical.com/role/OtherOperatingExpensesChangesinAccruedLiabilitiesDetails Other Operating Expenses (Changes in Accrued Liabilities) (Details) Details http://www.greatbatchmedical.com/role/OtherOperatingExpensesTables 84 false false R85.htm 240604037 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.greatbatchmedical.com/role/IncomeTaxesTables 85 false false R86.htm 240614038 - Disclosure - Income Taxes (Income Before Income Tax Domestic And Foreign) (Details) Sheet http://www.greatbatchmedical.com/role/IncomeTaxesIncomeBeforeIncomeTaxDomesticAndForeignDetails Income Taxes (Income Before Income Tax Domestic And Foreign) (Details) Details http://www.greatbatchmedical.com/role/IncomeTaxesTables 86 false false R87.htm 240624039 - Disclosure - Income Taxes (Provision Benefit of Income Taxes) (Details) Sheet http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails Income Taxes (Provision Benefit of Income Taxes) (Details) Details http://www.greatbatchmedical.com/role/IncomeTaxesTables 87 false false R88.htm 240634040 - Disclosure - Income Taxes (Effect Tax Rate Reconciliation) (Details) Sheet http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails Income Taxes (Effect Tax Rate Reconciliation) (Details) Details http://www.greatbatchmedical.com/role/IncomeTaxesTables 88 false false R89.htm 240644041 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details) Sheet http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails Income Taxes (Deferred Tax Assets and Liabilities) (Details) Details http://www.greatbatchmedical.com/role/IncomeTaxesTables 89 false false R90.htm 240654042 - Disclosure - Income Taxes (Income Tax Carry Forward) (Details) Sheet http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails Income Taxes (Income Tax Carry Forward) (Details) Details http://www.greatbatchmedical.com/role/IncomeTaxesTables 90 false false R91.htm 240664043 - Disclosure - Income Taxes (Unrecognized Tax Benefits) (Details) Sheet http://www.greatbatchmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes (Unrecognized Tax Benefits) (Details) Details http://www.greatbatchmedical.com/role/IncomeTaxesTables 91 false false R92.htm 240694044 - Disclosure - Commitments and Contingencies (Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies (Narrative) (Details) Details http://www.greatbatchmedical.com/role/CommitmentsandContingenciesTables 92 false false R93.htm 240704045 - Disclosure - Commitments and Contingencies (Change in Product Warranty Liability) (Details) Sheet http://www.greatbatchmedical.com/role/CommitmentsandContingenciesChangeinProductWarrantyLiabilityDetails Commitments and Contingencies (Change in Product Warranty Liability) (Details) Details http://www.greatbatchmedical.com/role/CommitmentsandContingenciesTables 93 false false R94.htm 240734046 - Disclosure - Leases (Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/LeasesNarrativeDetails Leases (Narrative) (Details) Details http://www.greatbatchmedical.com/role/LeasesTables 94 false false R95.htm 240744047 - Disclosure - Leases (Schedule of Lease Costs) (Details) Sheet http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails Leases (Schedule of Lease Costs) (Details) Details http://www.greatbatchmedical.com/role/LeasesTables 95 false false R96.htm 240754048 - Disclosure - Leases (Schedule of Operating Lease Liability Maturities) (Details) Sheet http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails Leases (Schedule of Operating Lease Liability Maturities) (Details) Details http://www.greatbatchmedical.com/role/LeasesTables 96 false false R97.htm 240764049 - Disclosure - Leases (Lease Term and Discount Rate) (Details) Sheet http://www.greatbatchmedical.com/role/LeasesLeaseTermandDiscountRateDetails Leases (Lease Term and Discount Rate) (Details) Details http://www.greatbatchmedical.com/role/LeasesTables 97 false false R98.htm 240774050 - Disclosure - Leases (Schedule of Operating Lease Supplemental Cash Flow Information) (Details) Sheet http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseSupplementalCashFlowInformationDetails Leases (Schedule of Operating Lease Supplemental Cash Flow Information) (Details) Details http://www.greatbatchmedical.com/role/LeasesTables 98 false false R99.htm 240804051 - Disclosure - Earnings Per Share (Details) Sheet http://www.greatbatchmedical.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.greatbatchmedical.com/role/EarningsPerShareTables 99 false false R100.htm 240814052 - Disclosure - Earnings Per Share (Antidilutive Securities) (Details) Sheet http://www.greatbatchmedical.com/role/EarningsPerShareAntidilutiveSecuritiesDetails Earnings Per Share (Antidilutive Securities) (Details) Details http://www.greatbatchmedical.com/role/EarningsPerShareTables 100 false false R101.htm 240844053 - Disclosure - Stockholders' Equity (Schedule of Changes in Number of Shares of Common Stock) (Details) Sheet http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails Stockholders' Equity (Schedule of Changes in Number of Shares of Common Stock) (Details) Details http://www.greatbatchmedical.com/role/StockholdersEquityTables 101 false false R102.htm 240854054 - Disclosure - Stockholders' Equity (Schedule of Accumulated Other Comprehensive Income) (Details) Sheet http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails Stockholders' Equity (Schedule of Accumulated Other Comprehensive Income) (Details) Details http://www.greatbatchmedical.com/role/StockholdersEquityTables 102 false false R103.htm 240884055 - Disclosure - Financial Instruments and Fair Value Measurements (Assets and Liabilities Recorded at Fair Value on a Recurring Basis) (Details) Sheet http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails Financial Instruments and Fair Value Measurements (Assets and Liabilities Recorded at Fair Value on a Recurring Basis) (Details) Details http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables 103 false false R104.htm 240894056 - Disclosure - Financial Instruments and Fair Value Measurements (Schedule of Interest Rate Swaps) (Details) Sheet http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails Financial Instruments and Fair Value Measurements (Schedule of Interest Rate Swaps) (Details) Details http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables 104 false false R105.htm 240904057 - Disclosure - Financial Instruments and Fair Value Measurements (Schedule of Foreign Currency Contracts) (Details) Sheet http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails Financial Instruments and Fair Value Measurements (Schedule of Foreign Currency Contracts) (Details) Details http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables 105 false false R106.htm 240914058 - Disclosure - Financial Instruments and Fair Value Measurements (Schedule of Derivative Instruments with Hedge Accounting Designation) (Details) Sheet http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails Financial Instruments and Fair Value Measurements (Schedule of Derivative Instruments with Hedge Accounting Designation) (Details) Details http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables 106 false false R107.htm 240924059 - Disclosure - Financial Instruments and Fair Value Measurements (Narratives) (Details) Sheet http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails Financial Instruments and Fair Value Measurements (Narratives) (Details) Details http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables 107 false false R108.htm 240934060 - Disclosure - Financial Instruments and Fair Value Measurements (Estimated Fair Values for Contingent Consideration) (Details) Sheet http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEstimatedFairValuesforContingentConsiderationDetails Financial Instruments and Fair Value Measurements (Estimated Fair Values for Contingent Consideration) (Details) Details http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables 108 false false R109.htm 240944061 - Disclosure - Financial Instruments and Fair Value Measurements (Contingent Consideration Measurement Inputs) (Details) Sheet http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails Financial Instruments and Fair Value Measurements (Contingent Consideration Measurement Inputs) (Details) Details http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables 109 false false R110.htm 240954062 - Disclosure - Financial Instruments and Fair Value Measurements (Equity Method Investments) (Details) Sheet http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails Financial Instruments and Fair Value Measurements (Equity Method Investments) (Details) Details http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables 110 false false R111.htm 240984063 - Disclosure - Segment and Geographic Information (Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/SegmentandGeographicInformationNarrativeDetails Segment and Geographic Information (Narrative) (Details) Details http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables 111 false false R112.htm 240994064 - Disclosure - Segment and Geographic Information (Sales by Product Lines) (Details) Sheet http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails Segment and Geographic Information (Sales by Product Lines) (Details) Details http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables 112 false false R113.htm 241004065 - Disclosure - Segment and Geographic Information (Sales by Geographic Information) (Details) Sheet http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyGeographicInformationDetails Segment and Geographic Information (Sales by Geographic Information) (Details) Details http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables 113 false false R114.htm 241014066 - Disclosure - Segment and Geographic Information (Significant Customers) (Details) Sheet http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails Segment and Geographic Information (Significant Customers) (Details) Details http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables 114 false false R115.htm 241024067 - Disclosure - Segment and Geographic Information (Schedule of Revenue by Ship To Location) (Details) Sheet http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails Segment and Geographic Information (Schedule of Revenue by Ship To Location) (Details) Details http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables 115 false false R116.htm 241034068 - Disclosure - Segment and Geographic Information (Reconciliation of Segment Information) (Details 1) Sheet http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1 Segment and Geographic Information (Reconciliation of Segment Information) (Details 1) Details http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables 116 false false R117.htm 241044069 - Disclosure - Segment and Geographic Information (Long lived Tangible Assets by Region) (Details) Sheet http://www.greatbatchmedical.com/role/SegmentandGeographicInformationLonglivedTangibleAssetsbyRegionDetails Segment and Geographic Information (Long lived Tangible Assets by Region) (Details) Details http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables 117 false false R118.htm 241074070 - Disclosure - Revenue From Contracts With Customers (Disaggregated Revenue) (Details) Sheet http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails Revenue From Contracts With Customers (Disaggregated Revenue) (Details) Details http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersTables 118 false false R119.htm 241084071 - Disclosure - Revenue From Contracts With Customers (Contract Balances) (Details) Sheet http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersContractBalancesDetails Revenue From Contracts With Customers (Contract Balances) (Details) Details http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersTables 119 false false R120.htm 241114072 - Disclosure - Discontinued Operations (AS&O Business Narrative) (Details) Sheet http://www.greatbatchmedical.com/role/DiscontinuedOperationsASOBusinessNarrativeDetails Discontinued Operations (AS&O Business Narrative) (Details) Details http://www.greatbatchmedical.com/role/DiscontinuedOperationsTables 120 false false R121.htm 241124073 - Disclosure - Discontinued Operations (Income from Discontinued Operations) (Details) Sheet http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails Discontinued Operations (Income from Discontinued Operations) (Details) Details http://www.greatbatchmedical.com/role/DiscontinuedOperationsTables 121 false false R122.htm 241134074 - Disclosure - Discontinued Operations (Cash Flow Information from Discontinued Operations) (Details) Sheet http://www.greatbatchmedical.com/role/DiscontinuedOperationsCashFlowInformationfromDiscontinuedOperationsDetails Discontinued Operations (Cash Flow Information from Discontinued Operations) (Details) Details http://www.greatbatchmedical.com/role/DiscontinuedOperationsTables 122 false false R123.htm 241154075 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details) Sheet http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails Schedule II - Valuation and Qualifying Accounts (Details) Details http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccounts 123 false false R9999.htm Uncategorized Items - gb-20211231.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - gb-20211231.htm Cover 124 false false All Reports Book All Reports gb-20211231.htm gb-20211231.xsd gb-20211231_cal.xml gb-20211231_def.xml gb-20211231_lab.xml gb-20211231_pre.xml itgr-20211231ex211.htm itgr-20211231ex231.htm itgr-20211231ex311.htm itgr-20211231ex312.htm itgr-20211231ex321.htm gb-20211231_g1.jpg gb-20211231_g2.jpg http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 145 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "gb-20211231.htm": { "axisCustom": 4, "axisStandard": 38, "contextCount": 454, "dts": { "calculationLink": { "local": [ "gb-20211231_cal.xml" ] }, "definitionLink": { "local": [ "gb-20211231_def.xml" ] }, "inline": { "local": [ "gb-20211231.htm" ] }, "labelLink": { "local": [ "gb-20211231_lab.xml" ] }, "presentationLink": { "local": [ "gb-20211231_pre.xml" ] }, "schema": { "local": [ "gb-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 937, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 6, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 10 }, "keyCustom": 61, "keyStandard": 593, "memberCustom": 64, "memberStandard": 80, "nsprefix": "gb", "nsuri": "http://www.greatbatchmedical.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000010001 - Document - Cover", "role": "http://www.greatbatchmedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210041002 - Disclosure - Business Acquisition", "role": "http://www.greatbatchmedical.com/role/BusinessAcquisition", "shortName": "Business Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ifa48350f582a46e3b47977137f99e122_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240814052 - Disclosure - Earnings Per Share (Antidilutive Securities) (Details)", "role": "http://www.greatbatchmedical.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "shortName": "Earnings Per Share (Antidilutive Securities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ifa48350f582a46e3b47977137f99e122_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i4a6087408c8648d2aa23e4ae61d4a02d_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240844053 - Disclosure - Stockholders' Equity (Schedule of Changes in Number of Shares of Common Stock) (Details)", "role": "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails", "shortName": "Stockholders' Equity (Schedule of Changes in Number of Shares of Common Stock) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i092bfef6f9384a2cb76b55833ca28965_I20191231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i4a6087408c8648d2aa23e4ae61d4a02d_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240854054 - Disclosure - Stockholders' Equity (Schedule of Accumulated Other Comprehensive Income) (Details)", "role": "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails", "shortName": "Stockholders' Equity (Schedule of Accumulated Other Comprehensive Income) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ia95dd0fd487943babbd34fe52d1fea61_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "id0395201c8694ec4ab8160c45685e331_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ForeignCurrencyContractAssetFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240884055 - Disclosure - Financial Instruments and Fair Value Measurements (Assets and Liabilities Recorded at Fair Value on a Recurring Basis) (Details)", "role": "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails", "shortName": "Financial Instruments and Fair Value Measurements (Assets and Liabilities Recorded at Fair Value on a Recurring Basis) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "id0395201c8694ec4ab8160c45685e331_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ForeignCurrencyContractAssetFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i92a39ca2b1e5467ab0ba6291c57f297d_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeLiabilityNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240894056 - Disclosure - Financial Instruments and Fair Value Measurements (Schedule of Interest Rate Swaps) (Details)", "role": "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails", "shortName": "Financial Instruments and Fair Value Measurements (Schedule of Interest Rate Swaps) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i92a39ca2b1e5467ab0ba6291c57f297d_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeLiabilityNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i32a2b996d0d846d1885feb5bc2a89634_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240904057 - Disclosure - Financial Instruments and Fair Value Measurements (Schedule of Foreign Currency Contracts) (Details)", "role": "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails", "shortName": "Financial Instruments and Fair Value Measurements (Schedule of Foreign Currency Contracts) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i32a2b996d0d846d1885feb5bc2a89634_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i089d592a4e3445b89ef6052b730a5c7c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240914058 - Disclosure - Financial Instruments and Fair Value Measurements (Schedule of Derivative Instruments with Hedge Accounting Designation) (Details)", "role": "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails", "shortName": "Financial Instruments and Fair Value Measurements (Schedule of Derivative Instruments with Hedge Accounting Designation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i089d592a4e3445b89ef6052b730a5c7c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240924059 - Disclosure - Financial Instruments and Fair Value Measurements (Narratives) (Details)", "role": "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "shortName": "Financial Instruments and Fair Value Measurements (Narratives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i4a6087408c8648d2aa23e4ae61d4a02d_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240934060 - Disclosure - Financial Instruments and Fair Value Measurements (Estimated Fair Values for Contingent Consideration) (Details)", "role": "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEstimatedFairValuesforContingentConsiderationDetails", "shortName": "Financial Instruments and Fair Value Measurements (Estimated Fair Values for Contingent Consideration) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i092bfef6f9384a2cb76b55833ca28965_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i97a7015cce0542c583ea36c1180fd8a2_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240944061 - Disclosure - Financial Instruments and Fair Value Measurements (Contingent Consideration Measurement Inputs) (Details)", "role": "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails", "shortName": "Financial Instruments and Fair Value Measurements (Contingent Consideration Measurement Inputs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i7be40e5af77740fbad2f2a438b464920_I20211231", "decimals": "3", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210121003 - Disclosure - Supplemental Cash Flow Information", "role": "http://www.greatbatchmedical.com/role/SupplementalCashFlowInformation", "shortName": "Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240954062 - Disclosure - Financial Instruments and Fair Value Measurements (Equity Method Investments) (Details)", "role": "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails", "shortName": "Financial Instruments and Fair Value Measurements (Equity Method Investments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "div", "gb:BasisOfAccountingAndConsolidationPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240984063 - Disclosure - Segment and Geographic Information (Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationNarrativeDetails", "shortName": "Segment and Geographic Information (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R112": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240994064 - Disclosure - Segment and Geographic Information (Sales by Product Lines) (Details)", "role": "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails", "shortName": "Segment and Geographic Information (Sales by Product Lines) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ic7129833b4ed455c9dba5c0ad8ba4729_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241004065 - Disclosure - Segment and Geographic Information (Sales by Geographic Information) (Details)", "role": "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyGeographicInformationDetails", "shortName": "Segment and Geographic Information (Sales by Geographic Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ic3f466667b144f0f818aa34a933434ae_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9192405bdfc049dca7d716bd5aaa05e1_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241014066 - Disclosure - Segment and Geographic Information (Significant Customers) (Details)", "role": "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails", "shortName": "Segment and Geographic Information (Significant Customers) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ia097bab7fd65457681f65b82a7092cdd_D20210101-20211231", "decimals": "2", "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i68e4ba3423c6413b876e9754234a07b1_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241024067 - Disclosure - Segment and Geographic Information (Schedule of Revenue by Ship To Location) (Details)", "role": "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails", "shortName": "Segment and Geographic Information (Schedule of Revenue by Ship To Location) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i68e4ba3423c6413b876e9754234a07b1_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241034068 - Disclosure - Segment and Geographic Information (Reconciliation of Segment Information) (Details 1)", "role": "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1", "shortName": "Segment and Geographic Information (Reconciliation of Segment Information) (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "gb:UnallocatedOtherExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R117": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241044069 - Disclosure - Segment and Geographic Information (Long lived Tangible Assets by Region) (Details)", "role": "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationLonglivedTangibleAssetsbyRegionDetails", "shortName": "Segment and Geographic Information (Long lived Tangible Assets by Region) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i295ff105c867499fbaa7730ab858d5ef_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "gb:PercentOfRevenueFromContractWithCustomerComparedToTotalRevenue", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241074070 - Disclosure - Revenue From Contracts With Customers (Disaggregated Revenue) (Details)", "role": "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "shortName": "Revenue From Contracts With Customers (Disaggregated Revenue) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "gb:PercentOfRevenueFromContractWithCustomerComparedToTotalRevenue", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R119": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241084071 - Disclosure - Revenue From Contracts With Customers (Contract Balances) (Details)", "role": "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersContractBalancesDetails", "shortName": "Revenue From Contracts With Customers (Contract Balances) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210151004 - Disclosure - Inventories", "role": "http://www.greatbatchmedical.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R120": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i3a8b9961de4845ba932f0a35231261b1_D20181229-20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "gb:ProceedsFromDivestitureOfBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241114072 - Disclosure - Discontinued Operations (AS&O Business Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/DiscontinuedOperationsASOBusinessNarrativeDetails", "shortName": "Discontinued Operations (AS&O Business Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i3a8b9961de4845ba932f0a35231261b1_D20181229-20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "gb:ProceedsFromDivestitureOfBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R121": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241124073 - Disclosure - Discontinued Operations (Income from Discontinued Operations) (Details)", "role": "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails", "shortName": "Discontinued Operations (Income from Discontinued Operations) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ia7d0a804d4e94f8c9c2d83ccf55e0a7e_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R122": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ia7d0a804d4e94f8c9c2d83ccf55e0a7e_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241134074 - Disclosure - Discontinued Operations (Cash Flow Information from Discontinued Operations) (Details)", "role": "http://www.greatbatchmedical.com/role/DiscontinuedOperationsCashFlowInformationfromDiscontinuedOperationsDetails", "shortName": "Discontinued Operations (Cash Flow Information from Discontinued Operations) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ia7d0a804d4e94f8c9c2d83ccf55e0a7e_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R123": { "firstAnchor": { "ancestors": [ "span", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i3a8b9961de4845ba932f0a35231261b1_D20181229-20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "gb:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToCostAndExpenseCustomerBankruptcy", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241154075 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)", "role": "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails", "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i3a8b9961de4845ba932f0a35231261b1_D20181229-20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "gb:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToCostAndExpenseCustomerBankruptcy", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210181005 - Disclosure - Property, Plant and Equipment, Net", "role": "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNet", "shortName": "Property, Plant and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210221006 - Disclosure - Goodwill and Other Intangible Assets, Net", "role": "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNet", "shortName": "Goodwill and Other Intangible Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210291007 - Disclosure - Accrued Expenses and Other Current Liabilities", "role": "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210321008 - Disclosure - Debt", "role": "http://www.greatbatchmedical.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210421009 - Disclosure - Benefit Plans", "role": "http://www.greatbatchmedical.com/role/BenefitPlans", "shortName": "Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210451010 - Disclosure - Stock-Based Compensation", "role": "http://www.greatbatchmedical.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210531011 - Disclosure - Other Operating Expenses", "role": "http://www.greatbatchmedical.com/role/OtherOperatingExpenses", "shortName": "Other Operating Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "000020002 - Document - Audit Information", "role": "http://www.greatbatchmedical.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210581012 - Disclosure - Income Taxes", "role": "http://www.greatbatchmedical.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210671013 - Disclosure - Commitments And Contingencies", "role": "http://www.greatbatchmedical.com/role/CommitmentsAndContingencies", "shortName": "Commitments And Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210711014 - Disclosure - Leases", "role": "http://www.greatbatchmedical.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210781015 - Disclosure - Earnings Per Share", "role": "http://www.greatbatchmedical.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210821016 - Disclosure - Stockholders' Equity", "role": "http://www.greatbatchmedical.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210861017 - Disclosure - Financial Instruments and Fair Value Measurements", "role": "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurements", "shortName": "Financial Instruments and Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210961018 - Disclosure - Segment and Geographic Information", "role": "http://www.greatbatchmedical.com/role/SegmentandGeographicInformation", "shortName": "Segment and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211051019 - Disclosure - Revenue From Contracts With Customers", "role": "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomers", "shortName": "Revenue From Contracts With Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211091020 - Disclosure - Discontinued Operations", "role": "http://www.greatbatchmedical.com/role/DiscontinuedOperations", "shortName": "Discontinued Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211141021 - Disclosure - Schedule II - Valuation and Qualifying Accounts", "role": "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccounts", "shortName": "Schedule II - Valuation and Qualifying Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010003 - Statement - Consolidated Balance Sheets", "role": "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "gb:BasisOfAccountingAndConsolidationPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "220022001 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "gb:BasisOfAccountingAndConsolidationPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230053001 - Disclosure - Business Acquisition (Tables)", "role": "http://www.greatbatchmedical.com/role/BusinessAcquisitionTables", "shortName": "Business Acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230133002 - Disclosure - Supplemental Cash Flow Information (Tables)", "role": "http://www.greatbatchmedical.com/role/SupplementalCashFlowInformationTables", "shortName": "Supplemental Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230163003 - Disclosure - Inventories (Tables)", "role": "http://www.greatbatchmedical.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230193004 - Disclosure - Property, Plant and Equipment, Net (Tables)", "role": "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetTables", "shortName": "Property, Plant and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230233005 - Disclosure - Goodwill and Other Intangible Assets, Net (Tables)", "role": "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetTables", "shortName": "Goodwill and Other Intangible Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230303006 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "role": "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230333007 - Disclosure - Debt (Tables)", "role": "http://www.greatbatchmedical.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230463008 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.greatbatchmedical.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230543009 - Disclosure - Other Operating Expenses (Tables)", "role": "http://www.greatbatchmedical.com/role/OtherOperatingExpensesTables", "shortName": "Other Operating Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020004 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230593010 - Disclosure - Income Taxes (Tables)", "role": "http://www.greatbatchmedical.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230683011 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230723012 - Disclosure - Leases (Tables)", "role": "http://www.greatbatchmedical.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230793013 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.greatbatchmedical.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230833014 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.greatbatchmedical.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230873015 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)", "role": "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables", "shortName": "Financial Instruments and Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230973016 - Disclosure - Segment and Geographic Information (Tables)", "role": "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables", "shortName": "Segment and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231063017 - Disclosure - Revenue From Contracts With Customers (Tables)", "role": "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersTables", "shortName": "Revenue From Contracts With Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231103018 - Disclosure - Discontinued Operations (Tables)", "role": "http://www.greatbatchmedical.com/role/DiscontinuedOperationsTables", "shortName": "Discontinued Operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "gb:BasisOfAccountingAndConsolidationPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240034001 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "INF", "lang": "en-US", "name": "gb:ConcentrationRiskNumberofCustomers", "reportCount": 1, "unique": true, "unitRef": "customer", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030005 - Statement - Consolidated Statements of Operations", "role": "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ibabbd0017ac145beb9f009cb23509c80_I20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "gb:AcquiredIntangibleAssetsMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "usdPerEUR", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240064002 - Disclosure - Business Acquisition (Acquisition of Assets from Oscor Inc Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "shortName": "Business Acquisition (Acquisition of Assets from Oscor Inc Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ibabbd0017ac145beb9f009cb23509c80_I20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "gb:AcquiredIntangibleAssetsMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "usdPerEUR", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240074003 - Disclosure - Business Acquisition (Allocation Of The Provisional Purchase Price ) (Details)", "role": "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails", "shortName": "Business Acquisition (Allocation Of The Provisional Purchase Price ) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "if4335f2d68e84f358429f133fa0a1600_I20211201", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240084004 - Disclosure - Business Acquisition (Acquisition of Assets from InoMec Ltd Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "shortName": "Business Acquisition (Acquisition of Assets from InoMec Ltd Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i1b9391fb28fb43c5853a75b6da0c6a06_I20200219", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240094005 - Disclosure - Business Acquisition (Acquisition of Assets from US BioDesign LLC Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "shortName": "Business Acquisition (Acquisition of Assets from US BioDesign LLC Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ibecbdecc059d43469d7c7758a67c138d_D20191007-20191007", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i2664c7ffd1a4488aa490a9b421332ddb_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240104006 - Disclosure - Business Acquisition (Indefinite-Lived Intangible Assets) (Details)", "role": "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails", "shortName": "Business Acquisition (Indefinite-Lived Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i2664c7ffd1a4488aa490a9b421332ddb_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i117f8997a56f423498194299ccf94737_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240114007 - Disclosure - Business Acquisition ( Pro Forma Information) (Details)", "role": "http://www.greatbatchmedical.com/role/BusinessAcquisitionProFormaInformationDetails", "shortName": "Business Acquisition ( Pro Forma Information) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240144008 - Disclosure - Supplemental Cash Flow Information (Details)", "role": "http://www.greatbatchmedical.com/role/SupplementalCashFlowInformationDetails", "shortName": "Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240174009 - Disclosure - Inventories (Details)", "role": "http://www.greatbatchmedical.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240204010 - Disclosure - Property, Plant and Equipment, Net (Details)", "role": "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails", "shortName": "Property, Plant and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gb:DepreciationExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240214011 - Disclosure - Property, Plant and Equipment, Net (Depreciation Expense) (Details)", "role": "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails", "shortName": "Property, Plant and Equipment, Net (Depreciation Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gb:DepreciationExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040006 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i4a6087408c8648d2aa23e4ae61d4a02d_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240244012 - Disclosure - Goodwill and Other Intangible Assets, Nets (Schedule of Goodwill) (Details)", "role": "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails", "shortName": "Goodwill and Other Intangible Assets, Nets (Schedule of Goodwill) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240254013 - Disclosure - Goodwill and Other Intangible Assets, Net (Schedule of Intangible Assets) (Details)", "role": "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets, Net (Schedule of Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240264014 - Disclosure - Goodwill and Other Intangible Assets, Net (Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "shortName": "Goodwill and Other Intangible Assets, Net (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i510e5e23f49e44118d9eede03c7f420b_D20200101-20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gb:ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240274015 - Disclosure - Goodwill and Other Intangible Assets, Net (Amortization Expense by categories) (Details)", "role": "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetAmortizationExpensebycategoriesDetails", "shortName": "Goodwill and Other Intangible Assets, Net (Amortization Expense by categories) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gb:ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240284016 - Disclosure - Goodwill and Other Intangible Assets, Net (Future Amortization Expense) (Details)", "role": "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetFutureAmortizationExpenseDetails", "shortName": "Goodwill and Other Intangible Assets, Net (Future Amortization Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedBonusesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240314017 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)", "role": "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails", "shortName": "Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedBonusesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240344018 - Disclosure - Debt (Schedule of Long-Term Debt) (Details)", "role": "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "shortName": "Debt (Schedule of Long-Term Debt) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "iff83a51f6e5f4a4f80305e3a39fb4249_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ia04b2d4f75174fd08869ecab71f0558a_I20210902", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240354019 - Disclosure - Debt (Senior Secured Credit Facilities) (Details)", "role": "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails", "shortName": "Debt (Senior Secured Credit Facilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ibb2b706d11a44631aa9f5c50ed2ad779_I20210902", "decimals": "INF", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ia04b2d4f75174fd08869ecab71f0558a_I20210902", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240364020 - Disclosure - Debt (Revolving Credit Facility) (Details)", "role": "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "shortName": "Debt (Revolving Credit Facility) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i33ba7757691846a48b1ead217de59760_I20200713", "decimals": "INF", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i0a97738eaa8f4446bf2ae4c93a582c68_I20211231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DebtWeightedAverageInterestRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240374021 - Disclosure - Debt (Term Loan Facilities) (Details)", "role": "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails", "shortName": "Debt (Term Loan Facilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i814a161b1c094319ab41fdf172ed9247_D20210101-20211231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050007 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i7e2cee97e8804663a814d9935ef3e54b_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "gb:DebtInstrumentCovenantMaximumLeverageRatio", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240384022 - Disclosure - Debt (Covenants) (Details)", "role": "http://www.greatbatchmedical.com/role/DebtCovenantsDetails", "shortName": "Debt (Covenants) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i7e2cee97e8804663a814d9935ef3e54b_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "gb:DebtInstrumentCovenantMaximumLeverageRatio", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240394023 - Disclosure - Debt (Long-term Debt Maturity Schedule) (Details)", "role": "http://www.greatbatchmedical.com/role/DebtLongtermDebtMaturityScheduleDetails", "shortName": "Debt (Long-term Debt Maturity Schedule) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i4a6087408c8648d2aa23e4ae61d4a02d_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240404024 - Disclosure - Debt (Deferred Financing Fees) (Details)", "role": "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails", "shortName": "Debt (Deferred Financing Fees) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gb:ScheduleOfDeferredFinancingCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ia09b6b9abeae44c9aca680ff79e64df9_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "gb:FinancingCostsDeferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240414025 - Disclosure - Debt (Deferred Debt Issuance Costs and Discounts) (Details)", "role": "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "shortName": "Debt (Deferred Debt Issuance Costs and Discounts) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "if8d3f5b2008e49f99bb70b9ee71dae35_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240434026 - Disclosure - Benefit Plans (Savings Plan Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/BenefitPlansSavingsPlanNarrativeDetails", "shortName": "Benefit Plans (Savings Plan Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240444027 - Disclosure - Benefit Plans (Defined Benefit Plans Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/BenefitPlansDefinedBenefitPlansNarrativeDetails", "shortName": "Benefit Plans (Defined Benefit Plans Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240474028 - Disclosure - Stock-Based Compensation (Narratives) (Details)", "role": "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails", "shortName": "Stock-Based Compensation (Narratives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240484029 - Disclosure - Stock-Based Compensation (Components of Stock-Based Compensation Expense) (Details)", "role": "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation (Components of Stock-Based Compensation Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i2a61112b44bc4a3d868b43e7b7b6660a_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240494030 - Disclosure - Stock-Based Compensation (Weighted-Average Fair Value and Assumptions) (Details)", "role": "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails", "shortName": "Stock-Based Compensation (Weighted-Average Fair Value and Assumptions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i2a61112b44bc4a3d868b43e7b7b6660a_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i4a6087408c8648d2aa23e4ae61d4a02d_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240504031 - Disclosure - Stock-Based Compensation (Stock Option Activity) (Details)", "role": "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails", "shortName": "Stock-Based Compensation (Stock Option Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i4a6087408c8648d2aa23e4ae61d4a02d_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ic932b9ed1a6e47ea9984c6c0a1887734_I20181228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060008 - Statement - Consolidated Statement of Stockholders' Equity", "role": "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity", "shortName": "Consolidated Statement of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ic932b9ed1a6e47ea9984c6c0a1887734_I20181228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gb:ScheduleOfStockOptionExerciseInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240514032 - Disclosure - Stock-Based Compensation (Exercise of Stock Option) (Details)", "role": "http://www.greatbatchmedical.com/role/StockBasedCompensationExerciseofStockOptionDetails", "shortName": "Stock-Based Compensation (Exercise of Stock Option) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gb:ScheduleOfStockOptionExerciseInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i2a61112b44bc4a3d868b43e7b7b6660a_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240524033 - Disclosure - Stock-Based Compensation (Restricted Stock and Restricted Stock Units) (Details)", "role": "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails", "shortName": "Stock-Based Compensation (Restricted Stock and Restricted Stock Units) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "id65747ffac934b888d97341bb88d86dd_D20210101-20211231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ib03b0c53a3804e758d62c8f26bea30ab_D20211002-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gb:BusinessCombinationAcquisitionAndIntegrationRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240554034 - Disclosure - Other Operating Expenses (Schedule of Other Operating Expenses) (Details)", "role": "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails", "shortName": "Other Operating Expenses (Schedule of Other Operating Expenses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ib03b0c53a3804e758d62c8f26bea30ab_D20211002-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gb:BusinessCombinationAcquisitionAndIntegrationRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240564035 - Disclosure - Other Operating Expenses (Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails", "shortName": "Other Operating Expenses (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i63437957b2f74330a8fa4df9bd268870_I20200703", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i4a6087408c8648d2aa23e4ae61d4a02d_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240574036 - Disclosure - Other Operating Expenses (Changes in Accrued Liabilities) (Details)", "role": "http://www.greatbatchmedical.com/role/OtherOperatingExpensesChangesinAccruedLiabilitiesDetails", "shortName": "Other Operating Expenses (Changes in Accrued Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i4a6087408c8648d2aa23e4ae61d4a02d_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240604037 - Disclosure - Income Taxes (Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240614038 - Disclosure - Income Taxes (Income Before Income Tax Domestic And Foreign) (Details)", "role": "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeBeforeIncomeTaxDomesticAndForeignDetails", "shortName": "Income Taxes (Income Before Income Tax Domestic And Foreign) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "idf4f5a1870bd44aeb7b6ba0d87deae9d_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240624039 - Disclosure - Income Taxes (Provision Benefit of Income Taxes) (Details)", "role": "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails", "shortName": "Income Taxes (Provision Benefit of Income Taxes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240634040 - Disclosure - Income Taxes (Effect Tax Rate Reconciliation) (Details)", "role": "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails", "shortName": "Income Taxes (Effect Tax Rate Reconciliation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240644041 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details)", "role": "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "shortName": "Income Taxes (Deferred Tax Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210011001 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gb:SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i8cb0b2d58cd24849b098a225172af803_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240654042 - Disclosure - Income Taxes (Income Tax Carry Forward) (Details)", "role": "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails", "shortName": "Income Taxes (Income Tax Carry Forward) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gb:SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i8cb0b2d58cd24849b098a225172af803_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i4a6087408c8648d2aa23e4ae61d4a02d_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240664043 - Disclosure - Income Taxes (Unrecognized Tax Benefits) (Details)", "role": "http://www.greatbatchmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes (Unrecognized Tax Benefits) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ic932b9ed1a6e47ea9984c6c0a1887734_I20181228", "decimals": "-3", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ie1e1d4567be7411f9e324e84cb19ea74_D20201001-20201031", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromLegalSettlements", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240694044 - Disclosure - Commitments and Contingencies (Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "ie1e1d4567be7411f9e324e84cb19ea74_D20201001-20201031", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromLegalSettlements", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i4a6087408c8648d2aa23e4ae61d4a02d_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240704045 - Disclosure - Commitments and Contingencies (Change in Product Warranty Liability) (Details)", "role": "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesChangeinProductWarrantyLiabilityDetails", "shortName": "Commitments and Contingencies (Change in Product Warranty Liability) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "gb:StandardProductWarrantyAccrualIncreaseForWarrantiesIssuedDecreaseForReversals", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "gb:FinanceLeasedAssetGrossAssetsAcquired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240734046 - Disclosure - Leases (Narrative) (Details)", "role": "http://www.greatbatchmedical.com/role/LeasesNarrativeDetails", "shortName": "Leases (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "gb:FinanceLeasedAssetGrossAssetsAcquired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240744047 - Disclosure - Leases (Schedule of Lease Costs) (Details)", "role": "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails", "shortName": "Leases (Schedule of Lease Costs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240754048 - Disclosure - Leases (Schedule of Operating Lease Liability Maturities) (Details)", "role": "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails", "shortName": "Leases (Schedule of Operating Lease Liability Maturities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240764049 - Disclosure - Leases (Lease Term and Discount Rate) (Details)", "role": "http://www.greatbatchmedical.com/role/LeasesLeaseTermandDiscountRateDetails", "shortName": "Leases (Lease Term and Discount Rate) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i58986b08f5b540d58d7cf6c0a583a2c0_I20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240774050 - Disclosure - Leases (Schedule of Operating Lease Supplemental Cash Flow Information) (Details)", "role": "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseSupplementalCashFlowInformationDetails", "shortName": "Leases (Schedule of Operating Lease Supplemental Cash Flow Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240804051 - Disclosure - Earnings Per Share (Details)", "role": "http://www.greatbatchmedical.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gb-20211231.htm", "contextRef": "i9100b2e0a41841fb89e2ee9f54c2983f_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9999": { "firstAnchor": null, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - gb-20211231.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - gb-20211231.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 156, "tag": { "country_CR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COSTA RICA", "terseLabel": "Costa Rica" } } }, "localname": "CR", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "country_IE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IRELAND", "terseLabel": "Ireland" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationLonglivedTangibleAssetsbyRegionDetails" ], "xbrltype": "domainItemType" }, "country_MX": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MEXICO", "terseLabel": "Mexico" } } }, "localname": "MX", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationLonglivedTangibleAssetsbyRegionDetails" ], "xbrltype": "domainItemType" }, "country_PR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PUERTO RICO", "verboseLabel": "Puerto Rico" } } }, "localname": "PR", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S.", "verboseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeBeforeIncomeTaxDomesticAndForeignDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationLonglivedTangibleAssetsbyRegionDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyGeographicInformationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r882", "r883", "r884" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r882", "r883", "r884" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r882", "r883", "r884" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r882", "r883", "r884" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r885" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r880" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r879" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r879" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r879" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r886" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r879" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r879" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r879" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r879" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r909" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r882", "r883", "r884" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r878" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r881" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.greatbatchmedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "gb_ASOBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AS&O Business [Member]", "label": "AS&O Business [Member]", "terseLabel": "AS&O Product Line" } } }, "localname": "ASOBusinessMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsASOBusinessNarrativeDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsCashFlowInformationfromDiscontinuedOperationsDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "gb_AccountsReceivableSaleCostOfSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable Sale, Cost Of Sale", "label": "Accounts Receivable Sale, Cost Of Sale", "terseLabel": "Costs incurred from sale of accounts receivable" } } }, "localname": "AccountsReceivableSaleCostOfSale", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gb_AccumulatedAdjustmentAttributableToParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated Adjustment Attributable To Parent", "label": "Accumulated Adjustment Attributable To Parent [Member]", "terseLabel": "Total Pre-Tax Amount" } } }, "localname": "AccumulatedAdjustmentAttributableToParentMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "gb_AccumulatedOtherComprehensiveIncomeTaxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated Other Comprehensive Income, Tax", "label": "Accumulated Other Comprehensive Income, Tax [Member]", "terseLabel": "Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeTaxMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "gb_AcquiredFiniteLivedIntangibleAssetsWeightedAverageDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired Finite-lived Intangible Assets, Weighted Average Discount Rate", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Discount Rate", "terseLabel": "Weighted Average Discount Rate" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageDiscountRate", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "percentItemType" }, "gb_AcquiredIntangibleAssetsMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired Intangible Assets, Measurement Input", "label": "Acquired Intangible Assets, Measurement Input", "terseLabel": "Measurement input" } } }, "localname": "AcquiredIntangibleAssetsMeasurementInput", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails" ], "xbrltype": "pureItemType" }, "gb_AdvancedSurgicalOrthopedicsandPortableMedicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advanced Surgical, Orthopedics, and Portable Medical [Member]", "label": "Advanced Surgical, Orthopedics, and Portable Medical [Member]", "terseLabel": "Advanced Surgical, Orthopedics & Portable Medical" } } }, "localname": "AdvancedSurgicalOrthopedicsandPortableMedicalMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails" ], "xbrltype": "domainItemType" }, "gb_AllOtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All Other Countries [Member]", "label": "All Other Countries [Member]", "terseLabel": "Rest of world" } } }, "localname": "AllOtherCountriesMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails" ], "xbrltype": "domainItemType" }, "gb_AllOtherCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All Other Customers [Member]", "label": "All Other Customers [Member]", "terseLabel": "All other customers" } } }, "localname": "AllOtherCustomersMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "gb_AnticipatedFutureCostsRemaining": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Anticipated Future Costs Remaining", "label": "Anticipated Future Costs Remaining", "terseLabel": "Anticipated future costs remaining" } } }, "localname": "AnticipatedFutureCostsRemaining", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gb_AssetAcquisitionContingentConsiderationLiabilityPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Contingent Consideration, Liability Paid", "label": "Asset Acquisition, Contingent Consideration, Liability Paid", "terseLabel": "Asset acquisition contingent consideration liability paid" } } }, "localname": "AssetAcquisitionContingentConsiderationLiabilityPaid", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gb_AssetAcquisitionTransactionCostsCapitalized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Transaction Costs Capitalized", "label": "Asset Acquisition, Transaction Costs Capitalized", "terseLabel": "Asset acquisition transaction costs capitalized" } } }, "localname": "AssetAcquisitionTransactionCostsCapitalized", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gb_AuditorInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Auditor Information [Abstract]", "label": "Auditor Information [Abstract]" } } }, "localname": "AuditorInformationAbstract", "nsuri": "http://www.greatbatchmedical.com/20211231", "xbrltype": "stringItemType" }, "gb_BasisOfAccountingAndConsolidationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis Of Accounting And Consolidation, Policy [Policy Text Block]", "label": "Basis Of Accounting And Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "BasisOfAccountingAndConsolidationPolicyPolicyTextBlock", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "gb_BusinessCombinationAcquisitionAndIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Acquisition And Integration Related Costs", "label": "Business Combination, Acquisition And Integration Related Costs", "terseLabel": "Acquisition and integration costs (adjustments)" } } }, "localname": "BusinessCombinationAcquisitionAndIntegrationRelatedCosts", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails" ], "xbrltype": "monetaryItemType" }, "gb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOperatingLeaseAssetsRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Operating Lease Assets, Right Of Use Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Operating Lease Assets, Right Of Use Assets", "terseLabel": "Lease ROU asset, adjustment" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOperatingLeaseAssetsRightOfUseAssets", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-of-use Asset", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-of-use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "gb_CardiacNeuromodulationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardiac Neuromodulation [Member]", "label": "Cardiac Neuromodulation [Member]", "terseLabel": "Cardiac & Neuromodulation" } } }, "localname": "CardiacNeuromodulationMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails" ], "xbrltype": "domainItemType" }, "gb_CardioAndVascularMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardio And Vascular [Member]", "label": "Cardio And Vascular [Member]", "terseLabel": "Cardio & Vascular" } } }, "localname": "CardioAndVascularMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails" ], "xbrltype": "domainItemType" }, "gb_ChineseVentureCapitalFundMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chinese Venture Capital Fund [Member]", "label": "Chinese Venture Capital Fund [Member]", "terseLabel": "Chinese Venture Capital Fund" } } }, "localname": "ChineseVentureCapitalFundMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "domainItemType" }, "gb_ClosingStockPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Closing stock price of entity", "label": "Closing Stock Price", "verboseLabel": "Closing stock price (in dollars per share)" } } }, "localname": "ClosingStockPrice", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails" ], "xbrltype": "perShareItemType" }, "gb_ConcentrationRiskNumberofCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration Risk, Number of Customers", "label": "Concentration Risk, Number of Customers", "terseLabel": "Number of customers" } } }, "localname": "ConcentrationRiskNumberofCustomers", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "gb_CostAndEquityMethodInvestmentsRealizedGainLoss": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This item represents the gain (loss) realized during the period from the sale of investments accounted for under the cost or equity method of accounting and any losses recognized thereon for impairments of other than a temporary nature.", "label": "Cost And Equity Method Investments Realized Gain Loss", "negatedLabel": "(Gain) loss on equity investments, net" } } }, "localname": "CostAndEquityMethodInvestmentsRealizedGainLoss", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "gb_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]", "terseLabel": "Customer A", "verboseLabel": "Customer A" } } }, "localname": "CustomerAMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "gb_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B [Member]", "label": "Customer B [Member]", "terseLabel": "Customer B", "verboseLabel": "Customer B" } } }, "localname": "CustomerBMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "gb_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer C [Member]", "label": "Customer C [Member]", "terseLabel": "Customer C", "verboseLabel": "Customer C" } } }, "localname": "CustomerCMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "gb_CustomerDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer D [Member]", "label": "Customer D [Member]", "terseLabel": "Customer D" } } }, "localname": "CustomerDMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "gb_CustomerEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer E", "label": "Customer E [Member]", "terseLabel": "Customer E" } } }, "localname": "CustomerEMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "gb_DebtInstrumentCovenantAdjustedEBITDAToInterestExpenseRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Covenant Adjusted EBITDA To Interest Expense Ratio", "label": "Debt Instrument Covenant Adjusted EBITDA To Interest Expense Ratio", "terseLabel": "Interest expense ratio" } } }, "localname": "DebtInstrumentCovenantAdjustedEBITDAToInterestExpenseRatio", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails" ], "xbrltype": "pureItemType" }, "gb_DebtInstrumentCovenantMaximumLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Covenant Maximum Leverage Ratio", "label": "Debt Instrument Covenant Maximum Leverage Ratio", "terseLabel": "Net leverage ratio incremental increase option" } } }, "localname": "DebtInstrumentCovenantMaximumLeverageRatio", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails" ], "xbrltype": "pureItemType" }, "gb_DebtInstrumentDiscountPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Discount, Percentage", "label": "Debt Instrument, Discount, Percentage", "terseLabel": "Discount percent" } } }, "localname": "DebtInstrumentDiscountPercentage", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "gb_DebtInstrumentInterestRateFloor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Interest Rate, Floor", "label": "Debt Instrument, Interest Rate, Floor", "terseLabel": "Interest rate floor" } } }, "localname": "DebtInstrumentInterestRateFloor", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "percentItemType" }, "gb_DebtInstrumentUnamortizedDiscountFinancingCostsIncurred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Unamortized Discount, Financing Costs Incurred", "label": "Debt Instrument, Unamortized Discount, Financing Costs Incurred", "terseLabel": "Unamortized discount on TLB Facility, Financing costs incurred" } } }, "localname": "DebtInstrumentUnamortizedDiscountFinancingCostsIncurred", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "monetaryItemType" }, "gb_DebtInstrumentUnamortizedDiscountWriteOffDuringThePeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Unamortized Discount, Write-Off During The Period", "label": "Debt Instrument, Unamortized Discount, Write-Off During The Period", "negatedLabel": "Unamortized discount on TLB Facility, Write-off during the period" } } }, "localname": "DebtInstrumentUnamortizedDiscountWriteOffDuringThePeriod", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "monetaryItemType" }, "gb_DeferredFinanceCostsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Deferred Finance Costs [Roll Forward]", "terseLabel": "Deferred Finance Costs [Roll Forward]" } } }, "localname": "DeferredFinanceCostsRollForward", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "stringItemType" }, "gb_DeferredTaxAssetsOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Operating Lease Liabilities", "label": "Deferred Tax Assets, Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "gb_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Operating Lease Right-Of-Use Assets", "label": "Deferred Tax Liabilities, Operating Lease Right-Of-Use Assets", "negatedTerseLabel": "Operating lease assets" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "gb_DefinedBenefitPlanExpectedFutureBenefitPaymentNextTwelveMonthsThroughYearFive": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months Through Year Five", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months Through Year Five", "terseLabel": "Expected future benefit payments first five years" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentNextTwelveMonthsThroughYearFive", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlansDefinedBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gb_DefinedContributionAndBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Defined Contribution And Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Contribution And Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedContributionAndBenefitPlanDisclosureLineItems", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlansSavingsPlanNarrativeDetails" ], "xbrltype": "stringItemType" }, "gb_DefinedContributionPlanEmployerMatchingContributionAmountMatchedPerDollar": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan, Employer Matching Contribution, Amount Matched Per Dollar", "label": "Defined Contribution Plan, Employer Matching Contribution, Amount Matched Per Dollar", "terseLabel": "Employer matching contribution, per dollar" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionAmountMatchedPerDollar", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlansSavingsPlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gb_DepreciationAndAmortizationIncludingInventoryStepUp": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation And Amortization Including Inventory Step-Up", "label": "Depreciation And Amortization Including Inventory Step-Up", "terseLabel": "Total depreciation and amortization" } } }, "localname": "DepreciationAndAmortizationIncludingInventoryStepUp", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1" ], "xbrltype": "monetaryItemType" }, "gb_DepreciationExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of depreciation expense.", "label": "Depreciation Expense Disclosure [Table Text Block]", "terseLabel": "Schedule of Depreciation Expense" } } }, "localname": "DepreciationExpenseDisclosureTableTextBlock", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "gb_EffectiveIncomeTaxRateReconciliationDeductibleExpenseInExcessOfNondeductibleExpenseShareBasedCompensationCostAmount": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Deductible Expense In Excess Of Nondeductible Expense, Share-Based Compensation Cost, Amount", "label": "Effective Income Tax Rate Reconciliation, Deductible Expense In Excess Of Nondeductible Expense, Share-Based Compensation Cost, Amount", "negatedTerseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductibleExpenseInExcessOfNondeductibleExpenseShareBasedCompensationCostAmount", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "gb_EffectiveIncomeTaxRateReconciliationDeductibleExpenseInExcessOfNondeductibleExpenseShareBasedCompensationCostPercent": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Deductible Expense In Excess Of Nondeductible Expense, Share-Based Compensation Cost, Percent", "label": "Effective Income Tax Rate Reconciliation, Deductible Expense In Excess Of Nondeductible Expense, Share-Based Compensation Cost, Percent", "negatedTerseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductibleExpenseInExcessOfNondeductibleExpenseShareBasedCompensationCostPercent", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "gb_EscrowDrawnDown": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Escrow Drawn Down", "label": "Escrow Drawn Down", "terseLabel": "Drawn down from the escrow" } } }, "localname": "EscrowDrawnDown", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gb_ExpendituresForAdditionsToLongLivedAssetsExcludingThoseAcquiredThroughAcquisition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenditures For Additions To Long-Lived Assets, Excluding Those Acquired Through Acquisition", "label": "Expenditures For Additions To Long-Lived Assets, Excluding Those Acquired Through Acquisition", "terseLabel": "Expenditures for tangible long-lived assets, excluding acquisitions" } } }, "localname": "ExpendituresForAdditionsToLongLivedAssetsExcludingThoseAcquiredThroughAcquisition", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1" ], "xbrltype": "monetaryItemType" }, "gb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyTranslation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Currency Translation", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Currency Translation", "terseLabel": "Foreign currency translation" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyTranslation", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEstimatedFairValuesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "gb_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails": { "order": 5.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Cost", "label": "Finance Lease, Cost", "totalLabel": "Finance lease cost" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "gb_FinanceLeasedAssetGrossAssetsAcquired": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Leased Asset, Gross Assets Acquired", "label": "Finance Leased Asset, Gross Assets Acquired", "terseLabel": "Gross assets acquired" } } }, "localname": "FinanceLeasedAssetGrossAssetsAcquired", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gb_FinancingAndUnamortizedDiscountCostsIncurred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing And Unamortized Discount, Costs Incurred", "label": "Financing And Unamortized Discount, Costs Incurred", "terseLabel": "Total, Financing costs incurred" } } }, "localname": "FinancingAndUnamortizedDiscountCostsIncurred", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "monetaryItemType" }, "gb_FinancingAndUnamortizedDiscountCostsWriteOff": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing And Unamortized Discount Costs, Write-Off", "label": "Financing And Unamortized Discount Costs, Write-Off", "negatedLabel": "Total, Write-off during the period" } } }, "localname": "FinancingAndUnamortizedDiscountCostsWriteOff", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "monetaryItemType" }, "gb_FinancingCostsDeferred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing costs deferred during the period.", "label": "Financing Costs Deferred", "terseLabel": "Financing costs incurred" } } }, "localname": "FinancingCostsDeferred", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "monetaryItemType" }, "gb_FiniteLivedIntangibleAssetsAmortizationExpenseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization expense by expense category", "label": "Finite Lived Intangible Assets Amortization Expense [Axis]", "terseLabel": "Finite Lived Intangible Assets Amortization Expense [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAxis", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetAmortizationExpensebycategoriesDetails" ], "xbrltype": "stringItemType" }, "gb_FiniteLivedIntangibleAssetsAmortizationExpenseDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization Expense by expense type", "label": "Finite Lived Intangible Assets Amortization Expense [Domain]", "terseLabel": "Finite Lived Intangible Assets Amortization Expense [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseDomain", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetAmortizationExpensebycategoriesDetails" ], "xbrltype": "domainItemType" }, "gb_FiniteLivedIntangibleAssetsAmortizationExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization expense by expense category", "label": "Finite Lived Intangible Assets Amortization Expense [Table]", "terseLabel": "Finite Lived Intangible Assets Amortization Expense [Table]" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTable", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetAmortizationExpensebycategoriesDetails" ], "xbrltype": "stringItemType" }, "gb_ForeignExchangeContractMaturingAugustTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Exchange Contract Maturing August Two Thousand Twenty One", "label": "Foreign Exchange Contract Maturing August Two Thousand Twenty One [Member]", "terseLabel": "Foreign Exchange Contract Maturing August 2021" } } }, "localname": "ForeignExchangeContractMaturingAugustTwoThousandTwentyOneMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "gb_ForeignExchangeContractMaturingDecemberTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Exchange Contract Maturing December Two Thousand Twenty One", "label": "Foreign Exchange Contract Maturing December Two Thousand Twenty One [Member]", "terseLabel": "Foreign Exchange Contract Maturing December 2021" } } }, "localname": "ForeignExchangeContractMaturingDecemberTwoThousandTwentyOneMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "gb_ForeignExchangeContractMaturingDecemberTwoThousandTwentyTwoContractOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract One", "label": "Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract One [Member]", "terseLabel": "Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract One" } } }, "localname": "ForeignExchangeContractMaturingDecemberTwoThousandTwentyTwoContractOneMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "gb_ForeignExchangeContractMaturingDecemberTwoThousandTwentyTwoContractThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Three", "label": "Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Three [Member]", "terseLabel": "Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Three" } } }, "localname": "ForeignExchangeContractMaturingDecemberTwoThousandTwentyTwoContractThreeMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "gb_ForeignExchangeContractMaturingDecemberTwoThousandTwentyTwoContractTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Two", "label": "Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Two [Member]", "terseLabel": "Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Two" } } }, "localname": "ForeignExchangeContractMaturingDecemberTwoThousandTwentyTwoContractTwoMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "gb_ForeignExchangeContractMaturingMarchTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Exchange Contract Maturing March Two Thousand Twenty One", "label": "Foreign Exchange Contract Maturing March Two Thousand Twenty One [Member]", "terseLabel": "Foreign Exchange Contract Maturing March 2021" } } }, "localname": "ForeignExchangeContractMaturingMarchTwoThousandTwentyOneMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "gb_ForeignExchangeContractMaturingNovemberTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Exchange Contract Maturing November Two Thousand Twenty One", "label": "Foreign Exchange Contract Maturing November Two Thousand Twenty One [Member]", "terseLabel": "Foreign Exchange Contract Maturing November 2021" } } }, "localname": "ForeignExchangeContractMaturingNovemberTwoThousandTwentyOneMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "gb_ForeignExchangeContractMaturingSeptemberTwoThousandTwentyOneContractOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Exchange Contract Maturing September Two Thousand Twenty One, Contract One", "label": "Foreign Exchange Contract Maturing September Two Thousand Twenty One, Contract One [Member]", "terseLabel": "Foreign Exchange Contract Maturing September 2021, Contract One" } } }, "localname": "ForeignExchangeContractMaturingSeptemberTwoThousandTwentyOneContractOneMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "gb_ForeignExchangeContractMaturingSeptemberTwoThousandTwentyOneContractTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Exchange Contract Maturing September Two Thousand Twenty One, Contract Two", "label": "Foreign Exchange Contract Maturing September Two Thousand Twenty One, Contract Two [Member]", "terseLabel": "Foreign Exchange Contract Maturing September 2021, Contract Two" } } }, "localname": "ForeignExchangeContractMaturingSeptemberTwoThousandTwentyOneContractTwoMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "gb_ForeignTaxCreditCarryforwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Tax Credit Carryforward [Member]", "label": "Foreign Tax Credit Carryforward [Member]", "terseLabel": "Foreign tax credits" } } }, "localname": "ForeignTaxCreditCarryforwardMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "domainItemType" }, "gb_ITGRTermLoanATLAFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ITGRTerm Loan A T L A Facility", "label": "ITGRTerm Loan A T L A Facility [Member]", "terseLabel": "ITGRTerm Loan A T L A Facility" } } }, "localname": "ITGRTermLoanATLAFacilityMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails" ], "xbrltype": "domainItemType" }, "gb_IncomeBeforeTaxComponentsByGeographicRegionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by geographic region of income before income taxes.", "label": "Income Before Tax Components by Geographic Region [Axis]", "terseLabel": "Income Before Tax Components by Geographic Region [Axis]" } } }, "localname": "IncomeBeforeTaxComponentsByGeographicRegionAxis", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeBeforeIncomeTaxDomesticAndForeignDetails" ], "xbrltype": "stringItemType" }, "gb_IncomeBeforeTaxComponentsByGeographicRegionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of income before income taxes by geographic region.", "label": "Income Before Tax Components by Geographic Region [Domain]", "terseLabel": "Income Before Tax Components by Geographic Region [Domain]" } } }, "localname": "IncomeBeforeTaxComponentsByGeographicRegionDomain", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeBeforeIncomeTaxDomesticAndForeignDetails" ], "xbrltype": "domainItemType" }, "gb_IncomeBeforeTaxComponentsByGeographicRegionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Table presenting income before taxes by geographic region", "label": "Income Before Tax Components by Geographic Region [Table]", "terseLabel": "Income Before Tax Components by Geographic Region [Table]" } } }, "localname": "IncomeBeforeTaxComponentsByGeographicRegionTable", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeBeforeIncomeTaxDomesticAndForeignDetails" ], "xbrltype": "stringItemType" }, "gb_IncomeTaxDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Income Tax Disclosure [Line Items]", "terseLabel": "Income Tax Disclosure [Line Items]" } } }, "localname": "IncomeTaxDisclosureLineItems", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeBeforeIncomeTaxDomesticAndForeignDetails" ], "xbrltype": "stringItemType" }, "gb_IncreaseDecreaseInContractWithCustomerAssetNetOfForeignCurrency": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Contract With Customer, Asset, Net Of Foreign Currency", "label": "Increase (Decrease) In Contract With Customer, Asset, Net Of Foreign Currency", "terseLabel": "Increase in contract assets" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAssetNetOfForeignCurrency", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "gb_InoMecLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "InoMec Ltd [Member]", "label": "InoMec Ltd [Member]", "terseLabel": "InoMec Ltd" } } }, "localname": "InoMecLtdMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_InterestRateSwapMaturingJuneTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Maturing June Two Thousand Twenty Three", "label": "Interest Rate Swap Maturing June Two Thousand Twenty Three [Member]", "terseLabel": "Interest Rate Swap Maturing June 2023" } } }, "localname": "InterestRateSwapMaturingJuneTwoThousandTwentyThreeMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "gb_InternationalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "International Jurisdiction [Member]", "terseLabel": "International" } } }, "localname": "InternationalJurisdictionMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "domainItemType" }, "gb_InternationalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "International [Member]", "terseLabel": "International" } } }, "localname": "InternationalMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeBeforeIncomeTaxDomesticAndForeignDetails" ], "xbrltype": "domainItemType" }, "gb_LakeRegionMedicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lake Region Medical [Member]", "label": "Lake Region Medical [Member]", "terseLabel": "Lake Region Medical" } } }, "localname": "LakeRegionMedicalMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_LondonInterbankOfferedRateOneMonthLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "London Interbank Offered Rate One - Month (LIBOR)", "label": "London Interbank Offered Rate One - Month (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate One - Month (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateOneMonthLIBORMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "gb_ManufacturingAlignmentToSupportGrowthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing Alignment To Support Growth [Member]", "label": "Manufacturing Alignment To Support Growth [Member]", "terseLabel": "Manufacturing alignment to support growth" } } }, "localname": "ManufacturingAlignmentToSupportGrowthMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails" ], "xbrltype": "domainItemType" }, "gb_MeasurementInputAnnualAttritionRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Annual Attrition Rate", "label": "Measurement Input, Annual Attrition Rate [Member]", "terseLabel": "Measurement Input, Annual Attrition Rate" } } }, "localname": "MeasurementInputAnnualAttritionRateMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_MeasurementInputRevenueVolatilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Revenue Volatility", "label": "Measurement Input, Revenue Volatility [Member]", "terseLabel": "Revenue\u00a0volatility" } } }, "localname": "MeasurementInputRevenueVolatilityMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails" ], "xbrltype": "domainItemType" }, "gb_MeasurementInputRoyaltyRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Royalty Rate", "label": "Measurement Input, Royalty Rate [Member]", "terseLabel": "Measurement Input, Royalty Rate" } } }, "localname": "MeasurementInputRoyaltyRateMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_MedicalSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Segment [Member]", "label": "Medical Segment [Member]", "terseLabel": "Medical" } } }, "localname": "MedicalSegmentMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "gb_NewRevolvingCreditFacility2015Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Revolving Credit Facility 2015 [Member]", "label": "New Revolving Credit Facility 2015 [Member]", "terseLabel": "New Revolving Credit Facility 2015" } } }, "localname": "NewRevolvingCreditFacility2015Member", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "gb_NonCashChargesRelatedToCustomerBankruptcy": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-Cash Charges Related To Customer Bankruptcy", "label": "Non-Cash Charges Related To Customer Bankruptcy", "terseLabel": "Non-cash (gains) charges related to customer bankruptcy" } } }, "localname": "NonCashChargesRelatedToCustomerBankruptcy", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "gb_NonCashCostAndEquityMethodInvestmentsRealizedGainLoss": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-cash portion of cost and equity method investments realized gain loss", "label": "Non-Cash Cost And Equity Method Investments Realized Gain Loss", "negatedLabel": "Non-cash (gain) loss on equity investments" } } }, "localname": "NonCashCostAndEquityMethodInvestmentsRealizedGainLoss", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "gb_NonMedicalSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Medical Segment [Member]", "label": "Non-Medical Segment [Member]", "terseLabel": "Non-Medical" } } }, "localname": "NonMedicalSegmentMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "gb_NonmarketableEquitySecurities": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_EquityMethodInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-marketable Equity Securities", "label": "Non-marketable Equity Securities", "terseLabel": "Non-marketable equity securities" } } }, "localname": "NonmarketableEquitySecurities", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "gb_NumberOfFacilitiesLeaseTermsExtended": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Facilities, Lease Terms Extended", "label": "Number Of Facilities, Lease Terms Extended", "terseLabel": "Number of facilities in which lease terms were extended" } } }, "localname": "NumberOfFacilitiesLeaseTermsExtended", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "gb_OfficeAndManufacturingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office And Manufacturing Facilities", "label": "Office And Manufacturing Facilities [Member]", "terseLabel": "Office And Manufacturing Facilities" } } }, "localname": "OfficeAndManufacturingFacilitiesMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_OperatingLeaseRightOfUseAssetAmortization": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Right-Of-Use Asset, Amortization", "label": "Operating Lease, Right-Of-Use Asset, Amortization", "terseLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortization", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "gb_OperationalExcellenceInitiativesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operational Excellence Initiatives", "label": "Operational Excellence Initiatives [Member]", "terseLabel": "Operational Excellence Initiatives" } } }, "localname": "OperationalExcellenceInitiativesMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails" ], "xbrltype": "domainItemType" }, "gb_OperationalExcellenceInitiativesTwoThousandTwentyOneInitiativesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operational Excellence Initiatives Two Thousand Twenty One Initiatives", "label": "Operational Excellence Initiatives Two Thousand Twenty One Initiatives [Member]", "terseLabel": "Operational Excellence Initiatives Two Thousand Twenty One Initiatives" } } }, "localname": "OperationalExcellenceInitiativesTwoThousandTwentyOneInitiativesMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_OscorIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oscor Inc", "label": "Oscor Inc [Member]", "terseLabel": "Oscor Inc" } } }, "localname": "OscorIncMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionProFormaInformationDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_OtherOperatingExpenseNetDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Operating expense net domain", "label": "Other Operating Expense Net [Domain]", "terseLabel": "Other Operating Expense Net [Domain]" } } }, "localname": "OtherOperatingExpenseNetDomain", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_OtherOperatingExpensesNetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The allocation (or location) of expense to (in) other operating expenses, net.", "label": "Other Operating Expenses, net [Member]", "terseLabel": "OOE" } } }, "localname": "OtherOperatingExpensesNetMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "gb_OtherOperatingExpensesNetTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Table showing components of Other Operating Expenses, net", "label": "Other Operating Expenses Net [Table]", "terseLabel": "Other Operating Expenses Net [Table]" } } }, "localname": "OtherOperatingExpensesNetTable", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails" ], "xbrltype": "stringItemType" }, "gb_OtherOperatingIncomeExpenseDetailLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Operating Income Expense Detail [Line Items]", "terseLabel": "Other Operating Income Expense Detail [Line Items]" } } }, "localname": "OtherOperatingIncomeExpenseDetailLineItems", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails" ], "xbrltype": "stringItemType" }, "gb_PaymentForEmploymentTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment For Employment Taxes", "label": "Payment For Employment Taxes", "terseLabel": "Payment for employment taxes" } } }, "localname": "PaymentForEmploymentTaxes", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gb_PercentOfRevenueFromContractWithCustomerComparedToTotalRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent Of Revenue From Contract With Customer Compared To Total Revenue", "label": "Percent Of Revenue From Contract With Customer Compared To Total Revenue", "terseLabel": "Percent of revenue from contract with customer compared to total revenue" } } }, "localname": "PercentOfRevenueFromContractWithCustomerComparedToTotalRevenue", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails" ], "xbrltype": "percentItemType" }, "gb_PerformanceVestedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance-Vested Restricted Stock Units", "label": "Performance-Vested Restricted Stock Units [Member]", "terseLabel": "Performance-vested restricted stock units" } } }, "localname": "PerformanceVestedRestrictedStockUnitsMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "gb_ProceedsFromDivestitureOfBusinessesGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Divestiture Of Businesses, Gross", "label": "Proceeds From Divestiture Of Businesses, Gross", "terseLabel": "Proceeds from sale of discontinued operations, gross" } } }, "localname": "ProceedsFromDivestitureOfBusinessesGross", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsASOBusinessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gb_PurchasedTechnologyTradenamesAndPatentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired in a business combination or other transaction, Purchased technology, tradenames and patents.", "label": "Purchased Technology, Tradenames And Patents [Member]", "terseLabel": "Purchased technology, tradenames and patents" } } }, "localname": "PurchasedTechnologyTradenamesAndPatentsMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "gb_RSUsAndPRSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RSUs and PRSUs", "label": "RSUs and PRSUs [Member]", "terseLabel": "RSUs and PRSUs" } } }, "localname": "RSUsAndPRSUsMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "gb_ReconciliationOfDepreciationAndAmortizationByReportableSegmentToConsolidatedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Reconciliation Of Depreciation And Amortization By Reportable Segment To Consolidated [Table Text Block]", "terseLabel": "Schedule of Segment Depreciation and Amortization" } } }, "localname": "ReconciliationOfDepreciationAndAmortizationByReportableSegmentToConsolidatedTableTextBlock", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "gb_RestOfWorldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rest Of World [Member]", "label": "Rest Of World [Member]", "terseLabel": "Rest of world" } } }, "localname": "RestOfWorldMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationLonglivedTangibleAssetsbyRegionDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "gb_RestrictedStockAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Restricted Stock and Restricted Stock Units [Member]", "terseLabel": "Restricted Stock and Restricted Stock Units" } } }, "localname": "RestrictedStockAndRestrictedStockUnitsMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "gb_RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure relating to restricted stock and restricted stock units that are performance-based vesting", "label": "Restricted Stock And Restricted Stock Units Performance Based [Member]", "terseLabel": "Performance Based Restricted Stock And Restricted Stock Units" } } }, "localname": "RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_RestrictedStockAndRestrictedStockUnitsTimeBasedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure relating to restricted stock and restricted stock units that are time-based vesting", "label": "Restricted Stock And Restricted Stock Units Time Based [Member]", "terseLabel": "Restricted Stock And Restricted Stock Units Time Based" } } }, "localname": "RestrictedStockAndRestrictedStockUnitsTimeBasedMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "gb_RestrictedStockAndUnitAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The allocation of expense to restricted stock and restricted stock units.", "label": "Restricted Stock And Unit Awards [Member]", "terseLabel": "Restricted Stock And Unit Awards" } } }, "localname": "RestrictedStockAndUnitAwardsMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_RestrictedStockAndUnitsTypeOfVestingAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Time based vesting versus Performance based vesting", "label": "Restricted Stock And Units Type Of Vesting [Axis]", "terseLabel": "Restricted Stock And Units Type Of Vesting [Axis]" } } }, "localname": "RestrictedStockAndUnitsTypeOfVestingAxis", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "gb_RestrictedStockAndUnitsTypeOfVestingDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Time based vesting versus Performance based vesting", "label": "Restricted Stock And Units Type Of Vesting [Domain]", "terseLabel": "Restricted Stock And Units Type Of Vesting [Domain]" } } }, "localname": "RestrictedStockAndUnitsTypeOfVestingDomain", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "gb_RestrictedStockAndUnitsTypeOfVestingTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Time based vesting versus Performance based vesting", "label": "Restricted Stock And Units Type Of Vesting [Table]", "terseLabel": "Restricted Stock And Units Type Of Vesting [Table]" } } }, "localname": "RestrictedStockAndUnitsTypeOfVestingTable", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "gb_RestructuringAndRelatedActivitiesCapitalExpendituresIncurredToDate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total capital expenditures incurred to date in connection with restructuring and related activities", "label": "Restructuring And Related Activities, Capital Expenditures Incurred To Date", "terseLabel": "Capital investments expended" } } }, "localname": "RestructuringAndRelatedActivitiesCapitalExpendituresIncurredToDate", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gb_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToCostAndExpenseCustomerBankruptcy": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Cost And Expense, Customer Bankruptcy", "label": "SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Cost And Expense, Customer Bankruptcy", "terseLabel": "SEC Schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense, customer bankruptcy" } } }, "localname": "SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToCostAndExpenseCustomerBankruptcy", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "gb_SalePurchaseOfCostEquityMethodInvestments": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net (proceeds from sale) purchase of cost and equity method investments, net", "label": "Sale Purchase Of Cost Equity Method Investments", "negatedLabel": "Purchase of equity investments" } } }, "localname": "SalePurchaseOfCostEquityMethodInvestments", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "gb_ScheduleOfAssetsUsefulLifeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Schedule of Assets Useful Life [Line Items]", "terseLabel": "Schedule of Assets Useful Life [Line Items]" } } }, "localname": "ScheduleOfAssetsUsefulLifeLineItems", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "gb_ScheduleOfAssetsUsefulLifeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Schedule of Assets Useful Life [Table]", "terseLabel": "Schedule of Assets Useful Life [Table]" } } }, "localname": "ScheduleOfAssetsUsefulLifeTable", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "gb_ScheduleOfDeferredFinancingCostsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of deferred financing costs", "label": "Schedule of Deferred Financing Costs [Table Text Block]", "terseLabel": "Schedule of Deferred Financing Costs" } } }, "localname": "ScheduleOfDeferredFinancingCostsTableTextBlock", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "gb_ScheduleOfDefinedContributionAndBenefitPlanDisclosuresTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Schedule Of Defined Contribution And Benefit Plan Disclosures [Table]", "terseLabel": "Schedule Of Defined Contribution And Benefit Plan Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedContributionAndBenefitPlanDisclosuresTable", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlansSavingsPlanNarrativeDetails" ], "xbrltype": "stringItemType" }, "gb_ScheduleOfExpendituresForTangibleLonglivedAssetsBySegmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Schedule Of Expenditures For Tangible Longlived Assets By Segment [Table Text Block]", "terseLabel": "Schedule of Expenditures for Tangible Long-Lived Assets, Excluding Acquisitions" } } }, "localname": "ScheduleOfExpendituresForTangibleLonglivedAssetsBySegmentTableTextBlock", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "gb_ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of amortization expense for finite-lived intangible assets", "label": "Schedule of Finite-Lived Intangible Assets, Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Amortization Expense" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "gb_ScheduleOfLongLivedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas.", "label": "Schedule Of Long Lived Assets [Table]", "terseLabel": "Schedule Of Long Lived Assets [Table]" } } }, "localname": "ScheduleOfLongLivedAssetsTable", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationLonglivedTangibleAssetsbyRegionDetails" ], "xbrltype": "stringItemType" }, "gb_ScheduleOfStockOptionExerciseInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting information relating to the exercise of stock options during the period.", "label": "Schedule Of Stock Option Exercise Information [Table Text Block]", "terseLabel": "Schedule Of Stock Option Exercise Information" } } }, "localname": "ScheduleOfStockOptionExerciseInformationTableTextBlock", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "gb_ScheduleofSharebasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Share-based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]", "label": "Schedule of Share-based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions" } } }, "localname": "ScheduleofSharebasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "gb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageIlliquidityDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Weighted Average Illiquidity Discount", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Weighted Average Illiquidity Discount", "terseLabel": "Illiquidity discount percent" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageIlliquidityDiscount", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails" ], "xbrltype": "percentItemType" }, "gb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodNetofForfeituresAndRSUVesting": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures And RSU Vesting", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures And RSU Vesting", "terseLabel": "Vesting of RSUs, net of shares withheld to cover taxes (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodNetofForfeituresAndRSUVesting", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails" ], "xbrltype": "sharesItemType" }, "gb_SimilarIdentifiableAssetsRelatingToALicenseToUseTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Similar Identifiable Assets Relating To A License To Use Technology", "label": "Similar Identifiable Assets Relating To A License To Use Technology [Member]", "terseLabel": "Similar Identifiable Assets Relating To A License To Use Technology" } } }, "localname": "SimilarIdentifiableAssetsRelatingToALicenseToUseTechnologyMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_StandardProductWarrantyAccrualIncreaseForWarrantiesIssuedDecreaseForReversals": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Standard Product Warranty Accrual, Increase For Warranties Issued, (Decrease) For Reversals", "label": "Standard Product Warranty Accrual, Increase For Warranties Issued, (Decrease) For Reversals", "terseLabel": "Additions to warranty reserve, net of reversals" } } }, "localname": "StandardProductWarrantyAccrualIncreaseForWarrantiesIssuedDecreaseForReversals", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesChangeinProductWarrantyLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "gb_StateTaxCreditCarryforwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "State Tax Credit Carryforward", "label": "State Tax Credit Carryforward [Member]", "terseLabel": "State tax credits" } } }, "localname": "StateTaxCreditCarryforwardMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "domainItemType" }, "gb_StatementOperatingExpensesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expenses reported in a statement", "label": "Statement, Operating Expenses [Axis]", "terseLabel": "Statement, Operating Expenses [Axis]" } } }, "localname": "StatementOperatingExpensesAxis", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "stringItemType" }, "gb_StockIssuedDuringPeriodValueStockOptionsExercisedOrVested": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Stock Options Exercised Or Vested", "label": "Stock Issued During Period, Value, Stock Options Exercised Or Vested", "terseLabel": "Stock awards exercised or vested" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedOrVested", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "gb_StrategicReorganizationAndAlignmentInitiativesTwoThousandTwentyOneInitiativesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strategic Reorganization And Alignment Initiatives Two Thousand Twenty One Initiatives", "label": "Strategic Reorganization And Alignment Initiatives Two Thousand Twenty One Initiatives [Member]", "terseLabel": "Strategic Reorganization And Alignment Initiatives Two Thousand Twenty One Initiatives" } } }, "localname": "StrategicReorganizationAndAlignmentInitiativesTwoThousandTwentyOneInitiativesMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_StrategicReorganizationAndAlignmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strategic Reorganization And Alignment [Member]", "label": "Strategic Reorganization And Alignment [Member]", "terseLabel": "Strategic reorganization and alignment" } } }, "localname": "StrategicReorganizationAndAlignmentMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesChangesinAccruedLiabilitiesDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails" ], "xbrltype": "domainItemType" }, "gb_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards and tax credit carryforwards, including an assessment of the likelihood of utilization.", "label": "Summary of Operating Loss and Tax Credit Carryforwards [Table Text Block]", "terseLabel": "Schedule of Operating Loss and Tax Credit Carryforwards" } } }, "localname": "SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "gb_SupplierFinancingArrangementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplier Financing Arrangements, Policy", "label": "Supplier Financing Arrangements, Policy [Policy Text Block]", "terseLabel": "Supplier Financing Arrangements" } } }, "localname": "SupplierFinancingArrangementsPolicyPolicyTextBlock", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "gb_SwinglineLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swingline Loans [Member]", "label": "Swingline Loans [Member]", "terseLabel": "Swingline Loans" } } }, "localname": "SwinglineLoansMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "gb_TechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Technology [Member]", "label": "Technology [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_TermLoanATLAFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan A (TLA) Facility [Member]", "label": "Term Loan A (TLA) Facility [Member]", "terseLabel": "Senior secured term loan A" } } }, "localname": "TermLoanATLAFacilityMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "domainItemType" }, "gb_TermLoanAndSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan And Senior Notes [Member]", "label": "Term Loan And Senior Notes [Member]", "terseLabel": "Term Loan And Senior Notes" } } }, "localname": "TermLoanAndSeniorNotesMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "domainItemType" }, "gb_TermLoanBTLBFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan B (TLB) Facility [Member]", "label": "Term Loan B (TLB) Facility [Member]", "terseLabel": "Senior secured term loan B" } } }, "localname": "TermLoanBTLBFacilityMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "domainItemType" }, "gb_TimeVestedStockOptionsRestrictedStockAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Time-Vested Stock Options, Restricted Stock And Restricted Stock Units", "label": "Time-Vested Stock Options, Restricted Stock And Restricted Stock Units [Member]", "terseLabel": "Time-vested stock options, restricted stock and restricted stock units" } } }, "localname": "TimeVestedStockOptionsRestrictedStockAndRestrictedStockUnitsMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "gb_TopCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Top Customers", "label": "Top Customers [Member]", "terseLabel": "Top Customers" } } }, "localname": "TopCustomersMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails" ], "xbrltype": "domainItemType" }, "gb_TwoThousandTwentyTwoRestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Two Restructuring Plan", "label": "Two Thousand Twenty Two Restructuring Plan [Member]", "terseLabel": "Operational excellence initiatives" } } }, "localname": "TwoThousandTwentyTwoRestructuringPlanMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesChangesinAccruedLiabilitiesDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_USBioDesignLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US BioDesign LLC [Member]", "label": "US BioDesign LLC [Member]", "terseLabel": "US BioDesign LLC" } } }, "localname": "USBioDesignLLCMember", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gb_UnallocatedOtherExpense": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total expenses other than operating not allocated to business segments", "label": "Unallocated Other Expense", "negatedTerseLabel": "Unallocated other income (expense), net" } } }, "localname": "UnallocatedOtherExpense", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1" ], "xbrltype": "monetaryItemType" }, "gb_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions", "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions", "negatedTerseLabel": "Additions (reductions) related to prior period tax returns" } } }, "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions", "nsuri": "http://www.greatbatchmedical.com/20211231", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r173", "r239", "r252", "r253", "r254", "r255", "r257", "r259", "r263", "r374", "r375", "r376", "r377", "r378", "r379", "r381", "r382", "r384", "r386", "r387", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908" ], "lang": { "en-us": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r173", "r239", "r252", "r253", "r254", "r255", "r257", "r259", "r263", "r374", "r375", "r376", "r377", "r378", "r379", "r381", "r382", "r384", "r386", "r387", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908" ], "lang": { "en-us": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r186", "r193", "r199", "r291", "r560", "r561", "r562", "r600", "r601", "r686", "r689", "r691", "r692", "r912" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r186", "r193", "r199", "r291", "r560", "r561", "r562", "r600", "r601", "r686", "r689", "r691", "r692", "r912" ], "lang": { "en-us": { "role": { "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r186", "r193", "r199", "r291", "r560", "r561", "r562", "r600", "r601", "r686", "r689", "r691", "r692", "r912" ], "lang": { "en-us": { "role": { "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Person serving on board of directors.", "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r269", "r475", "r481", "r830" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]", "verboseLabel": "Major Customers [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r392", "r430", "r517", "r519", "r768", "r769", "r770", "r771", "r772", "r773", "r775", "r827", "r831", "r876", "r877" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlansSavingsPlanNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r392", "r430", "r517", "r519", "r768", "r769", "r770", "r771", "r772", "r773", "r775", "r827", "r831", "r876", "r877" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r269", "r475", "r481", "r830" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]", "verboseLabel": "Name of Major Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r265", "r475", "r479", "r777", "r826", "r828" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r265", "r475", "r479", "r777", "r826", "r828" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r392", "r430", "r488", "r517", "r519", "r768", "r769", "r770", "r771", "r772", "r773", "r775", "r827", "r831", "r876", "r877" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlansSavingsPlanNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r392", "r430", "r488", "r517", "r519", "r768", "r769", "r770", "r771", "r772", "r773", "r775", "r827", "r831", "r876", "r877" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlansSavingsPlanNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r181", "r897" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "Schedule II - Valuation and Qualifying Accounts" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccounts" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r266", "r267", "r475", "r480", "r829", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r887", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationLonglivedTangibleAssetsbyRegionDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyGeographicInformationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r266", "r267", "r475", "r480", "r829", "r861", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r887", "r888" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationLonglivedTangibleAssetsbyRegionDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyGeographicInformationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r271", "r761" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2021-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r174", "r175", "r176", "r179", "r180", "r897" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r768", "r770", "r773", "r876", "r877" ], "lang": { "en-us": { "role": { "documentation": "Average of a range of values, calculated with consideration of proportional relevance.", "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r187", "r188", "r189", "r190", "r277", "r278", "r288", "r289", "r290", "r291", "r292", "r293", "r373", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r600", "r601", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r760", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r910", "r911", "r912", "r913", "r914" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities [Abstract]", "terseLabel": "Accounts Payable and Accrued Liabilities [Abstract]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r69", "r764" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r862" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r31", "r49", "r272", "r273" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, net of provision for credit losses of $0.1 million and $0.2 million as of December 31, 2021 and 2020, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableSale": { "auth_ref": [ "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease from sale of accounts receivable.", "label": "Accounts Receivable, Sale", "terseLabel": "Sale of accounts receivable" } } }, "localname": "AccountsReceivableSale", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r35", "r36", "r74" ], "calculation": { "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Profit sharing and bonuses" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrentAndNoncurrent": { "auth_ref": [ "r789", "r814" ], "calculation": { "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.", "label": "Accrued Bonuses", "terseLabel": "Salaries and benefits" } } }, "localname": "AccruedBonusesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEnvironmentalLossContingenciesCurrent": { "auth_ref": [ "r35", "r74", "r338", "r340", "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value of the obligation (known or estimated) arising from requirements to perform activities to remediate one or more sites, payable in twelve months or in the next operating cycle if longer.", "label": "Accrued Environmental Loss Contingencies, Current", "terseLabel": "Accrued environmental loss contingencies, current" } } }, "localname": "AccruedEnvironmentalLossContingenciesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r43", "r784", "r807" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "verboseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r74" ], "calculation": { "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Total", "verboseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails", "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent": { "auth_ref": [ "r789", "r814" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs.", "label": "Accrued Payroll Taxes", "terseLabel": "Deferred payroll taxes" } } }, "localname": "AccruedPayrollTaxesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r94", "r100", "r110", "r111", "r112", "r653" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined Benefit Plan Liability" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r67", "r330" ], "calculation": { "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r100", "r110", "r111", "r112", "r113", "r652" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Cash Flow Hedges" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r52", "r97", "r99", "r100", "r809", "r839", "r843" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r110", "r111", "r723", "r724", "r725", "r726", "r727", "r729" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r96", "r100", "r110", "r111", "r112", "r183", "r184", "r185", "r653", "r834", "r835", "r914" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income", "verboseLabel": "Net-of-Tax Amount" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r92", "r100", "r110", "r111", "r112", "r653", "r724", "r725", "r726", "r727", "r729" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted Average Amortization Period (Years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r50" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r521", "r523", "r566", "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r523", "r552", "r565" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r174", "r175", "r176", "r179", "r180" ], "lang": { "en-us": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]", "terseLabel": "Provision for credit losses" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r56", "r274", "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "verboseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "terseLabel": "Outstanding receivables previously reserved, written off" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r131", "r151", "r412", "r732" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "negatedTerseLabel": "Unamortized discount on TLB Facility, Amortization during the period" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r123", "r151", "r412", "r734" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "negatedLabel": "Amortization during the period" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r151", "r412", "r422", "r423", "r734" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "negatedLabel": "Total, Amortization during the period", "verboseLabel": "Debt related charges included in interest expense" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows", "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r151", "r311", "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Total intangible asset amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetAmortizationExpensebycategoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Securities excluded (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Asset Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Asset Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "AssetAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationTable": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about contingent consideration in asset acquisition.", "label": "Asset Acquisition, Contingent Consideration [Table]", "terseLabel": "Asset Acquisition, Contingent Consideration [Table]" } } }, "localname": "AssetAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r168", "r247", "r254", "r261", "r286", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r383", "r385", "r387", "r388", "r650", "r654", "r711", "r762", "r764", "r782", "r806" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets", "verboseLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r32", "r33", "r88", "r168", "r286", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r383", "r385", "r387", "r388", "r650", "r654", "r711", "r762", "r764" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r524", "r554" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r663", "r668" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings and building improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r515", "r518" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionProFormaInformationDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r515", "r518", "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionProFormaInformationDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of business acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Schedule of Business Acquisition, Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r619", "r620" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Income from continuing operations" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r619", "r620" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Sales" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r616" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r634", "r635", "r638" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r632", "r634", "r635", "r640" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Fair value of contingent consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": { "auth_ref": [ "r150", "r643" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset", "negatedTerseLabel": "Contingent consideration fair value adjustment" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r150", "r643" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Fair value reduction adjustment for acquisition-related contingent consideration liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r642" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Revenue-based payments", "verboseLabel": "Remaining Maximum Payout (undiscounted)" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r633", "r636", "r641" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Liabilities: Contingent consideration", "verboseLabel": "Fair Value" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r633", "r637" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Contingent consideration liability, current" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r700" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Unobservable Inputs" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r633", "r637" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration liability, noncurrent" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "BUSINESS ACQUISITIONS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized": { "auth_ref": [ "r625" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity.", "label": "Business Combination, Liabilities Arising from Contingencies, Amount Recognized", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": { "auth_ref": [ "r627" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory", "terseLabel": "Inventory adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "auth_ref": [ "r624" ], "calculation": { "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease obligation assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "negatedTerseLabel": "Operating lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r624" ], "calculation": { "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Current assets (excluding inventory)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r624" ], "calculation": { "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "negatedTerseLabel": "Current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r624" ], "calculation": { "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r623", "r624" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Acquired finite lived intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r623", "r624" ], "calculation": { "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]", "terseLabel": "Fair value of purchase consideration" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r624" ], "calculation": { "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other noncurrent assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r623", "r624" ], "calculation": { "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r624" ], "calculation": { "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Fair value of net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Fair value of net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Combination, Separately Recognized Transactions [Line Items]", "terseLabel": "Business Combination, Separately Recognized Transactions [Line Items]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionProFormaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing the disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.", "label": "Business Combination, Separately Recognized Transactions [Table]", "terseLabel": "Business Combination, Separately Recognized Transactions [Table]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionProFormaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Acquisitions and Contingent Consideration" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r156", "r157", "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property, plant and equipment purchases included in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r133" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Cash acquired from acquisition" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r39", "r154" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r146", "r153", "r159" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of year", "periodStartLabel": "Cash and cash equivalents, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r146", "r722" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r63" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "verboseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r22", "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Cash provided by investing activities" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsCashFlowInformationfromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r22", "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Cash used in operating activities" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsCashFlowInformationfromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r78", "r358", "r790", "r813" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 13)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r355", "r356", "r357", "r362", "r863" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).", "label": "Common Stock Including Additional Paid in Capital [Member]", "terseLabel": "Common stock and additional paid-in capital" } } }, "localname": "CommonStockIncludingAdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r183", "r184", "r691" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Shares outstanding at end of year (in shares)", "periodStartLabel": "Shares outstanding at beginning of year (in shares)", "verboseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r48", "r444" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Shares outstanding at beginning of year (in shares)", "periodStartLabel": "Shares outstanding at beginning of year (in shares)", "verboseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r48", "r764" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized; 33,063,336 and 32,908,178 shares issued and outstanding as of December 31, 2021 and 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]", "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r105", "r107", "r108", "r121", "r797", "r821" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Information technology hardware and software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r228", "r229", "r269", "r708", "r709", "r862" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r228", "r229", "r269", "r708", "r709", "r844", "r862" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r228", "r229", "r269", "r708", "r709", "r844", "r862" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r222", "r803" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r228", "r229", "r269", "r708", "r709" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r228", "r229", "r269", "r708", "r709", "r862" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction work in process" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Contract Assets and Contract Liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r455", "r457", "r476" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r455", "r456", "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r455", "r456", "r476" ], "calculation": { "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r477" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract with customer, liability, revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r127", "r777" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Expenses related to license agreements", "verboseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetAmortizationExpensebycategoriesDetails", "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "auth_ref": [ "r348", "r349", "r354" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "terseLabel": "Restructuring Expenses" } } }, "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r169", "r597", "r604" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r169", "r597" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "International" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r169", "r597", "r604", "r606" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r169", "r597", "r604" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r226", "r269" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerListsMember": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information.", "label": "Customer Lists [Member]", "terseLabel": "Customer lists", "verboseLabel": "Customer lists" } } }, "localname": "CustomerListsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt and equity securities.", "label": "Debt and Equity Securities, Realized Gain (Loss)", "negatedTotalLabel": "Total (gain) loss on equity investments, net" } } }, "localname": "DebtAndEquitySecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r164", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r406", "r413", "r414", "r416", "r424" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r42", "r43", "r44", "r167", "r173", "r389", "r390", "r391", "r392", "r393", "r394", "r396", "r402", "r403", "r404", "r405", "r407", "r408", "r409", "r410", "r411", "r412", "r420", "r421", "r422", "r423", "r736", "r783", "r786", "r805" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r44", "r417", "r786", "r805" ], "calculation": { "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": { "auth_ref": [ "r167" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.", "label": "Debt Instrument, Increase (Decrease), Net", "terseLabel": "Debt instrument increase" } } }, "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r76", "r167", "r173", "r389", "r390", "r391", "r392", "r393", "r394", "r396", "r402", "r403", "r404", "r405", "r407", "r408", "r409", "r410", "r411", "r412", "r420", "r421", "r422", "r423", "r736" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r76", "r167", "r173", "r389", "r390", "r391", "r392", "r393", "r394", "r396", "r402", "r403", "r404", "r405", "r407", "r408", "r409", "r410", "r411", "r412", "r415", "r420", "r421", "r422", "r423", "r445", "r448", "r449", "r450", "r732", "r733", "r736", "r737", "r802" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r402", "r732", "r737" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "periodEndLabel": "Unamortized discount on TLB Facility, Ending Balance", "periodStartLabel": "Unamortized discount on TLB Facility, Beginning Balance" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r402", "r418", "r420", "r421", "r734" ], "calculation": { "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized discount on term loan B and deferred debt issuance costs", "periodEndLabel": "Total, Ending Balance", "periodStartLabel": "Total, Beginning Balance", "terseLabel": "Unamortized debt issuance costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r402", "r732", "r733", "r734", "r735", "r737" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "terseLabel": "Original issue discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Debt Issuance Costs and Discounts" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt, Weighted Average Interest Rate", "terseLabel": "Weighted average interest rate" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r169", "r598", "r604" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r734" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r68", "r402", "r734" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "periodEndLabel": "Debt issuance costs, Ending Balance", "periodStartLabel": "Debt issuance costs, Beginning Balance" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r169", "r598", "r604" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "International" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r574", "r575" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Noncurrent deferred tax asset", "verboseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r151", "r169", "r598", "r604", "r605", "r606" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r45", "r46", "r587", "r785", "r804" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Gross deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r574", "r575" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "negatedLabel": "Noncurrent deferred tax liability", "verboseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r152" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "verboseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r169", "r598", "r604" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r588" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventories" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r590" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": { "auth_ref": [ "r593", "r595", "r596" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other", "terseLabel": "Tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpense": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.", "label": "Deferred Tax Assets, Tax Deferred Expense", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r589" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r575", "r590" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liability" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets", "negatedLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property, plant and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r497" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "terseLabel": "Expected future benefit payments next five years" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlansDefinedBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r498", "r507", "r508", "r509" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "terseLabel": "Net periodic pension cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlansDefinedBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": { "auth_ref": [ "r506", "r508" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "terseLabel": "Aggregated projected benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlansDefinedBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r514" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Net costs recognized" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlansSavingsPlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer matching contribution, percentage of employees' gross pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlansSavingsPlanNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r151", "r328" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r151", "r242" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotionalAmount": { "auth_ref": [ "r657", "r658", "r660" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative asset.", "label": "Derivative Asset, Notional Amount", "terseLabel": "Notional Amount", "verboseLabel": "Notional amount" } } }, "localname": "DerivativeAssetNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r89", "r90", "r91", "r666", "r774" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Fair Value", "verboseLabel": "Fair value" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r89", "r90", "r91", "r666", "r774" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "negatedTerseLabel": "Fair Value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Pay Fixed Rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeForwardExchangeRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual rate at which a foreign currency can be purchased or sold.", "label": "Derivative, Forward Exchange Rate", "terseLabel": "Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso)" } } }, "localname": "DerivativeForwardExchangeRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r90", "r664", "r667", "r672", "r676" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "auth_ref": [ "r682" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "terseLabel": "Gain (loss) reclassification from accumulated OCI to income, estimated net amount to be transferred" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotionalAmount": { "auth_ref": [ "r657", "r658", "r660" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative liability.", "label": "Derivative Liability, Notional Amount", "terseLabel": "Notional Amount" } } }, "localname": "DerivativeLiabilityNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeVariableInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.", "label": "Derivative, Variable Interest Rate", "terseLabel": "Receive Current Floating Rate" } } }, "localname": "DerivativeVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativesAndFairValueTextBlock": { "auth_ref": [ "r694", "r707" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.", "label": "Derivatives and Fair Value [Text Block]", "verboseLabel": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS" } } }, "localname": "DerivativesAndFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r172", "r656", "r659", "r661", "r662", "r678" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r475", "r479", "r480", "r481", "r482", "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r8", "r10", "r12" ], "calculation": { "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.", "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax", "negatedTerseLabel": "Gain on sale of discontinued operations" } } }, "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "auth_ref": [ "r8", "r10", "r12", "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.", "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax", "terseLabel": "Discontinued operation, gain (loss) on disposal of discontinued operation, net of tax" } } }, "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsASOBusinessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r8", "r9", "r10", "r11", "r12", "r20", "r118", "r818" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "terseLabel": "Income from discontinued operations before taxes", "totalLabel": "Income from discontinued operations before taxes" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Income from discontinued operations (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "verboseLabel": "Income from discontinued operations (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r9", "r10", "r11", "r12", "r20", "r25", "r576", "r603", "r610" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "terseLabel": "Provision for income taxes", "verboseLabel": "Provision for income taxes" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]", "terseLabel": "Discontinued operations:" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "auth_ref": [ "r6", "r7", "r24" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations, Held-for-sale [Member]", "terseLabel": "Discontinued Operations, Held-for-sale" } } }, "localname": "DiscontinuedOperationsHeldforsaleMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsASOBusinessNarrativeDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsCashFlowInformationfromDiscontinuedOperationsDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsASOBusinessNarrativeDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsCashFlowInformationfromDiscontinuedOperationsDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsASOBusinessNarrativeDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsCashFlowInformationfromDiscontinuedOperationsDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "auth_ref": [ "r21" ], "calculation": { "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "negatedTerseLabel": "Other income, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r151", "r327", "r332" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "negatedTerseLabel": "Gain on sale of discontinued operations" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r29", "r337" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "DISCONTINUED OPERATIONS" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r515", "r518" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsASOBusinessNarrativeDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsCashFlowInformationfromDiscontinuedOperationsDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "U.S. Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r122", "r191", "r192", "r193", "r194", "r195", "r200", "r202", "r207", "r208", "r209", "r213", "r214", "r692", "r693", "r798", "r822" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "totalLabel": "Basic earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "verboseLabel": "Basic earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r122", "r191", "r192", "r193", "r194", "r195", "r202", "r207", "r208", "r209", "r213", "r214", "r692", "r693", "r798", "r822" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "totalLabel": "Diluted earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r210", "r211" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share (EPS)" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r210", "r211", "r212", "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r722" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "verboseLabel": "Effect of foreign currency exchange rates on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r577" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r170", "r577", "r607" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r577", "r607" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r577", "r607" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign rate differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r577", "r607" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r577", "r607" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "terseLabel": "U.S. tax on foreign earnings, net of \u00a7250 deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r577", "r607" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": { "auth_ref": [ "r577", "r607" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent", "terseLabel": "Uncertain tax positions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r577", "r607" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "negatedTerseLabel": "Federal tax credits (including R&D)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r553" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r552" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Compensation expense tax benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Severance" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Major Customer [Line Items]", "terseLabel": "Revenue, Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EnvironmentalCostExpensePolicy": { "auth_ref": [ "r339", "r341", "r342" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for environmental remediation costs that are expensed during the period that resulted from improper or other than normal operation of a long-lived asset. This accounting policy may address (1) whether the obligation is measured on a discounted basis, (2) the event, situation, or set of circumstances that generally triggers recognition of loss contingencies arising from the entity's environmental remediation-related obligations, and (3) the timing of recognition of any recoveries. This accounting policy does not address: (1) accounting for pollution control costs of current operations or for costs of future site restoration or closure that are required upon the cessation of operations or sale of facilities (2) environmental remediation actions that are undertaken at the sole discretion of management and that are not induced by the threat, by governments or other parties, of litigation or of assertion of a claim or an assessment (3) recognition of liabilities of insurance companies for unpaid claims or (4) asset impairment issues.", "label": "Environmental Cost, Expense Policy [Policy Text Block]", "terseLabel": "Environmental Costs" } } }, "localname": "EnvironmentalCostExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r110", "r111", "r112", "r183", "r184", "r185", "r188", "r196", "r198", "r217", "r291", "r444", "r451", "r560", "r561", "r562", "r600", "r601", "r691", "r723", "r724", "r725", "r726", "r727", "r729", "r834", "r835", "r836", "r914" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r117", "r145", "r151", "r816" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Equity method investment, return of capital" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "auth_ref": [ "r282" ], "calculation": { "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.", "label": "Equity Method Investment, Other than Temporary Impairment", "terseLabel": "Impairment charges" } } }, "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Percentage of ownership interest" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r64", "r248", "r283" ], "calculation": { "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "totalLabel": "Total equity investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsFairValueDisclosure": { "auth_ref": [ "r281" ], "calculation": { "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_EquityMethodInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investments accounted under the equity method.", "label": "Equity Method Investments, Fair Value Disclosure", "terseLabel": "Equity method investment" } } }, "localname": "EquityMethodInvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r64", "r145", "r285", "r711" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]", "terseLabel": "Schedule of Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Non-marketable securities fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount", "terseLabel": "Non-marketable securities impairment" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r695", "r696", "r697", "r705" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r698" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r404", "r420", "r421", "r489", "r491", "r492", "r493", "r494", "r495", "r496", "r508", "r696", "r765", "r766", "r767" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r695", "r696", "r699", "r700", "r706" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r404", "r489", "r491", "r496", "r508", "r696", "r765" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r404", "r420", "r421", "r489", "r491", "r496", "r508", "r696", "r766" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r404", "r420", "r421", "r489", "r491", "r492", "r493", "r494", "r495", "r496", "r508", "r696", "r767" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r695", "r696" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Contingent Consideration Measurement Inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEstimatedFairValuesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r701", "r705" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Rollforward of Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r702" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Fair value measurement adjustment" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEstimatedFairValuesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r703" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "terseLabel": "Amount recorded for current year acquisitions" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEstimatedFairValuesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r703" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEstimatedFairValuesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r701" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEstimatedFairValuesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r404", "r420", "r421", "r489", "r491", "r492", "r493", "r494", "r495", "r496", "r508", "r765", "r766", "r767" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r704", "r706" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r663", "r669", "r679" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r680" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r741", "r747", "r757" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails": { "order": 2.0, "parentTag": "gb_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Finance lease cost" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r744", "r751" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r739", "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "totalLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r739" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "negatedTerseLabel": "Less: current portion of lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r740" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r739" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Total long-term lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r740" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Gross lease liabilities" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r743", "r751" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Principal payments on finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r738" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance lease right-of-use asset" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [ "r741", "r747" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "terseLabel": "Finance lease accumulated amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r741", "r747", "r757" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails": { "order": 1.0, "parentTag": "gb_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of lease assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r754", "r757" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesLeaseTermandDiscountRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r753", "r757" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - finance leases (in years)" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesLeaseTermandDiscountRateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r320" ], "calculation": { "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed.", "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]" } } }, "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "After 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r312", "r316", "r320", "r324", "r778", "r779" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r320", "r779" ], "calculation": { "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetAmortizationExpensebycategoriesDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r312", "r319" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r320", "r778" ], "calculation": { "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Fair Value Assigned" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Assets: Foreign currency hedging contracts" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r720", "r721" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Realized", "terseLabel": "Net foreign currency transaction gains (losses)" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r730" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Remeasurement" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r90", "r489", "r674" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign exchange contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Gain Contingencies [Line Items]", "terseLabel": "Gain Contingencies [Line Items]" } } }, "localname": "GainContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainContingenciesTable": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.", "label": "Gain Contingencies [Table]", "terseLabel": "Gain Contingencies [Table]" } } }, "localname": "GainContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "terseLabel": "Gain on litigation settlement" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r227", "r862" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r301", "r302", "r764", "r781" ], "calculation": { "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill acquired", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails", "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Acquisition" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r303", "r307" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Accumulated impairment loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r306", "r615" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "negatedTerseLabel": "Acquisition-related adjustments (Note 2)", "terseLabel": "Acquisition-related adjustments (Note 2)" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r125", "r168", "r247", "r253", "r257", "r260", "r263", "r286", "r374", "r375", "r376", "r379", "r380", "r381", "r383", "r385", "r387", "r388", "r711" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r661", "r677" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeApproachValuationTechniqueMember": { "auth_ref": [ "r698" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach converting future amounts to single current discounted amount.", "label": "Valuation, Income Approach [Member]", "terseLabel": "Valuation, Income Approach" } } }, "localname": "IncomeApproachValuationTechniqueMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r126", "r152", "r191", "r192", "r193", "r194", "r206", "r209", "r647" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Income from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r116", "r247", "r253", "r257", "r260", "r263", "r780", "r793", "r800", "r823" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income (loss) from continuing operations before income taxes", "totalLabel": "Income from continuing operations before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeBeforeIncomeTaxDomesticAndForeignDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r168", "r187", "r247", "r253", "r257", "r260", "r263", "r286", "r374", "r375", "r376", "r379", "r380", "r381", "r383", "r385", "r387", "r388", "r648", "r693", "r711" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Income from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r114", "r122", "r187", "r191", "r192", "r193", "r194", "r202", "r207", "r208", "r693", "r791", "r794", "r798", "r817" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Income from continuing operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r114", "r122", "r187", "r191", "r192", "r193", "r194", "r202", "r207", "r208", "r209", "r693", "r798", "r817", "r820", "r822" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Income from continuing operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r8", "r9", "r10", "r11", "r12", "r20", "r25", "r648" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "terseLabel": "Income from discontinued operations", "totalLabel": "Income from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails", "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r117", "r151", "r244", "r283", "r792", "r816" ], "calculation": { "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity method investment (income) loss" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsEquityMethodInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r515", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsASOBusinessNarrativeDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsCashFlowInformationfromDiscontinuedOperationsDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsASOBusinessNarrativeDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsCashFlowInformationfromDiscontinuedOperationsDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r5", "r14", "r15", "r16", "r17", "r18", "r19", "r23", "r26", "r27", "r28", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsASOBusinessNarrativeDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsCashFlowInformationfromDiscontinuedOperationsDetails", "http://www.greatbatchmedical.com/role/DiscontinuedOperationsIncomefromDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r333", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails", "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails", "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r170", "r578", "r585", "r592", "r602", "r608", "r611", "r612", "r613" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r171", "r197", "r198", "r245", "r576", "r603", "r609", "r824" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 }, "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "totalLabel": "Total provision for income taxes", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails", "http://www.greatbatchmedical.com/role/IncomeTaxesProvisionBenefitofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]", "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r109", "r572", "r573", "r585", "r586", "r591", "r599" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r577" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r577" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r577" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r577" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r577" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount", "terseLabel": "U.S. tax on foreign earnings, net of \u00a7250 deduction" } } }, "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r577" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State taxes, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "auth_ref": [ "r577" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount", "terseLabel": "Uncertain tax positions" } } }, "localname": "IncomeTaxReconciliationTaxContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "auth_ref": [ "r577" ], "calculation": { "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "negatedLabel": "Federal tax credits (including R&D)" } } }, "localname": "IncomeTaxReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesEffectTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r155" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r82", "r788", "r815" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Refundable income taxes" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r150" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r150" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r150" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r150" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "auth_ref": [ "r150" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Increase (Decrease) in Contract with Customer, Asset", "negatedTerseLabel": "Contract assets" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r150" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities, net of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r150" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r203", "r204", "r205", "r209" ], "calculation": { "http://www.greatbatchmedical.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "verboseLabel": "Effect of dilutive securities stock options, restricted stock and restricted stock units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r315", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r323" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets (excluding goodwill)" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r315", "r323" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r310", "r318" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r115", "r241", "r731", "r734", "r799" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r675" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails", "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r143", "r148", "r155" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r36", "r37", "r74" ], "calculation": { "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.", "label": "Interest Rate Derivative Liabilities, at Fair Value", "terseLabel": "Liabilities: Interest rate swaps" } } }, "localname": "InterestRateDerivativeLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r673" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r83" ], "calculation": { "http://www.greatbatchmedical.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r30", "r86", "r764" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r38", "r87", "r162", "r216", "r297", "r299", "r300", "r776" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r85" ], "calculation": { "http://www.greatbatchmedical.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r84" ], "calculation": { "http://www.greatbatchmedical.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r298" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Increase in inventory valuation reserves" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LandAndLandImprovementsMember": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Real estate held and assets that are an addition or improvement to real estate held.", "label": "Land and Land Improvements [Member]", "terseLabel": "Land and land improvements" } } }, "localname": "LandAndLandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r755", "r757" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r755" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Term, Discount Rate, Lease Costs and Supplemental Cash Flow Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r756" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease Liability Maturities (Topic 842)" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Gross lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r756" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r758" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessor, Lease, Description [Line Items]", "terseLabel": "Lessor, Lease, Description [Line Items]" } } }, "localname": "LessorLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorLeaseDescriptionTable": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessor's leases.", "label": "Lessor, Lease, Description [Table]", "terseLabel": "Lessor, Lease, Description [Table]" } } }, "localname": "LessorLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Outstanding standby letters of credit" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r73", "r168", "r255", "r286", "r374", "r375", "r376", "r379", "r380", "r381", "r383", "r385", "r387", "r388", "r651", "r654", "r655", "r711", "r762", "r763" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r55", "r168", "r286", "r711", "r764", "r787", "r811" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r75", "r168", "r286", "r374", "r375", "r376", "r379", "r380", "r381", "r383", "r385", "r387", "r388", "r651", "r654", "r655", "r711", "r762", "r763", "r764" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r44", "r786", "r805" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Outstanding amount" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Unused capacity commitment fee" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation.", "label": "Loans Payable [Member]", "terseLabel": "Loans Payable" } } }, "localname": "LoansPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r44", "r403", "r419", "r420", "r421", "r786", "r808" ], "calculation": { "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term Debt", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r72" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedTerseLabel": "Current portion of long-term debt", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r173", "r371", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "After 2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtLongtermDebtMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r173", "r371", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtLongtermDebtMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r173", "r371", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtLongtermDebtMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r173", "r371", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtLongtermDebtMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r173", "r371", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtLongtermDebtMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r173", "r371", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtLongtermDebtMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt [Member]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r76" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r76", "r372" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r358", "r359", "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Loss contingency damages sought" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Manufacturing machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Unallocated Amount to Segment" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r698" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r698" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsContingentConsiderationMeasurementInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "terseLabel": "Movement in Standard Product Warranty Accrual [Roll Forward]" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesChangeinProductWarrantyLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r146" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r146" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r146", "r149", "r152" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r28", "r103", "r106", "r112", "r119", "r152", "r168", "r187", "r191", "r192", "r193", "r194", "r197", "r198", "r206", "r247", "r253", "r257", "r260", "r263", "r286", "r374", "r375", "r376", "r379", "r380", "r381", "r383", "r385", "r387", "r388", "r693", "r711", "r795", "r819" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity", "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows", "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Comprehensive Income" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator for basic and diluted EPS:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Accounting Pronouncements Adopted, Accounting Guidance Not Yet Elected or Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationNarrativeDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office Equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenseMember": { "auth_ref": [ "r675" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "label": "Operating Expense [Member]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r247", "r253", "r257", "r260", "r263" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income", "verboseLabel": "Operating income as reported" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r742" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r739" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r739" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current portion of lease liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r739" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r745", "r751" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r738" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r754", "r757" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesLeaseTermandDiscountRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r753", "r757" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesLeaseTermandDiscountRateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r593" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r252", "r253", "r254", "r255", "r257", "r263" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r789", "r814" ], "calculation": { "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other Accrued Liabilities", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r663", "r679" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r68" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized.", "label": "Other Capitalized Property Plant and Equipment [Member]", "terseLabel": "Other" } } }, "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r648", "r649", "r652" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation gain (loss)" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r97" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Net change in cash flow hedges, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r93", "r97", "r665", "r670", "r681" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Gain (Loss) Recognized in OCI", "verboseLabel": "Gain (loss) recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativesDetails", "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r97", "r101", "r671" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Gain (Loss) Reclassified from AOCI" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r104", "r107", "r110", "r111", "r113", "r120", "r444", "r723", "r728", "r729", "r796", "r820" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive income (loss), net", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity", "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "verboseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r95", "r97" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Defined benefit plan liability adjustment, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r130", "r825" ], "calculation": { "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "terseLabel": "Other general expenses" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r487", "r569" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "verboseLabel": "OTHER OPERATING EXPENSES" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r77" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r152" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash (gains) losses" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r132" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) loss, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 }, "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedLabel": "Other operating expenses", "negatedTotalLabel": "Total other operating expenses" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r142" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Contingent consideration payments" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r144", "r345" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Cash payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesChangesinAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r141" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r139" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Tax withholdings related to net share settlements of restricted stock awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r135", "r639" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromInoMecLtdNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionAllocationOfTheProvisionalPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r135" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisitions, net" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r136" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchase of intangible asset", "terseLabel": "Payments to acquire intangible asset" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r136" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisition of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r488", "r490", "r496", "r499", "r500", "r501", "r502", "r503", "r504", "r508", "r510", "r513", "r514", "r520" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "verboseLabel": "BENEFIT PLANS" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "auth_ref": [ "r505", "r511", "r512", "r514", "r516" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "terseLabel": "Defined Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r47", "r428" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r47", "r428" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r47", "r764" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding as of December 31, 2021 and 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r32", "r61", "r62" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r133" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from sale of discontinued operations" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r138" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from issuance of term loans" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLegalSettlements": { "auth_ref": [ "r147" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for the settlement of litigation during the current period.", "label": "Proceeds from Legal Settlements", "terseLabel": "Proceeds from legal settlements" } } }, "localname": "ProceedsFromLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r134" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSecuredLinesOfCredit": { "auth_ref": [ "r138" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from Secured Lines of Credit", "terseLabel": "Proceeds from revolving credit facility" } } }, "localname": "ProceedsFromSecuredLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r137", "r555" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Cash received", "verboseLabel": "Proceeds from the exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows", "http://www.greatbatchmedical.com/role/StockBasedCompensationExerciseofStockOptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r67", "r331" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r337", "r864", "r865", "r866" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r66", "r329" ], "calculation": { "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r40", "r41", "r331", "r764", "r801", "r812" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Long-lived tangible assets", "totalLabel": "Total", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationLonglivedTangibleAssetsbyRegionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r65", "r331", "r864", "r865" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r40", "r331" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r40", "r329" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, plant and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r57", "r275" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Trade Accounts Receivable and Provision for Current Expected Credit Losses" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "negatedTerseLabel": "Reclassification from AOCI, current period, before tax, attributable to parent" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r100", "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTerseLabel": "Reclassification from AOCI, current period, net of tax, attributable to parent" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "auth_ref": [ "r98", "r102", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Reclassification from AOCI, Current Period, Tax", "terseLabel": "Reclassification from AOCI, current period, tax" } } }, "localname": "ReclassificationFromAociCurrentPeriodTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r254", "r257" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Schedule of Long-Lived Tangible Assets and Identifiable Assets by Geographic Area" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r253", "r257" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r253", "r257" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Schedule of Segment Income (Loss) from Operations" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r252", "r257" ], "lang": { "en-us": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyGeographicInformationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r140" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedLabel": "Payments of revolving credit facility" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r140" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.", "label": "Repayments of Other Long-term Debt", "negatedLabel": "Principal payments of term loans" } } }, "localname": "RepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r570" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "verboseLabel": "Research, development and engineering" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "RD&E" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research, Development and Engineering (RD&E)" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "R&D tax credits" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r344", "r347", "r351", "r353" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Costs incurred since inception" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r344", "r347", "r351", "r353" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Expected costs" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r151", "r343", "r348", "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Charges incurred, net of reversals" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesChangesinAccruedLiabilitiesDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r344", "r345", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesChangesinAccruedLiabilitiesDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r151" ], "calculation": { "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Restructuring Costs" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesChangesinAccruedLiabilitiesDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesChangesinAccruedLiabilitiesDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesScheduleofOtherOperatingExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r345", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Restructuring reserve, ending balance", "periodStartLabel": "Restructuring reserve, beginning balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesChangesinAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesChangesinAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r51", "r451", "r563", "r764", "r810", "r838", "r843" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r183", "r184", "r185", "r188", "r196", "r198", "r291", "r560", "r561", "r562", "r600", "r601", "r691", "r834", "r836" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r238", "r239", "r252", "r258", "r259", "r265", "r266", "r269", "r474", "r475", "r777" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Sales", "verboseLabel": "Total sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromUSBioDesignLLCNarrativeDetails", "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyGeographicInformationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r228", "r269" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Sales" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersDisaggregatedRevenueDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r163", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r486" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r478", "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE FROM CONTRACTS WITH CUSTOMERS" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.", "label": "Revenue, Performance Obligation, Description of Payment Terms", "terseLabel": "Description of payment terms" } } }, "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r752", "r757" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Assets acquired under finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r752", "r757" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Assets acquired under operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofOperatingLeaseSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r675" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofDerivativeInstrumentswithHedgeAccountingDesignationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r100", "r728", "r729" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r671" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "terseLabel": "Schedule of Changes in Number of Shares of Common Stock" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r5", "r14", "r15", "r16", "r17", "r18", "r19", "r23", "r26", "r27", "r28", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of Discontinued Operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r523", "r551", "r565" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r523", "r551", "r565" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of Segment Sales by Product Line" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r695", "r696" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r312", "r319", "r778" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r312", "r319" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r323", "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionTables", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r38", "r58", "r59", "r60" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.", "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]", "terseLabel": "Schedule of Other Operating Cost and Expense, by Component" } } }, "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Product Warranty Liability" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r67", "r331" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/PropertyPlantandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Summary of Final Allocation of Purchase Consideration" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r344", "r345", "r346", "r347", "r351", "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesChangesinAccruedLiabilitiesDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r345", "r352" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Restructuring Reserve by Type of Cost" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Schedule of Revenue by Major Customers by Reporting Segments" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r124", "r266" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Schedule of Sales by Geographic Area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r247", "r250", "r256", "r308" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r524", "r554" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r530", "r540", "r543" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r79", "r165", "r218", "r219", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r433", "r437", "r442", "r445", "r446", "r447", "r448", "r449", "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r225", "r228", "r229", "r230", "r708", "r710" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Concentration of Risk by Reveune and Accounts Receivable" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/RevenueFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtCovenantsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtScheduleofLongTermDebtDetails", "http://www.greatbatchmedical.com/role/DebtSeniorSecuredCreditFacilitiesDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r234", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r252", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r263", "r269", "r347", "r353", "r826" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAssetReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Asset Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingAssetReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationLonglivedTangibleAssetsbyRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r234", "r236", "r237", "r247", "r251", "r257", "r261", "r262", "r263", "r264", "r265", "r268", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "SEGMENT AND GEOGRAPHIC INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingRevenueReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyGeographicInformationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SelfInsuranceReserve": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Self Insurance Reserve", "terseLabel": "Self insurance reserve" } } }, "localname": "SelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r129" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "SG&A" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetAmortizationExpensebycategoriesDetails", "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r150" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Performance period (over)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Time-Vested and Performance-Vested Restricted Stock Units and Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair\u00a0Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r542" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of shares vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r542" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationExerciseofStockOptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Stock options exercised (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Grants in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average fair value(in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r554" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r532", "r554" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r545" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Vested and exercisable , aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Vested and exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested and exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r522", "r528" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationNarrativesDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails", "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails", "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r524", "r529" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r546", "r564" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationWeightedAverageFairValueandAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding, weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and exercisable , weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r748", "r757" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost (leases with initial term of 12 months or less)" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r161", "r182" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandardProductWarrantyAccrual": { "auth_ref": [ "r368" ], "calculation": { "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Product warranties" } } }, "localname": "StandardProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails", "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesChangeinProductWarrantyLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualAdditionsFromBusinessAcquisition": { "auth_ref": [ "r367" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard product warranty accrual from a business acquisition. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Additions from Business Acquisition", "terseLabel": "Acquisitions" } } }, "localname": "StandardProductWarrantyAccrualAdditionsFromBusinessAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesChangeinProductWarrantyLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualPayments": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Warranty claims settled" } } }, "localname": "StandardProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesChangeinProductWarrantyLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the standard product warranty accrual from changes in estimates attributable to preexisting product warranties. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties", "terseLabel": "Adjustments to pre-existing warranties" } } }, "localname": "StandardProductWarrantyAccrualPreexistingIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/CommitmentsandContingenciesChangeinProductWarrantyLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Product Warranties" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r363", "r370", "r646", "r845" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letters of Credit" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "U.S. State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r13", "r234", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r252", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r263", "r269", "r308", "r334", "r347", "r353", "r826" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Business Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetsScheduleofGoodwillDetails", "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationReconciliationofSegmentInformationDetails1", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSalesbyProductLinesDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationScheduleofRevenuebyShipToLocationDetails", "http://www.greatbatchmedical.com/role/SegmentandGeographicInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r81", "r110", "r111", "r112", "r183", "r184", "r185", "r188", "r196", "r198", "r217", "r291", "r444", "r451", "r560", "r561", "r562", "r600", "r601", "r691", "r723", "r724", "r725", "r726", "r727", "r729", "r834", "r835", "r836", "r914" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r183", "r184", "r185", "r217", "r777" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r47", "r48", "r444", "r451", "r534" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r48", "r53", "r54", "r168", "r276", "r286", "r711", "r764" ], "calculation": { "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Total stockholders\u2019 equity, ending balance", "periodStartLabel": "Total stockholders\u2019 equity, beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity", "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheets", "http://www.greatbatchmedical.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r166", "r429", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r451", "r454" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r750", "r757" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r579", "r584", "r586" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Schedule of Income Tax Contingencies" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Cash paid during the year for:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r593" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax Credit" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesIncomeTaxCarryForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Tradenames" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails", "http://www.greatbatchmedical.com/role/BusinessAcquisitionIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trademarks and tradenames" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails", "http://www.greatbatchmedical.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock, Common" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/StockholdersEquityScheduleofChangesinNumberofSharesofCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r80", "r453" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockReissuedAtLowerThanRepurchasePrice": { "auth_ref": [ "r48", "r444", "r451", "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "In cases when treasury stock is reissued at a price lower than the cost to repurchase, the excess difference between the selling price and cost to repurchase is charged against retained earnings (assuming that all APIC arising from treasury stock transactions has first been exhausted).", "label": "Treasury Stock Reissued at Lower than Repurchase Price", "terseLabel": "Treasury shares reissued" } } }, "localname": "TreasuryStockReissuedAtLowerThanRepurchasePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r444", "r451", "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Treasury shares purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r344", "r345", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/OtherOperatingExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r571", "r581" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance, end of year", "periodStartLabel": "Balance, beginning of year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r582" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions based upon tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r583" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefit" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r220", "r221", "r223", "r224", "r231", "r232", "r233" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r174", "r175", "r176", "r179", "r180" ], "lang": { "en-us": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "terseLabel": "Valuation allowance for deferred tax assets" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r174", "r180" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r177" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Charged to Costs & Expenses" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": { "auth_ref": [ "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account", "terseLabel": "Charged to Other Accounts- Describe" } } }, "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r179" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedTerseLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r174", "r175", "r176", "r179", "r180" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r174", "r175", "r176", "r179", "r180" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r698" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r698" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/BusinessAcquisitionAcquisitionofAssetsfromOscorIncNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r749", "r757" ], "calculation": { "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtRevolvingCreditFacilityDetails", "http://www.greatbatchmedical.com/role/DebtTermLoanFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r201", "r209" ], "calculation": { "http://www.greatbatchmedical.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Denominator for diluted EPS (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r200", "r209" ], "calculation": { "http://www.greatbatchmedical.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/ConsolidatedStatementsofOperations", "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator for basic EPS:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.", "label": "Write off of Deferred Debt Issuance Cost", "negatedLabel": "Write-off of debt issuance costs and unamortized discount", "terseLabel": "Write off of debt issuance cost" } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.greatbatchmedical.com/role/DebtDeferredDebtIssuanceCostsandDiscountsDetails", "http://www.greatbatchmedical.com/role/DebtDeferredFinancingFeesDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=124268079&loc=d3e32787-111569" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r29": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(1)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13185-110859" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13231-110859" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6571209&loc=d3e13669-110860" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r357": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(4))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1),(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r424": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=64906022&loc=d3e23086-112654" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r454": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r486": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r487": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r568": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r569": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r613": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=SL65897772-128472" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r645": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r694": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r707": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r730": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r758": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r878": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r879": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r880": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r881": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r882": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r883": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r884": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r885": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r886": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r887": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r888": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r889": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r890": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r891": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r892": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r893": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r894": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r895": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r896": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r897": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r898": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01" }, "r899": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "02" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r900": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(ii)", "Subsection": "01" }, "r901": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)", "Subsection": "01" }, "r902": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "01" }, "r903": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "02" }, "r904": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "01" }, "r905": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "02" }, "r906": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(C)", "Subsection": "02" }, "r907": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01" }, "r908": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02" }, "r909": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" } }, "version": "2.1" } ZIP 146 0001114483-22-000002-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001114483-22-000002-xbrl.zip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�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ⅅ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�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�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�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�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͡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end

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